Clustering O 0 3.556958108674735e-05
of O 0 3.370279500813922e-06
missense O 0 1.2578315363498405e-05
mutations O 0 1.5183071582214325e-06
in O 0 1.4074019816234795e-07
the O 0 1.4963926560085383e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 2.7052450604969636e-05
in O 0 8.299041098780435e-08
a O 0 9.129885114589342e-08
sporadic B-Disease 0 1.1950010957662016e-05
T I-Disease 1 0.9927276372909546
- I-Disease 0 0.034124091267585754
cell I-Disease 1 0.9996190071105957
leukaemia I-Disease 1 0.9999887943267822
. O 0 1.0962590749841183e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9861571788787842
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.6494925243223406e-08
is O 0 7.168150073511015e-09
a O 0 1.1214001283121888e-08
recessive B-Disease 0 1.7562164202900021e-06
multi I-Disease 0 0.0014485677238553762
- I-Disease 0 0.06603112816810608
system I-Disease 0 5.255525593383936e-06
disorder I-Disease 1 0.6649690866470337
caused O 0 7.938297130749561e-08
by O 0 4.634809869230594e-09
mutations O 0 1.5405596798245824e-08
in O 0 5.6193742992149964e-09
the O 0 3.1446543147239936e-08
ATM O 0 6.228236543392995e-06
gene O 0 4.4898544615534774e-07
at O 0 1.1130254051749944e-06
11q22 O 0 1.4433549949899316e-05
- O 0 7.0113760557433125e-06
q23 O 0 2.0892643078695983e-05
( O 0 3.967678878780134e-07
ref O 0 1.0534544344409369e-05
. O 0 2.4181832714020857e-07
3 O 0 8.267520570370834e-07
) O 0 1.4420739091747237e-07
. O 0 9.536078664496017e-07

The O 0 3.1527254122920567e-06
risk O 0 6.422797468985664e-06
of O 0 1.8884209112002281e-06
cancer B-Disease 0 0.0014060843968763947
, O 0 9.685199842124348e-08
especially O 0 8.023065447559929e-07
lymphoid B-Disease 1 0.9999852180480957
neoplasias I-Disease 1 0.9999165534973145
, O 0 4.64612419648347e-08
is O 0 8.842321541635556e-09
substantially O 0 1.8783343591621815e-07
elevated O 0 2.183997594329412e-06
in O 0 3.964803951816975e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 3.710553073688061e-06
and O 0 9.394238986715209e-08
has O 0 8.986227761909049e-09
long O 0 8.843164422955851e-09
been O 0 5.5324860248617824e-09
associated O 0 3.7812945663517894e-08
with O 0 6.545676711766646e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.0561641576932743e-05

By O 0 2.060313590845908e-06
analysing O 0 2.507365024939645e-05
tumour B-Disease 1 0.999649167060852
DNA O 0 1.6288682900267304e-06
from O 0 1.037359425026807e-07
patients O 0 1.8192123363292012e-08
with O 0 1.8779630295284733e-08
sporadic B-Disease 0 2.399999630142702e-06
T I-Disease 0 0.007073350250720978
- I-Disease 0 1.3019736798014492e-05
cell I-Disease 0 0.008939577266573906
prolymphocytic I-Disease 1 0.9445715546607971
leukaemia I-Disease 1 0.9999606609344482
( O 0 1.0932208169833757e-06
T B-Disease 0 0.01971360854804516
- I-Disease 0 4.852485653827898e-05
PLL I-Disease 0 7.320351869566366e-05
) O 0 2.835269086176595e-08
, O 0 6.194471158238457e-09
a O 0 6.638299687722338e-09
rare O 0 5.2652101345529445e-08
clonal B-Disease 0 2.209668082286953e-06
malignancy I-Disease 0 3.5129012303514173e-06
with O 0 1.587272002723239e-08
similarities O 0 1.3441274404613068e-07
to O 0 2.371170992887528e-08
a O 0 1.0952435758326828e-07
mature B-Disease 0 5.315567364050366e-07
T I-Disease 0 9.412150575371925e-06
- I-Disease 0 2.3126465293898946e-06
cell I-Disease 0 1.249622437171638e-05
leukaemia I-Disease 0 0.002851149532943964
seen O 0 1.4904762224432488e-07
in O 0 4.0873221252013536e-08
A B-Disease 1 0.986305832862854
- I-Disease 0 0.028514310717582703
T I-Disease 1 1.0
, O 0 3.828078831702442e-08
we O 0 7.997991602337606e-09
demonstrate O 0 2.51042440169158e-08
a O 0 7.922819733607867e-09
high O 0 2.2886119666054583e-08
frequency O 0 2.238365226503447e-08
of O 0 5.669859604040539e-08
ATM O 0 1.5194404113572091e-05
mutations O 0 2.3165669063018868e-06
in O 0 1.84156658633583e-06
T B-Disease 1 0.9996523857116699
- I-Disease 1 0.9705687165260315
PLL I-Disease 1 0.9898647665977478
. O 0 3.54184812749736e-05

In O 0 1.2605038364199572e-06
marked O 0 1.0058457746708882e-06
contrast O 0 1.2532241555618384e-07
to O 0 2.3849326069580457e-08
the O 0 1.323931115848609e-07
ATM O 0 6.553442744916538e-06
mutation O 0 1.574888841560096e-07
pattern O 0 2.0363553687730018e-07
in O 0 5.509574307893672e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999915361404419
T I-Disease 1 1.0
, O 0 3.6176736273318966e-08
the O 0 1.1804696775641332e-08
most O 0 6.670410446218966e-09
frequent O 0 1.4935432446350205e-08
nucleotide O 0 5.325547647316853e-08
changes O 0 1.2691963924282845e-08
in O 0 1.8158704762072375e-08
this O 0 6.039356748033242e-08
leukaemia B-Disease 0 0.0009484034962952137
were O 0 1.3027608929405687e-06
missense O 0 2.9802431527059525e-05
mutations O 0 2.4127817596308887e-05
. O 0 1.7569487681612372e-05

These O 0 1.1934371286770329e-06
clustered O 0 3.5584880606620573e-06
in O 0 4.436458667100851e-08
the O 0 4.6939117481770154e-08
region O 0 5.5514416175128645e-08
corresponding O 0 3.966339434668953e-08
to O 0 1.4674546910953268e-08
the O 0 5.401937741567053e-08
kinase O 0 7.777044856993598e-07
domain O 0 1.826235518365138e-07
, O 0 1.8858166583868297e-08
which O 0 4.655915208928718e-09
is O 0 3.2770517410796174e-09
highly O 0 1.4077988552685383e-08
conserved O 0 4.6782968610159514e-08
in O 0 1.1086800810744535e-08
ATM O 0 1.4552107131748926e-05
- O 0 1.2611783404281596e-06
related O 0 1.0852206600020509e-07
proteins O 0 2.4911257057169678e-08
in O 0 1.3139584531529636e-08
mouse O 0 6.760018322893302e-08
, O 0 1.6505079969419967e-08
yeast O 0 3.7811508946106187e-07
and O 0 2.2896384166415373e-07
Drosophila O 0 8.024419912544545e-06
. O 0 4.0152017390937544e-06

The O 0 1.053697633324191e-05
resulting O 0 2.4538435354770627e-06
amino O 0 1.140233166552207e-06
- O 0 4.3347381506464444e-07
acid O 0 7.657445877384816e-08
substitutions O 0 2.1110604109253472e-07
are O 0 1.1781079223283086e-08
predicted O 0 8.926867423042495e-08
to O 0 2.0362090680237088e-08
interfere O 0 3.0331301559272106e-07
with O 0 8.91847733441864e-08
ATP O 0 0.0006553733837790787
binding O 0 5.17993441917497e-07
or O 0 1.1524648613203681e-07
substrate O 0 7.170640969889064e-07
recognition O 0 1.3779698520011152e-06
. O 0 3.874219146382529e-06

Two O 0 2.960579422506271e-06
of O 0 4.027904196846066e-06
seventeen O 0 9.996231710829306e-06
mutated O 0 1.5755478671053424e-05
T B-Disease 0 0.00014166737673804164
- I-Disease 0 1.327753943769494e-05
PLL I-Disease 0 2.4636057787574828e-05
samples O 0 1.319026239343657e-07
had O 0 4.974904044274808e-08
a O 0 1.4506598589036912e-08
previously O 0 7.180714334253935e-08
reported O 0 3.118647953215259e-07
A B-Disease 0 0.06011781841516495
- I-Disease 1 0.587317168712616
T I-Disease 1 1.0
allele O 0 1.8741036910796538e-05
. O 0 7.103006737452233e-06

In O 0 5.932166118327586e-07
contrast O 0 5.987034228382981e-07
, O 0 5.821701520858369e-08
no O 0 2.5287921090466625e-08
mutations O 0 5.317225060252895e-08
were O 0 4.2216388607130284e-08
detected O 0 4.471245773629562e-08
in O 0 5.9512146322049375e-09
the O 0 1.801258164846331e-08
p53 O 0 1.216108529433768e-07
gene O 0 5.6118363289670015e-08
, O 0 1.0251560489393796e-08
suggesting O 0 3.137943949127475e-08
that O 0 4.029328426469192e-09
this O 0 1.7569799837247047e-08
tumour B-Disease 1 1.0
suppressor O 0 0.042871005833148956
is O 0 1.6812229830520664e-08
not O 0 7.862302808803179e-09
frequently O 0 5.4513407121703494e-08
altered O 0 9.593163952104078e-08
in O 0 2.6009011833139084e-08
this O 0 1.6833702431995334e-07
leukaemia B-Disease 0 0.17298376560211182
. O 0 5.919602699577808e-06

Occasional O 0 5.5559405154781416e-05
missense O 0 3.117324013146572e-05
mutations O 0 1.5422906471940223e-06
in O 0 1.301733476566369e-07
ATM O 0 0.00012482893362175673
were O 0 5.503603119905165e-07
also O 0 3.223854605494125e-08
found O 0 4.011692666949784e-08
in O 0 2.3983027119811595e-08
tumour B-Disease 1 0.999910831451416
DNA O 0 4.2613041273398267e-07
from O 0 6.294159504705021e-08
patients O 0 1.4981340612507665e-08
with O 0 1.7926794271261315e-08
B B-Disease 0 4.851222547586076e-05
- I-Disease 0 3.787570904023596e-06
cell I-Disease 0 0.002814168343320489
non I-Disease 1 0.89614337682724
- I-Disease 1 0.9517810344696045
Hodgkins I-Disease 1 0.9999985694885254
lymphomas I-Disease 0 0.00033732529846020043
( O 0 3.442209219883807e-07
B B-Disease 0 9.70053588389419e-06
- I-Disease 0 6.894366038068256e-07
NHL I-Disease 0 1.6917349057621323e-05
) O 0 1.6841273264844858e-08
and O 0 1.4749863552765419e-08
a O 0 6.884662440143074e-08
B B-Disease 0 8.824901669868268e-06
- I-Disease 0 2.406304474789067e-06
NHL I-Disease 0 0.0008082811255007982
cell O 0 3.368340912857093e-05
line O 0 3.211301373085007e-05
. O 0 4.31349826612859e-06

The O 0 8.930927037908987e-07
evidence O 0 7.409757358800562e-07
of O 0 9.902252884330665e-08
a O 0 1.2678125216325498e-08
significant O 0 3.3917938679906e-08
proportion O 0 6.123111973010964e-08
of O 0 3.0506079440328904e-08
loss O 0 1.6668663249674864e-07
- O 0 5.492796049111348e-07
of O 0 3.9449241739930585e-07
- O 0 3.2221646506513935e-07
function O 0 9.825995128665e-09
mutations O 0 9.740439566030545e-09
and O 0 1.498110413500342e-09
a O 0 1.5029184563530862e-09
complete O 0 4.87067319809853e-09
absence O 0 9.06419401758285e-08
of O 0 3.1222484153659025e-08
the O 0 1.4098922029859295e-08
normal O 0 1.0819424467456429e-08
copy O 0 3.0247036875152844e-08
of O 0 1.0217944712564986e-08
ATM O 0 1.853918888627959e-06
in O 0 1.0997165844628398e-08
the O 0 1.081426592719481e-08
majority O 0 4.322772362286287e-09
of O 0 6.126838769660026e-08
mutated O 0 1.2317271284700837e-05
tumours B-Disease 1 0.9999998807907104
establishes O 0 5.820618298457703e-07
somatic O 0 1.664126443756686e-06
inactivation O 0 6.595039394596824e-07
of O 0 7.194682183353507e-09
this O 0 1.2576601982061675e-09
gene O 0 8.16014100735174e-09
in O 0 5.678861381142042e-09
the O 0 4.0162326797599235e-08
pathogenesis O 0 0.0029010630678385496
of O 0 2.839317971847777e-07
sporadic B-Disease 0 5.8166104281554e-05
T I-Disease 1 0.9999749660491943
- I-Disease 1 0.9772608876228333
PLL I-Disease 1 0.9994422793388367
and O 0 1.3539100507387047e-07
suggests O 0 5.3786308740200184e-08
that O 0 6.281001052599322e-09
ATM O 0 4.106481810595142e-06
acts O 0 2.25735476533373e-07
as O 0 3.4821769645532186e-07
a O 0 1.3299868442118168e-06
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.0019676098600029945
. O 0 1.5292922398657538e-05

As O 0 2.9673831249965588e-06
constitutional O 0 1.1083141089329729e-06
DNA O 0 1.1328453410897055e-06
was O 0 1.3067185022919148e-07
not O 0 3.3438729563073366e-09
available O 0 2.704885915250088e-08
, O 0 5.8216760301377235e-09
a O 0 1.8514239030764656e-08
putative O 0 1.5805666407686658e-05
hereditary O 1 0.9999998807907104
predisposition O 1 0.9999927282333374
to O 0 1.1269768947386183e-05
T B-Disease 1 1.0
- I-Disease 1 0.9998528957366943
PLL I-Disease 0 0.008918318897485733
will O 0 6.123941176383596e-08
require O 0 2.9329576989312045e-08
further O 0 8.485726255003101e-08
investigation O 0 1.8999554640686256e-07
. O 0 1.6926911428072344e-07
. O 0 1.3080218650429742e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999994039535522
protein O 0 1.7988459148909897e-05
kinase O 0 7.956622539495584e-06
is O 0 3.193493114395096e-08
involved O 0 1.8663222078885155e-08
in O 0 3.5562630618102276e-09
the O 0 2.8542259666863856e-09
modulation O 0 1.5979066958493604e-08
of O 0 8.71889227482825e-09
the O 0 3.9510190674718615e-08
Ca2 O 0 2.9525124318752205e-06
+ O 0 6.2289727793540806e-06
homeostasis O 0 6.407178716472117e-06
in O 0 1.441838719529187e-07
skeletal O 0 0.0005781587096862495
muscle O 0 1.6514690287294798e-05
cells O 0 1.5291683666873723e-05
. O 0 3.0141932256810833e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9873222708702087
DM B-Disease 1 1.0
) O 0 3.626025772973662e-07
, O 0 1.2915067237884159e-08
the O 0 8.279906538177784e-09
most O 0 1.288440998337137e-08
prevalent O 0 3.636052497313358e-05
muscular B-Disease 1 0.9999992847442627
disorder I-Disease 1 0.9999978542327881
in O 0 4.04806428377924e-08
adults O 0 5.11091222676896e-08
, O 0 5.887346610222721e-09
is O 0 3.0585358690160547e-09
caused O 0 4.019244315145443e-08
by O 0 6.045694789236222e-08
( O 0 2.438546573557687e-07
CTG O 0 9.559931640978903e-06
) O 0 1.7479116820595664e-08
n O 0 6.659302442812987e-08
- O 0 1.0564281893721272e-07
repeat O 0 8.229512360458102e-08
expansion O 0 1.0257158322701798e-07
in O 0 1.0474112244196476e-08
a O 0 1.0986242138244506e-08
gene O 0 2.3730894582740802e-08
encoding O 0 1.2897187673388544e-07
a O 0 1.5153518972965685e-07
protein O 0 1.3048846767560462e-06
kinase O 0 7.498268587369239e-06
( O 0 1.0003489023802103e-06
DM B-Disease 1 0.9956041574478149
protein O 0 6.481966465798905e-07
kinase O 0 1.0696310255298158e-06
; O 0 1.0885667478532923e-07
DMPK O 0 0.0008668444934301078
) O 0 9.394540256835171e-09
and O 0 3.95546573273009e-09
involves O 0 4.817234611209642e-09
changes O 0 8.089753755768925e-09
in O 0 2.2494287321705997e-08
cytoarchitecture O 0 4.01971874453011e-06
and O 0 3.67544686241672e-07
ion O 0 2.8092428692616522e-05
homeostasis O 0 9.55946889007464e-05
. O 0 2.4536269847885706e-05

To O 0 2.2752938377834653e-07
obtain O 0 4.632612160548888e-07
clues O 0 1.7877662230603164e-06
to O 0 2.4006871157666865e-08
the O 0 3.2323576704129664e-08
normal O 0 7.106619648311607e-08
biological O 0 4.287179820039455e-07
role O 0 1.0235914515988043e-07
of O 0 2.0552903379211784e-07
DMPK O 1 0.8411060571670532
in O 0 7.890550079991954e-08
cellular O 0 4.871279202234291e-07
ion O 0 2.7821490675705718e-06
homeostasis O 0 1.5328298559325049e-06
, O 0 2.922130626359376e-08
we O 0 9.68427205094713e-09
have O 0 6.7693317618022775e-09
compared O 0 4.940493880667418e-08
the O 0 9.27530550143274e-08
resting O 0 2.486064659024123e-06
[ O 0 3.826247052529652e-07
Ca2 O 0 5.273552687867777e-07
+ O 0 2.249343538096582e-07
] O 0 1.0337881661826032e-07
i O 0 4.3301188412669944e-08
, O 0 6.1234834980439246e-09
the O 0 5.059870300527791e-09
amplitude O 0 1.7769043125781536e-08
and O 0 1.3680529598047997e-08
shape O 0 1.124536197494308e-07
of O 0 1.0954963869380663e-07
depolarization O 0 4.797138899448328e-07
- O 0 2.2256822376220953e-06
induced O 0 2.12237614505284e-06
Ca2 O 0 8.940556881498196e-07
+ O 0 3.0334686584865267e-07
transients O 0 3.4110794899788743e-07
, O 0 7.025417136929946e-09
and O 0 4.556614197070985e-09
the O 0 1.9304049914126153e-08
content O 0 7.100955912164864e-08
of O 0 1.282604671359877e-07
ATP O 0 1.6716001482564025e-05
- O 0 2.1371849925344577e-06
driven O 0 8.727496378924116e-07
ion O 0 1.0693119065763312e-06
pumps O 0 1.0076948910864303e-06
in O 0 5.96376139583299e-08
cultured O 0 7.633393579453696e-06
skeletal O 0 1.4623335118812975e-05
muscle O 0 6.60650869122037e-07
cells O 0 2.7519456580193946e-07
of O 0 7.587370021155948e-08
wild O 0 2.4242052631961997e-07
- O 0 1.7233921312254097e-07
type O 0 1.933478870341787e-07
and O 0 1.4293526362507691e-07
DMPK O 0 8.867656288202852e-05
[ O 0 1.1018119039363228e-06
- O 0 4.966796495864401e-06
/ O 0 8.686627552378923e-06
- O 0 1.711999357212335e-05
] O 0 3.930686489184154e-06
knockout O 0 8.152429654728621e-05
mice O 0 9.23485913517652e-06
. O 0 4.168071427557152e-06

In O 0 7.846844710002188e-06
vitro O 0 2.013182529481128e-05
- O 0 2.7797475922852755e-05
differentiated O 0 2.971159301523585e-05
DMPK O 0 0.0006943822372704744
[ O 0 5.031909495301079e-06
- O 0 1.0791376553243026e-05
/ O 0 8.5645242506871e-06
- O 0 3.987255240645027e-06
] O 0 1.0482665402378188e-06
myotubes O 0 3.831362391792936e-06
exhibit O 0 2.459301811086334e-07
a O 0 5.7786667895243227e-08
higher O 0 2.721446321629628e-07
resting O 0 1.3731685157836182e-06
[ O 0 2.803796519401658e-07
Ca2 O 0 3.856874855046044e-07
+ O 0 1.633792550137514e-07
] O 0 1.1807842525968226e-07
i O 0 3.616997545918821e-08
than O 0 8.114850125195971e-09
do O 0 1.862019871623488e-08
wild O 0 2.896550483910687e-07
- O 0 2.5529732283757767e-07
type O 0 2.4754012883931864e-07
myotubes O 0 2.145134430975304e-06
because O 0 2.7357890175494504e-08
of O 0 2.4652470287378492e-08
an O 0 8.42350811325332e-09
altered O 0 4.802704722806084e-08
open O 0 8.586489741446712e-08
probability O 0 2.9513810062553603e-08
of O 0 5.175400730195179e-08
voltage O 0 2.3069128474162426e-06
- O 0 1.0482085599505808e-06
dependent O 0 4.5278184757080453e-07
l O 0 4.998344707018987e-07
- O 0 3.3195303217326e-07
type O 0 2.0701145331258886e-07
Ca2 O 0 6.09956032349146e-07
+ O 0 3.2741488098508853e-07
and O 0 1.405045679803152e-07
Na O 0 2.278905867569847e-06
+ O 0 1.4027324368726113e-06
channels O 0 2.0160382518952247e-06
. O 0 1.795391654013656e-06

The O 0 1.6017664165701717e-05
mutant O 0 5.187523856875487e-05
myotubes O 0 6.430273788282648e-05
exhibit O 0 3.0442313345702132e-06
smaller O 0 4.4018963762937346e-07
and O 0 7.950707470172347e-08
slower O 0 4.263173991603253e-07
Ca2 O 0 5.486241434482508e-07
+ O 0 1.8235641618957743e-07
responses O 0 2.6303151656748014e-08
upon O 0 4.9544315317007204e-08
triggering O 0 9.197859895948568e-08
by O 0 2.3277667793308865e-08
acetylcholine O 0 7.389799634438532e-07
or O 0 1.2265374493836134e-07
high O 0 4.935525339533342e-07
external O 0 2.0297607079555746e-06
K O 0 6.742968707840191e-06
+ O 0 3.918257334589725e-06
. O 0 2.4497330741724e-06

In O 0 6.10831591529859e-07
addition O 0 2.9077844487801485e-07
, O 0 7.40948848942935e-08
we O 0 1.9714772037104922e-08
observed O 0 3.24687832176096e-08
that O 0 3.78717501803294e-09
these O 0 3.615900467934807e-08
Ca2 O 0 1.4841672282273066e-06
+ O 0 2.263214582853834e-06
transients O 0 1.6126758737300406e-06
partially O 0 2.0579575732426747e-07
result O 0 9.04990482553103e-09
from O 0 7.643609301055676e-09
an O 0 5.859888130288482e-09
influx O 0 1.1415328771136046e-07
of O 0 6.15746245102855e-08
extracellular O 0 5.259876161289867e-07
Ca2 O 0 7.51326240333583e-07
+ O 0 2.746418772403558e-07
through O 0 3.52735156639028e-08
the O 0 1.0117569360090783e-07
l O 0 5.746944680140587e-07
- O 0 4.6090886485217197e-07
type O 0 5.686570148100145e-07
Ca2 O 0 2.3530674297944643e-06
+ O 0 3.0657558909297222e-06
channel O 0 6.113477411417989e-06
. O 0 4.680171969084768e-06

Neither O 0 7.191664280981058e-06
the O 0 4.4447381242207484e-07
content O 0 2.0273741085929942e-07
nor O 0 2.5283128479713923e-07
the O 0 7.099656329501158e-08
activity O 0 2.3545798910618032e-07
of O 0 4.6740515813326056e-07
Na O 0 5.636935384245589e-06
+ O 0 2.2435087885241956e-06
/ O 0 2.6646125661500264e-06
K O 0 3.405300958547741e-06
+ O 0 1.2910456916870316e-06
ATPase O 0 1.8649078583621304e-06
and O 0 3.7001640862399654e-07
sarcoplasmic O 0 7.90609647083329e-06
reticulum O 0 5.411298388935393e-06
Ca2 O 0 1.6608048554189736e-06
+ O 0 1.075249087989505e-06
- O 0 5.963636340311496e-07
ATPase O 0 4.0479764606971003e-07
are O 0 1.1074626549145705e-08
affected O 0 1.8458141681776397e-08
by O 0 7.761968134900599e-08
DMPK O 0 0.1552893966436386
absence O 0 2.1926813133177347e-05
. O 0 7.202261713246116e-06

In O 0 8.533035043001291e-07
conclusion O 0 1.2025381010971614e-06
, O 0 6.174138178494104e-08
our O 0 2.849788494074801e-08
data O 0 6.485861803184889e-08
suggest O 0 6.97927475812321e-08
that O 0 1.5053492674610425e-08
DMPK O 0 0.0034316873643547297
is O 0 1.2902263257785762e-08
involved O 0 8.096051828943018e-09
in O 0 4.881628878905531e-09
modulating O 0 2.1150827933524852e-07
the O 0 1.7110043160073474e-08
initial O 0 2.5267478775958807e-08
events O 0 3.2502679658819034e-08
of O 0 3.438301021674306e-08
excitation O 0 1.4103101420914754e-05
- O 0 0.0002618680300656706
contraction O 0 1.6371160427297582e-06
coupling O 0 1.523584046481119e-06
in O 0 1.957918129846803e-07
skeletal O 0 0.0008854437037371099
muscle O 0 6.155998107715277e-06
. O 0 7.063308657961898e-07
. O 0 2.406012981737149e-06

Constitutional O 0 0.0004110643931198865
RB1 O 1 0.9987275004386902
- O 0 3.4937755117425695e-05
gene O 0 1.3726330507779494e-06
mutations O 0 6.393607350219099e-07
in O 0 3.575955886958582e-08
patients O 0 2.1184373366622822e-08
with O 0 2.0408398526683413e-08
isolated O 0 1.696885192359332e-06
unilateral B-Disease 0 6.105553438828792e-06
retinoblastoma I-Disease 1 0.9995104074478149
. O 0 3.0255687306635082e-05

In O 0 3.784209923196613e-07
most O 0 1.056256948572809e-07
patients O 0 5.504710642867394e-08
with O 0 7.299219006995372e-09
isolated O 0 5.527825805984321e-07
unilateral B-Disease 0 5.313412998475542e-07
retinoblastoma I-Disease 1 0.9999778270721436
, O 0 2.0944185052940156e-07
tumor B-Disease 0 4.022778011858463e-05
development O 0 7.702945481469214e-08
is O 0 3.1524236554503204e-09
initiated O 0 1.1688549683697147e-08
by O 0 3.996599495792452e-09
somatic O 0 1.3904246998208691e-06
inactivation O 0 7.629060974068125e-07
of O 0 3.8821152514856294e-08
both O 0 1.5969193967180217e-08
alleles O 0 9.164482861478973e-08
of O 0 1.151127051457479e-07
the O 0 1.0275442718921113e-06
RB1 O 0 0.0009990232065320015
gene O 0 3.5326818306202767e-06
. O 0 6.121166734374128e-06

However O 0 1.8831694887921913e-06
, O 0 9.315035498502766e-08
some O 0 1.907623925490043e-08
of O 0 1.7380779482323305e-08
these O 0 2.0444202775138365e-08
patients O 0 2.12726440906863e-08
can O 0 1.8591807204870747e-08
transmit O 0 2.527188917156309e-05
retinoblastoma B-Disease 1 0.9999926090240479
predisposition O 0 0.0007011563866399229
to O 0 8.703610632210257e-08
their O 0 2.777531449282833e-07
offspring O 0 2.1141879187780432e-05
. O 0 5.033286925026914e-06

To O 0 1.226125760922514e-07
determine O 0 2.1097964975069772e-07
the O 0 6.832936350065211e-08
frequency O 0 1.771798281424708e-07
and O 0 2.4555514954727187e-08
nature O 0 7.77975373011941e-08
of O 0 1.0828532737150454e-07
constitutional O 0 2.1782857402286027e-06
RB1 O 1 0.9982707500457764
- O 0 1.4847676084173145e-06
gene O 0 4.0675374179954815e-08
mutations O 0 3.039190232811961e-08
in O 0 6.360350468526121e-09
patients O 0 5.9856164469351825e-09
with O 0 3.6268399394856488e-09
isolated O 0 3.3829431345111516e-07
unilateral B-Disease 0 5.09120525293838e-07
retinoblastoma I-Disease 0 0.18908314406871796
, O 0 6.034865407400503e-08
we O 0 2.053208980612453e-08
analyzed O 0 8.151572927772577e-08
DNA O 0 1.8855583050481073e-07
from O 0 1.3082622274396272e-07
peripheral O 0 0.03692399337887764
blood O 0 6.078371370676905e-07
and O 0 6.857180778752081e-08
from O 0 3.623993336532294e-07
tumor B-Disease 0 0.00013501555076800287
tissue O 0 1.7165704775834456e-05
. O 0 3.928194473701296e-06

The O 0 1.8714749785431195e-06
analysis O 0 1.3362265463001677e-06
of O 0 1.5132304724829737e-06
tumors B-Disease 1 0.9999998807907104
from O 0 5.494027277563873e-07
54 O 0 5.484034204528143e-07
( O 0 6.984482325833596e-08
71 O 0 7.968165505189972e-08
% O 0 7.724053396884756e-09
) O 0 2.122901854306747e-09
of O 0 1.0791930016296192e-08
76 O 0 1.4479776666576072e-07
informative O 0 2.7164108473698434e-07
patients O 0 6.599658064487812e-08
showed O 0 1.1900611696091801e-07
loss O 0 2.389953692727431e-07
of O 0 2.2139680311283882e-07
constitutional O 0 5.822456387249986e-06
heterozygosity O 1 0.9999996423721313
( O 1 0.8581887483596802
LOH O 1 1.0
) O 0 9.189572551804304e-07
at O 0 1.4992193655416486e-06
intragenic O 0 6.150814442662522e-05
loci O 0 2.0709467207780108e-05
. O 0 6.584025413758354e-06

Three O 0 5.604665147984633e-06
of O 0 3.072306071771891e-06
13 O 0 6.6134957705799025e-06
uninformative O 0 0.01159235741943121
patients O 0 1.1412415688027977e-06
had O 0 4.196566862901818e-07
constitutional O 0 3.07729692394787e-06
deletions O 0 5.619943476631306e-05
. O 0 1.1019338671758305e-05

For O 0 4.429214186529862e-06
39 O 0 8.003890798136126e-06
randomly O 0 1.2239077022968559e-06
selected O 0 5.26885514773312e-06
tumors B-Disease 1 0.9999998807907104
, O 0 8.996175324682554e-07
SSCP O 1 0.9993492960929871
, O 0 1.045197905114037e-06
hetero O 0 1.0388834198238328e-05
- O 0 1.4431583394980407e-06
duplex O 0 6.593781449737435e-07
analysis O 0 5.252691792634323e-08
, O 0 7.016926595326822e-09
sequencing O 0 3.044231888793547e-08
, O 0 7.228629694822075e-09
and O 0 1.0266666627956056e-08
Southern O 0 6.386440531969129e-08
blot O 0 3.3737865123839583e-07
analysis O 0 3.99484108015713e-08
were O 0 2.843989221901211e-08
used O 0 2.6868683278280514e-08
to O 0 3.993606512153747e-08
identify O 0 2.413424226688221e-06
mutations O 0 8.87528858584119e-06
. O 0 1.2543410775833763e-05

Mutations O 0 9.602767022443004e-06
were O 0 6.728232619934715e-07
detected O 0 6.204903115758498e-07
in O 0 5.740251296515453e-08
21 O 0 4.0953216284833616e-07
( O 0 3.825560668246908e-08
91 O 0 1.0307915232488085e-07
% O 0 5.47304956910466e-09
) O 0 2.70834310533985e-09
of O 0 1.963764972856552e-08
23 O 0 6.126422704255674e-06
tumors B-Disease 1 1.0
with O 0 0.0002711566921789199
LOH O 1 1.0
. O 0 8.692383562447503e-05

In O 0 3.3483406696177553e-06
6 O 0 6.1347718656179495e-06
( O 0 1.9855423261105898e-07
38 O 0 5.588320846072747e-07
% O 0 1.02273816082743e-08
) O 0 3.0635158854153133e-09
of O 0 1.5887712478956928e-08
16 O 0 9.635806463847985e-07
tumors B-Disease 1 1.0
without O 0 0.013132895343005657
LOH O 1 1.0
, O 0 3.9527602524458416e-08
one O 0 6.54224141527493e-09
mutation O 0 6.961975440589185e-09
was O 0 9.394772959581132e-09
detected O 0 9.793196475982313e-09
, O 0 2.9498992137888536e-09
and O 0 5.2146664764052275e-09
in O 0 1.062121324224563e-08
9 O 0 1.9845654719574668e-07
( O 0 1.077194156096084e-08
56 O 0 2.7169487992750874e-08
% O 0 3.1347358042665974e-09
) O 0 6.205892466581986e-10
of O 0 2.951227484615515e-09
the O 0 9.116364907413299e-08
tumors B-Disease 1 1.0
without O 0 0.27337294816970825
LOH O 1 1.0
, O 0 1.0064178468383034e-07
both O 0 4.526980745822584e-08
mutations O 0 1.0683552176260491e-07
were O 0 1.3274204491153796e-07
found O 0 5.218171281740069e-07
. O 0 3.7569600408460246e-06

Thus O 0 2.2215660919755464e-06
, O 0 5.591664020698772e-08
a O 0 1.5825380117462373e-08
total O 0 1.2377682878650376e-08
of O 0 1.144442851597205e-08
45 O 0 3.128197434421054e-08
mutations O 0 3.458717756643637e-08
were O 0 4.671021258673136e-08
identified O 0 2.1890700452331657e-07
in O 0 6.986760325844443e-08
tumors B-Disease 1 1.0
of O 0 3.554387603799114e-06
36 O 0 9.030007277033292e-06
patients O 0 6.628849860135233e-07
. O 0 2.639719468788826e-06

Thirty O 0 3.990392360719852e-05
- O 0 3.5341913644515444e-06
nine O 0 4.7619684551136743e-07
of O 0 7.541014923617695e-08
the O 0 5.300093164350983e-08
mutations O 0 2.181910616627647e-07
- O 0 6.560637757502263e-07
including O 0 7.564885606825555e-08
34 O 0 2.2893676998592127e-07
small O 0 5.662262125838424e-08
mutations O 0 6.294146714935778e-08
, O 0 1.709119068493692e-08
2 O 0 1.3212570593168493e-07
large O 0 3.712899143692994e-08
structural O 0 2.2459246906691988e-07
alterations O 0 7.336803378166223e-07
, O 0 5.293526328387088e-08
and O 0 7.894976050693003e-08
hypermethylation O 0 4.745334081235342e-05
in O 0 2.7368989208298444e-07
3 O 0 1.0267086508974899e-05
tumors O 1 1.0
- O 0 1.1603340226429282e-06
were O 0 3.504216650185299e-08
not O 0 4.438360790004481e-09
detected O 0 3.479746268908457e-08
in O 0 6.300739485709528e-09
the O 0 2.818140387716994e-08
corresponding O 0 5.417104489424673e-07
peripheral O 0 0.0004077878256794065
blood O 0 3.6793046547245467e-06
DNA O 0 1.493698528065579e-05
. O 0 6.31236434855964e-06

In O 0 2.852986426660209e-06
6 O 0 8.05431955086533e-06
( O 0 2.0059550820406002e-07
17 O 0 2.4111298557727423e-07
% O 0 4.195692238084803e-09
) O 0 4.942119491424535e-10
of O 0 1.586956233090575e-09
the O 0 4.2045367187881766e-09
36 O 0 3.7201086655613835e-08
patients O 0 3.2671596539302072e-09
, O 0 1.0031091512985313e-09
a O 0 2.319451297694286e-09
mutation O 0 6.147273801104802e-09
was O 0 7.222937359330217e-09
detected O 0 4.8580917066942675e-09
in O 0 8.58695670125087e-10
constitutional O 0 9.515456866893146e-09
DNA O 0 6.655137951838697e-08
, O 0 9.004448742189197e-09
and O 0 5.5776863128187415e-09
1 O 0 3.067505360832001e-08
of O 0 4.60709959071437e-09
these O 0 3.6914733492210416e-09
mutations O 0 1.2115978442750475e-08
is O 0 3.0504203607506497e-09
known O 0 3.4266718351716463e-09
to O 0 4.447783918948289e-09
be O 0 1.2061978083011127e-08
associated O 0 1.801239761789475e-07
with O 0 1.203250121761812e-07
reduced O 0 2.874052370316349e-06
expressivity O 0 8.279126632260159e-05
. O 0 1.1778553016483784e-05

The O 0 1.1018329360013013e-06
presence O 0 3.7592323565149854e-07
of O 0 9.075629492372173e-08
a O 0 3.9949402008687684e-08
constitutional O 0 2.211621392689267e-07
mutation O 0 4.843337464421893e-08
was O 0 2.8750116953801808e-08
not O 0 1.908245339521386e-09
associated O 0 6.506079675006049e-09
with O 0 8.97628749108037e-10
an O 0 2.8233844151515086e-09
early O 0 7.073704466620256e-08
age O 0 1.6063613372807595e-07
at O 0 1.276964809449055e-07
treatment O 0 7.685310947636026e-07
. O 0 2.249164253953495e-06

In O 0 1.0623076605043025e-06
1 O 0 2.2240824364416767e-06
patient O 0 4.1703395936565357e-07
, O 0 1.614265556781902e-07
somatic O 1 0.5690771341323853
mosaicism O 1 0.9996756315231323
was O 0 3.0813183116151777e-07
demonstrated O 0 2.1539456440677895e-08
by O 0 3.422060634861168e-09
molecular O 0 2.1669835703619356e-08
analysis O 0 8.493024061806409e-09
of O 0 6.541043706675964e-09
DNA O 0 6.265078411615832e-08
and O 0 2.567733048408627e-08
RNA O 0 1.4969222092986456e-06
from O 0 8.709569669917983e-07
peripheral O 0 0.14043162763118744
blood O 0 1.1869687114085536e-05
. O 0 6.221255262062186e-06

In O 0 1.2379875897750026e-06
2 O 0 2.3390414298773976e-06
patients O 0 4.666693342869621e-08
without O 0 1.4844155238336043e-08
a O 0 1.1085996121096287e-08
detectable O 0 4.1059979594137985e-07
mutation O 0 2.4967148348764567e-08
in O 0 1.4189756925020447e-08
peripheral O 0 0.0185315553098917
blood O 0 1.9079316189163364e-06
, O 0 5.190149821032719e-08
mosaicism O 0 0.020464317873120308
was O 0 6.578405731261228e-08
suggested O 0 1.1214215334121036e-08
because O 0 3.027507355923831e-09
1 O 0 4.7903725430842314e-08
of O 0 6.721932344078141e-09
the O 0 2.55167034168835e-08
patients O 0 2.434018426811235e-07
showed O 0 6.466397280746605e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.3139464272171608e-07
the O 0 6.160833976309732e-08
other O 0 3.964523997979086e-08
later O 0 1.868538106464257e-07
developed O 0 2.663227860466577e-07
bilateral B-Disease 0 1.4469963389274199e-05
retinoblastoma I-Disease 0 0.0007785613997839391
. O 0 1.3788750038656872e-05

In O 0 6.499224127765046e-07
conclusion O 0 1.1356751201674342e-06
, O 0 1.028315210760411e-07
our O 0 5.741861386354685e-08
results O 0 5.4525781223446756e-08
emphasize O 0 1.8459097361755994e-07
that O 0 5.329365837525302e-09
the O 0 2.1275969430689656e-08
manifestation O 0 1.1318595625198213e-06
and O 0 2.517823460834734e-08
transmissibility O 0 6.515776931337314e-06
of O 0 9.677665957497084e-08
retinoblastoma B-Disease 0 2.6849581900023622e-06
depend O 0 7.333257912023328e-08
on O 0 3.065832387960654e-08
the O 0 7.033569282555163e-09
nature O 0 1.400137517038047e-08
of O 0 6.528430684937803e-09
the O 0 7.721800088233977e-09
first O 0 8.211148205816698e-09
mutation O 0 5.236244771111842e-09
, O 0 2.406958188316821e-09
its O 0 1.3072584126305742e-09
time O 0 2.5469331088601166e-09
in O 0 2.523418363153951e-09
development O 0 1.9637726111909615e-08
, O 0 2.4408737253622803e-09
and O 0 1.976510288770328e-09
the O 0 2.9291995495839274e-09
number O 0 5.087450460905529e-09
and O 0 2.650604846721194e-09
types O 0 4.507010231691311e-08
of O 0 1.7065163504526026e-08
cells O 0 2.866448056693116e-08
that O 0 5.167467342914733e-09
are O 0 1.0277619644227798e-08
affected O 0 1.2002976745861815e-07
. O 0 2.3385480574233952e-07
. O 0 2.306879650859628e-06

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.995301365852356
the I-Disease 0 2.8455808205762878e-05
fifth I-Disease 0 1.2700915249297395e-05
component I-Disease 0 1.09431186956499e-06
of I-Disease 0 4.838674527718467e-08
complement I-Disease 0 1.857221434420353e-07
in O 0 1.862510430328257e-07
man O 0 1.0957009180856403e-05
. O 0 7.3245037128799595e-06

I O 0 0.00446954695507884
. O 0 0.00031478292657993734

Clinical O 0 7.664791337447241e-05
, O 0 2.417089035589015e-06
immunochemical O 0 0.0008718406897969544
, O 0 7.006871101111756e-07
and O 0 2.7446645844975137e-07
family O 0 1.3949947970104404e-06
studies O 0 2.7013697945221793e-06
. O 0 3.4888723803305766e-06

The O 0 7.88023783115932e-07
first O 0 1.9582093102599174e-07
recognized O 0 3.4277920235581405e-07
human O 0 2.7631222110358067e-07
kindred O 0 0.04660438373684883
with O 0 1.663374433746867e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999969005584717
the I-Disease 0 0.0002835633640643209
fifth I-Disease 0 1.796361721062567e-05
component I-Disease 0 3.816185483174195e-07
of I-Disease 0 1.9990302746464295e-07
complement I-Disease 0 1.6076255633379333e-06
( O 0 1.934627334776451e-06
C5 O 1 0.9999709129333496
) O 0 1.3251842290173954e-07
is O 0 5.046678452913511e-08
described O 0 1.2625538374777534e-06
. O 0 4.602474291459657e-06

The O 0 1.1504488611535635e-05
proband O 0 9.251644951291382e-05
, O 0 4.787942771145026e-07
a O 0 2.590796555068664e-07
20 O 0 5.163692549103871e-07
- O 0 3.2030590091380873e-07
year O 0 6.914535788382636e-08
- O 0 2.9928514777566306e-07
old O 0 6.88190482378559e-07
black O 0 2.457173309267091e-07
female O 0 7.64340839509714e-08
with O 0 8.94611034141235e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.023509858176112175
age O 0 1.5571404219372198e-05
11 O 0 4.797221322405676e-07
, O 0 3.269181192422366e-08
lacked O 0 1.77175377302774e-06
serum O 0 2.5342178560094908e-06
hemolytic O 0 0.25188252329826355
complement O 0 1.203698047902435e-06
activity O 0 3.731027220510441e-07
, O 0 5.2861203414522606e-08
even O 0 5.454782936453739e-08
during O 0 2.533234066959267e-07
remission O 0 3.042373691641842e-06
. O 0 1.83991994617827e-06

C5 O 1 0.9998284578323364
was O 0 2.4145654606400058e-05
undetectable O 0 1.3303292689670343e-05
in O 0 1.8705135573782172e-07
her O 0 1.1082110518145782e-07
serum O 0 3.1001206934888614e-07
by O 0 2.8634696391804937e-08
both O 0 2.1613435308154294e-07
immunodiffusion O 0 0.001675834646448493
and O 0 1.4024354868524824e-06
hemolytic O 1 0.999890923500061
assays O 0 7.583545084344223e-05
. O 0 4.934988101013005e-05

Other O 0 7.182850936260365e-07
complement O 0 4.571877241232869e-07
components O 0 4.732770548798726e-07
were O 0 1.0186735721617879e-07
normal O 0 7.43414858561664e-08
during O 0 5.515767398378557e-08
remission O 0 7.214505899355572e-07
of O 0 2.5832221695054614e-07
lupus O 0 0.008123332634568214
, O 0 2.662636120476236e-07
but O 0 1.7586572198524664e-07
C1 O 0 6.407014734577388e-05
, O 0 4.4478761651589593e-07
C4 O 0 0.061444468796253204
, O 0 1.7087482717670355e-07
C2 O 0 4.698772045230726e-06
, O 0 1.468090715661674e-07
and O 0 3.74784889345392e-07
C3 O 1 0.9997908473014832
levels O 0 2.839728722392465e-06
fell O 0 2.5427090804441832e-05
during O 0 1.246763531526085e-06
exacerbations O 0 0.000171428473549895
. O 0 1.41711989272153e-05

A O 0 1.1557437574083451e-05
younger O 0 6.891493740113219e-06
half O 0 8.887687954484136e-07
- O 0 1.2508257896115538e-06
sister O 0 7.445329401889467e-07
, O 0 5.466083763394636e-08
who O 0 3.2503916003179256e-08
had O 0 6.12613746397983e-08
no O 0 1.8750823471691547e-07
underlying O 1 0.8586751818656921
disease O 1 0.9980031847953796
, O 0 2.3142469274262112e-08
was O 0 8.33455828797014e-08
also O 0 5.368481659218105e-09
found O 0 9.012008916897685e-09
to O 0 2.6802194241781763e-08
lack O 0 8.190172593458556e-06
immunochemically O 1 0.9998204112052917
detectable O 1 0.968575656414032
C5 O 1 0.9995338916778564
. O 0 1.1308138709864579e-05

By O 0 7.285011633939575e-06
hemolytic O 1 0.7184817790985107
assay O 0 2.1939384168945253e-05
, O 0 1.037595438901917e-06
she O 0 1.745144260212328e-07
exhibited O 0 4.3388578774283815e-07
1 O 0 4.1206058654097433e-07
- O 0 1.2848757080519135e-07
2 O 0 6.3624035817611e-08
% O 0 2.723687497763194e-09
of O 0 3.0683344753867914e-09
the O 0 9.533078326739997e-09
normal O 0 4.169256939690058e-08
serum O 0 4.0008083601605904e-07
C5 O 0 7.215279038064182e-05
level O 0 1.1610131878114771e-07
and O 0 7.258416534483558e-09
normal O 0 1.664170135029508e-08
concentrations O 0 1.6722800921797898e-07
of O 0 2.4940353782199054e-08
other O 0 3.362819356311775e-08
complement O 0 5.574891019932693e-07
components O 0 3.051489102290361e-06
. O 0 3.162928351230221e-06

C5 O 0 0.008894848637282848
levels O 0 5.97430982907099e-07
of O 0 4.0424474434530566e-08
other O 0 8.708637366794392e-09
family O 0 8.406110474368234e-09
members O 0 2.238116580954852e-09
were O 0 5.752227583144531e-09
either O 0 6.15255224545308e-09
normal O 0 7.578602634339404e-09
or O 0 3.0662985484042338e-09
approximately O 0 3.91293397683512e-09
half O 0 7.877885010998398e-09
- O 0 2.1372201786107325e-08
normal O 0 1.6138677949584235e-08
, O 0 4.6073194148732455e-09
consistent O 0 2.714669733450137e-08
with O 0 4.777841233760682e-09
autosomal O 0 4.4595901727007004e-07
codominant O 0 4.287227056920528e-06
inheritance O 0 1.4651213575689326e-07
of O 0 4.0464431805276035e-08
the O 0 6.50435794113946e-08
gene O 0 1.4441467328651925e-06
determining O 0 0.00034216619678772986
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.347791425767355e-05

Normal O 0 7.297399861272424e-05
hemolytic O 1 0.9999651908874512
titers O 0 0.000299145671306178
were O 0 8.457648732473899e-07
restored O 0 7.257858669618145e-07
to O 0 3.030166340067808e-08
both O 0 3.237479120343778e-07
homozygous O 0 2.4850598492776044e-05
C5 B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
deficient I-Disease 1 1.0
( O 0 7.092197392921662e-06
C5D B-Disease 1 1.0
) O 0 4.7703860417414035e-08
sera O 0 2.574280415501562e-07
by O 0 3.889539801349429e-09
addition O 0 1.8009007618502437e-08
of O 0 5.647948952969273e-08
highly O 0 1.9122803962545731e-07
purified O 0 1.5363568763859803e-06
human O 0 2.5788754101085942e-06
C5 O 0 0.32479625940322876
. O 0 4.446575530892005e-06

In O 0 2.66729989562009e-06
specific O 0 8.035676728468388e-06
C5 O 0 0.2733491063117981
titrations O 0 2.5066095986403525e-05
, O 0 8.841582399554682e-08
however O 0 8.678380680748887e-08
, O 0 1.5287604071545502e-08
it O 0 6.014202913462441e-09
was O 0 4.837595213302848e-08
noted O 0 1.907813285129123e-08
that O 0 2.804160459390914e-09
when O 0 7.362377374420248e-09
limited O 0 1.0880514267341823e-08
amounts O 0 3.518777447197863e-08
of O 0 9.907883224968828e-08
C5 O 0 0.00012164623331045732
were O 0 9.813955870185964e-08
assayed O 0 4.0770021314529004e-07
in O 0 7.543413893529305e-09
the O 0 1.4351190458228302e-08
presence O 0 3.0009079665660465e-08
of O 0 5.288136861736348e-08
low O 0 2.2298092972050654e-07
dilutions O 0 3.5618763831735123e-06
of O 0 2.7122510459776095e-07
either O 0 3.4442330161255086e-06
C5D B-Disease 1 1.0
serum O 0 5.038300969317788e-06
, O 0 1.9137415563363902e-07
curving O 0 8.297971021420381e-07
rather O 0 2.0417781243509125e-08
than O 0 6.663098961467995e-09
linear O 0 5.356598720140937e-08
dose O 0 1.1523571430416268e-07
- O 0 1.0673470285382791e-07
response O 0 4.191183577972879e-08
plots O 0 2.050933716191139e-07
were O 0 7.29355846829094e-08
consistently O 0 6.685289832830676e-08
obtained O 0 4.6226908523294696e-08
, O 0 1.616581890573343e-08
suggesting O 0 4.40462102346828e-08
some O 0 3.143293270113645e-08
inhibitory O 0 1.8541186364018358e-06
effect O 0 1.5370104620160419e-06
. O 0 3.2854854907782283e-06

Further O 0 4.052822987432592e-06
studies O 0 5.623498964268947e-07
suggested O 0 1.021171414095079e-07
that O 0 1.7366927451689662e-08
low O 0 3.427965395985666e-07
dilutions O 0 2.376193879172206e-05
of O 0 1.955808784259716e-06
C5D B-Disease 1 1.0
serum O 0 9.179699986816559e-07
contain O 0 8.411936391894415e-08
a O 0 2.6802757346899853e-08
factor O 0 1.1375749409126001e-07
( O 0 7.706645099858633e-09
or O 0 4.894065153138172e-09
factors O 0 3.739237541822149e-08
) O 0 1.7378184447025546e-09
interfering O 0 4.696586675123626e-09
at O 0 2.6403517150441758e-09
some O 0 7.095412590807371e-10
step O 0 6.222773851760621e-09
in O 0 6.889559589495775e-09
the O 0 4.4117260955545134e-08
hemolytic O 0 1.311732194153592e-05
assay O 0 8.875474009073514e-07
of O 0 1.4399056453839876e-06
C5 O 1 0.9991357922554016
, O 0 4.252940399851468e-08
rather O 0 1.7896557125141044e-08
than O 0 1.3027737111315218e-08
a O 0 1.1714645609117724e-07
true O 0 2.8395013487170218e-06
C5 O 0 0.00024881178978830576
inhibitor O 0 6.615741767745931e-06
or O 0 2.970494961118675e-06
inactivator O 0 0.00016878564201761037
. O 0 1.390584384353133e-05

Of O 0 5.507669357029954e-06
clinical O 0 7.4946656241081655e-06
interest O 0 4.14113458191423e-07
are O 0 2.832242351757941e-08
( O 0 2.9844457571925886e-08
a O 0 1.757043754935239e-08
) O 0 4.780256634973057e-09
the O 0 6.936658802914053e-09
documentation O 0 5.733040211453044e-07
of O 0 6.505766236841737e-07
membranous O 1 0.9999997615814209
glomerulonephritis B-Disease 1 1.0
, O 0 7.544174422946526e-06
vasculitis B-Disease 1 1.0
, O 0 1.134670583269326e-06
and O 0 1.5037591765576508e-05
arthritis B-Disease 1 1.0
in O 0 1.3803581566662615e-07
an O 0 4.5050160935034e-08
individual O 0 1.0132710315247095e-07
lacking O 0 9.613184374757111e-05
C5 O 1 0.9998536109924316
( O 0 6.197901569748865e-08
and O 0 9.679655299521528e-09
its O 0 1.385106163098726e-08
biologic O 0 1.4740153346792795e-06
functions O 0 2.5616866849986764e-08
) O 0 5.7286655419375165e-09
, O 0 6.234642135893864e-09
and O 0 1.042410691098894e-08
( O 0 1.290078710525222e-08
b O 0 6.205590352692525e-08
) O 0 2.4841402268549473e-09
a O 0 3.0026467978672144e-09
remarkable O 0 1.6828012761038735e-08
propensity O 0 1.3198767589983618e-07
to O 0 1.7027220522436437e-08
bacterial B-Disease 1 0.9999972581863403
infections I-Disease 1 0.9999996423721313
in O 0 9.195680661377992e-09
the O 0 3.073431997790976e-08
proband O 0 2.6015914045274258e-06
, O 0 9.34904775817813e-09
even O 0 1.0012021434135931e-08
during O 0 1.542026595302559e-08
periods O 0 1.4386920099696e-07
of O 0 6.723050205437175e-08
low O 0 4.1337997913615254e-07
- O 0 1.8601886608848872e-07
dose O 0 1.0065790689850473e-07
or O 0 2.6412596554337142e-08
alternate O 0 6.588903715964989e-07
- O 0 1.6147349697348545e-06
day O 0 6.49664571028552e-07
corticosteroid O 0 1.991182580241002e-05
therapy O 0 4.610865289578214e-06
. O 0 5.683529252564767e-06

Other O 0 1.7109607597376453e-06
observations O 0 1.408527509738633e-06
indicate O 0 1.703885885717682e-07
that O 0 1.2751728561966047e-08
the O 0 1.373647648961196e-07
C5D B-Disease 1 1.0
state O 0 4.651408502809318e-08
is O 0 4.486312210616461e-09
compatible O 0 7.733919460406469e-08
with O 0 2.942543542161502e-09
normal O 0 3.153393635102475e-08
coagulation O 0 3.4623582223503035e-07
function O 0 7.047991967823464e-09
and O 0 6.7606475973036595e-09
the O 0 1.0448292009357374e-08
capacity O 0 3.6642013867549394e-08
to O 0 2.5166281503175014e-08
mount O 0 1.8858581825043075e-06
a O 0 1.02942249213811e-06
neutrophilic O 0 0.09675908088684082
leukocytosis O 0 0.00963609479367733
during O 0 4.931803687213687e-06
pyogenic B-Disease 0 0.0024666425306349993
infection I-Disease 0 3.3827152492449386e-06
. O 0 6.037462298991159e-07
. O 0 2.8292135993979173e-06

Susceptibility O 0 0.00011175916733918712
to O 0 1.2371092452667654e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 2.588408278825227e-06
twins O 0 1.149991567217512e-05
: O 0 2.6814621634230207e-08
the O 0 2.364518714159658e-08
role O 0 4.385876195556193e-08
of O 0 3.8072897723395727e-08
genes O 0 9.543087031715913e-08
, O 0 6.643735872557954e-08
HLA O 1 0.9999996423721313
, O 0 2.3736062360057986e-07
and O 0 9.281782809011929e-08
the O 0 6.555759455295629e-07
environment O 0 6.779173872928368e-06
. O 0 5.249949936114717e-06

OBJECTIVE O 0 1.8353777704760432e-05
To O 0 3.30313980612118e-08
determine O 0 9.50093337337421e-08
the O 0 2.6011342413312377e-08
relative O 0 2.2547816058704484e-07
effects O 0 2.5092833766393596e-07
of O 0 2.4017680289034615e-08
genetic O 0 3.632394509622827e-07
and O 0 2.725346703869036e-08
environmental O 0 1.7407727170848375e-07
factors O 0 9.331537853540794e-08
in O 0 1.704447605277437e-08
susceptibility O 0 9.36341393753537e-07
to O 0 1.1498228786877007e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.022694477811455727
AS B-Disease 1 1.0
) O 0 1.7653715076448862e-06
. O 0 2.8071376618754584e-06

METHODS O 0 1.617946327314712e-05
Twins O 0 7.977934728842229e-06
with O 0 1.255586852266788e-07
AS B-Disease 1 0.9997432827949524
were O 0 2.3129627990670087e-08
identified O 0 3.439009432781859e-08
from O 0 8.996861033949699e-09
the O 0 2.011657507239306e-08
Royal O 0 1.3052978147243266e-06
National O 0 4.3879281292902306e-06
Hospital O 0 0.04810225963592529
for O 0 2.7512658107298193e-07
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 0.9999996423721313
database O 0 6.012832818669267e-05
. O 0 9.367108759761322e-06

Clinical O 0 1.6569192666793242e-05
and O 0 3.8453350725831115e-07
radiographic O 0 7.639569048478734e-06
examinations O 0 9.383097108184302e-07
were O 0 1.0225201663160988e-07
performed O 0 2.167355539484106e-08
to O 0 5.16798026595211e-09
establish O 0 1.354147656229543e-07
diagnoses O 0 0.0022644924465566874
, O 0 7.962970016706095e-08
and O 0 8.256617434199143e-08
disease O 0 0.08785440027713776
severity O 0 1.6628127923468128e-05
was O 0 9.136818590604889e-08
assessed O 0 3.079886923273989e-08
using O 0 4.7339732134332735e-09
a O 0 4.270406250839187e-09
combination O 0 1.119498094226401e-08
of O 0 1.875510946547365e-08
validated O 0 3.2166568075808755e-07
scoring O 0 1.2244073559486424e-06
systems O 0 6.4192336139967665e-06
. O 0 8.255266948253848e-06

HLA O 0 0.028164895251393318
typing O 0 2.3464534024242312e-05
for O 0 4.694445578934392e-06
HLA O 1 0.5380845069885254
- O 0 0.0001953259197762236
B27 O 0 7.346457277890295e-05
, O 0 6.704162842652295e-07
HLA O 0 5.8096535212825984e-05
- O 0 7.62059153203154e-06
B60 O 0 8.97240806807531e-06
, O 0 1.2613850230991375e-07
and O 0 1.344365898603428e-07
HLA O 1 0.9622736573219299
- O 0 0.25623276829719543
DR1 O 1 0.9472556710243225
was O 0 2.6292650545656215e-07
performed O 0 2.343564098339357e-08
by O 0 5.003039316164859e-09
polymerase O 0 2.664912415184517e-07
chain O 0 9.426565128478614e-08
reaction O 0 2.270152066330411e-08
with O 0 6.386279505221637e-09
sequence O 0 9.023946034858454e-09
- O 0 5.932935920327509e-08
specific O 0 1.2834129314853726e-08
primers O 0 4.4863404013995023e-07
, O 0 2.016547995253859e-08
and O 0 3.013405702745331e-08
zygosity O 0 3.7088834687892813e-06
was O 0 2.007608514986714e-07
assessed O 0 7.270750757015776e-07
using O 0 5.245313445811917e-07
microsatellite O 0 3.501533865346573e-05
markers O 0 3.4138931368943304e-05
. O 0 1.4515903785650153e-05

Genetic O 0 4.492065727390582e-06
and O 0 1.4013791371780826e-07
environmental O 0 2.275562849263224e-07
variance O 0 5.662748137069684e-08
components O 0 1.1217856155099071e-07
were O 0 2.9055964745339224e-08
assessed O 0 4.405645981364614e-08
with O 0 2.895873985053754e-09
the O 0 1.9070091283879265e-08
program O 0 7.375969168776919e-09
Mx O 0 1.556949058567625e-07
, O 0 1.4513648061154072e-09
using O 0 9.214304874660684e-10
data O 0 5.05507635750746e-09
from O 0 2.8299838028544855e-09
this O 0 1.0150186247059878e-09
and O 0 4.058561486885992e-09
previous O 0 2.069087479128484e-08
studies O 0 5.194388918994264e-08
of O 0 6.775340466447233e-08
twins O 0 2.9448299301293446e-06
with O 0 4.825724886359239e-07
AS B-Disease 1 1.0
. O 0 2.0456960555748083e-05

RESULTS O 0 4.27442864747718e-05
Six O 0 5.414901806943817e-06
of O 0 3.188574282830814e-06
8 O 0 5.6624248827574775e-06
monozygotic O 0 5.497177698998712e-05
( O 0 1.6656459820296732e-06
MZ O 1 0.9977952241897583
) O 0 2.0800391098418913e-07
twin O 0 6.475812028838845e-07
pairs O 0 4.772520014739712e-07
were O 0 3.8298287563520717e-07
disease O 0 5.302107638271991e-06
concordant O 0 5.584918199019739e-06
, O 0 3.515329183301219e-08
compared O 0 1.4533434011809732e-08
with O 0 2.774971585850494e-09
4 O 0 6.53087326440982e-08
of O 0 4.473898584933522e-08
15 O 0 2.3987175268302963e-07
B27 O 0 5.005513230571523e-06
- O 0 1.6301892173942178e-06
positive O 0 3.1490034757553076e-07
dizygotic O 0 1.4922563423169777e-05
( O 0 6.465339765782119e-07
DZ O 0 5.9433572459965944e-05
) O 0 1.0848668097196423e-07
twin O 0 8.84913902154949e-07
pairs O 0 2.018638127765371e-07
( O 0 4.202534142905279e-08
27 O 0 9.607593653981894e-08
% O 0 3.426645633908265e-09
) O 0 8.910613358281694e-10
and O 0 3.1650699838792207e-09
4 O 0 1.689123330095299e-08
of O 0 2.1032509067708816e-08
32 O 0 5.186498697185016e-07
DZ O 0 0.0015492197126150131
twin O 0 2.146867927876883e-06
pairs O 0 9.361502861793269e-07
overall O 0 2.5278961857111426e-06
( O 0 1.9676009799241e-07
12 O 0 2.301916737224019e-07
. O 0 3.52421771765421e-08
5 O 0 3.5806112919090083e-07
% O 0 4.5837516893243446e-08
) O 0 5.570873540250432e-08
. O 0 4.849923698202474e-07

Nonsignificant O 0 0.00014022183313500136
increases O 0 8.76494709700637e-07
in O 0 2.796508091762462e-08
similarity O 0 6.987119860468738e-08
with O 0 4.447173740373955e-09
regard O 0 2.9502047027563094e-08
to O 0 2.974102075725682e-09
age O 0 1.8838346704797004e-07
at O 0 8.572809662155123e-08
disease O 0 1.0300716439815005e-06
onset O 0 5.212163500800671e-07
and O 0 2.004750587758508e-09
all O 0 1.3206915561170263e-09
of O 0 9.00547902915605e-09
the O 0 2.530620690777141e-08
disease O 0 3.232650840345741e-07
severity O 0 1.9478443391562905e-07
scores O 0 6.207472580399553e-08
assessed O 0 8.852433097672474e-08
were O 0 2.719167824238866e-08
noted O 0 4.495660022030279e-08
in O 0 4.050558999324494e-08
disease O 0 4.256359261489706e-06
- O 0 1.0918893167399801e-05
concordant O 0 0.008734742179512978
MZ O 1 0.9998360872268677
twins O 0 6.879142347315792e-06
compared O 0 3.170757736370433e-07
with O 0 2.6213183446088806e-07
concordant O 0 0.001767149195075035
DZ O 1 0.9999932050704956
twins O 0 0.0005079935654066503
. O 0 2.2833633920527063e-05

HLA O 1 0.9982441663742065
- O 0 0.0008520480478182435
B27 O 0 0.00011938287934754044
and O 0 2.3378321145628433e-07
B60 O 0 3.347619212945574e-06
were O 0 2.9200021955944067e-08
associated O 0 2.396935450121873e-08
with O 0 2.3511113056429167e-09
the O 0 3.425275352242352e-08
disease O 0 0.0002812199527397752
in O 0 4.736999237309192e-09
probands O 0 0.0002204721822636202
, O 0 2.7090665266626957e-09
and O 0 1.5456360635823785e-09
the O 0 3.479731169875322e-09
rate O 0 1.3817787802850034e-08
of O 0 2.5309633500114614e-08
disease O 0 2.2891123307999806e-07
concordance O 0 2.7908313882107905e-07
was O 0 3.049909835795006e-08
significantly O 0 3.072458909514353e-08
increased O 0 3.005788329346615e-08
among O 0 2.0889426366466068e-07
DZ O 0 0.00307610840536654
twin O 0 5.738750701311801e-07
pairs O 0 7.353033737445003e-08
in O 0 9.187020921785916e-09
which O 0 4.930126973334836e-09
the O 0 6.855402290284474e-08
co O 0 2.666018303898454e-07
- O 0 1.5247817373165162e-06
twin O 0 1.1842785170301795e-06
was O 0 1.275090681929214e-07
positive O 0 1.9903231063267413e-08
for O 0 2.4392461384081798e-08
both O 0 2.0098423192393966e-07
B27 O 0 7.848742825444788e-05
and O 0 3.5118225696351146e-06
DR1 O 1 0.7053993344306946
. O 0 8.898170563043095e-06

Additive O 0 8.764313861320261e-06
genetic O 0 2.9402724521787604e-06
effects O 0 1.2695543318841374e-06
were O 0 7.644997879197035e-08
estimated O 0 2.0035741954416153e-08
to O 0 1.1066032534756687e-08
contribute O 0 5.2761478741558676e-08
97 O 0 1.3397250597790844e-07
% O 0 4.632149774863592e-09
of O 0 6.66850263897345e-09
the O 0 1.9191967126630516e-08
population O 0 2.33818830963628e-08
variance O 0 6.869655635455274e-07
. O 0 2.7384467102820054e-06

CONCLUSION O 0 3.347494202898815e-05
Susceptibility O 0 1.0473338988958858e-05
to O 0 3.192397457496554e-07
AS B-Disease 1 0.9999996423721313
is O 0 2.5146944082621303e-08
largely O 0 3.55256304374052e-08
genetically O 0 2.686407185592543e-08
determined O 0 1.2298892571038778e-08
, O 0 6.546510444849218e-09
and O 0 3.0490356905943372e-09
the O 0 8.697200293283913e-09
environmental O 0 8.895525382968117e-08
trigger O 0 2.0148165447153588e-07
for O 0 1.7702232568694853e-08
the O 0 2.8557582254506997e-07
disease O 0 1.3532852790376637e-05
is O 0 8.223000236284861e-08
probably O 0 1.2762844789904193e-06
ubiquitous O 0 1.9675086150527932e-05
. O 0 7.333204848691821e-06

HLA O 1 0.9999408721923828
- O 0 0.002170235849916935
B27 O 0 4.314670150051825e-05
accounts O 0 1.8310838356683234e-07
for O 0 1.4784252932997788e-08
a O 0 1.7845156463636158e-08
minority O 0 1.1519897924472389e-08
of O 0 9.09021302675228e-09
the O 0 1.7835832366586146e-08
overall O 0 2.6552422127679165e-07
genetic O 0 3.450958843131957e-07
susceptibility O 0 6.56557631373289e-07
to O 0 2.5929517732947716e-07
AS B-Disease 1 1.0
. O 0 6.916804068168858e-06

Cell O 0 2.0717330698971637e-05
cycle O 0 2.9311961498024175e-06
- O 0 1.9654721654660534e-06
dependent O 0 5.973591896690778e-07
colocalization O 0 6.097139703342691e-06
of O 0 1.6713806871848647e-07
BARD1 O 1 0.9360328912734985
and O 0 8.405216078699596e-08
BRCA1 O 0 1.8985009830885247e-07
proteins O 0 1.9352381031012555e-08
in O 0 1.1836463365000327e-08
discrete O 0 2.0528494815152953e-07
nuclear O 0 3.851901055895723e-06
domains O 0 4.968701432517264e-06
. O 0 3.5806838241114747e-06

Germ O 0 0.13001208007335663
- O 0 0.00014999564155004919
line O 0 5.6620961004227865e-06
mutations O 0 5.346284979168558e-07
of O 0 1.9620993896296568e-07
the O 0 2.922822943673964e-07
BRCA1 O 0 2.3324657831835793e-06
gene O 0 4.772998067892331e-07
predispose O 0 0.04415008798241615
women O 0 1.798546662712397e-07
to O 0 1.783164904622936e-08
early O 0 7.0433902692457195e-06
- O 0 0.00010598952212603763
onset O 1 0.9999995231628418
breast B-Disease 1 1.0
and I-Disease 1 0.9999980926513672
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.1596660520751811e-08
compromising O 0 1.2018165307381423e-07
the O 0 1.0499474178971013e-08
genes O 0 3.432351292076419e-08
presumptive O 0 8.172150955942925e-07
function O 0 2.219451289420249e-08
as O 0 7.134202917313814e-08
a O 0 1.347270313090121e-07
tumor B-Disease 0 8.667429028719198e-06
suppressor O 0 0.00011538227408891544
. O 0 9.130682883551344e-06

Although O 0 8.266810596069263e-07
the O 0 2.951677515738993e-07
biochemical O 0 5.3623462008545175e-06
properties O 0 7.722303507762263e-07
of O 0 2.897417914482503e-07
BRCA1 O 0 7.135018904591561e-07
polypeptides O 0 3.022806822627899e-07
are O 0 5.740434350087753e-09
not O 0 4.692835009478813e-09
understood O 0 7.78725137706715e-08
, O 0 7.693016002008335e-09
their O 0 3.5634877271206733e-09
expression O 0 2.69866067270641e-08
pattern O 0 4.6083588500778205e-08
and O 0 1.1944848665734753e-08
subcellular O 0 4.456282738374284e-07
localization O 0 1.8387325440016866e-07
suggest O 0 2.647711205838732e-08
a O 0 2.7725183926463615e-08
role O 0 7.184715400399e-08
in O 0 3.468508324999675e-08
cell O 0 2.530315214244183e-06
- O 0 1.9735425667022355e-06
cycle O 0 7.630501386302058e-07
regulation O 0 3.4101205983461114e-06
. O 0 4.445884314918658e-06

When O 0 3.284423428340233e-06
resting O 0 2.916540324804373e-05
cells O 0 1.2894731753476663e-06
are O 0 3.2228648194632115e-08
induced O 0 1.381526288923851e-07
to O 0 8.701182885317849e-09
proliferate O 0 1.615243263586308e-07
, O 0 9.236850395666352e-09
the O 0 1.235838631430397e-08
steady O 0 7.528210232976562e-08
- O 0 1.6469920538497718e-08
state O 0 4.583950996561725e-09
levels O 0 8.983074728519114e-09
of O 0 1.613664579735996e-08
BRCA1 O 0 3.816778360032913e-08
increase O 0 4.621710125718437e-09
in O 0 9.924391086713058e-09
late O 0 5.614421638711065e-07
G1 O 0 1.5655148217774695e-06
and O 0 1.1007196043522072e-08
reach O 0 3.9318940991961426e-08
a O 0 2.8041620581120696e-08
maximum O 0 3.000627657456789e-07
during O 0 6.825719083281001e-07
S O 0 1.4950439435779117e-05
phase O 0 7.5881098382524215e-06
. O 0 9.134523679676931e-06

Moreover O 0 1.5640609490219504e-05
, O 0 7.458476716237783e-07
in O 0 2.4158759970305255e-07
S O 0 5.295275514072273e-06
phase O 0 1.1079696378146764e-06
cells O 0 1.010556957226072e-06
, O 0 1.1143939815383419e-07
BRCA1 O 0 5.315445719134004e-07
polypeptides O 0 5.84129963954183e-07
are O 0 4.5587807306901595e-08
hyperphosphorylated O 0 3.4052266073558712e-06
and O 0 7.371429688873832e-08
accumulate O 0 1.8266868551108928e-07
into O 0 1.0102431247105415e-07
discrete O 0 9.291929359278583e-07
subnuclear O 0 1.8072869352181442e-05
foci O 0 1.576781869516708e-05
termed O 0 4.286082457838347e-06
" O 0 1.879674300653278e-06
BRCA1 O 0 1.5489795259782113e-05
nuclear O 0 4.564974733511917e-05
dots O 0 8.223631448345259e-05
. O 0 1.280143260373734e-05

" O 0 5.033627530792728e-05
BRCA1 O 0 0.0001579583331476897
associates O 0 1.722927117953077e-05
in O 0 5.087482577437186e-07
vivo O 0 1.6039701904446702e-06
with O 0 4.5639136914132905e-08
a O 0 1.8677667412703158e-07
structurally O 0 5.182753739063628e-06
related O 0 2.235981355624972e-06
protein O 0 1.0113841199199669e-05
termed O 0 1.8469554561306722e-05
BARD1 O 0 0.4460480511188507
. O 0 2.113337177434005e-05

Here O 0 3.227957677154336e-06
we O 0 2.762373867426504e-07
show O 0 1.11571687000378e-07
that O 0 8.826498643088598e-09
the O 0 4.036198930634782e-08
steady O 0 6.857429184492503e-07
- O 0 1.1523044207706334e-07
state O 0 2.04068424380921e-08
levels O 0 5.658418800180698e-08
of O 0 3.0236016357321205e-08
BARD1 O 0 0.13064055144786835
, O 0 8.965289843843038e-09
unlike O 0 9.455209948328047e-09
those O 0 4.631611094652044e-09
of O 0 5.358233678975921e-08
BRCA1 O 0 4.0869252870834316e-07
, O 0 1.103208191466365e-08
remain O 0 3.295883743703598e-08
relatively O 0 1.9155248054403273e-08
constant O 0 3.7201086655613835e-08
during O 0 5.1839762704730674e-08
cell O 0 1.6724967508707778e-06
cycle O 0 9.068358508557139e-07
progression O 0 1.4382009794644546e-05
. O 0 4.328114300733432e-06

However O 0 6.738854608556721e-06
, O 0 6.599607331736479e-07
immunostaining O 0 6.939777813386172e-05
revealed O 0 9.498629651716328e-07
that O 0 5.6894243982696935e-08
BARD1 O 1 0.9875314831733704
resides O 0 1.230830093845725e-06
within O 0 2.80085941994912e-07
BRCA1 O 0 9.71685608419648e-07
nuclear O 0 1.1557464176803478e-06
dots O 0 6.375572070282942e-07
during O 0 8.10313025567666e-08
S O 0 3.3810886179708177e-07
phase O 0 5.010108594660778e-08
of O 0 1.4485170396483227e-08
the O 0 1.2682332517499617e-08
cell O 0 8.234803772211308e-08
cycle O 0 1.5773307993072194e-08
, O 0 2.2580808334282665e-09
but O 0 1.291365570033065e-09
not O 0 3.6698368788279367e-09
during O 0 6.180441403103032e-08
the O 0 1.9507720594447164e-07
G1 O 0 1.70759030879708e-05
phase O 0 5.70180327486014e-06
. O 0 6.825206128269201e-06

Nevertheless O 0 5.061646515969187e-05
, O 0 2.8163997285446385e-06
BARD1 O 0 0.00020408247655723244
polypeptides O 0 3.4234706163260853e-06
are O 0 5.3244203712665694e-08
found O 0 2.01082901440941e-08
exclusively O 0 2.4202270410000892e-08
in O 0 1.9953927399285476e-09
the O 0 1.2129874882305103e-08
nuclear O 0 1.3653776420596841e-07
fractions O 0 1.3093244888295885e-07
of O 0 5.6670916848133857e-08
both O 0 1.3287250055782351e-07
G1 O 0 8.93889409780968e-06
- O 0 1.81960297140904e-06
and O 0 2.480274190475029e-07
S O 0 8.8293299995712e-06
- O 0 2.9288516998349223e-06
phase O 0 3.1416143428941723e-06
cells O 0 4.810314749192912e-06
. O 0 3.6023509437654866e-06

Therefore O 0 9.76822957454715e-06
, O 0 5.739998982789984e-07
progression O 0 1.8667727772481157e-06
to O 0 5.93276645588503e-08
S O 0 1.1524366527737584e-06
phase O 0 1.4960245664497052e-07
is O 0 6.9479271225247885e-09
accompanied O 0 3.2255954351967375e-08
by O 0 3.2431386465248124e-09
the O 0 1.5243754702964907e-08
aggregation O 0 1.6496856858339015e-07
of O 0 1.1398858390521127e-07
nuclear O 0 3.824032773991348e-06
BARD1 O 0 0.0006840216810815036
polypeptides O 0 3.996726263721939e-06
into O 0 1.3962353477836587e-06
BRCA1 O 0 7.671108505746815e-06
nuclear O 0 2.1190260667935945e-05
dots O 0 2.5952429496101104e-05
. O 0 9.94674519461114e-06

This O 0 1.4913534869265277e-06
cell O 0 7.475057827832643e-06
cycle O 0 1.6306013321809587e-06
- O 0 1.567014578540693e-06
dependent O 0 5.668491098731465e-07
colocalization O 0 5.44931981494301e-06
of O 0 2.5735266717674676e-07
BARD1 O 1 0.9519632458686829
and O 0 1.2514446723344008e-07
BRCA1 O 0 6.636300895479508e-07
indicates O 0 1.242956955138652e-07
a O 0 2.731794701560375e-08
role O 0 1.2100878166165785e-07
for O 0 1.1945468259000336e-07
BARD1 O 1 0.9998701810836792
in O 0 5.619188527816732e-07
BRCA1 O 0 2.3367061658063903e-05
- O 0 0.0002784208918455988
mediated O 0 0.0003681248635984957
tumor B-Disease 0 0.0004591503238771111
suppression O 0 0.00014058116357773542
. O 0 1.8496632037567906e-05

Ethnic O 0 2.3067867005011067e-05
differences O 0 1.0849712452909444e-05
in O 0 4.833186153518909e-07
the O 0 1.3916171610617312e-06
HFE O 0 0.0005784265813417733
codon O 0 2.5374936740263365e-05
282 O 0 2.0654128093156032e-05
( O 0 5.951255843683612e-06
Cys O 0 0.0016826806822791696
/ O 0 0.00013296506949700415
Tyr O 0 0.00012036717816954479
) O 0 6.726385208821739e-07
polymorphism O 0 5.055559995525982e-06
. O 0 3.7841084576939465e-06

Recent O 0 1.2715354387182742e-06
studies O 0 2.950427813175338e-07
have O 0 1.4442575135831248e-08
shown O 0 3.7744200653833104e-08
that O 0 8.216133551286475e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9999998807907104
HH B-Disease 1 1.0
) O 0 6.834878263362043e-08
is O 0 2.1145245554521352e-09
likely O 0 3.557097283390931e-09
to O 0 2.39896502662873e-09
be O 0 5.172970496403195e-09
caused O 0 4.046960455639237e-08
by O 0 1.4505076251225546e-08
homozygosity O 0 2.13269754567591e-06
for O 0 1.0228435876058484e-08
a O 0 2.0422456614710427e-08
Cys282Tyr O 0 7.934518180263694e-07
mutation O 0 2.07181223288444e-08
in O 0 1.623661205485405e-08
the O 0 3.2968935670396604e-07
HFE O 0 0.0004944257088936865
gene O 0 3.09362803818658e-06
located O 0 4.540095687843859e-06
4 O 0 3.1350298286270117e-06
. O 0 3.1090846732695354e-06

5 O 0 0.00015997902664821595
Mb O 0 0.00023990658519323915
telomeric O 0 0.00032724905759096146
to O 0 5.982838956697378e-06
HLA O 1 0.9929015040397644
- O 0 0.0005199118168093264
A O 0 5.170691292732954e-05
. O 0 1.6318710549967363e-05

Population O 0 7.45640761579125e-07
studies O 0 1.5474013537186693e-07
of O 0 2.086071404505674e-08
this O 0 1.6179104722624515e-09
polymorphism O 0 4.636642714217487e-08
are O 0 4.624223226556978e-09
facilitated O 0 5.296071137195213e-08
by O 0 2.7488797904595685e-09
the O 0 8.010326624230402e-09
fact O 0 8.349893221293314e-09
that O 0 3.483290766936875e-09
the O 0 5.401175329211583e-08
Cys282Tyr O 0 4.472086857276736e-06
mutation O 0 1.1147384526566384e-07
creates O 0 2.7390584023123665e-07
a O 0 3.5153837529833254e-07
Rsal O 0 1.2012901606794912e-05
restriction O 0 2.473662561897072e-06
site O 0 8.942458407545928e-06
. O 0 8.170185537892394e-06

We O 0 1.7738112774168258e-06
have O 0 2.976609891902626e-07
studied O 0 1.144178554568498e-06
the O 0 2.614420111513027e-07
codon O 0 3.5850437143380987e-06
282 O 0 7.145790732465684e-06
( O 0 1.4384975202119676e-06
Cys O 0 0.0008202606695704162
/ O 0 4.713942689704709e-05
Tyr O 0 1.7077727534342557e-05
) O 0 2.0440733550231016e-08
polymorphism O 0 5.182454287933069e-08
in O 0 6.060957069564665e-09
different O 0 6.001185770543316e-09
ethnic O 0 7.111786004543319e-08
groups O 0 1.0454835575046673e-07
. O 0 5.767951734014787e-07

In O 0 2.889117922677542e-07
agreement O 0 1.4354945676586794e-07
with O 0 2.1923600712625557e-08
previous O 0 7.775081201089051e-08
observations O 0 1.606031929668461e-07
the O 0 5.5584134628361426e-08
Tyr O 0 2.912832314905245e-06
allele O 0 1.9244004079155275e-07
appeared O 0 5.706236549940513e-08
to O 0 3.3302520741074204e-09
be O 0 6.771333271871072e-09
rare O 0 3.175253837639502e-08
or O 0 2.800858744933521e-08
absent O 0 3.040976537249662e-07
in O 0 1.9819585972413734e-08
Asiatic O 0 2.540851028243196e-06
( O 0 1.1392463861170654e-08
Indian O 0 2.063869075641378e-08
, O 0 1.488376177860573e-08
Chinese O 0 1.8971816473367653e-07
) O 0 4.0722259342373945e-08
populations O 0 2.019312148604513e-07
. O 0 1.6848862287588418e-06

The O 0 2.2669989903079113e-06
highest O 0 6.690889335914108e-07
allele O 0 4.861644811171573e-07
frequency O 0 2.3274856175703462e-07
( O 0 4.0738729722988865e-08
7 O 0 5.616976750388858e-08
. O 0 6.596999835295492e-09
5 O 0 2.1970610220023445e-08
% O 0 2.3443587071625416e-09
) O 0 5.729208774063466e-10
was O 0 2.9350939456662672e-09
found O 0 3.2650355752394944e-09
in O 0 1.56497215186846e-08
Swedes O 0 4.1731109376996756e-06
. O 0 5.440923359856242e-06

Saamis O 0 0.001011016545817256
( O 0 4.3705131247406825e-06
2 O 0 2.316240170330275e-06
% O 0 7.763507881008991e-08
) O 0 1.0946124895383491e-08
and O 0 1.9389105432310316e-08
Mordvinians O 0 2.4712953745620325e-06
( O 0 5.1686932067696034e-08
1 O 0 8.320787259208373e-08
. O 0 6.838213550963701e-09
8 O 0 3.28611662325784e-08
% O 0 2.854465330770495e-09
) O 0 5.471866848516527e-10
had O 0 2.2409059052819202e-09
significantly O 0 1.067926902464933e-08
lower O 0 1.3918513452892967e-08
frequencies O 0 4.3414150496801085e-08
of O 0 3.3229184737137984e-08
the O 0 6.198699793458218e-07
Tyr O 0 5.449503078125417e-05
allele O 0 1.2951909411640372e-05
. O 0 1.0652197488525417e-05

Comparisons O 0 4.3814720811496954e-06
with O 0 1.1304910429998927e-07
allele O 0 2.726761749727302e-07
frequencies O 0 1.208609319292009e-07
based O 0 5.3943189470828656e-08
on O 0 3.6175908491031805e-08
prevalence O 0 1.9406002138566691e-07
estimates O 0 1.4389431157724175e-07
of O 0 1.3060956405297475e-07
HH B-Disease 1 0.9999998807907104
showed O 0 3.8035196325836296e-07
some O 0 2.6851777690239942e-08
disagreements O 0 2.9567007686637226e-07
with O 0 8.749345248304508e-09
the O 0 2.8920611683247444e-08
RFLP O 0 5.229410362517228e-07
data O 0 1.121276511639735e-07
, O 0 1.8805689450118734e-08
particularly O 0 1.1109474939985375e-07
in O 0 1.7187339551583136e-07
Finns O 0 1.9979444914497435e-05
. O 0 5.631551175611094e-06

The O 0 1.1740088666556403e-05
newly O 0 3.182451837346889e-05
described O 0 6.517871497635497e-06
HFE O 1 0.9913423657417297
marker O 0 9.977859008358791e-06
provides O 0 1.6049646944793494e-07
a O 0 1.9020470531927458e-08
new O 0 1.129488502726872e-08
approach O 0 1.68487908069892e-08
to O 0 3.965346717649254e-09
the O 0 1.3520064179317615e-08
screening O 0 2.8795172468676355e-08
of O 0 8.080165514456894e-08
HH B-Disease 1 0.9999674558639526
as O 0 6.642861194450234e-08
well O 0 8.375765858659179e-09
as O 0 5.42811751103045e-09
studies O 0 7.306085958447284e-09
of O 0 3.951303728655375e-09
the O 0 2.2790544562667492e-08
relationship O 0 3.0372081738505585e-08
between O 0 1.9286444796762225e-07
the O 0 9.966219067791826e-07
HFE O 1 0.9982289671897888
Tyr O 0 2.5148221538984217e-05
allele O 0 4.895730398857268e-07
and O 0 9.610158713257988e-08
different O 0 7.810797910678957e-07
disorders O 1 0.9999995231628418
including O 0 0.03530602157115936
cancer B-Disease 1 0.9999996423721313

Autosomal B-Disease 1 0.9999538660049438
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 0 0.0004676693642977625
associated O 0 1.8904233911598567e-07
with O 0 1.4587812735555872e-08
a O 0 4.2020936064091075e-08
missense O 0 5.259253725853341e-07
mutation O 0 6.77636151635852e-08
encoding O 0 6.039288109604968e-07
Gly23 O 0 1.6931195204961114e-05
- O 0 7.08024890627712e-06
- O 0 5.7818915593088605e-06
> O 0 3.836847554339329e-06
Val O 0 3.6078999983146787e-06
in O 0 4.409488383316784e-07
neurophysin O 0 0.00017308983660768718
II O 1 0.9999979734420776
. O 0 2.5443052436457947e-05

Autosomal B-Disease 1 0.9996662139892578
dominant I-Disease 1 0.9999995231628418
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 2.8176812065794365e-06
ADNDI B-Disease 1 1.0
) O 0 2.785998631793518e-08
is O 0 2.9035784887554428e-09
an O 0 1.3558334899244073e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 6.210243554960471e-07
by O 0 9.507926890250928e-09
progressive O 1 0.9961258769035339
degeneration O 1 1.0
of O 0 1.1894110230059596e-07
the O 0 5.8282790149633e-08
magnocellular O 0 2.994972965097986e-05
neurons O 0 8.395976465180865e-07
of O 0 1.0226722224615514e-07
the O 0 1.538226115371799e-07
hypothalamus O 0 4.633505341189448e-06
leading O 0 1.4588628118872293e-06
to O 0 1.2889227463119823e-08
decreased O 0 6.714118683248671e-08
ability O 0 4.026977418192246e-09
to O 0 8.572004439599823e-09
produce O 0 5.789908996689519e-08
the O 0 2.429760286304372e-07
hormone O 0 1.88117712696112e-06
arginine O 0 6.407404725905508e-06
vasopressin O 0 1.5508700016653165e-05
( O 0 2.6306172458134824e-06
AVP O 0 8.15860548755154e-05
) O 0 1.089001330001338e-06
. O 0 3.1424951885128394e-06

Affected O 0 1.8753447648123256e-06
individuals O 0 4.857779245526217e-08
are O 0 8.599744916182317e-09
not O 0 1.2389658188283192e-08
symptomatic O 0 4.3289757741149515e-05
at O 0 1.1307476910360492e-07
birth O 0 1.0256218985205123e-07
, O 0 1.511111236141005e-08
but O 0 2.1463094412865757e-08
usually O 0 1.2568435181492532e-07
develop O 0 2.7135056370752864e-06
diabetes B-Disease 1 0.9999955892562866
insipidus I-Disease 0 0.08116842806339264
at O 0 8.455349984615168e-07
1 O 0 1.5378652733488707e-06
- O 0 1.954473873411189e-06
6 O 0 2.3590284854435595e-06
yr O 0 9.66684729064582e-06
of O 0 4.255545320575038e-07
age O 0 3.16062460115063e-06
. O 0 5.58450801690924e-06

The O 0 1.60975787366624e-06
genetic O 0 3.924334123439621e-06
locus O 0 1.7977765764953801e-06
of O 0 1.71045854813201e-07
the O 0 2.5313360652035044e-07
disease O 0 0.00036572825047187507
is O 0 2.1622149404265656e-08
the O 0 3.757447473162756e-07
AVP O 0 0.021617108955979347
- O 0 1.946393786056433e-05
neurophysin O 1 0.5482515096664429
II O 1 1.0
( O 0 1.0751639365480514e-06
NPII O 1 0.9897053837776184
) O 0 1.302589858198644e-08
gene O 0 1.3522384989528291e-08
, O 0 8.835341347435133e-09
and O 0 5.02219954512384e-09
mutations O 0 2.0354519847387564e-08
that O 0 5.736866537375818e-09
cause O 0 1.1476907275209669e-05
ADNDI B-Disease 1 0.9999995231628418
have O 0 1.0504201952699077e-08
been O 0 4.85165596586512e-09
found O 0 2.920830688424303e-09
in O 0 2.424152434343796e-09
both O 0 4.722961577385831e-09
the O 0 2.0964741054285696e-08
signal O 0 1.601547552354532e-07
peptide O 0 1.9801153428034013e-07
of O 0 1.3099126761062507e-07
the O 0 2.8259461259949603e-07
prepro O 0 0.0018832217901945114
- O 0 0.03252419829368591
AVP O 1 0.9706921577453613
- O 0 5.830650115967728e-05
NPII O 1 0.9374586939811707
precursor O 0 1.672695725574158e-05
and O 0 1.8857237193969922e-07
within O 0 8.143171612573497e-07
NPII O 1 0.9284948110580444
itself O 0 6.160796601761831e-06
. O 0 5.644169959850842e-06

An O 0 7.289927452802658e-07
affected O 0 8.211227395804599e-07
girl O 0 1.118229192798026e-06
who O 0 7.494170972677239e-08
presented O 0 2.0668873901286133e-07
at O 0 1.3690676325950335e-07
9 O 0 7.025231951729438e-08
months O 0 5.320488938309609e-09
of O 0 1.0471993938665491e-08
age O 0 3.070959309070531e-08
and O 0 1.5593437652228204e-08
her O 0 1.0400037275815066e-08
similarly O 0 2.038385282787658e-08
affected O 0 5.042002371169474e-08
younger O 0 3.6227007171873993e-07
brother O 0 2.7752014375437284e-07
and O 0 4.018324517574001e-08
father O 0 1.0596307475907452e-07
were O 0 5.222243970592899e-08
all O 0 9.892281660484059e-09
found O 0 9.664491429361988e-09
to O 0 3.7402343444625785e-09
have O 0 1.2795095649664745e-08
a O 0 5.89003406048505e-08
novel O 0 2.197698591999142e-07
missense O 0 1.3491749086824711e-06
mutation O 0 2.0874253436886647e-07
( O 0 1.6852223438945657e-07
G1758 O 0 4.652669758797856e-06
- O 0 3.4247245821461547e-06
- O 0 4.671899660024792e-06
> O 0 1.4540916026817285e-06
T O 0 1.5539808373432606e-06
) O 0 9.750589669010878e-09
encoding O 0 3.08424894512882e-08
the O 0 3.071726695225152e-08
amino O 0 2.367086260335327e-08
acid O 0 1.9578969556732773e-08
substitution O 0 2.4525425601495954e-07
Gly23 O 0 3.919482878700364e-06
- O 0 1.829175857892551e-06
- O 0 2.706228087845375e-06
> O 0 2.913849129981827e-06
Val O 0 3.578659288905328e-06
within O 0 1.4735684317201958e-06
NPII O 0 0.0026305054780095816
. O 0 1.0923163245024625e-05

The O 0 4.42871578343329e-06
mutation O 0 1.5096168226591544e-06
was O 0 4.951347136739059e-07
confirmed O 0 1.8320619687983708e-07
by O 0 5.218977960907978e-08
restriction O 0 8.089338621175557e-07
endonuclease O 0 1.052859897754388e-05
analysis O 0 2.4151258912752382e-06
. O 0 3.0287735626188805e-06

A O 0 8.444473496638238e-05
T1 O 0 0.002011646283790469
- O 0 1.4729454051121138e-05
weighted O 0 3.956844921049196e-06
magnetic O 0 7.414521405735286e-07
resonance O 0 3.077879284774099e-07
imaging O 0 1.0535933370192652e-06
of O 0 3.85115924927959e-07
the O 0 3.4234676604683045e-06
fathers O 1 0.9784084558486938
pituitary O 1 0.9985553622245789
gland O 0 0.0001541623059893027
demonstrates O 0 1.2483518503358937e-06
an O 0 3.5243866136625e-07
attenuated O 0 0.00011679922317853197
posterior O 0 0.0006454339018091559
pituitary O 1 0.9973082542419434
bright O 1 0.9275233149528503
spot O 0 0.00021653289149980992
. O 0 1.8969254597323015e-05

This O 0 1.7432563481634133e-07
mutation O 0 1.948968417764263e-07
may O 0 3.1422082713561394e-08
be O 0 5.8214095766118135e-09
valuable O 0 1.3409432142452715e-07
for O 0 8.303074672255661e-09
developing O 0 3.785320856763974e-08
models O 0 9.557586366781834e-08
of O 0 1.0098136016267745e-07
dominantly B-Disease 1 0.7385686635971069
inherited I-Disease 1 0.9998346567153931
neurodegeneration I-Disease 1 1.0
, O 0 4.6430592703927687e-08
as O 0 9.969183700775375e-09
the O 0 3.198691533867759e-09
early O 0 2.147558397780358e-08
age O 0 1.806808391791037e-08
of O 0 1.5320823720799126e-08
onset O 0 0.0007698176195845008
of O 0 5.278337198433292e-07
symptoms O 0 0.01059587299823761
suggests O 0 6.804622643130642e-08
that O 0 1.410924488354226e-09
this O 0 7.663706891314348e-10
mutation O 0 6.87740175919771e-09
may O 0 6.602085544926695e-09
be O 0 6.203386249126197e-09
particularly O 0 8.32077091672545e-08
deleterious O 0 1.1579363672353793e-06
to O 0 5.16118596749493e-08
the O 0 5.691355227099848e-07
magnocellular O 0 0.0003105068753939122
neuron O 0 2.4740285880398005e-05
. O 0 1.2529532114058384e-06
. O 0 4.956457360094646e-06

Frequent O 0 1.4399907740880735e-05
inactivation O 0 8.985079330159351e-05
of O 0 1.9759889255510643e-05
PTEN O 1 1.0
/ O 1 0.9999910593032837
MMAC1 O 1 1.0
in O 0 2.8649669729929883e-06
primary O 1 0.9999982118606567
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.8263333913637325e-05

Sporadic B-Disease 1 0.999983549118042
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 5.3231108410045636e-08
the O 0 9.637230569126132e-09
most O 0 2.9270492696298334e-09
common O 0 2.285654154832173e-08
male B-Disease 0 1.245308709485471e-07
cancer I-Disease 0 6.819616515940652e-08
in O 0 1.488188128284662e-09
the O 0 3.2584719367179105e-09
Western O 0 8.560832753801151e-08
world O 0 1.4667774550503054e-08
, O 0 2.686324052092459e-09
yet O 0 3.2276799011299317e-09
many O 0 2.062604753660935e-09
of O 0 4.997851021926181e-09
the O 0 1.0782136072862158e-08
major O 0 9.274810253145915e-08
genetic O 0 9.789464883169785e-08
events O 0 2.8944450392032195e-08
involved O 0 8.943616514045516e-09
in O 0 3.2186060483496703e-09
the O 0 9.52021306233064e-09
progression O 0 5.522894070963957e-07
of O 0 1.03275512586265e-08
this O 0 5.73961367322795e-09
often O 0 2.4989117264340166e-07
fatal O 0 0.06807509064674377
cancer B-Disease 0 0.005397348199039698
remain O 0 3.084525985741493e-07
to O 0 5.6568971729120676e-08
be O 0 4.6711818413314177e-07
elucidated O 0 0.00012237162445671856
. O 0 1.320654155279044e-05

Numerous O 0 1.1607918168010656e-05
cytogenetic O 0 0.00017663782637100667
and O 0 7.584822583339701e-07
allelotype O 0 6.394617957994342e-05
studies O 0 2.5648458290561393e-07
have O 0 8.35467250936972e-09
reported O 0 2.2332391935719897e-08
frequent O 0 3.942783521893034e-08
loss O 0 1.9563408670819626e-07
of O 0 9.113076657740748e-07
heterozygosity O 1 0.9999994039535522
on O 0 1.0340862900193315e-05
chromosomal O 0 0.14971226453781128
arm O 0 0.00026208709459751844
10q O 0 0.000282603083178401
in O 0 1.72036081380611e-07
sporadic B-Disease 1 0.9999737739562988
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.8532422473072074e-05

Deletion O 0 9.43213399295928e-06
mapping O 0 2.9721923056058586e-06
studies O 0 8.627866350252589e-07
have O 0 2.5803309711136535e-08
unambiguously O 0 3.704701327933435e-07
identified O 0 9.235532871798569e-08
a O 0 2.744234350871011e-08
region O 0 1.0828905061543992e-07
of O 0 7.65683196846112e-08
chromosome O 0 6.378381840477232e-07
10q23 O 0 2.5959852791856974e-06
to O 0 1.1693187751404821e-08
be O 0 1.2884802558232877e-08
the O 0 2.185212721883545e-08
minimal O 0 8.638033932584221e-07
area O 0 9.446072226637625e-07
of O 0 5.499201165548584e-07
loss O 0 1.405688362865476e-05
. O 0 1.8555445421952754e-05

A O 0 1.64784742082702e-05
new O 0 3.0581693408748833e-06
tumor B-Disease 0 2.9929571610409766e-05
suppressor O 0 4.044326124130748e-05
gene O 0 2.881335831261822e-06
, O 0 1.499724362474808e-06
PTEN O 1 0.9997807145118713
/ O 0 0.019146256148815155
MMAC1 O 1 0.9999994039535522
, O 0 1.2827453588215576e-07
was O 0 1.4051731511699472e-07
isolated O 0 1.1935243549032748e-07
recently O 0 2.2782765896067758e-08
at O 0 9.43852551671398e-09
this O 0 1.975044350288613e-09
region O 0 5.015099091565389e-08
of O 0 6.03141359079018e-08
chromosome O 0 5.091015964353574e-07
10q23 O 0 4.82815539726289e-06
and O 0 2.0296521796581146e-08
found O 0 5.505695011009948e-09
to O 0 2.6143682774204535e-09
be O 0 3.782071544833343e-09
inactivated O 0 3.5275132148626653e-08
by O 0 6.978763122944542e-10
mutation O 0 9.545341406180796e-09
in O 0 1.3696769940452214e-08
three O 0 1.6375095128751127e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.0002898816019296646
lines O 0 7.807633664924651e-06
. O 0 2.8116282919654623e-06

We O 0 9.388197213411331e-06
screened O 0 6.27643967163749e-05
80 O 0 1.3246905837149825e-05
prostate B-Disease 0 0.03355500474572182
tumors I-Disease 1 0.9999958276748657
by O 0 6.320903622736296e-08
microsatellite O 0 1.2091493317711866e-06
analysis O 0 3.39647456826242e-08
and O 0 8.356426661748628e-09
found O 0 2.5939604242353198e-08
chromosome O 0 2.1421014650968573e-07
10q23 O 0 1.1578358680708334e-06
to O 0 1.556927742285552e-08
be O 0 4.550805599023988e-08
deleted O 0 1.079818844118563e-06
in O 0 1.4924803792837338e-07
23 O 0 1.14431168185547e-06
cases O 0 6.46421199235192e-07
. O 0 3.8438943192886654e-06

We O 0 2.3626446363778086e-06
then O 0 4.6202714543142065e-07
proceeded O 0 3.068681735385326e-07
with O 0 4.188823510276052e-09
sequence O 0 1.1834905500052173e-08
analysis O 0 1.1467196969761062e-08
of O 0 3.0404365247704845e-08
the O 0 7.444236871378962e-08
entire O 0 9.997376082537812e-07
PTEN O 0 0.2725364863872528
/ O 0 1.4820930118730757e-05
MMAC1 O 0 3.7335805245675147e-05
coding O 0 7.480103363377566e-07
region O 0 1.9308971843656764e-07
and O 0 1.867689647383486e-08
tested O 0 2.903059304060207e-08
for O 0 1.1331783511536742e-08
homozygous O 0 6.116026440849964e-08
deletion O 0 4.9192241391438074e-08
with O 0 1.3734387849240193e-08
new O 0 1.054298550684507e-07
intragenic O 0 0.00010296849359292537
markers O 0 2.8915485472680302e-06
in O 0 2.0501214947898916e-08
these O 0 1.9999966127670632e-08
23 O 0 2.3581372943226597e-07
cases O 0 3.588370489637782e-08
with O 0 5.458030116756163e-08
10q23 O 0 0.003035089699551463
loss O 0 5.762372438766761e-06
of O 0 6.965377451706445e-06
heterozygosity O 1 0.9966506361961365
. O 0 4.160900061833672e-05

The O 0 5.89047715493507e-07
identification O 0 1.4130898762232391e-06
of O 0 4.832199920201674e-07
the O 0 3.8559701920348743e-07
second O 0 1.3804874470224604e-06
mutational O 0 3.869968713843264e-05
event O 0 8.009793077690119e-07
in O 0 1.7394997087194497e-07
10 O 0 3.335310907459643e-07
( O 0 1.367061059909247e-07
43 O 0 5.227475980973395e-07
% O 0 1.1943942013203923e-07
) O 0 2.113242061341225e-07
tumors B-Disease 1 0.9999982118606567
establishes O 0 1.803593841032125e-05
PTEN O 1 0.9999784231185913
/ O 0 0.0015859879786148667
MMAC1 O 1 0.9817179441452026
as O 0 8.513740112903179e-08
a O 0 3.881012133888362e-08
main O 0 2.1136995087545074e-07
inactivation O 0 5.139946779308957e-07
target O 0 7.267035329050486e-08
of O 0 4.652260443549494e-08
10q O 0 2.259313805552665e-05
loss O 0 1.511785058028181e-06
in O 0 1.574792776182221e-07
sporadic B-Disease 1 0.9999980926513672
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.356347752334841e-06
. O 0 3.181351530656684e-06

Risk O 0 3.0830145988147706e-05
reversals O 0 1.6239799151662737e-05
in O 0 8.25978361262969e-08
predictive O 0 4.030906666230294e-07
testing O 0 2.093250230927879e-07
for O 0 1.3256990314403083e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.7261309039895423e-05

The O 0 8.122423764689302e-07
first O 0 7.14669212698027e-08
predictive O 0 4.3759706613855087e-07
testing O 0 9.45716180922318e-08
for O 0 4.5376182811196486e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.857087793017854e-07
HD B-Disease 0 1.2141990737291053e-05
) O 0 4.26275681419952e-09
was O 0 4.487741733782968e-09
based O 0 4.755385418775404e-09
on O 0 5.676479286620406e-09
analysis O 0 9.313771087704481e-09
of O 0 1.1366938501566892e-08
linked O 0 1.4463766717653925e-07
polymorphic O 0 1.6561628513045434e-07
DNA O 0 1.517217356195033e-07
markers O 0 1.0115793713794119e-07
to O 0 5.926926949229028e-09
estimate O 0 2.7592662377173838e-08
the O 0 1.189415055335985e-08
likelihood O 0 1.147595369843657e-07
of O 0 5.151144932824536e-08
inheriting O 0 3.607345320233435e-07
the O 0 8.525960737415517e-08
mutation O 0 1.0575168118975853e-07
for O 0 4.1581279219826683e-07
HD B-Disease 0 0.00016838150622788817
. O 0 5.460213287733495e-06

Limits O 0 1.6443357253592694e-06
to O 0 1.4764407296752324e-07
accuracy O 0 9.615234830562258e-07
included O 0 1.5798137553701963e-07
recombination O 0 1.4175303419960983e-07
between O 0 1.247228027523306e-07
the O 0 2.3902515522422618e-08
DNA O 0 2.130080503093268e-07
markers O 0 6.150203262222931e-07
and O 0 1.3373922413961736e-08
the O 0 2.359193729262188e-08
mutation O 0 3.2412106776291694e-08
, O 0 1.6236922917300944e-08
pedigree O 0 2.002967249836729e-07
structure O 0 1.180483550911049e-07
, O 0 1.40463667364088e-08
and O 0 5.576866968226568e-09
whether O 0 4.620352545003925e-09
DNA O 0 4.425961463994099e-08
samples O 0 2.0720335669466294e-08
were O 0 1.2369091528796616e-08
available O 0 2.2429423651715297e-08
from O 0 5.322704410559709e-08
family O 0 3.0154848218444386e-07
members O 0 3.4987743902092916e-07
. O 0 3.367805447851424e-06

With O 0 2.2372839225681673e-07
direct O 0 1.8916460930995527e-07
tests O 0 1.1164232205373992e-08
for O 0 1.8157734871238063e-08
the O 0 4.47546923965092e-08
HD B-Disease 0 2.929307129306835e-06
mutation O 0 3.125507319623466e-08
, O 0 6.178447975457857e-09
we O 0 2.313972125023156e-09
have O 0 1.043651609577978e-09
assessed O 0 2.4146938670810414e-08
the O 0 5.467644559331575e-09
accuracy O 0 3.6096231781357346e-08
of O 0 1.0878003386949331e-08
results O 0 1.1892177020911276e-08
obtained O 0 4.1888096546927045e-08
by O 0 1.3923691533079818e-08
linkage O 0 4.370552915133885e-07
approaches O 0 3.7506303840473265e-08
when O 0 2.013967881353551e-09
requested O 0 9.425213498559515e-09
to O 0 3.045147467517495e-09
do O 0 5.247382084405672e-09
so O 0 5.417670756457937e-09
by O 0 4.397098241071262e-09
the O 0 1.4326684727450356e-08
test O 0 3.1854387572138876e-08
individuals O 0 1.1078665096420082e-07
. O 0 3.5487209970597178e-06

For O 0 5.71884243072418e-07
six O 0 1.465181611592925e-07
such O 0 1.860252041296917e-08
individuals O 0 9.708130299657114e-09
, O 0 7.586224093358851e-09
there O 0 5.533182356742827e-09
was O 0 3.406017512475046e-08
significant O 0 3.606347220852513e-08
disparity O 0 1.0205205853708321e-06
between O 0 6.76605509397632e-08
the O 0 1.3704601542485761e-07
tests O 0 1.3359344563923514e-07
. O 0 1.8453762322678813e-06

Three O 0 1.8762428908303264e-06
went O 0 9.707167691885843e-07
from O 0 6.723140444364617e-08
a O 0 1.9852880228654612e-08
decreased O 0 1.0243277159815989e-07
risk O 0 5.908055822345659e-09
to O 0 1.0572255293439525e-09
an O 0 1.7375666461205697e-09
increased O 0 1.1790632470365381e-08
risk O 0 1.2215850553332075e-08
, O 0 2.168516477496496e-09
while O 0 1.1101056740514537e-09
in O 0 9.56073220592657e-10
another O 0 3.5900391548437938e-09
three O 0 3.290775207887009e-09
the O 0 2.6212251924562224e-08
risk O 0 2.0015731649891677e-07
was O 0 7.251113061101933e-07
decreased O 0 2.5051208467630204e-06
. O 0 3.2477012155140983e-06

Knowledge O 0 6.236456556507619e-06
of O 0 4.843429906031815e-07
the O 0 1.4095726896812266e-07
potential O 0 3.7136683772587276e-07
reasons O 0 1.2344196420599474e-07
for O 0 4.437285650027434e-09
these O 0 3.4902469803199665e-09
changes O 0 4.4579335778394125e-09
in O 0 1.959390427686003e-09
results O 0 1.1006628497511883e-08
and O 0 6.94457513716884e-09
impact O 0 2.4591090053149856e-08
of O 0 6.781582850834411e-09
these O 0 1.2484330014217448e-08
risk O 0 5.859477170133687e-08
reversals O 0 4.62072534901381e-07
on O 0 7.0905628035689e-08
both O 0 1.7061518420291577e-08
patients O 0 9.017373514552673e-09
and O 0 6.078055392322312e-09
the O 0 2.5829015370959496e-08
counseling O 0 1.780001390727648e-08
team O 0 1.591297404957004e-08
can O 0 3.241412915855335e-09
assist O 0 6.126569473963173e-08
in O 0 8.406703777552593e-09
the O 0 1.334370303140986e-08
development O 0 5.190724294834581e-08
of O 0 1.2548261985045883e-08
strategies O 0 1.6913929812290007e-08
for O 0 4.780712714591573e-09
the O 0 2.1276862938179875e-08
prevention O 0 1.4992208718922484e-07
and O 0 9.139987433570695e-09
, O 0 4.727666258474983e-09
where O 0 4.828106803245191e-09
necessary O 0 1.7519035111490666e-08
, O 0 1.3960202771556851e-08
management O 0 1.2668021298622989e-08
of O 0 1.4184940333450413e-08
a O 0 2.9149997970989716e-08
risk O 0 1.601396206751815e-07
reversal O 0 1.10820472798423e-07
in O 0 8.64751115159379e-09
any O 0 2.897787254596551e-08
predictive O 0 1.7909948724081914e-07
testing O 0 4.565463740391351e-08
program O 0 1.2790732739631494e-07
. O 0 2.878589953070332e-07
. O 0 4.099669240531512e-06

A O 0 9.399699592904653e-06
novel O 0 1.737070761009818e-06
common O 0 5.417693387244071e-07
missense O 0 5.702096586901462e-06
mutation O 0 6.855937613181595e-07
G301C O 0 8.626265298516955e-06
in O 0 1.8230024068088824e-07
the O 0 3.3443694746893016e-07
N O 0 2.9292345971043687e-06
- O 0 3.9366213968605734e-06
acetylgalactosamine O 0 2.7352645702194422e-05
- O 0 7.551487669843482e-06
6 O 0 3.865372946165735e-06
- O 0 2.0885991034447215e-06
sulfate O 0 3.5024609132960904e-06
sulfatase O 0 2.699240758374799e-05
gene O 0 8.41060284528794e-07
in O 0 6.000690291330102e-07
mucopolysaccharidosis B-Disease 0 0.0012287308927625418
IVA I-Disease 1 0.9999511241912842
. O 0 6.26295804977417e-05

Mucopolysaccharidosis B-Disease 1 0.8716580867767334
IVA I-Disease 1 1.0
( O 0 0.0001460141211282462
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.7557379667086934e-07
is O 0 1.9734786249614444e-08
an O 0 3.561179084954347e-08
autosomal B-Disease 1 0.998860239982605
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 2.2805847038398497e-05
by O 0 1.7369412574907983e-08
a O 0 1.0474635558921364e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999996423721313
in O 0 2.5961188043766015e-07
N O 0 2.079799969578744e-06
- O 0 2.656812284840271e-06
acetylgalactosamine O 0 1.874566987680737e-05
- O 0 9.495382073509973e-06
6 O 0 5.594497451966163e-06
- O 0 6.384360858646687e-06
sulfate O 0 1.9862345652654767e-05
sulfatase O 0 0.00031177973141893744
( O 0 6.25973643764155e-06
GALNS O 0 0.04318692907691002
) O 0 1.9736271497095004e-06
. O 0 5.6768558351905085e-06

In O 0 4.5384882696453133e-07
previous O 0 5.549334787247062e-07
studies O 0 1.27954677964226e-07
, O 0 6.975027222466679e-09
we O 0 2.54259879817198e-09
have O 0 1.2194799614562157e-09
found O 0 3.1499833852421943e-09
two O 0 2.5657587165994755e-09
common O 0 7.572490190455028e-09
mutations O 0 2.2322556247900138e-08
in O 0 1.703647889428339e-08
Caucasians O 0 7.291909582818334e-07
and O 0 4.0855450578192176e-08
Japanese O 0 2.6255618195136776e-06
, O 0 2.055870425010653e-07
respectively O 0 1.210659775097156e-06
. O 0 1.5597950095980195e-06

To O 0 7.437864155690477e-07
characterize O 0 3.5980388020107057e-06
the O 0 4.7242252776413807e-07
mutational O 0 1.4057995940675028e-05
spectrum O 0 2.026095671681105e-06
in O 0 1.1309845504570148e-08
various O 0 2.5420568761092e-08
ethnic O 0 3.0973716036442056e-08
groups O 0 6.9863714813322986e-09
, O 0 1.891146572674529e-09
mutations O 0 5.1597068839726035e-09
in O 0 2.7236146671327788e-09
the O 0 3.735345543987023e-08
GALNS O 0 4.97452165291179e-05
gene O 0 3.288079142294009e-08
in O 0 1.9588531685599264e-08
Colombian O 0 1.2436439646990038e-06
MPS B-Disease 1 0.9999967813491821
IVA I-Disease 1 1.0
patients O 0 1.3841678025983128e-07
were O 0 5.982137452065217e-08
investigated O 0 1.6615764764082996e-07
, O 0 1.0017808804718698e-08
and O 0 8.214171565157358e-09
genetic O 0 5.5420468214606444e-08
backgrounds O 0 1.9926426375604933e-07
were O 0 5.235438393924596e-08
extensively O 0 2.0061554195649478e-08
analyzed O 0 8.30545054952836e-09
to O 0 1.8351520303383495e-09
identify O 0 4.468304481974883e-08
racial O 0 4.2516184350915864e-08
origin O 0 5.885800291594023e-08
, O 0 1.2870410515120057e-08
based O 0 3.774794876676424e-08
on O 0 4.828653032973307e-08
mitochondrial O 0 2.2504143259993725e-07
DNA O 0 6.434327133320039e-07
( O 0 2.9467639706126647e-07
mtDNA O 0 9.847009323493694e-07
) O 0 1.5998605817912903e-07
lineages O 0 2.3675909233134007e-06
. O 0 1.642655433897744e-06

Three O 0 3.5487209970597178e-06
novel O 0 1.810463800211437e-06
missense O 0 6.541766197187826e-06
mutations O 0 6.951242994546192e-07
never O 0 1.2446710684343998e-07
identified O 0 1.3527755982067902e-07
previously O 0 2.389312570016955e-08
in O 0 1.1323525450634975e-09
other O 0 2.5501412093120734e-09
populations O 0 9.914420395773504e-09
and O 0 2.784180663795155e-09
found O 0 6.5967102891306695e-09
in O 0 4.061170955083071e-09
16 O 0 4.154666299882592e-08
out O 0 1.2536539806262681e-08
of O 0 3.3222342210592615e-08
19 O 0 3.9037564647514955e-07
Colombian O 0 1.876951614576683e-06
MPS B-Disease 1 0.9988563060760498
IVA I-Disease 1 1.0
unrelated O 0 3.488892616587691e-06
alleles O 0 3.9192894973894e-07
account O 0 2.7809795710709295e-07
for O 0 2.179560567583394e-07
84 O 0 1.0116493285750039e-05
. O 0 4.399903900775826e-06

2 O 0 5.281754056341015e-06
% O 0 7.058609696741769e-08
of O 0 2.935677834159378e-08
the O 0 2.579582947248582e-08
alleles O 0 5.336112351983502e-08
in O 0 3.748063193143025e-08
this O 0 3.1852138704380195e-08
study O 0 3.651462350262591e-07
. O 0 2.3104817046259996e-06

The O 0 7.338276645896258e-06
G301C O 0 8.884390263119712e-05
and O 0 5.284376811687252e-07
S162F O 0 1.0167641448788345e-05
mutations O 0 4.087782770056947e-07
account O 0 1.981191957156625e-07
for O 0 1.9892382852049195e-07
68 O 0 5.414199677034048e-06
. O 0 3.5293041946715675e-06

4 O 0 5.421481546363793e-05
% O 0 1.0939174899249338e-06
and O 0 4.981484380550683e-07
10 O 0 1.94911876860715e-06
. O 0 2.9979844384797616e-06

5 O 0 9.406928256794345e-06
% O 0 1.2201941501643887e-07
of O 0 2.4963959788237844e-08
mutations O 0 6.705441535359569e-08
, O 0 1.6029035876385933e-08
respectively O 0 3.663796022124188e-08
, O 0 3.501114953508022e-09
whereas O 0 1.7106746241779547e-08
the O 0 2.6987121870547526e-08
remaining O 0 2.692979705898324e-06
F69V O 0 0.12530545890331268
is O 0 9.451514237923675e-09
limited O 0 7.138611035628628e-09
to O 0 6.594433443751768e-09
a O 0 5.3613003814234617e-08
single O 0 3.218163442397781e-07
allele O 0 3.3430439998483052e-06
. O 0 6.376755209203111e-06

The O 0 2.737211843850673e-06
skewed O 0 1.2948179573868401e-05
prevalence O 0 3.68632913705369e-06
of O 0 2.3274922966720624e-07
G301C O 0 4.430346507433569e-06
in O 0 1.611683764224381e-08
only O 0 1.4656951208280589e-08
Colombian O 0 2.0951316059836245e-07
patients O 0 1.6440450778532067e-08
and O 0 7.327242368404541e-09
haplotype O 0 8.061324052732743e-08
analysis O 0 8.333394418968965e-09
by O 0 3.0416182905668165e-09
restriction O 0 6.923443152118125e-08
fragment O 0 4.658978127736191e-07
length O 0 5.96150897536063e-08
polymorphisms O 0 1.8614984753639874e-07
in O 0 2.4047750457611983e-08
the O 0 8.969175979700594e-08
GALNS O 0 0.0015632534632459283
gene O 0 8.897104208926976e-08
suggest O 0 1.081224922927504e-07
that O 0 2.1091240753889906e-08
G301C O 0 3.0471269383269828e-06
originated O 0 2.2978197478096263e-07
from O 0 4.219489468937354e-08
a O 0 8.120583316895136e-08
common O 0 6.04833701345342e-07
ancestor O 0 1.1815432117145974e-05
. O 0 7.317828931263648e-06

Investigation O 0 2.325811010450707e-06
of O 0 3.856595185425249e-07
the O 0 1.0387968529812497e-07
genetic O 0 2.3467829635137605e-07
background O 0 1.8884591668211215e-07
by O 0 9.740273476666061e-09
means O 0 5.78061793987672e-08
of O 0 2.0883327067622304e-08
mtDNA O 0 1.6469834918098059e-07
lineages O 0 5.925551249674754e-08
indicate O 0 1.0618438572862487e-08
that O 0 1.4607238751906948e-09
all O 0 6.307256050774868e-09
our O 0 2.7285819825806357e-08
patients O 0 1.090869261588523e-08
are O 0 6.508636740676366e-09
probably O 0 4.306742695803223e-08
of O 0 6.028802346236262e-08
native O 0 3.334108669150737e-07
American O 0 2.787391849778942e-06
descent O 0 4.7644418373238295e-05

Low O 0 5.978315584798111e-06
frequency O 0 1.9826748030027375e-06
of O 0 1.0264874390486511e-06
BRCA1 O 0 1.2310823876759969e-05
germline O 0 2.633839540067129e-05
mutations O 0 5.974782766315911e-07
in O 0 2.878325666699766e-08
45 O 0 3.364469023381389e-07
German O 1 0.9999994039535522
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0775279406516347e-06
. O 0 2.39917790167965e-06

In O 0 5.769667836830195e-07
this O 0 4.4087229866818234e-08
study O 0 5.501278721453673e-08
we O 0 1.0439407560625114e-08
investigated O 0 1.2731283050015918e-07
45 O 0 1.5536666353455075e-07
German O 1 0.9041661024093628
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.737801676124036e-09
for O 0 1.0498673042036444e-08
germline O 0 1.1053944035666063e-06
mutations O 0 8.926135564024662e-08
in O 0 2.3350105848862768e-08
the O 0 2.4324913283635397e-07
BRCA1 O 0 2.6264758616889594e-06
gene O 0 1.8738342077995185e-06
. O 0 5.766880349256098e-06

We O 0 1.336496779913432e-06
identified O 0 1.0297809467374464e-06
four O 0 2.735627901984117e-07
germline O 0 9.216865691996645e-06
mutations O 0 6.222296065061528e-07
in O 0 8.119730665612224e-08
three O 0 3.5016518040720257e-07
breast B-Disease 0 0.13680672645568848
cancer I-Disease 0 1.0259275768476073e-05
families O 0 1.4513738655352881e-08
and O 0 1.3506222806825008e-08
in O 0 2.718664759981948e-08
one O 0 0.0003951787075493485
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.6398670865669374e-08
. O 0 1.6942981462264584e-09
among O 0 2.4307178492222192e-09
these O 0 1.4188721308983077e-09
were O 0 8.27218737953217e-09
one O 0 1.3630261364028229e-08
frameshift O 0 2.435894543850736e-07
mutation O 0 4.104509443436655e-08
, O 0 1.625849321840178e-08
one O 0 2.674311261330331e-08
nonsense O 0 3.912410591055959e-07
mutation O 0 5.827322624440967e-08
, O 0 3.2282109430070705e-08
one O 0 5.5379683061573814e-08
novel O 0 9.412030976818642e-08
splice O 0 1.4542856661137193e-06
site O 0 1.7438283350657002e-07
mutation O 0 4.369610806520541e-08
, O 0 3.516952062909695e-08
and O 0 4.492591187954531e-08
one O 0 2.190803485291326e-07
missense O 0 1.3163939911464695e-05
mutation O 0 4.404413175507216e-06
. O 0 1.1725072909030132e-05

The O 0 3.3651151625235798e-06
missense O 0 1.7551350538269617e-05
mutation O 0 1.29057673348143e-06
was O 0 7.985874503901869e-07
also O 0 6.937270313756017e-08
found O 0 4.0089467745474394e-08
in O 0 1.1292077317648364e-07
2 O 0 4.7067237574083265e-06
. O 0 3.4978975236299448e-06

8 O 0 1.1611571608227678e-05
% O 0 5.025785654311221e-08
of O 0 1.7239864646967362e-08
the O 0 1.0277560136273678e-08
general O 0 1.1927960485991207e-07
population O 0 2.0846234960458787e-08
, O 0 8.567198506170826e-09
suggesting O 0 1.7398489760012126e-08
that O 0 1.7184504930156663e-09
it O 0 1.980748454144532e-09
is O 0 6.2240084197640044e-09
not O 0 3.375729917820536e-08
disease O 0 6.538260549859842e-06
associated O 0 5.403279374149861e-06
. O 0 6.310860044322908e-06

The O 0 9.283319855057925e-07
average O 0 2.5935528924492246e-07
age O 0 8.000359486004527e-08
of O 0 1.0286585450103303e-07
disease O 1 0.6997552514076233
onset O 0 0.36313262581825256
in O 0 1.1652355524915947e-08
those O 0 9.76406333563773e-09
families O 0 7.349107988829928e-08
harbouring O 0 5.7550955716578756e-06
causative O 0 1.4143572570901597e-06
mutations O 0 2.906270708535885e-07
was O 0 3.362210634350049e-07
between O 0 2.04425731453739e-07
32 O 0 2.325666855540476e-06
. O 0 2.9368313789746026e-06

3 O 0 0.00014125139568932354
and O 0 9.402604518982116e-06
37 O 0 9.425269672647119e-05
. O 0 1.7963910067919642e-05

4 O 0 1.5023400919744745e-05
years O 0 5.793035029455496e-07
, O 0 4.5460950559572666e-08
whereas O 0 8.616693492058403e-08
the O 0 4.5842941887030975e-08
family O 0 1.2715520369965816e-07
harbouring O 0 2.3021193555905484e-06
the O 0 2.8848219812971365e-08
missense O 0 4.999993734600139e-07
mutation O 0 2.169336532631405e-08
had O 0 1.0886639145724075e-08
an O 0 2.719093838976505e-09
average O 0 1.4391264180346752e-08
age O 0 2.6164798327954486e-08
of O 0 7.306368132731222e-08
onset O 0 1.633748979656957e-05
of O 0 5.1206975513196085e-06
51 O 0 7.19875970389694e-06
. O 0 4.356688805273734e-06

2 O 0 0.0003124543000012636
years O 0 2.67622344836127e-05
. O 0 3.87059262720868e-05

These O 0 6.467671482823789e-07
findings O 0 1.4139081940811593e-06
show O 0 1.5535052000359428e-07
that O 0 2.934759635309092e-08
BRCA1 O 0 5.996525942464359e-07
is O 0 1.68570863934292e-08
implicated O 0 1.6596807483892917e-07
in O 0 4.392169294931136e-09
a O 0 4.452325175208216e-09
small O 0 3.2481590750421674e-09
fraction O 0 3.934152204010388e-08
of O 0 7.206536452031287e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.9464064138219328e-08
suggesting O 0 1.1975417990583992e-08
the O 0 7.996206363714009e-09
involvement O 0 4.342409098967437e-08
of O 0 2.6695207822058364e-08
another O 0 5.787115853195246e-08
susceptibility O 0 5.309300377120962e-07
gene O 0 1.2939102589371032e-06
( O 0 5.027899078413611e-06
s O 0 4.6186418330762535e-05
) O 0 7.01779754308518e-06

Paternal O 0 0.002126385224983096
transmission O 1 0.9976198077201843
of O 1 0.9994887113571167
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9996885061264038

We O 0 2.023307388299145e-06
report O 0 6.354242145789613e-07
a O 0 1.2988452624540514e-07
rare O 0 2.833934615864564e-07
case O 0 4.500662100781483e-07
of O 0 8.759315051065641e-07
paternally O 1 0.9998335838317871
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999972581863403
DM B-Disease 1 1.0
) O 0 4.432341484061908e-06
. O 0 3.2074653972813394e-06

The O 0 4.583962891047122e-06
proband O 0 6.239417416509241e-05
is O 0 6.963066567777787e-08
a O 0 5.410063153021838e-08
23 O 0 3.0119380767246184e-07
year O 0 2.7047724060480505e-08
old O 0 4.534721483651083e-06
, O 0 1.6966473594948184e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.999653697013855
who O 0 4.64521281173802e-06
suffers O 1 0.9997803568840027
severe O 1 0.9999995231628418
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.00023307872470468283

He O 0 3.1563747597829206e-06
presented O 0 3.3544006328156684e-06
with O 0 2.7209065933675447e-07
respiratory O 1 0.9999953508377075
and O 0 2.8381775791785913e-06
feeding O 0 7.768633804516867e-05
difficulties O 0 0.06453688442707062
at O 0 1.3278019650897477e-05
birth O 0 3.551090776454657e-05
. O 0 1.2221173165016808e-05

His O 0 1.8959199223900214e-05
two O 0 1.2162573511886876e-05
sibs O 1 0.9999828338623047
suffer O 0 0.004410936031490564
from O 0 9.28533700061962e-06
childhood O 0 0.018130015581846237
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 8.624677866464481e-05

Their O 0 1.6674275684636086e-06
late O 0 9.298558325099293e-06
father O 0 1.720153932183166e-06
had O 0 1.3150885536106216e-07
the O 0 3.537066817216328e-08
adult O 0 3.43971144900479e-08
type O 0 9.639513365300445e-08
of O 0 2.1040399644789431e-07
DM B-Disease 1 1.0
, O 0 8.979240817552636e-08
with O 0 2.338786053712738e-08
onset O 0 0.14536988735198975
around O 0 2.2248472930641583e-07
30 O 0 5.919281420574407e-07
years O 0 3.845206606456486e-07
. O 0 3.6963235743314726e-06

Only O 0 6.605419002880808e-07
six O 0 1.4270059978116478e-07
other O 0 1.4790826341481988e-08
cases O 0 6.2627578678586815e-09
of O 0 1.7761113468850454e-08
paternal O 0 9.861948637990281e-05
transmission O 1 0.9999816417694092
of O 1 0.9999967813491821
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 8.84694600244984e-06
been O 0 1.65201100799095e-07
reported O 0 2.5892404664773494e-07
recently O 0 3.8493968190778105e-07
. O 0 1.216181885865808e-06

We O 0 1.5540371123279328e-06
review O 0 6.822510840720497e-07
the O 0 1.848943753657295e-07
sex O 0 9.281782809011929e-08
related O 0 1.9991257715901156e-07
effects O 0 3.1278366918741085e-07
on O 0 2.3615535837961943e-07
transmission O 0 6.902895256644115e-05
of O 0 5.131649231771007e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.2262325882911682

Decreased O 0 4.296948191040428e-06
fertility O 0 8.622865266261215e-07
of O 0 7.100022259010075e-08
males O 0 8.226212599993232e-09
with O 0 1.9286447994204536e-09
adult O 0 2.621745132103115e-08
onset O 0 1.911627987283282e-05
DM B-Disease 1 1.0
and O 0 2.2120977050121837e-08
contraction O 0 3.4867753129219636e-08
of O 0 7.954131575615975e-09
the O 0 4.2767966945689295e-09
repeat O 0 2.6633873773107553e-08
upon O 0 4.885990634306836e-08
male O 0 5.054770468859715e-08
transmission O 0 8.024322539768036e-08
contribute O 0 4.926958840911766e-09
to O 0 2.2056001469650255e-09
the O 0 8.9351939180915e-09
almost O 0 1.2796657955504998e-08
absent O 0 6.862859436296276e-08
occurrence O 0 3.103563273043619e-08
of O 0 3.129384751332509e-08
paternal O 0 6.476420367107494e-06
transmission O 0 0.0003866722690872848
of O 0 0.08445782214403152
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.49789464473724365

Also O 0 1.0164178547711344e-06
the O 0 2.5388547442162235e-07
fathers O 0 7.394008321170986e-07
of O 0 1.2180281316886976e-07
the O 0 1.9612014057202032e-07
reported O 0 1.1635553391897702e-06
congenitally O 0 0.0024095834232866764
affected O 0 2.1743909428550978e-07
children O 0 9.629773245478646e-08
showed O 0 1.63672126518577e-07
, O 0 1.8343410346233213e-08
on O 0 4.2906073360882147e-08
average O 0 9.624302066413293e-08
, O 0 4.891968430342786e-08
shorter O 0 1.3168471468816279e-06
CTG O 0 2.8431151804397814e-05
repeat O 0 6.459368364630791e-07
lengths O 0 2.7249675440543797e-06
and O 0 2.338513915844942e-08
hence O 0 7.451695438476236e-08
less O 0 4.7130829017305587e-08
severe O 0 1.8245797264171415e-06
clinical O 0 3.4548216376606433e-07
symptoms O 0 2.1999129273808649e-07
than O 0 3.1245999121409795e-09
the O 0 1.8884732000401527e-08
mothers O 0 6.618957826276528e-08
of O 0 6.419573850280358e-08
children O 0 1.3418352864391636e-06
with O 0 2.9035218176431954e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.027981949970126152

We O 0 8.113288458844181e-07
conclude O 0 8.52494167702389e-07
that O 0 3.355867406185098e-08
paternal O 0 4.388572506286437e-06
transmission O 0 0.03685075044631958
of O 1 0.984067440032959
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.3453900982749474e-07
rare O 0 4.146962950812849e-08
and O 0 4.027269184803117e-09
preferentially O 0 7.421437686616628e-09
occurs O 0 2.1677679651332937e-09
with O 0 8.750108415611635e-10
onset O 0 8.480845394842618e-07
of O 0 7.252330078699742e-07
DM B-Disease 1 1.0
past O 0 8.181571615750727e-07
30 O 0 6.213193159965158e-08
years O 0 5.953462167695989e-09
in O 0 4.622379812246891e-09
the O 0 2.3855104558379026e-08
father O 0 3.4422058092786756e-07
. O 0 1.2972485308182513e-07
. O 0 1.8505944581193035e-06

The O 0 2.0814863091800362e-05
RB1 O 0 0.0012668255949392915
gene O 0 7.89532748513011e-07
mutation O 0 1.60559238793212e-07
in O 0 2.4262446274292415e-08
a O 0 5.2799126848412925e-08
child O 0 6.100683549448149e-07
with O 0 1.3886343595004291e-06
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.00022607864229939878

The O 0 2.515728738217149e-05
RB1 O 0 0.0008152491063810885
gene O 0 1.0285089047101792e-06
mutation O 0 2.9217082442301034e-07
was O 0 1.649553382776503e-07
investigated O 0 4.3893912504699983e-08
in O 0 6.447032685485965e-09
a O 0 1.4309233797860088e-08
child O 0 3.1267242661670025e-07
with O 0 5.352554808268906e-07
ectopic B-Disease 1 0.9999995231628418
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 0 3.052955798921175e-05
using O 0 1.4787665314486276e-08
DNA O 0 4.561781707934642e-08
obtained O 0 1.7869680846160918e-08
from O 0 8.587468514065222e-09
both O 0 1.4211614995929267e-08
the O 0 6.983136557892067e-08
pineal B-Disease 0 0.39325016736984253
and I-Disease 0 3.0501576020469656e-07
retinal I-Disease 1 1.0
tumours I-Disease 1 1.0
of O 0 2.3147451884142356e-06
the O 0 7.639764021405426e-07
patient O 0 2.0417060113686603e-06
. O 0 5.408486686064862e-06

A O 0 2.1365010979934596e-05
nonsense O 0 1.5641953723388724e-05
mutation O 0 1.4030856618774123e-06
in O 0 5.630340638163034e-07
exon O 0 9.270577720599249e-06
17 O 0 2.4464995931339217e-06
( O 0 2.608828992833878e-07
codon O 0 1.0477966725375154e-06
556 O 0 2.460719315422466e-06
) O 0 2.3944725313640447e-08
of O 0 4.485895388484096e-08
the O 0 1.8320653794035024e-07
RB1 O 0 0.008259128779172897
gene O 0 6.57292531514031e-08
was O 0 5.5341352833693236e-08
found O 0 2.848395963539474e-09
to O 0 2.0756758534190567e-09
be O 0 3.57537466300073e-09
present O 0 2.548635436028235e-08
homozygously O 0 2.589161704236176e-05
in O 0 2.4729844838589088e-08
both O 0 3.934970393970616e-08
the O 0 1.1814409361932121e-07
retinal B-Disease 1 0.6951403617858887
and I-Disease 0 1.6933222468651365e-06
the I-Disease 0 2.0881092495983467e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 2.904851316998247e-05

The O 0 7.298135642486159e-07
same O 0 7.536601032143153e-08
mutation O 0 8.87645867919673e-08
was O 0 5.1544965629091166e-08
present O 0 1.827207007920606e-08
heterozygously O 0 1.4604761418013368e-06
in O 0 4.665658970282038e-09
the O 0 6.640553884551537e-09
DNA O 0 3.377017776529101e-08
from O 0 1.0786826543096595e-08
the O 0 8.311250354609001e-09
constitutional O 0 3.401232717692437e-08
cells O 0 3.0634826231334955e-08
of O 0 6.921565542938879e-09
the O 0 1.0078485601638931e-08
patient O 0 4.877089665455969e-08
, O 0 1.2316875519502446e-08
proving O 0 1.292825686505239e-07
it O 0 1.59316149161981e-09
to O 0 4.954447518912275e-09
be O 0 2.988729619346486e-08
of O 0 4.2564786895127327e-07
germline O 0 3.463368921075016e-05
origin O 0 1.6285192032228224e-05
. O 0 1.0859265785256866e-05

The O 0 5.740217829952599e-07
initial O 0 2.3785506186868588e-07
mutation O 0 1.802748670343135e-07
was O 0 6.007223163351227e-08
shown O 0 1.0498433233863125e-08
to O 0 5.5520104069728404e-09
have O 0 1.587411269099448e-08
occurred O 0 2.716631115617929e-07
in O 0 3.951569382820708e-08
the O 0 3.229233982438018e-07
paternally O 0 3.115375147899613e-05
derived O 0 1.1249045201111585e-05
RB1 O 0 0.0005668243393301964
allele O 0 2.932191091531422e-05
. O 0 1.1247147995163687e-05

The O 0 6.778790861972084e-07
mutation O 0 2.385319817221898e-07
is O 0 1.1349780670855125e-08
in O 0 1.964022500189344e-09
an O 0 1.8057015882533278e-09
area O 0 6.038492017523822e-08
of O 0 1.3699591683291601e-08
the O 0 2.9304469961743962e-08
gene O 0 2.1586382459304332e-08
that O 0 1.0928205895766041e-08
encodes O 0 9.753512841825795e-08
the O 0 3.1018647206337846e-08
protein O 0 1.1834301005819725e-07
- O 0 4.834080868931778e-08
binding O 0 2.627502304619611e-08
region O 0 7.508506882913935e-08
known O 0 1.6297736493697812e-08
as O 0 9.546287316197777e-09
the O 0 2.144656185976146e-08
pocket O 0 0.29027169942855835
region O 0 5.076011575511075e-07
and O 0 3.8117512701774103e-08
has O 0 1.105118307975772e-08
been O 0 7.256838241431751e-09
detected O 0 2.3907851698368177e-08
in O 0 4.5261239201010994e-09
other O 0 1.3424576117415654e-08
cases O 0 5.226688060133711e-08
of O 0 4.058029787756823e-07
retinoblastoma B-Disease 0 0.00029725421336479485
. O 0 1.0380258572695311e-06
. O 0 6.652106094406918e-06

Low O 0 5.958462224953109e-06
levels O 0 3.0656312333121605e-07
of O 0 6.254141737827013e-08
beta O 0 3.625569604537304e-07
hexosaminidase O 0 3.1545839647151297e-06
A O 0 8.623516833949907e-08
in O 0 1.0382219528537462e-08
healthy O 0 2.0368267072967683e-08
individuals O 0 3.2871367849907074e-09
with O 0 1.3958497468991027e-08
apparent O 0 0.00020105016301386058
deficiency O 1 0.9982956051826477
of O 0 8.602929710832541e-07
this O 0 5.4075769639894133e-08
enzyme O 0 4.581244411383523e-06
. O 0 3.0448989036813146e-06

Appreciable O 0 0.00016900207265280187
beta O 0 3.108341115876101e-05
hexosaminidase O 0 7.559062214568257e-05
A O 0 4.167681709077442e-06
( O 0 3.4450991392986907e-07
hex O 0 8.072036507655866e-06
A O 0 4.67212629473579e-07
) O 0 9.582187487922056e-09
activity O 0 1.821736717033673e-08
has O 0 2.391518316713359e-09
been O 0 2.6196294022895472e-09
detected O 0 2.4609624560412158e-08
in O 0 7.297395576699728e-09
cultured O 0 5.313724159350386e-06
skin O 0 3.5205778203817317e-06
fibroblasts O 0 6.60499927107594e-06
and O 0 5.37460948635271e-07
melanoma B-Disease 0 0.15201930701732635
tissue O 0 8.335200618603267e-07
from O 0 7.98589141481898e-08
healthy O 0 4.1252370408528805e-08
individuals O 0 2.076871563616578e-09
previously O 0 1.3129714204751508e-08
reported O 0 2.1959801088655695e-08
as O 0 1.7083953807173202e-08
having O 0 4.9400696866541693e-08
deficiency B-Disease 0 0.0017031640745699406
of I-Disease 0 2.1976284187985584e-06
hex I-Disease 0 4.81197057524696e-05
A I-Disease 0 2.044487388275229e-07
activity O 0 4.314051693654619e-08
indistinguishable O 0 1.491687839916267e-07
from O 0 8.271650919766671e-09
that O 0 1.3184137115374028e-09
of O 0 1.0061008026696072e-08
patients O 0 1.9175610432853318e-08
with O 0 8.425454893767892e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.0003038846480194479
TSD B-Disease 1 0.999998927116394
) O 0 7.931499226287997e-07
. O 0 1.4122477978162351e-06

Identification O 0 7.6028213698009495e-06
and O 0 8.827122996990511e-07
quantitation O 0 0.00010694200318539515
of O 0 2.649156385814422e-06
hex O 0 0.00011834962788270786
A O 0 4.112403530598385e-06
, O 0 1.862297409616076e-07
amounting O 0 5.20564583439409e-07
to O 0 2.2275479238942353e-07
3 O 0 5.557614258577814e-06
. O 0 3.715563934747479e-06

5 O 0 9.645680256653577e-05
% O 0 5.178643277758965e-06
- O 0 1.856211747508496e-05
6 O 0 1.628096833883319e-05
. O 0 6.347885573632084e-06

9 O 0 1.0323402420908678e-05
% O 0 1.0321686971792587e-07
of O 0 4.758690508310792e-08
total O 0 3.8441175576053865e-08
beta O 0 4.630876162536879e-07
hexosaminidase O 0 1.9340443486726144e-06
activity O 0 8.001244822253284e-08
, O 0 1.355298362426538e-08
has O 0 5.174944028851769e-09
been O 0 7.661197010122578e-09
obtained O 0 4.801523090236515e-08
by O 0 6.651787742839588e-08
cellulose O 0 9.39178789849393e-06
acetate O 0 3.3463709314673906e-06
gel O 0 1.0059627584269037e-06
electrophoresis O 0 5.852138542650209e-07
, O 0 2.036339736832815e-07
DEAE O 0 3.0109153158264235e-05
- O 0 1.8473837144483696e-06
cellulose O 0 4.080198323208606e-06
ion O 0 5.846800831932342e-06
- O 0 3.113856337222387e-06
exchange O 0 1.252964011655422e-06
chromatography O 0 1.955144853127422e-06
, O 0 1.6560507276608405e-07
radial O 0 5.709088782168692e-06
immunodiffusion O 0 1.5986457583494484e-05
, O 0 3.85377887823779e-07
and O 0 7.078156727402529e-07
radioimmunoassay O 0 0.0009366419399157166
. O 0 1.8669863493414596e-05

Previous O 0 5.66773542232113e-06
family O 0 4.1623056290518434e-07
studies O 0 9.344308438130611e-08
suggested O 0 2.2599476068307922e-08
that O 0 9.422206348475015e-10
these O 0 3.760965761046009e-09
individuals O 0 2.195593706844079e-09
may O 0 7.596881346216833e-09
be O 0 4.818024645913965e-09
compound O 0 9.216720542326584e-08
heterozygotes O 0 2.724702881096164e-07
for O 0 5.7297913080844864e-09
the O 0 1.8971665127764936e-08
common O 0 7.526444534278198e-08
mutant O 0 1.2562616120703751e-06
TSD B-Disease 0 1.1766158422688022e-05
gene O 0 3.417796534677109e-08
and O 0 1.619461365010011e-08
a O 0 2.8751212965971717e-08
rare O 0 3.509173609472782e-07
( O 0 2.365732711950841e-07
allelic O 0 3.7479815091501223e-06
) O 0 1.6755190301864786e-07
mutant O 0 1.7071566844606423e-06
gene O 0 2.7546814180823276e-06
. O 0 5.606590093520936e-06

Thus O 0 7.379098406090634e-06
, O 0 2.0566076841532777e-07
the O 0 1.1164129887220042e-07
postulated O 0 2.285895334352972e-06
rate O 0 1.0734022737324267e-07
mutant O 0 2.2598533178097568e-07
gene O 0 4.357991301162656e-08
appears O 0 3.1521064869366455e-08
to O 0 1.841937602442556e-09
code O 0 4.5191366204733185e-09
for O 0 9.753453156235992e-09
the O 0 3.8300434823668184e-08
expression O 0 7.179961869496765e-08
of O 0 1.0978893527635591e-07
low O 0 1.9511890059220605e-07
amounts O 0 1.7655268891303422e-07
of O 0 4.872143790635164e-07
hex O 0 4.308987990953028e-05
A O 0 1.4556993846781552e-05
. O 0 1.2268887076061219e-05

Heterozygotes O 0 4.629789691534825e-05
for O 0 4.942425562148856e-07
the O 0 2.364395186305046e-07
rare O 0 2.635747193835414e-07
mutant O 0 3.81167893692691e-07
may O 0 2.478916094617034e-08
be O 0 8.044792387806865e-09
indistinguishable O 0 2.1057942944935348e-07
from O 0 2.4586773506030113e-08
heterozygotes O 0 2.6216633841613657e-07
for O 0 1.639945423903555e-08
the O 0 1.0364416880292993e-07
common O 0 2.553809054006706e-06
TSD B-Disease 0 0.0017396780895069242
mutant O 0 2.6185569367953576e-05
. O 0 1.2191001587780192e-05

However O 0 3.2429720704385545e-06
, O 0 3.381562692084117e-07
direct O 0 2.601772735033592e-07
visualization O 0 2.356260665692389e-06
and O 0 1.0373870651392281e-07
quantitation O 0 4.9255941121373326e-05
of O 0 1.2035419558742433e-06
hex O 0 8.114209776977077e-06
A O 0 1.6966119176231587e-07
by O 0 9.971275360953769e-09
the O 0 1.013574024710806e-08
methods O 0 1.8398248258222338e-08
described O 0 2.3829910489325812e-08
may O 0 1.6121941115443406e-08
prevent O 0 5.946224845843062e-08
false O 0 4.861301476921653e-07
- O 0 5.672920906363288e-07
positive O 0 7.65493481935664e-08
prenatal O 0 2.1603109701118228e-07
diagnosis O 0 3.229560263662279e-07
of O 0 5.950013814981503e-07
TSD B-Disease 1 0.9999914169311523
in O 0 8.862789258046178e-08
fetuses O 0 3.3432374380026886e-07
having O 0 1.722014530969318e-08
the O 0 1.6207806652346335e-08
incomplete O 0 9.463798846809368e-07
hex B-Disease 0 3.2504616683581844e-05
A I-Disease 0 1.5484023379030987e-06
deficiency I-Disease 0 0.0008363340748474002
of O 0 3.5805396692012437e-07
the O 0 4.414149756826191e-08
type O 0 2.0498424646575586e-07
described O 0 5.25449550536905e-08
in O 0 1.679796568510028e-08
the O 0 2.1278775363953173e-07
four O 0 1.614216103007493e-06
healthy O 0 9.089484592550434e-06
individuals O 0 6.738025604136055e-06

The O 0 1.217154294863576e-05
tumor B-Disease 0 3.739081876119599e-05
suppressor O 0 7.445526716765016e-05
gene O 0 3.71141686628107e-06
Smad4 O 0 0.00023873169266153127
/ O 0 1.1557614016055595e-05
Dpc4 O 0 3.4651700389076723e-06
is O 0 3.4943701265888194e-09
required O 0 2.0318862148371863e-09
for O 0 7.123132750308514e-09
gastrulation O 0 1.1680358511512168e-06
and O 0 1.3221213457370595e-08
later O 0 7.920677091988182e-08
for O 0 2.869878024114314e-08
anterior O 0 1.14704209863703e-06
development O 0 2.5383221213814977e-07
of O 0 1.4352879418311204e-07
the O 0 4.4069284399483877e-07
mouse O 0 4.098003955732565e-06
embryo O 0 1.9136305127176456e-05
. O 0 9.941093594534323e-06

Mutations O 0 1.4527619896398392e-05
in O 0 8.84115934240981e-07
the O 0 3.1357326406578068e-06
SMAD4 O 1 1.0
/ O 1 0.9998847246170044
DPC4 O 1 0.9999728202819824
tumor B-Disease 0 1.4564450793841388e-05
suppressor O 0 8.841598173603415e-06
gene O 0 8.169519816192405e-08
, O 0 1.9359875480517985e-08
a O 0 1.4181179786021403e-08
key O 0 1.4786940027988749e-07
signal O 0 2.3743126575936913e-07
transducer O 0 4.819984837922675e-07
in O 0 5.874830932839359e-08
most O 0 9.548111989943209e-08
TGFbeta O 0 1.312683252763236e-05
- O 0 1.0055483699034085e-06
related O 0 4.2560162683003e-07
pathways O 0 3.527507033140864e-07
, O 0 7.899807918931856e-09
are O 0 2.2508481745120434e-09
involved O 0 4.217049376364912e-09
in O 0 4.723132551731624e-09
50 O 0 3.6724085106243365e-08
% O 0 2.2142758737686563e-08
of O 0 8.55126884857782e-08
pancreatic B-Disease 1 0.9931721687316895
cancers I-Disease 0 0.42141851782798767
. O 0 6.2524763961846475e-06

Homozygous O 0 0.00018011352221947163
Smad4 O 0 0.0008890526951290667
mutant O 0 5.5442011216655374e-05
mice O 0 6.909334388183197e-06
die O 0 2.2315120986604597e-06
before O 0 3.466379041583423e-07
day O 0 4.6097258632471494e-07
7 O 0 2.6473530851944815e-06
. O 0 1.243831320607569e-06

5 O 0 7.202443521237001e-05
of O 0 1.267063544219127e-05
embryogenesis O 0 0.0002672327682375908
. O 0 7.341421587625518e-05

Mutant O 0 1.0369106348662172e-05
embryos O 0 3.5839498195855413e-06
have O 0 8.248023419810124e-08
reduced O 0 9.213961504883628e-08
size O 0 1.025866467330161e-07
, O 0 1.5301958811164695e-08
fail O 0 5.5053934744364597e-08
to O 0 4.5687826855100866e-08
gastrulate O 0 1.692164187261369e-05
or O 0 1.1532135602010385e-07
express O 0 8.136520790458235e-08
a O 0 8.063430101401536e-08
mesodermal O 0 1.6399368178099394e-05
marker O 0 7.23856283002533e-06
, O 0 1.4353905442021642e-07
and O 0 1.3540042687054665e-07
show O 0 5.873620239071897e-07
abnormal O 0 5.903867531742435e-06
visceral O 0 0.0058948141522705555
endoderm O 1 0.9978358149528503
development O 0 3.176006430294365e-05
. O 0 7.4987551670346875e-06

Growth B-Disease 1 0.9999994039535522
retardation I-Disease 1 1.0
of O 0 1.0204310456174426e-05
the O 0 3.1694380595581606e-06
Smad4 O 1 0.9787870049476624
- O 0 4.9902959290193394e-05
deficient O 0 3.1171396130957874e-06
embryos O 0 2.6762052129924996e-07
results O 0 3.716122876085137e-08
from O 0 1.4792489011483667e-08
reduced O 0 4.772779860218179e-08
cell O 0 4.847219088333077e-07
proliferation O 0 8.975540026767703e-07
rather O 0 2.413791300170942e-08
than O 0 2.1599726451881907e-08
increased O 0 8.902366488428015e-08
apoptosis O 0 3.087046934524551e-06
. O 0 3.3896517379616853e-06

Aggregation O 0 3.057296999031678e-05
of O 0 5.954525477136485e-06
mutant O 0 2.952824070234783e-05
Smad4 O 0 0.0006644770037382841
ES O 0 0.0001690127101028338
cells O 0 4.896061795989226e-07
with O 0 5.1007546630899014e-08
wild O 0 6.121658202573599e-07
- O 0 8.208331223613641e-07
type O 0 9.580105597706279e-07
tetraploid O 0 2.7887988835573196e-05
morulae O 0 6.0070669860579073e-05
rescues O 0 9.656232577981427e-06
the O 0 2.141014192602597e-06
gastrulation B-Disease 0 0.00023579408298246562
defect I-Disease 0 0.00010576165368547663
. O 0 2.0085763026145287e-05

These O 0 1.8284642919752514e-06
results O 0 8.158726245710568e-07
indicate O 0 3.754044826109748e-07
that O 0 2.287259093236571e-08
Smad4 O 0 3.978086624556454e-06
is O 0 6.127572671488224e-09
initially O 0 5.745133702106386e-09
required O 0 1.2935694737592485e-09
for O 0 3.711976948039819e-09
the O 0 9.30897670059494e-09
differentiation O 0 1.0234606406811508e-07
of O 0 4.157520194780773e-08
the O 0 6.106387218096643e-08
visceral O 0 4.64950653622509e-06
endoderm O 0 1.1669519153656438e-05
and O 0 1.436712970814824e-08
that O 0 4.3703254348770315e-09
the O 0 5.032989847109093e-08
gastrulation B-Disease 0 6.9774710027559195e-06
defect I-Disease 0 5.068330324320414e-07
in O 0 3.809367399298935e-08
the O 0 1.9435319131844153e-07
epiblast O 0 4.566916686599143e-05
is O 0 4.3696857687791635e-08
secondary O 0 4.900896897197526e-07
and O 0 5.396850610850379e-08
non O 0 4.928644102619728e-06
- O 0 9.055715963768307e-06
cell O 0 6.669565482297912e-05
autonomous O 0 2.054078686342109e-05
. O 0 4.577209438139107e-06

Rescued O 0 8.181104203686118e-05
embryos O 0 2.5728893888299353e-05
show O 0 2.56893395089719e-06
severe O 0 6.366622255882248e-05
anterior O 0 0.00021999824093654752
truncations O 0 0.29219773411750793
, O 0 1.2041844854593364e-07
indicating O 0 1.6222691101575037e-07
a O 0 2.0956186119747144e-08
second O 0 6.081525327772397e-08
important O 0 8.91012987835893e-08
role O 0 1.0348929890824365e-07
for O 0 9.618869967198407e-08
Smad4 O 0 0.007750093936920166
in O 0 7.252585874084616e-07
anterior O 0 6.90297456458211e-05
patterning O 0 7.103890675352886e-05
during O 0 4.684932264353847e-06
embryogenesis O 0 5.369274003896862e-05
. O 0 8.138186785799917e-06

Prevalence O 0 8.138835983118042e-05
of O 0 2.848734311555745e-06
p16 O 0 1.1776532119256444e-05
and O 0 7.340099728025962e-07
CDK4 O 1 0.9998592138290405
germline O 0 0.00021915054821874946
mutations O 0 1.1848048870888306e-06
in O 0 8.223926073469556e-08
48 O 0 1.0882860124183935e-06
melanoma B-Disease 0 0.00850449688732624
- O 0 2.929457878053654e-06
prone O 0 1.0331204975955188e-06
families O 0 8.505072912612377e-08
in O 0 9.616704943482546e-08
France O 0 3.8044699977035634e-06
. O 0 3.07831533064018e-06

The O 0 6.049968305887887e-06
French O 0 8.451055327896029e-05
Familial B-Disease 0 0.0003614962624851614
Melanoma I-Disease 0 0.09039173275232315
Study O 0 8.308668952849985e-07
Group O 0 1.182885739581252e-06
. O 0 1.9553892798285233e-06

Germline O 0 0.0005503451102413237
mutations O 0 7.1306781137536746e-06
in O 0 2.2987904912952217e-07
the O 0 2.5370178491357365e-07
p16 O 0 1.7018558082781965e-06
and O 0 9.510597465123283e-08
CDK4 O 0 0.001096728490665555
genes O 0 6.796217633109336e-08
have O 0 5.923118440165354e-09
been O 0 5.8597762198076e-09
reported O 0 6.7642460521710746e-09
in O 0 1.2709108210273712e-09
a O 0 3.3011984257313998e-09
subset O 0 8.630575365486948e-08
of O 0 1.4149843252653227e-07
melanoma B-Disease 0 0.004186838399618864
pedigrees O 0 1.9840574623231078e-06
, O 0 1.9157440078743093e-08
but O 0 7.502091392552757e-09
their O 0 1.1113984399457877e-08
prevalence O 0 4.822932169190608e-07
is O 0 8.192079015145737e-09
not O 0 8.811158025423538e-09
well O 0 1.2308355223922263e-07
known O 0 7.15367434622749e-07
. O 0 4.227305907988921e-06

We O 0 7.717031849097111e-07
searched O 0 1.0408668913441943e-06
for O 0 4.904440586983583e-08
such O 0 1.3823868982854037e-07
germline O 0 2.638792466314044e-05
mutations O 0 7.128095376174315e-07
in O 0 8.609366375367244e-08
48 O 0 5.601959287560021e-07
French O 0 3.823565748461988e-06
melanoma B-Disease 0 0.0005057204398326576
- O 0 2.2561052901437506e-06
prone O 0 4.2356407448096434e-07
families O 0 2.525485420790119e-08
selected O 0 2.5739753439779633e-08
according O 0 5.552942550224316e-09
to O 0 2.531367560010267e-09
two O 0 3.4893283817893916e-09
major O 0 3.968223438732821e-08
criteria O 0 2.0096788233558982e-08
families O 0 5.526210600237391e-09
with O 0 3.002016857323042e-09
at O 0 1.1748362283015013e-08
least O 0 8.359152481318688e-09
three O 0 6.670028973587705e-09
affected O 0 2.4676037213566815e-08
members O 0 1.6297549976229675e-08
( O 0 2.2035827385025186e-08
n O 0 2.940923593541811e-08
= O 0 7.128694079483466e-08
20 O 0 1.2339542720951613e-08
) O 0 5.358923305109897e-10
or O 0 5.610096831532019e-10
families O 0 4.889976201738477e-10
with O 0 4.1455119892397363e-10
two O 0 2.111083086120402e-09
affected O 0 3.6043101836469305e-09
members O 0 1.6832467641947346e-09
, O 0 1.278089412082295e-09
one O 0 1.3502429174749864e-09
of O 0 2.0568298175760447e-09
them O 0 3.0885212165543408e-09
affected O 0 7.428901493966578e-09
before O 0 5.327638330498985e-09
the O 0 8.78040662399826e-09
age O 0 2.5595182862048205e-08
of O 0 3.89713079584908e-08
50 O 0 6.227026716487671e-08
( O 0 2.7385246070821267e-08
n O 0 1.224040317993058e-07
= O 0 3.0007680607013754e-07
28 O 0 1.1186532589135822e-07
) O 0 2.455906145115705e-09
, O 0 2.329133552692042e-09
and O 0 2.682790878338892e-09
one O 0 9.653327914804777e-09
additional O 0 6.866420676487905e-08
minor O 0 3.1278923415811732e-06
criterion O 0 7.349126099143177e-05
. O 0 1.1325201739964541e-05

Sixteen O 0 3.487733192741871e-05
different O 0 1.5866384046603343e-06
p16 O 0 9.757745829119813e-06
germline O 0 1.1079919204348698e-05
mutations O 0 2.2977758362685563e-07
were O 0 3.705541473664198e-08
found O 0 5.8636895339247985e-09
in O 0 1.7942144436844387e-09
21 O 0 3.5163552070116566e-08
families O 0 5.655750534572235e-09
, O 0 5.755432574972019e-09
while O 0 5.8730695862152515e-09
one O 0 6.63746346774019e-09
germline O 0 1.1777751751651522e-06
mutation O 0 4.014685828224174e-08
, O 0 1.8508202970224374e-08
Arg24His O 0 3.0965738915256225e-06
, O 0 2.0243748011239404e-08
was O 0 4.305420731043341e-08
detected O 0 4.6591246416483045e-08
in O 0 2.260111564567069e-08
the O 0 7.977585028129397e-07
CDK4 O 1 0.906284749507904
gene O 0 6.141157427919097e-06
. O 0 7.45717852623784e-06

The O 0 1.7121017208410194e-06
frequency O 0 1.3152970268492936e-06
of O 0 3.325388888697489e-07
p16 O 0 1.259989403479267e-06
gene O 0 7.25877953300369e-08
mutation O 0 1.9632370396038823e-08
in O 0 7.538810464779999e-09
our O 0 8.715433708061937e-09
sample O 0 6.860461976287979e-09
( O 0 4.661371288960936e-09
44 O 0 1.5892318572241493e-08
% O 0 1.0446155052079575e-09
) O 0 2.441501167904647e-10
is O 0 2.7509397537706093e-10
among O 0 1.6320562679084105e-09
the O 0 2.969748669201522e-09
highest O 0 1.0921286985876577e-08
rates O 0 6.0405525026396845e-09
yet O 0 4.548251997249508e-09
reported O 0 1.192045040454559e-08
and O 0 4.5255106329022965e-09
the O 0 1.9674164519756232e-08
CDK4 O 0 3.273402762715705e-05
mutation O 0 1.52542547482426e-08
is O 0 3.1352800355932686e-09
the O 0 7.105803945250955e-09
second O 0 1.272044070077527e-08
mutation O 0 8.718626709480759e-09
detected O 0 1.4457844699222733e-08
in O 0 1.1150862455622246e-09
this O 0 5.802808455968034e-09
gene O 0 2.0636139197449666e-07
worldwide O 0 7.3653711751831e-07
. O 0 3.695318810059689e-06

In O 0 8.133105779961625e-07
summary O 0 6.706555723212659e-06
, O 0 1.9016576402464125e-07
our O 0 8.887232638699061e-08
results O 0 8.907971249527691e-08
show O 0 2.90756432264061e-08
frequent O 0 5.4765401102940814e-08
involvement O 0 6.533490193305624e-08
of O 0 3.902077239104074e-08
the O 0 3.710881202323435e-08
p16 O 0 4.4050079850421753e-07
gene O 0 8.908786952588343e-08
in O 0 2.791914077704405e-08
familial B-Disease 0 8.962368156062439e-05
melanoma I-Disease 1 0.8451427221298218
and O 0 1.871619481619291e-08
confirm O 0 7.554201886250667e-08
the O 0 6.151874032411797e-08
role O 0 6.936833329973524e-08
of O 0 1.4589265617814817e-07
the O 0 1.8427842007895379e-07
CDK4 O 1 0.9979959726333618
gene O 0 2.1710488340431766e-07
as O 0 1.5820285170775605e-07
a O 0 3.1449968673769035e-07
melanoma B-Disease 0 0.2935176193714142
- O 0 8.320949564222246e-05
predisposing O 0 0.00011551372153917328
gene O 0 1.3045810192124918e-06
. O 0 6.857952143946022e-07
. O 0 3.463574557827087e-06

Progression O 0 0.0001233682269230485
of O 0 8.791000254859682e-06
somatic O 1 0.9990033507347107
CTG O 0 0.05566883832216263
repeat O 0 1.6035158978411346e-06
length O 0 9.832898228978593e-08
heterogeneity O 0 7.16769420705532e-07
in O 0 1.03209734092502e-08
the O 0 3.160028683169003e-08
blood O 0 2.667658520749683e-07
cells O 0 5.999368681841588e-07
of O 0 2.3439204142050585e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0620686374604702
. O 0 1.6554156900383532e-05

The O 0 6.113070867286297e-07
genetic O 0 9.900040822685696e-07
basis O 0 4.6485527605000243e-07
of O 0 9.912984069160302e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.5962010025978088
DM B-Disease 1 1.0
) O 0 2.8404977925333696e-08
is O 0 2.3518738068162293e-09
the O 0 2.6771884709120286e-09
expansion O 0 3.897874378822053e-08
of O 0 2.1883119316612465e-08
an O 0 3.1324841387458946e-08
unstable O 0 8.728547072678339e-06
CTG O 0 0.00024282714002765715
repeat O 0 4.323050859511568e-07
in O 0 3.801288883664711e-08
the O 0 1.0283505957886518e-07
34 O 0 1.0016797205025796e-06
UTR O 0 0.00013854217831976712
of O 0 2.812575417010521e-07
the O 0 7.473528853552125e-07
DM B-Disease 1 0.9999997615814209
protein O 0 2.12926306630834e-06
kinase O 0 3.7630234146490693e-06
gene O 0 6.437162483052816e-07
on O 0 1.3669728105014656e-06
chromosome O 0 5.792256160930265e-06
19 O 0 8.297573003801517e-06
. O 0 4.509874997893348e-06

One O 0 8.608001280663302e-07
of O 0 3.3225799711544823e-07
the O 0 1.737607959739762e-07
principal O 0 6.800839287279814e-07
features O 0 1.1274291011886817e-07
of O 0 8.242141547043502e-08
the O 0 2.977203337195533e-07
DM B-Disease 1 1.0
mutation O 0 6.564367538430815e-08
is O 0 3.3466802662474038e-09
an O 0 3.465543629843637e-09
extraordinarily O 0 3.509260082523724e-08
high O 0 7.023383830073726e-08
level O 0 7.205134977539274e-08
of O 0 6.169841526570963e-08
somatic O 1 0.8362836837768555
mosaicism O 1 0.9125356674194336
, O 0 1.237680891108539e-08
due O 0 6.5002376814504714e-09
to O 0 1.2328456033827706e-09
an O 0 2.393206521844604e-09
extremely O 0 7.134254964569209e-09
high O 0 1.8695216041919593e-08
degree O 0 3.714826135592375e-08
of O 0 3.4435711171454386e-08
somatic O 0 4.623180575435981e-05
instability O 0 9.94622268990497e-07
both O 0 3.6604991038302614e-08
within O 0 6.399329066653081e-08
and O 0 3.4874805265872055e-08
between O 0 8.964507003383915e-08
different O 0 1.4230798228709318e-07
tissues O 0 9.72647285379935e-06
. O 0 4.0026311580732e-06

This O 0 1.4655870472779498e-06
instability O 0 1.0214454960078001e-05
appears O 0 4.1016537011273613e-07
to O 0 1.9717669275109984e-08
be O 0 2.3122879611037206e-08
biased O 0 5.50462630144466e-07
towards O 0 1.0829111829480098e-07
further O 0 1.5281132803579567e-08
expansion O 0 3.9308666544002335e-08
and O 0 3.6252145729775975e-09
continuous O 0 2.1347267065152664e-08
throughout O 0 1.4878539289497894e-08
the O 0 9.408473111705007e-09
life O 0 1.4137374826361793e-08
of O 0 9.514367960150594e-09
an O 0 3.689600847067709e-09
individual O 0 6.287677045690998e-09
, O 0 5.679533288116545e-09
features O 0 7.882167807338192e-09
that O 0 3.7006783748516625e-10
could O 0 2.8191764478435744e-09
be O 0 3.709542228946816e-09
associated O 0 3.107265200696929e-08
with O 0 9.283885660238411e-09
the O 0 1.3029406886744255e-07
progressive O 0 2.2717043975717388e-05
nature O 0 1.1542775979478392e-07
of O 0 1.1162831015099073e-07
the O 0 1.6352139482478378e-06
disease O 0 0.00015871759387664497
. O 0 6.941385890968377e-06

Although O 0 1.0413752988824854e-06
increasing O 0 3.0461313826890546e-07
measured O 0 7.048357275607486e-08
allele O 0 1.0046897358506612e-07
size O 0 4.7715236206613554e-08
between O 0 4.208181181297732e-08
patients O 0 2.3652042102639825e-08
clearly O 0 3.5822981914179763e-08
correlates O 0 4.560859423463626e-08
with O 0 1.275841210457429e-09
an O 0 9.838030390341146e-10
increased O 0 4.228172034714817e-09
severity O 0 1.1445153802469576e-07
of O 0 3.6882379816916e-08
symptoms O 0 4.367527992599207e-07
and O 0 6.47308073808972e-09
an O 0 1.940437588388022e-09
earlier O 0 8.775182358533584e-09
age O 0 1.6441045858073267e-08
of O 0 2.3074063548733648e-08
onset O 0 5.000170517632796e-07
, O 0 1.005914640472838e-08
this O 0 2.9643891785724463e-09
correlation O 0 1.874220068032173e-08
is O 0 9.900659181383276e-10
not O 0 1.1730487692318547e-09
precise O 0 5.855667595255909e-08
and O 0 1.77827743641501e-08
measured O 0 4.2779575437634776e-08
allele O 0 4.629979599712897e-08
length O 0 1.4661146074956832e-08
cannot O 0 8.588500577388913e-09
be O 0 2.5582480578378863e-09
used O 0 5.1016959545791e-09
as O 0 6.8734022917738e-09
an O 0 1.5914696227525837e-09
accurate O 0 7.941856239312983e-08
predictor O 0 2.1648452275258023e-06
of O 0 1.0132941952178953e-07
age O 0 7.556232617389469e-07
of O 0 1.2623009979506605e-06
onset O 0 0.008902990259230137
. O 0 1.9129392967442982e-05

In O 0 8.390238122046867e-07
order O 0 2.1709928432755987e-07
to O 0 6.093588922340132e-08
further O 0 2.327738712892824e-07
characterize O 0 8.630096317574498e-07
the O 0 1.3942140242306778e-07
dynamics O 0 2.194972466895706e-06
of O 0 1.6406718259531772e-06
DM B-Disease 1 1.0
CTG O 0 0.003467824077233672
repeat O 0 2.2266524410952115e-06
somatic O 0 6.296727224253118e-05
instability O 0 2.2768442704546032e-06
, O 0 2.087910466741505e-08
we O 0 6.961975440589185e-09
have O 0 5.326713292674867e-09
studied O 0 7.363883014477324e-08
repeat O 0 2.774830143437157e-08
length O 0 7.732588791498074e-09
changes O 0 5.370980549201931e-09
over O 0 8.237956983236927e-09
time O 0 1.2812483518587214e-08
in O 0 1.7645060523818756e-08
111 O 0 3.0309522571769776e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.961810435271218e-08
with O 0 2.27185759094084e-09
varying O 0 5.1152227342754486e-08
clinical O 0 1.653919952104843e-07
severity O 0 2.3002935449767392e-06
and O 0 4.309541168368014e-07
CTG O 0 1.2457363482099026e-05
repeat O 0 1.1556665668877031e-07
size O 0 2.900065254607398e-08
over O 0 1.9538678230901496e-08
time O 0 1.5011488940785966e-08
intervals O 0 1.3246244634501636e-07
of O 0 1.5189633018053428e-07
1 O 0 1.5905910686342395e-06
- O 0 1.4093699292061501e-06
7 O 0 1.4406130048882915e-06
years O 0 7.167454896261916e-07
. O 0 2.550880935814348e-06

We O 0 5.978002945994376e-07
have O 0 5.804792735375486e-08
found O 0 2.9059068040737657e-08
a O 0 1.3064838100262932e-08
direct O 0 6.870508428846733e-08
progression O 0 3.931069727514114e-07
of O 0 3.69898849328365e-08
the O 0 1.8004545410121864e-08
size O 0 5.017883353275465e-08
heterogeneity O 0 3.022221619630727e-07
over O 0 1.6693013193957995e-08
time O 0 9.435574099825317e-09
related O 0 4.162654221318007e-08
to O 0 1.0119764581872914e-08
initial O 0 9.112835641644779e-08
CTG O 0 4.837908363697352e-06
repeat O 0 9.506933906777704e-08
size O 0 3.580275986792003e-08
and O 0 7.979873650754143e-09
the O 0 1.897126722383291e-08
time O 0 1.7595622736621408e-08
interval O 0 9.951538970653928e-08
and O 0 3.342382370874475e-08
always O 0 1.2734197696318006e-07
biased O 0 1.119270564231556e-06
towards O 0 3.4532632753325743e-07
further O 0 2.0700750269497803e-07
expansion O 0 4.740730219054967e-06
. O 0 4.9803147703642026e-06

Attempts O 0 2.013477114815032e-06
to O 0 1.7837763266470574e-07
mathematically O 0 1.3234732705313945e-06
model O 0 3.878252812228311e-07
the O 0 1.8021556513758696e-07
dynamics O 0 8.016655783649185e-07
have O 0 4.711717238592428e-08
proved O 0 7.868552529544104e-07
only O 0 6.804583563280175e-08
partially O 0 2.3519316982856253e-07
successful O 0 1.9567917064478024e-08
suggesting O 0 4.4287059353109726e-08
that O 0 1.281350359150224e-09
individual O 0 3.1083544627108495e-09
specific O 0 1.1967630442200061e-08
genetic O 0 1.1559321677623302e-07
and O 0 2.989060021718615e-08
/ O 0 8.362694075003674e-07
or O 0 2.1924561721675673e-08
environmental O 0 9.738140249737626e-08
factors O 0 4.076360227145415e-08
also O 0 3.6717060503121957e-09
play O 0 1.1162996749192189e-08
a O 0 1.3085513117516712e-08
role O 0 4.154587074367555e-08
in O 0 5.893765120390526e-08
somatic O 0 0.0013662836281582713
mosaicism O 0 0.001026788610033691
. O 0 1.230783141181746e-06
. O 0 2.896543946917518e-06

Aspartylglucosaminuria B-Disease 1 0.999997615814209
among O 0 3.870430009556003e-05
Palestinian O 0 0.0005968470359221101
Arabs O 0 0.00015247799456119537
. O 0 2.508173383830581e-05

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.9614148736000061
AGU B-Disease 1 1.0
) O 0 3.250832492085465e-07
is O 0 2.253740483126876e-08
a O 0 2.467712079123885e-08
rare O 0 1.5701348274888005e-06
disorder B-Disease 1 0.9999998807907104
of I-Disease 0 0.00012449610221665353
glycoprotein I-Disease 0 1.497627999924589e-05
metabolism I-Disease 0 7.926917078293627e-07
caused O 0 4.031390687941894e-08
by O 0 3.503573431373752e-09
the O 0 8.497582371091994e-08
deficiency B-Disease 1 0.8018686771392822
of I-Disease 0 1.698580376796599e-06
the I-Disease 0 7.208653869383852e-07
lysosomal I-Disease 0 7.328523497562855e-05
enzyme I-Disease 0 6.325489721348276e-06
aspartylglucosaminidase I-Disease 0 0.00015069036453496665
( O 0 8.752384701438132e-07
AGA O 0 0.0023685223422944546
) O 0 1.516637098575302e-06
. O 0 3.688854121719487e-06

AGU B-Disease 1 1.0
is O 0 2.8540475796035025e-06
inherited O 0 0.0002258298045489937
as O 0 3.7675229691558343e-07
an O 0 1.0264790972769333e-07
autosomal O 0 7.025883678579703e-05
recessive O 0 0.0003275018825661391
trait O 0 1.0917590316239512e-06
and O 0 6.055283385819621e-09
occurs O 0 3.1842284364813622e-09
with O 0 7.323257000813044e-10
a O 0 2.5947308746054887e-09
high O 0 2.0809489242878954e-08
frequency O 0 1.1756476681057393e-08
in O 0 5.871097830123517e-09
Finland O 0 1.1731606264220318e-07
because O 0 1.743363498007966e-08
of O 0 1.3277623622798274e-07
a O 0 3.895689815180958e-07
founder O 0 1.4952948731661309e-05
effect O 0 4.104762865608791e-06
. O 0 1.0611781362968031e-05

While O 0 9.396225095770205e-07
very O 0 1.556447273287631e-07
few O 0 2.095936935120335e-07
patients O 0 8.162432862945934e-08
with O 0 8.328170508775656e-08
AGU B-Disease 1 1.0
have O 0 4.604079961723073e-08
been O 0 2.0213304807725763e-08
reported O 0 1.826234985458086e-08
from O 0 1.3166578938239581e-08
non O 0 1.1151190904001851e-07
- O 0 7.910441013336822e-08
Finnish O 0 6.184575340739684e-07
origin O 0 9.810961643097471e-08
, O 0 2.1110398762402838e-08
we O 0 4.32857447663082e-08
diagnosed O 0 7.709139936196152e-06
the O 0 1.0296047037172684e-07
disorder O 0 4.6764347644057125e-05
in O 0 1.7631805349083152e-08
8 O 0 3.446797691708525e-08
patients O 0 2.2647190789371052e-09
originating O 0 1.7143101160854712e-08
from O 0 7.535246204781743e-09
3 O 0 3.16047490400706e-08
unrelated O 0 1.8869393159093306e-08
families O 0 3.4383256242165317e-09
, O 0 2.6854427570555117e-09
all O 0 2.3371973245644995e-09
Palestinian O 0 5.22644882039458e-07
Arabs O 0 1.2176670338703843e-07
from O 0 1.5028218669499438e-08
the O 0 2.3265549486950476e-08
region O 0 2.74199322802815e-07
of O 0 3.3253601827709645e-07
Jerusalem O 0 0.00018453858501743525
. O 0 1.4758476027054712e-05

The O 0 1.7527646605230984e-06
clinical O 0 1.6509918623341946e-06
diagnosis O 0 0.0003833073133137077
of O 0 0.10221624374389648
AGU B-Disease 1 1.0
is O 0 4.465560721200745e-08
often O 0 5.5323909897708745e-09
difficult O 0 7.89295473424545e-09
, O 0 3.847438367898803e-09
in O 0 1.1885163964109324e-09
particular O 0 5.497950539279373e-09
early O 0 3.685706317924087e-08
in O 0 2.4298048018067675e-09
the O 0 4.939077591359364e-09
course O 0 1.1231660046462366e-08
of O 0 1.0071030231983968e-08
the O 0 4.001299913625189e-08
disease O 0 7.613034540554509e-07
, O 0 5.766816357777316e-09
and O 0 3.423437977545518e-09
most O 0 5.832657468118896e-09
of O 0 6.716549538765548e-09
the O 0 1.822035677889744e-08
patients O 0 3.204934628797673e-08
are O 0 3.5634485584523645e-08
diagnosed O 0 9.508263474344858e-07
after O 0 2.131016607620495e-08
the O 0 2.5091750899264298e-08
age O 0 1.2579624808495282e-07
of O 0 2.0767130592957983e-07
5 O 0 1.2117569667680073e-06
years O 0 9.01266332675732e-07
. O 0 5.941558356425958e-06

However O 0 1.7964911194212618e-06
, O 0 1.5002062525582005e-07
since O 0 6.009939568230038e-08
these O 0 4.353189453354389e-08
patients O 0 3.0516087434762085e-08
excrete O 0 1.6179460260445921e-07
early O 0 3.1000077171938756e-08
large O 0 6.046915856927626e-09
amounts O 0 1.3362371653613536e-08
of O 0 2.2116250164572193e-08
aspartylglucosamine O 0 2.5463282327109482e-06
in O 0 2.108637353614995e-08
urine O 0 9.87437758226406e-08
, O 0 1.631030066562289e-08
biochemical O 0 2.5043371465471864e-07
screening O 0 2.1144328954392222e-08
is O 0 6.972367128099677e-09
easy O 0 8.534534856607934e-08
by O 0 9.154542368605689e-08
urine O 0 9.620848686608952e-07
chromatography O 0 6.9583934418915305e-06
. O 0 9.254732731278636e-07
. O 0 6.560927886312129e-06

Detection O 0 2.291425971634453e-06
of O 0 3.335552776206896e-07
heterozygous O 0 2.2749726724669017e-07
carriers O 0 3.2944325312200817e-07
of O 0 1.9666610739932366e-07
the O 0 1.2860382412327453e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.8182512222847436e-06
ATM O 0 0.00027597942971624434
) O 0 3.1504718833730294e-08
gene O 0 2.0803298639293644e-08
by O 0 1.5704022970908227e-08
G2 O 0 1.2706997040368151e-05
phase O 0 7.298143032130611e-07
chromosomal O 0 4.589124273479683e-06
radiosensitivity O 0 0.00010356159327784553
of O 0 2.311952130185091e-06
peripheral O 1 0.9999715089797974
blood O 0 0.005595313850790262
lymphocytes O 0 6.340931577142328e-05
. O 0 7.334931979130488e-06

In O 0 4.854726284975186e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999555349349976
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.7383261880231657e-08
patients O 0 7.996694861844844e-09
, O 0 1.600532151257994e-09
mutations O 0 3.3220681761036985e-09
in O 0 9.186175708997268e-10
a O 0 1.31873323372389e-09
single O 0 2.132666265808325e-09
gene O 0 6.975745758808216e-09
, O 0 5.979169159786579e-09
ATM O 0 2.366811941101332e-06
, O 0 5.275903713908292e-09
result O 0 5.996128482621543e-09
in O 0 8.569013054682273e-09
an O 0 1.1571972180490775e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.6113693845909438e-07
embraces O 0 2.1143064543593937e-07
a O 0 7.972175808390602e-09
variety O 0 2.7424238879802942e-08
of O 0 3.113756008588098e-08
clinical O 0 6.402161289997821e-08
features O 0 4.724153157553701e-08
and O 0 2.4575333767984375e-08
manifests O 0 2.69021256826818e-07
extreme O 0 8.635332164885767e-07
radiosensitivity O 0 1.8512389942770824e-05
and O 0 9.568822889605144e-08
a O 0 1.1735019000980174e-07
strong O 0 1.2621107998711523e-06
pre O 0 7.200860181910684e-06
- O 0 8.686197361384984e-06
disposition O 0 1.3913351722294465e-05
to O 0 2.231931375717977e-06
malignancy B-Disease 0 0.0013516561593860388
. O 0 1.7462945834267884e-05

Heterozygotes O 0 3.9635338907828555e-05
for O 0 3.890885409418843e-07
the O 0 1.9758239488965046e-07
ATM O 0 1.7193935491377488e-05
gene O 0 3.6819861293224676e-07
have O 0 5.247174428291146e-08
no O 0 6.324991375095124e-08
clinical O 0 1.6939961255957314e-07
expression O 0 7.937509849398339e-08
of O 0 5.2885309287376e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 6.744885183707083e-08
may O 0 5.457374285811056e-08
be O 0 5.4186244824450114e-08
cancer B-Disease 0 6.87993633619044e-07
prone O 0 4.941633946486945e-08
with O 0 2.834910972637772e-09
a O 0 2.0175059844973475e-08
moderate O 0 2.845392543804337e-07
increase O 0 1.027166085521003e-08
in O 0 1.8925621958487682e-08
in O 0 1.2549296002362098e-07
vitro O 0 3.934973392460961e-06
radiosensitivity O 0 0.0001884868397610262
. O 0 9.939520168700255e-06

We O 0 4.04619959226693e-06
performed O 0 1.9935923774028197e-06
a O 0 5.738023105550383e-07
blind O 0 1.8794161178448121e-06
chromosomal O 0 2.058100108115468e-06
analysis O 0 7.060870643726957e-07
on O 0 9.20026138828689e-07
G2 O 0 2.1293775716912933e-05
- O 0 1.047123419084528e-06
phase O 0 6.251887612052087e-07
lymphocytes O 0 5.123854975863651e-07
from O 0 9.468315909089142e-08
7 O 0 2.8646013561228756e-07
unrelated O 0 1.2248990515217884e-06
A B-Disease 1 0.9999979734420776
- I-Disease 1 0.9999829530715942
T I-Disease 1 1.0
patients O 0 3.6729625207954086e-07
, O 0 5.640606559609296e-08
13 O 0 1.4038830897789012e-07
obligate O 0 4.3720453390960756e-07
A B-Disease 1 0.9999791383743286
- I-Disease 1 0.9970928430557251
T I-Disease 1 1.0
heterozygotes O 0 6.307622697931947e-06
( O 0 2.346641458927934e-08
parents O 0 5.897022870016144e-09
of O 0 1.572077579226061e-08
the O 0 1.946168914912505e-08
patients O 0 1.3620204519781964e-08
) O 0 2.261804965542069e-09
, O 0 4.2208152528644405e-09
and O 0 8.978894960876005e-09
14 O 0 9.881875939754536e-08
normal O 0 3.0856785571131695e-08
controls O 0 3.23567022064708e-08
following O 0 1.2455504183606081e-08
X O 0 4.6445512680293177e-07
- O 0 1.4368107770224015e-07
irradiation O 0 2.587359517747245e-07
with O 0 2.706382495887283e-08
1 O 0 4.799920816367376e-07
Gy O 0 4.242155227984767e-06
in O 0 3.163428186070405e-09
order O 0 5.704155370267472e-09
to O 0 4.829378230652992e-09
evaluate O 0 5.623633825280194e-08
this O 0 8.952764751768427e-09
cytogenetic O 0 8.418218158112722e-07
method O 0 3.9511849792006615e-08
as O 0 1.053369391712522e-08
a O 0 6.321250634044873e-09
tool O 0 7.843538440965858e-08
for O 0 1.918753866902989e-08
detection O 0 7.785274647176266e-07
of O 0 6.305207307377714e-07
ATM O 0 0.0017664167098701
carriers O 0 3.034995279449504e-05
. O 0 2.0967392629245296e-05

Both O 0 1.9814422557828948e-05
A B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
homozygotes O 0 0.000160918541951105
and O 0 2.096732600875839e-07
heterozygotes O 0 3.8758962546125986e-06
showed O 0 9.490990038329983e-08
significantly O 0 2.8428285503423467e-08
increased O 0 1.130335469667898e-08
levels O 0 1.684692918502151e-08
of O 0 2.1082030343677616e-08
radiation O 0 3.944574564229697e-05
- O 0 2.6570910449663643e-06
induced O 0 3.877175913657993e-05
chromatid O 0 5.369832433643751e-05
damage O 0 2.3921732008602703e-06
relative O 0 1.5722282853403158e-07
to O 0 9.427729708022525e-09
that O 0 8.757359282185462e-09
of O 0 7.196290141564532e-08
normal O 0 3.0376835979950556e-07
controls O 0 1.6394158137700288e-06
. O 0 3.008750809385674e-06

These O 0 7.2348728963334e-07
results O 0 3.3803050314418215e-07
show O 0 8.453497457594494e-08
that O 0 1.8391055789379607e-08
the O 0 2.3143932992297778e-07
G2 O 0 0.00011378813360352069
- O 0 3.855256636597915e-06
phase O 0 1.1206066119484603e-06
chromosomal O 0 2.507377303118119e-06
radiosensitivity O 0 2.4211701656895457e-06
assay O 0 1.1061098348363885e-07
can O 0 3.947635107692804e-09
be O 0 3.433109130313028e-09
used O 0 3.995646924437324e-09
for O 0 1.8160669634781357e-09
the O 0 2.3429729267832045e-09
detection O 0 1.0936550864926176e-07
of O 0 3.999953719358018e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.17117160558700562
. O 0 3.952383849537e-05

In O 0 3.2628025792291737e-07
combination O 0 5.497182087310648e-07
with O 0 2.8085139547329163e-08
molecular O 0 5.363950208447932e-07
genetic O 0 1.2156910145222355e-07
analyses O 0 6.099135418935475e-08
, O 0 3.5047897917195314e-09
this O 0 8.56257120762649e-10
test O 0 2.6559288102134815e-09
may O 0 5.279809922598133e-09
be O 0 3.244710056193867e-09
of O 0 9.584747218127632e-09
value O 0 1.9456900091086027e-08
in O 0 3.298969986076372e-09
studies O 0 1.4867760356196413e-08
of O 0 1.633221557995057e-08
familial B-Disease 0 3.42581159884503e-07
and I-Disease 0 6.872369340271689e-08
sporadic I-Disease 0 1.0266175195283722e-05
cancers I-Disease 0 0.3011529743671417
aimed O 0 3.2400643590335676e-07
at O 0 3.4945450977375e-08
determination O 0 1.0692843943616026e-08
of O 0 1.7321902134881384e-08
the O 0 2.1196337129936182e-08
potential O 0 3.2646047998241556e-07
involvement O 0 4.713546388757095e-07
of O 0 2.9640835919053643e-07
ATM O 0 0.08012677729129791
mutations O 0 2.5271101549151354e-06
in O 0 1.5746395831683913e-07
tumor B-Disease 0 0.37043535709381104
risk O 0 1.0453753702677204e-06
or O 0 1.4670607129119162e-07
development O 0 6.862924237793777e-07
. O 0 2.55288824746458e-07
. O 0 2.887125901906984e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 5.882051254957332e-07
identification O 0 3.061782933855284e-07
and O 0 2.7465489438327495e-08
detection O 0 4.3944092453784833e-07
of O 0 4.151150392317504e-07
founder O 0 7.70964688854292e-05
- O 0 2.491659188308404e-06
effect O 0 1.314851516553972e-07
mutations O 0 3.542407256418301e-08
in O 0 7.026221382488984e-09
the O 0 1.2341944355398482e-08
ATM O 0 1.7246545667148894e-06
gene O 0 4.982776502515662e-08
in O 0 1.7764806514719567e-08
ethnic O 0 2.567577155332401e-07
populations O 0 1.0960853842334473e-06
. O 0 1.7676375136943534e-06

To O 0 2.5096926492551574e-07
facilitate O 0 5.895990966564568e-07
the O 0 7.220419462328209e-08
evaluation O 0 1.3761598438577494e-07
of O 0 1.3232822482223128e-07
ATM O 1 0.7363753914833069
heterozygotes O 0 4.043743683723733e-05
for O 0 3.061665765358157e-08
susceptibility O 0 1.8700623627410096e-07
to O 0 1.0200263744764015e-08
other O 0 9.779611076510264e-08
diseases O 0 0.2766095697879791
, O 0 5.319179763318971e-09
such O 0 1.2530373183494703e-08
as O 0 3.1999645671021426e-06
breast B-Disease 1 0.8932973742485046
cancer I-Disease 0 7.063388329697773e-05
, O 0 8.027854825343184e-09
we O 0 3.1685247758872492e-09
have O 0 1.702568641626101e-09
attempted O 0 1.2888441425218389e-08
to O 0 2.527869691348883e-09
define O 0 3.302761797385756e-08
the O 0 1.5790163843121263e-08
most O 0 1.077374900404493e-08
common O 0 1.1938380950482497e-08
mutations O 0 1.174475450227419e-08
and O 0 4.612428217143361e-09
their O 0 1.1678745082122077e-08
frequencies O 0 3.0494740599351644e-07
in O 0 2.331079684836368e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.6583766937255859
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.2782293740419846e-07
homozygotes O 0 1.1758470463973936e-06
from O 0 5.5895636563718654e-08
10 O 0 7.319590622500982e-08
ethnic O 0 1.4713313589709287e-07
populations O 0 4.042848900098761e-07
. O 0 2.191475459767389e-06

Both O 0 2.477966972946888e-06
genomic O 0 4.834864284930518e-06
mutations O 0 1.017938870973012e-06
and O 0 1.1202760674677847e-07
their O 0 2.1340550659942892e-08
effects O 0 4.759907028528687e-07
on O 0 2.638803096033371e-07
cDNA O 0 2.4703667804715224e-06
were O 0 4.2851524995057844e-07
characterized O 0 1.883625714071968e-06
. O 0 4.266039013600675e-06

Protein O 0 2.160637995984871e-05
- O 0 4.043160060973605e-06
truncation O 0 2.2366830307873897e-06
testing O 0 1.9177663546088297e-07
of O 0 1.5628700111847138e-07
the O 0 1.004795180392648e-07
entire O 0 2.6635859740054e-07
ATM O 0 3.516551487336983e-06
cDNA O 0 2.799595904434682e-06
detected O 0 4.059438936110382e-07
92 O 0 4.530008368419658e-07
( O 0 4.2099152608443546e-08
66 O 0 1.2071302535332507e-07
% O 0 1.0129072691711372e-08
) O 0 6.0597775686233035e-09
truncating O 0 5.883712361764992e-08
mutations O 0 2.1670869543299887e-08
in O 0 2.1158772511853385e-08
140 O 0 1.9702636677720875e-07
mutant O 0 1.274325200029125e-06
alleles O 0 2.84184216070571e-06
screened O 0 9.502357897872571e-06
. O 0 7.666705641895533e-06

The O 0 2.5978874873544555e-06
haplotyping O 0 0.0005685493815690279
of O 0 8.785551131040847e-07
patients O 0 1.001103129283365e-07
with O 0 9.643776444079322e-09
identical O 0 1.6992481732813758e-07
mutations O 0 1.0059303434672984e-07
indicates O 0 5.5759656447662564e-08
that O 0 9.281951873774119e-10
almost O 0 2.1608699274366927e-09
all O 0 7.927667966534102e-10
of O 0 1.891994561020738e-09
these O 0 9.945894108298603e-10
represent O 0 3.737638643031005e-09
common O 0 1.9807492535051097e-08
ancestry O 0 3.068049281296226e-08
and O 0 5.918477263833211e-09
that O 0 4.971439260259558e-09
very O 0 3.3381837738488684e-08
few O 0 1.6079246734079788e-07
spontaneously O 0 9.540572136756964e-07
recurring O 0 1.4903723695169901e-06
ATM O 0 3.26959379890468e-05
mutations O 0 2.828323431458557e-06
exist O 0 6.972429218876641e-06
. O 0 1.0985510925820563e-05

Assays O 0 2.873421863114345e-06
requiring O 0 6.953285378585861e-07
minimal O 0 1.6987570461424184e-06
amounts O 0 2.205801479249203e-07
of O 0 6.150654030534497e-08
genomic O 0 1.2793807968591864e-07
DNA O 0 7.12873529096214e-08
were O 0 2.1098323088608595e-08
designed O 0 1.6532805346969326e-08
to O 0 2.580359259596321e-09
allow O 0 1.2229466328506078e-08
rapid O 0 1.146625052683703e-07
screening O 0 2.6816410425567483e-08
for O 0 1.6670229641135847e-08
common O 0 1.1348854656034746e-07
ethnic O 0 7.771091077302117e-07
mutations O 0 4.397563316160813e-06
. O 0 5.633629825751996e-06

These O 0 1.3572224588642712e-06
rapid O 0 3.31072033077362e-06
assays O 0 1.672445591793803e-06
detected O 0 6.027090080351627e-07
mutations O 0 1.1233743180127931e-07
in O 0 2.316128089319136e-08
76 O 0 1.3418296873624058e-07
% O 0 4.8264769958450415e-09
of O 0 6.71790756356927e-09
Costa O 0 8.574493648438875e-08
Rican O 0 2.9213819630058424e-07
patients O 0 1.718946407436306e-08
( O 0 1.2293240203575806e-08
3 O 0 2.5544656168108304e-08
) O 0 1.5605241543426018e-09
, O 0 1.3334690018851347e-09
50 O 0 2.0268002831613785e-09
% O 0 6.477794967096884e-10
of O 0 2.7799462731792346e-09
Norwegian O 0 1.0622635926438306e-07
patients O 0 5.244340517407409e-09
( O 0 9.837227921138947e-09
1 O 0 4.1453656507428605e-08
) O 0 1.3286477473783975e-09
, O 0 1.6569101646268791e-09
25 O 0 5.606387798451351e-09
% O 0 1.579458341893769e-09
of O 0 2.9116806743445522e-09
Polish O 0 9.63501634032582e-07
patients O 0 1.5637100503340662e-08
( O 0 8.92701734755974e-09
4 O 0 3.41756170030294e-08
) O 0 9.908290854454549e-10
, O 0 1.2231978763210805e-09
and O 0 1.8481770558409494e-09
14 O 0 1.0820745188766523e-08
% O 0 8.154364405932313e-10
of O 0 2.2795925147534035e-09
Italian O 0 4.472874692851292e-08
patients O 0 3.6742773268372275e-09
( O 0 2.7890385556617048e-09
1 O 0 1.362943002902739e-08
) O 0 8.71306915506409e-10
, O 0 8.226490599838598e-10
as O 0 2.504831897454096e-09
well O 0 4.4159080836436715e-09
as O 0 8.895708170086891e-09
in O 0 6.139130537263782e-09
patients O 0 1.4205598475314218e-08
of O 0 9.996472982720661e-08
Amish O 0 3.7475024328159634e-06
/ O 0 6.175367161631584e-06
Mennonite O 0 2.257429514429532e-05
and O 0 2.639825140704488e-07
Irish O 0 1.038065533975896e-06
English O 0 1.3384841395236435e-06
backgrounds O 0 1.910776882141363e-05
. O 0 1.1472289770608768e-05

Additional O 0 2.9964178338559577e-06
mutations O 0 2.2980964331509313e-06
were O 0 4.533669084594294e-07
observed O 0 1.0758865442994647e-07
in O 0 1.896982126936564e-08
Japanese O 0 3.015959180174832e-07
, O 0 3.165077444577946e-08
Utah O 0 3.145621008115995e-07
Mormon O 0 3.246269102419319e-07
, O 0 1.4122498726010235e-08
and O 0 2.1589757537299192e-08
African O 0 2.2204278593562776e-07
American O 0 5.380969128054858e-07
patients O 0 3.9517772165709175e-07
. O 0 2.260757355543319e-06

These O 0 2.3576048988616094e-06
assays O 0 1.4612508039135719e-06
should O 0 1.3873673765374406e-07
facilitate O 0 3.2698582685952715e-07
screening O 0 1.8734397144726245e-07
for O 0 1.788363022114936e-07
A B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
heterozygotes O 0 1.6659823813824914e-05
in O 0 5.219853704829802e-08
the O 0 3.822322369728681e-08
populations O 0 1.6525356727470353e-07
studied O 0 3.3498213269922417e-07
. O 0 1.6498792376751226e-07
. O 0 1.5784132756380131e-06

The O 0 6.486244092229754e-05
von B-Disease 1 0.9989292025566101
Hippel I-Disease 1 0.9999980926513672
- I-Disease 1 0.9999841451644897
Lindau I-Disease 1 0.9999876022338867
tumor I-Disease 0 0.0002191415842389688
suppressor O 0 1.0410980394226499e-05
gene O 0 1.0734534328094014e-07
is O 0 3.6082996590636185e-09
required O 0 2.908145280144936e-09
for O 0 7.401661061834375e-09
cell O 0 3.827327645922196e-07
cycle O 0 1.8485187069927633e-07
exit O 0 2.953482578504918e-07
upon O 0 1.9257718975040916e-07
serum O 0 1.2980618748770212e-06
withdrawal O 0 3.7691650049964665e-06
. O 0 7.941664080135524e-06

The O 0 6.868824584671529e-06
inactivation O 0 2.117947042279411e-05
of O 0 9.136833796219435e-07
the O 0 1.235701688528934e-06
von B-Disease 1 0.9999803304672241
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 0.04440493509173393
VHL I-Disease 1 1.0
) I-Disease 0 1.56165867792879e-06
tumor I-Disease 0 7.956715853651986e-05
suppressor O 0 0.000548135896679014
gene O 0 8.48790932650445e-07
predisposes O 0 1.755658922775183e-05
affected O 0 7.057087714201771e-08
individuals O 0 1.8492560815985826e-09
to O 0 5.652213364015779e-09
the O 0 1.0773856473633714e-07
human O 1 0.5212827324867249
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 0.999998927116394
and O 0 1.0073450518177651e-08
is O 0 1.4038081808109837e-09
associated O 0 9.935357425661095e-09
with O 0 1.1201217731127144e-08
sporadic B-Disease 1 0.6367795467376709
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.9968320727348328
RCC B-Disease 1 1.0
) O 0 5.771054816250398e-07
and O 0 7.677041367060156e-07
brain B-Disease 1 0.6138952374458313
hemangioblastomas I-Disease 1 0.6834678649902344
. O 0 1.191900810226798e-05

VHL O 1 0.9999209642410278
- O 0 0.0010772449895739555
negative O 0 2.8021520847687498e-05
786 O 0 8.027035801205784e-05
- O 0 3.0237544706324115e-05
0 O 0 9.804535693547223e-06
RCC B-Disease 1 0.9846364259719849
cells O 0 7.153155934247479e-07
are O 0 2.2724568893295327e-08
tumorigenic O 0 0.0008626373019069433
in O 0 1.022367968062099e-07
nude O 0 4.194725079287309e-06
mice O 0 3.25129079215003e-08
which O 0 1.8809447333012486e-09
is O 0 2.1421817653077824e-09
suppressed O 0 2.0421987656504825e-08
by O 0 2.8676168106755995e-09
the O 0 3.2110531122953034e-08
reintroduction O 0 1.5265816273313249e-06
of O 0 9.565864047544892e-07
VHL B-Disease 1 0.9864371418952942
. O 0 1.3991269042890053e-05

Remarkably O 0 2.351435432501603e-05
, O 0 5.088773136208147e-08
this O 0 1.9875112666767336e-09
occurs O 0 5.240980538445683e-09
without O 0 5.989019058461054e-09
affecting O 0 3.0734611300431425e-08
the O 0 8.839522003256661e-09
growth O 0 1.5441074197042326e-08
rate O 0 5.397465141498969e-09
and O 0 4.426896182962992e-09
cell O 0 1.0238784398097778e-07
cycle O 0 3.0946139872867207e-08
profile O 0 2.8046329703101947e-08
of O 0 1.0908816960863987e-08
these O 0 2.353598205218077e-08
cells O 0 1.2107966540497728e-07
in O 0 4.395347730223875e-08
culture O 0 2.1263124381221132e-06
. O 0 2.15113686863333e-06

The O 0 1.4153153642837424e-05
786 O 0 8.336237806361169e-05
- O 0 6.620872227358632e-06
0 O 0 1.4753992445548647e-06
cell O 0 6.791862574573315e-07
line O 0 5.346917077986291e-07
, O 0 7.896960418918297e-09
like O 0 7.751002506495297e-09
many O 0 4.0949224455744115e-08
cancer B-Disease 0 8.675928597767779e-07
cells O 0 6.641809591201309e-08
, O 0 6.756612602742962e-09
fails O 0 1.1264076782424581e-08
to O 0 5.137140934863282e-09
exit O 0 5.251910906167723e-08
the O 0 1.9423788799599606e-08
cell O 0 2.0464068484216114e-07
cycle O 0 1.193542402688763e-07
upon O 0 1.3137635335169762e-07
serum O 0 1.1856254786835052e-06
withdrawal O 0 3.0110672923910897e-06
. O 0 6.277389729802962e-06

Here O 0 5.328409770299913e-06
, O 0 2.898158300013165e-07
it O 0 1.477154221163346e-08
is O 0 3.984770735598886e-09
shown O 0 2.401212784164386e-09
that O 0 8.009115592955141e-10
reintroduction O 0 1.1998800175661017e-07
of O 0 3.0605505685343815e-08
the O 0 5.8407650271874445e-08
wild O 0 2.6998864086635876e-06
- O 0 6.0988841141806915e-06
type O 0 1.0802600627357606e-05
VHL B-Disease 1 0.9982776641845703
gene O 0 4.421738708515477e-07
restores O 0 1.266601088900643e-06
the O 0 6.221969073294531e-08
ability O 0 9.27672161310511e-08
of O 0 1.4387842384167016e-06
VHL O 1 1.0
- O 1 0.9999971389770508
negative O 0 0.03542693704366684
RCC B-Disease 1 1.0
cancer I-Disease 0 2.0920555471093394e-05
cells O 0 3.76501532173279e-08
to O 0 5.12399855878698e-09
exit O 0 4.617553273078556e-08
the O 0 1.899570811758622e-08
cell O 0 1.1736204896806157e-07
cycle O 0 3.553830651981116e-08
and O 0 2.4753820326850473e-08
enter O 0 5.10270126596879e-07
G0 O 0 0.0003506023494992405
/ O 0 7.673713298572693e-06
quiescence O 0 4.231403636367759e-06
in O 0 2.8002344265587453e-07
low O 0 3.677768290799577e-06
serum O 0 6.449977263400797e-06
. O 0 3.821312930085696e-06

Both O 0 4.689376874011941e-05
VHL O 1 0.9999973773956299
- O 0 0.0002933960349764675
positive O 0 2.7855714961333433e-06
and O 0 9.532823241897859e-07
VHL O 1 1.0
- O 0 0.44454944133758545
negative O 0 7.04239027982112e-06
RCC B-Disease 1 0.9999954700469971
cells O 0 7.124194780772086e-07
exit O 0 2.4844547397151473e-07
the O 0 2.1489187318479708e-08
cell O 0 1.6108438671835756e-07
cycle O 0 6.108588479492028e-08
by O 0 3.878074394947362e-08
contact O 0 4.789504828295321e-07
inhibition O 0 2.673868266356294e-06
. O 0 3.837103577097878e-06

The O 0 5.375016917241737e-05
cyclin O 0 0.00010771213419502601
- O 0 3.2352341804653406e-05
dependent O 0 3.7500765301956562e-06
kinase O 0 5.314240752340993e-06
inhibitor O 0 1.5035765272841672e-06
, O 0 1.3975753176964645e-07
p27 O 0 2.3499840153817786e-06
, O 0 1.2907137580953076e-08
accumulates O 0 1.047407636178832e-07
upon O 0 1.4895917388457747e-08
serum O 0 3.6005193493338083e-08
withdrawal O 0 2.673250598661525e-08
, O 0 3.906468926118123e-09
only O 0 2.183615732676003e-09
in O 0 2.0593144967051558e-09
the O 0 4.0555745428605405e-09
presence O 0 4.6854321311684544e-08
of O 0 8.593453770799897e-08
VHL B-Disease 1 0.9999926090240479
, O 0 2.266829035590945e-08
as O 0 9.264410572029647e-09
a O 0 3.109587698446603e-09
result O 0 5.2019011320680875e-09
of O 0 8.20424439496037e-09
the O 0 1.337012189850384e-08
stabilization O 0 3.636165217812959e-07
of O 0 1.3407628784989356e-07
the O 0 3.6466946085056406e-07
protein O 0 3.2520929380552843e-06
. O 0 3.574528591343551e-06

We O 0 1.2552077350846957e-06
propose O 0 2.999623518462613e-07
that O 0 4.9923276179697496e-08
the O 0 1.0539767458794813e-07
loss O 0 3.799988235186902e-07
of O 0 5.503754891833523e-07
wild O 0 8.756343959248625e-06
- O 0 2.440062780806329e-05
type O 0 0.00037704294663853943
VHL B-Disease 1 0.9999980926513672
gene O 0 6.806491370525691e-08
results O 0 4.254092544897503e-08
in O 0 5.084705545499446e-09
a O 0 4.448318602356949e-09
specific O 0 2.145470467951327e-08
cellular O 0 4.3903628466068767e-07
defect O 0 6.552828040184977e-07
in O 0 5.7453885204949984e-08
serum O 0 1.5161193687163177e-06
- O 0 2.7710914309864165e-06
dependent O 0 6.190252292981313e-07
growth O 0 5.5495991801990385e-08
control O 0 2.7179078543326796e-08
, O 0 1.2071804889046689e-08
which O 0 5.433161476275927e-09
may O 0 3.2600091515178065e-08
initiate O 0 2.5221163468813756e-07
tumor B-Disease 0 9.795852747629397e-06
formation O 0 7.830196409486234e-06
. O 0 7.001300673437072e-06

This O 0 3.880057874994236e-07
is O 0 6.318902734392395e-08
corrected O 0 4.2745566020130354e-07
by O 0 1.6725202556244767e-08
the O 0 3.505313017626577e-08
reintroduction O 0 7.690568395446462e-07
of O 0 1.0621278079270269e-07
wild O 0 2.1557475520239677e-06
- O 0 8.757070645515341e-06
type O 0 0.00021628073591273278
VHL B-Disease 1 1.0
, O 0 8.579897894378519e-07
implicating O 1 0.8596552610397339
VHL B-Disease 1 1.0
as O 0 3.4604204302013386e-07
the O 0 5.4682733008348805e-08
first O 0 6.875489333424412e-08
tumor B-Disease 0 1.2263869848538889e-06
suppressor O 0 2.4661017050675582e-06
involved O 0 1.4515759261257699e-08
in O 0 4.4263308573988525e-09
the O 0 1.098928148479672e-08
regulation O 0 7.209520447304385e-08
of O 0 3.599681619448347e-08
cell O 0 1.730638956587427e-07
cycle O 0 5.0497305892349686e-08
exit O 0 7.476623409274907e-08
, O 0 6.780561001562546e-09
which O 0 1.5761388860724423e-09
is O 0 1.4293624062133858e-09
consistent O 0 1.6597828889075572e-08
with O 0 2.2587658410344602e-09
its O 0 1.1172986980056976e-08
gatekeeper O 0 2.3601126031280728e-07
function O 0 8.957666608466752e-09
in O 0 2.574687307799195e-08
the O 0 2.7249316758570785e-07
kidney O 0 6.064798799343407e-05
. O 0 6.102650331740733e-07
. O 0 3.203008418495301e-06

Piebaldism B-Disease 1 1.0
with O 0 0.021739037707448006
deafness B-Disease 1 1.0
: O 0 1.7807997210184112e-06
molecular O 0 1.453570348530775e-06
evidence O 0 2.036788373516174e-07
for O 0 3.300142381590376e-08
an O 0 8.095375392258575e-08
expanded O 0 4.879718289885204e-06
syndrome O 1 0.9987039566040039
. O 0 1.1323938451823778e-05

In O 0 4.569340319449111e-07
a O 0 3.3505691021673556e-07
South O 0 6.598392587875423e-07
African O 0 3.490472693101765e-07
girl O 0 3.199474747361819e-07
of O 0 6.96851429893286e-08
Xhosa O 0 2.442394361423794e-06
stock O 0 2.957803530989622e-07
with O 0 1.2602181520549038e-08
severe O 0 4.007837105746148e-06
piebaldism B-Disease 1 0.9928931593894958
and O 0 4.558443379210075e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.2627980140678119e-05
identified O 0 2.640605600845447e-07
a O 0 1.5125529273518623e-08
novel O 0 4.7400657621210485e-08
missense O 0 1.4678583681870805e-07
substitution O 0 1.8455348538282124e-07
at O 0 8.208301949252927e-08
a O 0 1.6809375225079748e-08
highly O 0 2.4516065622037786e-08
conserved O 0 1.3390747710673168e-07
residue O 0 1.9071370616075e-07
in O 0 1.4557294036876556e-08
the O 0 5.9510696814868425e-08
intracellular O 0 7.836799795768457e-07
kinase O 0 1.3127707916282816e-06
domain O 0 2.8449693445509183e-07
of O 0 2.540089951708069e-07
the O 0 4.539284645943553e-07
KIT O 0 0.0002494384243618697
proto O 0 0.00017491001926828176
- O 0 5.5279881053138524e-05
oncogene O 0 0.00016166553541552275
, O 0 2.845994458766654e-06
R796G O 0 0.00014422093227040023
. O 0 1.2920316294184886e-05

Though O 0 3.7175593661231687e-06
auditory B-Disease 0 0.2490740269422531
anomalies I-Disease 0 0.25422534346580505
have O 0 1.0620447454812165e-07
been O 0 6.714925859796494e-08
observed O 0 7.18293406976045e-08
in O 0 1.022178430787335e-08
mice O 0 4.419246835141166e-08
with O 0 1.4279052606980258e-08
dominant O 0 0.00022408667427953333
white O 0 1.293696755055862e-06
spotting O 0 0.009141199290752411
( O 0 1.0931238421107992e-06
W O 1 0.9998688697814941
) O 0 1.6602388797082313e-08
due O 0 2.2607322236467553e-08
to O 0 1.2051168951643376e-08
KIT O 1 0.7958212494850159
mutations O 0 0.0001056929977494292
, O 0 1.935587715706788e-05
deafness B-Disease 1 1.0
is O 0 3.4268435200601743e-08
not O 0 5.658059798463455e-09
typical O 0 7.261382251044779e-08
in O 0 5.953442538952913e-08
human O 0 1.3152945257388637e-06
piebaldism B-Disease 0 0.00016711662465240806
. O 0 9.60239049163647e-06

Thus O 0 2.4238545393018285e-06
, O 0 1.1213984407731914e-07
the O 0 3.539685167197604e-08
occurrence O 0 1.3165997643227456e-06
of O 0 8.334649464813992e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 2.647306610015221e-05
this O 0 3.207588505915737e-08
patient O 0 6.241569394660473e-08
extends O 0 2.6329303182137664e-08
considerably O 0 2.2246261721647898e-08
the O 0 4.7096300193061325e-09
phenotypic O 0 2.932728371263238e-08
range O 0 1.3699558110147336e-07
of O 0 4.963028388260682e-08
piebaldism B-Disease 0 4.094792984687956e-06
due O 0 7.325429152160723e-08
to O 0 1.521134151971637e-08
KIT O 0 1.2392857797749457e-06
gene O 0 3.2913479941498736e-08
mutation O 0 1.1818168665911344e-08
in O 0 5.332497554633164e-09
humans O 0 1.9017750929606336e-08
and O 0 1.3415539790173625e-08
tightens O 0 2.520904445191263e-07
the O 0 2.568340384812018e-08
clinical O 0 7.833088488951034e-08
similarity O 0 9.163048986238209e-08
between O 0 1.0941912620410221e-07
piebaldism B-Disease 0 1.6265528756775893e-05
and O 0 1.378851077760146e-08
the O 0 1.2463251763961125e-08
various O 0 1.8867233109176595e-08
forms O 0 9.93630848711291e-08
of O 0 2.3173715817392804e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 2.0267857507860754e-06
. O 0 1.0006905540649313e-05

Cycloheximide O 0 0.0001809012464946136
facilitates O 0 2.616623078210978e-06
the O 0 1.9163771014518716e-07
identification O 0 6.175723115120491e-07
of O 0 4.267839699423348e-07
aberrant O 0 3.474332970654359e-06
transcripts O 0 2.211322907896829e-06
resulting O 0 4.7620815735172073e-07
from O 0 1.19544367294111e-07
a O 0 6.453186784938225e-08
novel O 0 1.8188174522038025e-07
splice O 0 7.304385690076742e-06
- O 0 1.0273207635691506e-06
site O 0 1.5799328423327097e-07
mutation O 0 5.262599600541762e-08
in O 0 3.763708633641727e-08
COL17A1 O 1 0.8431275486946106
in O 0 2.3598733633889424e-08
a O 0 4.1170387987676804e-08
patient O 0 1.3011774058213632e-07
with O 0 1.4477843990334804e-07
generalized O 1 0.9999362230300903
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.999968409538269
. O 0 9.55493887886405e-05

Patients O 0 1.8650964648259105e-06
with O 0 2.3833348450352787e-07
generalized O 1 0.9434091448783875
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999959468841553
often O 0 3.1887765317151207e-07
show O 0 9.616282881097504e-08
decreased O 0 1.0869877797858862e-07
expression O 0 4.6679573983965383e-08
of O 0 5.3992391002566364e-08
type O 0 2.64056552623515e-06
XVII O 1 0.9999960660934448
collagen O 0 1.2612837963388301e-05
, O 0 2.310168127905854e-07
a O 0 2.2199239424480766e-07
transmembrane O 0 7.361196821875637e-06
hemidesmosomal O 0 9.197320650855545e-06
protein O 0 6.846640303592721e-07
encoded O 0 4.3773397351287713e-07
by O 0 6.713714810757665e-07
COL17A1 O 1 0.5736894607543945
. O 0 1.534529474156443e-05

This O 0 7.48744014344993e-07
report O 0 6.871005666653218e-07
documents O 0 1.605531110726588e-06
a O 0 3.684437785977934e-07
novel O 0 9.512980341241928e-07
splice O 0 3.297622606623918e-05
- O 0 2.783069930956117e-06
site O 0 3.9816205799070303e-07
mutation O 0 6.532928864544374e-08
in O 0 3.9314890898367594e-08
COL17A1 O 1 0.9983964562416077
in O 0 1.4848884788420946e-08
a O 0 1.688350259598792e-08
patient O 0 4.260092723029629e-08
with O 0 2.944886290379145e-08
generalized O 1 0.9999574422836304
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9962779879570007
, O 0 1.0791563909151591e-07
and O 0 1.375027203209811e-08
applies O 0 3.3806976773576025e-08
a O 0 7.305863025663939e-09
new O 0 5.8910982758675345e-09
methodology O 0 3.458565700498184e-08
to O 0 7.656859146720763e-09
define O 0 1.306865584638217e-07
and O 0 8.184647981579474e-08
characterize O 0 8.633060133433901e-07
the O 0 3.370085437381931e-07
resulting O 0 8.421390020885156e-07
mRNA O 0 6.827230208727997e-06
splice O 0 3.494268821668811e-05
variants O 0 2.422915531496983e-05
. O 0 1.4228467989596538e-05

Mutational O 0 0.00024312411551363766
analysis O 0 5.7203978940378875e-06
of O 0 2.9873897346988088e-06
COL17A1 O 1 0.8059589266777039
identified O 0 2.3185207282949705e-06
a O 0 3.7940603192510025e-07
maternally O 0 3.123662509096903e-06
inherited O 0 3.1073861919139745e-06
G O 0 1.0505269528948702e-05
- O 0 2.6715692911238875e-06
to O 0 3.08326121967184e-07
- O 0 1.2234525456733536e-05
T O 0 1.5276524209184572e-05
transversion O 0 5.934468390478287e-06
at O 0 1.1484657136406895e-07
the O 0 6.10800654499144e-08
- O 0 2.1982476994253375e-07
1 O 0 1.716925481787257e-07
position O 0 1.3575133550602914e-07
of O 0 1.3517502850390883e-07
exon O 0 3.322308884889935e-06
32 O 0 8.949625225795899e-06
. O 0 3.903130163962487e-06

This O 0 1.022137439576909e-06
acceptor O 0 1.1966410966124386e-05
splice O 0 0.00010252720676362514
- O 0 5.53975496586645e-06
site O 0 3.344203491906228e-07
mutation O 0 7.135346180575652e-08
led O 0 5.150909032636264e-08
to O 0 5.820877113649203e-09
the O 0 1.5358361693529332e-08
formation O 0 1.7962771892143792e-07
of O 0 8.860828870638215e-08
aberrant O 0 2.628999311582447e-07
transcripts O 0 4.655092311622866e-07
present O 0 8.281552510425172e-08
at O 0 1.888617759959743e-07
extremely O 0 3.3219433248632413e-07
low O 0 1.2678749499173136e-06
levels O 0 1.1672329947032267e-06
. O 0 2.7321939342073165e-06

Based O 0 4.932810043101199e-06
on O 0 6.99614133736759e-07
our O 0 1.6979068107048079e-07
recent O 0 7.12545897840755e-08
finding O 0 8.258098205260467e-08
that O 0 2.9042666938039474e-08
cycloheximide O 0 2.0293355191824958e-05
stabilized O 0 6.596463663299801e-06
mutant O 0 4.3595064198598266e-06
COL17A1 O 0 0.0001029184422804974
transcripts O 0 7.895071689745237e-07
in O 0 4.494391347975579e-08
keratinocytes O 0 1.0128234180228901e-06
homozygous O 0 7.984901628788066e-08
for O 0 7.919269684464325e-09
a O 0 1.3181654878735571e-08
frameshift O 0 2.9827731395926094e-07
mutation O 0 2.3060467313484878e-08
, O 0 5.32951816012428e-09
the O 0 2.0721284244018534e-08
effects O 0 2.5369283207510307e-07
of O 0 1.6816294134969212e-07
the O 0 2.1930485161192337e-07
splice O 0 1.0762446436274331e-05
- O 0 1.6886230014279136e-06
site O 0 3.021443717443617e-07
mutation O 0 2.934602960635857e-08
on O 0 1.229992960816162e-07
splicing O 0 8.410883651777112e-07
of O 0 4.78275865134492e-07
COL17A1 O 0 0.00015818262181710452
transcripts O 0 1.7064761550500407e-06
were O 0 7.605743235217233e-08
determined O 0 5.7945491960254e-08
using O 0 2.6063588620672817e-08
reverse O 0 1.5374693873582146e-07
transcriptase O 0 3.1966808933248103e-07
polymerase O 0 3.962082928410382e-07
chain O 0 5.950309400759579e-08
reaction O 0 5.748096043589612e-08
of O 0 5.139191827652212e-08
total O 0 2.4734232439982407e-08
RNA O 0 4.937497806167812e-07
from O 0 1.526188526668193e-07
keratinocytes O 0 1.3384917565417709e-06
incubated O 0 1.320016963290982e-06
for O 0 1.3996775294344843e-07
2 O 0 3.3477660963399103e-06
. O 0 1.747637156768178e-06

5 O 0 1.9643232008093037e-05
h O 0 2.6716404590843013e-06
in O 0 7.811097191279259e-08
the O 0 1.113420964315992e-07
presence O 0 2.071680711424051e-07
or O 0 1.1757556706015748e-07
absence O 0 3.239500983909238e-06
of O 0 1.8490826505512814e-06
10 O 0 2.405576879027649e-06
microg O 0 5.9111789596499875e-05
cycloheximide O 0 2.859495180018712e-05
per O 0 9.505362186246202e-07
ml O 0 9.981999937735964e-06
. O 0 2.9852765237592394e-06

Using O 0 6.829632184235379e-07
this O 0 7.64317533707981e-08
approach O 0 2.240858378854682e-07
, O 0 4.156600397209331e-08
an O 0 4.759597871384358e-08
abnormally O 0 1.0012746542997775e-06
spliced O 0 1.8773167766994447e-06
transcript O 0 1.7090299024857813e-06
was O 0 1.4224026756437524e-07
identified O 0 5.2393140492768e-08
that O 0 3.3635361162964728e-09
contains O 0 6.6678920163099065e-09
an O 0 6.410687980462626e-09
extra O 0 3.435279083419118e-08
264 O 0 7.461152762289203e-08
bases O 0 1.4097339828822442e-07
upstream O 0 3.047101984066103e-07
from O 0 4.3457482945541415e-08
exon O 0 2.9619616270792903e-07
32 O 0 1.548894061897954e-07
, O 0 8.90051143898063e-09
resulting O 0 2.5739014475334443e-08
in O 0 7.252590528139535e-09
a O 0 2.9169907378445714e-08
premature O 0 8.538977454009e-07
termination O 0 1.2240524256412755e-06
codon O 0 6.595117156393826e-06
27 O 0 6.007262982166139e-06
bp O 0 4.2044689507747535e-06
downstream O 0 6.71547695674235e-06
from O 0 6.324195283013978e-07
the O 0 1.4240154087019619e-06
cryptic O 0 6.118458259152249e-05
splice O 0 0.00024712044978514314
site O 0 6.23527739662677e-05
. O 0 2.760952338576317e-05

Three O 0 1.7751651739672525e-06
other O 0 1.9068787082687777e-07
splice O 0 7.55723749534809e-06
variants O 0 5.577262527367566e-07
, O 0 2.110041386060857e-08
including O 0 1.5961612476189657e-08
one O 0 9.066991601969221e-09
derived O 0 4.7363513999698625e-08
from O 0 3.505332912823178e-08
the O 0 5.0898989911729586e-08
skipping O 0 2.527114872918901e-07
of O 0 9.022124913826701e-08
exon O 0 5.008379275750485e-07
32 O 0 3.8708401461917674e-07
, O 0 2.530934573030663e-08
were O 0 7.254890022068139e-08
also O 0 1.1364699759042196e-07
identified O 0 1.0858952919079456e-06
. O 0 3.620750021582353e-06

These O 0 5.284155122353695e-07
results O 0 3.348154109517054e-07
indicate O 0 2.3574199303766363e-07
the O 0 7.353665409937094e-08
usefulness O 0 1.0292351362295449e-06
of O 0 6.504519234340478e-08
cycloheximide O 0 6.995593594183447e-06
treatment O 0 7.465921925131624e-08
in O 0 9.466542216785001e-09
evaluating O 0 6.602868296567976e-08
the O 0 3.374725565663539e-08
abnormal O 0 4.1683346552190415e-08
processing O 0 7.916116118167338e-08
of O 0 6.344396297208732e-08
mRNA O 0 4.52107002502089e-07
due O 0 1.3089673700505955e-07
to O 0 6.284466280703782e-08
splice O 0 7.982927854754962e-06
- O 0 5.885417522222269e-07
site O 0 2.1200487765327125e-07
mutations O 0 6.586843426248379e-08
, O 0 1.890696843531714e-08
because O 0 3.4889705347040945e-08
( O 0 1.1682826084324915e-07
i O 0 2.553545641603705e-07
) O 0 3.794472291929196e-08
aberrant O 0 9.995633831749728e-08
splicing O 0 2.1057522303635778e-07
often O 0 2.2170988600578312e-08
generates O 0 6.243081429602171e-08
a O 0 1.9661598571474315e-08
premature O 0 2.2569308555375756e-07
termination O 0 1.6385156698106584e-07
codon O 0 3.9447999711228476e-07
, O 0 8.628403236343729e-08
( O 0 5.8869787267212814e-08
ii O 0 5.661852810590062e-06
) O 0 1.4441777551610357e-08
transcripts O 0 1.0519524096253008e-07
with O 0 1.2475880772910841e-08
premature O 0 2.2760229967389023e-07
termination O 0 1.3110900454194052e-07
codons O 0 1.6386391621381335e-07
can O 0 1.1198782345900327e-08
occur O 0 2.6668489638836945e-08
at O 0 2.4470187653946596e-08
low O 0 7.583695094126597e-08
or O 0 1.0327354083017326e-08
undetectable O 0 9.050839366864238e-08
levels O 0 6.824180776021649e-09
due O 0 9.515855659003591e-09
to O 0 6.999896218218282e-09
nonsense O 0 1.34860712819318e-07
- O 0 1.9735810496968043e-07
mediated O 0 2.2140272903925506e-07
mRNA O 0 2.3798983761480486e-07
decay O 0 1.6464589691622677e-07
, O 0 1.336410537788879e-08
and O 0 9.209407458854457e-09
( O 0 8.565695708284693e-09
iii O 0 1.5851290982027422e-06
) O 0 6.925130691115555e-09
the O 0 6.877270308791594e-09
levels O 0 7.748194086332205e-09
of O 0 4.705320133524538e-09
these O 0 5.2521986759757056e-09
transcripts O 0 7.311330563197771e-08
can O 0 4.826937960444866e-09
be O 0 2.046269464983652e-08
increased O 0 8.444006027730211e-08
by O 0 1.4248641377889726e-07
cycloheximide O 0 0.0001189253234770149
. O 0 7.65762979426654e-06

A O 0 6.543469226016896e-06
deletion O 0 1.9140111362503376e-06
mutation O 0 7.937189820950152e-07
in O 0 2.7823219284073275e-07
COL17A1 O 1 0.9701169729232788
in O 0 4.337450931757303e-08
five O 0 6.817145248305678e-08
Austrian O 0 2.5257465949835023e-06
families O 0 8.354119529485615e-08
with O 0 8.54579056408511e-08
generalized O 1 0.8879225850105286
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9931780099868774
represents O 0 7.915751325526799e-07
propagation O 0 2.311835260115913e-06
of O 0 2.566274588389206e-07
an O 0 1.5813014897503308e-07
ancestral O 0 8.977775905805174e-06
allele O 0 1.111807614506688e-05
. O 0 9.730611054692417e-06

Patients O 0 5.859549673914444e-06
with O 0 5.842837254022015e-07
generalized O 1 0.9994334578514099
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999629259109497
, O 0 2.1679535677776585e-07
a O 0 3.78406461720715e-08
usually O 0 3.1489697960296326e-08
nonlethal O 0 2.4702821974642575e-06
form O 0 2.091099275958186e-07
of O 0 2.08305550586374e-06
junctional B-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999961853027344
, O 0 5.618572345156281e-07
have O 0 7.232135601498157e-08
generalized O 0 1.5968150819389848e-06
blistering B-Disease 0 7.767277566017583e-06
, O 0 1.2688838069152553e-06
nail B-Disease 1 0.9996465444564819
dystrophy I-Disease 1 1.0
, O 0 0.0004351109091658145
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.004524849820882082
and O 1 0.837203323841095
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.999943733215332

Skin B-Disease 1 0.999940037727356
fragility I-Disease 0 0.008799056522548199
in O 0 7.710148253181615e-08
most O 0 2.2074740257949088e-08
cases O 0 1.029698548649094e-08
is O 0 2.8807023433330414e-09
due O 0 8.724315492258938e-09
to O 0 3.578656482261522e-09
mutations O 0 2.570001456092541e-08
in O 0 4.2172105807480875e-09
the O 0 6.637425720157353e-09
gene O 0 2.2133425758852354e-08
encoding O 0 3.856466435081529e-07
type O 0 7.845775144232903e-06
XVII O 1 0.9999929666519165
collagen O 0 0.00019191800674889237
( O 0 6.066399237170117e-06
COL17A1 O 1 0.8382713198661804
) O 0 2.4015862436499447e-06
. O 0 3.2782093057903694e-06

Recently O 0 6.153896720206831e-06
, O 0 3.188864639014355e-07
we O 0 5.170034000911983e-08
reported O 0 1.2044647235143202e-07
five O 0 3.169330398122838e-08
Austrian O 0 9.557373914503842e-07
families O 0 4.923166585513172e-08
with O 0 4.823065680170657e-08
generalized O 1 0.6747499108314514
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999996423721313
who O 0 8.005310405678756e-07
share O 0 1.30139213183611e-07
the O 0 7.218271491638006e-08
same O 0 2.2043315084374626e-07
COL17A1 O 0 0.0004534065374173224
mutation O 0 2.2462081687990576e-06
. O 0 3.913036380254198e-06

Affected O 0 1.4467315168076311e-06
individuals O 0 2.5291972960417297e-08
in O 0 8.773008097762158e-09
three O 0 5.2110173953678895e-09
families O 0 2.92491164621822e-09
are O 0 2.2017079270852946e-09
homozygous O 0 1.3303425028254878e-08
for O 0 6.731747603794247e-09
4003delTC O 0 1.4505442891277198e-07
, O 0 6.530298080065222e-09
whereas O 0 8.105801363456067e-09
those O 0 5.782611278704053e-09
in O 0 6.268087826555302e-09
two O 0 1.699312157654731e-08
others O 0 7.55395674900683e-08
are O 0 7.1202421736416e-08
compound O 0 6.432826012314763e-06
heterozygotes O 0 6.851871876278892e-05
. O 0 1.395493200107012e-05

To O 0 1.618180505147393e-07
determine O 0 2.2236912400330766e-07
if O 0 4.048450463756126e-08
the O 0 1.993803522282178e-08
occurrence O 0 1.1884177553156405e-07
of O 0 2.9669362078266204e-08
4003delTC O 0 3.72068740261966e-07
in O 0 5.780394385368481e-09
these O 0 8.557661246300086e-09
unrelated O 0 1.7672435603799386e-07
families O 0 1.509642011399137e-08
signifies O 0 4.539388598345795e-08
propagation O 0 1.3502595663794636e-07
of O 0 2.1291842955406537e-08
an O 0 1.3651336061570873e-08
ancestral O 0 3.7381826700766396e-07
allele O 0 7.91706753489052e-08
or O 0 2.1006650641197666e-08
a O 0 3.862948005917133e-08
mutational O 0 4.960935712006176e-06
hot O 0 2.6088812319358112e-06
spot O 0 1.0223928939012694e-06
, O 0 4.936706687885817e-08
haplotypes O 0 6.683434321530513e-07
were O 0 2.5407432602264635e-08
determined O 0 4.500138217622407e-08
for O 0 4.518966534305946e-08
polymorphisms O 0 2.077104227282689e-06
both O 0 2.933520875103568e-07
within O 0 4.0228303532785503e-07
and O 0 1.1236448926865705e-06
flanking O 0 0.001912602805532515
COL17A1 O 1 0.9999943971633911
. O 0 4.900336716673337e-05

Five O 0 9.516568752587773e-06
intragenic O 0 4.720667493529618e-05
polymorphisms O 0 3.968548753618961e-06
were O 0 2.2166258872857725e-07
chosen O 0 1.998864433971903e-07
based O 0 2.3720765796042542e-07
on O 0 2.7679539016389754e-07
their O 0 2.2444558567258355e-07
informativeness O 0 0.000458553055068478
. O 0 1.2326613614277449e-05

One O 0 1.0500534699531272e-06
of O 0 2.428627396966476e-07
these O 0 8.318089328440692e-08
, O 0 1.9615150392837677e-08
not O 0 9.732212369328863e-09
previously O 0 4.0314596105872624e-08
reported O 0 5.064083197225955e-08
, O 0 9.29247878644901e-09
was O 0 5.859097029770055e-08
2988 O 0 1.344935526503832e-06
A O 0 2.0926295007939189e-07
or O 0 5.081663800865499e-08
C O 0 1.1387464837753214e-06
that O 0 9.324933714083272e-09
introduces O 0 5.631791566429456e-08
a O 0 1.7578985378463585e-08
new O 0 3.9725019718162e-08
restriction O 0 1.701158112155099e-07
site O 0 5.394019808591111e-07
for O 0 2.66145832483744e-07
Eco0109 O 0 0.00010502398799872026
I O 0 5.097229950479232e-05
. O 0 1.4760221347387414e-05

All O 0 9.750096978677902e-07
the O 0 6.948631607883726e-07
4003delTC O 0 5.689125828212127e-06
alleles O 0 6.642772518716811e-07
showed O 0 1.5513110440679156e-07
the O 0 1.646872682670164e-08
same O 0 1.3704922530166641e-08
haplotype O 0 2.8629025905502203e-07
for O 0 1.4773428702596902e-08
these O 0 3.84877587578103e-08
five O 0 2.9505292786780046e-07
polymorphic O 0 6.716040843457449e-06
markers O 0 5.184442125027999e-05
. O 0 1.945380608958658e-05

Fourteen O 0 8.611833618488163e-05
microsatellite O 0 2.1033865778008476e-05
polymorphisms O 0 4.805215667147422e-06
were O 0 2.3239833524257847e-07
selected O 0 9.816876200829938e-08
based O 0 4.0852256688594935e-08
on O 0 3.553871152917054e-08
their O 0 1.516013270475014e-08
high O 0 8.157201705216721e-07
heterozygosity O 0 0.00018024217570200562
and O 0 7.704208826453396e-08
their O 0 3.255156499903933e-08
location O 0 6.332523980745464e-07
within O 0 4.459109561594232e-07
10q23 O 0 6.0833692259620875e-05
- O 0 2.2666969016427174e-05
q25 O 0 0.0001824076462071389
near O 0 2.2474025172414258e-05
COL17A1 O 0 0.003385742660611868
. O 0 2.5131292204605415e-05

Three O 0 4.496883320825873e-06
families O 0 1.6543930314583122e-06
shared O 0 4.232803803461138e-06
microsatellite O 0 4.362436447991058e-05
polymorphisms O 0 3.2220286811934784e-05
covering O 0 7.528363312303554e-06
at O 0 2.8076362923457054e-07
most O 0 1.154182953655436e-07
19 O 0 3.279361067143327e-07
cM O 0 1.9097652170785295e-07
, O 0 5.915294920555425e-09
whereas O 0 1.6418358228520447e-08
the O 0 1.6261656909932753e-08
others O 0 3.488904098958301e-08
shared O 0 4.176683177092855e-08
smaller O 0 3.985297425401768e-08
regions O 0 3.662517400471188e-08
consistent O 0 9.336059747511172e-08
with O 0 2.3773571555807393e-08
cross O 0 1.1413003448978998e-06
- O 0 1.0114517863257788e-06
over O 0 5.2253227522669476e-08
events O 0 3.4414505023505626e-08
during O 0 1.571636865094206e-08
passage O 0 4.5402369863722924e-08
of O 0 1.0341013378933894e-08
this O 0 6.324326395912294e-09
mutation O 0 2.335193194369367e-08
through O 0 2.4736072745668025e-08
several O 0 1.868538106464257e-07
generations O 0 5.12180122314021e-06
. O 0 7.382963303825818e-06

These O 0 6.385831738953129e-07
results O 0 4.989348099115887e-07
indicate O 0 3.328320303808141e-07
that O 0 1.7480884295650867e-08
4003delTC O 0 7.034282702989003e-07
occurs O 0 2.5345768150941694e-08
on O 0 3.22524478235664e-08
a O 0 2.3951896466201106e-08
single O 0 8.047405231081939e-08
ancestral O 0 2.2665385586151388e-06
allele O 0 1.190890429825231e-06
. O 0 5.937712899140024e-07
. O 0 3.1619176752428757e-06

The O 0 2.1901629224885255e-05
haptoglobin O 0 0.00031560988281853497
- O 0 8.734075890970416e-06
gene O 0 5.391879653871001e-07
deletion O 0 4.4461114612204256e-07
responsible O 0 5.658763484461815e-07
for O 0 5.421399009719607e-07
anhaptoglobinemia B-Disease 0 0.0010152269387617707
. O 0 1.7167996702482924e-05

We O 0 6.24809672444826e-07
have O 0 3.478750798535657e-08
found O 0 3.0093222136429176e-08
an O 0 2.0746515616565375e-08
allelic O 0 7.046321002235345e-07
deletion O 0 1.1723698634114044e-07
of O 0 3.031779556295078e-07
the O 0 7.44072963243525e-07
haptoglobin O 0 0.0004232853534631431
( O 0 1.9713237975338416e-07
Hp O 0 1.243469114342588e-07
) O 0 6.201706259645334e-09
gene O 0 7.069722141039847e-09
from O 0 1.2437413765553629e-08
an O 0 5.970177685554745e-09
individual O 0 2.1242719583369762e-08
with O 0 1.7400491003627394e-07
anhaptoglobinemia B-Disease 0 0.0016085130628198385
. O 0 8.068081115197856e-06

The O 0 5.366781806515064e-06
Hp O 0 1.9666777006932534e-06
gene O 0 3.7387744100669806e-07
cluster O 0 5.965968625787355e-07
consists O 0 3.996159492203333e-08
of O 0 7.390234202375723e-09
coding O 0 1.3691851563635282e-07
regions O 0 4.866552316684647e-08
of O 0 9.045368898341621e-08
the O 0 6.268891183935921e-08
alpha O 0 8.443071664032686e-08
chain O 0 1.806115790259355e-08
and O 0 5.363118393830746e-09
beta O 0 3.2200386357317257e-08
chain O 0 3.63448009466083e-08
of O 0 2.5441766027256563e-08
the O 0 6.1964477993115e-08
haptoglobin O 0 1.9093222363153473e-06
gene O 0 8.44587475512526e-08
( O 0 2.255576703191764e-08
Hp O 0 1.921251424619186e-08
) O 0 8.969613385367836e-10
and O 0 1.1073733041655487e-09
of O 0 4.324050451032235e-09
the O 0 1.3981093616166618e-08
alpha O 0 5.99332992123891e-08
chain O 0 2.025587519938199e-08
and O 0 1.1203525218661525e-08
beta O 0 1.0778213521689395e-07
chain O 0 9.130303624260705e-08
of O 0 7.147659886186375e-08
the O 0 1.597712184775446e-07
haptoglobin O 0 7.90893864177633e-06
- O 0 1.2072424624420819e-06
related O 0 3.4362923884145857e-07
gene O 0 2.85467990579491e-07
( O 0 8.268531814792368e-08
Hpr O 0 7.843776188565244e-07
) O 0 1.053831599762134e-08
, O 0 8.030260012503732e-09
in O 0 8.352378344511635e-09
tandem O 0 3.6321173979558807e-07
from O 0 8.697420383896315e-08
the O 0 2.3811605842638528e-07
5 O 0 9.557957127981354e-07
side O 0 3.889348135999171e-06
. O 0 7.160177119658329e-06

Southern O 0 1.7897187717608176e-05
blot O 0 1.810787398426328e-05
and O 0 1.1125697341185514e-07
PCR O 0 1.104182842937007e-06
analyses O 0 2.5614042442612117e-07
have O 0 1.3689926525728424e-08
indicated O 0 3.009362359307488e-08
that O 0 1.5836876254837762e-09
the O 0 8.443873156238624e-09
individual O 0 4.963044641925762e-09
with O 0 8.55913029340627e-09
anhaptoglobinemia B-Disease 0 9.40734116738895e-06
was O 0 9.422610247611374e-08
homozygous O 0 2.4136530996088368e-08
for O 0 5.033937711118597e-09
the O 0 1.3274858545742063e-08
gene O 0 1.8182964467428064e-08
deletion O 0 1.9901561287838376e-08
and O 0 7.45321315775982e-09
that O 0 2.093172968287149e-09
the O 0 1.299088925321712e-08
gene O 0 1.2781241842674262e-08
deletion O 0 2.7093365773112055e-08
was O 0 3.492899125490112e-08
included O 0 1.859858222985622e-08
at O 0 1.0256293592192378e-08
least O 0 5.0517123817428455e-09
from O 0 1.5147211485100343e-08
the O 0 3.6461099028883837e-08
promoter O 0 1.3614967429020908e-06
region O 0 2.9570139759016456e-07
of O 0 1.3151424127499922e-07
Hp O 0 2.403083954050089e-07
to O 0 1.1098335050974129e-07
Hpr O 0 3.2859052225830965e-06
alpha O 0 1.708769445940561e-07
but O 0 9.653253307817522e-09
not O 0 6.6994947367504665e-09
to O 0 6.2448563653561e-08
Hpr O 0 1.195706681755837e-05
beta O 0 1.9880787931469968e-06
( O 0 6.404378609659034e-07
Hpdel O 0 1.6314586900989525e-05
) O 0 5.546984880311356e-07
. O 0 1.9847595922328765e-06

In O 0 3.939082091619639e-07
addition O 0 1.8289266279225558e-07
, O 0 3.162567097092506e-08
we O 0 1.1917291153906717e-08
found O 0 1.6532489155451913e-08
seven O 0 9.510448428784457e-09
individuals O 0 2.6464928026825874e-09
with O 0 5.351367349248903e-09
hypohaptoglobinemia B-Disease 0 1.8312495058125933e-06
in O 0 5.255565760364789e-09
three O 0 3.1354174812037172e-09
families O 0 2.814888766522472e-09
, O 0 2.4384030350432795e-09
and O 0 1.4638058543070542e-09
the O 0 6.234131433302537e-09
genotypes O 0 2.9809729085172876e-07
of O 0 3.4293936579388173e-08
six O 0 3.742027132602743e-08
of O 0 2.053635839160961e-08
the O 0 4.211874937709581e-08
seven O 0 5.0146780949944514e-08
individuals O 0 1.1635055585657028e-08
were O 0 7.156936732144459e-08
found O 0 3.379214774668071e-08
to O 0 2.9425562431129038e-08
be O 0 5.481461471390503e-07
Hp2 O 0 0.0006539002642966807
/ O 0 0.00022959230409469455
Hpdel O 0 0.00025990826543420553
. O 0 1.1838260434160475e-05

The O 0 2.0366674107208382e-06
phenotypes O 0 5.5073228395485785e-06
and O 0 9.393379230004939e-08
genotypes O 0 1.6523243857591297e-06
in O 0 1.3269718657227259e-08
one O 0 5.3307789293910446e-09
of O 0 4.033664957603378e-09
these O 0 2.8000666230099114e-09
three O 0 6.787522544016156e-09
families O 0 8.75061267890942e-09
showed O 0 4.49283099612785e-08
the O 0 4.085443805479372e-08
father O 0 1.0141371831196011e-07
to O 0 4.1926544014359024e-08
be O 0 1.5852151591388974e-07
hypohaptoglobinemic B-Disease 0 4.3190837459405884e-05
( O 0 2.9946014024062606e-07
Hp2 O 0 9.3668404588243e-06
) O 0 5.7766172290030227e-08
and O 0 1.1076489414563184e-07
Hp2 O 0 2.3786806195857935e-05
/ O 0 2.9737516342720482e-06
Hpdel O 0 1.6612926629022695e-05
, O 0 3.7456334922580936e-08
the O 0 4.382548013381893e-08
mother O 0 6.10637584941287e-08
to O 0 1.7359278459139205e-08
be O 0 6.512004091518975e-08
Hp2 O 0 7.853717761463486e-06
- O 0 1.5062603324622614e-06
1 O 0 5.720293074773508e-07
and O 0 9.724553251544421e-08
Hp1 O 0 8.179720680345781e-06
/ O 0 6.569289894287067e-07
Hp2 O 0 1.5209897128443117e-06
, O 0 4.72530414796779e-09
one O 0 2.306635327187223e-09
of O 0 5.794590585139758e-09
the O 0 1.4297584449707301e-08
two O 0 1.4229001088494897e-08
children O 0 1.5043360335198486e-08
to O 0 1.07512097002882e-08
be O 0 9.564681135998399e-08
hypohaptoglobinemic B-Disease 0 5.494567449204624e-05
( O 0 2.9826790637343947e-07
Hp2 O 0 5.1270258154545445e-06
) O 0 3.343434329394768e-08
and O 0 5.051840545888808e-08
Hp2 O 0 1.8681455912883393e-05
/ O 0 2.2263168375502573e-06
Hpdel O 0 1.0123249012394808e-05
, O 0 1.8065843931935888e-08
and O 0 4.224334659852502e-09
the O 0 9.675447998347408e-09
other O 0 2.7884549780310408e-08
child O 0 3.827224759334058e-08
to O 0 1.1678165101614013e-08
be O 0 7.707853910687845e-08
Hp1 O 0 1.4422376807488035e-05
and O 0 5.029890530749981e-07
Hp1 O 0 0.00024967349600046873
/ O 0 2.953736657218542e-05
Hpdel O 0 5.831723683513701e-05
, O 0 5.616976750388858e-08
showing O 0 8.812052243456492e-08
an O 0 1.2824097339603213e-08
anomalous O 0 2.9552620617323555e-06
inheritance O 0 1.62200433351245e-06
of O 0 4.590834805640043e-07
Hp O 0 2.8235402282916766e-07
phenotypes O 0 7.527068532908743e-07
in O 0 3.655782165878918e-08
the O 0 1.5197369407360384e-07
child O 0 4.5543268356595945e-07
with O 0 3.822804046649253e-07
Hp1 O 0 0.013133581727743149
. O 0 1.9574919861042872e-05

The O 0 1.545113991596736e-05
Hp2 O 0 0.0010402867337688804
/ O 0 5.423730908660218e-05
Hpdel O 0 2.295426202181261e-05
individuals O 0 4.292964561614099e-08
had O 0 4.070758308216682e-08
an O 0 3.5401088727127217e-09
extremely O 0 1.9540467022238772e-08
low O 0 4.6639168971296385e-08
level O 0 7.779784283457047e-08
of O 0 5.910482059334754e-08
Hp O 0 9.778828058415456e-08
( O 0 6.156123077971642e-08
mean O 0 1.5616065240919852e-07
+ O 0 4.493388701121148e-07
/ O 0 1.17577087621612e-06
- O 0 2.11241899705783e-06
SD O 0 1.226909807883203e-05
= O 0 2.2031179014447844e-06
0 O 0 7.42778411222389e-07
. O 0 6.501616667264898e-08
049 O 0 2.332461463083746e-06
+ O 0 3.991818005033565e-07
/ O 0 5.058782903688552e-07
- O 0 4.5786578084516805e-07
0 O 0 3.403901018828037e-07
. O 0 4.730681624209865e-08
043 O 0 2.5595682018320076e-06
mg O 0 1.5898207266218378e-06
/ O 0 4.227460692618479e-07
ml O 0 3.804575499088969e-07
; O 0 3.374866963667955e-08
n O 0 4.856204327552405e-08
= O 0 1.848492274802993e-07
6 O 0 6.573890942718208e-08
) O 0 1.3412873034468475e-09
, O 0 5.903479927127364e-10
compared O 0 8.877093504722211e-10
with O 0 4.3641676383820993e-10
the O 0 5.478282272264323e-09
level O 0 1.8208648810968953e-08
( O 0 8.816638974451507e-09
1 O 0 3.367042467061765e-08
. O 0 5.200829544804719e-09
64 O 0 4.187300106650582e-08
+ O 0 5.851290652003627e-08
/ O 0 1.2493315182382503e-07
- O 0 3.1895157803774055e-07
1 O 0 1.663301532062178e-07
. O 0 2.475542437707645e-08
07 O 0 4.823792210117972e-07
mg O 0 7.085450874910748e-07
/ O 0 2.4179342972274753e-07
ml O 0 2.1272971650887484e-07
) O 0 3.856372110533357e-09
obtained O 0 1.562955631584373e-08
from O 0 2.8287333364573897e-08
52 O 0 1.3270407350773894e-07
healthy O 0 5.179282069889268e-08
volunteers O 0 9.853042826080127e-08
having O 0 2.4033674606016575e-08
phenotype O 0 3.345246568642324e-07
Hp2 O 0 1.881979187601246e-06
, O 0 2.3848325980679874e-08
whereas O 0 3.952119342898186e-08
the O 0 3.198131892645506e-08
serum O 0 1.835923768567227e-07
Hp O 0 4.8891791948335594e-08
level O 0 5.0114461913608466e-08
of O 0 1.3205814219929835e-08
an O 0 7.839662252706603e-09
individual O 0 1.2085282996565638e-08
with O 0 4.6693642730133433e-08
Hp1 O 0 0.00014563255535904318
/ O 0 1.9264571164967492e-05
Hpdel O 0 3.43779829563573e-05
was O 0 2.6224361135973595e-06
0 O 0 7.36913398213801e-06
. O 0 2.7454705104901223e-06

50 O 0 1.809382411011029e-05
mg O 0 2.8547954570967704e-05
/ O 0 1.9937406250392087e-06
ml O 0 1.1987503967247903e-06
, O 0 2.68920636870007e-08
which O 0 5.450630613523799e-09
was O 0 1.7692208587050118e-08
approximately O 0 4.3391286119742745e-09
half O 0 4.077057802476247e-09
the O 0 4.495529282166899e-09
level O 0 4.2389057597347346e-08
of O 0 1.5017359800140184e-08
Hp O 0 3.5780981733068984e-08
in O 0 7.940428758956841e-09
control O 0 5.482601750372851e-08
sera O 0 9.253187727154e-07
from O 0 3.481392596427213e-08
the O 0 2.0422423574473214e-07
Hp1 O 0 8.446584615739994e-06
phenotype O 0 7.682468208258797e-07
( O 0 9.786850796444924e-08
1 O 0 2.0251904686574562e-07
. O 0 4.4927112696768745e-08
26 O 0 3.2465817412230535e-07
+ O 0 2.1859095511445048e-07
/ O 0 3.1682640155850095e-07
- O 0 4.543728380212997e-07
0 O 0 2.464239230448584e-07
. O 0 1.6279159353871364e-08
33 O 0 2.441432229716156e-07
mg O 0 7.699873663113976e-07
/ O 0 2.225668680466697e-07
ml O 0 4.09330283446252e-07
; O 0 2.7620147946549878e-08
n O 0 1.0364338010049323e-07
= O 0 3.577566474177729e-07
9 O 0 1.862368463889652e-07
) O 0 6.4351408646246e-09
, O 0 8.091327607928633e-09
showing O 0 3.536547055205119e-08
a O 0 2.7842032679359363e-08
gene O 0 1.4649677382294612e-07
- O 0 1.8865416677726898e-06
dosage O 0 2.5276597170886816e-06
effect O 0 2.760140432656044e-06
. O 0 4.865698429057375e-06

The O 0 1.8503315004636534e-06
other O 0 3.45853322869516e-07
allele O 0 1.6426600950580905e-06
( O 0 4.661382604354003e-07
Hp2 O 0 5.928874088567682e-06
) O 0 2.9815439006597444e-08
of O 0 2.6723430579522756e-08
individuals O 0 9.707500581157547e-09
with O 0 3.4750176070019734e-08
Hp2 O 0 0.4303235709667206
/ O 0 1.4336807907966431e-05
Hpdel O 0 6.240240509214345e-06
was O 0 8.921706040609934e-09
found O 0 1.1797037791083653e-09
to O 0 5.935895663888857e-10
have O 0 2.0275503498368153e-09
, O 0 4.717217727545631e-09
in O 0 3.213361576825946e-09
all O 0 1.0869064759333469e-08
exons O 0 1.9395659478504967e-07
, O 0 1.2155466855290342e-08
no O 0 1.519730652432827e-08
mutation O 0 1.1130893540212128e-08
, O 0 7.207867636083165e-09
by O 0 1.8003067481231483e-08
DNA O 0 6.083091648179106e-07
sequencing O 0 5.922493528487394e-06
. O 0 6.449928605434252e-06

On O 0 1.9651479306048714e-06
the O 0 8.450128774484256e-08
basis O 0 1.5569075628718565e-07
of O 0 2.6438856437493996e-08
the O 0 1.3905141038605962e-08
present O 0 1.7794310025465165e-08
study O 0 1.4767147504812783e-08
, O 0 5.796193303098107e-09
the O 0 1.4458755082102925e-08
mechanism O 0 1.4445170393173612e-07
of O 0 5.590117879705758e-08
anhaptoglobinemia B-Disease 0 1.1681299838528503e-05
and O 0 2.523722919534066e-08
the O 0 1.861377185718993e-08
mechanism O 0 2.5287300786658307e-07
of O 0 3.9038042132233386e-08
anomalous O 0 4.10716302212677e-06
inheritance O 0 2.84896509583632e-06
of O 0 5.057818270870484e-07
Hp O 0 4.5727929887107166e-07
phenotypes O 0 1.5913345805529389e-06
were O 0 3.4054400543936936e-07
well O 0 4.3280795125610894e-07
explained O 0 3.3771193557186052e-06
. O 0 7.428708613588242e-06

However O 0 6.891414614074165e-06
, O 0 4.4909165808348916e-07
the O 0 2.2020580559001246e-07
mechanism O 0 2.5619981443014694e-06
of O 0 9.838054211286362e-07
hypohaptoglobinemia B-Disease 1 0.9666734933853149
remains O 0 9.659837087383494e-05
unknown O 0 0.00018971506506204605

ATM O 0 0.0004659118130803108
mutations O 0 1.2460487596399616e-05
and O 0 4.488951219627779e-07
phenotypes O 0 2.5039144020411186e-05
in O 0 4.2865912064371514e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 8.922048664317117e-07
in O 0 1.1741238203910598e-08
the O 0 1.4214353249997203e-08
British O 0 3.547370042156217e-08
Isles O 0 8.761673342405629e-08
: O 0 1.1169940528077404e-08
expression O 0 2.7807960378822827e-08
of O 0 1.7683099429177673e-08
mutant O 0 1.9439360698925157e-07
ATM O 0 3.846269919449696e-06
and O 0 3.909810075697351e-08
the O 0 4.239180739773474e-08
risk O 0 1.1306462965876563e-07
of O 0 1.5542978815119568e-07
leukemia B-Disease 1 1.0
, O 0 0.0006934835109859705
lymphoma B-Disease 1 1.0
, O 1 0.9437116980552673
and O 1 0.9999853372573853
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999974966049194
. O 0 3.58046090696007e-05

We O 0 9.573894885761547e-07
report O 0 3.1836594871492707e-07
the O 0 1.0888678048104339e-07
spectrum O 0 1.5683481251471676e-06
of O 0 2.009359292287627e-07
59 O 0 6.202654958542553e-07
ATM O 0 1.3073836271360051e-05
mutations O 0 5.873984605386795e-07
observed O 0 3.7950229625494103e-07
in O 0 2.4062487113951647e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999819993972778
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.797114800363488e-08
patients O 0 5.963190385926964e-09
in O 0 3.421642968959304e-09
the O 0 3.178805130232831e-08
British O 0 2.5661228164608474e-07
Isles O 0 2.054335254797479e-06
. O 0 3.17827652906999e-06

Of O 0 1.1253907359787263e-05
51 O 0 7.567535703856265e-06
ATM O 0 1.8088336219079792e-05
mutations O 0 5.699839675799012e-07
identified O 0 2.1606076927582762e-07
in O 0 5.7410698417470485e-09
families O 0 4.179239176949068e-09
native O 0 4.34900471191213e-09
to O 0 1.4585245233789124e-09
the O 0 1.133424731847299e-08
British O 0 5.111477818786625e-08
Isles O 0 6.500997073999315e-08
, O 0 1.6244419143163213e-08
11 O 0 1.0545598883027196e-07
were O 0 8.995834832603578e-08
founder O 0 6.983962066442473e-07
mutations O 0 6.249776873801238e-08
, O 0 1.7646843986085514e-08
and O 0 1.4137968129546152e-08
2 O 0 8.117083183378782e-08
of O 0 1.0476669309866793e-08
these O 0 7.888891317975322e-09
11 O 0 4.6376246842783075e-08
conferred O 0 3.9997203771235945e-08
a O 0 4.641985018594141e-09
milder O 0 1.5572253175832884e-07
clinical O 0 5.21199439162956e-08
phenotype O 0 3.112473478950051e-08
with O 0 5.902379029976146e-09
respect O 0 4.7820648774177243e-08
to O 0 8.341031332292914e-08
both O 0 3.539925955919898e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 1.916380369948456e-06
cellular O 0 7.266540706041269e-06
features O 0 3.580420752768987e-06
. O 0 4.980286121281097e-06

We O 0 9.333377875009319e-07
report O 0 5.472201110023889e-07
, O 0 4.600147818223377e-08
in O 0 2.991980352362589e-08
two O 0 8.636207837753318e-08
A B-Disease 1 0.9999123811721802
- I-Disease 1 0.970520555973053
T I-Disease 1 1.0
families O 0 1.3555766997797036e-07
, O 0 3.161391148864823e-08
an O 0 1.7675544583539704e-08
ATM O 0 1.4176306422086782e-06
mutation O 0 8.484091296168117e-08
( O 0 4.239940665229369e-08
7271T O 0 1.0055291568278335e-06
- O 0 3.2750764944466937e-07
- O 0 2.414468553979532e-07
> O 0 2.0161063218893105e-07
G O 0 4.297237126138498e-07
) O 0 1.933174953450134e-09
that O 0 4.206796300199045e-10
may O 0 7.266626744772964e-10
be O 0 5.603210673221781e-10
associated O 0 2.8230884296931436e-09
with O 0 4.2180126058610767e-10
an O 0 7.947469904401316e-10
increased O 0 4.724385327392611e-09
risk O 0 2.5814680171265536e-08
of O 0 1.0714733633676587e-07
breast B-Disease 0 0.01728029176592827
cancer I-Disease 0 6.141668791315169e-07
in O 0 8.233998372020324e-09
both O 0 3.111974677949547e-08
homozygotes O 0 1.1935213706237846e-06
and O 0 6.149527820298317e-08
heterozygotes O 0 1.7699381942293257e-06
( O 0 5.3255273968488837e-08
relative O 0 4.426016460001847e-07
risk O 0 1.7938975815923186e-07
12 O 0 1.5147088561207056e-07
. O 0 1.874598964946017e-08
7 O 0 2.4410641685790324e-07
; O 0 8.087936009815166e-08
P O 0 1.3779934988633613e-06
= O 0 5.320512173057068e-07
. O 0 5.6510952362032185e-08
0025 O 0 1.6387156165365013e-06
) O 0 5.395540902952689e-09
, O 0 2.069923343839264e-09
although O 0 2.582180691490521e-09
there O 0 1.7676379249209617e-09
is O 0 6.207159231053083e-10
a O 0 1.4276757553943753e-09
less O 0 1.3655425235015173e-08
severe O 0 1.4269831808633171e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 1.0704805930572547e-07
in O 0 2.4336821446979684e-09
terms O 0 9.909259190976627e-09
of O 0 7.336793839129996e-09
the O 0 2.109759833501812e-08
degree O 0 2.6860007551476883e-07
of O 0 1.820710508582124e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.00016634365601930767

This O 0 3.6153294331597863e-06
mutation O 0 2.9373634333751397e-06
( O 0 1.0743061693574418e-06
7271T O 0 1.1284200809313916e-05
- O 0 1.936779881361872e-06
- O 0 9.322551477453089e-07
> O 0 3.1563004654344695e-07
G O 0 7.851334657971165e-07
) O 0 1.2084337086548658e-08
also O 0 1.5773751194103625e-09
allows O 0 1.626986989577972e-09
expression O 0 1.4222190536372636e-08
of O 0 1.7925392725715028e-08
full O 0 7.783791744486734e-08
- O 0 2.049975478257693e-07
length O 0 6.089337034609343e-08
ATM O 0 7.376154371740995e-07
protein O 0 8.213830682279877e-08
at O 0 2.2866744942007244e-08
a O 0 4.155306321251828e-09
level O 0 1.0277384276946577e-08
comparable O 0 3.066265108486732e-08
with O 0 1.0160957630844791e-09
that O 0 2.7950615155702963e-09
in O 0 2.0502778141917588e-08
unaffected O 0 9.34825493459357e-07
individuals O 0 2.3075126875937713e-07
. O 0 2.601001142465975e-06

In O 0 7.462631970156508e-07
addition O 0 2.1701896457670955e-07
, O 0 6.869538538012421e-08
we O 0 2.0968981218061344e-08
have O 0 1.5992574375900404e-08
studied O 0 3.142268667488679e-07
18 O 0 3.6990809348935727e-07
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.3695678780532035e-07
, O 0 1.4016339200395578e-08
in O 0 5.6621400901235575e-09
15 O 0 2.674311261330331e-08
families O 0 8.315564237193485e-09
, O 0 1.290514362040085e-08
who O 0 1.8817063462961414e-08
developed O 0 2.978018471821997e-07
leukemia B-Disease 1 0.9999998807907104
, O 0 1.8326527424505912e-05
lymphoma B-Disease 1 1.0
, O 0 3.492206451483071e-05
preleukemic O 1 0.9999990463256836
T O 1 0.9999524354934692
- O 0 0.00017894980555865914
cell O 0 0.4805237352848053
proliferation O 1 0.9629934430122375
, O 0 1.1776118213902009e-07
or O 0 1.4582410585717298e-06
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.244221943532466e-06
mostly O 0 4.234251491652685e-07
in O 0 9.6708390628919e-08
childhood O 0 7.031632321741199e-06
. O 0 5.763734861830017e-06

A O 0 1.7501590264146216e-05
wide O 0 7.599146556458436e-06
variety O 0 7.215593313958379e-07
of O 0 2.0657107313581946e-07
ATM O 0 4.2754190872074105e-06
mutation O 0 6.400867391676002e-08
types O 0 1.2541040916858037e-07
, O 0 1.6432142757594193e-08
including O 0 2.9370891496682816e-08
missense O 0 8.683493888383964e-07
mutations O 0 1.412983152704328e-07
and O 0 9.319816740571696e-08
in O 0 6.449618439319238e-08
- O 0 4.589757907069725e-07
frame O 0 6.56773693208379e-07
deletions O 0 3.749275379050232e-07
, O 0 5.53657422130982e-08
were O 0 8.964011044554354e-08
seen O 0 7.780170108162565e-08
in O 0 9.9869978953393e-09
these O 0 7.003411894856981e-08
patients O 0 4.776868536282564e-07
. O 0 3.1788647447683616e-06

We O 0 1.5429026234414778e-06
also O 0 3.708094595822331e-07
show O 0 4.718074819720641e-08
that O 0 3.219490229966482e-09
25 O 0 3.0342668821958796e-08
% O 0 2.4724455816027557e-09
of O 0 7.807295254735891e-09
all O 0 4.73905323872259e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 2.6085825766131165e-07
carried O 0 2.0393035526922176e-07
in O 0 4.066645331590735e-08
- O 0 6.454282015511126e-07
frame O 0 1.443539645151759e-06
deletions O 0 1.0002830777011695e-06
or O 0 8.323596745185569e-08
missense O 0 3.369696344179829e-07
mutations O 0 4.700586586636746e-08
, O 0 6.088393789127622e-09
many O 0 2.0470178885290125e-09
of O 0 4.4799932652495045e-09
which O 0 9.617632246161634e-10
were O 0 1.1906157837415776e-08
also O 0 3.450966179485704e-09
associated O 0 1.5794983099226556e-08
with O 0 6.296390520077466e-09
expression O 0 1.0258234084403739e-07
of O 0 1.8035447624242806e-07
mutant O 0 3.186853746228735e-06
ATM O 0 7.926394027890638e-05
protein O 0 1.1945966434723232e-05
. O 0 5.989752025925554e-06

The O 0 4.939287464367226e-06
DMPK O 1 0.7719101309776306
gene O 0 1.2918931133754086e-06
of O 0 8.415007073381275e-07
severely O 1 0.9911301136016846
affected O 0 0.08879131078720093
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9944127202033997
is O 0 8.056588995941638e-08
hypermethylated O 0 2.2248810637393035e-05
proximal O 0 5.529736881726421e-06
to O 0 5.702156613551779e-08
the O 0 3.130928689643042e-07
largely O 0 8.912778639569297e-07
expanded O 0 2.842346020770492e-06
CTG O 0 0.00018098407599609345
repeat O 0 2.3965296350070275e-05
. O 0 2.1224175725365058e-05

Using O 0 1.768429910953273e-06
methylation O 0 8.61164244270185e-06
- O 0 1.0146436579816509e-05
sensitive O 0 1.0829251095856307e-06
restriction O 0 1.2525836723398243e-07
enzymes O 0 5.313555107022694e-08
, O 0 2.2102081942421137e-08
we O 0 6.088927584357862e-09
characterized O 0 1.644935920808166e-08
the O 0 8.14390777037488e-09
methylation O 0 3.664739622877278e-08
pattern O 0 8.99523442399186e-08
on O 0 3.466292497478207e-08
the O 0 1.6662061952388285e-08
5 O 0 5.1018737678987236e-08
side O 0 3.7214000769836275e-08
of O 0 3.116726787766311e-08
the O 0 1.6510281852788466e-07
CTG O 0 2.91034175461391e-05
repeat O 0 2.3233407375755633e-07
in O 0 2.557751699328037e-08
the O 0 5.081906095938393e-08
DMPK O 0 5.027740553487092e-05
gene O 0 2.108062346906081e-08
of O 0 1.5036073719443266e-08
normal O 0 1.7015434394807016e-08
individuals O 0 2.0907189313135177e-09
and O 0 5.522280410730218e-09
of O 0 2.294267353875057e-08
patients O 0 5.840363925813108e-08
affected O 0 2.1075240397294692e-07
with O 0 8.309295367325831e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.401220288244076e-06
showing O 0 3.939085786441865e-07
expansions O 0 7.071477625686384e-07
of O 0 1.6436570149380714e-07
the O 0 2.729345283114526e-07
repetitive O 0 3.067724037464359e-06
sequence O 0 1.4348228205562918e-06
. O 0 4.04028469347395e-06

The O 0 4.385426109365653e-06
gene O 0 1.685459892541985e-06
segment O 0 9.759428394318093e-07
analyzed O 0 1.5668231867493887e-07
corresponds O 0 9.928049138352435e-08
to O 0 1.71460445841376e-08
the O 0 1.1859472692776762e-07
genomic O 0 2.204713155151694e-06
SacI O 0 5.3984509577276185e-05
- O 0 3.596549731810228e-06
HindIII O 0 6.295579623838421e-06
fragment O 0 1.966913941942039e-06
carrying O 0 1.227573648066027e-06
exons O 0 5.854226856172318e-06
11 O 0 4.37169683209504e-06
- O 0 5.415320174506633e-06
15 O 0 6.715291874570539e-06
. O 0 7.325782007683301e-06

There O 0 3.1658794341637986e-06
is O 0 1.3964842082714313e-07
constitutive O 0 1.3378894436755218e-06
methylation O 0 1.1690243582052062e-06
in O 0 2.699783863135963e-07
intron O 0 4.4959284423384815e-05
12 O 0 8.388398100578343e-07
at O 0 5.974907679728858e-08
restriction O 0 7.097720100546212e-08
sites O 0 1.2994510711905605e-07
of O 0 1.6792094470474694e-07
SacII O 0 7.056104095681803e-06
and O 0 2.449641556268034e-07
HhaI O 0 8.917335435398854e-06
, O 0 1.0420354357165706e-07
localized O 0 8.974615752777027e-07
1 O 0 1.9903559689282702e-07
, O 0 1.564184337610186e-08
159 O 0 9.577879467315142e-08
- O 0 2.0409768808349327e-07
1 O 0 1.8419918035306182e-07
, O 0 1.8424795911187175e-08
232 O 0 8.426307829267898e-08
bp O 0 1.6053182605446636e-07
upstream O 0 3.955864826821198e-07
of O 0 5.457603435843339e-08
the O 0 1.7427193199637259e-07
CTG O 0 2.1854561055079103e-05
repeat O 0 2.46134334247472e-07
, O 0 1.51410013415898e-08
whereas O 0 1.6149732218195822e-08
most O 0 2.786161967804901e-09
, O 0 8.33474178563165e-10
if O 0 5.317097873103194e-10
not O 0 1.1679942568676438e-09
all O 0 2.779251717655029e-09
, O 0 2.8237077120962795e-09
of O 0 3.1404510103527628e-09
the O 0 6.532042462481513e-09
other O 0 1.0063406996607682e-08
sites O 0 1.4754286326024157e-07
of O 0 1.2959168316228897e-07
SacII O 0 5.650707862514537e-06
, O 0 8.228067827076302e-08
HhaI O 0 2.4825108084769454e-06
, O 0 2.499664475408281e-08
and O 0 2.4492790018371124e-08
HpaII O 0 1.9929516383854207e-06
in O 0 5.335142549967031e-09
this O 0 3.090454114840213e-09
region O 0 6.061802793055904e-08
are O 0 1.0277324768992457e-08
unmethylated O 0 3.0049170618440257e-06
, O 0 1.95394989077613e-08
in O 0 3.941743820234933e-09
normal O 0 8.97242369291007e-09
individuals O 0 1.189305542936836e-09
and O 0 6.78013378774267e-09
most O 0 7.340643648490186e-09
of O 0 3.745904919583154e-08
the O 0 2.257645377312656e-07
patients O 0 3.8618802022938326e-07
. O 0 3.6309368169895606e-06

In O 0 2.584429807939159e-07
a O 0 4.4643428509516525e-08
number O 0 5.890235854622006e-08
of O 0 7.690525904990864e-08
young O 0 8.404845175391529e-07
and O 0 1.9539989182248974e-07
severely O 0 0.0008786843973211944
affected O 0 1.5314986967496225e-07
patients O 0 3.301124351651197e-08
, O 0 3.8405900681937055e-09
however O 0 9.19047415948171e-09
, O 0 2.3066881738031952e-09
complete O 0 5.035147854215438e-09
methylation O 0 3.384143099083303e-08
of O 0 2.6204453718037257e-08
these O 0 1.1122637033622595e-08
restriction O 0 9.871703809949395e-08
sites O 0 1.0422123608577749e-07
was O 0 5.998293062248194e-08
found O 0 1.2182274744532151e-08
in O 0 2.395875142724435e-08
the O 0 1.7282209796576353e-07
mutated O 0 3.7490110571525292e-06
allele O 0 7.299428034457378e-06
. O 0 9.577260243531782e-06

In O 0 3.463798350367142e-07
most O 0 6.99855036145891e-08
of O 0 2.548299882221272e-08
these O 0 8.144498409023981e-09
patients O 0 1.3806275234173881e-08
, O 0 4.107977069622848e-09
the O 0 9.36021660180586e-09
onset O 0 0.00014789329725317657
of O 0 2.2208767802567309e-07
the O 0 3.528971092237043e-06
disease O 1 1.0
was O 1 0.6495779752731323
congenital O 1 1.0
. O 0 0.00019588356371968985

Preliminary O 0 9.326187864644453e-06
in O 0 1.7730636727719684e-06
vivo O 0 1.2876623259217013e-05
footprinting O 0 3.007239502039738e-05
data O 0 8.291603421639593e-07
gave O 0 2.27510298600464e-07
evidence O 0 2.615904293179483e-07
for O 0 3.104960910604859e-08
protein O 0 1.2561461915083783e-07
- O 0 5.745816267221926e-08
DNA O 0 7.23086657217209e-08
contact O 0 4.551682408759916e-08
in O 0 4.7831663074759945e-09
normal O 0 2.2445771463708297e-08
genes O 0 1.0707680964117117e-08
at O 0 1.6718312068064733e-08
an O 0 8.624335912088554e-09
Sp1 O 0 5.33028412519343e-07
consensus O 0 8.317153543657696e-08
binding O 0 5.007547798641099e-08
site O 0 1.3626575423586473e-07
upstream O 0 3.195821420831635e-07
of O 0 8.078023228108577e-08
the O 0 2.536086469717702e-07
CTG O 0 5.674620479112491e-05
repeat O 0 2.5551827320668963e-07
and O 0 1.807653049468172e-08
for O 0 4.472352266304824e-09
a O 0 2.6594113577971257e-09
significant O 0 8.346279223303554e-09
reduction O 0 3.627706490760829e-08
of O 0 6.732556290245384e-09
this O 0 1.510176983465783e-09
interaction O 0 2.7382737854964034e-08
in O 0 1.0996976662625002e-08
cells O 0 3.571600259988372e-08
with O 0 1.2327874721052012e-08
a O 0 1.671541696168788e-07
hypermethylated O 0 0.00015615602023899555
DMPK O 0 0.00042484630830585957
gene O 0 8.772532282819157e-07
. O 0 8.147342782649503e-07
. O 0 4.078712208865909e-06

The O 0 2.4869632397894748e-05
hemochromatosis B-Disease 1 1.0
gene O 0 3.7893266835453687e-06
product O 0 4.769567567564081e-07
complexes O 0 4.32746873002543e-07
with O 0 3.2718507014806164e-08
the O 0 1.8946195723401615e-07
transferrin O 0 1.0594165360089391e-05
receptor O 0 7.378444479400059e-06
and O 0 2.027232852697125e-07
lowers O 0 6.481718628492672e-07
its O 0 2.3451113051464745e-08
affinity O 0 2.1520939696983987e-07
for O 0 9.787896715351962e-08
ligand O 0 7.990788617462385e-06
binding O 0 8.652777978568338e-06
. O 0 1.03300308182952e-05

We O 0 2.607013357192045e-06
recently O 0 8.458051752313622e-07
reported O 0 1.7522603457109653e-07
the O 0 3.58960932089758e-08
positional O 0 2.0635188775486313e-06
cloning O 0 3.8712170180588146e-07
of O 0 6.936290475323403e-08
a O 0 3.039375684465995e-08
candidate O 0 1.5921862939194398e-07
gene O 0 3.577058009796019e-07
for O 0 2.088866040139692e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 4.3888161599170417e-05

The O 0 1.147974444393185e-06
gene O 0 2.8621326464417507e-07
product O 0 2.8864440082543297e-07
, O 0 2.536704890587771e-08
a O 0 1.3301927559439264e-08
member O 0 3.128155512399644e-08
of O 0 6.421092280106677e-08
the O 0 1.3537305676436517e-07
major O 0 3.5759949241764843e-06
histocompatibility O 0 0.022565046325325966
complex O 0 7.240878403536044e-07
class O 0 1.6317153495037928e-07
I O 0 7.879839358793106e-07
- O 0 3.707620805926126e-07
like O 0 4.515735341215077e-08
family O 0 3.8287069514808536e-08
, O 0 1.245802216942593e-08
was O 0 1.7767652238376286e-08
found O 0 3.645336033031299e-09
to O 0 2.9265747603091086e-09
have O 0 1.0970245156727287e-08
a O 0 4.202518155693724e-08
mutation O 0 9.734259265314904e-08
, O 0 1.320632208035022e-07
Cys O 0 1.2935812264913693e-05
- O 0 4.485315002966672e-06
282 O 0 2.924709633589373e-06
- O 0 3.472375283308793e-06
- O 0 3.872328306897543e-06
> O 0 3.070284947170876e-06
Tyr O 0 1.6483631043229252e-05
( O 0 7.399716395184441e-08
C282Y O 0 1.7352494978695177e-06
) O 0 1.0492147595186907e-08
, O 0 6.122303997102563e-09
in O 0 4.7945931669346464e-09
85 O 0 9.482557317141982e-08
% O 0 1.3888388217253578e-08
of O 0 2.4920144170437197e-08
patient O 0 2.6468029545867466e-07
chromosomes O 0 3.660175480035832e-06
. O 0 7.923192242742516e-06

This O 0 3.6681245774161653e-07
mutation O 0 1.341428401246958e-06
eliminates O 0 2.5675622055132408e-06
the O 0 1.3960180922367726e-07
ability O 0 1.181687636631068e-07
of O 0 5.236497031546605e-07
HFE O 0 0.06974301487207413
to O 0 1.9251970684308617e-07
associate O 0 1.198769723487203e-06
with O 0 5.669729929991263e-08
beta2 O 0 0.2588439881801605
- O 0 0.0002547711774241179
microglobulin O 0 0.04447248950600624
( O 0 3.9726467093714746e-07
beta2m O 0 1.8960317902383395e-05
) O 0 3.0269486472889184e-08
and O 0 2.85174603931182e-08
prevents O 0 2.899512878684618e-07
cell O 0 1.0925747119472362e-05
- O 0 5.439963842945872e-06
surface O 0 1.8823615164365037e-06
expression O 0 2.4304702037625248e-06
. O 0 2.9885411549912533e-06

A O 0 4.7384701247210614e-06
second O 0 3.769855823065882e-07
mutation O 0 6.30864249728802e-08
that O 0 4.961152377802591e-09
has O 0 3.856269081836672e-09
no O 0 1.141560712625278e-08
effect O 0 6.994920909164648e-08
on O 0 1.0851855591909043e-07
beta2m O 0 2.6685627744882368e-05
association O 0 3.6342692055768566e-07
, O 0 1.0334017730428968e-07
H63D O 1 0.9862431883811951
, O 0 2.943106380826066e-08
was O 0 3.201128606633574e-08
found O 0 1.0817814199981513e-08
in O 0 2.6617963388986254e-09
eight O 0 1.7113469752416677e-08
out O 0 4.77142103605388e-09
of O 0 2.0434690384263376e-08
nine O 0 1.2148588268701133e-07
patients O 0 2.918905295246077e-08
heterozygous O 0 2.5908155620868456e-08
for O 0 3.630038847290962e-08
the O 0 8.542772889086336e-07
C282Y O 0 6.568789103766903e-05
mutant O 0 1.7651509551797062e-05
. O 0 8.482013981847558e-06

In O 0 4.936899813401396e-07
this O 0 4.7444164152921076e-08
report O 0 9.043557014365433e-08
, O 0 1.87704269904998e-08
we O 0 1.89634175029596e-08
demonstrate O 0 9.605577844240543e-08
in O 0 7.886021791136955e-08
cultured O 0 4.085813088750001e-06
293 O 0 1.4477486729447264e-06
cells O 0 1.1641714081633836e-06
overexpressing O 0 6.798966751375701e-06
wild O 0 8.205091148738575e-07
- O 0 6.498851803371508e-07
type O 0 3.051414410037978e-07
or O 0 1.253209802598576e-07
mutant O 0 1.061805164681573e-06
HFE O 0 4.755042937176768e-06
proteins O 0 3.375871315824952e-08
that O 0 4.648621487746141e-09
both O 0 1.2142999494813012e-08
the O 0 5.446351991622578e-08
wild O 0 8.134772997436812e-07
- O 0 1.0960059171338798e-06
type O 0 2.5989083951571956e-06
and O 0 2.285106347699184e-06
H63D O 1 0.9999905824661255
HFE O 0 0.0001360669411951676
proteins O 0 2.0378804777010373e-07
form O 0 1.1932489485388942e-07
stable O 0 4.711977794613631e-07
complexes O 0 1.4311927998278406e-07
with O 0 2.838266688343083e-08
the O 0 2.573065387423412e-07
transferrin O 0 2.1097788703627884e-05
receptor O 0 2.5076926249312237e-05
( O 0 2.33473610933288e-06
TfR O 0 4.1455161408521235e-05
) O 0 1.159166117759014e-06
. O 0 3.400923105800757e-06

The O 0 6.872775429656031e-06
C282Y O 0 8.693892596056685e-05
mutation O 0 5.376409717428032e-07
nearly O 0 1.208144908559916e-07
completely O 0 1.2176309382994077e-07
prevents O 0 4.77370818430245e-08
the O 0 1.8282459990359712e-08
association O 0 6.87281485056701e-08
of O 0 5.89874673551094e-08
the O 0 2.2656409726096172e-07
mutant O 0 4.876857019553427e-06
HFE O 0 6.006070179864764e-05
protein O 0 5.425418407867255e-07
with O 0 8.176004229198952e-08
the O 0 1.5216759265967994e-06
TfR O 0 0.00022294353402685374
. O 0 1.3213193597039208e-05

Studies O 0 1.0633359124767594e-05
on O 0 1.7396471321262652e-06
cell O 0 2.9974810331623303e-06
- O 0 1.233998773386702e-06
associated O 0 6.845458528914605e-07
transferrin O 0 6.006174771755468e-06
at O 0 3.357142190907325e-07
37 O 0 2.2558053558441316e-07
degrees O 0 1.0648113857314456e-07
C O 0 2.0899609864954982e-07
suggest O 0 1.559584816845927e-08
that O 0 3.5623799465867023e-09
the O 0 5.86532529212036e-08
overexpressed O 0 4.2880119508481584e-06
wild O 0 1.55189263750799e-06
- O 0 2.5124566036538454e-06
type O 0 1.7100439890782582e-06
HFE O 0 2.6927615181193687e-05
protein O 0 2.9850608029846626e-07
decreases O 0 6.381594630511245e-08
the O 0 5.207440256782547e-09
affinity O 0 8.66387566134108e-08
of O 0 4.359205263426702e-08
the O 0 2.4369774109800346e-07
TfR O 0 1.0489182386663742e-05
for O 0 5.067981874162797e-07
transferrin O 0 0.00017181759176310152
. O 0 1.6459045582450926e-05

The O 0 3.694479164551012e-05
overexpressed O 0 0.0020879979711025953
H63D O 0 0.002406262792646885
protein O 0 9.82682081485109e-07
does O 0 1.7787760597798297e-08
not O 0 3.871937881427812e-09
have O 0 1.9067245560222545e-09
this O 0 1.09964670702567e-09
effect O 0 2.7241721767268245e-08
, O 0 3.2325349064166176e-09
providing O 0 1.1861165383209027e-08
the O 0 5.418032245074755e-09
first O 0 4.931499653082483e-09
direct O 0 1.081820677484302e-08
evidence O 0 4.2116095499977746e-08
for O 0 8.572772713932864e-09
a O 0 1.2546921723810556e-08
functional O 0 2.2930363741124893e-07
consequence O 0 2.1741007572018134e-07
of O 0 1.1340404881821087e-07
the O 0 1.0411608855065424e-06
H63D O 0 0.013793418183922768
mutation O 0 4.8201782192336395e-06
. O 0 8.220637027989142e-06

Addition O 0 7.365515557467006e-06
of O 0 2.9315594929357758e-06
soluble O 0 5.201651219977066e-05
wild O 0 1.0849267710000277e-05
- O 0 1.3457435670716222e-05
type O 0 3.368977195350453e-05
HFE O 1 0.9999982118606567
/ O 0 0.054548151791095734
beta2m O 0 6.569860124727711e-05
heterodimers O 0 4.314983925723936e-06
to O 0 2.1449261922157348e-08
cultured O 0 3.865543192205223e-07
cells O 0 6.187860890349839e-08
also O 0 5.392742252752214e-09
decreased O 0 1.831572227217748e-08
the O 0 3.1900215802238563e-09
apparent O 0 3.4358293987679644e-08
affinity O 0 5.6887078159206794e-08
of O 0 2.6056927282525066e-08
the O 0 6.610012803776044e-08
TfR O 0 8.981378982753085e-07
for O 0 1.6642399458532964e-08
its O 0 8.13496559004534e-09
ligand O 0 2.979259932089917e-07
under O 0 5.1357037733623656e-08
steady O 0 4.255496435234818e-07
- O 0 3.8167417670820214e-08
state O 0 8.007988938629751e-09
conditions O 0 6.138723307458349e-08
, O 0 1.371227043023282e-08
both O 0 5.937562885804937e-09
in O 0 1.0350702517314403e-08
293 O 0 1.1612999628596299e-07
cells O 0 7.745921237756193e-08
and O 0 3.302503870372675e-08
in O 0 1.4980803086928063e-07
HeLa O 0 4.076892219018191e-05
cells O 0 6.604980626434553e-06
. O 0 4.330026058596559e-06

Furthermore O 0 1.0144462976313662e-05
, O 0 9.203420745507174e-07
at O 0 5.869667347724317e-07
4 O 0 3.277441749105492e-07
degrees O 0 3.0518540938828664e-07
C O 0 7.120140139704745e-07
, O 0 1.4485612709336237e-08
the O 0 3.296305095545904e-08
added O 0 3.138476927233569e-07
soluble O 0 1.1657211871352047e-06
complex O 0 2.5909940859492053e-07
of O 0 3.7733411772933323e-07
HFE O 1 0.9999927282333374
/ O 0 0.019609950482845306
beta2m O 0 2.5811492378124967e-05
inhibited O 0 4.2319018689340737e-07
binding O 0 2.043411342356194e-07
of O 0 1.7202918911607412e-07
transferrin O 0 3.1286322155210655e-06
to O 0 2.120538056260557e-07
HeLa O 0 3.2551801268709823e-05
cell O 0 7.754628313705325e-06
TfR O 0 4.434971287992084e-06
in O 0 3.741363485687543e-08
a O 0 4.196230563024983e-08
concentration O 0 1.3678726418220322e-06
- O 0 1.0255627103106235e-06
dependent O 0 6.051314471733349e-07
manner O 0 1.3119272352923872e-06
. O 0 1.936885155373602e-06

Scatchard O 0 0.0006476854905486107
plots O 0 6.719872089888668e-06
of O 0 3.0512717330566375e-07
these O 0 4.079152660096952e-08
data O 0 9.804993794659822e-08
indicate O 0 9.722717209115217e-08
that O 0 1.2098359647438883e-08
the O 0 8.199774015338335e-08
added O 0 3.647974722298386e-07
heterodimer O 0 1.3783707117909216e-06
substantially O 0 1.729985541487622e-07
reduced O 0 2.4253330010992613e-08
the O 0 1.539000216155273e-08
affinity O 0 1.743198083659081e-07
of O 0 1.889358003381858e-07
TfR O 0 1.018027433019597e-05
for O 0 9.106213383347495e-07
transferrin O 0 0.00020913316984660923
. O 0 1.8456808902556077e-05

These O 0 1.5690333157181158e-06
results O 0 9.735351795825409e-07
establish O 0 6.605015983041085e-07
a O 0 9.931665800877454e-08
molecular O 0 1.914272388603422e-06
link O 0 2.751874490058981e-06
between O 0 7.057181505842891e-07
HFE O 1 0.996713399887085
and O 0 1.0978978082221147e-07
a O 0 4.439505829623158e-08
key O 0 2.6140986619793694e-07
protein O 0 1.1834097790597298e-07
involved O 0 1.8850615290944006e-08
in O 0 1.3140437182812548e-08
iron O 0 9.02873296126927e-07
transport O 0 1.1168681339768227e-06
, O 0 1.7774194560615797e-08
the O 0 5.649500423032805e-08
TfR O 0 7.356733476626687e-06
, O 0 1.9961246877642225e-08
and O 0 9.871681250217534e-09
raise O 0 1.874702704185438e-08
the O 0 9.630340080946098e-09
possibility O 0 2.7005658154166667e-08
that O 0 1.7793011508615564e-09
alterations O 0 7.396188550501392e-08
in O 0 3.765983080938895e-09
this O 0 1.6003611769122017e-09
regulatory O 0 3.78340097029195e-08
mechanism O 0 9.654178256823798e-08
may O 0 1.6812261804943773e-08
play O 0 2.3796618009441772e-08
a O 0 1.9060964362438426e-08
role O 0 2.4049494840028274e-08
in O 0 4.181902379940539e-09
the O 0 3.319611963092939e-08
pathogenesis O 1 0.9999340772628784
of O 0 5.9574358601821586e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.08162893354892731
. O 0 1.5613159121130593e-05

Genomic O 0 4.46561498392839e-05
organization O 0 6.080022103560623e-06
of O 0 1.7260384765904746e-06
the O 0 5.941700237599434e-06
UBE3A O 1 0.9998574256896973
/ O 0 0.09503946453332901
E6 O 1 0.9999614953994751
- O 0 1.7102518540923484e-05
AP O 0 2.0281939214328304e-05
gene O 0 1.931786783870848e-07
and O 0 8.350741609319812e-08
related O 0 8.631034233985702e-07
pseudogenes O 0 2.639517333591357e-05
. O 0 5.4207039283937775e-06

The O 0 5.4314787121256813e-05
UBE3A O 0 0.0015019865240901709
gene O 0 8.16153442428913e-06
encodes O 0 7.798630576871801e-06
the O 0 2.5700587684696075e-06
E6 O 0 0.001888024853542447
- O 0 1.6754862372181378e-05
AP O 0 3.925234705093317e-05
ubiquitin O 0 3.5124489841109607e-06
- O 0 6.494706781268178e-07
protein O 0 1.1250961762243605e-07
ligase O 0 2.8928153028573433e-07
and O 0 2.1379989334491256e-08
has O 0 4.813551335303146e-09
recently O 0 5.149757065225913e-09
been O 0 1.6067289720922417e-09
shown O 0 5.127056001974495e-10
to O 0 3.168843520917619e-10
be O 0 1.5756640436848102e-09
mutated O 0 4.0780173549137544e-07
in O 0 4.485489455419156e-07
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 9.180136657960247e-06
who O 0 2.4053952074609697e-07
lack O 0 2.0196994228172116e-05
15q11 O 0 0.24562899768352509
- O 0 0.00012268582941032946
q13 O 0 6.129512621555477e-05
deletions O 0 5.7593451856519096e-06
or O 0 9.625932761991862e-07
chromosome O 0 1.3767503332928754e-05
15 O 0 1.0791787644848228e-05
paternal O 0 0.011309423483908176
uniparental B-Disease 1 0.9997881054878235
disomy I-Disease 0 0.44586771726608276
. O 0 6.776121153961867e-05

Previous O 0 3.026443300768733e-05
UBE3A O 0 0.0003354721120558679
cDNA O 0 1.3709487575397361e-05
analysis O 0 2.1939962380201905e-07
has O 0 2.2486480233396833e-08
shown O 0 7.520299050156609e-09
a O 0 5.388660184735272e-09
coding O 0 4.1879474110828596e-07
region O 0 4.205384698252601e-07
of O 0 1.375982776607998e-07
approximately O 0 3.1717377169115935e-07
2 O 0 2.772397238004487e-06
. O 0 2.4267503704322735e-06

6 O 0 5.926927406108007e-05
kb O 0 7.77533496147953e-05
and O 0 1.0032781574409455e-06
a O 0 7.00737984971056e-07
3 O 0 1.6117148788907798e-06
- O 0 1.158518443844514e-06
untranslated O 0 0.0002023786073550582
region O 0 1.1793262046921882e-06
( O 0 1.4287994076767063e-07
UTR O 0 0.00011620354780461639
) O 0 3.0852724819396826e-08
of O 0 8.497419656805505e-08
< O 0 4.2909755393338855e-07
50 O 0 1.2336346344454796e-07
bp O 0 1.0418366969133785e-07
, O 0 8.529534412105022e-09
whereas O 0 1.593302023650267e-08
Northern O 0 4.3772349300752467e-08
analysis O 0 1.6199988905896134e-08
has O 0 6.166627208870068e-09
indicated O 0 3.823795324819912e-08
mRNA O 0 5.455219138639222e-07
sizes O 0 1.0052416428152355e-06
of O 0 4.767561847529578e-07
5 O 0 2.3511249764851527e-06
- O 0 4.8390156734967604e-06
8 O 0 5.744742793467594e-06
kb O 0 8.565215102862567e-05
. O 0 9.222836524713784e-06

We O 0 1.9360356873221463e-06
have O 0 1.499328021736801e-07
analyzed O 0 8.316073376590793e-07
additional O 0 4.018754395929136e-07
cDNA O 0 3.549621396814473e-06
clones O 0 2.3687086923018796e-06
and O 0 4.8588169931917946e-08
provide O 0 5.579359196872247e-08
evidence O 0 1.4422225547150447e-07
for O 0 1.731106991087472e-08
an O 0 4.7996277174888746e-08
additional O 0 3.389634741779446e-07
0 O 0 5.9381145547376946e-06
. O 0 1.95200186681177e-06

5 O 0 4.794473716174252e-05
kb O 0 0.00010685036977520213
of O 0 1.1140259630337823e-05
5 O 0 1.0992007446475327e-05
- O 0 7.730688594165258e-06
UTR O 0 0.000257752399193123
and O 0 3.8888819631210936e-07
> O 0 1.911504796225927e-06
2 O 0 1.0046262559626484e-06
kb O 0 4.5137476263334975e-06
of O 0 1.3442585213851999e-06
3 O 0 1.070362122845836e-05
- O 0 2.271414086862933e-05
UTR O 0 0.010367629118263721
. O 0 1.2276167581148911e-05

We O 0 1.130375267166528e-06
have O 0 1.4239851964248373e-07
established O 0 2.4456849700982275e-07
the O 0 3.5240027784766426e-08
genomic O 0 4.2058059079863597e-07
organization O 0 1.9918238081118034e-07
of O 0 2.193140460349241e-07
UBE3A O 0 0.0036819165106862783
and O 0 8.384240857139957e-08
the O 0 9.697252068008311e-08
sequence O 0 2.1273356765050266e-07
of O 0 4.394258326101408e-07
intron O 0 6.081333413021639e-05
- O 0 4.7051755245774984e-05
exon O 0 2.289318035764154e-05
borders O 0 9.73644000623608e-06
. O 0 8.163690836227033e-06

We O 0 2.8505089630925795e-06
have O 0 5.634068429571926e-07
also O 0 3.15515677584699e-07
mapped O 0 5.638987090605951e-07
two O 0 8.249234895174595e-08
highly O 0 2.1613763578898215e-07
homologous O 0 4.2641616460059595e-07
processed O 0 9.414630426363146e-07
pseudogenes O 0 3.694758561323397e-06
, O 0 1.6755878107233002e-07
UBE3AP1 O 0 0.00135259167291224
and O 0 1.5756805282762798e-07
UBE3AP2 O 0 0.036594800651073456
, O 0 5.802312941227683e-08
to O 0 1.9237814896655436e-08
chromosomes O 0 1.1747111727800075e-07
2 O 0 9.364649145027215e-08
and O 0 1.5009598897108845e-08
21 O 0 1.0029933861233076e-07
, O 0 9.650786836346015e-09
respectively O 0 3.2678219241688566e-08
, O 0 7.003715829512203e-09
and O 0 7.039017813070814e-09
determined O 0 5.566168326254228e-08
their O 0 7.569519056005447e-08
genomic O 0 2.6204211280855816e-06
organization O 0 4.714162514574127e-06
. O 0 5.871912435395643e-06

These O 0 5.814010819449322e-07
results O 0 1.6168107208613947e-07
will O 0 1.247295422501793e-08
form O 0 7.42904271433531e-09
the O 0 9.210636697787322e-09
basis O 0 1.4459113018006065e-08
for O 0 2.5868145403507015e-09
studies O 0 1.906998292611206e-08
of O 0 1.0023026852934436e-08
mutation O 0 5.177553319413164e-08
and O 0 8.415097596525811e-08
imprinting O 0 1.9565663023968227e-05
of O 0 2.2934087610337883e-05
UBE3A O 1 0.9997393488883972
. O 0 5.862037869519554e-05

Mutation O 0 6.975833457545377e-06
spectrum O 0 9.976441106118727e-06
and O 0 4.582082624438044e-07
genotype O 0 4.593384346662788e-06
- O 0 3.881430075125536e-06
phenotype O 0 8.1871365864572e-07
analyses O 0 2.0332116434929048e-07
in O 0 8.245663707384665e-08
Cowden B-Disease 1 0.9987303614616394
disease I-Disease 0 0.35034045577049255
and O 0 1.1336580882925773e-06
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.575323089284211e-07
two O 0 6.212192147359019e-07
hamartoma B-Disease 1 0.9999988079071045
syndromes I-Disease 1 0.9999974966049194
with O 0 0.002627260982990265
germline O 1 1.0
PTEN O 1 1.0
mutation O 0 2.0103812857996672e-05
. O 0 1.3226102964836173e-05

The O 0 0.00010006610682466999
tumour B-Disease 1 1.0
suppressor O 1 0.995506763458252
gene O 0 0.00020569727348629385
PTEN O 1 0.9998950958251953
, O 0 3.3719115322128346e-07
which O 0 3.9888945480015536e-08
maps O 0 8.381121574529971e-07
to O 0 4.965131097378617e-07
10q23 O 0 0.0004008422256447375
. O 0 2.1623776774504222e-05

3 O 0 2.877536644518841e-05
and O 0 4.4871194404549897e-07
encodes O 0 1.1801521395682357e-06
a O 0 1.986142734722307e-07
403 O 0 4.762667629165662e-07
amino O 0 1.7044222033746337e-07
acid O 0 1.7240003558072203e-07
dual O 0 6.331442818918731e-07
specificity O 0 1.1075396741944132e-06
phosphatase O 0 1.7225902411155403e-05
( O 0 8.123524253278447e-07
protein O 0 7.49053981508041e-07
tyrosine O 0 1.064255457094987e-06
phosphatase O 0 2.239778041257523e-06
; O 0 8.51484429631455e-08
PTPase O 0 1.6567423699598294e-06
) O 0 1.140002847677124e-08
, O 0 7.3992896254537754e-09
was O 0 2.442989632811532e-08
shown O 0 1.0985466758484108e-08
recently O 0 5.572677430620843e-09
to O 0 2.8906479432322385e-09
play O 0 3.1586548487894106e-08
a O 0 4.30791793348817e-08
broad O 0 2.924930981862417e-07
role O 0 1.7301505295108655e-07
in O 0 1.5767253103149415e-07
human O 0 2.609453531476902e-06
malignancy B-Disease 0 0.004423954989761114
. O 0 8.837678251438774e-06

Somatic O 0 0.18820708990097046
PTEN O 0 0.009365834295749664
deletions O 0 1.1528463801369071e-05
and O 0 2.3382200708965684e-07
mutations O 0 2.564432577401021e-07
were O 0 6.694374832250105e-08
observed O 0 3.5803580544779834e-08
in O 0 8.946124729902749e-09
sporadic B-Disease 0 8.378424354305025e-06
breast I-Disease 0 0.3764527142047882
, I-Disease 0 9.956949043044006e-08
brain I-Disease 1 0.9998784065246582
, I-Disease 0 6.885738343953562e-07
prostate I-Disease 1 1.0
and I-Disease 0 0.3548262417316437
kidney I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cell O 0 0.19091284275054932
lines O 0 2.4279350441247516e-07
and O 0 2.2506378982711794e-09
in O 0 2.6938868913362057e-09
several O 0 2.6841075140282555e-08
primary O 0 3.4568622595543275e-06
tumours B-Disease 1 1.0
such O 0 5.041098205538219e-08
as O 0 3.2072114208858693e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9722490906715393
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999978542327881
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.0003631272993516177

In O 0 9.099815656554711e-07
addition O 0 9.389435149387282e-07
, O 0 4.131903779125423e-07
PTEN O 1 0.5524855256080627
was O 0 3.6963371030651615e-07
identified O 0 1.477345108469308e-07
as O 0 2.3434386875464952e-08
the O 0 2.1913566072839785e-08
susceptibility O 0 1.2647431901768869e-07
gene O 0 8.529310946414626e-08
for O 0 6.12653465736912e-08
two O 0 1.8429720967105823e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 3.5336117889528396e-06
CD B-Disease 0 0.1343490034341812
; O 0 9.607938409317285e-07
MIM O 0 2.113571099471301e-05
158350 O 0 8.146666004904546e-06
) O 0 5.2954444385022725e-08
and O 0 1.5562544319891458e-07
Bannayan B-Disease 0 4.4219075789442286e-05
- I-Disease 0 0.0001546665735077113
Zonana I-Disease 1 0.9774347543716431
( I-Disease 0 5.670498467225116e-06
BZS I-Disease 0 0.0007956249173730612
) I-Disease 0 2.937986494089273e-07
or I-Disease 0 1.5405707642912603e-07
Ruvalcaba I-Disease 0 1.581050491950009e-05
- I-Disease 0 3.0564315238734707e-06
Riley I-Disease 0 1.1517233360791579e-05
- I-Disease 0 0.00026194445672445
Smith I-Disease 0 0.000367295288015157
syndrome I-Disease 1 1.0
( O 0 0.00019437060109339654
MIM O 1 0.9258837103843689
153480 O 0 0.0008164820610545576
) O 0 2.6091249765158864e-06
. O 0 4.155509486736264e-06

Constitutive O 0 2.2827518478152342e-05
DNA O 0 7.278948487510206e-06
from O 0 7.26551775187545e-07
37 O 0 8.925835572881624e-07
CD B-Disease 0 1.304685497416358e-06
families O 0 4.5540183180037275e-08
and O 0 1.8737125628831564e-08
seven O 0 1.621367289317277e-07
BZS B-Disease 0 0.0001256102987099439
families O 0 5.733215857617324e-08
was O 0 1.9524695460404473e-07
screened O 0 3.1341821227215405e-07
for O 0 2.3507612922912813e-07
germline O 0 0.3586331605911255
PTEN O 1 0.9916640520095825
mutations O 0 4.191301923128776e-05
. O 0 1.1073178939113859e-05

PTEN O 0 0.0020985212177038193
mutations O 0 1.1172516678925604e-05
were O 0 7.851836016925517e-07
identified O 0 6.640505034738453e-07
in O 0 5.148070414406902e-08
30 O 0 2.0718150040011096e-07
of O 0 7.658658773834759e-08
37 O 0 2.3479582011987077e-07
( O 0 2.1303664610172746e-08
81 O 0 8.23452026565974e-08
% O 0 3.2537892380446465e-09
) O 0 5.906565236912797e-10
CD B-Disease 0 3.279623328467096e-08
families O 0 4.652861651521789e-09
, O 0 3.2636782165695877e-09
including O 0 1.013162354013275e-08
missense O 0 6.653690434177406e-07
and O 0 9.894437624780039e-08
nonsense O 0 8.211650879275112e-07
point O 0 5.471131316880928e-07
mutations O 0 1.544936054642676e-07
, O 0 5.235268218939382e-08
deletions O 0 5.281011112856504e-07
, O 0 4.924622132307377e-08
insertions O 0 9.18605792321614e-07
, O 0 4.67213503441144e-08
a O 0 5.4042157415779e-08
deletion O 0 5.355766461434541e-07
/ O 0 5.184904694033321e-06
insertion O 0 1.2459826166377752e-06
and O 0 4.859452360506111e-07
splice O 0 7.766167254885659e-05
site O 0 8.108918336802162e-06
mutations O 0 5.405856882134685e-06
. O 0 9.138836503552739e-06

These O 0 7.537706778748543e-07
mutations O 0 1.0743327720774687e-06
were O 0 2.1480873613199947e-07
scattered O 0 3.258067238220974e-07
over O 0 4.352857629896789e-08
the O 0 4.8011479236720334e-08
entire O 0 6.053321754961871e-08
length O 0 3.880042598325417e-08
of O 0 6.972821608997037e-08
PTEN O 0 3.828299668384716e-05
, O 0 1.7246902572765066e-08
with O 0 2.3354727041180467e-09
the O 0 1.1338962657703178e-08
exception O 0 4.552133958668492e-08
of O 0 1.4963806194145945e-08
the O 0 1.14339124834828e-08
first O 0 4.03792377312584e-08
, O 0 4.8054719314905014e-08
fourth O 0 7.30410988580843e-07
and O 0 1.1773086328048521e-07
last O 0 1.9563387922971742e-06
exons O 0 5.536820026463829e-05
. O 0 2.390548979747109e-05

A O 0 5.419656736194156e-05
hot O 0 6.279085937421769e-05
spot O 0 2.0166373360552825e-05
for O 0 6.850813747405482e-07
PTEN O 0 0.00016190511814784259
mutation O 0 2.1595879218239133e-07
in O 0 6.339327995874555e-08
CD B-Disease 0 3.2106481739901938e-06
was O 0 1.6756963816533244e-07
identified O 0 1.1598832116987978e-07
in O 0 2.814621957725194e-08
exon O 0 4.7117708845689776e-07
5 O 0 1.2135907923038758e-07
that O 0 2.6972493127885855e-09
contains O 0 1.6772577993151572e-08
the O 0 5.473219033547139e-08
PTPase O 0 4.705179890152067e-06
core O 0 8.112376121971465e-07
motif O 0 2.656483104601648e-07
, O 0 7.341567354046674e-09
with O 0 3.255117508871308e-09
13 O 0 2.733598414295102e-08
of O 0 1.9908545922930898e-08
30 O 0 5.95902029942863e-08
( O 0 1.1510848274554064e-08
43 O 0 3.8251883438533696e-08
% O 0 3.938039228046364e-09
) O 0 1.4492071986893507e-09
CD B-Disease 0 1.1092789975464257e-07
mutations O 0 4.207105774867159e-08
identified O 0 5.8633901289795176e-08
in O 0 2.0175711767933535e-08
this O 0 5.654642620811501e-08
exon O 0 7.463937436114065e-06
. O 0 3.2308896606991766e-06

Seven O 0 8.349461495527066e-06
of O 0 1.706957959868305e-06
30 O 0 7.412131708406378e-07
( O 0 5.6062415154656264e-08
23 O 0 9.379128584896534e-08
% O 0 2.858486336521082e-09
) O 0 5.742862851931818e-10
were O 0 2.2902437724070523e-09
within O 0 7.105912303018158e-09
the O 0 1.5876443271167773e-08
core O 0 1.2028003482100758e-07
motif O 0 7.241190047579948e-08
, O 0 2.1718444820351124e-09
the O 0 4.375596329708742e-09
majority O 0 2.1705441888286714e-09
( O 0 3.5487350835694542e-09
five O 0 4.566785172244181e-09
of O 0 1.0364175295762834e-08
seven O 0 1.5325120727993635e-08
) O 0 2.802316156902407e-09
of O 0 5.993350260524721e-09
which O 0 5.257821733550827e-09
were O 0 3.035302853504618e-08
missense O 0 4.0559328340350476e-07
mutations O 0 1.5429790778398456e-07
, O 0 3.174999818611468e-08
possibly O 0 2.1170646391510672e-07
pointing O 0 3.661575078695023e-07
to O 0 1.102322677581924e-08
the O 0 2.9345132546154673e-08
functional O 0 2.5350658461320563e-07
significance O 0 3.5492320193952764e-07
of O 0 5.883959275365669e-08
this O 0 4.742860326700793e-08
region O 0 4.560734851111192e-06
. O 0 4.667361736210296e-06

Germline O 0 0.060182929039001465
PTEN O 0 0.0022110696882009506
mutations O 0 3.860314791381825e-06
were O 0 4.553644998850359e-07
identified O 0 1.6848382244916138e-07
in O 0 1.3346656224655362e-08
four O 0 2.1657811544173455e-08
of O 0 4.4369492968598934e-08
seven O 0 1.6243218681211147e-07
( O 0 9.209498585960318e-08
57 O 0 6.830302936577937e-07
% O 0 6.744421909843368e-08
) O 0 6.962667953303026e-08
BZS B-Disease 0 0.0003049998194910586
families O 0 4.858696911469451e-07
studied O 0 5.300257271301234e-06
. O 0 3.2830268992256606e-06

Interestingly O 0 2.4119834051816724e-05
, O 0 3.9733401990815764e-07
none O 0 2.982448563670914e-07
of O 0 5.5635787532537506e-08
these O 0 2.2886815997935628e-08
mutations O 0 1.1192081217359373e-07
was O 0 1.330289620682379e-07
observed O 0 3.6912638279318344e-08
in O 0 1.1253769471863961e-08
the O 0 1.9579385934775928e-07
PTPase O 0 0.0005394264589995146
core O 0 1.6284586308756843e-05
motif O 0 1.3265590496303048e-05
. O 0 3.656745548141771e-06

It O 0 2.3387396197449561e-07
is O 0 4.21996446675621e-08
also O 0 1.3679225752127877e-08
worthy O 0 1.852749278441479e-07
of O 0 2.7170838023948818e-08
note O 0 2.7884176745374134e-08
that O 0 2.5599855568714247e-09
a O 0 9.486533336655611e-09
single O 0 2.2145123068639805e-08
nonsense O 0 3.3125317600024573e-07
point O 0 1.7595044710105867e-07
mutation O 0 4.436298084442569e-08
, O 0 1.8843424598458114e-08
R233X O 0 1.1468627008071053e-06
, O 0 1.669320326413981e-08
was O 0 2.4830992373381378e-08
observed O 0 1.560215423523914e-08
in O 0 5.815771864092767e-09
the O 0 3.699891948372169e-08
germline O 0 2.2639267172053223e-06
DNA O 0 2.074163631959891e-07
from O 0 5.03492927350635e-08
two O 0 3.0121302785346415e-08
unrelated O 0 2.055991927818468e-07
CD B-Disease 0 1.5382056517410092e-06
families O 0 1.1335268368384277e-07
and O 0 1.5694806165811315e-07
one O 0 2.100482333844411e-06
BZS B-Disease 1 0.8206781148910522
family O 0 7.270727564900881e-06
. O 0 1.0689105693018064e-05

Genotype O 0 3.0332015739986673e-05
- O 0 6.7766204665531404e-06
phenotype O 0 8.485189937346149e-07
studies O 0 1.3589679781489394e-07
were O 0 1.3819763999833867e-08
not O 0 2.3034654184073133e-09
performed O 0 1.0847939435620901e-08
on O 0 1.6173682837461456e-08
this O 0 2.1493111734827153e-09
small O 0 3.806258774829985e-08
group O 0 4.85052069620906e-08
of O 0 6.312421874099527e-07
BZS B-Disease 1 0.9996300935745239
families O 0 3.5656014460982988e-06
. O 0 1.1769210686907172e-05

However O 0 3.079636826441856e-06
, O 0 3.5761786421062425e-07
genotype O 0 2.19702906179009e-06
- O 0 1.5054589539431618e-06
phenotype O 0 2.7543873670765606e-07
analysis O 0 1.191688596691165e-07
inthe O 0 1.304682996305928e-06
group O 0 5.8662429580635944e-08
of O 0 6.052641055021013e-08
CD B-Disease 0 5.81337371841073e-06
families O 0 7.347117758627064e-08
revealed O 0 9.670008438433797e-08
two O 0 9.339316875411896e-09
possible O 0 5.760993104786394e-08
associations O 0 1.0527933369530729e-07
worthy O 0 1.7536807490614592e-06
of O 0 1.311655353219976e-07
follow O 0 3.0908981329957896e-07
- O 0 1.1053396065108245e-06
up O 0 1.1459242443834228e-07
in O 0 6.491802650998579e-08
independent O 0 4.243468367803871e-07
analyses O 0 3.4576867165014846e-06
. O 0 5.958752353762975e-06

The O 0 2.158310508093564e-06
first O 0 5.608989681604726e-07
was O 0 2.7607515562522167e-07
an O 0 2.6942633013504746e-08
association O 0 1.3697651013444556e-07
noted O 0 7.713957472788024e-08
in O 0 8.64617533125056e-09
the O 0 2.3860792452978785e-08
group O 0 1.4096070977132058e-08
of O 0 2.4338923765299114e-08
CD B-Disease 0 0.01410470437258482
families O 0 4.1020604157893104e-07
with O 0 3.580171551220701e-06
breast B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9997420907020569
. O 0 1.0510350875847507e-05

A O 0 5.610601419903105e-06
correlation O 0 2.140144488294027e-06
was O 0 2.73514274340414e-07
observed O 0 5.5039340196572084e-08
between O 0 1.7225763926376203e-08
the O 0 1.972522767346163e-08
presence O 0 3.166074122873397e-07
/ O 0 1.5172465282375924e-05
absence O 0 1.7203934703502455e-06
of O 0 1.6931124946495402e-07
a O 0 9.130391021017203e-08
PTEN O 0 3.100294998148456e-05
mutation O 0 2.0857411797692293e-08
and O 0 4.7130805924666674e-09
the O 0 4.68837058065219e-09
type O 0 8.149179109295801e-08
of O 0 1.883866929119904e-07
breast O 0 2.745233905443456e-05
involvement O 0 2.396795025561005e-06
( O 0 8.019209758458601e-07
unaffected O 0 5.050773688708432e-05
versus O 0 0.00534093426540494
benign O 1 0.5958297252655029
versus O 0 0.0003081770264543593
malignant O 0 4.479677591007203e-05
) O 0 1.1318271617710707e-06
. O 0 3.1476542972086463e-06

Specifically O 0 2.16927628571284e-06
and O 0 1.4610959908623045e-07
more O 0 2.3180108499332164e-08
directly O 0 1.3156278555470635e-07
, O 0 8.63376570237051e-09
an O 0 6.024294396667074e-09
association O 0 9.80953913654048e-08
was O 0 1.5627774985205178e-07
also O 0 1.2145988215195302e-08
observed O 0 1.529883597584103e-08
between O 0 1.0058609944962882e-08
the O 0 1.4941416992542145e-08
presence O 0 5.2146393869634267e-08
of O 0 7.354520903390949e-08
a O 0 1.9178376930995e-07
PTEN O 1 0.9996811151504517
mutation O 0 9.087802936846856e-06
and O 0 0.003922766074538231
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999934434890747
. O 0 1.3916655916546006e-05

Secondly O 0 4.4682776206173e-05
, O 0 5.767456627836509e-07
there O 0 9.431654035552128e-08
appeared O 0 6.660560103455282e-08
to O 0 3.771208678671201e-09
be O 0 1.112866421237868e-08
an O 0 2.5444872875368674e-08
interdependent O 0 1.9313608845550334e-06
association O 0 5.708309345209273e-07
between O 0 1.2350426459306618e-07
mutations O 0 2.7313163286635245e-07
upstream O 0 7.499731964344392e-07
and O 0 2.127921661099208e-08
within O 0 8.844888554904173e-08
the O 0 1.5575075451579323e-07
PTPase O 0 5.631778549286537e-05
core O 0 1.5761044096507248e-06
motif O 0 6.044306815056188e-07
, O 0 1.3363774087338243e-08
the O 0 3.922815139389968e-08
core O 0 3.704542166360625e-07
motif O 0 1.5285512233731424e-07
containing O 0 1.38532545435055e-08
the O 0 1.1082233797310437e-08
majority O 0 4.814405318853687e-09
of O 0 2.3849690222732534e-08
missense O 0 2.670102219326509e-07
mutations O 0 6.405251440355642e-08
, O 0 7.527173551125088e-09
and O 0 3.069241749642515e-09
the O 0 1.4500181499954579e-08
involvement O 0 9.38390556370905e-08
of O 0 2.88697989958564e-08
all O 0 1.2486188083471461e-08
major O 0 3.388151128547179e-07
organ O 0 0.43626707792282104
systems O 0 0.0002357740595471114
( O 0 2.9107505383763055e-07
central O 0 4.73206227979972e-06
nervous O 0 1.4980174682932557e-06
system O 0 2.519179133742e-06
, O 0 7.572983236059372e-07
thyroid O 1 0.9999996423721313
, O 0 0.0001431650889571756
breast O 1 0.9999996423721313
, O 0 1.2357744708424434e-05
skin O 1 0.9999996423721313
and O 1 0.986548125743866
gastrointestinal O 1 1.0
tract O 1 0.999998927116394
) O 0 7.954398824949749e-06
. O 0 1.4699706298415549e-05

However O 0 1.4322251900011906e-06
, O 0 6.650671480201709e-08
these O 0 9.96884086390537e-09
observations O 0 7.164653226254813e-08
would O 0 5.349754861327938e-09
need O 0 8.004385598781028e-09
to O 0 3.87721499350846e-09
be O 0 6.660443307993091e-09
confirmed O 0 2.4150255129029574e-08
by O 0 4.101689654589791e-09
studying O 0 2.5835616312974707e-08
a O 0 4.09864009398575e-09
larger O 0 1.8875439877774625e-08
number O 0 1.7010016506446846e-08
of O 0 6.538376595699447e-08
CD B-Disease 0 1.160788451670669e-05
families O 0 7.680292242184805e-07
. O 0 3.1834820219955873e-06

Molecular O 1 0.8538230061531067
defects O 1 0.9999984502792358
leading O 0 1.9454548237263225e-05
to O 0 1.2868132159837842e-07
human O 0 5.450331173051381e-07
complement B-Disease 0 5.099313966638874e-06
component I-Disease 1 0.9999973773956299
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.234573935946173e-08
an O 0 1.6955112869254663e-08
African O 0 1.1070322614159522e-07
- O 0 3.499555134567345e-07
American O 0 4.09414610658132e-07
family O 0 5.310839696903713e-07
. O 0 1.8155071757064434e-06

Complement B-Disease 0 0.00010148428555112332
component I-Disease 1 0.9943859577178955
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 4.257873570168158e-06
C6D B-Disease 1 0.9999798536300659
) O 0 5.242982936692897e-08
was O 0 2.0834953318171756e-07
diagnosed O 0 9.268956802088724e-08
in O 0 2.591214354197291e-09
a O 0 1.5752862125850697e-08
16 O 0 7.372469923438985e-08
- O 0 5.549197013010598e-08
year O 0 2.5172282036578508e-08
- O 0 1.2572955654377438e-07
old O 0 4.833619300370628e-07
African O 0 4.0335061157747987e-07
- O 0 5.952704213996185e-07
American O 0 1.552912607394319e-07
male O 0 1.1865989080206418e-07
with O 0 8.333032042173727e-08
meningococcal B-Disease 1 0.9999853372573853
meningitis I-Disease 1 0.9999985694885254
. O 0 1.3861118532076944e-05

The O 0 2.565834165579872e-06
patients O 0 4.0240738030661305e-07
father O 0 5.182671998227306e-07
and O 0 9.684479351790287e-08
two O 0 1.5105730710729404e-07
brothers O 0 2.9593684303108603e-06
also O 0 5.229719235444463e-08
had O 0 8.224505876341937e-08
C6D B-Disease 1 0.9999516010284424
, O 0 1.8323444095358354e-08
but O 0 1.0018477603068732e-08
gave O 0 6.095321225529915e-08
no O 0 3.506971424371841e-08
history O 0 2.5635372935539635e-07
of O 0 1.707119423599579e-07
meningitis B-Disease 1 0.9999998807907104
or O 0 1.2321314670771244e-06
other O 0 3.942335752071813e-06
neisserial B-Disease 1 0.9993332028388977
infection I-Disease 0 3.772872514673509e-05
. O 0 5.327774942998076e-06

By O 0 1.2811099168175133e-06
using O 0 7.654655860278581e-07
exon O 0 2.7761359433498e-06
- O 0 1.4193811921359156e-06
specific O 0 1.20785230706133e-07
polymerase O 0 8.075333539636631e-07
chain O 0 2.099860267890108e-07
reaction O 0 1.5563998090328823e-07
( O 0 2.345281124860321e-08
PCR O 0 1.6534453095573554e-07
) O 0 1.6063559371559677e-08
/ O 0 5.479695275312224e-08
single O 0 4.031621259059648e-08
- O 0 1.483380316358307e-07
strand O 0 8.668157391866771e-08
conformation O 0 1.701465635051136e-08
polymorphism O 0 1.97478904340187e-08
as O 0 5.873875608131129e-09
a O 0 2.949640753868721e-09
screening O 0 6.955286124821214e-09
step O 0 1.3602135418011585e-08
and O 0 4.173312806443619e-09
nucleotide O 0 1.4651892144001977e-08
sequencing O 0 2.476845928356397e-08
of O 0 1.7193922730029954e-08
target O 0 3.971827666759964e-08
exons O 0 1.283289776665697e-07
, O 0 9.26854593075177e-09
we O 0 5.362770671979433e-09
determined O 0 1.394992832359776e-08
that O 0 4.85281326234599e-09
the O 0 5.174295480969704e-08
proband O 0 4.952979907102417e-06
was O 0 1.5425597155172e-07
a O 0 3.971782192024875e-08
compound O 0 6.297750019257364e-07
heterozygote O 0 4.782558335136855e-06
for O 0 2.57101220313416e-07
two O 0 1.1789798008976504e-06
C6 O 1 0.9949390888214111
gene O 0 4.226971213938668e-06
mutations O 0 9.118909474636894e-06
. O 0 1.0062007277156226e-05

The O 0 5.298528776620515e-06
first O 0 1.7765945585779264e-06
, O 0 5.46198691608879e-07
1195delC O 0 9.926200618792791e-06
located O 0 6.060959094611462e-07
in O 0 2.495043993633317e-08
exon O 0 6.483481342911546e-07
7 O 0 3.0128344974400534e-07
, O 0 7.314926442347769e-09
is O 0 1.5403854858320187e-09
a O 0 2.0575201542527566e-09
novel O 0 7.506384847033587e-09
mutation O 0 3.803310555383632e-09
, O 0 4.454185464908278e-09
while O 0 6.064391211424436e-09
the O 0 1.0984712695005783e-08
second O 0 9.92320181580908e-08
, O 0 2.750087269021151e-08
1936delG O 0 4.104012987227179e-07
in O 0 2.529785803062623e-08
exon O 0 5.062673267275386e-07
12 O 0 4.066839665028965e-07
, O 0 1.685444850352269e-08
has O 0 4.895820637784709e-09
been O 0 6.463852120219826e-09
described O 0 1.794721882220074e-08
before O 0 1.1206239491912129e-08
to O 0 2.079151784073474e-08
cause O 0 5.491442152560921e-06
C6D B-Disease 1 0.9999877214431763
in O 0 2.064309967408917e-08
an O 0 1.6135476954559635e-08
unrelated O 0 2.4753282445999503e-07
African O 0 1.9438618892309023e-07
- O 0 4.0204562878898287e-07
American O 0 1.5767824379508966e-07
individual O 0 2.8151811193311005e-07
. O 0 2.2809781512478366e-06

Both O 0 1.7973582089325646e-06
mutations O 0 1.5456830624316353e-06
result O 0 2.6174490130870254e-07
in O 0 6.068037805562199e-08
premature O 0 1.8645094996827538e-06
termination O 0 2.060490487565403e-06
codons O 0 1.5813084246474318e-05
and O 0 4.274469119991409e-06
C6 O 1 0.9991507530212402
null O 0 3.27102534356527e-05
alleles O 0 9.92383502307348e-06
. O 0 1.2237057489983272e-05

Allele O 0 8.32915884529939e-06
- O 0 3.3824828733486356e-06
specific O 0 2.3006833771432866e-07
PCR O 0 7.563600661342207e-07
indicated O 0 1.2107076940992556e-07
that O 0 3.7818983500415015e-09
the O 0 3.613618559938914e-08
probands O 0 3.523389068504912e-06
two O 0 6.043620004447803e-08
brothers O 0 1.0267507377648144e-06
also O 0 5.981909367847038e-08
inherited O 0 3.652827444966533e-07
the O 0 6.040254874051243e-08
1195delC O 0 1.9478889612400963e-07
mutation O 0 1.0875472966631605e-08
from O 0 1.0383209847475428e-08
their O 0 9.531986755462185e-09
heterozygous O 0 5.1056410654837237e-08
mother O 0 4.104290241002673e-08
and O 0 1.986227360362136e-08
the O 0 2.8444992139498027e-08
1936delG O 0 2.8711599497910356e-07
mutation O 0 2.3904251023054712e-08
from O 0 2.0543724943422603e-08
their O 0 2.0892091612267905e-08
homozygous O 0 4.665901656153437e-07
father O 0 2.0960999336239183e-06
. O 0 1.1171451888003503e-06
. O 0 5.662209332513157e-06

PAX6 O 0 0.0639917328953743
mutations O 0 0.0003090968239121139
reviewed O 0 0.00020344015501905233
. O 0 5.3737505368189886e-05

Mutations O 0 1.8978282241732813e-05
in O 0 1.1643090829238645e-06
PAX6 O 0 0.041913289576768875
are O 0 7.007165692130002e-08
responsible O 0 1.0928437887969267e-07
for O 0 3.6453311480499906e-08
human O 0 1.7775655578589067e-06
aniridia B-Disease 1 1.0
and O 0 5.4842963947976386e-08
have O 0 3.767369527452047e-09
also O 0 4.2662380295155344e-09
been O 0 2.3189203890439103e-09
found O 0 2.4386492825101413e-09
in O 0 2.5181441376531666e-09
patients O 0 5.098836020067665e-09
with O 0 1.2018297468330275e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.8045476483384846e-06
with O 1 0.9975784420967102
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.04033886641263962
with O 0 7.77777927396528e-07
autosomal B-Disease 1 0.9999929666519165
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 1.6493333987455117e-07
and O 0 5.520335477626759e-08
with O 0 2.4255280095530907e-07
isolated B-Disease 1 0.9999526739120483
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.2301553189754486

No O 0 3.6327655834611505e-06
locus O 0 1.5380691138489055e-06
other O 0 9.120156363451315e-08
than O 0 3.627727451771534e-08
chromosome O 0 4.7488842369602935e-07
11p13 O 0 2.7893595415662276e-06
has O 0 1.5566039124337294e-08
been O 0 1.772750657380584e-08
implicated O 0 2.2727996906724002e-07
in O 0 2.7770910904223456e-08
aniridia B-Disease 1 1.0
, O 0 1.0704193442734322e-07
and O 0 1.6942884428772231e-07
PAX6 O 1 0.9996131062507629
is O 0 2.850979008428567e-08
clearly O 0 5.005657399692609e-08
the O 0 2.766501516759945e-08
major O 0 7.906569976512401e-07
, O 0 1.92654638908607e-08
if O 0 5.918386669634401e-09
not O 0 7.603099483333153e-09
only O 0 3.430028172601851e-08
, O 0 5.2538243977551247e-08
gene O 0 3.469554030743893e-07
responsible O 0 1.4376840908880695e-06
. O 0 3.991158337157685e-06

Twenty O 0 4.5628330553881824e-05
- O 0 6.0265883803367615e-06
eight O 0 4.7248832402146945e-07
percent O 0 9.703801850946547e-08
of O 0 4.4405560117866116e-08
identified O 0 4.803245587936544e-07
PAX6 O 0 2.164940451621078e-05
mutations O 0 6.983968319218548e-07
are O 0 1.495419610364479e-07
C O 0 0.0008133766241371632
- O 0 3.266823114245199e-05
T O 0 1.2675602192757651e-05
changes O 0 9.078382134930507e-08
at O 0 1.1147213996309802e-07
CpG O 0 3.758271702736238e-07
dinucleotides O 0 1.2447142125893151e-06
, O 0 2.5952173743348794e-08
20 O 0 2.4846199764283483e-08
% O 0 1.9829711206398315e-09
are O 0 6.194019186445132e-10
splicing O 0 4.7332445518577515e-08
errors O 0 1.5140257403345458e-07
, O 0 8.04684852084847e-09
and O 0 2.9227478215432257e-09
more O 0 1.2482515021616791e-09
than O 0 2.299681112205576e-09
30 O 0 2.5139557990883077e-08
% O 0 4.547592968862091e-09
are O 0 3.0151692254065665e-09
deletion O 0 6.860085477455868e-08
or O 0 6.612989267296143e-08
insertion O 0 3.855808188291121e-07
events O 0 1.6997601051116362e-06
. O 0 7.84725671110209e-06

There O 0 1.9698495634656865e-06
is O 0 1.0979375275610437e-07
a O 0 1.5734791247723479e-07
noticeably O 0 1.4235565686249174e-05
elevated O 0 8.431567948719021e-06
level O 0 1.1509172992418826e-07
of O 0 1.765899959593753e-08
mutation O 0 7.046916383757207e-09
in O 0 6.000796304306277e-09
the O 0 1.531731719239815e-08
paired O 0 3.413411775454733e-08
domain O 0 1.8026776515966958e-08
compared O 0 5.500310873429726e-09
with O 0 1.0095893010486634e-09
the O 0 9.08056030368698e-09
rest O 0 8.505478632514496e-08
of O 0 6.490675730219664e-08
the O 0 2.1433480412724748e-07
gene O 0 1.8852288121706806e-06
. O 0 5.81330687055015e-06

Increased O 0 1.2141423439970822e-06
mutation O 0 1.560138684908452e-07
in O 0 2.5524981239755107e-08
the O 0 3.077315113841905e-08
homeodomain O 0 3.416328127059387e-06
is O 0 7.036466964649435e-09
accounted O 0 2.345290184280202e-08
for O 0 5.847148987214723e-09
by O 0 1.3467661652555307e-08
the O 0 3.2866313404156244e-07
hypermutable O 0 4.055739191244356e-05
CpG O 0 6.177605882839998e-06
dinucleotide O 0 1.4770556845178362e-05
in O 0 7.469175216101576e-07
codon O 0 1.1789094060077332e-05
240 O 0 3.329159881104715e-06
. O 0 4.006801191280829e-06

Very O 0 8.676028073750786e-07
nearly O 0 1.6925733348216454e-07
all O 0 2.8734930879181775e-08
mutations O 0 8.912390114801383e-08
appear O 0 3.489303423975798e-08
to O 0 4.876938408671094e-09
cause O 0 4.5455919917003484e-07
loss O 0 1.4668285075458698e-07
of O 0 2.4127187359113123e-08
function O 0 1.058943421838876e-08
of O 0 2.958979017364527e-08
the O 0 1.8407057211788924e-08
mutant O 0 4.722801705270285e-08
allele O 0 2.9300167625478934e-08
, O 0 2.891585415554232e-09
and O 0 1.4778326340447734e-09
more O 0 7.863064088731164e-10
than O 0 1.5279989495908808e-09
80 O 0 9.167450798486243e-09
% O 0 2.3453154973651635e-09
of O 0 4.6483732418778345e-09
exonic O 0 6.205270324244339e-07
substitutions O 0 2.4629235895190504e-07
result O 0 1.108576768160674e-07
in O 0 1.0972843256240594e-07
nonsense O 0 6.468321771535557e-06
codons O 0 4.631061528925784e-05
. O 0 1.4707728041685186e-05

In O 0 6.46054502340121e-07
a O 0 8.39073592828754e-08
gene O 0 5.750695208917023e-08
with O 0 1.1072027739089663e-08
such O 0 3.174739049427444e-08
extraordinarily O 0 5.081489007352502e-07
high O 0 1.0606297706772239e-07
sequence O 0 1.3171149504387358e-08
conservation O 0 3.22728759272195e-08
throughout O 0 3.9395717799095564e-09
evolution O 0 4.527602470716374e-08
, O 0 4.80414996673062e-09
there O 0 6.319418321965031e-09
are O 0 1.0526624905082826e-08
presumed O 0 1.4592538946089917e-06
undiscovered O 0 7.185240519902436e-06
missense O 0 5.161787157703657e-07
mutations O 0 7.000005552981747e-08
, O 0 8.839387000136867e-09
these O 0 7.49985940018405e-09
are O 0 3.5017628796651934e-09
hypothesized O 0 3.347505383999305e-08
to O 0 3.7971639166300974e-09
exist O 0 7.519241052023062e-08
in O 0 1.823996775840442e-08
as O 0 1.2769403667789447e-07
- O 0 6.612459060306719e-07
yet O 0 2.3913739255476685e-07
unidentified O 0 5.9915460042248014e-06
phenotypes O 0 3.214244770788355e-06
. O 0 1.2245078551131883e-06
. O 0 5.5427303777833e-06

Genetic O 0 1.928105666593183e-05
heterogeneity O 0 1.9298295228509232e-05
and O 0 1.8424607617362199e-07
penetrance O 0 1.2626044281205395e-06
analysis O 0 4.237127271267127e-08
of O 0 2.3858016007238803e-08
the O 0 8.253940819713534e-08
BRCA1 O 0 2.667170065251412e-06
and O 0 2.620485872739664e-07
BRCA2 O 0 1.7850039512268268e-05
genes O 0 1.033742364597856e-06
in O 0 3.3922456168511417e-06
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9919254183769226
families O 0 2.383592345722718e-06
. O 0 7.196988462965237e-06

The O 0 0.0003949914826080203
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.0002832628961186856
Consortium O 0 2.4267263142974116e-05
. O 0 6.561290774698136e-06

The O 0 9.684772521723062e-07
contribution O 0 9.479462619310652e-07
of O 0 4.7426433980035654e-07
BRCA1 O 0 1.0112731615663506e-05
and O 0 5.918558940720686e-07
BRCA2 O 0 0.002731078304350376
to O 0 1.0138118113900418e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 6.437365414058149e-07
assessed O 0 5.491696342119212e-08
by O 0 7.137112678634594e-09
linkage O 0 7.833886002117652e-07
and O 0 1.8008458724239063e-08
mutation O 0 1.0150540852293943e-08
analysis O 0 8.29582447181565e-09
in O 0 3.022654793127799e-09
237 O 0 3.783574342719476e-08
families O 0 4.47831904892837e-09
, O 0 2.8984104005758127e-09
each O 0 1.0377819714690872e-09
with O 0 1.6754343468150523e-09
at O 0 8.715932864333809e-09
least O 0 4.351875748653811e-09
four O 0 8.785616678608221e-09
cases O 0 2.8313349886843753e-08
of O 0 4.670019393415714e-07
breast B-Disease 1 0.9593791365623474
cancer I-Disease 0 3.2150539936992573e-06
, O 0 8.023981479254871e-09
collected O 0 2.3509421964718058e-08
by O 0 1.0280618134572705e-08
the O 0 3.1098320505407173e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999984502792358
Linkage O 0 2.3239897927851416e-05
Consortium O 0 5.080281425762223e-06
. O 0 3.366604460097733e-06

Families O 0 6.766287015125272e-07
were O 0 1.5936704755858955e-07
included O 0 8.305296006483331e-08
without O 0 4.586025781350145e-08
regard O 0 9.521704669168685e-08
to O 0 8.699191589300881e-09
the O 0 1.6276425540695527e-08
occurrence O 0 2.724687249155977e-07
of O 0 5.597426024905872e-07
ovarian B-Disease 1 0.9999988079071045
or I-Disease 0 4.15774911743938e-06
other I-Disease 0 6.832206508988747e-06
cancers I-Disease 1 0.9764520525932312
. O 0 4.949094090989092e-06

Overall O 0 6.1724720580969e-05
, O 0 1.0249369779558037e-06
disease O 0 0.007458842359483242
was O 0 1.7502378568678978e-07
linked O 0 1.117088217483797e-07
to O 0 1.1560750579064916e-08
BRCA1 O 0 1.6555027571030223e-07
in O 0 3.3124001319606577e-09
an O 0 1.5260737118438783e-09
estimated O 0 2.687553957159139e-09
52 O 0 7.499787457732054e-09
% O 0 5.961481308602856e-10
of O 0 7.349704178594152e-10
families O 0 2.135678744963343e-09
, O 0 1.9681285490236178e-09
to O 0 8.094260373070483e-09
BRCA2 O 0 1.3860184822078736e-07
in O 0 5.046935758201698e-09
32 O 0 3.970153628074513e-08
% O 0 1.717179176630168e-09
of O 0 3.306706242156565e-09
families O 0 1.6243947298377748e-09
, O 0 3.0670939121790752e-09
and O 0 2.541600041539027e-09
to O 0 4.970822864436286e-09
neither O 0 4.7879698428232587e-08
gene O 0 1.7379056416189087e-08
in O 0 1.845286057289286e-08
16 O 0 1.0967236363512711e-07
% O 0 6.747571390519624e-09
( O 0 3.6326068819647617e-09
95 O 0 1.6278880465847578e-08
% O 0 5.816127135460647e-09
confidence O 0 3.643593515789689e-08
interval O 0 2.7208028541281237e-07
[ O 0 1.5552514014416374e-06
CI O 0 3.55078955180943e-05
] O 0 5.681675361302041e-07
6 O 0 3.7243259498609405e-07
% O 0 3.610545817878119e-08
- O 0 9.55592796003657e-08
28 O 0 1.1524802800977341e-07
% O 0 5.1701296577277844e-09
) O 0 1.6271731739792017e-09
, O 0 2.167160229049614e-09
suggesting O 0 3.917880064818746e-08
other O 0 5.1690872027165824e-08
predisposition O 0 6.411280082829762e-06
genes O 0 2.1934615688223857e-06
. O 0 5.902431894355686e-06

The O 0 2.735956513788551e-06
majority O 0 4.407340270518034e-07
( O 0 1.4033652462330792e-07
81 O 0 3.0960430308368814e-07
% O 0 7.040790173107325e-09
) O 0 1.182239972585819e-09
of O 0 6.054913459507816e-09
the O 0 3.4847150232053536e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.735461019336526e-08
were O 0 7.254997491656923e-09
due O 0 6.876759162111057e-09
to O 0 8.135788043261982e-09
BRCA1 O 0 6.949162667524433e-08
, O 0 4.377207485362078e-09
with O 0 1.8413685021201331e-09
most O 0 1.0135372541242305e-08
others O 0 4.482354754031803e-08
( O 0 1.9947657747820813e-08
14 O 0 9.198403461141424e-08
% O 0 8.771418258390895e-09
) O 0 3.864102815498427e-09
due O 0 3.758988142976705e-08
to O 0 2.558786889039766e-07
BRCA2 O 0 3.828226908808574e-05
. O 0 5.964358024357352e-06

Conversely O 0 8.49759999255184e-06
, O 0 1.3111849739289028e-07
the O 0 5.122193869055991e-08
majority O 0 7.635347465395625e-09
of O 0 1.4676786008749332e-08
families O 0 1.003098226703969e-08
with O 0 5.043240491886536e-09
male B-Disease 0 1.628958330002206e-06
and I-Disease 0 3.868987903388188e-07
female I-Disease 1 0.759093165397644
breast I-Disease 1 0.9972012042999268
cancer I-Disease 0 0.001450866344384849
were O 0 7.125404266616897e-08
due O 0 9.826055702433223e-08
to O 0 1.3225960060481157e-07
BRCA2 O 0 5.84138297199388e-06
( O 0 3.388348375210626e-07
76 O 0 1.4590507362299832e-06
% O 0 1.0544996342787272e-07
) O 0 1.419214470388397e-07
. O 0 1.0907787100222777e-06

The O 0 2.844428763637552e-06
largest O 0 1.7608333564567147e-06
proportion O 0 4.098353372228303e-07
( O 0 2.6353520254929208e-08
67 O 0 2.975902368973493e-08
% O 0 1.795011916883027e-09
) O 0 2.51032611364721e-10
of O 0 7.881593155900646e-10
families O 0 7.609479157899557e-10
due O 0 1.898142976131112e-09
to O 0 9.045498794435503e-10
other O 0 2.5042443674294645e-09
genes O 0 3.4416587357810613e-09
was O 0 2.7993618534338793e-09
found O 0 1.0955121254596634e-09
in O 0 5.503403288642517e-10
families O 0 1.6888616061194739e-09
with O 0 1.7055131751320118e-09
four O 0 1.1318693537987201e-08
or O 0 5.061627117441958e-09
five O 0 8.310347077156166e-09
cases O 0 1.0985969467469658e-08
of O 0 2.794557190100022e-07
female O 1 0.9975281357765198
breast B-Disease 1 0.999729573726654
cancer I-Disease 0 1.9970741050201468e-05
only O 0 5.917114549447433e-07
. O 0 3.0702206004207255e-06

These O 0 3.8563743487429747e-07
estimates O 0 5.318087801242655e-07
were O 0 6.727604073830662e-08
not O 0 9.653125410125085e-09
substantially O 0 1.023343472184024e-07
affected O 0 8.057231326574765e-09
either O 0 3.0757174585005487e-09
by O 0 1.924239212414136e-09
changing O 0 1.955374173689961e-08
the O 0 1.478084143968772e-08
assumed O 0 5.60941835203721e-08
penetrance O 0 2.809508430345886e-07
model O 0 2.6902631233838292e-08
for O 0 1.914166425365238e-08
BRCA1 O 0 1.5860469204653782e-07
or O 0 1.0981466402881779e-08
by O 0 9.250991084286397e-09
including O 0 6.841086275244379e-08
or O 0 5.758789143328613e-07
excluding O 0 7.268938588822493e-06
BRCA1 O 0 2.671194579306757e-06
mutation O 0 5.044272484155954e-07
data O 0 2.0610937099263538e-06
. O 0 4.290315246180398e-06

Among O 0 1.5988873656169744e-06
those O 0 1.3560409684032493e-07
families O 0 7.729347828444588e-08
with O 0 2.3761058898230658e-08
disease O 0 0.0004494460590649396
due O 0 2.618042316271385e-08
to O 0 5.19534681941991e-09
BRCA1 O 0 2.443241164939991e-08
that O 0 1.253787296207065e-09
were O 0 3.330442366333841e-09
tested O 0 1.880736677506434e-09
by O 0 9.170559867044403e-10
one O 0 3.5308771462183586e-09
of O 0 3.3610669802897064e-09
the O 0 4.335041658976024e-09
standard O 0 6.6549574739838135e-09
screening O 0 1.7069190505480947e-09
methods O 0 5.195425867299264e-09
, O 0 4.386928154076486e-09
mutations O 0 1.6924870394063873e-08
were O 0 3.029917650110292e-08
detected O 0 4.640119755094929e-08
in O 0 7.1957111380527294e-09
the O 0 2.0140726419981547e-08
coding O 0 1.290149356236725e-07
sequence O 0 4.187923252629844e-08
or O 0 3.262783465629582e-08
splice O 0 1.1661370535875903e-06
sites O 0 9.488618957220751e-08
in O 0 9.295740177606149e-09
an O 0 1.3396669551468676e-08
estimated O 0 2.9640798260288648e-08
63 O 0 8.809515605889828e-08
% O 0 1.0543604211932234e-08
( O 0 8.837566234376482e-09
95 O 0 8.624783021105031e-08
% O 0 4.5483933064360826e-08
CI O 0 5.487086582434131e-06
51 O 0 2.7574046157496923e-07
% O 0 3.253213876064365e-08
- O 0 1.4097192035933404e-07
77 O 0 2.2221374251785164e-07
% O 0 2.519298369918488e-08
) O 0 4.631066019555874e-08
. O 0 6.014842597323877e-07

The O 0 7.822180805305834e-07
estimated O 0 3.266513886046596e-07
sensitivity O 0 2.2838963786853128e-07
was O 0 5.806287362020157e-08
identical O 0 2.9634579234993907e-08
for O 0 7.466104179343347e-09
direct O 0 3.847608809337544e-08
sequencing O 0 1.166813987651949e-07
and O 0 6.398633445314772e-08
other O 0 1.216253338043316e-07
techniques O 0 3.3876933684950927e-06
. O 0 4.686085048888344e-06

The O 0 6.544517418660689e-06
penetrance O 0 0.00017934420611709356
of O 0 8.812506166577805e-06
BRCA2 O 0 1.1989689483016264e-05
was O 0 3.3757982009774423e-07
estimated O 0 4.12456842013853e-08
by O 0 1.5306220291222417e-08
maximizing O 0 9.301530781158363e-07
the O 0 3.052840611417196e-07
LOD O 0 0.19825120270252228
score O 0 4.623493339295237e-07
in O 0 1.3049663039055304e-07
BRCA2 O 0 1.6132541986735305e-06
- O 0 4.839504867959477e-07
mutation O 0 6.000066576916652e-08
families O 0 2.6022657806379357e-08
, O 0 1.572305485808556e-08
over O 0 1.8555034841938323e-08
all O 0 4.468099845666984e-08
possible O 0 5.575752197728434e-07
penetrance O 0 2.5719080440467224e-05
functions O 0 3.0342609989020275e-06
. O 0 4.799293947144179e-06

The O 0 1.4601990869778092e-06
estimated O 0 1.1620760460573365e-06
cumulative O 0 1.8660891782928957e-06
risk O 0 1.1479559134386363e-06
of O 0 1.156119992629101e-06
breast B-Disease 1 0.6990649700164795
cancer I-Disease 0 9.368922292196658e-06
reached O 0 3.011995488577668e-07
28 O 0 2.662529539065872e-07
% O 0 7.227774823093114e-09
( O 0 5.84058401642551e-09
95 O 0 4.9715175975961756e-08
% O 0 2.387499620226663e-08
CI O 0 1.628422523936024e-06
9 O 0 9.89402195727962e-08
% O 0 4.96850027786877e-09
- O 0 1.6207899022901984e-08
44 O 0 1.841864794016601e-08
% O 0 9.207856699333661e-10
) O 0 1.9272833329253558e-10
by O 0 5.911626188570551e-10
age O 0 6.5447003372298695e-09
50 O 0 7.452999994939091e-09
years O 0 5.060121655020566e-09
and O 0 7.02907643201911e-09
84 O 0 6.8671020869715e-08
% O 0 7.575134297610475e-09
( O 0 3.265415493558521e-09
95 O 0 2.187848480161847e-08
% O 0 1.823394946143253e-08
CI O 0 2.2021683889761334e-06
43 O 0 9.182119242723275e-08
% O 0 9.922838550835422e-09
- O 0 2.5928326152779846e-08
95 O 0 1.3523648867419524e-08
% O 0 2.5211237542066556e-09
) O 0 5.840157801806356e-10
by O 0 1.3011142163676936e-09
age O 0 6.304288291403282e-08
70 O 0 7.118178046994217e-08
years O 0 9.9927561336699e-08
. O 0 1.0649977184584714e-06

The O 0 6.299952019617194e-06
corresponding O 1 0.9994999170303345
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 4.238796827849001e-05
were O 0 7.879418717493536e-07
0 O 0 4.780574272444937e-06
. O 0 2.139660864486359e-06

4 O 0 2.572308039816562e-05
% O 0 7.728668833806296e-07
( O 0 1.6855550200034486e-07
95 O 0 2.39243718169746e-07
% O 0 5.712487194386995e-08
CI O 0 2.5638478291512e-06
0 O 0 1.6342102071575937e-07
% O 0 7.990260897372536e-09
- O 0 1.8856656680554806e-08
1 O 0 1.6364989363637505e-08
% O 0 8.230351955518245e-10
) O 0 7.26744081580577e-11
by O 0 2.545635369166632e-10
age O 0 2.1090706958659666e-09
50 O 0 4.899014971471161e-09
years O 0 2.6908364425537457e-09
and O 0 8.62802096435189e-09
27 O 0 5.8525412072185645e-08
% O 0 3.955420879719895e-09
( O 0 3.6934455494019858e-09
95 O 0 2.079972816204645e-08
% O 0 1.181501296798615e-08
CI O 0 7.473478831343527e-07
0 O 0 5.072405784289913e-08
% O 0 3.7135419184153307e-09
- O 0 2.1597129418182703e-08
47 O 0 4.230957273421154e-08
% O 0 3.2010780692814933e-09
) O 0 1.044258901572448e-09
by O 0 3.0169755582676316e-09
age O 0 9.11940816195056e-08
70 O 0 2.611574529964855e-07
years O 0 3.7831128452125995e-07
. O 0 2.0665534066210967e-06

The O 0 4.700048975792015e-06
lifetime O 0 7.485236437787535e-06
risk O 0 2.1819156245328486e-05
of O 0 0.0003622756339609623
breast B-Disease 1 1.0
cancer I-Disease 1 0.747658371925354
appears O 0 1.4589760510830274e-08
similar O 0 7.759651809990942e-10
to O 0 1.0181832044153794e-09
the O 0 9.19438303270681e-09
risk O 0 1.758975187726719e-08
in O 0 6.005067110237405e-09
BRCA1 O 0 8.707894494364155e-08
carriers O 0 2.011903355025879e-08
, O 0 3.685282523591127e-09
but O 0 3.420749017379876e-09
there O 0 4.50473880420077e-09
was O 0 1.3375147212002503e-08
some O 0 1.702906371470192e-09
suggestion O 0 1.8015983371810762e-08
of O 0 1.2214825595435741e-08
a O 0 1.656140113936999e-08
lower O 0 1.2387310732719925e-07
risk O 0 6.936886620678706e-08
in O 0 2.7958627413227077e-08
BRCA2 O 0 3.03764295495057e-07
carriers O 0 5.5000299425955745e-08
< O 0 3.213590389350429e-07
50 O 0 9.493089692114154e-08
years O 0 3.999132758281121e-08
of O 0 2.7336199082128587e-07
age O 0 3.4769479952956317e-06
. O 0 1.2019879250146914e-05

Eye B-Disease 1 0.9998089671134949
movement I-Disease 0 0.0017337043536826968
abnormalities I-Disease 0 0.0009813840733841062
correlate O 0 6.156112135613512e-07
with O 0 2.326657089213313e-08
genotype O 0 1.0791857221192913e-06
in O 0 8.864327583069098e-08
autosomal O 0 0.0050386846996843815
dominant O 1 0.9999881982803345
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999997615814209
I I-Disease 1 0.9999446868896484
. O 0 1.4341523637995124e-05

We O 0 4.311717475502519e-06
compared O 0 5.373880412662402e-06
horizontal O 0 5.8836441894527525e-05
eye O 0 0.00013298357953317463
movements O 0 1.0846153600141406e-05
( O 0 8.615787123744667e-07
visually O 0 2.5057540824491298e-06
guided O 0 5.146096100361319e-06
saccades O 0 1.9981178411399014e-05
, O 0 2.12838486390865e-07
antisaccades O 0 4.528428689809516e-06
, O 0 7.418977787665426e-08
and O 0 3.814616889030731e-08
smooth O 0 1.3157119838069775e-07
pursuit O 0 3.062986309032567e-07
) O 0 1.2729080900442113e-08
in O 0 8.044178656518852e-09
control O 0 5.8934052304948636e-08
subjects O 0 5.109489507049148e-07
( O 0 6.379537609291219e-08
n O 0 1.0491270785450979e-07
= O 0 3.5883368809663807e-07
14 O 0 5.9603163293786565e-08
) O 0 2.886108463329151e-09
and O 0 1.763364565476877e-09
patients O 0 1.1351138917703452e-09
with O 0 5.472796105188138e-10
three O 0 2.4738984194527802e-09
forms O 0 1.7533411167391932e-08
of O 0 6.024308163432579e-08
autosomal O 0 4.3839678255608305e-05
dominant O 1 0.9974039196968079
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.6650256514549255
type I-Disease 0 0.0005107858451083302
I I-Disease 0 0.0002553034573793411
spinocerebellar B-Disease 0 0.39507216215133667
ataxias I-Disease 0 4.438477481016889e-05
1 I-Disease 0 6.07015692821733e-07
and I-Disease 0 7.854393402340065e-08
2 I-Disease 0 4.495613268318266e-07
( O 0 9.324278948952269e-08
SCA1 B-Disease 0 2.0015299014630727e-05
, O 0 1.4679858395538758e-07
n O 0 2.3071453369993833e-07
= O 0 7.868545708333841e-07
11 O 0 1.8020318748313002e-07
; O 0 1.0811734085791613e-07
SCA2 B-Disease 0 1.0813701010192744e-05
, O 0 1.1587964365844527e-07
n O 0 1.0474435185869879e-07
= O 0 3.0121361760393484e-07
10 O 0 7.680191060899233e-08
) O 0 1.1985151537885486e-08
and O 0 1.526757813508084e-07
SCA3 B-Disease 1 1.0
/ O 0 1.3369391126616392e-05
Machado B-Disease 0 8.440094461548142e-06
- I-Disease 0 1.6409223462687805e-05
Joseph I-Disease 0 0.0632074773311615
disease I-Disease 1 0.9994021654129028
( O 0 3.802438413913478e-06
MJD B-Disease 1 1.0
) O 0 4.1560031149856513e-07
( O 0 1.9088329850092123e-07
n O 0 4.926012593386986e-07
= O 0 1.6848282484716037e-06
16 O 0 1.1997042292932747e-06
) O 0 2.0437757086710917e-07
. O 0 1.0683230584618286e-06

In O 0 1.1066538718296215e-05
SCA1 B-Disease 0 0.009553197771310806
, O 0 7.147380074457033e-07
saccade O 0 4.091599748790031e-06
amplitude O 0 6.252567459341662e-07
was O 0 9.609022555423508e-08
significantly O 0 2.956028843925651e-08
increased O 0 3.278097437942051e-08
, O 0 9.53478629384108e-09
resulting O 0 6.393814544480847e-08
in O 0 1.6967317151284078e-07
hypermetria B-Disease 0 7.0305606641341e-05
. O 0 7.0758010224381e-06

The O 0 1.212704046338331e-05
smooth O 0 1.3620741810882464e-05
pursuit O 0 7.813607226125896e-06
gain O 0 6.973566542001208e-06
was O 0 5.325910478859441e-06
decreased O 0 1.1222302418900654e-05
. O 0 4.424266990099568e-06

In O 0 1.8412296412861906e-05
SCA2 B-Disease 0 0.02025756798684597
, O 0 1.629884536669124e-06
saccade O 0 1.5296584024326876e-05
velocity O 0 3.4276588394277496e-06
was O 0 2.094241608574521e-06
markedly O 0 1.4317664863483515e-05
decreased O 0 1.4400594409380574e-05
. O 0 6.679594207525952e-06

The O 0 2.391940597590292e-06
percentage O 0 2.1039948023826582e-06
of O 0 2.0289908775339427e-07
errors O 0 4.583726877172012e-06
in O 0 1.4144474391741824e-07
antisaccades O 0 0.39755457639694214
was O 0 1.687509154635336e-07
greatly O 0 1.2839851137869118e-07
increased O 0 3.452245422863598e-08
and O 0 1.0663759653084526e-08
was O 0 2.295742440594495e-08
significantly O 0 2.0720335669466294e-08
correlated O 0 7.183783168329683e-08
with O 0 5.125826874063932e-09
age O 0 3.46608828749595e-07
at O 0 5.84334998166014e-07
disease O 0 9.310387213190552e-06
onset O 0 2.7337127903592773e-05
. O 0 5.545220119529404e-06

In O 0 4.1622223534432123e-07
addition O 0 1.6856289164479676e-07
, O 0 2.152741984673412e-08
a O 0 2.1361360680316466e-08
correlation O 0 1.3665565745668573e-07
between O 0 3.414102067722524e-08
smooth O 0 2.150579945237041e-07
pursuit O 0 2.2665636834062752e-07
gain O 0 8.088152725349573e-08
and O 0 8.253432604021782e-09
the O 0 1.5156171428998277e-08
number O 0 5.343496312093521e-08
of O 0 2.609998261959845e-07
trinucleotide O 0 0.00020658865105360746
repeats O 0 1.9980061551905237e-06
was O 0 7.95678090526053e-07
found O 0 5.367034532355319e-07
. O 0 2.3184170458989684e-06

In O 0 3.874026515404694e-05
SCA3 B-Disease 1 1.0
, O 0 1.2272656022105366e-05
gaze B-Disease 0 0.00035705146729014814
- I-Disease 0 5.699578468920663e-05
evoked I-Disease 0 0.0002327305410290137
nystagmus I-Disease 0 0.00021889098570682108
was O 0 4.124014765238826e-07
often O 0 2.0342294959618812e-08
present O 0 1.484911216209639e-08
as O 0 4.053086044564225e-08
was O 0 1.643232252490634e-07
saccade O 0 1.6809716498755733e-06
hypometria O 0 4.374837317300262e-06
and O 0 1.1787016518383098e-07
smooth O 0 8.168146337084181e-07
pursuit O 0 1.5706350495747756e-06
gain O 0 1.4128055454420974e-06
was O 0 2.3505219814978773e-06
markedly O 0 1.3316658623807598e-05
decreased O 0 8.078744940576144e-06
. O 0 4.953820734954206e-06

Three O 0 5.395396328822244e-06
major O 0 7.470211130566895e-06
criteria O 0 2.4861783458618447e-06
, O 0 3.4982471674993576e-07
saccade O 0 3.6306182664702646e-06
amplitude O 0 1.2462083986974903e-06
, O 0 1.0624337676290452e-07
saccade O 0 7.989904133864911e-07
velocity O 0 3.7866718116674747e-07
, O 0 2.6276225639776385e-08
and O 0 1.7388240181048786e-08
presence O 0 1.5978113765413582e-07
of O 0 1.0862639783226768e-06
gaze B-Disease 0 0.0020686916541308165
- I-Disease 0 5.1554772653616965e-05
evoked I-Disease 0 5.8909768995363265e-05
nystagmus I-Disease 0 5.767110906162998e-06
, O 0 1.5513222706431407e-08
permitted O 0 1.9698273234780572e-08
the O 0 1.726717790972998e-08
correct O 0 4.8557041054664296e-08
assignment O 0 2.9250024624616344e-08
of O 0 1.568037788501897e-08
90 O 0 2.856318381816436e-08
% O 0 4.534981279391559e-09
of O 0 8.7033402706993e-09
the O 0 4.455207402997985e-08
SCA1 B-Disease 0 2.174732435378246e-05
, O 0 1.2882764188759666e-08
90 O 0 1.6736306562847858e-08
% O 0 2.5413526838491407e-09
of O 0 3.2047740017304704e-09
the O 0 1.2056663223347641e-08
SCA2 B-Disease 0 1.5236946637742221e-05
, O 0 1.0901536562357705e-08
and O 0 5.30499555395636e-09
93 O 0 2.1820973472586047e-08
% O 0 8.529530970413646e-10
of O 0 1.4762154831871044e-09
the O 0 5.88868287465516e-09
patients O 0 9.888037943994732e-09
with O 0 2.576082103189492e-08
SCA3 B-Disease 1 1.0
to O 0 2.0383307486326885e-08
their O 0 9.023050751011397e-09
genetically O 0 1.710228474394171e-07
confirmed O 0 6.3558545093656e-08
patient O 0 1.5341496961696066e-08
group O 0 8.277648788634906e-09
and O 0 4.35463221037935e-09
, O 0 4.524544294781663e-09
therefore O 0 2.7716035688740703e-08
, O 0 1.166013685605094e-08
may O 0 2.232332363405476e-08
help O 0 1.5020616217498173e-07
orient O 0 0.000261278502875939
diagnoses O 0 1.3846466572431382e-05
of O 0 8.991140703074052e-07
SCA1 B-Disease 1 0.9999991655349731
, O 0 3.2875811939447885e-07
SCA2 B-Disease 1 0.9999344348907471
, O 0 1.1015811907100215e-07
and O 0 3.590619996884925e-07
SCA3 B-Disease 1 1.0
at O 0 3.272013486821379e-07
early O 0 2.879408214084833e-07
clinical O 0 2.0758457708325295e-07
stages O 0 1.97577676885885e-07
of O 0 7.836824522655661e-08
the O 0 6.716859388689045e-07
diseases O 1 0.971177875995636
. O 0 7.253215130731405e-07
. O 0 4.465962774702348e-06

Genetic O 0 8.678612175572198e-06
basis O 0 1.0314361134078354e-06
and O 0 3.185505548231049e-08
molecular O 0 3.651274482763256e-07
mechanism O 0 1.2288128345971927e-06
for O 0 9.559315685692127e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999711513519287

Ventricular B-Disease 1 0.9999982118606567
fibrillation I-Disease 1 0.9999643564224243
causes O 0 4.496537439990789e-05
more O 0 3.0743699142021796e-08
than O 0 7.698197634908865e-09
300 O 0 2.900192441757099e-08
, O 0 4.9297415039006864e-09
000 O 0 6.157391396754974e-08
sudden O 0 3.1020778834545126e-08
deaths O 0 1.784965064643984e-08
each O 0 2.56390952912966e-09
year O 0 3.9160101827917515e-09
in O 0 1.2045998865062302e-08
the O 0 2.4840332457642944e-07
USA O 0 1.3954759197076783e-05
alone O 0 1.8313542113901349e-06
. O 0 3.444012691034004e-06

In O 0 1.7051519307642593e-06
approximately O 0 8.878810149326455e-07
5 O 0 4.344824446889106e-07
- O 0 1.297477325579166e-07
12 O 0 4.516751772598582e-08
% O 0 1.1242156094937172e-09
of O 0 4.496873429182813e-10
these O 0 3.2799454818821516e-10
cases O 0 1.0773908432071266e-09
, O 0 5.788302059883677e-10
there O 0 9.52745549120948e-10
are O 0 1.2173929642145254e-09
no O 0 4.781262674669051e-08
demonstrable O 0 0.006383056752383709
cardiac O 0 0.20874671638011932
or O 0 2.2211299892660463e-06
non O 1 0.9999891519546509
- O 0 0.08000851422548294
cardiac O 0 0.07221286743879318
causes O 0 1.0399109839909215e-07
to O 0 2.2372417252114474e-09
account O 0 7.982309924159381e-09
for O 0 3.944323090365742e-09
the O 0 2.3827954720445632e-08
episode O 0 2.674423527082581e-08
, O 0 3.1560816182718554e-09
which O 0 1.4003398440820547e-09
is O 0 8.830922659797125e-10
therefore O 0 7.4390817950131805e-09
classified O 0 1.376460545543523e-07
as O 0 4.030153206713294e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9997588992118835
IVF B-Disease 1 1.0
) O 0 6.0258071243879385e-06
. O 0 5.933370630373247e-06

A O 0 2.500604750821367e-06
distinct O 0 9.419381967745721e-07
group O 0 1.7309261579612212e-07
of O 0 3.309677367724362e-07
IVF B-Disease 1 1.0
patients O 0 1.1699862625391688e-05
has O 0 8.844074805836044e-09
been O 0 2.1856410015175243e-09
found O 0 1.7838409638315511e-09
to O 0 2.2999795401545953e-09
present O 0 1.2987346309500936e-08
with O 0 1.1298245894408865e-08
a O 0 9.915028442719631e-08
characteristic O 0 3.243201035729726e-06
electrocardiographic O 0 0.00012713756586890668
pattern O 0 1.3600869351648726e-05
. O 0 9.14115571504226e-06

Because O 0 5.190199772187043e-07
of O 0 2.262026868038447e-07
the O 0 5.4555844286596766e-08
small O 0 1.1765091123550064e-08
size O 0 2.034919965865356e-08
of O 0 1.4172905515863476e-08
most O 0 7.136214730252277e-09
pedigrees O 0 1.3993278002999432e-07
and O 0 9.39276567635261e-09
the O 0 2.0268087652652866e-08
high O 0 5.701166401195223e-07
incidence O 0 8.419896175837494e-07
of O 0 4.731042224648263e-08
sudden B-Disease 0 8.589058779762127e-07
death I-Disease 0 1.852333525675931e-06
, O 0 1.2924973091799075e-08
however O 0 1.2372089130963104e-08
, O 0 2.5456801111545246e-09
molecular O 0 2.048847136393306e-08
genetic O 0 3.181303753763132e-08
studies O 0 1.7024037290980232e-08
of O 0 2.9350953667517388e-08
IVF B-Disease 1 1.0
have O 0 2.5003224379815947e-08
not O 0 1.2860619236221282e-08
yet O 0 1.0043851261798409e-07
been O 0 1.1073870354039173e-07
done O 0 5.93827394368418e-07
. O 0 4.998424174118554e-06

Because O 0 6.696375294268364e-06
IVF B-Disease 1 1.0
causes O 0 0.10095364600419998
cardiac O 1 0.9910373687744141
rhythm O 0 0.0037926246877759695
disturbance O 0 0.014152692630887032
, O 0 2.0539337342029285e-08
we O 0 1.1534628363563115e-08
investigated O 0 5.7834302680248584e-08
whether O 0 1.6015222925602757e-08
malfunction O 0 1.5016378256405005e-06
of O 0 3.04235108217199e-08
ion O 0 4.885665134679584e-07
channels O 0 5.335878228152069e-08
could O 0 1.553631889805729e-08
cause O 0 3.1812953693588497e-07
the O 0 4.026556865710518e-08
disorder O 0 3.6881115761389083e-07
by O 0 6.163911159262625e-09
studying O 0 2.5796026648094994e-08
mutations O 0 1.3246808094891094e-08
in O 0 8.119665828587586e-09
the O 0 4.547551668565575e-08
cardiac O 0 2.3277195850823773e-06
sodium O 0 5.346725174604217e-06
channel O 0 1.1683633829306928e-06
gene O 0 1.5785426512593403e-06
SCN5A O 0 0.0017686799401417375
. O 0 5.685036740032956e-06

We O 0 1.2994057669857284e-06
have O 0 2.2387159503978182e-07
now O 0 1.0299267216851149e-07
identified O 0 1.506665370243354e-07
a O 0 2.8115634265191147e-08
missense O 0 8.867809242474323e-07
mutation O 0 1.31107384504503e-07
, O 0 2.442728685991824e-08
a O 0 4.183643653732361e-08
splice O 0 4.10309530707309e-06
- O 0 5.232034254731843e-07
donor O 0 6.999498225468415e-08
mutation O 0 1.5601232306039492e-08
, O 0 6.334273106034516e-09
and O 0 3.7109859629680386e-09
a O 0 9.253955823851356e-09
frameshift O 0 7.035074389705187e-08
mutation O 0 6.054856171999745e-09
in O 0 2.542734689470194e-09
the O 0 2.5886950361098116e-09
coding O 0 1.3369515272643184e-07
region O 0 1.0040939457667264e-07
of O 0 1.0827727692230837e-07
SCN5A O 1 0.9406701922416687
in O 0 7.600203133506511e-08
three O 0 6.302935275925847e-07
IVF B-Disease 1 0.9999998807907104
families O 0 3.834104063571431e-06
. O 0 8.590078323322814e-06

We O 0 1.6554125750189996e-06
show O 0 4.465740062187251e-07
that O 0 3.2378309811065265e-08
sodium O 0 2.793081250729301e-07
channels O 0 4.360036598427541e-08
with O 0 2.7602859997699625e-09
the O 0 1.03947819241057e-08
missense O 0 1.93884275745404e-07
mutation O 0 2.601198723084508e-08
recover O 0 9.208849149899834e-08
from O 0 2.206821392292113e-08
inactivation O 0 1.7004218477723043e-07
more O 0 2.3258972525752597e-09
rapidly O 0 1.0234543879050761e-08
than O 0 4.1328090949477314e-10
normal O 0 1.8522848810320625e-09
and O 0 1.047246955820924e-09
that O 0 1.2413329253391225e-09
the O 0 1.1686677403588419e-08
frameshift O 0 2.566323473729426e-07
mutation O 0 3.114753965860473e-08
causes O 0 4.7410782855195066e-08
the O 0 2.6070946290701613e-08
sodium O 0 1.2573111973779305e-07
channel O 0 4.2240550612859806e-08
to O 0 7.800671220081767e-09
be O 0 7.195178852725803e-08
non O 0 5.4177276069822256e-06
- O 0 8.290406185551547e-06
functional O 0 9.187493560602888e-06
. O 0 5.847620286658639e-06

Our O 0 3.845188530249288e-06
results O 0 8.712593739801378e-07
indicate O 0 5.186350335861789e-07
that O 0 1.6972455441077727e-08
mutations O 0 1.6642677280742646e-07
in O 0 4.085482530058471e-08
cardiac O 0 1.2383228522594436e-06
ion O 0 2.0904242774122395e-05
- O 0 0.0006809945916756988
channel O 0 8.058279377110011e-08
genes O 0 6.8432499666926105e-09
contribute O 0 3.896126088420715e-09
to O 0 1.1777859798556278e-09
the O 0 4.762365612975827e-09
risk O 0 2.7137948777067322e-08
of O 0 2.3510855484687454e-08
developing O 0 5.617586680273234e-07
IVF B-Disease 1 0.9999982118606567
. O 0 9.614684586267686e-07
. O 0 2.9043940230621956e-06

Molecular O 0 3.397475666133687e-05
heterogeneity O 0 2.402719655947294e-05
in O 0 5.661948421220586e-07
mucopolysaccharidosis B-Disease 0 0.0005413182661868632
IVA I-Disease 1 0.9987694621086121
in O 0 1.1017512946409624e-07
Australia O 0 2.2776118768774722e-08
and O 0 8.894080139043581e-09
Northern O 0 6.765770876882016e-08
Ireland O 0 3.714032459356531e-08
: O 0 1.81174666380457e-08
nine O 0 5.806974101574269e-08
novel O 0 3.4274322047167516e-08
mutations O 0 4.520000729257845e-08
including O 0 3.62855772095827e-08
T312S O 0 1.8072851162287407e-05
, O 0 1.472024013793316e-08
a O 0 6.651607264984705e-09
common O 0 1.805144655975255e-08
allele O 0 2.9510996313319993e-08
that O 0 9.146474688748185e-09
confers O 0 3.5409891552262707e-07
a O 0 1.2990744835406076e-07
mild O 0 4.634389370039571e-06
phenotype O 0 7.887080755608622e-06
. O 0 5.233389401837485e-06

Mucopolysaccharidosis B-Disease 1 0.9539396166801453
IVA I-Disease 1 1.0
( O 0 0.00010286761244060472
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.71341264124203e-07
is O 0 1.183763753687117e-08
an O 0 1.98520861971474e-08
autosomal B-Disease 1 0.9996930360794067
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 5.655792392644798e-06
by O 0 1.1992628223822521e-08
a O 0 5.949231152158063e-08
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999972581863403
in O 0 1.2997709575301997e-07
N O 0 1.3015935564908432e-06
- O 0 1.6261567452602321e-06
acetylgalactosamine O 0 1.196659286506474e-05
- O 0 5.082296866021352e-06
6 O 0 3.728903720912058e-06
- O 0 3.1327106171374908e-06
sulfate O 0 9.545928151055705e-06
sulfatase O 0 0.00012123017950216308
( O 0 3.0689734558109194e-06
GALNS O 0 0.005011069122701883
) O 0 1.4369946939041256e-06
. O 0 2.898920683946926e-06

Previous O 0 1.4878675074214698e-06
studies O 0 2.242823313736153e-07
of O 0 2.914254793040527e-08
patients O 0 9.320097582588005e-09
from O 0 4.950621690369417e-09
a O 0 3.22670734576036e-09
British O 0 3.400285919497037e-08
- O 0 5.791024548784662e-08
Irish O 0 2.451456815322217e-08
population O 0 2.841661350672098e-09
showed O 0 5.1601598549666505e-09
that O 0 6.642830729930438e-10
the O 0 6.2934604194708754e-09
I113F O 0 3.4500737911002943e-07
mutation O 0 3.866122977314035e-09
is O 0 5.757768151148923e-10
the O 0 6.966168752953195e-10
most O 0 8.362353032254077e-10
common O 0 1.800900095716429e-09
single O 0 2.075216443131467e-09
mutation O 0 8.015431873786838e-09
among O 0 6.316805922779167e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 6.753039656359761e-07
and O 0 2.769833251647924e-08
produces O 0 4.9314181183035544e-08
a O 0 3.7292519294851445e-08
severe O 0 2.4852774913597386e-06
clinical O 0 3.624750888775452e-06
phenotype O 0 1.020504078041995e-05
. O 0 6.340461823128862e-06

We O 0 3.784303544307477e-06
studied O 0 3.113113962172065e-06
mutations O 0 6.404280838978593e-07
in O 0 6.118010276168206e-08
the O 0 1.645928335847202e-07
GALNS O 0 0.0002273865247843787
gene O 0 1.4898536448981758e-07
from O 0 8.346840729700489e-08
23 O 0 2.3157487305525137e-07
additional O 0 1.4276116644396097e-07
MPS B-Disease 1 0.9999945163726807
IVA I-Disease 1 1.0
patients O 0 1.8955900316086627e-07
( O 0 2.1609121603205494e-08
15 O 0 2.1901490399045542e-08
from O 0 8.454751565523111e-09
Australia O 0 2.490459172221904e-09
, O 0 3.4876916910064892e-09
8 O 0 1.0818041573656956e-08
from O 0 4.131148312325195e-09
Northern O 0 1.8460395878605595e-08
Ireland O 0 1.0438014896863024e-08
) O 0 1.8180390526367773e-09
, O 0 1.1283144418783309e-09
with O 0 1.4302868889259912e-09
various O 0 2.206804516902139e-08
clinical O 0 5.677737817677553e-07
phenotypes O 0 0.00010827791265910491
( O 0 8.133539495247533e-07
severe O 0 0.0009713960462249815
, O 0 1.5272500775154185e-07
16 O 0 2.737723718837515e-07
cases O 0 3.2892330636968836e-08
; O 0 3.5671952502980275e-08
intermediate O 0 1.5246844213834265e-06
, O 0 3.1435028802206944e-08
4 O 0 1.223273642381173e-07
cases O 0 2.2774424124349935e-08
; O 0 3.258635317138214e-08
mild O 0 2.738682098879508e-07
, O 0 2.7778856548366093e-08
3 O 0 1.0646611059428324e-07
cases O 0 4.973129819063615e-08
) O 0 1.0940389216784752e-07
. O 0 1.1556901426956756e-06

We O 0 5.568732035499124e-07
found O 0 1.758056811240749e-07
two O 0 3.176004881311201e-08
common O 0 2.3752086519834847e-08
mutations O 0 1.963214479872022e-08
that O 0 2.962891265667622e-09
together O 0 3.963365191594903e-09
accounted O 0 2.381895924941091e-08
for O 0 2.50456921868647e-09
32 O 0 3.241154900024412e-08
% O 0 1.7333892099458126e-09
of O 0 2.1735764299535276e-09
the O 0 4.271220710450052e-09
44 O 0 5.052196883070792e-08
unrelated O 0 7.392013401386066e-08
alleles O 0 3.9060758183495636e-08
in O 0 1.91946760708106e-08
these O 0 1.1717551018364247e-07
patients O 0 4.491477625379048e-07
. O 0 3.074372443734319e-06

One O 0 1.4284031522038276e-06
is O 0 1.351983627273512e-07
the O 0 2.003007324447026e-07
T312S O 0 5.658128429786302e-06
mutation O 0 1.1394706689316081e-07
, O 0 1.0372204428676923e-08
a O 0 6.194802448789005e-09
novel O 0 3.6805147374252556e-08
mutation O 0 2.6038891931534636e-08
found O 0 1.2794778569968912e-08
exclusively O 0 7.538081092661741e-08
in O 0 2.681185939934494e-08
milder O 0 4.9065733946918044e-06
patients O 0 6.298554922068433e-07
. O 0 4.71495377496467e-06

The O 0 1.0462100590302725e-06
other O 0 1.9582803645334934e-07
is O 0 2.4020520683620816e-08
the O 0 3.921648072946482e-08
previously O 0 4.3471821697949053e-08
described O 0 7.815865643578945e-08
I113F O 0 1.5193370472843526e-06
that O 0 1.1421335877059846e-08
produces O 0 7.390054435063576e-08
a O 0 6.978530109336134e-08
severe O 0 3.643347326942603e-06
phenotype O 0 5.99349459662335e-06
. O 0 4.660734248318477e-06

The O 0 1.1114759217889514e-05
I113F O 0 0.0001583507255418226
and O 0 1.4312516896097804e-06
T312S O 0 1.7681146346149035e-05
mutations O 0 6.425497076634201e-07
accounted O 0 2.1687559126348788e-07
for O 0 4.173314849253984e-08
8 O 0 1.7907662197558238e-07
( O 0 2.1666735960934602e-08
18 O 0 3.834765394117312e-08
% O 0 3.806808646089621e-09
) O 0 1.0990848231529071e-09
and O 0 4.2743177885995465e-09
6 O 0 4.685208665478058e-08
( O 0 5.195782470934773e-09
14 O 0 2.1766894064967346e-08
% O 0 1.8519317190879292e-09
) O 0 7.028335136105568e-10
of O 0 3.443510143696926e-09
44 O 0 4.107281625920223e-08
unrelated O 0 8.645503157822532e-08
alleles O 0 7.581236616260867e-08
, O 0 1.0262891692036646e-07
respectively O 0 7.388961194010335e-07
. O 0 1.712818630039692e-06

The O 0 1.9901178802683717e-06
relatively O 0 2.4465532533213263e-06
high O 0 2.278230340380105e-06
residual O 0 5.010122913517989e-05
GALNS O 1 0.937429666519165
activity O 0 1.7312480338205205e-07
seen O 0 4.286468069381044e-08
when O 0 1.3602057258310651e-08
the O 0 3.8172661476210124e-08
T312S O 0 1.5219241049635457e-06
mutant O 0 3.891842652592459e-07
cDNA O 0 1.0338646916352445e-06
is O 0 3.483863508790819e-08
overexpressed O 0 1.0086487236549146e-06
in O 0 1.489063450321737e-08
mutant O 0 1.5946920939313713e-07
cells O 0 2.4428871370218985e-08
provides O 0 7.40410355248855e-09
an O 0 1.0984497755828215e-09
explanation O 0 1.482375555639237e-08
for O 0 4.9882227237674215e-09
the O 0 3.182869789952747e-08
mild O 0 5.689162776434387e-07
phenotype O 0 1.7217132608493557e-07
in O 0 1.3465068171569783e-08
patients O 0 6.629113702416589e-09
with O 0 5.377847944743053e-09
this O 0 3.2888131329400494e-08
mutation O 0 7.0501454274563e-07
. O 0 2.0689515167759964e-06

The O 0 4.564601852052874e-07
distribution O 0 1.4166640482926596e-07
and O 0 1.569821250768655e-08
relative O 0 1.214988571973663e-07
frequencies O 0 1.4131610726053623e-07
of O 0 3.1461119931464054e-08
the O 0 5.328209695676378e-08
I113F O 0 2.416192273813067e-06
and O 0 4.497873007380804e-08
T312S O 0 8.506661401952442e-07
mutations O 0 5.5070319859851224e-08
in O 0 9.299800929341018e-09
Australia O 0 5.019891613500249e-09
corresponded O 0 1.7563500875894533e-08
to O 0 3.5966187805769323e-09
those O 0 8.153482333739248e-09
observed O 0 1.0746453504850706e-08
in O 0 3.587390384751643e-09
Northern O 0 1.8597553719246207e-08
Ireland O 0 1.0933313809857736e-08
and O 0 3.7096412608406126e-09
are O 0 2.052495506887908e-09
unique O 0 7.695232007165487e-09
to O 0 2.4939958986891497e-09
these O 0 5.009532788591287e-09
two O 0 1.2785703162876416e-08
populations O 0 2.8761084180928265e-08
, O 0 6.545886499509379e-09
suggesting O 0 1.828821538651937e-08
that O 0 1.4862988617636574e-09
both O 0 1.755794087898721e-08
mutations O 0 4.7825942317558656e-08
were O 0 5.5307058488551775e-08
probably O 0 3.503908985180715e-08
introduced O 0 6.584905953843645e-09
to O 0 4.0575085513694376e-09
Australia O 0 3.921653668470526e-09
by O 0 4.53083126572551e-09
Irish O 0 7.487984277076976e-08
migrants O 0 1.31674624981315e-07
during O 0 3.695180694762712e-08
the O 0 7.463815165920096e-08
19th O 0 7.543123956565978e-06
century O 0 1.953959508682601e-05
. O 0 8.384404281969182e-06

Haplotype O 0 5.087900353828445e-05
analysis O 0 4.376736342237564e-06
using O 0 1.825909635044809e-06
6 O 0 4.046739832119783e-06
RFLPs O 0 1.0818745977303479e-05
provides O 0 3.4565744044812163e-08
additional O 0 7.446435024149878e-09
data O 0 1.2510622759975831e-08
that O 0 3.551362315334927e-09
the O 0 3.8219869935574025e-08
I113F O 0 1.3615187981486088e-06
mutation O 0 1.7284081721413713e-08
originated O 0 7.725309103534528e-08
from O 0 1.9393173289472543e-08
a O 0 3.381561697324287e-08
common O 0 2.941303023362707e-07
ancestor O 0 9.402460818819236e-06
. O 0 4.983050985174486e-06

The O 0 3.381689566595014e-06
other O 0 1.0504561487323372e-06
9 O 0 1.178706725113443e-06
novel O 0 8.524008876520384e-08
mutations O 0 5.083951393203279e-08
identified O 0 3.276697313481236e-08
in O 0 2.1937935912319517e-09
these O 0 4.3648107350691134e-09
23 O 0 5.940625058542537e-08
patients O 0 6.740677349625912e-09
were O 0 9.040829418438534e-09
each O 0 1.89791116156357e-09
limited O 0 3.065631748455644e-09
to O 0 7.880078811695057e-09
a O 0 5.8664440416578145e-08
single O 0 2.127966922671476e-07
family O 0 8.929811201596749e-07
. O 0 2.8042347821610747e-06

These O 0 1.0458101087351679e-06
data O 0 4.841443796976819e-07
provide O 0 1.7249789152629091e-07
further O 0 8.610253843244209e-08
evidence O 0 1.380994234523314e-07
for O 0 2.010085076165069e-08
extensive O 0 1.673044067729279e-07
allelic O 0 1.6172223240573658e-06
heterogeneity O 0 2.035224724750151e-06
in O 0 1.8489720332581783e-07
MPS B-Disease 1 0.9929754734039307
IVA I-Disease 1 1.0
in O 0 8.669000095551382e-08
British O 0 2.5804448000599223e-07
- O 0 2.779068211111735e-07
Irish O 0 1.534053950535963e-07
patients O 0 9.611860640745817e-09
and O 0 3.202305309812914e-09
provide O 0 8.485770308652718e-09
evidence O 0 6.71842244059917e-08
for O 0 7.850045946611317e-09
their O 0 1.3216572725127662e-08
transmission O 0 7.159011516932878e-08
to O 0 5.888054488423222e-09
Australia O 0 6.39610497898957e-09
by O 0 1.0529034533135473e-08
British O 0 1.245467728949734e-07
- O 0 5.154506652615964e-07
Irish O 0 5.009831625102379e-07
migrants O 0 9.297469318880758e-07
. O 0 2.8434746468519734e-07
. O 0 3.3015169265127042e-06

Identification O 0 5.501013220055029e-06
of O 0 2.478846226949827e-06
constitutional O 0 1.2974322999070864e-05
WT1 O 1 0.9998921155929565
mutations O 0 3.1869997201283695e-06
, O 0 5.1608616047360556e-08
in O 0 6.625599624499046e-09
patients O 0 8.952764751768427e-09
with O 0 9.565606973183094e-09
isolated O 0 2.5607088900869712e-05
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 5.000208602723433e-08
and O 0 3.857372199433939e-09
analysis O 0 1.90706384017858e-08
of O 0 4.8039048294867825e-08
genotype O 0 1.371422740703565e-06
/ O 0 3.87430691262125e-06
phenotype O 0 1.3625822248286568e-07
correlations O 0 1.4031805051217816e-07
by O 0 4.931894892479249e-09
use O 0 1.798257898144584e-08
of O 0 5.780320577741804e-08
a O 0 4.840354250745804e-08
computerized O 0 9.853857818598044e-07
mutation O 0 2.607851286029472e-07
database O 0 2.703457539610099e-06
. O 0 4.9957034207182005e-06

Constitutional O 0 8.316720595757943e-06
mutations O 0 2.3577060801471816e-06
of O 0 1.0940406127701863e-06
the O 0 7.66405719332397e-07
WT1 O 0 7.136972271837294e-05
gene O 0 2.507436533960572e-07
, O 0 5.272355352303748e-08
encoding O 0 1.2049473241404485e-07
a O 0 1.4952343008189928e-07
zinc O 0 1.246738634108624e-06
- O 0 6.23103062480368e-07
finger O 0 2.818853488406603e-07
transcription O 0 9.543274472889607e-07
factor O 0 1.9967858122527105e-07
involved O 0 1.947791616885297e-08
in O 0 2.2936635701853447e-08
renal O 1 1.0
and O 0 2.900427716667764e-06
gonadal O 1 0.9999933242797852
development O 0 2.9997715955687454e-06
, O 0 8.518267868851126e-09
are O 0 2.2953077216669726e-09
found O 0 4.441536027854909e-09
in O 0 1.6915115974569517e-09
most O 0 1.0387825710722609e-08
patients O 0 1.7696089926744207e-08
with O 0 9.261693634243784e-08
Denys B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.2734084129333496
DDS B-Disease 1 1.0
) O 0 3.444320668677392e-07
, O 0 8.79628458960724e-08
or O 0 4.1995053834398277e-07
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 9.620317723602057e-05
DMS B-Disease 1 0.9930773973464966
) O 0 3.127898651200667e-08
associated O 0 3.524197822457609e-08
with O 0 2.504417651039148e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.8334686728849192e-06
/ O 0 0.002507126424461603
or O 0 3.589247853597044e-06
Wilms B-Disease 1 0.9999133348464966
tumor I-Disease 0 0.012220818549394608
( O 0 2.9406876365101198e-06
WT B-Disease 1 0.9999998807907104
) O 0 1.0996368473570328e-06
. O 0 2.001085704250727e-06

Most O 0 5.175591923034517e-06
mutations O 0 1.4112775716057513e-05
in O 0 2.9946295398985967e-06
DDS B-Disease 1 1.0
patients O 0 2.2877946321386844e-05
lie O 0 5.623758625006303e-06
in O 0 2.6182053147749684e-07
exon O 0 2.1040227693447378e-06
8 O 0 5.967368679193896e-07
or O 0 5.762003496556645e-08
exon O 0 4.6835734224259795e-07
9 O 0 3.290372774245043e-07
, O 0 2.004327015470153e-08
encoding O 0 3.9315574440479395e-07
zinc O 0 5.711256562790368e-06
finger O 0 5.008449534216197e-06
2 O 0 2.3807024263078347e-06
or O 0 3.0092019187577534e-07
zinc O 0 2.671469928827719e-06
finger O 0 9.672053238318767e-07
3 O 0 1.7141898922545806e-07
, O 0 9.867144434849706e-09
respectively O 0 1.251761627685255e-08
, O 0 2.3418469385916296e-09
with O 0 1.7745426239557105e-09
a O 0 3.670566783853246e-08
hot O 0 1.1348469115546322e-06
spot O 0 2.230895006505307e-06
( O 0 1.7569607280165656e-07
R394W O 0 7.316600658668904e-06
) O 0 1.2905813662200671e-07
in O 0 2.3786549263604684e-07
exon O 0 1.5679617717978545e-05
9 O 0 1.8932874809252098e-05
. O 0 7.090810868248809e-06

We O 0 1.101393650060345e-06
analyzed O 0 1.518970520919538e-06
a O 0 9.553085078550794e-08
series O 0 1.0389791782472457e-07
of O 0 6.11715833542803e-08
24 O 0 4.1051558241633757e-07
patients O 0 4.77674149124141e-08
, O 0 2.916479147074824e-08
10 O 0 1.1239487918146551e-07
with O 0 5.000466174465146e-08
isolated B-Disease 0 3.6814730265177786e-05
DMS I-Disease 1 1.0
( O 0 7.248890597111313e-06
IDMS B-Disease 1 0.9999858140945435
) O 0 1.0152035656574299e-07
, O 0 3.1354609575373615e-08
10 O 0 6.205590352692525e-08
with O 0 2.4998932701691956e-08
DDS B-Disease 1 1.0
, O 0 1.3861109948720696e-07
and O 0 5.016897830500966e-08
4 O 0 3.3663044973764045e-07
with O 0 9.768816511268597e-08
urogenital B-Disease 1 0.9999269247055054
abnormalities I-Disease 1 0.9999997615814209
and O 0 0.4168938994407654
/ O 1 0.9999996423721313
or O 1 0.8286650776863098
WT B-Disease 1 1.0
. O 0 2.234108978882432e-05

We O 0 6.548363671754487e-06
report O 0 6.971545190026518e-06
WT1 O 0 0.0007002234924584627
heterozygous O 0 1.6431255289717228e-06
mutations O 0 8.17007844489126e-07
in O 0 9.517819421489548e-08
16 O 0 3.1126310773288424e-07
patients O 0 1.768026614001883e-08
, O 0 1.0853320908665864e-08
4 O 0 1.248895529215588e-07
of O 0 3.976557749751919e-08
whom O 0 3.4250930980306293e-07
presented O 0 1.5207214119072887e-06
with O 0 1.7329872434856952e-06
IDMS B-Disease 1 1.0
. O 0 5.497413803823292e-05

One O 0 2.214839014413883e-06
male O 0 1.2893501661892515e-06
and O 0 6.433130295135925e-08
two O 0 8.882504687335313e-08
female O 0 3.2299683425662806e-06
IDMS B-Disease 1 0.9999998807907104
patients O 0 1.4626966731157154e-06
with O 0 1.1591793054321897e-06
WT1 O 1 1.0
mutations O 0 0.0005979890120215714
underwent O 0 2.0175357349216938e-05
normal O 0 5.487002908921568e-06
puberty O 0 5.882343612029217e-05
. O 0 8.513741704518907e-06

Two O 0 1.911333583848318e-06
mutations O 0 1.6630713162157917e-06
associated O 0 7.190170663307072e-07
with O 0 7.010855540556804e-08
IDMS B-Disease 1 0.9999967813491821
are O 0 9.880101181636292e-09
different O 0 4.658847085892148e-09
from O 0 1.5415032805776718e-08
those O 0 8.938346951481435e-09
described O 0 9.722717209115217e-08
in O 0 2.493900410627248e-07
DDS B-Disease 1 1.0
patients O 0 2.9847358291590353e-06
. O 0 5.244526164460694e-06

No O 0 1.8741431631497107e-05
WT1 O 0 0.0009145796648226678
mutations O 0 2.513158733563614e-06
were O 0 1.5386956420115894e-07
detected O 0 1.4464525577295717e-07
in O 0 3.3227143259040304e-09
the O 0 7.398583079520904e-09
six O 0 3.8821745818040654e-08
other O 0 2.0271787093406601e-07
IDMS B-Disease 1 1.0
patients O 0 1.2990388995604008e-06
, O 0 2.5261261527020906e-08
suggesting O 0 8.063291545568063e-08
genetic O 0 4.829113322557532e-07
heterogeneity O 0 8.835309927235357e-06
of O 0 3.8447629435722774e-07
this O 0 1.9551526975192246e-07
disease O 0 0.005261825397610664
. O 0 4.992369667888852e-06

We O 0 2.8357344490359537e-06
analyzed O 0 9.42601946007926e-06
genotype O 0 1.1251728210481815e-05
/ O 0 4.1241382859880105e-06
phenotype O 0 9.448072546547337e-07
correlations O 0 6.093868591960927e-07
, O 0 1.410107230981339e-08
on O 0 8.957205643866928e-09
the O 0 2.883005389975324e-09
basis O 0 8.82178596839367e-09
of O 0 4.1741485823365565e-09
the O 0 8.819564634166e-09
constitution O 0 3.085778743638912e-08
of O 0 4.8084334736131495e-08
a O 0 1.0589741350486293e-07
WT1 O 0 1.0166603715333622e-05
mutation O 0 4.738971881579346e-08
database O 0 8.635614534568958e-08
of O 0 7.066071816552721e-08
84 O 0 2.800629772536922e-07
germ O 0 6.766969454474747e-05
- O 0 5.584412519965554e-06
line O 0 1.2819446055800654e-06
mutations O 0 7.090224585226679e-08
, O 0 6.5534941917633205e-09
to O 0 2.576926227959575e-09
compare O 0 2.4504517526224845e-08
the O 0 6.463062973693923e-09
distribution O 0 1.96871159374723e-08
and O 0 2.5757171950857582e-09
type O 0 2.816716282438847e-08
of O 0 1.7537692187374887e-08
mutations O 0 4.127385722085819e-08
, O 0 6.958789100508511e-09
according O 0 4.825078558923224e-09
to O 0 7.31400540132654e-09
the O 0 2.624531880712766e-08
different O 0 1.8098182863468537e-07
symptoms O 0 1.7890497474581935e-05
. O 0 5.6673034123377874e-06

This O 0 1.1209648391741212e-06
demonstrated O 0 2.65039443547721e-06
( O 0 1.633674031609189e-07
1 O 0 2.7984137318526336e-07
) O 0 1.2001392768468122e-08
the O 0 1.758626133607777e-08
association O 0 9.104548581717609e-08
between O 0 4.114244234187936e-08
mutations O 0 3.9164604004326975e-08
in O 0 3.683653915231844e-08
exons O 0 5.891516821066034e-07
8 O 0 2.594188686089183e-07
and O 0 4.3619166945063625e-08
9 O 0 3.0897959391040786e-07
and O 0 8.775287341222793e-08
DMS B-Disease 0 2.1776937501272187e-05
; O 0 1.3417439959084732e-07
( O 0 3.770959011717423e-08
2 O 0 1.1776443642474987e-07
) O 0 3.358138656039955e-09
among O 0 9.626740293811054e-09
patients O 0 5.6629398947904974e-09
with O 0 8.828468622823493e-09
DMS B-Disease 0 0.1143590658903122
, O 0 1.4376998258569529e-08
a O 0 3.884180088675748e-09
higher O 0 1.2880700062112282e-08
frequency O 0 1.207813848935757e-08
of O 0 1.4822059135610743e-08
exon O 0 1.8255042277814937e-07
8 O 0 5.0794348283034196e-08
mutations O 0 2.6263096586376378e-08
among O 0 3.673746462595773e-08
46 O 0 1.7119469930548803e-07
, O 0 3.3500668905617204e-08
XY O 0 9.645170393923763e-06
patients O 0 1.2428995610491711e-08
with O 0 1.0408670370054551e-08
female O 0 5.3304056280012446e-08
phenotype O 0 3.4976661567043266e-08
than O 0 5.646933143310662e-09
among O 0 2.5443805284908194e-08
46 O 0 1.0069420142144736e-07
, O 0 3.335300746698522e-08
XY O 0 2.0590605345205404e-05
patients O 0 2.264616405511788e-08
with O 0 5.573028261096624e-09
sexual O 0 4.745655957094641e-08
ambiguity O 0 2.5443009121772775e-07
or O 0 8.496382974954031e-08
male O 0 9.715228088680306e-08
phenotype O 0 5.946417758195821e-08
; O 0 1.3605145454675949e-08
and O 0 3.627415878781903e-08
( O 0 2.579858460194373e-08
3 O 0 7.104193855411722e-08
) O 0 3.004686055518846e-09
statistically O 0 1.3954053024178847e-08
significant O 0 1.0437616104752578e-08
evidence O 0 3.032779716249934e-08
that O 0 6.598233071031245e-09
mutations O 0 4.9572861371416366e-08
in O 0 5.024913107831708e-08
exons O 0 9.911140068652458e-07
8 O 0 4.987702482139866e-07
and O 0 9.563604663753722e-08
9 O 0 3.434926156842266e-07
preferentially O 0 2.4362987005588366e-07
affect O 0 5.782657908071087e-08
amino O 0 3.040372931195634e-08
acids O 0 1.7437592703117843e-08
with O 0 2.1147867901305517e-09
different O 0 7.712467997578187e-09
functions O 0 3.42221895266448e-08
. O 0 1.0239722314508981e-07
. O 0 9.357245858154783e-07

The O 0 1.003204579319572e-05
185delAG O 0 4.1511779272696e-05
BRCA1 O 0 2.212723529737559e-06
mutation O 0 1.398371267669063e-07
originated O 0 1.0115986981418246e-07
before O 0 6.697130405797225e-09
the O 0 4.4484882444351115e-09
dispersion O 0 6.26959675287253e-08
of O 0 2.1461293187030606e-08
Jews O 0 1.9062352407672734e-07
in O 0 4.80198814045707e-09
the O 0 1.2918122571647928e-08
diaspora O 0 7.35606420221302e-08
and O 0 9.309260029510824e-09
is O 0 3.574290641239486e-09
not O 0 4.870598591111275e-09
limited O 0 5.0158451614379373e-08
to O 0 1.7302676269537187e-07
Ashkenazim O 0 0.0003487418871372938
. O 0 8.259731657744851e-06

The O 0 4.7145940698101185e-06
185delAG O 0 1.2752096154144965e-05
mutation O 0 3.9155574427240936e-07
in O 0 1.230954040920551e-07
BRCA1 O 0 3.8370890820260684e-07
is O 0 1.0245578607737116e-08
detected O 0 3.215331290107315e-08
in O 0 7.056936812688264e-09
Ashkenazi O 0 4.203872947527998e-07
Jews O 0 3.361351446073968e-07
both O 0 1.9082207813880814e-08
in O 0 1.884737876878262e-08
familial B-Disease 1 0.9988381266593933
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.975632623109959e-08
in O 0 5.471129327361268e-09
the O 0 2.5140279191759873e-08
general O 0 2.738452167250216e-07
population O 0 1.0629810276441276e-07
. O 0 8.634302730570198e-07

All O 0 2.118875499945716e-06
tested O 0 1.6769350850154296e-06
Ashkenazi O 0 2.496301931387279e-06
mutation O 0 1.5799056996002037e-07
carriers O 0 1.2699840112873062e-07
share O 0 1.63201026026627e-08
the O 0 1.354709056045067e-08
same O 0 1.6603117103386467e-08
allelic O 0 2.0686436528194463e-06
pattern O 0 1.2323911278144806e-06
at O 0 4.592739912823163e-07
the O 0 1.2218365554872435e-06
BRCA1 O 0 2.1748506696894765e-05
locus O 0 8.540185262972955e-06
. O 0 1.1747132703021634e-05

Our O 0 1.9772744508372853e-06
previous O 0 4.0287852698384086e-07
study O 0 6.348330572336636e-08
showed O 0 1.7723314371664856e-08
that O 0 9.802124667501744e-10
this O 0 3.1313831527768343e-09
Ashkenazi O 0 3.027387833753892e-07
mutation O 0 1.3432926770917675e-08
also O 0 4.604991055146002e-09
occurs O 0 3.3331433169081492e-09
in O 0 3.1383313725541484e-09
Iraqi O 0 4.5802562453900464e-07
Jews O 0 2.8264042839509784e-07
with O 0 7.3260406630026864e-09
a O 0 1.9628698666451783e-08
similar O 0 1.0197408073508996e-07
allelic O 0 1.985315975616686e-05
pattern O 0 1.2478669304982759e-05
. O 0 1.360482656309614e-05

We O 0 1.9717872419278137e-06
extended O 0 1.9116980638500536e-06
our O 0 1.0658843052624434e-07
analysis O 0 3.040256757458337e-08
to O 0 1.4006717563574966e-08
other O 0 9.139886714137901e-08
non O 0 1.023262939270353e-06
- O 0 1.0172150268772384e-06
Ashkenazi O 0 1.1567861974981497e-06
subsets O 0 7.953215117595391e-07
354 O 0 3.171513753841282e-07
of O 0 2.6976520572929985e-08
Moroccan O 0 1.1211999435545295e-06
origin O 0 2.1625166368721693e-07
, O 0 6.802157059837555e-08
200 O 0 1.417138406623053e-07
Yemenites O 0 3.4428865092195338e-06
and O 0 7.625381925890906e-08
150 O 0 2.8818448072343017e-07
Iranian O 0 7.488463779736776e-06
Jews O 0 2.280467379023321e-05
. O 0 9.485426744504366e-06

Heteroduplex O 0 0.00016554302419535816
analysis O 0 1.999136429731152e-06
complemented O 0 2.2305948732537217e-06
by O 0 4.199505454494101e-08
direct O 0 9.657787813921459e-08
DNA O 0 1.851917232897904e-07
sequencing O 0 4.319568631672155e-07
of O 0 1.9674227758059715e-07
abnormally O 0 1.0424603260617005e-06
migrating O 0 3.057753303892241e-07
bands O 0 4.076399591212976e-07
were O 0 2.0097213848657702e-07
employed O 0 1.5290687542801606e-06
. O 0 2.322601858395501e-06

Four O 0 4.4247731239011046e-06
of O 0 2.206328417742043e-06
Moroccan O 0 1.997062463487964e-05
origin O 0 6.991758709773421e-07
( O 0 5.616109177708495e-08
1 O 0 7.265705193049143e-08
. O 0 3.6342076015216662e-09
1 O 0 2.221382366940361e-08
% O 0 1.1471609218105527e-09
) O 0 3.013799487749935e-10
and O 0 5.621944021427794e-10
none O 0 6.575543221032376e-09
of O 0 8.580935961788327e-09
the O 0 2.976362267759214e-08
Yemenites O 0 1.8296434518561e-06
or O 0 3.7487779991352e-08
Iranians O 0 2.4419932742603123e-07
was O 0 5.94582800772514e-08
a O 0 1.059687004811849e-08
carrier O 0 6.016396980612626e-08
of O 0 5.880110975908792e-08
the O 0 6.218321004780591e-07
185delAG O 0 2.447438964736648e-05
mutation O 0 5.583229722105898e-06
. O 0 1.6259215044556186e-05

BRCA1 O 0 5.641341340378858e-05
allelic O 0 1.7018321159412153e-05
patterns O 0 9.410402981302468e-07
were O 0 9.60030277497026e-08
determined O 0 2.485089112269634e-08
for O 0 6.134401875357298e-09
four O 0 7.39655137138584e-09
of O 0 4.812201748194411e-09
these O 0 2.5326041264150945e-09
individuals O 0 1.6481728204453816e-09
and O 0 4.650953844276273e-09
for O 0 6.917289407937233e-09
12 O 0 5.661679125523733e-08
additional O 0 3.99137540796346e-08
non O 0 5.23395101481583e-07
- O 0 4.4564185941453616e-07
Ashkenazi O 0 7.783752380419173e-07
185delAG O 0 2.583328466698731e-07
mutation O 0 3.035817996988044e-08
carriers O 0 7.814718117060693e-08
who O 0 1.2026845297441469e-07
had O 0 4.808516223420156e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.010260479641147e-05

Six O 0 1.4285653378465213e-05
non O 0 2.588544703030493e-05
- O 0 3.981016561738215e-06
Ashkenazi O 0 2.789553718685056e-06
individuals O 0 1.560292872682112e-08
shared O 0 1.4770865419677648e-08
the O 0 1.1092405216572843e-08
common O 0 4.106952644633566e-08
Ashkenazi O 0 4.700353315456596e-07
haplotype O 0 3.6763267985406856e-07
, O 0 1.9951958307729e-08
four O 0 2.0525199317944498e-08
had O 0 1.5285738896864132e-08
a O 0 1.1768591434702103e-08
closely O 0 2.6162053856637613e-08
related O 0 3.911078039209315e-08
pattern O 0 1.1050302362036746e-07
, O 0 8.555963937340039e-09
and O 0 1.1294281954121743e-08
the O 0 6.565695542803951e-08
rest O 0 4.3720453390960756e-07
( O 0 1.0422063922987945e-07
n O 0 3.052214765375538e-07
= O 0 1.2754693443639553e-06
6 O 0 4.595727887135581e-07
) O 0 1.497596890942532e-08
displayed O 0 1.626474954719015e-07
a O 0 8.36802485082444e-08
distinct O 0 1.5812457831998472e-06
BRCA1 O 0 8.85984718479449e-06
allelic O 0 3.4755976230371743e-05
pattern O 0 2.983148988278117e-05
. O 0 2.031025906035211e-05

We O 0 9.382470693708456e-07
conclude O 0 1.3689478919332032e-06
that O 0 3.692235850394354e-08
the O 0 2.262410987441399e-07
185delAG O 0 7.322911187657155e-06
BRCA1 O 0 7.837689395273628e-07
mutation O 0 3.0645928461581207e-08
occurs O 0 1.0262046323816776e-08
in O 0 2.692592371289493e-09
some O 0 7.530303491876111e-09
non O 0 1.7748965319697163e-07
- O 0 1.976246011281546e-07
Ashkenazi O 0 6.959162988096068e-07
populations O 0 4.4927883635637045e-08
at O 0 1.3822584854494835e-08
rates O 0 6.70958399950905e-09
comparable O 0 2.1223765855893362e-08
with O 0 6.353233494849064e-09
that O 0 2.695882628245272e-08
of O 0 7.806776238794555e-07
Ashkenazim O 0 0.00029568778700195253
. O 0 1.2431491995812394e-05

The O 0 1.427166807843605e-06
majority O 0 1.6031948746331182e-07
of O 0 2.3626121503639297e-07
Jewish O 0 2.0121563011343824e-06
185delAG O 0 5.376219860409037e-07
mutation O 0 3.7180797107794206e-08
carriers O 0 2.921801822708403e-08
have O 0 1.9928405592395393e-09
a O 0 8.008738561215978e-09
common O 0 3.132364767566287e-08
allelic O 0 9.539444363326766e-07
pattern O 0 4.873481884715147e-07
, O 0 3.7690679022261975e-08
supporting O 0 8.270171036883767e-08
the O 0 1.2101848767542833e-07
founder O 0 7.796151635375281e-07
effect O 0 7.792020539909572e-08
notion O 0 2.0746087159295712e-07
, O 0 1.3926506170491848e-08
but O 0 6.714064859636437e-09
dating O 0 4.876456927149775e-08
the O 0 1.0738134825771795e-08
mutations O 0 1.040414421282776e-08
origin O 0 1.1051858095356693e-08
to O 0 2.8969622256624916e-09
an O 0 3.994953257091538e-09
earlier O 0 1.922974490753404e-08
date O 0 8.794154382485431e-08
than O 0 1.9404904350039942e-08
currently O 0 8.366796322434311e-08
estimated O 0 5.625349785987055e-07
. O 0 2.5166771138174227e-06

However O 0 2.315179926881683e-06
, O 0 1.1270034150356878e-07
the O 0 1.689010531435997e-08
different O 0 1.1899460083952818e-08
allelic O 0 9.887378382700263e-07
pattern O 0 6.640897254328593e-07
at O 0 6.129597096560246e-08
the O 0 3.5495965278187214e-08
BRCA1 O 0 2.521063322546979e-07
locus O 0 2.6964791288719425e-08
even O 0 5.824008830757066e-09
in O 0 2.267844356751425e-09
some O 0 3.1340183781480846e-09
Jewish O 0 5.176723760769164e-08
mutation O 0 1.1696534407690251e-08
carriers O 0 2.4890358218954134e-08
, O 0 4.3792285353561056e-09
might O 0 2.3632967582898345e-08
suggest O 0 3.387087588180293e-08
that O 0 1.1310363312588834e-08
the O 0 7.504211652076265e-08
mutation O 0 1.5558447330477065e-07
arose O 0 4.847593118029181e-07
independently O 0 2.2745929584289115e-07
. O 0 3.5634832329378696e-07
. O 0 2.393900786046288e-06

Crystal O 0 0.00014246634964365512
structure O 0 8.857253305905033e-06
of O 0 3.010168711625738e-06
the O 0 5.847447027917951e-06
hemochromatosis B-Disease 1 1.0
protein O 1 0.9919514656066895
HFE O 1 0.9999994039535522
and O 0 1.5661134966649115e-07
characterization O 0 5.667226332661812e-07
of O 0 1.0160830044014801e-07
its O 0 3.470572806918426e-08
interaction O 0 2.2368529073446553e-07
with O 0 1.6321823181897344e-07
transferrin O 0 0.00010524574463488534
receptor O 0 0.00011480697139631957
. O 0 1.1574435120564885e-05

HFE O 1 0.9977319240570068
is O 0 2.580075715741259e-06
an O 0 9.784860139916418e-07
MHC O 1 0.9977578520774841
- O 0 0.0020649621728807688
related O 0 1.8949552895719535e-06
protein O 0 2.1960977392154746e-07
that O 0 2.289003431243941e-09
is O 0 1.413782646508821e-09
mutated O 0 3.7179589185143413e-08
in O 0 1.2214103506380525e-08
the O 0 2.1614670231429045e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9999909400939941

HFE O 0 0.005567556247115135
binds O 0 2.6401115974294953e-05
to O 0 2.176238467654912e-06
transferrin O 0 8.996378164738417e-05
receptor O 0 5.530988710233942e-05
( O 0 1.0045706630990026e-06
TfR O 0 9.164356924884487e-06
) O 0 1.923880610377182e-08
and O 0 6.2087250896070145e-09
reduces O 0 2.4416200616883543e-08
its O 0 5.9881282155060944e-09
affinity O 0 6.063294222258264e-08
for O 0 3.9967080311953396e-08
iron O 0 6.883493369969074e-06
- O 0 2.3564159619127167e-06
loaded O 0 7.003831342444755e-06
transferrin O 0 2.154138383048121e-05
, O 0 6.923548312443017e-07
implicating O 0 0.0011824548710137606
HFE O 1 0.999998927116394
in O 0 7.589579126943136e-06
iron O 1 0.9770246744155884
metabolism O 0 0.0006275985506363213
. O 0 2.023468550760299e-05

The O 0 0.00010110747098224238
2 O 0 0.00010990978626068681
. O 0 2.1779367671115324e-05

6 O 0 0.00011066455044783652
A O 0 9.384688382851891e-06
crystal O 0 7.98853361629881e-05
structure O 0 6.060258783691097e-06
of O 0 5.277675882098265e-06
HFE O 1 0.9999996423721313
reveals O 0 1.4004961030877894e-06
the O 0 8.550062347012499e-08
locations O 0 1.8712576377311052e-07
of O 0 6.695178740301344e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.003972738981246948
and O 0 4.1862861621666525e-07
a O 0 1.5029786482045893e-07
patch O 0 0.0027548805810511112
of O 0 2.223329602202284e-06
histidines O 0 0.0013428296661004424
that O 0 8.320530042738028e-09
could O 0 1.3961639844239926e-08
be O 0 2.1302282604551692e-08
involved O 0 5.1764473596449534e-08
in O 0 7.326882212055352e-08
pH O 0 2.510250624254695e-06
- O 0 7.991969141585287e-06
dependent O 0 3.2986499718390405e-06
interactions O 0 2.783508080028696e-06
. O 0 8.5612409748137e-06

We O 0 1.665701574893319e-06
also O 0 3.069665410748712e-07
demonstrate O 0 2.7407332936491e-07
that O 0 1.1116766529539746e-07
soluble O 0 2.029165261774324e-05
TfR O 0 3.272809772170149e-05
and O 0 4.3827367335325107e-07
HFE O 0 0.00011211739183636382
bind O 0 6.779844738957763e-07
tightly O 0 2.7869162977367523e-07
at O 0 5.0327592759913387e-08
the O 0 1.5307387357665903e-08
basic O 0 5.1303871373420407e-08
pH O 0 5.1234245290743274e-08
of O 0 1.8362595000098736e-08
the O 0 2.933489184897553e-08
cell O 0 1.2717146091745235e-07
surface O 0 6.490440540574127e-08
, O 0 5.559226856632904e-09
but O 0 3.105118828727882e-09
not O 0 8.505101511957491e-09
at O 0 7.165487403426596e-08
the O 0 7.249163758160648e-08
acidic O 0 9.958105238183634e-07
pH O 0 1.648792135711119e-06
of O 0 4.2993195847884635e-07
intracellular O 0 9.883598977467045e-06
vesicles O 0 9.725060954224318e-05
. O 0 1.200758561026305e-05

TfR O 0 0.031875185668468475
HFE O 0 0.010889936238527298
stoichiometry O 0 0.00014742204803042114
( O 0 5.130875251779798e-06
2 O 0 2.734422650974011e-06
1 O 0 8.64494040797581e-07
) O 0 1.9085995006662415e-08
differs O 0 1.1819097522902666e-07
from O 0 1.7216541436937405e-07
TfR O 0 4.491761501412839e-06
transferrin O 0 4.661836555897025e-06
stoichiometry O 0 3.633618007370387e-06
( O 0 1.6794112411844253e-07
2 O 0 2.3306817809043423e-07
2 O 0 7.201507656873218e-08
) O 0 3.815829874298515e-09
, O 0 2.729762194064733e-09
implying O 0 1.4644236934202581e-08
a O 0 2.0776838027813938e-09
different O 0 2.4475730331374734e-09
mode O 0 3.4621891131791926e-08
of O 0 1.1282051737282472e-08
binding O 0 5.2184400800570074e-08
for O 0 2.1190300003581797e-07
HFE O 0 0.001767622889019549
and O 0 2.708546844587545e-07
transferrin O 0 4.4310859266261104e-06
to O 0 1.424748603540138e-07
TfR O 0 9.44397925195517e-06
, O 0 3.4275039695330634e-08
consistent O 0 1.7868632085082936e-07
with O 0 1.862556153753303e-08
our O 0 7.925211065185067e-08
demonstration O 0 7.126470791263273e-07
that O 0 7.698275084067063e-08
HFE O 0 0.00016065391537267715
, O 0 1.8521750178024377e-07
transferrin O 0 6.352900072670309e-06
, O 0 1.8731002171534783e-07
and O 0 1.562406453103904e-07
TfR O 0 4.5236806727189105e-06
form O 0 5.350961984618152e-08
a O 0 1.982823221169383e-07
ternary O 0 2.4761620807112195e-06
complex O 0 7.807187103026081e-06
. O 0 7.707934855716303e-06

Identification O 0 6.096035576774739e-06
of O 0 1.4950559261706076e-06
three O 0 1.935794387009082e-07
novel O 0 1.5098184746875631e-07
mutations O 0 1.2856294517860078e-07
and O 0 1.1055230508816294e-08
a O 0 1.3914956298322068e-08
high O 0 3.2583677977982006e-08
frequency O 0 2.6549578535650653e-08
of O 0 1.0023275542891952e-08
the O 0 2.040384394774719e-08
Arg778Leu O 0 1.9424662696110317e-06
mutation O 0 3.175060214744008e-08
in O 0 2.0021223789967735e-08
Korean O 0 1.2125605053370236e-06
patients O 0 4.459364788544917e-08
with O 0 8.767207049231729e-08
Wilson B-Disease 0 1.6796588170109317e-05
disease I-Disease 0 0.04560370370745659
. O 0 4.796548637386877e-06

Four O 0 1.4039896086615045e-05
mutations O 0 7.992236533027608e-06
- O 0 1.6313950254698284e-05
- O 0 1.4613993698731065e-05
R778L O 0 2.513757317501586e-05
, O 0 3.400092225547269e-07
A874V O 0 6.554198989761062e-06
, O 0 1.3620625338717218e-07
L1083F O 0 3.947825007344363e-06
, O 0 6.018956355546834e-08
and O 0 4.371161210769969e-08
2304delC O 0 8.61120383888192e-07
- O 0 7.367183911810571e-07
- O 0 7.91477077655145e-07
in O 0 7.056334538901865e-08
the O 0 1.3245094976355176e-07
copper O 0 1.3905228115618229e-06
- O 0 5.483777840709081e-07
transporting O 0 8.844219792081276e-07
enzyme O 0 2.0383293986014905e-07
, O 0 1.1957573065046745e-07
P O 0 1.732859914227447e-06
- O 0 5.674381213793822e-07
type O 0 3.878914753840945e-07
ATPase O 0 1.022426999952586e-06
( O 0 9.85947252729602e-08
ATP7B O 0 8.858546607370954e-06
) O 0 2.692633449541404e-09
, O 0 2.1292441143572205e-09
were O 0 2.4924171615481328e-09
identified O 0 9.877180850992318e-09
in O 0 5.340131448150487e-09
Korean O 0 4.265020265847852e-07
Patients O 0 2.6251878892935565e-08
with O 0 4.109898910087395e-08
Wilson B-Disease 0 1.0726837899710517e-05
disease I-Disease 0 0.30642038583755493
. O 0 3.952729912271025e-06

Arg778Leu O 0 0.0005553417722694576
, O 0 6.050402703294822e-07
the O 0 1.0901998592771633e-07
most O 0 3.138548265724239e-08
frequently O 0 2.8633987625426016e-08
reported O 0 1.9048535193633143e-08
mutation O 0 5.025121652124653e-09
of O 0 4.204296022436438e-09
this O 0 7.509172728070723e-10
enzyme O 0 1.4637869583111751e-08
, O 0 6.3978617959037365e-09
was O 0 1.3635957252233766e-08
found O 0 2.822593048179556e-09
in O 0 2.2360810980615042e-09
six O 0 8.973228382558318e-09
of O 0 1.0060374755482826e-08
eight O 0 2.65727813086869e-08
unrelated O 0 1.218809018155298e-07
patients O 0 9.75369562894457e-09
studied O 0 3.042588758717102e-08
, O 0 2.3020465533818424e-09
an O 0 1.4464568431904468e-09
allele O 0 1.5605488457026695e-08
frequency O 0 4.764875782825584e-08
of O 0 1.6532166569049878e-07
37 O 0 4.896145128441276e-06
. O 0 2.791991846606834e-06

5 O 0 5.363813670555828e-06
% O 0 5.0142574536948814e-08
, O 0 6.606506897099962e-09
which O 0 1.8055639205982743e-09
is O 0 8.210501722949459e-10
considerably O 0 1.950632189107182e-08
higher O 0 1.1055526272230054e-08
than O 0 1.0569835007245842e-09
those O 0 1.6071641795178948e-09
in O 0 4.141104348320823e-09
other O 0 2.1265096350475687e-08
Asian O 0 3.356629747486295e-07
populations O 0 3.8476937902487407e-07
. O 0 1.361089061902021e-06

The O 0 3.229180038033519e-06
novel O 0 1.0077833394461777e-06
single O 0 8.446051680266464e-08
nucleotide O 0 3.7894031379437365e-07
deletion O 0 1.7166718180305907e-07
, O 0 3.831679862287274e-08
2304delC O 0 3.78423152369578e-07
, O 0 1.4158044514545054e-08
was O 0 3.149107996591738e-08
found O 0 1.1692384838113412e-08
in O 0 1.3900313788894891e-08
one O 0 1.4082935706483113e-07
patient O 0 1.3587921330326935e-06
. O 0 6.319134627119638e-06

Since O 0 2.667994522198569e-06
a O 0 3.249295161822374e-07
mutation O 0 3.2837866115187353e-07
at O 0 2.351081747065109e-07
cDNA O 0 2.802248218358727e-06
nucleotide O 0 4.679609446611721e-06
2302 O 0 5.610812877421267e-05
( O 0 1.856035254377275e-07
2302insC O 0 1.4921303090886795e-06
) O 0 1.2514513869632538e-08
had O 0 9.73080194199838e-09
been O 0 4.799680652922689e-09
previously O 0 5.306027617280051e-09
described O 0 4.894028293733754e-09
, O 0 6.995568568868293e-10
this O 0 6.277129371845547e-10
region O 0 2.9430612613623452e-08
of O 0 2.0457973093357396e-08
the O 0 1.6688022697053384e-07
ATP7B O 1 0.9999997615814209
gene O 0 2.2683197187234327e-07
may O 0 5.5482132665929385e-08
be O 0 1.5894229932200687e-08
susceptible O 0 3.868766214054631e-07
to O 0 4.093227801149624e-08
gene O 0 1.4406377886189148e-06
rearrangements O 0 0.3612847328186035
causing O 1 0.8646145462989807
Wilson B-Disease 0 0.00027626747032627463
disease I-Disease 0 0.32326722145080566
. O 0 9.795599908102304e-06

Disruption O 0 0.0001260446588275954
of O 0 1.5053240076667862e-06
splicing O 0 3.368589204910677e-06
regulated O 0 4.6674500708832056e-07
by O 0 4.1932700867164385e-08
a O 0 1.3335323956198408e-07
CUG O 0 9.6562085673213e-05
- O 0 8.96188907972828e-07
binding O 0 3.792103484556719e-07
protein O 0 1.877091222013405e-06
in O 0 6.184386620589066e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005723813083022833

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9985284805297852
DM B-Disease 1 1.0
) O 0 4.4301171442384657e-07
is O 0 1.995157639100853e-08
caused O 0 5.3491454821141815e-08
by O 0 1.3488845596043575e-08
a O 0 4.978349466000509e-08
CTG O 0 2.1607327653327957e-05
expansion O 0 2.6587767365526815e-07
in O 0 1.5823721000174373e-08
the O 0 4.5639488632787106e-08
3 O 0 2.1097463331898325e-07
untranslated O 0 1.3082528312224895e-05
region O 0 2.70924715550791e-07
of O 0 1.6211231468332699e-07
the O 0 2.4650034902151674e-06
DM B-Disease 1 1.0
gene O 0 3.813538569374941e-05
. O 0 2.9485361665138043e-05

One O 0 8.447233881270222e-07
model O 0 7.519226414842706e-07
of O 0 2.8146462227596203e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9999566078186035
suggests O 0 3.413796889617515e-07
that O 0 5.5281823563291255e-09
RNAs O 0 4.529226416138954e-08
from O 0 6.401816854406661e-09
the O 0 1.1892721474282553e-08
expanded O 0 2.3673660365375326e-08
allele O 0 2.202935611705925e-08
create O 0 2.4287448496806974e-08
a O 0 2.2364321949908117e-08
gain O 0 2.1780438430596405e-07
- O 0 3.3349607519994606e-07
of O 0 1.4406649029297114e-07
- O 0 1.3011674582230626e-07
function O 0 7.025832804430365e-09
mutation O 0 4.973374156946875e-09
by O 0 3.4927643000060016e-09
the O 0 1.5992389634789106e-08
inappropriate O 0 4.599270653216081e-08
binding O 0 6.381338835126371e-08
of O 0 5.373821565513026e-08
proteins O 0 2.4535056653007814e-08
to O 0 7.939326707173677e-08
the O 0 1.574914335833455e-06
CUG O 1 0.6313837766647339
repeats O 0 2.0346293240436353e-05
. O 0 7.4631116149248555e-06

Data O 0 4.088436526217265e-06
presented O 0 2.292978251716704e-06
here O 0 2.166263044500738e-07
indicate O 0 1.9292386355118651e-07
that O 0 2.4891784633496172e-08
the O 0 1.411256675964978e-07
conserved O 0 1.4341360383696156e-06
heterogeneous O 0 8.640829946671147e-06
nuclear O 0 2.5114763047895394e-05
ribonucleoprotein O 0 0.00010970664880005643
, O 0 1.9613339645729866e-06
CUG O 0 0.00013968694838695228
- O 0 2.9239481591503136e-06
binding O 0 7.991756092451396e-07
protein O 0 2.0755896912305616e-06
( O 0 3.988818946254469e-07
CUG O 0 0.0033554299734532833
- O 0 8.61832177179167e-06
BP O 0 4.3476907194417436e-06
) O 0 3.013710525578972e-08
, O 0 1.209342226360377e-08
may O 0 1.429205020997415e-08
mediate O 0 3.277644680110825e-07
the O 0 2.437963075863081e-07
trans O 0 2.63010292655963e-06
- O 0 6.840296009613667e-07
dominant O 0 6.940055072846008e-07
effect O 0 1.1307757574741117e-07
of O 0 5.6493711042548966e-08
the O 0 1.9127507755456463e-07
RNA O 0 6.797449259465793e-06
. O 0 3.695600526043563e-06

CUG O 1 0.9998370409011841
- O 0 0.0040237619541585445
BP O 0 4.6568980906158686e-05
was O 0 2.995301144892437e-07
found O 0 1.024796336679401e-08
to O 0 3.3629588003236677e-09
bind O 0 1.9156784603069354e-08
to O 0 9.746293549994789e-09
the O 0 7.965765291828575e-08
human O 0 1.5026147366370424e-06
cardiac O 1 0.9635443091392517
troponin O 0 0.049542926251888275
T O 0 0.058359019458293915
( O 0 4.598178691139765e-07
cTNT O 0 4.964731942891376e-06
) O 0 3.25864775163609e-08
pre O 0 4.954001724399859e-07
- O 0 5.224839014772442e-07
messenger O 0 5.823955575579021e-07
RNA O 0 7.045372854008747e-07
and O 0 5.4621125400444726e-08
regulate O 0 8.99574885693255e-08
its O 0 5.4668550575343033e-08
alternative O 0 7.437970452883746e-07
splicing O 0 1.2644959497265518e-05
. O 0 6.250878413993632e-06

Splicing O 0 4.87393481307663e-05
of O 0 1.4453426047111861e-05
cTNT O 0 0.00014038490189705044
was O 0 5.004153081245022e-06
disrupted O 0 1.5783463823026977e-05
in O 0 1.056377300301392e-06
DM B-Disease 1 1.0
striated O 0 0.000122769721201621
muscle O 0 5.244931344350334e-06
and O 0 1.0217559065495152e-07
in O 0 3.0568749309622945e-08
normal O 0 1.2656265369059838e-07
cells O 0 2.2079292705257103e-07
expressing O 0 7.537923352174403e-08
transcripts O 0 2.845476672064251e-07
that O 0 4.382289375826076e-08
contain O 0 8.562993230043503e-07
CUG O 0 0.000527228054124862
repeats O 0 1.808393790270202e-05
. O 0 6.885594302730169e-06

Altered O 0 2.3036367565509863e-05
expression O 0 3.972717877331888e-06
of O 0 5.032783860769996e-07
genes O 0 5.742824100707367e-07
regulated O 0 1.0710600690799765e-06
posttranscriptionally O 0 3.853488578897668e-06
by O 0 1.9650337890197989e-07
CUG O 1 0.9999740123748779
- O 0 6.987857341300696e-05
BP O 0 8.886315299605485e-06
therefore O 0 1.1301537483632274e-07
may O 0 4.5581025176488765e-08
contribute O 0 1.962264093435806e-07
to O 0 6.086364692237112e-07
DM B-Disease 1 1.0
pathogenesis O 1 0.9944021105766296
. O 0 1.2597454315255163e-06
. O 0 4.011833425465738e-06

Identification O 0 3.892461791110691e-06
of O 0 8.623563871879014e-07
a O 0 1.7276592245707434e-07
novel O 0 2.5542519210830505e-07
nonsense O 0 2.2644313446562592e-07
mutation O 0 3.8566756899172105e-08
and O 0 1.1696757340473596e-08
a O 0 1.9443508136873788e-08
missense O 0 2.0919250687256863e-07
substitution O 0 2.3213031852264976e-07
in O 0 3.7522831064507045e-08
the O 0 9.008333989868333e-08
vasopressin O 0 1.9498568235576386e-06
- O 0 1.553562924527796e-06
neurophysin O 0 1.0301119800715242e-05
II O 0 0.44235339760780334
gene O 0 3.2474979150265426e-08
in O 0 1.0348808032745183e-08
two O 0 1.6468664654212262e-08
Spanish O 0 3.846123775019805e-07
kindreds O 0 3.673271066872985e-06
with O 0 2.9044556981716596e-07
familial B-Disease 0 0.4856516718864441
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999969005584717
. O 0 1.967628486454487e-05

Familial B-Disease 1 0.9999908208847046
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.0009062414173968136
FNDI B-Disease 1 1.0
) O 0 1.0027580543692238e-07
is O 0 4.479010495828106e-09
an O 0 5.941687142296814e-09
autosomal B-Disease 1 0.5452260971069336
dominant I-Disease 1 0.9999990463256836
disease I-Disease 1 0.995890200138092
caused O 0 3.5638740314425377e-07
by O 0 3.7296075561243924e-08
deficiency O 1 0.998580813407898
in O 0 2.446093105845648e-07
the O 0 2.6993354822479887e-06
antidiuretic O 0 2.083077015413437e-05
hormone O 0 3.1692145512352e-06
arginine O 0 4.221383733238326e-06
vasopressin O 0 6.457135441451101e-06
( O 0 6.171760560391704e-07
AVP O 0 4.080789949512109e-06
) O 0 1.1853702019948287e-08
encoded O 0 3.631382483604284e-08
by O 0 2.980605628977173e-08
the O 0 4.2716101233963855e-07
AVP O 0 5.332727960194461e-05
- O 0 9.58240434556501e-06
neurophysin O 0 0.0001973625912796706
II O 1 1.0
( O 0 1.1793615158239845e-05
AVP O 0 0.03521797060966492
- O 0 4.872238787356764e-05
NPII O 0 0.06969289481639862
) O 0 1.264427282876568e-07
gene O 0 1.6853186934895348e-07
on O 0 6.148854367893364e-07
chromosome O 0 5.0817739065678325e-06
20p13 O 0 9.540681639919057e-05
. O 0 9.397181202075444e-06

In O 0 2.6770754857352586e-07
this O 0 3.423550865022662e-08
study O 0 3.894218281175199e-08
, O 0 8.35046698455244e-09
we O 0 5.134623393132642e-09
analyzed O 0 3.58665310784545e-08
two O 0 1.2880160049633105e-08
families O 0 2.1934351224217608e-08
with O 0 2.622390482542869e-08
FNDI B-Disease 1 0.9999998807907104
using O 0 1.1016147993814229e-07
direct O 0 1.5710860168383078e-07
automated O 0 5.643274789690622e-07
fluorescent O 0 8.756308034207905e-07
, O 0 3.5850732160724874e-08
solid O 0 2.6242449280289293e-07
phase O 0 1.395469695353313e-07
, O 0 2.720770986286425e-08
single O 0 3.772210988017832e-08
- O 0 1.97491203834943e-07
stranded O 0 1.9991867361568438e-07
DNA O 0 7.876355567759674e-08
sequencing O 0 1.0052130505755486e-07
of O 0 1.2043808794715005e-07
PCR O 0 3.1597805900673848e-06
- O 0 1.45235198942828e-05
amplified O 0 4.015089507447556e-05
AVP O 0 0.0005358285270631313
- O 0 4.654842632589862e-05
NPII O 0 0.00039688454126007855
DNA O 0 2.3635735487914644e-05
. O 0 1.9435521608102135e-05

In O 0 3.361469964602293e-07
one O 0 1.0481129919526211e-07
of O 0 5.145930259686793e-08
the O 0 3.510170287768233e-08
families O 0 4.186533431038697e-08
, O 0 1.2839467267156124e-08
affected O 0 2.5517046253753506e-08
individuals O 0 6.273709107773584e-09
presented O 0 6.736155455655535e-08
a O 0 2.4837953915834987e-08
novel O 0 5.594000640485319e-08
nonsense O 0 1.1766441332383692e-07
mutation O 0 3.624656486067579e-08
in O 0 1.792911952236409e-08
exon O 0 3.1290181823351304e-07
3 O 0 1.1772659291864329e-07
of O 0 1.3203949933426884e-08
the O 0 1.8118745614970067e-08
gene O 0 2.145994315583266e-08
, O 0 7.186672146275441e-09
consisting O 0 1.4184127650196388e-08
in O 0 4.705176692709756e-09
a O 0 2.9743757679057126e-08
G O 0 6.89445812440681e-07
to O 0 9.05082231383858e-08
T O 0 1.1102057214884553e-05
transition O 0 4.785756004821451e-07
at O 0 2.684691935428418e-07
nucleotide O 0 8.103174877760466e-07
2101 O 0 8.581210749980528e-06
, O 0 4.0413603130673437e-08
which O 0 5.325707874703767e-09
produces O 0 6.503325877815769e-09
a O 0 7.233953436269758e-09
stop O 0 6.091973858701749e-08
signal O 0 3.189165909134317e-07
in O 0 5.2212776324722654e-08
codon O 0 2.2671288206765894e-06
82 O 0 7.208542228909209e-06
( O 0 7.834169650777767e-07
Glu O 0 0.00011434951011324301
) O 0 3.0555699481737975e-07
of O 0 1.3612084330816288e-06
NPII O 1 0.9765943884849548
. O 0 2.329250673938077e-05

The O 0 6.815754659328377e-06
premature O 0 1.6068443073891103e-05
termination O 0 2.1714474769396475e-06
eliminates O 0 1.8304533568880288e-06
part O 0 7.526286083248124e-08
of O 0 6.001165075986137e-08
the O 0 1.1355794526934915e-07
C O 0 1.3349846085475292e-05
- O 0 8.60475950048567e-07
terminal O 0 5.001487011213612e-07
domain O 0 7.029736082131421e-08
of O 0 8.245380911375833e-08
NPII O 0 0.02041168138384819
, O 0 1.862630760740558e-08
including O 0 1.1671418498337971e-08
a O 0 2.3423753603424302e-08
cysteine O 0 6.40125819018067e-08
residue O 0 1.9159365649557003e-07
in O 0 1.0838715702732316e-08
position O 0 5.5908749629907106e-08
85 O 0 3.4046145458432875e-08
, O 0 3.0678839468833985e-09
which O 0 1.0179734832860277e-09
could O 0 4.115474183663537e-09
be O 0 5.220448517917475e-09
involved O 0 1.2045240360691878e-08
in O 0 7.308315730369941e-09
the O 0 7.409531832536231e-08
correct O 0 1.2513233969002613e-06
folding O 0 8.264648386102635e-06
of O 0 7.750176109766471e-07
the O 0 5.347857040760573e-06
prohormone O 0 0.004589153919368982
. O 0 2.502441748220008e-05

In O 0 3.9301625065490953e-07
the O 0 2.3400515658522636e-07
second O 0 4.302194724914443e-07
family O 0 6.692102516581144e-08
, O 0 1.3792167408155365e-08
a O 0 1.3757434302874572e-08
G279A O 0 3.73672463638286e-07
substitution O 0 1.227185748575721e-07
at O 0 8.458577838155179e-08
position O 0 9.9542148745968e-08
- O 0 1.1477617078980984e-07
1 O 0 5.5233162044032724e-08
of O 0 6.27991081358914e-09
the O 0 6.547434594494916e-09
signal O 0 3.801238435130472e-08
peptide O 0 4.813912113377228e-08
was O 0 1.896508194931812e-08
observed O 0 5.87061643742004e-09
in O 0 2.8178541722212458e-09
all O 0 1.0619835677516676e-08
affected O 0 1.2381264014038607e-07
individuals O 0 1.1446245196111704e-07
. O 0 3.171581965943915e-06

This O 0 1.0208174217041233e-06
missense O 0 1.794572381186299e-05
mutation O 0 1.875902853498701e-06
, O 0 1.0790287774398166e-07
which O 0 6.445019096190663e-08
replaces O 0 2.709109594434267e-06
Ala O 0 9.746083378558978e-06
with O 0 9.943797607547822e-08
Thr O 0 6.103317718952894e-05
, O 0 2.923842323809822e-08
is O 0 3.794861314077025e-09
frequent O 0 1.698281870687879e-08
among O 0 1.7649375649853027e-07
FNDI B-Disease 1 1.0
patients O 0 1.1135754220958916e-06
and O 0 2.2058365800603497e-08
is O 0 5.338481212646684e-09
thought O 0 7.676423940949917e-09
to O 0 2.1510910830357943e-09
reduce O 0 9.57258006195616e-09
the O 0 2.933080800460175e-08
efficiency O 0 1.8334043261347688e-07
of O 0 7.543604141346805e-08
cleavage O 0 7.142589311115444e-07
by O 0 1.324140725955658e-07
signal O 0 6.427025255106855e-06
peptidases O 0 2.896207479352597e-05
. O 0 1.426966719009215e-06
. O 0 6.497360118373763e-06

Genetic O 0 2.5321780412923545e-05
heterogeneity O 0 8.801281364867464e-05
of O 0 1.0996778655680828e-05
Saethre B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 8.146024299549026e-08
due O 0 8.675798568447135e-08
to O 0 3.210838883660472e-08
TWIST O 0 3.618797563831322e-05
and O 0 6.594008254978689e-07
FGFR O 1 0.9815782308578491
mutations O 0 9.706801392894704e-06
. O 0 4.990527486370411e-06

Thirty O 0 0.0001184354186989367
- O 0 9.553478776069824e-06
two O 0 3.4469593401809107e-07
unrelated O 0 1.1853936712213908e-06
patients O 0 2.6472010361544562e-08
with O 0 5.800517843823627e-09
features O 0 1.0533738503681889e-07
of O 0 2.9252043987071374e-07
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.4039391749729475e-08
a O 0 1.1771824404149811e-08
common O 0 9.989516058794834e-08
autosomal B-Disease 0 0.0001089933211915195
dominant I-Disease 1 0.9780406951904297
condition I-Disease 0 0.0014840380754321814
of O 0 6.0701381698891055e-06
craniosynostosis B-Disease 1 0.9999996423721313
and O 0 2.564993701525964e-05
limb B-Disease 1 0.9999997615814209
anomalies I-Disease 1 0.9999786615371704
, O 0 2.1880703116039513e-07
were O 0 1.4912809831457707e-07
screened O 0 5.779162748353883e-08
for O 0 7.474753260794387e-09
mutations O 0 5.613999221054655e-08
in O 0 6.53993623700444e-08
TWIST O 0 1.6444877473986708e-05
, O 0 5.985715461065411e-07
FGFR2 O 1 0.9807283282279968
, O 0 9.287091984333529e-07
and O 0 3.152851832055603e-06
FGFR3 O 1 0.9986757636070251
. O 0 3.402290531084873e-05

Nine O 0 8.302805326820817e-06
novel O 0 1.061692842085904e-06
and O 0 1.2972620311302308e-07
three O 0 1.2417295636169e-07
recurrent O 0 2.230912059530965e-06
TWIST O 0 4.827331395063084e-06
mutations O 0 5.58849137632933e-07
were O 0 1.3144490651484375e-07
found O 0 4.4166512225274346e-08
in O 0 6.664436114078853e-08
12 O 0 7.397055128421925e-07
families O 0 6.078099090700562e-07
. O 0 3.942899638786912e-06

Seven O 0 2.1859898424736457e-06
families O 0 1.813782120052565e-07
were O 0 7.387503586642197e-08
found O 0 1.0464805910714858e-08
to O 0 5.138415026806342e-09
have O 0 1.0659855220751524e-08
the O 0 1.0698294516942042e-07
FGFR3 O 0 0.28639134764671326
P250R O 0 2.591545126051642e-06
mutation O 0 3.6758564192496124e-08
, O 0 6.607212110765204e-09
and O 0 2.9493367748045785e-09
one O 0 6.719855338843672e-09
individual O 0 6.714909961402782e-09
was O 0 4.698542710457332e-08
found O 0 3.6641507605850165e-09
to O 0 4.5912393886737846e-09
have O 0 1.5370464012676166e-08
an O 0 2.278083854889701e-07
FGFR2 O 0 0.09847082942724228
VV269 O 0 9.497066639596596e-05
- O 0 2.3530055841547437e-05
270 O 0 6.311786364676664e-06
deletion O 0 6.867245701869251e-06
. O 0 1.0635611033649184e-05

To O 0 3.5474587889439135e-07
date O 0 8.698712576915568e-07
, O 0 6.388938089685325e-08
our O 0 1.4786819768630721e-08
detection O 0 7.418029923655922e-08
rate O 0 3.332871401084958e-08
for O 0 1.2556809814157077e-08
TWIST O 0 3.8846442294016015e-06
or O 0 2.1292680685291998e-07
FGFR O 0 0.000439798051957041
mutations O 0 1.5232892280891974e-07
is O 0 1.3988376679208159e-08
68 O 0 6.9466445040689e-08
% O 0 4.492863414640169e-09
in O 0 7.993736339528823e-09
our O 0 1.876169903880509e-07
Saethre B-Disease 1 0.9987565279006958
- I-Disease 1 0.9915430545806885
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
patients O 0 1.6282861281524674e-07
, O 0 9.377639997865117e-09
including O 0 2.0722076499168907e-08
our O 0 8.330680145718361e-08
five O 0 6.272587427247345e-08
patients O 0 2.117096364884219e-08
elsewhere O 0 4.5538968151959125e-08
reported O 0 3.263586378920991e-08
with O 0 1.946317240708595e-08
TWIST O 0 9.181117093248758e-06
mutations O 0 3.620584266172955e-06
. O 0 7.235739758471027e-06

More O 0 3.6431805483516655e-07
than O 0 8.075681279251512e-08
35 O 0 1.5486236293327238e-07
different O 0 1.1088851614715622e-08
TWIST O 0 5.447337798614171e-07
mutations O 0 6.965696996985571e-08
are O 0 8.642234483602351e-09
now O 0 9.38447541898313e-09
known O 0 2.00345944278979e-08
in O 0 9.886283791615824e-09
the O 0 9.397966493907006e-08
literature O 0 2.2367407837009523e-06
. O 0 3.4384238460916094e-06

The O 0 9.870608437267947e-07
most O 0 1.226191272962751e-07
common O 0 7.652116806866616e-08
phenotypic O 0 1.264789091237617e-07
features O 0 6.194580493001922e-08
, O 0 7.12696479610031e-09
present O 0 4.1688497098846256e-09
in O 0 1.3930404607620517e-09
more O 0 7.948182667583126e-10
than O 0 4.822702237561316e-10
a O 0 2.2690340717446134e-09
third O 0 2.210591887319424e-08
of O 0 1.8171732563132537e-08
our O 0 5.978235861903158e-08
patients O 0 2.1278404815916474e-08
with O 0 1.8503754972698516e-08
TWIST O 0 1.1177196029166225e-05
mutations O 0 4.6094052663647744e-07
, O 0 5.3101711472436364e-08
are O 0 4.289936583745657e-08
coronal B-Disease 1 0.6131493449211121
synostosis I-Disease 1 0.9108362793922424
, O 0 6.491282533716003e-07
brachycephaly B-Disease 1 0.6055627465248108
, O 0 1.946382553796866e-06
low B-Disease 0 0.00618342449888587
frontal I-Disease 1 0.9999998807907104
hairline I-Disease 1 0.9999998807907104
, O 0 4.422292477102019e-06
facial B-Disease 1 0.9999992847442627
asymmetry I-Disease 1 0.9999997615814209
, O 0 9.109713573707268e-06
ptosis B-Disease 1 0.9987514019012451
, O 0 1.1473298400233034e-06
hypertelorism B-Disease 1 0.9966078996658325
, O 0 1.1103518318122951e-06
broad B-Disease 0 0.00023996285744942725
great I-Disease 1 0.9987730383872986
toes I-Disease 1 0.9850580096244812
, O 0 1.5235665387081099e-06
and O 0 3.6687790725409286e-06
clinodactyly B-Disease 1 0.9485943913459778
. O 0 2.544744529586751e-05

Significant O 0 2.331059477000963e-05
intra O 0 0.00017441574891563505
- O 0 9.775051694305148e-06
and O 0 1.828068718623399e-07
interfamilial O 0 9.062220669875387e-06
phenotypic O 0 4.2306669456593227e-07
variability O 0 6.587307552763377e-07
is O 0 5.9889395664924905e-09
present O 0 3.597099063057385e-09
for O 0 6.167097499343299e-09
either O 0 1.0069016553870824e-07
TWIST O 0 1.1721473129000515e-05
mutations O 0 2.799444018819486e-06
or O 0 1.7833200445238617e-06
FGFR O 0 0.16211147606372833
mutations O 0 1.2029810932290275e-05
. O 0 9.611663699615747e-06

The O 0 2.8866440970887197e-06
overlap O 0 1.8918855175797944e-06
in O 0 7.053306916304791e-08
clinical O 0 1.4013670579515747e-07
features O 0 3.9342346269677364e-08
and O 0 6.168062505196303e-09
the O 0 1.94449558676979e-08
presence O 0 3.9535066775897576e-08
, O 0 7.007403990400007e-09
in O 0 1.9311183763193185e-09
the O 0 4.544818299478948e-09
same O 0 2.247754871120833e-09
genes O 0 6.111092076821478e-09
, O 0 3.87751031283301e-09
of O 0 5.325809571132822e-09
mutations O 0 6.853150935626218e-09
for O 0 6.602185909088121e-09
more O 0 4.024082844722443e-09
than O 0 6.529152773993019e-09
one O 0 4.960634214512538e-08
craniosynostotic B-Disease 0 2.9035188617854146e-06
condition I-Disease 0 2.5298805894635734e-07
- O 0 3.9439723309442343e-07
such O 0 5.301629713017064e-08
as O 0 4.1056219401980343e-07
Saethre B-Disease 0 2.197437424911186e-05
- I-Disease 0 3.260325229348382e-06
Chotzen I-Disease 0 2.1166852093301713e-05
, I-Disease 0 1.4344038845592877e-07
Crouzon I-Disease 0 1.5371440895251e-05
, I-Disease 0 1.7476658342729934e-07
and I-Disease 0 3.317495043120289e-07
Pfeiffer I-Disease 0 0.0005514940130524337
syndromes I-Disease 1 0.9992826581001282
- O 0 0.023749861866235733
support O 0 4.0901616671362717e-07
the O 0 6.78140423815421e-08
hypothesis O 0 1.0067999056673216e-07
that O 0 4.9001465107778586e-09
TWIST O 0 8.492662573189591e-07
and O 0 3.53826798971113e-08
FGFRs O 0 1.268813662136381e-06
are O 0 4.0370364828845595e-09
components O 0 1.2913250202473137e-07
of O 0 1.4187455654735004e-08
the O 0 1.2330179544051134e-08
same O 0 1.0620341939215905e-08
molecular O 0 1.0264458438768997e-07
pathway O 0 6.310676070597765e-08
involved O 0 9.547033386070325e-09
in O 0 3.044293928056163e-09
the O 0 1.0754799717460628e-08
modulation O 0 5.63647631679487e-07
of O 0 5.646300564876583e-07
craniofacial O 1 1.0
and O 1 0.9293413758277893
limb O 1 1.0
development O 0 0.00015550476382486522
in O 0 1.237061866277145e-07
humans O 0 5.344393798623059e-07
. O 0 3.606055543059483e-07
. O 0 4.202969648758881e-06

Mutation O 0 1.804100406843645e-06
analysis O 0 6.496410378531436e-07
of O 0 1.4540306665367098e-06
UBE3A O 1 1.0
in O 0 0.012232105247676373
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9822180867195129
. O 0 2.3122909624362364e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9236491322517395
AS B-Disease 1 1.0
) O 0 8.077206814505189e-08
is O 0 9.327139949277807e-09
caused O 0 5.144634940279502e-08
by O 0 2.3821957739755817e-08
chromosome O 0 2.2484180135506904e-06
15q11 O 0 5.94446828472428e-05
- O 0 3.4778204280883074e-06
q13 O 0 4.369979706098093e-06
deletions O 0 3.9280530472751707e-07
of O 0 5.664865554422249e-08
maternal O 0 2.842189701368625e-07
origin O 0 1.3202394200106937e-07
, O 0 2.8484734571065928e-08
by O 0 6.81576750594104e-08
paternal O 1 0.9988957643508911
uniparental B-Disease 1 0.9999998807907104
disomy I-Disease 1 0.9999995231628418
( O 0 2.9123129934305325e-05
UPD B-Disease 1 1.0
) O 0 6.807478314385662e-08
15 O 0 6.900872762116705e-08
, O 0 2.701193047016659e-09
by O 0 4.1401406747354486e-09
imprinting O 0 6.985067102505127e-06
defects O 1 0.6954123973846436
, O 0 1.83955819466064e-08
and O 0 6.246843042845285e-09
by O 0 5.694686500135049e-09
mutations O 0 8.024935027606261e-08
in O 0 4.684493504214515e-08
the O 0 7.738825047454156e-07
UBE3A O 0 0.13525819778442383
gene O 0 6.150247827463318e-06
. O 0 7.509003353334265e-06

UBE3A O 0 0.015711059793829918
encodes O 0 4.533436367637478e-05
a O 0 4.7558687583659776e-06
ubiquitin O 0 2.3160782802733593e-05
- O 0 5.536126991501078e-06
protein O 0 1.3515250429918524e-06
ligase O 0 9.935843081620988e-06
and O 0 3.370098227151175e-07
shows O 0 4.4596836801247264e-07
brain O 0 3.538228384059039e-06
- O 0 8.798983230917656e-07
specific O 0 3.9104449456317525e-07
imprinting O 0 1.0559378097241279e-05
. O 0 2.75686284112453e-06

Here O 0 1.1642207027762197e-05
we O 0 1.2939151474711252e-06
describe O 0 5.091713319416158e-06
UBE3A O 0 0.0006132255075499415
coding O 0 3.495638520689681e-05
- O 0 3.1292318453779444e-05
region O 0 8.891664151633449e-07
mutations O 0 3.047613290618756e-07
detected O 0 1.0604193789731653e-07
by O 0 1.6791430468288127e-08
SSCP O 0 9.238244820153341e-05
analysis O 0 7.082520170342832e-08
in O 0 2.4226931572002286e-08
13 O 0 2.8011825747853436e-07
AS B-Disease 1 0.9998264908790588
individuals O 0 2.547002608821458e-08
or O 0 1.40289017735995e-07
families O 0 3.228190053050639e-07
. O 0 2.2620729396294337e-06

Two O 0 1.712944867904298e-05
identical O 0 2.8383366952766664e-05
de O 0 3.610531348385848e-05
novo O 0 3.0694649467477575e-05
5 O 0 8.163776328729e-06
- O 0 4.102696493646363e-06
bp O 0 2.3107197648641886e-06
duplications O 0 4.606404218066018e-06
in O 0 2.1422813745175517e-07
exon O 0 1.5739849459350808e-06
16 O 0 1.1278683587079286e-06
were O 0 2.930392213329469e-07
found O 0 5.860527494405687e-07
. O 0 1.9366359538253164e-06

Among O 0 2.0140703327342635e-06
the O 0 2.1529069726966554e-07
other O 0 1.5403664122004557e-07
11 O 0 1.9656447136640054e-07
unique O 0 5.152874393843376e-08
mutations O 0 6.690596165981333e-08
, O 0 2.3782551039630562e-08
8 O 0 7.909007138096058e-08
were O 0 2.9136545620644938e-08
small O 0 2.6738625535926985e-08
deletions O 0 2.718657867717411e-07
or O 0 6.551984199631988e-08
insertions O 0 9.931342219715589e-07
predicted O 0 2.7329681984156196e-07
to O 0 2.883292715694097e-08
cause O 0 1.1906382724191644e-06
frameshifts O 0 1.8433940567774698e-05
, O 0 4.5962362804630175e-08
1 O 0 9.843631687544985e-08
was O 0 1.6863646479237104e-08
a O 0 3.3245526331882047e-09
mutation O 0 2.725906611544815e-09
to O 0 3.82961795608594e-09
a O 0 1.9028126629905273e-08
stop O 0 5.753119580731436e-08
codon O 0 2.6729708224593196e-07
, O 0 4.2268275990409165e-08
1 O 0 1.4102154466399952e-07
was O 0 4.9219366360375716e-08
a O 0 1.1262465626771245e-08
missense O 0 1.675127663247622e-07
mutation O 0 1.8179706628984604e-08
, O 0 1.2144876215813838e-08
and O 0 1.2028732676583331e-08
1 O 0 1.7880888947274798e-07
was O 0 4.2202700001325866e-08
predicted O 0 2.130951592960173e-08
to O 0 3.2770954838667876e-09
cause O 0 4.679100129578728e-08
insertion O 0 5.059776952975881e-08
of O 0 7.903005894149828e-08
an O 0 7.817684632982491e-08
isoleucine O 0 1.160747433459619e-05
in O 0 4.949142251575722e-08
the O 0 1.6250004364337656e-07
hect O 0 6.128514542069752e-06
domain O 0 2.597438992779644e-07
of O 0 2.010618658232488e-07
the O 0 9.738370181366918e-07
UBE3A O 0 0.00013464438961818814
protein O 0 5.775294766863226e-07
, O 0 4.724387636656502e-08
which O 0 9.372543630092878e-09
functions O 0 5.7746010639903034e-08
in O 0 5.089228949373137e-08
E2 O 0 4.71139355795458e-06
binding O 0 3.778685027100437e-07
and O 0 1.5055681501507934e-07
ubiquitin O 0 4.079334303241922e-06
transfer O 0 7.300381639652187e-06
. O 0 8.955669727583881e-06

Eight O 0 3.897387159668142e-06
of O 0 1.308090133989026e-07
the O 0 2.2074695849028103e-08
cases O 0 2.308145852225607e-08
were O 0 5.369077626937724e-08
familial O 0 2.53939731464925e-07
, O 0 2.2507677499561396e-08
and O 0 1.504938751395457e-08
five O 0 5.182196716191356e-08
were O 0 1.55210869934308e-07
sporadic O 0 3.04119021166116e-06
. O 0 2.720143584156176e-06

In O 0 1.3909100289311027e-06
two O 0 4.606606012202974e-07
familial O 0 1.8237900576423272e-06
cases O 0 1.1767698282483252e-07
and O 0 2.2933660304147452e-08
one O 0 1.3135775134287542e-08
sporadic O 0 1.7679631980627164e-07
case O 0 1.2877855226633983e-07
, O 0 4.9583640304717846e-08
mosaicism O 0 5.168699499336071e-05
for O 0 1.819053352392075e-07
UBE3A O 0 0.00282344501465559
mutations O 0 2.744334892668121e-07
was O 0 3.5546577237255406e-08
detected O 0 1.1933531496310934e-08
in O 0 1.3500266460297894e-09
the O 0 8.657346839413549e-09
mother O 0 1.725417320130873e-08
of O 0 2.059056214420707e-08
three O 0 3.984575158710868e-08
AS B-Disease 1 1.0
sons O 0 1.3834865058015566e-05
, O 0 1.2300534812936803e-08
in O 0 3.884868871040226e-09
the O 0 4.7188940754949726e-08
maternal O 0 1.9576748400140787e-06
grandfather O 0 2.953433522634441e-06
of O 0 1.681861903080062e-07
two O 0 8.504813564513825e-08
AS B-Disease 1 1.0
first O 0 1.548061163703096e-07
cousins O 0 5.16730324306991e-07
, O 0 1.9634466497109315e-08
and O 0 1.1807826716392356e-08
in O 0 8.248145277889307e-09
the O 0 9.24534973023583e-08
mother O 0 1.0016302809390254e-07
of O 0 9.599168038221251e-08
an O 0 1.8131869694570923e-07
AS B-Disease 1 1.0
daughter O 0 0.00018713802273850888
. O 0 3.080796159338206e-05

The O 0 8.5047224729351e-07
frequencies O 0 4.765239225434925e-07
with O 0 9.450162430368891e-09
which O 0 4.468481140662561e-09
we O 0 6.481605030472792e-09
detected O 0 3.226610445494771e-08
mutations O 0 3.306064755292937e-08
were O 0 4.033128320202195e-08
5 O 0 7.941295621094469e-08
( O 0 1.4278480620077971e-08
14 O 0 2.95068307565316e-08
% O 0 1.8261644418871015e-09
) O 0 4.4143391719764224e-10
of O 0 1.6109760192506428e-09
35 O 0 6.868356550171484e-09
in O 0 1.697578189130411e-09
sporadic O 0 3.284330674091507e-08
cases O 0 1.6161132876391093e-08
and O 0 1.1308530112330573e-08
8 O 0 9.464849171081369e-08
( O 0 7.822111847133328e-09
80 O 0 1.5103102768421195e-08
% O 0 1.3578099755662265e-09
) O 0 5.401221692125091e-10
of O 0 2.564344736555313e-09
10 O 0 1.5739106018486382e-08
in O 0 6.5566072571243694e-09
familial O 0 1.7385926298629784e-07
cases O 0 5.8087685772534314e-08
. O 0 1.5980582190877612e-07
. O 0 1.698776372904831e-06

The O 0 0.00012195646559121087
hemochromatosis B-Disease 1 1.0
845 O 0 0.00018210803682450205
G O 0 5.2597824833355844e-05
- O 0 1.0982536878145766e-05
- O 0 2.5756310151336947e-06
> O 0 5.220958883001003e-07
A O 0 3.4408932947371795e-07
and O 0 4.0918305188597515e-08
187 O 0 5.980506045943912e-08
C O 0 6.779139880563889e-07
- O 0 1.9466928335987177e-07
- O 0 1.9377485216409696e-07
> O 0 1.5375954376395384e-07
G O 0 4.4749143057742913e-07
mutations O 0 5.9119702910948035e-08
: O 0 3.769527978647602e-08
prevalence O 0 1.1836038993351394e-07
in O 0 2.2146220857166554e-08
non O 0 5.769464337390673e-07
- O 0 1.7796264728531241e-06
Caucasian O 0 1.8035636912827613e-06
populations O 0 1.0191268984272028e-06
. O 0 1.4583216625396744e-06

Hemochromatosis B-Disease 1 0.9999998807907104
, O 0 5.500394308910472e-06
the O 0 4.7326575440820307e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 0.999930739402771
, O 0 3.472837875051482e-07
leads O 0 1.0510972060728818e-05
, O 0 5.286442572582928e-08
if O 0 8.219095803951859e-08
untreated O 1 0.9999992847442627
, O 0 2.8473110091908893e-08
to O 0 4.020279575911445e-08
progressive O 1 0.9999759197235107
iron B-Disease 1 0.9999696016311646
overload I-Disease 1 0.999992847442627
and O 0 7.682800969632808e-06
premature B-Disease 0 0.00035907691926695406
death I-Disease 0 0.00012907615746371448
. O 0 2.0157143808319233e-05

The O 0 6.524215132230893e-05
hemochromatosis B-Disease 1 1.0
gene O 0 0.00020556806703098118
, O 0 5.725741175410803e-06
HFE O 1 0.9999996423721313
, O 0 4.216520892441622e-07
recently O 0 8.060109024654594e-08
has O 0 6.261085871983596e-09
been O 0 7.066526919174976e-09
identified O 0 2.8181457167875124e-08
, O 0 7.627778408902941e-09
and O 0 5.94735594106055e-09
characterization O 0 1.7181113776132406e-07
of O 0 5.4253980863450124e-08
this O 0 7.974867877180714e-09
gene O 0 7.999764761734696e-08
has O 0 6.733121615809523e-09
shown O 0 2.6304092237694476e-09
that O 0 5.758965526680981e-10
it O 0 8.173377530340531e-10
contains O 0 4.239776529857409e-09
two O 0 2.1947101913610823e-09
mutations O 0 7.835446069748286e-09
that O 0 1.794221216044889e-09
result O 0 1.7695480636348293e-08
in O 0 2.0752056073547465e-08
amino O 0 5.1085145003071375e-08
acid O 0 4.398777875280757e-08
substitutions O 0 2.513690446903638e-07
- O 0 6.300212476162415e-07
cDNA O 0 1.7196339285874274e-06
nucleotides O 0 2.670481649147405e-07
845 O 0 9.039596875481948e-07
G O 0 1.0861936061701272e-06
- O 0 8.122904660012864e-07
- O 0 8.919190008782607e-07
> O 0 5.911023208682309e-07
A O 0 8.255481702690304e-07
( O 0 1.3311691304807027e-07
C282Y O 0 1.2528433899205993e-06
) O 0 1.66120184275087e-08
and O 0 1.1026949131576202e-08
187 O 0 6.363264759556841e-08
C O 0 4.154275359269377e-07
- O 0 2.3232276191720302e-07
- O 0 5.624759182865091e-07
> O 0 5.579731237048691e-07
G O 0 7.858579920139164e-06
( O 0 6.730799668730469e-07
H63D O 0 0.0002359888458158821
) O 0 3.191946973402082e-07
. O 0 9.227588861904223e-07

Although O 0 4.1412455175304785e-05
hemochromatosis B-Disease 1 1.0
is O 0 7.653122793271905e-07
common O 0 5.434801551018609e-07
in O 0 9.817381396715064e-08
Caucasians O 0 2.887536311391159e-06
, O 0 8.984757471353078e-08
affecting O 0 1.8631465081853094e-07
> O 0 2.4369867901441467e-07
= O 0 3.689188190492132e-07
1 O 0 1.3164036261059664e-07
/ O 0 3.582913166155777e-08
300 O 0 2.0957215962624787e-09
individuals O 0 2.9888061470195737e-10
of O 0 1.3126502107496663e-09
northern O 0 6.003864516657131e-09
European O 0 6.294456955657779e-09
origin O 0 1.3576475055288029e-08
, O 0 2.0723331939365153e-09
it O 0 8.982145582869805e-10
has O 0 6.908583705111937e-10
not O 0 6.257262485931392e-10
been O 0 7.576694827093888e-09
recognized O 0 1.3672026177857788e-08
in O 0 1.6599477348222536e-08
other O 0 1.2752134637139534e-07
populations O 0 1.0625770983097027e-06
. O 0 3.2723587537475396e-06

The O 0 1.7516800880912342e-06
present O 0 3.360832465659769e-07
study O 0 3.867526032763635e-08
used O 0 1.4301948958461708e-08
PCR O 0 2.593045849152986e-07
and O 0 2.705443158390608e-08
restriction O 0 1.9904888404198573e-07
- O 0 1.8170835858200007e-07
enzyme O 0 4.0291073588605286e-08
digestion O 0 2.3883604427510363e-08
to O 0 2.4101969309242577e-09
analyze O 0 1.840446017808972e-08
the O 0 7.545398972297335e-09
frequency O 0 2.184454395148805e-08
of O 0 3.9855180489212216e-08
the O 0 1.4644984958067653e-07
845 O 0 7.580223950753862e-07
G O 0 1.244358145413571e-06
- O 0 7.216632980089344e-07
- O 0 6.765035323041957e-07
> O 0 2.0587938820426643e-07
A O 0 2.789873576602986e-07
and O 0 3.676206716818342e-08
187 O 0 1.0684529883064897e-07
C O 0 5.297313805385784e-07
- O 0 3.7239388461784984e-07
- O 0 3.478307064597175e-07
> O 0 3.927083014332311e-07
G O 0 1.228941755471169e-06
mutations O 0 1.0598390076665964e-07
in O 0 7.829414272464419e-08
HLA O 0 1.5990499377949163e-05
- O 0 5.749915317210252e-07
typed O 0 3.923668145944248e-08
samples O 0 7.271941271369542e-09
from O 0 1.1933644294970236e-08
non O 0 1.9169765153037588e-07
- O 0 1.3931506259723392e-07
Caucasian O 0 1.2626703949081275e-07
populations O 0 2.3366188983686698e-08
, O 0 3.900713529958466e-09
comprising O 0 1.0907609926391615e-08
Australian O 0 2.2940485067124428e-08
Aboriginal O 0 4.834698330569154e-08
, O 0 1.2592666465138791e-08
Chinese O 0 1.3011600685786107e-07
, O 0 3.286154282022835e-08
and O 0 1.617981411072833e-07
Pacific O 0 2.21433219849132e-06
Islanders O 0 1.5083565813256428e-05
. O 0 6.484194727818249e-06

Results O 0 7.065289082675008e-06
showed O 0 1.5326925222325372e-06
that O 0 5.818804282853307e-08
the O 0 3.683689726585726e-07
845 O 0 2.862121164071141e-06
G O 0 3.6146432194072986e-06
- O 0 1.2939583484694595e-06
- O 0 3.846186018563458e-07
> O 0 9.124610755861795e-08
A O 0 3.867393516543416e-08
mutation O 0 6.382407491400954e-09
was O 0 1.285873008072258e-08
present O 0 1.5050469759358975e-09
in O 0 2.016973921215026e-09
these O 0 7.943762092565976e-09
populations O 0 4.024598965202131e-08
( O 0 9.498972275423512e-09
allele O 0 2.416960853679484e-08
frequency O 0 1.3288334876904173e-08
0 O 0 1.7621349712726442e-08
. O 0 1.2662531023721613e-09
32 O 0 1.7373819716226535e-08
% O 0 1.1799040633420077e-09
) O 0 3.432334971797957e-10
, O 0 5.378441025882807e-10
and O 0 1.7481776026784246e-09
, O 0 1.8020613890001869e-09
furthermore O 0 1.0331531186125176e-08
, O 0 2.5907054279628028e-09
it O 0 1.2007477234732278e-09
was O 0 2.2610514349707955e-08
always O 0 1.818119699237286e-08
seen O 0 3.034712392491201e-08
in O 0 5.41212452631612e-09
conjunction O 0 3.894849598395922e-08
with O 0 3.203993159672791e-08
HLA O 1 0.9999703168869019
haplotypes O 0 1.7243572074221447e-05
common O 0 1.083640484011994e-07
in O 0 2.6590068813447942e-08
Caucasians O 0 5.844865995641157e-07
, O 0 3.227866329780227e-08
suggesting O 0 9.664643130236072e-08
that O 0 4.4077307137513344e-08
845 O 0 1.068507458512613e-06
G O 0 1.7613976979191648e-06
- O 0 1.326796905232186e-06
- O 0 9.023895017890027e-07
> O 0 2.1438590636080335e-07
A O 0 1.252603993862067e-07
may O 0 1.3311724167408556e-08
have O 0 2.9242646082394685e-09
been O 0 2.6960149668298072e-09
introduced O 0 2.0358041918910885e-09
into O 0 1.2921810288446522e-09
these O 0 1.445521702336805e-09
populations O 0 1.2931483439615477e-08
by O 0 2.6710997858003793e-08
Caucasian O 0 3.979976554546738e-06
admixture O 0 9.62693684414262e-06
. O 0 4.237970188114559e-06

187 O 0 3.144278525724076e-05
C O 0 1.9769426216953434e-05
- O 0 3.260577159380773e-06
- O 0 1.0787896371766692e-06
> O 0 4.817384251509793e-07
G O 0 1.277100182051072e-06
was O 0 6.315396205991419e-08
present O 0 9.463221317673742e-09
at O 0 1.1768951146962081e-08
an O 0 2.182866332134381e-09
allele O 0 1.9301767295587524e-08
frequency O 0 4.6439183165603026e-08
of O 0 1.0343799061729442e-07
2 O 0 2.209944113928941e-06
. O 0 2.0222003058734117e-06

68 O 0 1.3524880159820896e-05
% O 0 9.885665264164345e-08
in O 0 9.885434693046591e-09
the O 0 1.3478918425846587e-08
two O 0 9.00556518246276e-09
populations O 0 1.4777176815528037e-08
analyzed O 0 6.424939158478082e-08
( O 0 1.4022970340477059e-08
Australian O 0 6.520045303659572e-08
Aboriginal O 0 2.6031821676042455e-07
and O 0 3.4667355208739536e-08
Chinese O 0 8.668386044519139e-07
) O 0 2.5075203780033917e-07
. O 0 1.2354212231002748e-06

In O 0 7.273247319972143e-07
the O 0 4.7293460170294566e-07
Australian O 0 4.560050967938878e-07
Aboriginal O 0 1.9218822444599937e-07
samples O 0 5.088375232276121e-08
, O 0 1.9414677865370322e-08
187 O 0 5.440267969447632e-08
C O 0 3.418664107357472e-07
- O 0 1.2998415854781342e-07
- O 0 1.5116077634047542e-07
> O 0 1.0774246561595646e-07
G O 0 4.27726433827047e-07
was O 0 2.9488150588008466e-08
found O 0 1.4407296466956154e-09
to O 0 9.201009953940797e-10
be O 0 1.4550818328018522e-09
associated O 0 3.443912888201339e-08
with O 0 2.035844026693212e-08
HLA O 1 0.9999996423721313
haplotypes O 0 0.00012375468213576823
common O 0 1.0628917834765161e-07
in O 0 1.3968032952504927e-08
Caucasians O 0 5.732586600970535e-07
, O 0 1.499471835586519e-08
suggesting O 0 2.217534422754852e-08
that O 0 3.2983284992127437e-09
it O 0 3.065415477010447e-09
was O 0 3.954140126438688e-08
introduced O 0 3.0831312614054696e-08
by O 0 2.3472905397170507e-08
recent O 0 4.668247015615634e-07
admixture O 0 1.630029328225646e-05
. O 0 9.734712875797413e-06

In O 0 1.4624733921664301e-06
the O 0 8.08894526471704e-07
Chinese O 0 6.961665235394321e-07
samples O 0 1.0882428824743329e-07
analyzed O 0 2.0771645381501003e-07
, O 0 4.236238737576059e-08
187 O 0 7.07913017095052e-08
C O 0 4.116050149605144e-07
- O 0 1.5673163034080062e-07
- O 0 1.3467204951211897e-07
> O 0 1.0594832389188014e-07
G O 0 4.5760037892250693e-07
was O 0 2.640363128136869e-08
present O 0 5.485611520583689e-09
in O 0 3.1945577294578698e-09
association O 0 1.5417914056570226e-08
with O 0 2.5152688820639924e-09
a O 0 1.0241045345082966e-08
wide O 0 6.770405747147379e-08
variety O 0 4.5086611777378494e-08
of O 0 1.5238427408803545e-07
HLA O 1 0.9999979734420776
haplotypes O 0 0.00020192314696032554
, O 0 2.5788942537019466e-08
showing O 0 1.9375981707980827e-08
this O 0 1.3380498931070406e-09
mutation O 0 1.4813913429279069e-09
to O 0 1.7848245104090665e-09
be O 0 3.4911791235714418e-09
widespread O 0 3.694997374736886e-08
and O 0 1.1548673128913833e-08
likely O 0 1.896410317669961e-08
to O 0 8.322990296960597e-09
predate O 0 1.0665243053153972e-06
the O 0 3.637573087189594e-08
more O 0 1.8266391066390497e-08
genetically O 0 2.6342596015638264e-07
restricted O 0 3.9935693507686665e-07
845 O 0 1.5306328577935346e-06
G O 0 2.346783730899915e-06
- O 0 2.4032954115682514e-06
- O 0 2.346403107367223e-06
> O 0 1.2584955584316049e-06
A O 0 1.0133149999091984e-06
mutation O 0 7.244470339173859e-07
. O 0 2.182382104365388e-06

Genotype O 0 0.0001920029171742499
- O 0 7.938557246234268e-05
phenotype O 0 2.1229945559753105e-05
correlations O 0 2.751804822764825e-05
in O 0 2.005887381528737e-06
attenuated B-Disease 1 0.9991612434387207
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
. O 0 0.00012329696619417518

Germ O 1 0.9075854420661926
- O 0 0.00038351459079422057
line O 0 8.099798833427485e-06
mutations O 0 4.4822394329457893e-07
of O 0 1.3942471355221642e-07
the O 0 1.8272041302225261e-07
tumor B-Disease 0 7.197942522907397e-06
suppressor O 0 7.378253940260038e-05
APC O 0 1.0675969406293007e-06
are O 0 1.1459587945239491e-08
implicated O 0 1.8949683067148726e-07
in O 0 6.523279694192752e-08
attenuated B-Disease 1 0.9999669790267944
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9986585378646851
AAPC B-Disease 1 1.0
) O 0 6.506219563107152e-08
, O 0 1.0280030160458864e-08
a O 0 1.2180625397206768e-08
variant O 0 1.8047973071588785e-06
of O 0 7.046387054288061e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.999984622001648
FAP B-Disease 1 0.9999798536300659
) O 0 3.798285206357832e-06
. O 0 4.130830348003656e-06

AAPC B-Disease 1 1.0
is O 0 6.472009204117057e-07
recognized O 0 1.8100098486684146e-07
by O 0 2.391701947601632e-08
the O 0 6.113962314202581e-08
occurrence O 0 2.2699555302096996e-07
of O 0 2.0752696627823752e-07
< O 0 3.955124611820793e-06
100 O 0 8.397658461944957e-07
colonic B-Disease 0 4.10124848713167e-05
adenomas I-Disease 0 1.3462236893246882e-05
and O 0 1.692712991996359e-08
a O 0 6.324241574873213e-09
later O 0 5.4310405062096834e-08
onset O 0 1.0290947102475911e-05
of O 0 0.0013718812260776758
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.1715561498704119e-07
age O 0 7.466832840918869e-08
> O 0 2.1725546162087994e-07
40 O 0 2.3241209134994278e-07
years O 0 9.826673874613334e-08
) O 0 1.483316651729183e-07
. O 0 9.726711596158566e-07

The O 0 1.8209188965556677e-06
aim O 0 1.112738914343936e-06
of O 0 6.687611175948405e-08
this O 0 8.105755178178242e-09
study O 0 1.1436747548998483e-08
was O 0 1.8181994576593752e-08
to O 0 6.644341965511558e-09
assess O 0 3.5055376201853505e-07
genotype O 0 3.5079731333098607e-06
- O 0 1.2103701010346413e-05
phenotype O 0 4.489860202738782e-06
correlations O 0 1.4976180864323396e-05
in O 0 3.266599605922238e-06
AAPC B-Disease 1 1.0
families O 0 1.4907783224771265e-05
. O 0 2.0899817172903568e-05

By O 0 1.7018898006426753e-06
protein O 0 6.624200977967121e-06
- O 0 2.5395113425474847e-06
truncation O 0 2.5581625777704176e-06
test O 0 1.9752266666728246e-07
( O 0 1.6373488165299932e-07
PTT O 0 1.0323798278477625e-06
) O 0 2.988357561406474e-09
assay O 0 4.420393295845315e-08
, O 0 6.025799859088465e-09
the O 0 5.801612967815117e-09
entire O 0 1.0432202657284506e-08
coding O 0 1.0856616938781372e-07
region O 0 7.017786174401408e-08
of O 0 4.286975041623009e-08
the O 0 6.243200800781779e-08
APC B-Disease 0 4.1060997091335594e-07
gene O 0 3.4376125057633544e-08
was O 0 1.8924814071397122e-07
screened O 0 8.026939468663841e-08
in O 0 5.734022145986728e-09
affected O 0 2.038027524520203e-08
individuals O 0 1.5652469542715153e-08
from O 0 4.2699892333075695e-07
11 O 0 1.1516882295836695e-05
AAPC B-Disease 1 1.0
kindreds O 0 3.4183074603788555e-05
, O 0 6.225482707122865e-08
and O 0 2.052347625181028e-08
their O 0 1.6932684587800395e-08
phenotypic O 0 6.209224352460296e-07
differences O 0 1.6660241044519353e-06
were O 0 9.227236432707286e-07
examined O 0 1.1196036211913452e-05
. O 0 7.043767254799604e-06

Five O 0 1.619544309505727e-05
novel O 0 6.217103418748593e-06
germ O 0 0.0006883770693093538
- O 0 7.214886136353016e-05
line O 0 1.377832541038515e-05
APC B-Disease 0 1.9737683487619506e-06
mutations O 0 2.5225398303518887e-07
were O 0 1.0607834610709688e-07
identified O 0 3.147361269384419e-07
in O 0 8.14409801819238e-08
seven O 0 8.690138884048793e-07
kindreds O 0 9.371917258249596e-05
. O 0 8.853124199958984e-06

Mutations O 0 3.1608894914825214e-06
were O 0 4.264849167157081e-07
located O 0 1.2224666079418967e-07
in O 0 5.2589546051251546e-09
three O 0 2.589030767552458e-09
different O 0 2.4126207698316193e-09
regions O 0 1.5541239406502427e-08
of O 0 2.1324314758430774e-08
the O 0 8.508513360538927e-08
APC B-Disease 0 2.9668294132534356e-07
gene O 0 4.447260337769876e-08
( O 0 1.865820387081385e-08
1 O 0 4.065032399580559e-08
) O 0 2.108471397477274e-09
at O 0 8.237077686601424e-09
the O 0 1.5264529196201693e-08
5 O 0 5.630062815953352e-08
end O 0 4.453975321894177e-08
spanning O 0 2.006473636129158e-07
exons O 0 2.391823272773763e-07
4 O 0 6.161456411746258e-08
and O 0 1.8211183672178777e-08
5 O 0 6.068292890404337e-08
, O 0 2.4544091203893004e-08
( O 0 2.8054781608943813e-08
2 O 0 7.03440363736263e-08
) O 0 4.511893525460664e-09
within O 0 1.0699270802660976e-08
exon O 0 8.02804223098974e-08
9 O 0 7.152569736490477e-08
, O 0 9.347051133090645e-09
and O 0 1.2963092821394184e-08
( O 0 2.0090196173327968e-08
3 O 0 5.500575994688006e-08
) O 0 3.213116217537504e-09
at O 0 1.2979620045427964e-08
the O 0 1.6432956329026638e-08
3 O 0 2.026919645459202e-07
distal O 0 4.620967501978157e-07
end O 0 1.6073833819518768e-07
of O 0 1.346305680272053e-07
the O 0 5.200996611165465e-07
gene O 0 3.7544746191997547e-06
. O 0 9.195434358844068e-06

Variability O 0 3.096677755820565e-05
in O 0 9.222436148093038e-08
the O 0 2.9783894461843374e-08
number O 0 5.4799670579086524e-08
of O 0 1.4550404330293532e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 2.6351767701271456e-07
most O 0 5.480717213401931e-09
apparent O 0 1.6011405534754886e-08
in O 0 1.6751117160040963e-09
individuals O 0 1.1261557242292497e-09
with O 0 1.819353667720236e-09
mutations O 0 2.5101945411165616e-08
in O 0 6.657280948729749e-09
region O 0 8.486357216952456e-08
1 O 0 1.313088375809457e-07
, O 0 1.2275667593542039e-08
and O 0 5.532478297709531e-08
upper O 0 0.00012583087664097548
- O 0 0.05932832136750221
gastrointestinal O 1 0.99542635679245
manifestations O 1 0.9937517046928406
were O 0 5.019018090024474e-07
more O 0 2.2469974325645126e-08
severe O 0 2.1477751488419017e-06
in O 0 6.274501629377482e-08
them O 0 3.878918448663171e-07
. O 0 6.122392733232118e-06

In O 0 3.551314193828148e-07
individuals O 0 6.647601935583225e-08
with O 0 2.1265016414417914e-08
mutations O 0 6.348003722678186e-08
in O 0 1.3259573883317444e-08
either O 0 2.8470827473370264e-08
region O 0 7.493598985774952e-08
2 O 0 3.951501170718075e-08
or O 0 4.6044466017747254e-09
region O 0 2.326337522617905e-08
3 O 0 1.5139095310701123e-08
, O 0 1.3901633177937356e-09
the O 0 2.1940365080297397e-09
average O 0 4.537179076891107e-09
number O 0 1.1205768757349688e-08
of O 0 3.14870547413193e-08
adenomas B-Disease 0 1.075209070222627e-06
tended O 0 7.607469143522394e-08
to O 0 5.918906254009926e-09
be O 0 5.868769470396273e-09
lower O 0 2.5992248353645664e-08
than O 0 2.8992672707062184e-09
those O 0 3.3122293796594704e-09
in O 0 2.954883004946396e-09
individuals O 0 1.3849390523290595e-09
with O 0 2.7349422726530292e-09
mutations O 0 2.7463393337257003e-08
in O 0 6.764943272230539e-09
region O 0 6.47345359539031e-08
1 O 0 8.800731166047626e-08
, O 0 5.569616767786556e-09
although O 0 6.2183600491039215e-09
age O 0 8.887402458412907e-08
at O 0 9.085761121241376e-08
diagnosis O 0 2.3456193787296797e-07
was O 0 2.5487767629783775e-07
similar O 0 3.212386161521863e-07
. O 0 3.8459329516626894e-06

In O 0 6.7176420088799205e-06
all O 0 1.72127693076618e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.000533444166649133
, O 0 4.3352261513973644e-07
a O 0 2.608092302125442e-07
predominance O 0 4.5105116441845894e-05
of O 0 5.619217517960351e-06
right O 1 0.9997320771217346
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.07047752290964127
rectal B-Disease 1 0.9999997615814209
polyp I-Disease 0 0.00024024992308113724
sparing O 0 1.7064639905584045e-05
was O 0 5.097281700727763e-06
observed O 0 5.060007424617652e-06
. O 0 5.100164798932383e-06

No O 0 5.8854402595898136e-05
desmoid B-Disease 1 0.9999972581863403
tumors I-Disease 1 1.0
were O 0 9.909156233334215e-07
found O 0 1.771804960526424e-07
in O 0 9.430305425439656e-08
these O 0 7.341009791161923e-07
kindreds O 0 0.00034530815901234746
. O 0 1.5581073967041448e-05

Our O 0 2.1992091205902398e-06
data O 0 7.239656270030537e-07
suggest O 0 1.2597787701906782e-07
that O 0 1.6688682435983537e-08
, O 0 6.264946961209716e-08
in O 0 1.2431608809038153e-07
AAPC B-Disease 1 1.0
families O 0 1.0919021065092238e-07
, O 0 1.0924725124539236e-08
the O 0 9.601416550708564e-09
location O 0 7.446055150239772e-08
of O 0 7.055015771584294e-08
the O 0 1.9482919810798194e-07
APC B-Disease 0 4.053151315019932e-06
mutation O 0 2.119533206723645e-07
may O 0 7.042968519499482e-08
partially O 0 2.015887190509602e-07
predict O 0 1.6265121871583688e-07
specific O 0 2.3137620530633285e-07
phenotypic O 0 2.429153937555384e-06
expression O 0 1.0052961442852393e-05
. O 0 9.925083759299014e-06

This O 0 2.909881686719018e-07
should O 0 1.8102861076840782e-07
help O 0 7.81175231168163e-08
in O 0 1.9672027562478434e-08
the O 0 2.985721181403278e-08
design O 0 1.2394544057769963e-07
of O 0 6.426238030599052e-08
tailored O 0 1.4508641470456496e-06
clinical O 0 2.5651247597124893e-06
- O 0 2.94227538688574e-06
management O 0 6.33230712310251e-08
protocols O 0 3.425929548939166e-07
in O 0 9.139831114168828e-09
this O 0 5.220577747877542e-09
subset O 0 2.4705218493181746e-07
of O 0 3.066563749598572e-07
FAP B-Disease 0 0.015624070540070534
patients O 0 2.95433324026817e-07
. O 0 2.809754846566648e-07
. O 0 2.275641691085184e-06

Wilms B-Disease 1 0.9976521134376526
' I-Disease 0 0.00034660365781746805
tumor I-Disease 0 8.986064494820312e-05
1 O 0 6.079129434510833e-06
and O 0 6.788353061892849e-07
Dax O 1 0.7895833849906921
- O 0 3.4792567475960823e-06
1 O 0 6.3730493593539e-07
modulate O 0 6.11833741004375e-07
the O 0 2.24417121330589e-07
orphan O 0 2.8352314984658733e-06
nuclear O 0 3.423581802053377e-06
receptor O 0 8.847097888065036e-06
SF O 0 0.32939669489860535
- O 0 7.0507362579519395e-06
1 O 0 9.925016684064758e-07
in O 0 2.8271365692944528e-08
sex O 0 3.28130020932349e-08
- O 0 1.2173244101632008e-07
specific O 0 4.992765312294978e-08
gene O 0 3.206818348644447e-07
expression O 0 1.1153854302392574e-06
. O 0 1.8921615492217825e-06

Products O 0 2.359553582209628e-05
of O 0 5.309002972353483e-06
steroidogenic O 0 0.00023388460977002978
factor O 0 1.1524714864208363e-05
1 O 0 4.528191311692353e-06
( O 0 4.1259383465330757e-07
SF O 0 0.001049598096869886
- O 0 2.8990202736167703e-06
1 O 0 6.666559215773304e-07
) O 0 2.117160846637489e-08
and O 0 5.709894423944206e-08
Wilms B-Disease 0 3.3760719816200435e-05
tumor I-Disease 0 3.433364554439322e-06
1 O 0 1.3818902289131074e-06
( O 0 1.664329687400823e-07
WT1 O 0 1.0451227353769355e-05
) O 0 9.082725682674209e-09
genes O 0 7.262432433208232e-09
are O 0 2.1263624194745034e-09
essential O 0 2.2124098109088663e-08
for O 0 1.7248185102403113e-08
mammalian O 0 2.0741154003189877e-06
gonadogenesis O 0 3.884480975102633e-06
prior O 0 1.27961612861327e-07
to O 0 5.193160035332767e-08
sexual O 0 2.7336093921803695e-07
differentiation O 0 8.029349373828154e-06
. O 0 5.5167793107102625e-06

In O 0 1.3300781347425072e-06
males O 0 7.865273801144212e-07
, O 0 3.83244099566582e-07
SF O 1 0.9392910003662109
- O 0 1.1639098374871537e-05
1 O 0 1.1039154514946858e-06
participates O 0 1.0213057777264112e-07
in O 0 4.156162525248419e-09
sexual O 0 7.292150439042189e-09
development O 0 7.997396522796407e-09
by O 0 5.873383113197406e-09
regulating O 0 7.24838926657867e-08
expression O 0 3.7830975685437807e-08
of O 0 4.025428168574763e-08
the O 0 2.2723251902334596e-07
polypeptide O 0 1.542164318379946e-05
hormone O 0 5.516389592230553e-06
Mullerian O 0 6.808032776461914e-05
inhibiting O 0 8.353181328857318e-06
substance O 0 4.969942438037833e-06
( O 0 3.702430376506527e-06
MIS O 0 0.0009780797408893704
) O 0 1.398415520270646e-06
. O 0 3.1537329050479457e-06

Here O 0 8.838310350256506e-06
, O 0 5.188729801375302e-07
we O 0 2.648464203502954e-07
show O 0 5.275383614389284e-07
that O 0 2.4659905761836853e-07
WT1 O 0 0.00040224779513664544
- O 0 4.855230508837849e-05
KTS O 0 0.0002037375670624897
isoforms O 0 5.2672121455543675e-06
associate O 0 2.8982074127270607e-06
and O 0 1.3562504364017514e-07
synergize O 0 4.704372258856893e-06
with O 0 3.58320392024325e-07
SF O 1 0.9999452829360962
- O 0 3.457827915553935e-05
1 O 0 1.5124296623980626e-06
to O 0 2.0100952724533272e-07
promote O 0 4.029187039122917e-06
MIS O 0 0.0007043858058750629
expression O 0 2.562323061283678e-06
. O 0 3.761753532671719e-06

In O 0 1.8136070139007643e-06
contrast O 0 4.217520654492546e-06
, O 0 1.1224335594306467e-06
WT1 O 0 0.0005606996128335595
missense O 0 1.1225363778066821e-05
mutations O 0 9.326269037046586e-07
, O 0 5.059844454535778e-08
associated O 0 1.22595281482063e-07
with O 0 5.436046279783113e-08
male B-Disease 0 2.641957144078333e-05
pseudohermaphroditism I-Disease 1 1.0
in O 0 1.6390157497880864e-06
Denys B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 5.514609711099183e-07
fail O 0 4.780793005920714e-07
to O 0 1.8751860864085756e-07
synergize O 0 1.2003864867438097e-05
with O 0 9.009913242152834e-07
SF O 1 0.9999988079071045
- O 0 0.00985800288617611
1 O 0 4.468460974749178e-05
. O 0 7.209161140053766e-06

Additionally O 0 1.8419530533719808e-05
, O 0 9.681225492386147e-07
the O 0 6.141440849205537e-07
X O 0 1.636153319850564e-05
- O 0 6.030434633430559e-06
linked O 0 3.617502216002322e-06
, O 0 6.005356567584386e-08
candidate O 0 1.1097065311105325e-07
dosage O 0 4.020042467800522e-07
- O 0 6.447109512919269e-07
sensitive O 0 4.3922136683249846e-07
sex O 0 6.300032140416079e-08
- O 0 2.378130972147119e-07
reversal O 0 3.1227250474330503e-07
gene O 0 1.2636461121928733e-07
, O 0 1.7959071385575953e-07
Dax O 0 0.0006899888394400477
- O 0 7.633179848198779e-07
1 O 0 3.4902294032690406e-07
, O 0 3.465796538648647e-08
antagonizes O 0 7.186852712948166e-07
synergy O 0 6.404641226254171e-07
between O 0 7.447587790920807e-07
SF O 0 0.11020906269550323
- O 0 4.847116997552803e-06
1 O 0 6.533696250698995e-07
and O 0 8.156316511076511e-08
WT1 O 0 1.6259449694189243e-05
, O 0 2.157691447735033e-08
most O 0 8.354529512644149e-09
likely O 0 1.8971519466504105e-08
through O 0 3.6689691285118897e-09
a O 0 9.631974329238346e-09
direct O 0 6.593153045741929e-08
interaction O 0 1.6261569157904887e-07
with O 0 3.1473760486733227e-07
SF O 1 0.9999850988388062
- O 0 0.00036130816442891955
1 O 0 2.4380458853556775e-05
. O 0 2.720057864280534e-06

We O 0 2.4297632990055718e-06
propose O 0 2.3013908503344283e-06
that O 0 5.686993631570658e-07
WT1 O 0 0.0002496596716810018
and O 0 2.576289261924103e-06
Dax O 1 0.9994518160820007
- O 0 4.47684442406171e-06
1 O 0 5.799596465294599e-07
functionally O 0 2.1384990134265536e-07
oppose O 0 3.238244516978739e-08
each O 0 8.002584372945876e-09
other O 0 1.492828438642846e-08
in O 0 2.565647427843487e-08
testis O 0 2.175238250856637e-06
development O 0 1.3537562892906863e-07
by O 0 9.521959754010823e-08
modulating O 0 8.602785783295985e-06
SF O 1 0.9933816194534302
- O 0 4.031095886602998e-05
1 O 0 8.727364729566034e-06
- O 0 4.657419594877865e-06
mediated O 0 8.836962479108479e-06
transactivation O 0 2.6921914468402974e-05
. O 0 1.3216367733548395e-06
. O 0 4.068906491738744e-06

A O 0 1.6048381439759396e-05
mouse O 0 2.908751639552065e-06
model O 0 2.3199520455818856e-06
for O 0 2.154362164219492e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999998807907104
- O 1 0.9999997615814209
centre O 1 0.5810171365737915
mutations O 0 7.730873221589718e-06
. O 0 5.835292085976107e-06

Imprinting O 0 0.00012961107131559402
in O 0 2.688355607460835e-06
the O 0 2.515914047762635e-06
15q11 O 0 0.000125556907732971
- O 0 1.5199531844700687e-05
q13 O 0 2.8929804102517664e-05
region O 0 4.1707889408826304e-07
involves O 0 6.838712351964205e-08
an O 0 3.9423021291895566e-08
imprinting O 0 2.9256441393954447e-06
centre O 0 4.365614131529583e-06
( O 0 1.0254067461801242e-07
IC O 0 0.013318246230483055
) O 0 3.297594020068573e-08
, O 0 7.982674965489878e-09
mapping O 0 1.8452404049185134e-08
in O 0 4.993048641210862e-09
part O 0 5.636742628212232e-09
to O 0 7.038238880596737e-09
the O 0 8.704008536142283e-08
promoter O 0 1.8901109797297977e-06
and O 0 8.521408290107502e-08
first O 0 5.737120432058873e-07
exon O 0 5.6655089792911895e-06
of O 0 3.3932906262634788e-06
SNRPN O 1 0.9999008178710938
. O 0 3.0019327823538333e-05

Deletion O 0 6.756274160579778e-06
of O 0 8.507131497026421e-07
this O 0 2.141887165407752e-07
IC O 0 0.0009242667001672089
abolishes O 0 2.0304158169892617e-05
local O 0 7.035000066935027e-07
paternally O 0 2.5749973247002345e-06
derived O 0 1.0202953149018867e-07
gene O 0 3.033161632970405e-08
expression O 0 3.087957267666752e-08
and O 0 1.0709765518868153e-08
results O 0 6.887985648518224e-08
in O 0 2.8279356456550886e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 2.4501967345713638e-05
. O 0 7.056777576508466e-06

We O 0 9.821686717259581e-07
have O 0 1.2572618857120688e-07
created O 0 1.4081444987823488e-07
two O 0 4.1149505136672815e-08
deletion O 0 1.0870479627556051e-07
mutations O 0 1.628522170449287e-07
in O 0 4.1219259117042384e-08
mice O 0 6.588778234117854e-08
to O 0 2.240731689084896e-08
understand O 0 4.297333362046629e-06
PWS B-Disease 1 1.0
and O 0 1.2429592288754066e-07
the O 0 6.504060223733177e-08
mechanism O 0 1.7820130437939952e-07
of O 0 5.740799124964724e-08
this O 0 8.459320355314048e-08
IC O 0 0.2696220576763153
. O 0 1.5461782822967507e-05

Mice O 0 4.7979996452340856e-05
harbouring O 0 7.393227861030027e-05
an O 0 3.8901876564523263e-07
intragenic O 0 8.680483006173745e-06
deletion O 0 2.4212846483351314e-07
in O 0 5.973210193133127e-08
Snrpn O 0 1.865455851657316e-05
are O 0 4.1747320267404575e-08
phenotypically O 0 1.9191262254025787e-05
normal O 0 1.0393795690788465e-07
, O 0 9.932552558211682e-09
suggesting O 0 2.489976225206192e-08
that O 0 2.448492963935678e-09
mutations O 0 6.440349409331247e-08
of O 0 8.929269057489364e-08
SNRPN O 1 0.9993828535079956
are O 0 2.7663434210012383e-08
not O 0 1.7466254220721567e-08
sufficient O 0 6.870691322546918e-07
to O 0 6.221185913091176e-07
induce O 0 0.007942846976220608
PWS B-Disease 1 1.0
. O 0 0.00014012718747835606

Mice O 0 6.493415185104823e-06
with O 0 5.0204299384404294e-08
a O 0 3.60374841079647e-08
larger O 0 7.561034465197736e-08
deletion O 0 1.2607607402514986e-07
involving O 0 1.1754541873187918e-07
both O 0 1.0466866484648563e-07
Snrpn O 0 7.1720210144121666e-06
and O 0 5.3194973759218556e-08
the O 0 1.731444712049779e-07
putative O 0 4.292967059882358e-05
PWS O 1 1.0
- O 0 0.01026440691202879
IC O 1 0.9999862909317017
lack O 0 1.2712965826722211e-06
expression O 0 1.313638193778388e-07
of O 0 7.338280738622416e-08
the O 0 1.2259224035915395e-07
imprinted O 0 2.288224777657888e-06
genes O 0 1.0817906286320067e-06
Zfp127 O 0 3.0952960514696315e-05
( O 0 1.9186664701464906e-07
mouse O 0 4.5982224605722877e-07
homologue O 0 2.078209718092694e-06
of O 0 2.849354245881841e-07
ZNF127 O 0 0.0012336211511865258
) O 0 1.4261556202654901e-07
, O 0 1.0618948209639711e-07
Ndn O 0 1.6978216081042774e-05
and O 0 4.295593925007779e-08
Ipw O 0 6.1798918977729045e-06
, O 0 3.876477094877373e-08
and O 0 1.1859174975370479e-08
manifest O 0 1.098213999739528e-07
several O 0 3.80653446541146e-08
phenotypes O 0 1.1923949614356388e-06
common O 0 5.508376261786907e-07
to O 0 1.5351997717516497e-06
PWS B-Disease 1 1.0
infants O 1 0.9999994039535522
. O 0 3.6763231037184596e-05

These O 0 3.5278335985822196e-07
data O 0 1.6009457226573431e-07
demonstrate O 0 3.450763941259538e-08
that O 0 3.4780525126620887e-09
both O 0 6.477230751755769e-09
the O 0 1.280307859730101e-08
position O 0 4.146235710322799e-08
of O 0 1.8622650088673254e-08
the O 0 2.5486254884299342e-08
IC O 0 0.001010365318506956
and O 0 1.3737087023457661e-08
its O 0 6.066716462527211e-09
role O 0 1.4112453428083427e-08
in O 0 3.643265023001163e-09
the O 0 1.1774361929894894e-08
coordinate O 0 5.551208559495535e-08
expression O 0 4.5540183180037275e-08
of O 0 2.4310343960110004e-08
genes O 0 1.344656386237375e-08
is O 0 2.960022005282781e-09
conserved O 0 6.380948747164439e-08
between O 0 1.8844863447498028e-08
mouse O 0 4.829251665228185e-08
and O 0 1.1777079755859177e-08
human O 0 2.4989875058167854e-08
, O 0 5.62060709086154e-09
and O 0 3.733975795228162e-09
indicate O 0 2.4662863751245823e-08
that O 0 2.1948105555225084e-09
the O 0 2.326657089213313e-08
mouse O 0 3.404153403607779e-08
is O 0 1.715624198261878e-09
a O 0 1.5592478419534928e-09
suitable O 0 3.442283968979609e-08
model O 0 2.0622950458459854e-08
system O 0 1.0631569402619334e-08
in O 0 3.5037270862403602e-09
which O 0 1.9651205107606984e-09
to O 0 2.2625687989830112e-09
investigate O 0 3.1550481338626923e-08
the O 0 1.2205463306713682e-08
molecular O 0 7.107704647069113e-08
mechanisms O 0 7.727520312528213e-08
of O 0 2.6959751764366047e-08
imprinting O 0 2.443847790800646e-07
in O 0 4.2854688686588815e-09
this O 0 3.2614937417463352e-09
region O 0 5.583809326026312e-08
of O 0 4.184330038015105e-08
the O 0 7.181276373557921e-08
genome O 0 3.686395757540595e-07
. O 0 4.524818564277666e-07
. O 0 2.4573985228926176e-06

Mutations O 0 6.466082595579792e-06
of O 0 6.740801836713217e-07
the O 0 2.1856281762211438e-07
ATM O 0 1.3242282875580713e-05
gene O 0 2.535385306146054e-07
detected O 0 2.1235068459191098e-07
in O 0 2.1357163149104963e-08
Japanese O 0 0.021399613469839096
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0004938087658956647
: O 0 1.861466003560963e-08
possible O 0 9.521595956130113e-08
preponderance O 0 2.7551426683203317e-05
of O 0 8.557665154285132e-08
the O 0 7.133346002774488e-08
two O 0 9.904274378413902e-08
founder O 0 6.1997143347980455e-06
mutations O 0 8.864190021995455e-07
4612del165 O 0 3.10673494823277e-05
and O 0 1.5053183233249001e-06
7883del5 O 0 0.0001721705193631351
. O 0 2.2595162590732798e-05

The O 0 6.0102142924733926e-06
ATM O 0 0.0339164100587368
( O 0 1.93880005099345e-05
A O 1 1.0
- O 1 0.9999998807907104
T O 1 1.0
, O 0 1.681416108567646e-07
mutated O 0 4.7035371153469896e-07
) O 0 2.5699085526298404e-08
gene O 0 6.441381117383571e-08
on O 0 1.822154302999479e-07
human O 0 4.2413890355419426e-07
chromosome O 0 8.666867870488204e-06
11q22 O 0 8.766285463934764e-05
. O 0 6.779070190532366e-06

3 O 0 2.3765132937114686e-05
has O 0 2.0703394909560302e-07
recently O 0 1.249907199962763e-07
been O 0 2.2921328834968335e-08
identified O 0 5.70465843452439e-08
as O 0 1.023952211909318e-08
the O 0 6.179661671268377e-09
gene O 0 1.1528755727852058e-08
responsible O 0 1.6546055192634412e-08
for O 0 9.997670247230417e-09
the O 0 1.279003782883592e-07
human O 0 4.302040542825125e-05
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9998960494995117
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.6411896694989991e-06
. O 0 2.655229309311835e-06

In O 0 2.4716695179449744e-07
order O 0 5.264678293315228e-08
to O 0 2.1079779699562096e-08
define O 0 6.800392782224662e-08
the O 0 2.654025976767116e-08
types O 0 1.8076707419822924e-07
of O 0 2.3370385804355465e-07
disease O 0 0.0012845858000218868
- O 0 1.5512682693952229e-06
causing O 0 7.260302368194971e-07
ATM O 0 7.408644250972429e-06
mutations O 0 8.478057367256042e-08
in O 0 2.732534731819669e-08
Japanese O 0 2.9052528134343447e-06
A B-Disease 1 0.9999967813491821
- I-Disease 1 0.9996640682220459
T I-Disease 1 1.0
patients O 0 9.304790182795841e-08
as O 0 2.2695720858223467e-08
well O 0 6.385061812608228e-09
as O 0 2.8704183474559386e-09
to O 0 2.194258108545455e-09
look O 0 1.4820166427398362e-08
for O 0 1.0903325353694981e-08
possible O 0 2.053485843589442e-07
mutational O 0 1.0041003406513482e-05
hotspots O 0 4.002798959845677e-06
, O 0 8.561550401964269e-08
reverse O 0 3.435463327150501e-07
- O 0 4.1748197077140503e-07
transcribed O 0 8.415819507945344e-08
RNA O 0 9.476229934080038e-08
derived O 0 2.7727931950494167e-08
from O 0 9.682389112697365e-09
ten O 0 5.0248367244876135e-08
patients O 0 5.5480726679491e-09
belonging O 0 2.2455408199562044e-08
to O 0 7.025685366812695e-09
eight O 0 5.447682127623921e-08
unrelated O 0 2.238750198557682e-07
Japanese O 0 1.6898505919016316e-06
A B-Disease 1 0.9931011199951172
- I-Disease 0 0.04559618979692459
T I-Disease 1 0.9999998807907104
families O 0 4.032136402543074e-08
was O 0 3.632304057532565e-08
analyzed O 0 1.2467626042678148e-08
for O 0 1.9254544625368908e-09
mutations O 0 1.288209983130173e-08
by O 0 1.4068942455480737e-08
the O 0 5.989318907495544e-08
restriction O 0 4.92333583679283e-07
endonuclease O 0 2.882251010305481e-06
fingerprinting O 0 8.587355182498868e-07
method O 0 1.8519468767408398e-06
. O 0 3.205948360118782e-06

As O 0 1.99585224436305e-06
has O 0 7.129850132514548e-08
been O 0 2.0373823517161327e-08
reported O 0 2.0331780703486402e-08
by O 0 8.9607254949442e-09
others O 0 4.0622804675649604e-08
, O 0 9.730283245801274e-09
mutations O 0 1.896898815800796e-08
that O 0 7.207042518331264e-09
lead O 0 1.2745861965868244e-07
to O 0 6.45887539008072e-08
exon O 0 1.4914360235707136e-06
skipping O 0 1.0845238875845098e-06
or O 0 1.0774472514185618e-07
premature O 0 2.9601994810946053e-07
protein O 0 1.0619475432349645e-07
truncation O 0 5.523694426301518e-07
were O 0 6.752441095159156e-08
also O 0 2.71502198501139e-08
predominant O 0 6.192300929797057e-07
in O 0 3.298896444903221e-08
our O 0 5.58675992579083e-07
mutants O 0 8.206396159948781e-06
. O 0 9.746139767230488e-06

Six O 0 2.6286659249308286e-06
different O 0 8.401930529089441e-08
mutations O 0 9.219463947829354e-08
were O 0 5.276107728491297e-08
identified O 0 5.717948781125415e-08
on O 0 3.2168401276067016e-08
12 O 0 2.855637681875578e-08
of O 0 1.553137174425956e-08
the O 0 1.325821301634278e-07
16 O 0 7.293035650945967e-07
alleles O 0 1.1200895642105024e-06
examined O 0 1.0888717952184379e-05
. O 0 7.401109087368241e-06

Four O 0 3.4214340303151403e-06
were O 0 4.35616357208346e-07
deletions O 0 2.816985215758905e-06
involving O 0 3.654493241356249e-07
a O 0 8.073695312305063e-08
loss O 0 3.0681317753078474e-07
of O 0 9.460770655778106e-08
a O 0 7.15898451630892e-08
single O 0 1.5047915269406076e-07
exon O 0 1.2210257409606129e-06
exon O 0 2.3912746200949186e-06
7 O 0 8.439672569693357e-07
, O 0 9.336416439964523e-08
exon O 0 1.404636009283422e-06
16 O 0 8.938928885982023e-07
, O 0 7.830070813952261e-08
exon O 0 1.3821684206050122e-06
33 O 0 1.1145358485009638e-06
or O 0 3.590897392768966e-07
exon O 0 8.73829958436545e-06
35 O 0 9.920011507347226e-06
. O 0 5.2408609008125495e-06

The O 0 4.427824933372904e-06
others O 0 1.1210877346456982e-06
were O 0 3.110530144567747e-07
minute O 0 9.981562243410735e-07
deletions O 0 2.275355427627801e-06
, O 0 2.0122837440794683e-07
4649delA O 0 1.8426242149871541e-06
in O 0 4.3933447102517675e-08
exon O 0 7.831301331862051e-07
33 O 0 9.583760629539029e-07
and O 0 6.321386081253877e-08
7883del5 O 0 4.470521616894985e-06
in O 0 1.4581128482404893e-07
exon O 0 9.157847671303898e-06
55 O 0 4.408800577948568e-06
. O 0 3.874175035889493e-06

The O 0 4.613680630427552e-06
mutations O 0 5.85789575779927e-06
4612del165 O 0 2.133093039446976e-05
and O 0 1.4789280555760342e-07
7883del5 O 0 3.546535253917682e-06
were O 0 6.133316077239215e-08
found O 0 9.73737535048258e-09
in O 0 1.7193554358030383e-09
more O 0 8.061377676504833e-10
than O 0 1.0344184397936829e-09
two O 0 2.3179609343060292e-09
unrelated O 0 1.1492025997483779e-08
families O 0 3.5255673935807863e-09
; O 0 3.492191424925295e-09
44 O 0 2.3456703246438337e-08
% O 0 2.68558109084438e-09
( O 0 1.0400389438558477e-09
7 O 0 8.890721048260275e-09
of O 0 3.8547982583736484e-09
16 O 0 1.5948709020108254e-08
) O 0 5.470813246866157e-10
of O 0 1.2651690806109173e-09
the O 0 3.771928103191158e-09
mutant O 0 3.393023462194833e-08
alleles O 0 1.9871139400606808e-08
had O 0 1.8817349456412558e-08
one O 0 8.127785555700484e-09
of O 0 2.896880779701405e-08
the O 0 1.425179476655103e-07
two O 0 3.312203205041442e-07
mutations O 0 3.195332510586013e-06
. O 0 6.875528470118297e-06

The O 0 5.125280495121842e-06
4612del165 O 0 1.76450648723403e-05
mutations O 0 2.4630219286336796e-07
in O 0 9.667497025134253e-09
three O 0 2.438937718451939e-09
different O 0 9.4900043379198e-10
families O 0 2.094550533016104e-09
were O 0 7.948551150604999e-09
all O 0 4.3587538023359684e-09
ascribed O 0 5.747712350512302e-08
to O 0 7.391263157074945e-09
the O 0 4.437948319946372e-08
same O 0 7.586907457834968e-08
T O 0 8.501786510350939e-07
- O 0 4.0574687432126666e-07
- O 0 4.0195325823333405e-07
> O 0 1.1766732654905354e-07
A O 0 4.749631443701219e-08
substitution O 0 1.499079331779285e-07
at O 0 6.186527201634817e-08
the O 0 4.736134684435456e-08
splice O 0 2.6734094262792496e-06
donor O 0 6.626574418078235e-07
site O 0 1.999601636271109e-06
in O 0 8.79348078797193e-07
intron O 0 0.0001935168111231178
33 O 0 4.1467221308266744e-05
. O 0 1.599963434273377e-05

Microsatellite O 0 0.00016724367742426693
genotyping O 0 2.9201721190474927e-05
around O 0 8.197902729989437e-07
the O 0 2.7822611059491464e-07
ATM O 0 7.70569167798385e-05
locus O 0 9.341472946289286e-07
also O 0 2.4457683878154057e-08
indicated O 0 1.57525015254123e-08
that O 0 1.245269443117536e-09
a O 0 6.773102523283114e-09
common O 0 3.125024505834517e-08
haplotype O 0 4.113679779038648e-07
was O 0 6.557560539022234e-08
shared O 0 9.86571357941557e-09
by O 0 2.2189676762707222e-09
the O 0 1.536864679962946e-08
mutant O 0 2.1037850217453524e-07
alleles O 0 5.135586178539597e-08
in O 0 3.0326177125061804e-08
both O 0 2.1029083541179716e-07
mutations O 0 3.909828592441045e-06
. O 0 4.4672538024315145e-06

This O 0 3.6462495245359605e-07
suggests O 0 3.803225752108119e-07
that O 0 1.496323420724366e-08
these O 0 2.8704091548092947e-08
two O 0 7.060723561380655e-08
founder O 0 1.281365257455036e-06
mutations O 0 1.5903545147466502e-07
may O 0 2.2193750837118387e-08
be O 0 1.9309904786268817e-08
predominant O 0 9.896500614559045e-07
among O 0 7.439935956199406e-08
Japanese O 0 9.096492021853919e-07
ATM O 0 2.2327969418256544e-05
mutant O 0 7.545714197476627e-06
alleles O 0 1.2036914995405823e-05
. O 0 1.1993189218628686e-05

W474C O 0 0.00016205335850827396
amino O 0 3.4251559100084705e-06
acid O 0 3.9509518501290586e-07
substitution O 0 4.1025063524102734e-07
affects O 0 6.486109072056934e-08
early O 0 1.899650570180711e-08
processing O 0 4.6640145967558055e-08
of O 0 2.70793147905124e-08
the O 0 2.046823865953229e-08
alpha O 0 7.426466908100338e-08
- O 0 2.4728054270894972e-08
subunit O 0 1.6952654391388933e-08
of O 0 2.2196459781298472e-08
beta O 0 1.0769480240924167e-07
- O 0 1.4849130991478887e-07
hexosaminidase O 0 1.1943183153562131e-06
A O 0 1.3831913747708313e-07
and O 0 9.361859731882305e-09
is O 0 4.2362522378880385e-09
associated O 0 5.440786665644737e-08
with O 0 1.0290038687799097e-07
subacute O 0 0.04019349440932274
G B-Disease 1 0.9997755885124207
( I-Disease 0 2.6839883503271267e-05
M2 I-Disease 1 0.9986010193824768
) I-Disease 0 1.3430130820779596e-06
gangliosidosis I-Disease 0 0.00010216698137810454
. O 0 9.22809795156354e-06

Mutations O 0 7.097663456079317e-06
in O 0 5.63371941098012e-07
the O 0 1.394292553413834e-06
HEXA O 0 6.300246604951099e-05
gene O 0 2.1480177281318902e-07
, O 0 3.245633806159276e-08
encoding O 0 6.925622386688701e-08
the O 0 9.267171208193759e-08
alpha O 0 2.409491060006985e-07
- O 0 4.233427475242024e-08
subunit O 0 3.337527942903762e-08
of O 0 3.622085387178231e-08
beta O 0 2.1197615751589183e-07
- O 0 5.284416602080455e-07
hexosaminidase O 0 5.04696117786807e-06
A O 0 8.30336205126514e-07
( O 0 1.3014776811814954e-07
Hex O 0 1.3690183777725906e-06
A O 0 1.988874060998569e-07
) O 0 1.0893679736057038e-08
, O 0 7.122005207804705e-09
that O 0 6.675985542159424e-09
abolish O 0 2.8430625320652325e-07
Hex O 0 1.803567101887893e-06
A O 0 1.0605548084186012e-07
enzyme O 0 2.4445517965432373e-07
activity O 0 1.9840111065150268e-07
cause O 0 3.666022894321941e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.9504611827869667e-06
TSD B-Disease 1 0.9999254941940308
) O 0 2.473881011155754e-08
, O 0 9.536169187640553e-09
the O 0 3.870979981002165e-08
fatal O 0 1.5146395071496954e-06
infantile B-Disease 0 4.82712448501843e-06
form I-Disease 0 6.750109804443127e-08
of I-Disease 0 1.668251570663415e-06
G I-Disease 0 0.0151493139564991
( I-Disease 0 3.3693088425934548e-06
M2 I-Disease 0 0.2515459954738617
) I-Disease 0 2.058787913483684e-07
gangliosidosis I-Disease 0 7.601422112202272e-06
, I-Disease 0 1.2081368083727284e-07
Type I-Disease 0 1.7253901205549482e-06
1 I-Disease 0 8.409692782151978e-06
. O 0 4.1124344534182455e-06

Less O 0 8.922371307562571e-06
severe O 0 7.962773815961555e-05
, O 0 8.136487963383843e-07
subacute O 0 0.00041243640589527786
( O 0 4.5254657266013965e-07
juvenile O 1 0.6661920547485352
- O 0 7.513000127801206e-06
onset O 0 0.0028934525325894356
) O 0 2.8009546682028486e-08
and O 0 6.768365778953012e-08
chronic O 1 0.9557734727859497
( O 0 3.4106655277810205e-08
adult O 0 2.2451260406342044e-07
- O 0 1.7842408794876974e-07
onset O 0 1.9377576165879873e-07
) O 0 1.7730608092847433e-09
variants O 0 8.711461774169038e-09
are O 0 7.399073576053183e-10
characterized O 0 9.87911641381345e-10
by O 0 6.599815693952849e-10
a O 0 2.9240303511812726e-09
broad O 0 2.750386407512906e-08
spectrum O 0 6.365486626691563e-08
of O 0 1.6091403765017276e-08
clinical O 0 4.317558222055595e-08
manifestations O 0 2.861646919427585e-07
and O 0 1.8663934397977755e-08
are O 0 4.3270618199642286e-09
associated O 0 3.8114748690531997e-08
with O 0 1.1183434622807908e-08
residual O 0 1.158574377768673e-05
levels O 0 3.098033687365387e-07
of O 0 1.420709452304436e-07
Hex O 0 2.1771227238787105e-06
A O 0 4.87245984004403e-07
enzyme O 0 9.53750713961199e-07
activity O 0 1.2462868426155183e-06
. O 0 3.1941076485964004e-06

We O 0 4.213267402519705e-06
identified O 0 4.481445103010628e-06
a O 0 1.7197749002662022e-06
1422 O 0 4.183387500233948e-05
G O 0 1.3885463886254001e-05
- O 0 8.729038199817296e-06
- O 0 5.614594556391239e-06
> O 0 1.4808517789788311e-06
C O 0 4.902214186586207e-06
( O 0 4.430691191714686e-08
amino O 0 2.9887409880302584e-08
acid O 0 2.3313392105706043e-08
W474C O 0 2.050317675639235e-07
) O 0 7.180037120413374e-10
substitution O 0 8.930202355372785e-09
in O 0 3.456539499069322e-09
the O 0 3.590847397205721e-09
first O 0 1.4227698130753197e-08
position O 0 5.766401045548264e-08
of O 0 2.8436367927042738e-08
exon O 0 4.3103014490952773e-07
13 O 0 4.194950520286511e-07
of O 0 2.033653885291642e-07
HEXA O 0 0.0021091620437800884
of O 0 2.7773964461630385e-07
a O 0 1.4589433305900457e-07
non O 0 7.371453648374882e-06
- O 0 3.207719146303134e-06
Jewish O 0 2.9085214919177815e-05
proband O 0 0.00010298135748598725
who O 0 3.5873409842679393e-07
manifested O 0 1.398842300659453e-06
a O 0 2.3006811034065322e-07
subacute O 0 7.2083776103681885e-06
variant O 0 3.10066366182582e-06
of O 0 3.029741264981567e-06
G B-Disease 0 0.4118240773677826
( I-Disease 0 1.3214365026215091e-05
M2 I-Disease 1 0.992365300655365
) I-Disease 0 1.3727417353948113e-06
gangliosidosis I-Disease 0 0.00010263186413794756
. O 0 7.641142474312801e-06

On O 0 3.919969003618462e-06
the O 0 3.91069107763542e-07
second O 0 9.552862820783048e-07
maternally O 0 4.6772447603871115e-06
inherited O 0 1.1796029184552026e-06
allele O 0 4.050806978739274e-07
, O 0 2.553062827814756e-08
we O 0 7.079356656447544e-09
identified O 0 6.03218452965848e-08
the O 0 6.965696996985571e-08
common O 0 5.8777227422979195e-06
infantile O 1 1.0
disease O 1 0.9999996423721313
- O 0 0.012646983377635479
causing O 0 4.158158481004648e-05
4 O 0 2.005210262723267e-06
- O 0 6.695676688650565e-07
bp O 0 3.845734681817703e-07
insertion O 0 2.7517671696841717e-07
, O 0 2.598194441816304e-07
+ O 0 1.950824071172974e-06
TATC O 0 0.001313226530328393
1278 O 0 3.5614040825748816e-05
, O 0 1.54971857568853e-07
in O 0 1.622465646278215e-07
exon O 0 4.570866622088943e-06
11 O 0 5.994735147396568e-06
. O 0 5.10140989717911e-06

Pulse O 0 0.0002114744420396164
- O 0 2.2620906747761182e-05
chase O 0 2.0780273644049885e-06
analysis O 0 2.724630121520022e-07
using O 0 1.3414880584150524e-07
proband O 0 9.045746082847472e-06
fibroblasts O 0 9.984503321902594e-07
revealed O 0 1.133148543885909e-07
that O 0 8.3090636593397e-09
the O 0 7.15710086751642e-08
W474C O 0 2.9673917651962256e-06
- O 0 4.660649040033604e-07
containing O 0 1.1005436562072646e-07
alpha O 0 1.8034829452062695e-07
- O 0 9.919153143300719e-08
subunit O 0 6.475305980302437e-08
precursor O 0 6.033968702467973e-07
was O 0 5.982764861300893e-08
normally O 0 1.0522328786066737e-08
synthesized O 0 4.0755672614523064e-08
, O 0 3.644794022150677e-09
but O 0 2.2467689930749657e-09
not O 0 3.520346458785184e-09
phosphorylated O 0 8.328424172532323e-08
or O 0 1.3087659844757127e-08
secreted O 0 4.2839999991883815e-08
, O 0 1.2038968932870375e-08
and O 0 1.5240731343624248e-08
the O 0 7.652437972183179e-08
mature O 0 2.7008522351934516e-07
lysosomal O 0 2.116770701832138e-06
alpha O 0 2.685280833247816e-07
- O 0 1.2150522366027872e-07
subunit O 0 7.565405013565396e-08
was O 0 5.869040364814282e-08
not O 0 3.6290973781660796e-08
detected O 0 1.2228541663716896e-06
. O 0 1.5123273442441132e-06

When O 0 2.5747126528585795e-06
the O 0 1.4413687949854648e-06
W474C O 0 1.458449423807906e-05
- O 0 1.5553343928331742e-06
containing O 0 2.4575999191256415e-07
alpha O 0 4.3194654608669225e-07
- O 0 2.8208086177983205e-07
subunit O 0 1.6723406304208766e-07
was O 0 2.499705544778408e-07
transiently O 0 1.4231560498956242e-06
co O 0 3.293044414931501e-07
- O 0 1.5168497213835508e-07
expressed O 0 2.0303104975027964e-08
with O 0 2.7299389415702535e-09
the O 0 1.6164740657131915e-08
beta O 0 2.4058026681927913e-08
- O 0 1.786651004920259e-08
subunit O 0 6.984239853125018e-09
to O 0 5.014637594058513e-09
produce O 0 4.759879601579087e-08
Hex O 0 1.6208136912609916e-06
A O 0 7.936674819575273e-07
( O 0 1.6687735637788137e-07
alphabeta O 0 3.6597145935957087e-06
) O 0 5.6439212414716167e-08
in O 0 8.046652766324769e-08
COS O 0 0.024620220065116882
- O 0 2.3609866275364766e-06
7 O 0 2.9853572414140217e-07
cells O 0 5.2673399864033854e-08
, O 0 1.0517593906911316e-08
the O 0 1.6985119088985812e-08
mature O 0 2.4559309252936146e-08
alpha O 0 2.3041607732920966e-08
- O 0 1.4606467146904833e-08
subunit O 0 4.315539037236249e-09
was O 0 5.689139381814812e-09
present O 0 2.3104969049114743e-09
, O 0 1.519483316947401e-09
but O 0 8.747271795783718e-10
its O 0 1.7970502863562388e-09
level O 0 1.8087945363731706e-08
was O 0 1.1525721710370362e-08
much O 0 3.9524494788167885e-09
lower O 0 1.5354553184465658e-08
than O 0 9.331708739068745e-10
that O 0 2.3557706896326636e-09
from O 0 2.1364865432360602e-08
normal O 0 2.6723737889255972e-08
alpha O 0 4.6820996857377395e-08
- O 0 4.110259510525793e-08
subunit O 0 5.3850872205885025e-08
transfections O 0 4.680568395087903e-07
, O 0 4.807523268368641e-09
although O 0 3.903467327148746e-09
higher O 0 1.595680210186856e-08
than O 0 1.575994557079241e-09
in O 0 3.206265697386357e-09
those O 0 1.2046205810634092e-08
cells O 0 4.765175276588707e-08
transfected O 0 2.483194521119003e-07
with O 0 5.512735601342911e-09
an O 0 1.8614624508472843e-08
alpha O 0 1.0036229980414646e-07
- O 0 8.56950705951931e-08
subunit O 0 1.0038641562459816e-07
associated O 0 3.2748013722994074e-07
with O 0 6.166606567603594e-07
infantile O 1 0.9939613342285156
TSD B-Disease 1 0.9999052286148071
. O 0 3.516606011544354e-05

Furthermore O 0 6.717232281516772e-06
, O 0 2.2993256720837962e-07
the O 0 9.31983450414009e-08
precursor O 0 2.395613591943402e-06
level O 0 3.380176281098102e-07
of O 0 8.243367943805424e-08
the O 0 1.6199871311073366e-07
W474C O 0 2.6221412099403096e-06
alpha O 0 2.349452188354917e-07
- O 0 4.8140403663410325e-08
subunit O 0 3.1168337244480426e-08
was O 0 3.651977209528923e-08
found O 0 3.9123819739472765e-09
to O 0 4.29121893574802e-09
accumulate O 0 3.389123293118246e-08
in O 0 6.856602396965172e-09
comparison O 0 2.6187816359879434e-08
to O 0 6.744715452811079e-09
the O 0 4.5213546684408357e-08
normal O 0 1.0548012596700573e-07
alpha O 0 4.976840273229755e-07
- O 0 2.668859906407306e-07
subunit O 0 3.8670475532853743e-07
precursor O 0 2.0476204554142896e-06
levels O 0 9.803466127777938e-07
. O 0 2.120864792232169e-06

We O 0 3.1388469778903527e-06
conclude O 0 6.022876732458826e-06
that O 0 4.1407398043702415e-07
the O 0 1.6200812069655512e-06
1422 O 0 7.182950503192842e-05
G O 0 4.036050086142495e-05
- O 0 1.699764106888324e-05
- O 0 6.10864026384661e-06
> O 0 9.486842031947162e-07
C O 0 1.0645002248566016e-06
mutation O 0 2.1822097906465387e-08
is O 0 1.7517824968393825e-09
the O 0 3.474929455293818e-09
cause O 0 7.88555496455956e-08
of O 0 1.3368750728659506e-07
Hex B-Disease 0 2.924238287960179e-05
A I-Disease 0 5.051183961768402e-06
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.7834089760526695e-07
the O 0 8.463627523269679e-07
proband O 0 0.00017445330740883946
. O 0 9.49315472098533e-06

The O 0 1.0885935807891656e-05
resulting O 0 5.714563485526014e-06
W474C O 0 1.7147214748547412e-05
substitution O 0 3.224932925149915e-06
clearly O 0 8.397137776228192e-07
interferes O 0 2.7287231318950944e-07
with O 0 1.6939177172048403e-08
alpha O 0 8.780411064890359e-08
- O 0 2.218139449894352e-08
subunit O 0 6.953614573035338e-09
processing O 0 1.2195968679407088e-08
, O 0 1.5900345484709533e-09
but O 0 9.071743911626129e-10
because O 0 9.85841075440419e-10
the O 0 2.5368873668440983e-09
base O 0 8.178902000111066e-09
substitution O 0 2.478783578396815e-08
falls O 0 1.6808516534183582e-07
at O 0 1.2234738555605418e-08
the O 0 1.302838281702634e-08
first O 0 2.0222058694230327e-08
position O 0 9.179457549635117e-08
of O 0 6.544116359918917e-08
exon O 0 6.998536719038384e-07
13 O 0 4.004736240403872e-07
, O 0 3.370306345118479e-08
aberrant O 0 1.5507222883570648e-07
splicing O 0 4.2628482788131805e-07
may O 0 6.118897033502435e-08
also O 0 2.197178261553745e-08
contribute O 0 2.177469937691967e-08
to O 0 1.7974279842292162e-08
Hex B-Disease 0 0.00026546482695266604
A I-Disease 0 1.2170533409516793e-05
deficiency I-Disease 0 0.005023790989071131
in O 0 3.064499409788368e-08
this O 0 3.130548975605052e-08
proband O 0 2.4231512725236826e-05
. O 0 4.1926267613234813e-07
. O 0 3.0579651593143353e-06

Two O 0 3.240276555516175e-06
frequent O 0 3.30381294588733e-06
missense O 0 6.265872798394412e-05
mutations O 0 2.1225492673693225e-05
in O 0 7.922769327706192e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0003739007224794477

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.317929267472209e-07
an O 0 7.585792332065466e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 3.72807880921755e-06
by O 0 3.174079310497291e-08
early O 0 0.31452733278274536
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 1.0
goiter B-Disease 1 1.0
. O 1 0.9883348941802979

A O 0 8.878845619619824e-06
century O 0 2.152384467990487e-06
after O 0 8.690638253483485e-08
its O 0 5.966546812175011e-09
recognition O 0 5.8679546555140405e-08
as O 0 4.982558010624416e-08
a O 0 5.66525422129871e-08
syndrome O 0 2.3987158783711493e-06
by O 0 2.177573676931388e-08
Vaughan O 0 2.535175099183107e-06
Pendred O 0 0.027575062587857246
, O 0 6.405606001180786e-08
the O 0 9.071233364466025e-08
disease O 0 4.433030426298501e-06
gene O 0 3.1712386316939956e-07
( O 0 5.04100285070308e-07
PDS O 1 0.9999836683273315
) O 0 3.458222508356812e-08
was O 0 6.447170619594544e-08
mapped O 0 6.99042601581823e-08
to O 0 1.0149266671533042e-07
chromosome O 0 9.85707447398454e-06
7q22 O 0 0.00021166041551623493
- O 0 0.00022842104954179376
q31 O 0 0.0006772655760869384
. O 0 1.6108135241665877e-05

1 O 0 9.834781849349383e-06
and O 0 4.109950566544285e-07
, O 0 8.539029039411616e-08
recently O 0 6.461956303382976e-08
, O 0 1.5286905963307618e-08
found O 0 8.173755006168903e-09
to O 0 8.91673845870855e-09
encode O 0 4.2931694110848184e-07
a O 0 5.073993065707327e-07
putative O 0 2.2278707547229715e-05
sulfate O 0 4.7688237827969715e-05
transporter O 0 0.0006650941213592887
. O 0 1.2146786502853502e-05

We O 0 9.993600542657077e-07
performed O 0 2.3299350004890584e-07
mutation O 0 4.376183326826322e-08
analysis O 0 4.531645814154217e-08
of O 0 3.815606319790277e-08
the O 0 1.0074761291889445e-07
PDS B-Disease 1 0.9993533492088318
gene O 0 1.0102643699383407e-07
in O 0 1.4223220823339489e-08
patients O 0 1.7473050561989112e-08
from O 0 4.987854396176772e-08
14 O 0 1.5522167018389155e-07
Pendred B-Disease 0 9.876069952952093e-07
families O 0 1.4593991792821726e-08
originating O 0 5.507809319738044e-08
from O 0 1.1264979171698997e-08
seven O 0 1.1565735924534692e-08
countries O 0 6.853516421045924e-09
and O 0 2.182392933036681e-08
identified O 0 2.2419592937694688e-07
all O 0 2.0604694839221338e-07
mutations O 0 2.5413016828679247e-06
. O 0 3.921793904737569e-06

The O 0 1.4583453094019205e-06
mutations O 0 9.483513281338674e-07
include O 0 1.63282521725705e-07
three O 0 5.305433603552956e-08
single O 0 4.939937880976686e-08
base O 0 1.9853264632274659e-07
deletions O 0 7.240657282636676e-07
, O 0 5.1706059878142696e-08
one O 0 4.3652459424947665e-08
splice O 0 3.915649813279742e-06
site O 0 5.126680093781033e-07
mutation O 0 8.922731353777635e-08
and O 0 1.0081719636900743e-07
10 O 0 7.584403078908508e-07
missense O 0 9.839285667112563e-06
mutations O 0 1.0353632205806207e-05
. O 0 8.63977493281709e-06

One O 0 4.835021172766574e-06
missense O 0 2.6492767574382015e-05
mutation O 0 1.1705772067216458e-06
( O 0 2.399825120846799e-07
L236P O 0 2.660382278918405e-06
) O 0 8.239544158072931e-09
was O 0 7.33778771078164e-09
found O 0 1.6031657112947073e-09
in O 0 7.042075811369841e-10
a O 0 2.583845803982854e-09
homozygous O 0 1.2707515928411794e-08
state O 0 4.8662895935081e-09
in O 0 4.8333217428364605e-09
two O 0 1.1483721529259583e-08
consanguineous O 0 3.484914543605555e-07
families O 0 1.1793264143022952e-08
and O 0 5.3370050601131425e-09
in O 0 2.426104428465692e-09
a O 0 7.929093825964628e-09
heterozygous O 0 1.4814061088941344e-08
state O 0 8.472331280984235e-09
in O 0 1.2691165451883535e-08
five O 0 3.0910392467831116e-08
additional O 0 1.8844005467144598e-07
non O 0 6.59150782666984e-06
- O 0 1.0362325156165753e-05
consanguineous O 0 4.732007801067084e-05
families O 0 1.5073883332661353e-06
. O 0 4.901120519207325e-06

Another O 0 6.901866072439589e-06
missense O 0 1.2723658983304631e-05
mutation O 0 8.430751563537342e-07
( O 0 2.1746794232058164e-07
T416P O 0 3.3254345908062533e-06
) O 0 8.769527326535353e-09
was O 0 8.168892229321045e-09
found O 0 1.2259072645903757e-09
in O 0 5.656147217258933e-10
a O 0 1.7414152342354328e-09
homozygous O 0 1.1708856106906751e-08
state O 0 3.643994439528342e-09
in O 0 3.75219544324068e-09
one O 0 7.462046092143737e-09
family O 0 6.829454335388618e-09
and O 0 4.985968082849013e-09
in O 0 3.738579668066677e-09
a O 0 1.1476604555582526e-08
heterozygous O 0 1.9346549251508804e-08
state O 0 1.3567440504402839e-08
in O 0 3.7971222610622135e-08
four O 0 2.1951912287931918e-07
families O 0 6.824403726568562e-07
. O 0 6.4578007368254475e-06

Pendred B-Disease 0 0.003136376617476344
patients O 0 1.4969107269280357e-06
in O 0 8.255058503436885e-08
three O 0 1.2371101831831766e-07
non O 0 1.731161887619237e-06
- O 0 9.48899526065361e-07
consanguineous O 0 1.6686110484442906e-06
families O 0 1.9415121954580172e-08
were O 0 1.2719276298867044e-08
shown O 0 4.901108852095604e-09
to O 0 4.111739393408698e-09
be O 0 1.5716787871156157e-08
compound O 0 5.182523068469891e-07
heterozygotes O 0 2.259289658468333e-06
for O 0 2.7771395139097876e-07
L236P O 0 3.0196222724043764e-05
and O 0 1.22889480280719e-06
T416P O 0 8.049164898693562e-05
. O 0 7.6199157774681225e-06

In O 0 3.8107847899482294e-07
total O 0 7.070440233292175e-08
, O 0 1.9696731357043973e-08
one O 0 7.258139422816612e-09
or O 0 5.369239275410109e-09
both O 0 4.642347839478589e-09
of O 0 5.1333701733824455e-09
these O 0 2.0105364040290397e-09
mutations O 0 1.4993517538641754e-08
were O 0 1.1861210680308432e-08
found O 0 3.7364551452867545e-09
in O 0 2.0656796273499367e-09
nine O 0 3.400117165597294e-08
of O 0 2.3964783935070955e-08
the O 0 8.970578591060985e-08
14 O 0 4.877070978182019e-07
families O 0 1.1335905725218254e-07
analyzed O 0 1.8950113371829502e-06
. O 0 2.742623337326222e-06

The O 0 4.134769540087291e-07
identification O 0 1.1710718581525725e-06
of O 0 4.4196855242262245e-07
two O 0 1.4208544030225312e-07
frequent O 0 1.22597077734099e-06
PDS B-Disease 1 0.9999986886978149
mutations O 0 2.646616223955789e-07
will O 0 1.0563552699238699e-08
facilitate O 0 1.4192197284046415e-07
the O 0 2.7072960762097864e-08
molecular O 0 9.452037375012878e-07
diagnosis O 0 5.196987785893725e-06
of O 0 3.317564187454991e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00040202582022175193

Insertional O 0 0.00017026692512445152
mutation O 0 1.528801931272028e-06
by O 0 2.1134657401944423e-07
transposable O 0 7.339844614762114e-06
element O 0 6.482300136667618e-07
, O 0 1.5647729867396265e-07
L1 O 0 1.9651681213872507e-05
, O 0 5.113886203389484e-08
in O 0 2.237165830365484e-08
the O 0 2.775413463496079e-07
DMD B-Disease 1 1.0
gene O 0 3.572343700852798e-07
results O 0 6.740229423485289e-07
in O 0 3.4266741977262427e-07
X B-Disease 1 0.9999979734420776
- I-Disease 1 0.9999990463256836
linked I-Disease 1 0.9999992847442627
dilated I-Disease 1 0.9997329115867615
cardiomyopathy I-Disease 1 1.0
. O 0 0.0018067335477098823

X B-Disease 1 0.9999957084655762
- I-Disease 1 0.9999911785125732
linked I-Disease 1 0.9999924898147583
dilated I-Disease 1 0.9999651908874512
cardiomyopathy I-Disease 1 1.0
( O 0 0.04818321019411087
XLDCM B-Disease 1 1.0
) O 0 3.498219669495484e-08
is O 0 2.6010880116444923e-09
a O 0 3.3157503409597666e-09
clinical O 0 6.414848741087553e-08
phenotype O 0 2.6648436346476956e-07
of O 0 1.5110600770640303e-07
dystrophinopathy B-Disease 0 0.0019291054923087358
which O 0 1.0739056754971443e-08
is O 0 2.855826908287895e-09
characterized O 0 1.0493107716058603e-08
by O 0 7.085651620997169e-09
preferential O 0 6.865150226076366e-06
myocardial B-Disease 1 0.9999998807907104
involvement I-Disease 0 1.3190643812777125e-06
without O 0 6.740846458797023e-08
any O 0 4.66074254745763e-08
overt O 0 1.5342147889896296e-06
clinical O 0 2.140222022717353e-06
signs O 0 1.8370765246800147e-05
of O 0 1.0291555554431397e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0005291583947837353

To O 0 5.318300395629194e-07
date O 0 2.019076418946497e-06
, O 0 7.381419209195883e-08
several O 0 2.628284256900315e-08
mutations O 0 1.0068767153370572e-07
in O 0 3.889215349772712e-08
the O 0 1.92978677659994e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9748600125312805
, O 0 6.121505066403188e-06
DMD O 1 1.0
, O 0 3.4245175584146637e-08
have O 0 4.136312625746541e-09
been O 0 4.309896439735894e-09
identified O 0 1.1895489038238338e-08
in O 0 3.179700724942336e-09
patients O 0 5.1325379502031865e-09
with O 0 1.7575933597413496e-08
XLDCM B-Disease 1 1.0
, O 0 2.182842528952733e-08
but O 0 4.398657882376256e-09
a O 0 8.349447355726625e-09
pathogenic O 0 8.008130691905535e-08
correlation O 0 5.999151397872993e-08
of O 0 1.1206132022323345e-08
these O 0 2.1520646598105486e-08
cardiospecific O 0 4.626303507393459e-06
mutations O 0 2.0229511221714347e-07
in O 0 4.453593049902338e-08
DMD O 1 1.0
with O 0 2.717047387079674e-08
the O 0 8.015386470106023e-07
XLDCM B-Disease 1 0.9999997615814209
phenotype O 0 1.3759305375060649e-06
has O 0 5.015616011405655e-08
remained O 0 4.137270082082978e-07
to O 0 2.5182895768693925e-08
be O 0 5.488857937052671e-07
elucidated O 0 0.00014356864267028868
. O 0 1.4466540960711427e-05

We O 0 1.3369467524171341e-06
report O 0 4.4018540279466833e-07
here O 0 3.8174697181148076e-08
the O 0 1.0401524974668064e-08
identification O 0 5.1357719854649986e-08
of O 0 3.839500806179785e-08
a O 0 6.895754722791025e-08
unique O 0 3.852345855648309e-07
de O 0 2.845950803020969e-06
novo O 0 5.18478600497474e-06
L1 O 0 1.5663896192563698e-05
insertion O 0 3.882086332396284e-07
in O 0 8.77287789080583e-08
the O 0 1.5309160517062992e-07
muscle O 0 2.965570615742763e-07
exon O 0 8.36211142996035e-07
1 O 0 5.442975634650793e-07
in O 0 3.774779955278973e-08
DMD O 1 1.0
in O 0 6.273795349898137e-08
three O 0 1.1975821223586536e-07
XLDCM B-Disease 1 0.9997949004173279
patients O 0 3.8178487926643356e-08
from O 0 3.697606132391229e-08
two O 0 3.7703475896933014e-08
unrelated O 0 6.952522539904749e-07
Japanese O 0 3.160850383210345e-06
families O 0 4.5958330474604736e-07
. O 0 2.7008932192984503e-06

The O 0 2.5397630452062003e-06
insertion O 0 3.2270986594085116e-06
was O 0 1.3952291055829846e-06
a O 0 1.4173208739975962e-07
5 O 0 2.8870300639027846e-07
- O 0 1.7316790490440326e-07
truncated O 0 1.0625674917719152e-07
form O 0 1.985412900751271e-08
of O 0 4.5902087464355645e-08
human O 0 1.1692691259668209e-07
L1 O 0 4.0463305595039856e-06
inversely O 0 9.657609325586236e-07
integrated O 0 1.0895346491679447e-07
in O 0 7.50412265659861e-09
the O 0 2.8307518107340002e-08
5 O 0 1.2580775887727214e-07
- O 0 1.2921182701575162e-07
untranslated O 0 7.069319508445915e-06
region O 0 1.0863804789096321e-07
in O 0 1.27418573470095e-08
the O 0 2.140598098776536e-08
muscle O 0 5.999734753459052e-08
exon O 0 2.74828437341057e-07
1 O 0 1.550885002643554e-07
, O 0 2.9460196504516034e-09
which O 0 1.0209055822940627e-09
affected O 0 2.6617252846250494e-09
the O 0 1.1878388272990037e-09
transcription O 0 2.7948178882297725e-08
or O 0 3.716496888017673e-09
the O 0 1.0456226995358975e-08
stability O 0 1.274572696274845e-07
of O 0 4.232249040114766e-08
the O 0 3.9700783105445225e-08
muscle O 0 5.7129561525925965e-08
form O 0 2.707693980141812e-08
of O 0 1.2533915594303835e-07
dystrophin O 0 9.218353511641908e-07
transcripts O 0 1.7530642537622043e-07
but O 0 8.061165956974037e-09
not O 0 2.8462938672646487e-09
that O 0 2.8438902344163353e-09
of O 0 3.330736220163999e-08
the O 0 1.8870585449803912e-07
brain O 0 1.1980819181189872e-05
or O 0 1.5543542986051762e-07
Purkinje O 0 0.07868703454732895
cell O 0 1.5063824321259744e-06
form O 0 5.401515679182012e-08
, O 0 1.3649357200051782e-08
probably O 0 4.453380597624346e-08
due O 0 1.687091710778077e-08
to O 0 5.945099079696092e-09
its O 0 7.755083686333819e-09
unique O 0 3.151631844389158e-08
site O 0 1.66920486321942e-07
of O 0 1.0359673296989058e-07
integration O 0 3.2652603749738773e-06
. O 0 9.45034025789937e-06

We O 0 1.3031958587816916e-06
speculate O 0 1.4227380233933218e-06
that O 0 9.998871952632271e-09
this O 0 2.769498852472907e-09
insertion O 0 4.5236145496119207e-08
of O 0 3.7412565490058114e-08
an O 0 3.729450881451157e-08
L1 O 0 8.17103500594385e-06
sequence O 0 6.179510592119186e-08
in O 0 4.108394335844423e-08
DMD O 1 1.0
is O 0 1.2355346079573337e-08
responsible O 0 8.093040904100235e-09
for O 0 2.3912034574635754e-09
some O 0 1.6666853452917962e-09
of O 0 3.661279501798731e-09
the O 0 2.6889381832262416e-09
population O 0 2.2469790472712248e-09
of O 0 7.341497632040728e-09
Japanese O 0 3.348566224303795e-07
patients O 0 3.0211346313535614e-08
with O 0 6.348184911075805e-08
XLDCM B-Disease 1 0.9904850721359253
. O 0 8.230138064391213e-07
. O 0 3.3946760140679544e-06

Severe O 0 0.000356753240339458
early O 0 0.00011653944238787517
- O 0 0.0014918609522283077
onset O 1 0.999998927116394
obesity B-Disease 1 1.0
, O 0 1.7373225773553713e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9986422657966614
red O 1 1.0
hair O 1 0.9343724250793457
pigmentation O 1 0.9870378971099854
caused O 0 2.4166476578102447e-05
by O 0 7.261119208124001e-07
POMC O 1 0.9999936819076538
mutations O 0 1.6664514532749308e-06
in O 0 2.404750603091088e-07
humans O 0 8.893945846466522e-07
. O 0 1.0821466958077508e-06

Sequential O 0 3.6127425119047984e-05
cleavage O 0 3.277920404798351e-05
of O 0 3.3715268727974035e-06
the O 0 5.418975206339383e-07
precursor O 0 4.862831701757386e-06
protein O 0 1.3145283901394578e-06
pre O 0 3.094625299127074e-06
- O 0 4.225681550451554e-06
pro O 0 1.7978854884859174e-05
- O 0 2.0611585568985902e-05
opiomelanocortin O 0 0.00013748410856351256
( O 0 2.1100734102219576e-06
POMC O 0 0.0001308464998146519
) O 0 1.2891149481220054e-07
generates O 0 2.130525444954401e-07
the O 0 3.481705448393768e-07
melanocortin O 0 2.3670449081691913e-05
peptides O 0 3.410000317671802e-06
adrenocorticotrophin O 0 6.566139200003818e-05
( O 0 1.2186526419100119e-06
ACTH O 0 8.967977009888273e-06
) O 0 1.3488438810327352e-07
, O 0 1.1603036398355471e-07
melanocyte O 0 1.691276702331379e-05
- O 0 1.0899980225076433e-05
stimulating O 0 2.0493923784670187e-06
hormones O 0 7.270043624885147e-07
( O 0 1.2761819334627944e-07
MSH O 0 6.390994713001419e-06
) O 0 5.383184564777821e-09
alpha O 0 1.9572471643414247e-08
, O 0 2.0225907615412098e-09
beta O 0 6.274582631249359e-09
and O 0 3.0677143048052358e-09
gamma O 0 4.0080905705508485e-08
as O 0 9.876596429592155e-09
well O 0 8.659113426290332e-09
as O 0 2.0895399188702868e-08
the O 0 4.3298545193692917e-08
opioid O 0 1.5416288761116448e-06
- O 0 1.8652458493306767e-06
receptor O 0 2.6856241674977355e-06
ligand O 0 9.748584488988854e-06
beta O 0 1.0299351743014995e-05
- O 0 2.2186373826116323e-05
endorphin O 0 0.00016172981122508645
. O 0 1.1131020073662512e-05

While O 0 1.1370958645784413e-06
a O 0 1.3563564493779268e-07
few O 0 8.285802977070489e-08
cases O 0 1.0990731169613355e-07
of O 0 5.285495490170433e-07
isolated O 1 0.9525426626205444
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999996423721313
have O 0 5.4667925297735565e-08
been O 0 5.088811860787246e-08
reported O 0 1.7100427385230432e-07
( O 0 1.4606125375848933e-07
OMIM O 1 0.992247462272644
201400 O 0 1.9511588106979616e-05
) O 0 2.4000005538482583e-08
, O 0 9.722583627080894e-09
an O 0 3.6672219039246556e-08
inherited O 1 0.999969482421875
POMC O 1 1.0
defect O 1 0.9983108043670654
has O 0 3.135329507131246e-08
not O 0 8.08609712521502e-09
been O 0 2.0043653847778842e-08
described O 0 3.418213623263e-08
so O 0 4.49252262058053e-08
far O 0 5.714769599762803e-07
. O 0 1.8424291283736238e-06

Recent O 0 4.108600933250273e-06
studies O 0 8.60305249261728e-07
in O 0 3.842841778123329e-08
animal O 0 3.5990160540677607e-07
models O 0 1.3289860589793534e-07
elucidated O 0 7.847531833249377e-07
a O 0 2.9579464211337836e-08
central O 0 1.3180529379042127e-07
role O 0 6.113204165103525e-08
of O 0 1.4881611321015953e-07
alpha O 0 1.2279798511372064e-06
- O 0 3.0478245207632426e-06
MSH O 0 0.01964869163930416
in O 0 2.1909931646746372e-08
the O 0 2.14024300504434e-08
regulation O 0 8.485726255003101e-08
of O 0 2.9831934256208115e-08
food O 0 5.899084598581794e-08
intake O 0 1.9650052252018213e-08
by O 0 2.1906074731958824e-09
activation O 0 7.5828566536984e-08
of O 0 1.059309511219908e-07
the O 0 3.2477831268806767e-07
brain O 0 7.872742571635172e-06
melanocortin O 0 6.242476229090244e-05
- O 0 3.956236923841061e-06
4 O 0 1.451482717129693e-06
- O 0 1.0885351002798416e-06
receptor O 0 1.3921281833972898e-06
( O 0 3.121218696833239e-07
MC4 O 0 3.058778020204045e-05
- O 0 1.6187963183256215e-06
R O 0 5.638266316054796e-07
; O 0 5.052370610769685e-08
refs O 0 9.09578091068397e-07
3 O 0 2.793789803945401e-07
- O 0 6.79109888324092e-08
5 O 0 1.6049257922645666e-08
) O 0 5.08090236550629e-10
and O 0 6.209432412696003e-10
the O 0 2.52371679110297e-09
linkage O 0 3.2101598890221794e-07
of O 0 3.8258161083604136e-08
human O 0 4.6850792045916023e-07
obesity B-Disease 1 0.9999873638153076
to O 0 9.442757686883851e-09
chromosome O 0 5.818348824959685e-08
2 O 0 7.773969201707587e-08
in O 0 3.9874468171774424e-09
close O 0 2.175568525331073e-08
proximity O 0 4.244431650590741e-08
to O 0 1.0087409130221658e-08
the O 0 1.8018600655977934e-07
POMC O 0 0.0003300753014627844
locus O 0 2.9491931741176813e-07
, O 0 1.762709800345874e-08
led O 0 2.5317650198530828e-08
to O 0 6.862935109097634e-09
the O 0 2.0796832700398227e-08
proposal O 0 3.298393025374935e-08
of O 0 2.2678841915535486e-08
an O 0 1.766880330933418e-08
association O 0 4.721464392787311e-07
of O 0 1.8494652067602146e-06
POMC O 1 1.0
with O 0 1.7950696928892285e-06
human O 1 0.9858524799346924
obesity B-Disease 1 1.0
. O 0 9.587302884028759e-06

The O 0 4.434924903762294e-06
dual O 0 3.75826061826956e-06
role O 0 1.4364547951117856e-06
of O 0 1.107146886170085e-06
alpha O 0 6.249233138078125e-06
- O 0 1.1059396456403192e-05
MSH O 0 0.13837262988090515
in O 0 3.548012728060712e-08
regulating O 0 2.756471246811998e-07
food O 0 2.0410467982401315e-07
intake O 0 2.0395951594309736e-07
and O 0 2.8582803679455537e-08
influencing O 0 1.943937604664825e-06
hair O 0 2.474852226441726e-05
pigmentation O 0 3.259112054365687e-05
predicts O 0 2.7863927698490443e-07
that O 0 4.514346674255876e-09
the O 0 9.803288847365366e-09
phenotype O 0 5.228632460330118e-08
associated O 0 2.9080137409209783e-08
with O 0 4.140883191894318e-09
a O 0 3.103225765244133e-08
defect O 0 3.2097389066620963e-06
in O 0 2.348672722973788e-07
POMC O 1 0.9999788999557495
function O 0 2.9775545584698193e-08
would O 0 1.4208280774141713e-08
include O 0 2.48416569093024e-07
obesity B-Disease 1 1.0
, O 0 3.789713076685075e-08
alteration O 0 1.5244386304402724e-06
in O 0 3.5303676781950344e-07
pigmentation O 1 0.9999959468841553
and O 1 0.5361378192901611
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
. O 0 7.891226414358243e-05

The O 0 2.4638236482132925e-06
observation O 0 1.1060229553550016e-05
of O 0 1.0057461707901894e-07
these O 0 8.936441986406862e-08
symptoms O 0 0.22364820539951324
in O 0 2.2076674710547195e-08
two O 0 3.58048097837127e-08
probands O 0 7.507310510845855e-05
prompted O 0 7.640362298388936e-08
us O 0 1.2066740495697559e-08
to O 0 2.1438166797338454e-09
search O 0 2.160252776661764e-08
for O 0 1.764519552693855e-08
mutations O 0 2.637172826780443e-07
within O 0 3.375331232291501e-07
their O 0 8.466856797895161e-07
POMC O 1 0.9836603403091431
genes O 0 1.0967966773023363e-05
. O 0 1.4025147720531095e-05

Patient O 0 4.0804161471896805e-06
1 O 0 1.0503780458748224e-06
was O 0 5.4974712782041024e-08
found O 0 4.390017238620203e-09
to O 0 1.2750481781509393e-09
be O 0 4.487604510217125e-09
a O 0 1.3163665713022965e-08
compound O 0 2.5068030140573683e-07
heterozygote O 0 1.6466707393192337e-06
for O 0 2.0282396206994235e-08
two O 0 2.02574987895332e-08
mutations O 0 7.898228915337313e-08
in O 0 4.944490683556069e-08
exon O 0 1.1369691037543816e-06
3 O 0 6.593058401449525e-07
( O 0 4.649803031497868e-08
G7013T O 0 1.695831997494679e-06
, O 0 4.195806724283102e-08
C7133delta O 0 6.664028546765621e-07
) O 0 4.657443319899812e-09
which O 0 1.604046562242445e-09
interfere O 0 1.2758126999301567e-08
with O 0 2.512305696811268e-09
appropriate O 0 8.722888367174164e-08
synthesis O 0 7.8530644032071e-07
of O 0 5.549535444515641e-07
ACTH O 0 1.3416953152045608e-05
and O 0 5.433184924186207e-07
alpha O 0 1.2163246537966188e-05
- O 0 4.7540805098833516e-05
MSH O 0 0.00535612553358078
. O 0 9.2409018179751e-06

Patient O 0 9.689015314506833e-06
2 O 0 5.352490461518755e-06
was O 0 7.506214956265467e-07
homozygous O 0 1.2713095998151402e-07
for O 0 1.930213500145328e-08
a O 0 2.2736099225539874e-08
mutation O 0 4.394803099216915e-08
in O 0 4.921908569599509e-08
exon O 0 1.7012180251185782e-06
2 O 0 2.273875907121692e-06
( O 0 1.849345778737188e-07
C3804A O 0 3.6185992939863354e-06
) O 0 5.684488613155736e-08
which O 0 6.615953651589734e-08
abolishes O 0 1.8344589989283122e-05
POMC O 0 0.0006090576061978936
translation O 0 2.9768625608994626e-05
. O 0 1.0151924470847007e-05

These O 0 3.671085551104625e-07
findings O 0 2.8751057357112586e-07
represent O 0 4.336565595508546e-08
the O 0 1.7192054002634904e-08
first O 0 9.511428089581386e-09
examples O 0 4.52494361979916e-08
of O 0 1.6154878323959565e-08
a O 0 3.897101308325546e-08
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999997615814209
within O 0 1.7254626527574146e-07
the O 0 1.732614123284293e-07
POMC O 0 9.490593947703019e-05
gene O 0 4.5002931159388027e-08
and O 0 1.7041287492247648e-08
define O 0 5.1342052387326476e-08
a O 0 2.8410722663352317e-08
new O 0 2.6980413281307847e-07
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9998981952667236
resulting O 0 5.989193141431315e-07
in O 0 3.17199138066826e-08
early O 0 2.8820477382396348e-06
- O 0 2.0976352971047163e-05
onset O 1 0.9999934434890747
obesity B-Disease 1 1.0
, O 0 1.9551559944375185e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.997277557849884
red O 1 1.0
hair O 0 0.025788702070713043
pigmentation O 0 0.011332085356116295
. O 0 3.4283061722817365e-06
. O 0 9.556677468935959e-06

A O 0 8.015731509658508e-06
European O 0 4.973636350769084e-06
multicenter O 0 6.202411896083504e-05
study O 0 5.59542968403548e-07
of O 0 8.695220685694949e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.878148385818349e-07
classification O 0 1.1853700243591447e-06
of O 0 1.6994944473935902e-07
105 O 0 1.5717364476586226e-07
mutations O 0 2.5166185579905687e-08
and O 0 5.671912273186308e-09
a O 0 4.532612063457009e-09
general O 0 2.0299193437267604e-08
system O 0 3.6123075641825153e-09
for O 0 3.4498741641186825e-09
genotype O 0 7.292668158243032e-08
- O 0 1.5424362231897248e-07
based O 0 5.4987712161391755e-08
prediction O 0 5.094007633488218e-07
of O 0 1.9802190820428223e-07
metabolic O 0 0.00023617743863724172
phenotype O 0 2.0063400370418094e-05
. O 0 1.0686067980714142e-05

Phenylketonuria B-Disease 1 0.9396560192108154
( O 0 4.5288034016266465e-05
PKU B-Disease 1 0.9997285008430481
) O 0 4.499275974012562e-07
and O 0 2.445535756123718e-07
mild B-Disease 1 0.9421374201774597
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.0005222362815402448
MHP B-Disease 1 1.0
) O 0 6.096995264215366e-08
are O 0 1.7480417113802105e-08
allelic B-Disease 1 0.6237624287605286
disorders I-Disease 1 0.9999834299087524
caused O 0 2.4118750729940075e-07
by O 0 1.2630142265379618e-08
mutations O 0 5.022977589419497e-08
in O 0 8.369648973882704e-09
the O 0 2.3391606873701676e-08
gene O 0 7.7527943176392e-08
encoding O 0 8.931651223065273e-07
phenylalanine O 0 1.4633588762080763e-05
hydroxylase O 0 0.00018242762598674744
( O 0 8.24191010906361e-06
PAH O 1 1.0
) O 0 1.1011742344635422e-06
. O 0 1.779823378456058e-06

Previous O 0 5.3854487305216026e-06
studies O 0 1.0576374052106985e-06
have O 0 1.8789627631576877e-08
suggested O 0 4.2533866206895254e-08
that O 0 4.000717979124602e-09
the O 0 1.589792830714032e-08
highly O 0 4.95901666397458e-08
variable O 0 4.3307429109518125e-07
metabolic O 0 0.2937032878398895
phenotypes O 0 0.10010957717895508
of O 1 0.9934753775596619
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.22661638259887695
with O 0 2.8454045605030842e-05
PAH O 1 1.0
genotypes O 1 0.9969412684440613
. O 0 1.9168617654941045e-05

We O 0 6.933591976121534e-07
identified O 0 7.013081813056488e-07
both O 0 1.6653061152283044e-07
causative O 0 2.9248992632346926e-06
mutations O 0 3.8169281424416113e-07
in O 0 5.041338724254274e-08
686 O 0 5.627674909192137e-06
patients O 0 5.192318397462259e-08
from O 0 9.145100676732909e-08
seven O 0 1.9594386913013295e-07
European O 0 2.0302193206589436e-06
centers O 0 3.56963664671639e-06
. O 0 6.203664725035196e-06

On O 0 1.2358536878309678e-06
the O 0 4.970701894535523e-08
basis O 0 6.436727062464342e-08
of O 0 1.3455440317500234e-08
the O 0 1.508720970377908e-08
phenotypic O 0 1.5528044627899362e-07
characteristics O 0 3.751317763089901e-07
of O 0 1.5899755112513958e-07
297 O 0 7.940217869872868e-07
functionally O 0 1.3919330967837595e-06
hemizygous O 0 3.54221219822648e-06
patients O 0 2.2781854625009146e-08
, O 0 6.02205441069259e-09
105 O 0 5.6166342687902215e-08
of O 0 1.058099563522319e-08
the O 0 1.6391792811987216e-08
mutations O 0 2.215665695359803e-08
were O 0 1.9057184275084182e-08
assigned O 0 1.5480914328236395e-08
to O 0 4.56006565840994e-09
one O 0 1.5644051387653235e-08
of O 0 7.237944998905732e-08
four O 0 6.347023173702837e-08
arbitrary O 0 8.511984788128757e-07
phenotype O 0 3.3578219245100627e-06
categories O 0 6.266503987717442e-06
. O 0 7.287269454536727e-06

We O 0 1.566243554407265e-06
proposed O 0 7.427203172483132e-07
and O 0 8.181464039580533e-08
tested O 0 4.6572413481271724e-08
a O 0 5.956801274464851e-09
simple O 0 9.47380396354447e-09
model O 0 8.987118604864008e-09
for O 0 8.413745256063976e-09
correlation O 0 3.307477314251628e-08
between O 0 3.157992267688314e-08
genotype O 0 3.56034462356547e-07
and O 0 6.69996964575148e-08
phenotypic O 0 8.0453463624508e-07
outcome O 0 4.676896878663683e-06
. O 0 1.0582069990050513e-05

The O 0 1.899869971566659e-06
observed O 0 5.757240728598845e-07
phenotype O 0 3.666064856133744e-07
matched O 0 3.4343364063715853e-07
the O 0 5.860472285235119e-08
predicted O 0 1.7608707025829062e-07
phenotype O 0 1.3369999862788973e-07
in O 0 1.3715121482960058e-08
79 O 0 8.4014011747513e-08
% O 0 2.6884356962852962e-09
of O 0 1.7089974990724954e-09
the O 0 2.1590407239813203e-09
cases O 0 4.582333623659451e-09
, O 0 3.176706231400317e-09
and O 0 3.2161451279932862e-09
in O 0 3.0802025374754294e-09
only O 0 5.892188070788507e-09
5 O 0 1.2851987030160217e-08
of O 0 5.42622347055044e-09
184 O 0 1.828720286312091e-08
patients O 0 1.7359963466745398e-09
was O 0 8.57148130251062e-09
the O 0 6.331869695230807e-09
observed O 0 1.4612068000019462e-08
phenotype O 0 1.5384543416985252e-08
more O 0 7.251106937111729e-10
than O 0 1.1740336480769997e-09
one O 0 4.014867549528844e-09
category O 0 2.3685947425633458e-08
away O 0 3.528717584799779e-08
from O 0 2.382363817332589e-08
that O 0 2.6638751648988546e-08
expected O 0 9.538243830320425e-07
. O 0 5.04923355038045e-06

Among O 0 8.845005140756257e-06
the O 0 4.907823836219904e-07
seven O 0 2.311001168209259e-07
contributing O 0 1.780353500180354e-07
centers O 0 1.0010630546730681e-07
, O 0 4.7104209421888754e-09
the O 0 5.238921740868818e-09
proportion O 0 1.9565007391975087e-08
of O 0 9.291804659028458e-09
patients O 0 5.306523664927454e-09
for O 0 1.0610259337795469e-08
whom O 0 1.8613492613894778e-07
the O 0 8.577225685257872e-08
observed O 0 4.326568614487769e-08
phenotype O 0 2.930296183478731e-08
did O 0 1.0841630704305771e-08
not O 0 5.709347217219829e-09
match O 0 1.344783839840602e-07
the O 0 1.3202155457747722e-07
predicted O 0 3.426436023801216e-07
phenotype O 0 1.9625204572548682e-07
was O 0 1.7595932888525567e-07
4 O 0 1.2634835400149314e-07
% O 0 2.220238926042839e-08
- O 0 9.74492166960772e-08
23 O 0 1.412677477219404e-07
% O 0 7.83886910937781e-09
( O 0 7.15098469328268e-09
P O 0 1.2860733988873108e-07
< O 0 7.626181997011372e-08
. O 0 8.576272136906482e-09
0001 O 0 6.870507718303998e-07
) O 0 4.26989332780181e-09
, O 0 2.5101647427305807e-09
suggesting O 0 4.404467901508724e-09
that O 0 6.979974376264408e-10
differences O 0 5.868131314201719e-09
in O 0 7.914237043493699e-10
methods O 0 1.888371237157571e-09
used O 0 2.2256521070573854e-09
for O 0 9.489732333278766e-10
mutation O 0 4.698110345202622e-09
detection O 0 2.5728413177716902e-08
or O 0 1.2523204695469303e-08
phenotype O 0 5.0979050314481356e-08
classification O 0 8.161016040730829e-08
may O 0 1.2159687479140757e-08
account O 0 1.0329186395097167e-08
for O 0 5.240580858156818e-09
a O 0 9.42898914502166e-09
considerable O 0 6.940181407344426e-08
proportion O 0 1.4154649363717908e-07
of O 0 1.925331076790826e-07
genotype O 0 4.8245842663163785e-06
- O 0 5.8906618505716324e-05
phenotype O 0 1.4805093996983487e-05
inconsistencies O 0 8.494401117786765e-05
. O 0 3.398538683541119e-05

Our O 0 2.5161491521430435e-06
data O 0 1.2159534890088253e-06
indicate O 0 4.5361775846686214e-07
that O 0 4.4823888600831197e-08
the O 0 4.011544092463737e-07
PAH O 1 1.0
- O 0 2.239434252260253e-06
mutation O 0 2.399483101100941e-08
genotype O 0 2.5368983358475816e-08
is O 0 1.5228344141249295e-09
the O 0 2.0829888924822626e-09
main O 0 5.0877346779998334e-08
determinant O 0 2.6310132739126857e-07
of O 0 5.415307668954483e-08
metabolic O 0 0.4113732576370239
phenotype O 0 6.598329491680488e-07
in O 0 1.7464653723209267e-08
most O 0 4.907846573587449e-08
patients O 0 3.4934961945509713e-07
with O 0 0.0002516931272111833
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.8097075819969177

In O 0 4.383840064292599e-07
the O 0 1.242044476157389e-07
present O 0 5.332601915597479e-08
study O 0 1.9063836731447736e-08
, O 0 4.7009516279672425e-09
the O 0 7.051689898673885e-09
classification O 0 2.621048338369292e-07
of O 0 3.705652034113882e-07
105 O 0 1.5013189113233238e-05
PAH O 1 1.0
mutations O 0 2.69639741645733e-07
may O 0 8.254110284156013e-09
allow O 0 4.372234574390177e-09
the O 0 6.841501143384221e-09
prediction O 0 1.5206343562113034e-07
of O 0 1.894656875833789e-08
the O 0 4.5476298282665084e-08
biochemical O 0 9.304486070504936e-07
phenotype O 0 2.4090613237603975e-07
in O 0 4.032551714772126e-08
> O 0 2.957439733108913e-07
10 O 0 2.332540702809638e-07
, O 0 2.643517582612276e-08
000 O 0 1.9988321753316995e-07
genotypes O 0 3.6166358086120454e-07
, O 0 1.619016565257425e-08
which O 0 4.60958737846795e-09
may O 0 7.96560950533376e-09
be O 0 3.3495539675243435e-09
useful O 0 3.7265355246063336e-08
for O 0 1.0855805143705766e-08
the O 0 5.60986741504621e-08
management O 0 9.786850796444924e-08
of O 0 4.463721836600598e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.4629058568971232e-06
newborns O 0 1.574506859469693e-05
. O 0 1.0585400559648406e-05

Somatic O 0 0.0012618473265320063
instability O 0 0.0001156179714598693
of O 0 2.4261164526251378e-06
the O 0 1.6966829434750252e-06
CTG O 1 0.9601504802703857
repeat O 0 2.273416384923621e-06
in O 0 1.0678071760139574e-07
mice O 0 1.2672727223161928e-07
transgenic O 0 1.7369519866861083e-07
for O 0 1.459839005235608e-08
the O 0 2.3088796297088265e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.8035216271528043e-05
is O 0 1.2837899632245353e-08
age O 0 2.1430164309776956e-08
dependent O 0 2.5949498549948657e-08
but O 0 3.954395033645142e-09
not O 0 5.379715339870472e-09
correlated O 0 4.133262621053291e-08
to O 0 6.163746402165771e-09
the O 0 3.3351479800103334e-08
relative O 0 8.626385010757076e-07
intertissue O 0 4.339653969509527e-06
transcription O 0 3.7480815535673173e-06
levels O 0 9.945235888153547e-07
and O 0 8.571981311433774e-07
proliferative O 1 0.8184526562690735
capacities O 0 0.00014948048919904977
. O 0 1.2273440006538294e-05

A O 0 0.0002461969561409205
( O 0 2.5984352760133334e-05
CTG O 0 0.00104042561724782
) O 0 3.9932569961820263e-07
nexpansion O 0 6.332473731163191e-06
in O 0 4.623863603114842e-08
the O 0 1.0761472424292151e-07
3 O 0 8.707841629984614e-07
- O 0 7.193984288278443e-07
untranslated O 0 0.00022337546397466213
region O 0 1.7001150354190031e-06
( O 0 1.4812074766723526e-07
UTR O 0 0.1508057415485382
) O 0 4.354144422791251e-08
of O 0 9.112488186246992e-08
the O 0 3.978644826929667e-07
DM O 1 1.0
protein O 0 2.04554567062587e-06
kinase O 0 2.564346914368798e-06
gene O 0 4.64516290321626e-07
( O 0 3.292365988727397e-07
DMPK O 1 0.9999738931655884
) O 0 2.8794731932180184e-08
is O 0 3.1156848212532395e-09
responsible O 0 6.1226423930804685e-09
for O 0 1.8086046438270387e-08
causing O 0 0.000900755578186363
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9954244494438171
DM B-Disease 1 1.0
) O 0 2.256636889796937e-06
. O 0 2.06222807719314e-06

Major O 0 7.186135917436332e-05
instability O 0 1.4814656424277928e-05
, O 0 9.179107962609123e-08
with O 0 8.283934427311124e-09
very O 0 1.1281621858927338e-08
large O 0 3.807492987562e-08
expansions O 0 1.22442443739601e-07
between O 0 2.4056101111114003e-08
generations O 0 5.3704912517105186e-08
and O 0 1.7867908042035197e-08
high O 0 5.6981228624408686e-08
levels O 0 3.260624481526975e-08
of O 0 2.710628876911869e-08
somatic O 0 0.0003047719073947519
mosaicism O 0 0.02077515423297882
, O 0 8.403581119864612e-08
is O 0 1.3238321550090859e-08
observed O 0 1.0106421655109443e-07
in O 0 8.521147520923478e-08
patients O 0 4.5974462636877433e-07
. O 0 2.6602856451063417e-06

There O 0 6.766209139641433e-07
is O 0 6.29533616347544e-08
a O 0 7.087601261446252e-08
good O 0 8.024842657050613e-08
correlation O 0 1.2847702635099267e-07
between O 0 6.810076058627601e-08
repeat O 0 1.1434876512339542e-07
size O 0 1.1219910334148153e-07
( O 0 2.0992992233459518e-08
at O 0 1.553178563540314e-08
least O 0 7.164596027564585e-09
in O 0 6.368799709832729e-09
leucocytes O 0 1.3104541949360282e-06
) O 0 5.61193003179028e-09
, O 0 4.042152390582032e-09
clinical O 0 2.5384181867593725e-08
severity O 0 3.931954495328682e-07
and O 0 6.285222298174631e-08
age O 0 6.471885285463941e-07
of O 0 1.3673612784259603e-06
onset O 0 0.0005106223397888243
. O 0 1.676685133134015e-05

The O 0 1.025426718115341e-05
trinucleotide O 1 0.9995688796043396
repeat O 0 1.989242809941061e-05
instability O 0 1.7317137462669052e-05
mechanisms O 0 9.988169949792791e-06
involved O 0 2.711151978473936e-07
in O 0 9.199351325150928e-08
DM B-Disease 1 1.0
and O 0 9.710133497264906e-08
other O 0 1.6577082817548217e-07
human O 0 1.9698027244885452e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 1.219762566506688e-07
unknown O 0 7.0331007009372115e-06
. O 0 2.1891025880904635e-06

We O 0 1.6821807093947427e-06
studied O 0 4.364198957773624e-06
somatic O 0 2.6121371774934232e-05
instability O 0 1.770588255567418e-06
by O 0 8.103099702339023e-08
measuring O 0 1.825373374231276e-06
the O 0 3.518187554618635e-07
CTG O 0 3.341345291119069e-05
repeat O 0 2.154455529534971e-07
length O 0 5.825789273217197e-08
at O 0 2.2790024090113548e-08
several O 0 1.14539933093738e-08
ages O 0 1.0684427564910948e-07
in O 0 5.924666979240101e-09
various O 0 2.4535104614642478e-08
tissues O 0 1.058307859125307e-07
of O 0 3.42867423341886e-08
transgenic O 0 6.631986479987972e-07
mice O 0 8.55286756973328e-08
carrying O 0 1.6365542876428663e-07
a O 0 2.1433112351587624e-07
( O 0 2.7684711767506087e-07
CTG O 0 2.6840702048502862e-05
) O 0 1.1370510577535242e-07
55expansion O 0 3.6281815027905395e-06
surrounded O 0 3.9797529893803585e-07
by O 0 1.643650016092124e-08
45 O 0 1.1335895777619953e-07
kb O 0 1.0418372085041483e-06
of O 0 6.766429549998065e-08
the O 0 1.1888882056609873e-07
human O 0 1.2112463991797995e-06
DM B-Disease 1 1.0
region O 0 5.589674856310012e-07
, O 0 3.172523932448712e-08
using O 0 3.569509843259766e-08
small O 0 1.389069979040869e-07
- O 0 1.4735740023752442e-06
pool O 0 3.3579597129573813e-06
PCR O 0 1.3874569049221464e-05
. O 0 7.561829534097342e-06

These O 0 2.2328001705318457e-06
mice O 0 4.4682323618872033e-07
have O 0 1.9122577299413024e-08
been O 0 1.1108538977566695e-08
shown O 0 3.5052043489969265e-09
to O 0 1.1106711106378953e-09
reproduce O 0 2.2177077951823776e-08
the O 0 2.642589969070741e-08
intergenerational O 0 6.17607042840973e-07
and O 0 2.351942285372388e-08
somatic O 0 6.4191481214948e-06
instability O 0 7.6223409450904e-07
of O 0 1.3560124045852717e-07
the O 0 2.659494384715799e-07
55 O 0 9.450685638512368e-07
CTG O 0 2.0756209778483026e-05
repeat O 0 2.52318443472177e-07
suggesting O 0 1.5453647961294337e-07
that O 0 5.2076094547715e-09
surrounding O 0 2.9343116381141954e-08
sequences O 0 1.3169390911116352e-08
and O 0 9.662463718029812e-09
the O 0 1.8549551228375094e-08
chromatin O 0 1.4471744407273945e-06
environment O 0 9.79430225811484e-08
are O 0 1.3580774727017797e-08
involved O 0 3.794523095734803e-08
in O 0 6.263955043550595e-08
instability O 0 4.485986210056581e-06
mechanisms O 0 3.134417056571692e-05
. O 0 1.030110888677882e-05

As O 0 7.563492658846371e-07
observed O 0 1.519435528507529e-07
in O 0 1.0353486068481743e-08
some O 0 8.964213371598362e-09
of O 0 2.1909595915303726e-08
the O 0 2.3931393755560748e-08
tissues O 0 7.950872031869949e-07
of O 0 1.1763585234803031e-06
DM B-Disease 1 1.0
patients O 0 1.8834376191989577e-07
, O 0 3.849596197369465e-09
there O 0 3.424045269539988e-09
is O 0 2.4738466830598327e-09
a O 0 3.865614051079547e-09
tendency O 0 3.1890316165572585e-08
for O 0 1.5457015223319104e-08
repeat O 0 9.339444062561597e-08
length O 0 4.275518605822981e-08
and O 0 3.463781084178663e-08
somatic O 0 8.466908184345812e-06
mosaicism O 0 2.3302070530917263e-06
to O 0 3.744381249504158e-09
increase O 0 3.458933361955019e-09
with O 0 1.2226333279130586e-09
the O 0 1.1579994740884558e-08
age O 0 6.907456651106259e-08
of O 0 6.760018322893302e-08
the O 0 2.8744804581037897e-07
mouse O 0 3.4805707400664687e-06
. O 0 5.488499937200686e-06

Furthermore O 0 6.8306758294056635e-06
, O 0 2.0481738260968996e-07
we O 0 2.9327004824608593e-08
observed O 0 4.661978181275117e-08
no O 0 1.682435346594957e-08
correlation O 0 3.222661959512152e-08
between O 0 1.0658614435499203e-08
the O 0 1.3623556505137913e-08
somatic O 0 1.888746851363976e-06
mutation O 0 7.2730124145437e-08
rate O 0 3.9374775440137455e-08
and O 0 3.6113444679131135e-08
tissue O 0 5.048752427683212e-06
proliferation O 0 0.016041433438658714
capacity O 0 4.1958496694860514e-06
. O 0 2.687391770450631e-06

The O 0 1.6385185972467298e-06
somatic O 0 1.3334462892089505e-05
mutation O 0 2.8402115503922687e-07
rates O 0 4.5949214211304934e-08
in O 0 3.884090826744568e-09
different O 0 4.192492575327833e-09
tissues O 0 5.121763635429488e-08
were O 0 2.254815356650397e-08
also O 0 3.6761560462394982e-09
not O 0 1.838599605896718e-09
correlated O 0 2.0525941835103367e-08
to O 0 2.2561563728373812e-09
the O 0 2.386015474087344e-08
relative O 0 8.01016028617596e-07
inter O 0 0.0017150319181382656
- O 0 1.965950104931835e-06
tissue O 0 4.024714428396692e-07
difference O 0 6.50846558869489e-08
in O 0 2.84640799819158e-09
transcriptional O 0 6.674319763533276e-08
levels O 0 1.9037857512671508e-08
of O 0 1.1841295943781915e-08
the O 0 1.6795144830439312e-08
three O 0 1.7714256728140754e-08
genes O 0 1.234875384170664e-07
( O 0 2.65265782672941e-07
DMAHP O 1 0.687454104423523
, O 0 2.12574775559915e-07
DMPK O 0 0.0032784079667180777
and O 0 2.6381187012702867e-07
59 O 0 9.085359806704218e-07
) O 0 3.565698847296517e-08
surrounding O 0 1.5243892903527012e-07
the O 0 1.6346481856999162e-07
repeat O 0 2.1577054667432094e-06
. O 0 1.0583295306787477e-06
. O 0 5.1160504881409e-06

A O 0 9.13256371859461e-06
novel O 0 1.6705598682165146e-06
missense O 0 5.026254711992806e-06
mutation O 0 1.893118763973689e-07
in O 0 2.835117740573878e-08
patients O 0 2.6962579724454372e-08
from O 0 3.9608053725714853e-08
a O 0 8.368822790316699e-08
retinoblastoma B-Disease 1 0.768752932548523
pedigree O 0 7.150139481382212e-06
showing O 0 3.7271612995937176e-07
only O 0 4.161185174211823e-08
mild O 0 2.4762820771684346e-07
expression O 0 5.2943338602062795e-08
of O 0 4.9814843805506825e-08
the O 0 1.7288739684317989e-07
tumor B-Disease 0 1.1062445082643535e-05
phenotype O 0 3.8620419218204916e-06
. O 0 3.8309167393890675e-06

We O 0 1.0998822972396738e-06
have O 0 7.006096325312683e-08
used O 0 1.062828971498675e-07
single O 0 1.7509674421489763e-07
strand O 0 4.343892214819789e-07
conformation O 0 5.1419863922319564e-08
polymorphism O 0 6.042179023779681e-08
analysis O 0 1.1317398573851278e-08
to O 0 4.128549058179942e-09
study O 0 9.070952877721083e-09
the O 0 2.0055967553389564e-08
27 O 0 1.4785261726046883e-07
exons O 0 3.7604945646307897e-07
of O 0 4.223749172638236e-08
the O 0 2.834937617990363e-07
RB1 O 0 0.0006234112079255283
gene O 0 5.211934706039756e-08
in O 0 1.387822035070485e-08
individuals O 0 7.812375635296576e-09
from O 0 1.452689435410548e-08
a O 0 1.349383715876229e-08
family O 0 3.0328088485021e-08
showing O 0 1.7190554046919715e-07
mild O 0 2.647752239681722e-07
expression O 0 7.437524374154236e-08
of O 0 6.866316226705749e-08
the O 0 4.636660833057249e-07
retinoblastoma B-Disease 0 6.595471495529637e-05
phenotype O 0 9.960527677321807e-06
. O 0 7.0009259616199415e-06

In O 0 5.241108738118783e-07
this O 0 5.338830533219152e-08
family O 0 1.1441191816174978e-07
affected O 0 4.2900836660919595e-08
individuals O 0 6.256477558252982e-09
developed O 0 1.0700682651076932e-07
unilateral B-Disease 0 8.887790272638085e-07
tumors I-Disease 1 1.0
and O 0 6.503551475134373e-08
, O 0 6.9861583185115705e-09
as O 0 7.664793244543944e-09
a O 0 2.5288773297660327e-09
result O 0 1.5623177418433443e-08
of O 0 2.165871926251839e-08
linkage O 0 3.9386011962960765e-07
analysis O 0 3.6202415287789336e-08
, O 0 1.651137715441564e-08
unaffected O 0 8.802947348840462e-08
mutation O 0 1.5341672821023167e-08
carriers O 0 5.223778032359405e-08
were O 0 4.036576584098839e-08
also O 0 1.8399967771642878e-08
identified O 0 6.844741307077129e-08
within O 0 1.1794213605753612e-07
the O 0 5.389925945564755e-07
pedigree O 0 2.4524571927031502e-05
. O 0 9.097836482396815e-06

A O 0 9.915339433064219e-06
single O 0 7.087891162882443e-07
band O 0 8.629520493741438e-07
shift O 0 2.1381380577167874e-07
using O 0 9.84686181482175e-08
SSCP O 0 0.0003316847141832113
was O 0 1.0457387844553523e-07
identified O 0 8.786877714328512e-08
in O 0 1.6867828023237053e-08
exon O 0 3.0259909067353874e-07
21 O 0 1.4137623338683625e-07
which O 0 4.434628664284901e-09
resulted O 0 3.995610597939958e-08
in O 0 1.0909940506564908e-08
a O 0 4.864538638571503e-08
missense O 0 9.9841986411775e-07
mutation O 0 1.0042893450190604e-07
converting O 0 6.197618063197297e-07
a O 0 2.945876076410059e-07
cys O 0 1.7049087546183728e-05
- O 0 5.18960314366268e-06
- O 0 5.503710326593136e-06
> O 0 2.12753161576984e-06
arg O 0 2.7734392915590433e-06
at O 0 8.426903264080465e-08
nucleotide O 0 1.888425060769805e-07
position O 0 2.923450210801093e-07
28 O 0 2.621270880354132e-07
in O 0 2.0769320485669596e-08
the O 0 3.004166728715063e-07
exon O 0 1.298770439461805e-05
. O 0 6.348127953970106e-06

The O 0 5.9546846387092955e-06
mutation O 0 3.651511406133068e-06
destroyed O 0 1.3573308024206199e-05
an O 0 5.389284183365817e-07
NdeI O 0 3.561967969289981e-05
restriction O 0 4.032339347759262e-06
enzyme O 0 7.992282007762697e-06
site O 0 1.1393307431717403e-05
. O 0 5.214831162447808e-06

Analysis O 0 1.0982796538883122e-06
of O 0 2.4412830157416465e-07
all O 0 7.728699102926839e-08
family O 0 7.18977304359214e-08
members O 0 2.1647444725658715e-08
demonstrated O 0 3.6236539102674215e-08
that O 0 2.676677990365306e-09
the O 0 1.2747181088457182e-08
missense O 0 4.967489530827152e-07
mutation O 0 1.518386767429547e-07
co O 0 6.294753802649211e-07
- O 0 3.2017260309658013e-06
segregated O 0 3.305210896087374e-07
with O 0 1.4374228030078484e-08
patients O 0 4.721811208696636e-08
with O 0 9.753196650308382e-08
tumors B-Disease 1 1.0
or O 0 4.550668109004619e-06
who O 0 8.736208911841459e-08
, O 0 4.225866323537275e-09
as O 0 1.866687915352827e-09
a O 0 1.2646576008634725e-09
result O 0 3.4668130588499935e-09
of O 0 9.27355081614678e-09
linkage O 0 2.57172075635026e-07
analysis O 0 3.530434256049375e-08
had O 0 2.6678463882490178e-08
been O 0 8.0090281073808e-09
predicted O 0 3.4012590077736604e-08
to O 0 6.85755718876635e-09
carry O 0 8.322962230522535e-08
the O 0 3.640908516899799e-07
predisposing O 0 4.345491106505506e-05
mutation O 0 4.3029594962717965e-06
. O 0 6.5454851210233755e-06

These O 0 1.3367670135266962e-06
observations O 0 1.6831788798299385e-06
point O 0 2.5421499572075845e-07
to O 0 1.6314842810061236e-08
another O 0 5.530768731887292e-08
region O 0 2.406060275461641e-07
of O 0 8.465421075243285e-08
the O 0 4.6070582016000117e-07
RB1 O 0 0.3934381902217865
gene O 0 1.0458864352358432e-07
where O 0 2.1993082910398698e-08
mutations O 0 6.092366167109731e-09
only O 0 1.1465177696123874e-09
modify O 0 6.216012149451444e-09
the O 0 2.565103018881132e-09
function O 0 1.8789583222655892e-09
of O 0 1.8532354539857465e-09
the O 0 4.030358269346834e-09
gene O 0 7.887657638150358e-09
and O 0 8.650316019043203e-09
raise O 0 1.8204030283186512e-08
important O 0 1.937383764527567e-08
questions O 0 9.009379020596953e-09
for O 0 4.417281207480528e-09
genetic O 0 7.380250366395558e-08
counseling O 0 2.7811728031679195e-08
in O 0 9.397998823601483e-09
families O 0 6.439093702681475e-09
with O 0 6.269534225111784e-09
these O 0 6.549635145347565e-08
distinctive O 0 1.481863364460878e-06
phenotypes O 0 3.098739398410544e-06
. O 0 5.878546289750375e-07
. O 0 3.5358873446966754e-06

Maternal B-Disease 0 0.0005802017403766513
disomy I-Disease 0 0.04660491272807121
and O 0 2.1530069716391154e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.0007498328923247755
with O 0 1.5809517606157897e-07
gamete O 0 2.6620660719345324e-05
complementation O 0 1.494332536822185e-05
in O 0 2.919417774194244e-08
a O 0 2.631388973384219e-08
case O 0 1.2071049582118576e-07
of O 0 2.5836067152340547e-07
familial O 0 1.9749563762161415e-06
translocation O 0 1.0362206921854522e-05
( O 0 3.841589091280184e-07
3 O 0 4.772015245180228e-07
; O 0 3.799092596068476e-08
15 O 0 1.3878437243874941e-07
) O 0 3.513526181109228e-08
( O 0 6.069242175499312e-08
p25 O 0 2.958778395623085e-06
; O 0 8.955380792485812e-08
q11 O 0 2.834839506249409e-06
. O 0 1.9509788273808226e-07
2 O 0 1.3431232446237118e-06
) O 0 3.0777707138440746e-07
. O 0 1.3113242403051117e-06

Maternal B-Disease 1 0.9991740584373474
uniparental I-Disease 1 0.9999995231628418
disomy I-Disease 1 0.9999964237213135
( I-Disease 0 6.652263255091384e-05
UPD I-Disease 1 1.0
) I-Disease 0 1.4828880523509724e-07
for I-Disease 0 3.633093825783362e-08
chromosome I-Disease 0 2.572810160472727e-07
15 I-Disease 0 2.7372923483426348e-08
is O 0 1.1212241135538648e-09
responsible O 0 1.6486758624978393e-09
for O 0 1.1337961680624176e-09
an O 0 1.4622152377796738e-09
estimated O 0 4.042846502017028e-09
30 O 0 6.0403686497068065e-09
% O 0 6.731564194950579e-10
of O 0 7.909890520352292e-10
cases O 0 6.860226164917549e-09
of O 0 2.2280279665665148e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
PWS B-Disease 1 1.0
) O 0 1.1777811778301839e-05
. O 0 3.86388774131774e-06

We O 0 6.756343964298139e-07
report O 0 3.1306092296290444e-07
on O 0 4.695156263778699e-08
an O 0 3.6800846814344368e-09
unusual O 0 1.1557707679799023e-08
case O 0 5.459539664798285e-08
of O 0 1.1730923432651252e-07
maternal B-Disease 0 0.12504899501800537
disomy I-Disease 1 0.9999516010284424
15 I-Disease 0 1.5557527603959898e-06
in O 0 1.1149596446102805e-07
PWS B-Disease 1 1.0
that O 0 2.1827757379355717e-08
is O 0 9.135508349800148e-09
most O 0 5.392659652159182e-09
consistent O 0 5.1491511499079934e-08
with O 0 1.5754755722241498e-08
adjacent O 0 4.927703685098095e-07
- O 0 6.239319532141963e-07
1 O 0 3.3758271911210613e-07
segregation O 0 1.4391022773452278e-07
of O 0 2.4074276794294747e-08
a O 0 4.711600354312395e-08
paternal O 0 2.9509417345252587e-06
t O 0 9.014020747599716e-07
( O 0 8.364274606265099e-08
3 O 0 1.83805227038647e-07
; O 0 2.5729493202675258e-08
15 O 0 5.098955568882957e-08
) O 0 7.751106423370402e-09
( O 0 1.757908485444659e-08
p25 O 0 8.05286902050284e-07
; O 0 2.8818304187439026e-08
q11 O 0 7.980384566508292e-07
. O 0 1.5583358603521447e-08
2 O 0 4.085466898118284e-08
) O 0 1.6261896274016863e-09
with O 0 1.2712308983253706e-09
simultaneous O 0 1.056277056932231e-07
maternal O 0 2.3489913019147934e-06
meiotic O 0 2.0119654436712153e-05
nondisjunction O 0 5.6235618103528395e-05
for O 0 3.938285715321399e-07
chromosome O 0 3.921692496078322e-06
15 O 0 2.253653974548797e-06
. O 0 2.1030680272815516e-06

The O 0 6.090956048865337e-06
patient O 0 7.0038577177911066e-06
( O 0 5.878389401914319e-07
J O 0 6.184656285768142e-06
. O 0 6.704610910901465e-08
B O 0 6.050668162060902e-07
. O 0 6.550332720678398e-09
) O 0 2.313980784762748e-09
, O 0 2.403416576868267e-09
a O 0 6.329575530372722e-09
17 O 0 4.911199269486133e-08
- O 0 4.476937576214368e-08
year O 0 2.1801461969062075e-08
- O 0 3.117645803740743e-07
old O 0 1.648301690693188e-06
white O 0 1.2546927052881074e-07
male O 0 1.023566014168864e-07
with O 0 8.189160638494286e-08
PWS B-Disease 1 1.0
, O 0 2.2506053198867448e-07
was O 0 5.599038743753226e-08
found O 0 4.324075320027987e-09
to O 0 6.949451236692994e-09
have O 0 1.546839989430282e-08
47 O 0 2.213932219774506e-07
chromosomes O 0 6.958234166631883e-08
with O 0 1.3103044871343172e-08
a O 0 8.312981947256048e-08
supernumerary O 0 1.6423437045887113e-05
, O 0 1.9459523059595085e-07
paternal O 0 0.00010365671914769337
der O 0 0.13004504144191742
( O 0 8.84470310325014e-08
15 O 0 1.5127989172469825e-07
) O 0 2.248655261993804e-09
consisting O 0 6.570202604194719e-09
of O 0 9.372204345936552e-09
the O 0 2.4023361078207017e-08
short O 0 6.843383459909091e-08
arm O 0 9.866545980230512e-08
and O 0 1.974510333013768e-08
the O 0 2.3950531158334343e-07
proximal O 0 0.2192106395959854
long O 0 8.48786044116423e-07
arm O 0 2.4372152438445482e-06
of O 0 4.0411106283499976e-07
chromosome O 0 1.8750390609056922e-06
15 O 0 1.1828360584331676e-06
, O 0 1.6597188334799284e-07
and O 0 5.906103979214095e-07
distal O 0 0.00012104051711503416
chromosome O 0 0.0004516034678090364
arm O 0 0.003760515945032239
3p O 1 0.6000173687934875
. O 0 4.575788261718117e-05

The O 0 1.4410004041565116e-05
t O 0 5.8992472986574285e-06
( O 0 3.0246263804656337e-07
3 O 0 1.3735258619362867e-07
; O 0 8.030244025292177e-09
15 O 0 1.5506330441894534e-08
) O 0 7.788595879354432e-10
was O 0 3.3361897688877207e-09
present O 0 1.1163970858873995e-09
in O 0 8.501155890350276e-10
the O 0 2.6262032548629577e-09
balanced O 0 7.544277202953253e-09
state O 0 1.9406523055209846e-09
in O 0 2.165515766705539e-09
the O 0 1.552532857829192e-08
patients O 0 1.949862138417302e-08
father O 0 2.244089785108372e-07
and O 0 7.76884050424087e-08
a O 0 5.190971705815173e-07
sister O 0 1.050382707035169e-05
. O 0 7.1197919169208035e-06

Fluorescent O 0 4.3761196138802916e-05
in O 0 4.717157366940228e-07
situ O 0 1.184127199849172e-06
hybridization O 0 1.2651484837533644e-07
analysis O 0 2.0719467030971828e-08
demonstrated O 0 4.930571506633896e-08
that O 0 7.691093983908104e-09
the O 0 1.305606218693356e-07
PWS B-Disease 1 1.0
critical O 0 1.5192312048384338e-06
region O 0 4.3643424874062475e-07
resided O 0 3.2508199865333154e-07
on O 0 5.996748342340652e-08
the O 0 1.48837333568963e-08
derivative O 0 4.3543852967786734e-08
chromosome O 0 5.069920305800224e-08
3 O 0 2.9415797797582854e-08
and O 0 1.7337793423166659e-09
that O 0 6.724031331728497e-10
there O 0 4.075207726828012e-09
was O 0 1.396361071215324e-08
no O 0 4.348424287314856e-09
deletion O 0 1.362010060290686e-08
of O 0 4.879127146750761e-08
the O 0 3.622061797159404e-07
PWS B-Disease 1 1.0
region O 0 2.9452398848661687e-06
on O 0 2.017787466002119e-07
the O 0 5.1882494744859287e-08
normal O 0 1.464115797489285e-07
pair O 0 3.272672302045976e-07
of O 0 2.9710852800235443e-07
15s O 0 1.723290370136965e-05
present O 0 8.057278932938061e-07
in O 0 8.856863473738485e-07
J O 0 0.00034918065648525953
. O 0 8.71142401592806e-06

B O 0 0.027375712990760803
. O 0 0.0001286171464016661

Methylation O 0 1.2751804206345696e-05
analysis O 0 3.4268091440026183e-06
at O 0 8.488621574542776e-07
exon O 0 1.5757257187942741e-06
alpha O 0 6.245463737286627e-07
of O 0 4.715187174042512e-08
the O 0 5.0070894985765335e-08
small O 0 1.1125633392339296e-07
nuclear O 0 1.960565214176313e-06
ribonucleoprotein O 0 1.590094507264439e-05
- O 0 1.988676103792386e-06
associated O 0 4.3820512019010494e-07
polypeptide O 0 4.25115422331146e-06
N O 0 3.02078592540056e-06
( O 0 1.2086461254057212e-07
SNRPN O 0 0.00016081945796031505
) O 0 1.1634256225079298e-08
gene O 0 9.195558980934493e-09
showed O 0 1.0005434702975435e-08
a O 0 3.0251350313648118e-09
pattern O 0 2.4931553710416665e-08
characteristic O 0 2.5733566388908002e-08
of O 0 5.534903202430996e-09
only O 0 7.163735382675895e-09
the O 0 5.345820497382192e-08
maternal O 0 5.082185907667736e-06
chromosome O 0 2.1744706373283407e-06
15 O 0 1.2176186601209338e-06
in O 0 4.365758172752976e-07
J O 0 0.0002369081776123494
. O 0 1.2639835404115729e-05

B O 0 0.029713550582528114
. O 0 0.00018029716738965362

Maternal B-Disease 0 0.0067448425106704235
disomy I-Disease 0 0.0013027348322793841
was O 0 2.2054468900023494e-06
confirmed O 0 2.301896984135965e-07
by O 0 1.8966094472716577e-08
polymerase O 0 5.498561108652211e-07
chain O 0 1.923831547401278e-07
reaction O 0 7.584563377349696e-08
analysis O 0 9.079646190457424e-08
of O 0 1.316365825232424e-07
microsatellite O 0 1.8530049601395149e-06
repeats O 0 7.727732622697658e-07
at O 0 1.6571517846841743e-07
the O 0 1.736584351874626e-07
gamma O 0 2.329469225514913e-06
- O 0 2.6835243716050172e-06
aminobutyric O 0 1.0254051630909089e-05
acid O 0 6.166089292491961e-07
receptor O 0 1.963740714927553e-06
beta3 O 0 4.6811496758891735e-06
subunit O 0 1.056468022397894e-06
( O 0 1.0735984687926248e-06
GABRB3 O 0 0.00017243502952624112
) O 0 8.607180461694952e-07
locus O 0 7.19847776053939e-06
. O 0 5.493212483997922e-06

A O 0 5.309928019414656e-05
niece O 0 7.129489677026868e-05
( O 0 9.217439469466626e-07
B O 0 4.5780566324538086e-06
. O 0 4.2868606442425516e-08
B O 0 4.694592234955053e-07
. O 0 6.6903131923368164e-09
) O 0 2.186491654398992e-09
with O 0 1.5557215515826783e-09
45 O 0 1.347763323167328e-08
chromosomes O 0 1.4422039562589362e-08
and O 0 4.769028283391208e-09
the O 0 5.720040441303809e-09
derivative O 0 3.0517778526473194e-08
3 O 0 1.6737647712261605e-08
but O 0 1.7956591769063834e-09
without O 0 1.15836620295795e-08
the O 0 9.20642477808542e-08
der O 0 1.6550762666156515e-05
( O 0 2.0490579899501427e-08
15 O 0 3.429720862868635e-08
) O 0 2.715838887112909e-09
demonstrated O 0 1.1091770169002757e-08
a O 0 6.334744284686167e-09
phenotype O 0 5.457384588680725e-08
consistent O 0 7.079778185925534e-08
with O 0 4.770802419784559e-09
that O 0 7.231663268214561e-09
reported O 0 8.037465448751391e-08
for O 0 6.912241445888867e-08
haploinsufficiency O 0 4.631154297385365e-05
of O 0 1.1961398058701889e-06
distal O 0 8.161219011526555e-05
3 O 0 4.350363451521844e-05
p O 0 1.444225199520588e-05
. O 0 6.571498033736134e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999973773956299
associated O 0 6.302193469309714e-06
with O 0 2.0798684374767618e-07
unbalanced O 0 2.202361065428704e-05
segregation O 0 9.452612175664399e-06
of O 0 7.80987363668828e-07
non O 0 1.1798092600656673e-05
- O 0 2.163819544875878e-06
Robertsonian O 0 8.753839210839942e-06
translocations O 0 1.5159170061451732e-06
has O 0 1.2154540485198595e-08
been O 0 7.461135709263544e-09
reported O 0 1.0468199640456533e-08
previously O 0 6.480715075696253e-09
but O 0 2.1770369951212842e-09
has O 0 1.6335510721887658e-09
not O 0 1.5580675638560137e-09
, O 0 2.9623770103626157e-09
to O 0 2.7713749073399185e-09
our O 0 1.8619843444867e-08
knowledge O 0 1.2166024987436685e-07
, O 0 1.687461725907724e-08
been O 0 1.3119525021920708e-08
observed O 0 2.1802877725463077e-08
in O 0 6.7245995438725e-09
a O 0 2.5404768067005534e-08
case O 0 6.76634499541251e-07
of O 0 1.2318246263021138e-05
PWS B-Disease 1 1.0
. O 0 0.00010051443678094074

Furthermore O 0 2.7599204258876853e-05
, O 0 6.754675609954575e-07
our O 0 2.6461214019946055e-07
findings O 0 2.8910665150760906e-07
are O 0 2.281089805933334e-08
best O 0 7.202235963177372e-08
interpreted O 0 4.2081492779288965e-07
as O 0 1.2507716462550889e-07
true O 0 5.670345899488893e-07
gamete O 0 9.353969289804809e-06
complementation O 0 2.454422792652622e-05
resulting O 0 1.106468175748887e-06
in O 0 7.866939881751023e-07
maternal B-Disease 1 0.9979962706565857
UPD I-Disease 1 1.0
15 I-Disease 0 0.00018731722957454622
and O 0 4.913921657134779e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.8925551176071167
- I-Disease 1 0.9999523162841797
Jampel I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999971389770508
type I-Disease 0 1.3329300600162242e-05
2 I-Disease 0 2.7632379442366073e-06
and O 0 1.7358011916712712e-07
Stuve B-Disease 1 0.7927059531211853
- I-Disease 0 0.17434678971767426
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
: O 0 5.95281797188818e-08
a O 0 2.6964739774371083e-08
case O 0 5.657566148897786e-08
for O 0 3.0922240767949916e-08
" O 0 3.4881662713814876e-07
lumping O 0 4.7282642299251165e-06
" O 0 2.475392420819844e-06
. O 0 6.092902367527131e-06

Recent O 0 2.4418682187388185e-06
studies O 0 5.976515353722789e-07
demonstrated O 0 1.8483882513464778e-07
the O 0 4.1316074117503376e-08
existence O 0 6.947942665647133e-08
of O 0 3.710393414735336e-08
a O 0 2.5794403057943782e-08
genetically O 0 1.692872046987759e-07
distinct O 0 8.115813443509978e-08
, O 0 7.257945799921117e-09
usually O 0 5.809507985787832e-09
lethal O 0 2.6909816597253666e-08
form O 0 1.214937128679594e-08
of O 0 4.267029396487487e-08
the O 0 1.3435904122616193e-07
Schwartz B-Disease 0 9.432931256014854e-05
- I-Disease 1 0.9761631488800049
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.34607781143859e-05
SJS B-Disease 1 1.0
) O 0 2.82647704352712e-07
of O 0 8.548497135052457e-06
myotonia B-Disease 1 1.0
and O 0 0.1394045650959015
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.956155983862118e-06
which O 0 2.638988760850225e-08
we O 0 5.4146674699495634e-08
called O 0 4.1231140812669764e-07
SJS B-Disease 0 0.05416855216026306
type I-Disease 0 6.849442797829397e-06
2 I-Disease 0 8.800227078609169e-06
. O 0 1.4727872894582106e-06

This O 0 1.8519274362915894e-06
disorder O 1 0.9981845021247864
is O 0 6.05252594709782e-08
reminiscent O 0 1.0368268021920812e-06
of O 0 7.557588332929299e-08
another O 0 6.213880965333374e-08
rare O 0 8.025026687619174e-08
condition O 0 5.305185482029628e-07
, O 0 3.8460608919876904e-08
the O 0 1.6151679460563173e-07
Stuve B-Disease 1 0.9998515844345093
- I-Disease 1 0.9999946355819702
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9863976836204529
SWS B-Disease 1 0.9999998807907104
) O 0 3.454313457496028e-08
, O 0 6.70451827389229e-09
which O 0 4.108203999209081e-09
comprises O 0 5.1254382071874716e-08
campomelia B-Disease 0 1.99228434212273e-05
at O 0 2.3270970928024326e-07
birth O 0 2.1097353055665735e-06
with O 0 5.728733185605961e-07
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 0.00043026081402786076
contractures B-Disease 1 0.9999979734420776
, O 0 2.903184679325932e-07
and O 0 7.989806505293018e-08
early B-Disease 0 2.3617658371222205e-06
death I-Disease 0 8.557771252526436e-06
. O 0 5.452366622193949e-06

To O 0 1.5733741065560025e-07
test O 0 5.136261904681305e-08
for O 0 2.089802997318202e-08
possible O 0 2.5191502572852187e-07
nosologic O 0 3.088561788899824e-05
identity O 0 1.5639344042028824e-07
between O 0 6.773131389081755e-08
these O 0 8.739725387840735e-08
disorders O 0 0.10727108269929886
, O 0 1.766974833117274e-08
we O 0 7.810274205155565e-09
reviewed O 0 2.9420231584253997e-08
the O 0 6.064495128299541e-09
literature O 0 4.126527741732389e-08
and O 0 2.9076461238730644e-09
obtained O 0 7.596518969421595e-09
a O 0 5.631175969966762e-09
follow O 0 1.314682940289913e-08
- O 0 5.3154305845737326e-08
up O 0 1.1675759914453465e-08
of O 0 4.633819994381838e-09
the O 0 4.500788630679153e-09
only O 0 5.659667845492322e-09
two O 0 1.083040856997286e-08
surviving O 0 4.5058845898893196e-07
patients O 0 1.4155939531690365e-08
, O 0 8.497059056367107e-09
one O 0 1.60823834249868e-08
with O 0 4.105354989292209e-08
SJS B-Disease 0 0.0022422599140554667
type I-Disease 0 4.0374163745582337e-07
2 I-Disease 0 2.5494236410850135e-07
at O 0 2.4498769235492546e-08
age O 0 1.4488707122950473e-08
10 O 0 1.2353154055233517e-08
years O 0 5.6092654965311795e-09
and O 0 3.6215517251747542e-09
another O 0 1.4188214159105428e-08
with O 0 2.5446327711620143e-08
SWS B-Disease 0 0.03161532059311867
at O 0 2.5919925406014954e-07
age O 0 4.7642029699090926e-07
7 O 0 1.117824012908386e-06
years O 0 5.420628781394043e-07
. O 0 3.6188789636071306e-06

Patients O 0 1.508676859884872e-06
reported O 0 2.9589460837087245e-07
as O 0 7.014774894287257e-08
having O 0 7.684792535656015e-08
either O 0 5.72821477362595e-07
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.0006288756849244237
SWS B-Disease 1 0.9779008030891418
presented O 0 5.889258503088968e-08
a O 0 7.373226473816885e-09
combination O 0 2.1713857378813373e-08
of O 0 1.599492271964209e-08
a O 0 3.044075214120312e-08
severe O 0 2.3113279894459993e-06
, O 0 1.6487436482748308e-07
prenatal O 0 0.00010505985119380057
- O 1 0.9073508381843567
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.015212110243737698
with O 0 0.021980172023177147
congenital B-Disease 1 1.0
joint I-Disease 1 0.9999997615814209
contractures I-Disease 1 1.0
, O 0 0.11939626932144165
respiratory O 1 1.0
and O 0 0.0005341488285921514
feeding O 0 0.06371268630027771
difficulties O 1 0.9528986811637878
, O 0 1.09267297432325e-07
tendency O 0 1.419731461282936e-07
to O 0 1.7010307828968507e-08
hyperthermia B-Disease 0 0.1940019279718399
, O 0 3.288292305114737e-08
and O 0 9.82957537587481e-09
frequent O 0 4.465935532493859e-08
death O 0 2.873373148304381e-07
in O 0 5.609557263142051e-08
infancy O 0 1.5539718560830806e-06
) O 0 1.0200809086313711e-08
with O 0 3.1860143412387743e-09
a O 0 3.978977858309918e-08
distinct O 0 8.941570968090673e-07
campomelic B-Disease 0 0.31559568643569946
- I-Disease 1 0.563267171382904
metaphyseal I-Disease 1 0.9997195601463318
skeletal I-Disease 1 0.9999203681945801
dysplasia I-Disease 1 0.9999982118606567
. O 0 0.00018515827832743526

The O 0 1.237432798006921e-06
similarity O 0 1.9172705378878163e-06
of O 0 2.843580659828149e-07
the O 0 1.4763773492632026e-07
clinical O 0 6.700033736706246e-07
and O 0 6.015524434133113e-08
radiographic O 0 0.00021188917162362486
findings O 0 5.43202418157307e-07
is O 0 9.992370486600066e-09
so O 0 5.099536348751599e-09
extensive O 0 5.834451854980216e-08
that O 0 6.672765007209591e-09
these O 0 2.242592245238484e-07
disorders O 1 0.9975987076759338
appear O 0 9.636828934844743e-08
to O 0 1.1723157555820762e-08
be O 0 1.2343215338717073e-08
a O 0 8.259216599526553e-08
single O 0 2.6918704065792554e-07
entity O 0 4.562574758892879e-06
. O 0 5.983317805657862e-06

The O 0 3.6083749819226796e-06
follow O 0 1.6504219502166961e-06
- O 0 3.0273470201791497e-06
up O 0 2.2019469270162517e-07
observation O 0 1.3964763638796285e-06
of O 0 2.2199085236707106e-08
an O 0 5.617841747351804e-09
identical O 0 2.354145856031664e-08
and O 0 7.518793587735217e-09
unique O 0 2.1317118736874363e-08
pattern O 0 1.1557673360584886e-06
of O 0 2.1492012365342816e-06
progressive O 1 0.9999998807907104
bone B-Disease 1 0.9999998807907104
dysplasia I-Disease 1 0.9999997615814209
in O 0 3.442803020448082e-08
the O 0 4.1599793831892384e-08
two O 0 1.3705497181604187e-08
patients O 0 1.4300503003994436e-08
( O 0 1.2869183052544031e-08
one O 0 1.7614024017120755e-08
with O 0 5.4903242840964595e-08
SJS B-Disease 0 0.0005951902712695301
type I-Disease 0 3.26491942814755e-07
2 I-Disease 0 2.450478007176571e-07
, O 0 7.868453444359602e-09
one O 0 8.719390542921701e-09
with O 0 2.6792942975362166e-08
SWS B-Disease 0 0.0003567964013200253
) O 0 1.7568492438613248e-08
surviving O 0 2.9501818517019274e-06
beyond O 0 5.952289257038501e-07
infancy O 0 5.88095758757845e-07
adds O 0 8.845766075182837e-08
to O 0 1.0197890532026577e-08
the O 0 1.1413126443926558e-08
evidence O 0 1.168494350167748e-07
in O 0 1.5273061038101332e-08
favor O 0 1.600426742243144e-07
of O 0 1.326405651980167e-07
identity O 0 2.2529040961671853e-06
. O 0 5.833578143210616e-06

The O 0 5.94632001593709e-06
hypothesis O 0 1.0176177056564484e-05
that O 0 4.772857096213556e-07
SWS B-Disease 0 0.00036272488068789244
and O 0 8.754320788284531e-07
SJS B-Disease 0 0.006416263524442911
type I-Disease 0 1.1021596719729132e-06
2 I-Disease 0 3.0902734238225094e-07
are O 0 4.73185179927782e-09
the O 0 8.343796764620492e-09
same O 0 2.9320627703555147e-08
disorder O 0 1.4352004654938355e-05
should O 0 1.0527909211077713e-08
be O 0 7.098448495668208e-09
testable O 0 3.1467337180401955e-07
by O 0 1.1597279581110342e-08
molecular O 0 1.2806954430288897e-07
methods O 0 1.903397759406289e-07
. O 0 3.035233930859249e-07
. O 0 3.1002170999272494e-06

A O 0 1.0137296158063691e-05
mouse O 0 2.1527293938561343e-06
model O 0 9.95368054645951e-07
of O 0 4.5384146574178885e-07
severe O 1 0.9701359272003174
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9708757400512695
defects O 1 1.0
in O 0 3.08476614918618e-06
hemostasis O 1 0.9994170665740967
and O 0 9.16198860068107e-06
thrombosis B-Disease 1 0.9931743741035461
. O 0 2.173737266275566e-05

von B-Disease 1 0.9985474944114685
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.7971788644790649
( I-Disease 0 0.0002582894521765411
vWf I-Disease 1 0.9999983310699463
) I-Disease 0 3.4235697967233136e-05
deficiency I-Disease 1 1.0
causes O 1 0.9999978542327881
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 7.180822194641223e-06
humans O 0 4.5668061829928774e-06
. O 0 1.3628620081362897e-06

We O 0 1.077845581676229e-06
generated O 0 4.2166092839579505e-07
a O 0 5.7264180952643073e-08
mouse O 0 1.001349474449853e-07
model O 0 4.604800096785766e-08
for O 0 5.923615820080386e-09
this O 0 6.9853052231394486e-09
disease O 0 9.037280790380464e-08
by O 0 8.125971895367456e-09
using O 0 5.1850840065981174e-08
gene O 0 1.6950512815583352e-07
targeting O 0 2.3613783923792653e-06
. O 0 2.0864470116066514e-06

vWf B-Disease 0 0.3127956688404083
- I-Disease 1 0.9917852878570557
deficient I-Disease 0 0.007905518636107445
mice O 0 1.262710384253296e-06
appeared O 0 1.897952586205065e-07
normal O 0 2.4953676458494556e-08
at O 0 2.3081943467673227e-08
birth O 0 1.9536406270503903e-08
; O 0 5.32430588506827e-09
they O 0 4.749547422022715e-09
were O 0 5.6693728822665435e-08
viable O 0 1.60450110797683e-06
and O 0 4.4839876522928535e-07
fertile O 0 2.3235377739183605e-05
. O 0 6.021458375471411e-06

Neither O 0 0.0007215645164251328
vWf O 0 0.00894257239997387
nor O 0 0.00036939868004992604
vWf O 0 0.0029554495122283697
propolypeptide O 0 0.0006226992118172348
( O 0 5.244131443760125e-06
von B-Disease 0 0.01636648364365101
Willebrand I-Disease 1 0.6954463720321655
antigen O 0 1.84314794751117e-05
II O 1 0.9999995231628418
) O 0 5.779284251161698e-08
were O 0 2.4621595429152876e-08
detectable O 0 2.886372101329471e-07
in O 0 1.2275737759637195e-08
plasma O 0 4.5850725882701227e-07
, O 0 1.1774249131235592e-08
platelets O 0 4.589250295339298e-07
, O 0 7.382485733842259e-09
or O 0 7.179356664721581e-09
endothelial O 0 2.2792443132857443e-07
cells O 0 1.3455850655930135e-08
of O 0 1.1573082936422452e-08
the O 0 4.944679332652413e-08
homozygous O 0 9.18327259569196e-07
mutant O 0 6.851245871075662e-06
mice O 0 3.299801392131485e-06
. O 0 3.1789857075636974e-06

The O 0 4.776823516294826e-06
mutant O 0 5.007095023756847e-05
mice O 0 5.949587375653209e-06
exhibited O 0 7.819704478606582e-06
defects O 0 0.015021286904811859
in O 0 9.54132133301755e-08
hemostasis O 0 5.798534857603954e-06
with O 0 9.826670144263971e-09
a O 0 3.18957269485054e-08
highly O 0 2.8661042961175554e-07
prolonged O 0 9.595314622856677e-05
bleeding O 1 0.7826372981071472
time O 0 6.140877673033174e-08
and O 0 8.011628693793682e-08
spontaneous O 0 4.42354985352722e-06
bleeding O 0 0.11013630777597427
events O 0 2.7937891999840758e-08
in O 0 8.197893031081094e-09
approximately O 0 2.1869972499644064e-08
10 O 0 5.018620541363816e-08
% O 0 1.6485573794966513e-08
of O 0 6.599493929115852e-08
neonates O 0 6.418890734494198e-06
. O 0 4.039275154354982e-06

As O 0 1.3187863032726455e-06
in O 0 4.499623429410349e-08
the O 0 9.00108645396358e-08
human O 0 4.567728524307313e-07
disease O 0 5.99887061980553e-06
, O 0 3.931412528856981e-09
the O 0 8.318275845908829e-09
factor O 0 6.29461567314138e-08
VIII O 1 0.9787861108779907
level O 0 2.2786119302509178e-07
in O 0 5.542720504791987e-09
these O 0 5.7681912579710115e-09
mice O 0 2.1712821762776002e-08
was O 0 9.920965382548275e-09
reduced O 0 5.27620569457099e-09
strongly O 0 4.742532144774714e-09
as O 0 1.8284018743486286e-09
a O 0 9.136200684878304e-10
result O 0 3.249745361699752e-09
of O 0 6.956506037880672e-09
the O 0 1.271573424332928e-08
lack O 0 1.0012406193027346e-07
of O 0 6.248656347906945e-08
protection O 0 1.3665712685906328e-06
provided O 0 1.074591978067474e-06
by O 0 8.312949262290203e-07
vWf O 0 0.0003509804082568735
. O 0 1.5353170965681784e-05

Defective O 0 0.029377296566963196
thrombosis B-Disease 1 0.9816546440124512
in O 0 2.724069076975866e-07
mutant O 0 2.7531737032404635e-06
mice O 0 2.3674616045354924e-07
was O 0 4.245184470619279e-08
also O 0 4.4461216930358205e-09
evident O 0 3.667214798497298e-08
in O 0 3.0034486009355987e-09
an O 0 2.704115820151287e-09
in O 0 4.221322402742089e-09
vivo O 0 1.4530614578234236e-07
model O 0 1.3845703961123945e-07
of O 0 5.072295152785955e-07
vascular B-Disease 1 0.9999990463256836
injury I-Disease 1 0.9999998807907104
. O 0 0.0005934207583777606

In O 0 3.875838103795104e-07
this O 0 2.6126897978429042e-08
model O 0 2.3338091637015168e-07
, O 0 5.678929326791149e-08
the O 0 2.6320421397940663e-07
exteriorized O 0 5.806357512483373e-05
mesentery O 0 7.723458111286163e-05
was O 0 1.1705259339578333e-06
superfused O 0 1.0692878277041018e-05
with O 0 1.1388558363023549e-07
ferric O 0 5.265824438538402e-05
chloride O 0 8.026768045965582e-05
and O 0 1.5739294667582726e-07
the O 0 9.842299419915435e-08
accumulation O 0 3.9544611354358494e-05
of O 0 5.151811819814611e-06
fluorescently O 0 0.0001229898916790262
labeled O 0 5.415289251686772e-06
platelets O 0 7.828091838746332e-06
was O 0 3.6416136595107673e-07
observed O 0 1.0756136958889329e-07
by O 0 8.991340649799895e-08
intravital O 0 1.912065636133775e-05
microscopy O 0 2.7639584004646167e-05
. O 0 8.389314643864054e-06

We O 0 1.061521743395133e-06
conclude O 0 2.0196387140458683e-06
that O 0 3.580166918482064e-08
these O 0 6.754450510015886e-08
mice O 0 2.913286039074592e-07
very O 0 3.2383990600237667e-08
closely O 0 8.488963487707224e-08
mimic O 0 1.398536824126495e-06
severe O 0 0.0005821474478580058
human O 0 5.252669507171959e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 4.4412757915779366e-08
will O 0 3.1182532111984074e-09
be O 0 1.8240131627322853e-09
very O 0 2.1745012457330404e-09
useful O 0 1.3847759383622815e-08
for O 0 3.72239927770579e-09
investigating O 0 2.5196781550107517e-08
the O 0 2.9104885612696307e-08
role O 0 4.6493774163991475e-08
of O 0 1.1246391551367196e-07
vWf O 0 1.1261883628321812e-05
in O 0 4.4275232369273e-08
normal O 0 2.1300135699675593e-07
physiology O 0 1.599656116013648e-06
and O 0 4.122735930423005e-08
in O 0 4.237038453425157e-08
disease O 0 5.678815000464965e-07
models O 0 3.05299806768744e-07
. O 0 4.0457416616845876e-07
. O 0 2.6855291253014e-06

Oral O 0 0.00010104703687829897
contraceptives O 0 0.00021841897978447378
and O 0 1.5247600515522208e-07
the O 0 1.0139572736989066e-07
risk O 0 1.5288355825759936e-06
of O 0 0.0004842638736590743
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.5211518732248805e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 0 8.473807611153461e-06
Study O 0 3.810988289387751e-07
Group O 0 4.1337878542435647e-07
. O 0 9.661764579504961e-07

BACKGROUND O 0 0.00383898988366127
Women O 0 8.472413810522994e-07
with O 0 3.104102219708693e-08
mutations O 0 6.626903825690533e-08
in O 0 1.144377392847673e-08
either O 0 3.306058005136947e-08
the O 0 5.5754235006588715e-08
BRCA1 O 0 2.5726924945956853e-07
or O 0 1.6465994789882643e-08
the O 0 4.363805672369381e-08
BRCA2 O 0 2.559523863965296e-07
gene O 0 1.181634257108044e-08
have O 0 4.5726422648328935e-09
a O 0 1.1041850100923511e-08
high O 0 1.5280848231213895e-07
lifetime O 0 2.08032659543278e-07
risk O 0 2.0632274754461832e-05
of O 1 0.9985560774803162
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1074241885798983e-05

Oral O 0 0.00023967382730916142
contraceptives O 1 0.804973840713501
protect O 0 2.879394742194563e-05
against O 1 0.9999972581863403
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.467773813601525e-08
general O 0 4.946669562855277e-08
, O 0 9.75683533965821e-10
but O 0 5.293833704733686e-10
it O 0 2.838729529219819e-10
is O 0 2.335173165946003e-10
not O 0 3.29708760293812e-10
known O 0 6.084249104532091e-09
whether O 0 5.711482398140788e-09
they O 0 8.57772874951479e-09
also O 0 2.6278831555259785e-08
protect O 0 4.8373827610248554e-08
against O 0 2.2370683439021377e-07
hereditary B-Disease 1 0.9999940395355225
forms I-Disease 0 0.20180165767669678
of I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.469160780397942e-06

METHODS O 0 7.219439339678502e-06
We O 0 3.607132157412707e-07
enrolled O 0 7.360000040534942e-07
207 O 0 5.694281526302802e-07
women O 0 1.1514970310599892e-07
with O 0 7.363854592767893e-08
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5138979847506562e-08
161 O 0 2.412787658556681e-08
of O 0 1.137973804077319e-08
their O 0 1.0515668336097406e-08
sisters O 0 3.7699348354180984e-07
as O 0 3.6286476046143434e-08
controls O 0 2.831540157899326e-08
in O 0 9.256144295477498e-09
a O 0 1.7608817515224473e-08
case O 0 1.579655588557216e-07
- O 0 1.264141815227049e-06
control O 0 5.62294644623762e-07
study O 0 7.528540209023049e-07
. O 0 2.070737991743954e-06

All O 0 1.18234993351507e-06
the O 0 4.366694952295802e-07
patients O 0 8.742976120856838e-08
carried O 0 3.9036478938214714e-08
a O 0 5.74909098105536e-09
pathogenic O 0 5.029544425383392e-08
mutation O 0 2.6368100591867005e-08
in O 0 1.1999379267990662e-08
either O 0 9.663389732850192e-08
BRCA1 O 0 5.743569317928632e-07
( O 0 7.163396276155254e-08
179 O 0 1.6378751865886443e-07
women O 0 8.825896458120042e-08
) O 0 4.011371501633221e-08
or O 0 1.7254954798318067e-07
BRCA2 O 0 5.070184670330491e-06
( O 0 2.951179283172678e-07
28 O 0 2.979696091642836e-06
women O 0 4.473868955301441e-07
) O 0 3.4160404993599514e-07
. O 0 1.4666510423921864e-06

The O 0 6.706886779284105e-07
control O 0 3.349354926740489e-07
women O 0 7.224717535336822e-08
were O 0 3.912637680514308e-08
enrolled O 0 2.7885985076636643e-08
regardless O 0 1.652432501941803e-08
of O 0 8.044669819184946e-09
whether O 0 3.856504449117892e-09
or O 0 5.168798722365864e-09
not O 0 3.452171215556632e-09
they O 0 6.259198936930943e-09
had O 0 6.441651834165896e-08
either O 0 9.448633875308587e-08
mutation O 0 7.376260100500076e-07
. O 0 2.2807237201050157e-06

Lifetime O 0 2.413543188595213e-05
histories O 0 2.1227637262200005e-05
of O 0 2.7373423563403776e-06
oral O 0 3.535506039042957e-06
- O 0 1.1286248309261282e-06
contraceptive O 0 1.1468589633523152e-07
use O 0 1.1731769333778175e-08
were O 0 9.989359561757283e-09
obtained O 0 1.411789263272567e-08
by O 0 4.800669195503815e-09
interview O 0 1.7123037210353687e-08
or O 0 1.8208812235798177e-09
by O 0 1.2147998162959084e-09
written O 0 1.8551347125139728e-09
questionnaire O 0 1.7400241247855774e-09
and O 0 2.1948105555225084e-09
were O 0 6.913952521614419e-09
compared O 0 7.461377293793703e-09
between O 0 1.0213891954435894e-08
patients O 0 3.679551108248802e-09
and O 0 5.95366644873252e-09
control O 0 7.052486239444988e-08
women O 0 6.4990992143521e-08
, O 0 7.976008298271609e-09
after O 0 6.82056322531821e-09
adjustment O 0 2.157658585133504e-08
for O 0 6.592949297612449e-09
year O 0 1.339914845743806e-08
of O 0 6.467875124371858e-08
birth O 0 8.753235647418478e-07
and O 0 7.61519856951054e-07
parity O 0 4.842694761464372e-05
. O 0 2.0662520910263993e-05

RESULTS O 0 2.796151238726452e-05
The O 0 6.97568111718283e-07
adjusted O 0 1.4382285371539183e-06
odds O 0 1.5618969655406545e-06
ratio O 0 4.594860172346671e-07
for O 0 3.7734056945737393e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.879045872347888e-08
with O 0 1.023022555557418e-09
any O 0 5.876676922866864e-09
past O 0 2.600390303086897e-08
use O 0 1.5286438781458855e-08
of O 0 7.385925471226074e-08
oral O 0 2.6065063138958067e-06
contraceptives O 0 1.7761285562301055e-05
was O 0 2.729459538386436e-06
0 O 0 7.398116849799408e-06
. O 0 2.11026440410933e-06

5 O 0 4.75796296086628e-05
( O 0 1.0600750783851254e-06
95 O 0 1.1166754347868846e-06
percent O 0 1.744229223277216e-07
confidence O 0 1.8116193700734584e-07
interval O 0 2.3327521603278e-07
, O 0 1.1340858208086502e-07
0 O 0 1.4043477847280883e-07
. O 0 1.3381143304513898e-08
3 O 0 3.5345173898804205e-08
to O 0 1.3533014708855262e-08
0 O 0 2.255001021467251e-07
. O 0 2.2818470668539703e-08
8 O 0 3.091841449531785e-07
) O 0 1.8161983916797908e-07
. O 0 9.163912295662158e-07

The O 0 3.1642316571378615e-06
risk O 0 2.0248344299034216e-06
decreased O 0 3.37343266210155e-07
with O 0 6.721496692563278e-09
increasing O 0 3.600834830308486e-08
duration O 0 6.055874735011457e-08
of O 0 2.2203405336540527e-08
use O 0 2.989441938439086e-08
( O 0 3.7291449928034126e-08
P O 0 2.3335152832260064e-07
for O 0 1.563811480309596e-08
trend O 0 1.7644025263052754e-07
, O 0 1.6164648286576266e-08
< O 0 1.0567708130793108e-07
0 O 0 6.266105856411741e-08
. O 0 7.601403950729946e-09
001 O 0 2.4866497483344574e-07
) O 0 1.391277426598947e-09
; O 0 4.600143321820127e-10
use O 0 8.396539574739847e-10
for O 0 2.400164067495325e-09
six O 0 4.969069156146588e-09
or O 0 2.508522944921765e-09
more O 0 8.220154557037063e-10
years O 0 1.8279346924998663e-09
was O 0 4.9725961126512175e-09
associated O 0 3.6445018114505956e-09
with O 0 9.976388604115982e-10
a O 0 3.2123135262907e-09
60 O 0 9.847834547827006e-09
percent O 0 4.7649093559698485e-09
reduction O 0 1.1601438920649798e-08
in O 0 2.825584033416817e-08
risk O 0 1.200261522171786e-06
. O 0 3.1810905056772754e-06

Oral O 0 0.00015243918460328132
- O 0 2.3091526600182988e-05
contraceptive O 0 2.9945895221317187e-06
use O 0 2.8684394237643573e-07
protected O 0 3.13179953081999e-05
against O 1 0.974943995475769
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 4.906749229149909e-09
for O 0 1.4920591429046226e-09
carriers O 0 8.001058482420831e-09
of O 0 1.0134058925359568e-08
the O 0 3.185153119034112e-08
BRCA1 O 0 2.9658366429430316e-07
mutation O 0 6.624237158803226e-08
( O 0 5.7975668710241735e-08
odds O 0 5.263894991003326e-07
ratio O 0 9.259927225002684e-08
, O 0 1.6355658161160136e-08
0 O 0 6.899464466414429e-08
. O 0 1.0977529107947248e-08
5 O 0 3.296694828236468e-08
; O 0 5.150798454423011e-09
95 O 0 3.671994974752124e-08
percent O 0 8.285609531810678e-09
confidence O 0 2.7411060088411432e-08
interval O 0 5.720370310768885e-08
, O 0 2.3753807809612226e-08
0 O 0 9.533626155189268e-08
. O 0 8.975812981759645e-09
3 O 0 1.6495606658395445e-08
to O 0 5.166048477889262e-09
0 O 0 5.436792704927029e-08
. O 0 5.938061597987598e-09
9 O 0 3.6245804579948526e-08
) O 0 1.012899097929676e-09
and O 0 9.305562986838822e-10
for O 0 1.1633739527283637e-09
carriers O 0 1.5176565781871432e-08
of O 0 1.835446994391532e-08
the O 0 1.7286183151554724e-07
BRCA2 O 0 7.56234555865376e-07
mutation O 0 5.3972932789747574e-08
( O 0 7.605250118558615e-08
odds O 0 6.062277293494844e-07
ratio O 0 9.338607043218872e-08
, O 0 3.029253292652356e-08
0 O 0 8.735542422755316e-08
. O 0 6.677055353065953e-09
4 O 0 3.11374392936159e-08
; O 0 5.994630569716719e-09
95 O 0 4.205838166626563e-08
percent O 0 1.2035457075398881e-08
confidence O 0 1.9315503863026606e-08
interval O 0 5.803685354521804e-08
, O 0 2.442696001025979e-08
0 O 0 5.334921482358368e-08
. O 0 6.16819173515637e-09
2 O 0 2.1851045417520254e-08
to O 0 4.541352183196068e-09
1 O 0 6.211392644672742e-08
. O 0 1.493366674765184e-08
1 O 0 3.474080187970685e-07
) O 0 5.142319992046396e-08
. O 0 4.3777362179753254e-07

CONCLUSIONS O 0 0.00011874900519615039
Oral O 0 3.549760003807023e-05
- O 0 3.1277522793971e-06
contraceptive O 0 4.5602985210280167e-07
use O 0 1.2475285693369642e-08
may O 0 6.071138258789688e-09
reduce O 0 7.560583270560528e-09
the O 0 9.008606305371814e-09
risk O 0 1.0793786486829049e-07
of O 0 0.00036875918158330023
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.9631620773452596e-08
women O 0 7.559199488582635e-09
with O 0 2.0915245091401857e-09
pathogenic O 0 5.373114220219577e-08
mutations O 0 3.213044408312271e-08
in O 0 1.882560773935893e-08
the O 0 3.4317761787860945e-07
BRCA1 O 0 1.943948882399127e-05
or O 0 5.811699338664766e-06
BRCA2 O 0 0.0002868852752726525
gene O 0 0.00013027247041463852

A O 0 1.2309544217714574e-05
Japanese O 0 1.3381163626036141e-05
family O 0 3.4702722473411995e-07
with O 0 1.3635272466672177e-07
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.1554449719806144e-08
a O 0 3.631361522593579e-08
codon O 0 2.6167575128965836e-07
291 O 0 1.8719198635608336e-07
deletion O 0 3.729173414512843e-08
: O 0 2.070714089086323e-08
a O 0 2.540152088670311e-08
clinical O 0 2.5799010927585186e-07
, O 0 3.979957341471163e-08
biochemical O 0 2.120374483638443e-05
, O 0 1.3484348926340317e-07
pathological O 0 0.00019625748973339796
, O 0 2.4352860350518313e-07
and O 0 2.554534717091883e-07
genetic O 0 1.201033501274651e-05
report O 0 4.418658591021085e-06
. O 0 7.931507752800826e-06

We O 0 1.453355480407481e-06
report O 0 3.4501263712627406e-07
a O 0 1.0796875926644134e-07
Japanese O 0 2.0057439087395323e-06
family O 0 2.7104150035484054e-07
with O 0 3.1207602546601265e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9683513641357422
ALD B-Disease 1 1.0
) O 0 2.2131526833391035e-08
with O 0 2.7659039503191707e-09
a O 0 6.653193551642289e-09
three O 0 8.06533417829769e-09
base O 0 7.455277994949938e-08
pair O 0 1.7899584747738118e-07
deletion O 0 2.717084441883344e-07
( O 0 2.6708607947512064e-07
delGAG O 0 4.128112777834758e-06
291 O 0 4.264271638021455e-07
) O 0 2.243969277060387e-08
in O 0 2.813849064864371e-08
the O 0 8.796600354799011e-07
ALD B-Disease 1 1.0
gene O 0 2.463840792188421e-05
. O 0 1.8644403098733164e-05

A O 0 5.9658314057742245e-06
variety O 0 1.841677203628933e-06
of O 0 3.634355607573525e-07
phenotypes O 0 4.432493824424455e-06
were O 0 1.779567497806056e-07
observed O 0 1.0639870851036903e-07
within O 0 2.3278378336044625e-08
this O 0 2.4492228689609874e-08
family O 0 7.474027938769723e-07
. O 0 2.7521368792804424e-06

While O 0 3.343892331031384e-06
the O 0 1.1169726121806889e-06
proband O 0 6.772645429009572e-05
( O 0 1.6928332513543864e-07
patient O 0 9.463098393780456e-08
1 O 0 2.3599167775500973e-07
) O 0 5.319089169120161e-09
was O 0 6.572045130326387e-09
classified O 0 1.679921446395838e-08
as O 0 4.488974081340302e-09
having O 0 3.6286318394473938e-09
a O 0 3.0241196213864896e-09
rare O 0 1.7526589957128635e-08
intermediate O 0 1.294912266303072e-07
type O 0 7.98313450900423e-08
of O 0 6.871032098842988e-08
adult O 0 5.998928145345417e-07
cerebral O 0 1.336155128228711e-05
and O 0 5.081669200990291e-07
cerebello O 1 0.9999926090240479
- O 0 0.43644341826438904
brain O 0 1.7223488612216897e-05
stem O 0 2.4261504449896165e-07
forms O 0 3.721122965316681e-08
, O 0 6.148868525457374e-09
his O 0 2.5145984849928027e-08
younger O 0 6.02232717028528e-07
brother O 0 2.119069449690869e-06
( O 0 6.69867930014334e-08
patient O 0 1.1023252000086359e-07
2 O 0 1.5174184397892532e-07
) O 0 6.659274465192766e-09
and O 0 1.643715741295182e-08
nephew O 0 3.2175814794754842e-06
( O 0 6.715860934036755e-08
patient O 0 1.6783080525328842e-07
3 O 0 5.131982447892369e-07
) O 0 1.3884098315486426e-08
had O 0 1.9588082267318896e-08
a O 0 1.1962409018906328e-07
childhood O 0 4.277262996765785e-05
ALD B-Disease 1 1.0
type O 0 0.15327416360378265
. O 0 2.8444819690776058e-05

Another O 0 1.579231866344344e-05
nephew O 0 0.00025832097162492573
( O 0 1.9188582882634364e-06
patient O 0 1.508607851974375e-06
4 O 0 8.339542318935855e-07
) O 0 1.0223129898179195e-08
of O 0 1.1906839070263686e-08
patient O 0 3.8084664311099914e-08
1 O 0 2.510403760425106e-07
was O 0 2.202544813201257e-08
classified O 0 2.4836060319444186e-08
as O 0 1.2624700396202115e-08
having O 0 1.3366016737847985e-08
an O 0 3.639231849206226e-08
adolescent O 0 5.838252832290891e-07
form O 0 2.998673664933449e-07
. O 0 3.838794782495825e-06

The O 0 4.427668500284199e-06
tau O 0 6.7081932684232015e-06
level O 0 9.673694876255468e-07
in O 0 5.4472558019824646e-08
the O 0 7.425348513834251e-08
cerebrospinal O 0 2.8155563995824195e-06
fluid O 0 2.8422487048374023e-06
( O 0 4.870982479587838e-07
CSF O 1 0.999997615814209
) O 0 1.0185702059573032e-08
in O 0 2.8103288585157316e-09
patient O 0 1.6457988749607466e-08
1 O 0 7.98724713035881e-08
was O 0 1.7512020278331875e-08
as O 0 5.486072041094303e-09
high O 0 1.3464195092183218e-08
as O 0 2.5799458125419505e-09
that O 0 6.822472586875961e-10
of O 0 1.2192107767816651e-08
patients O 0 7.20715505053704e-08
with O 0 5.632338684335991e-07
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 7.617603046128352e-07
AD B-Disease 0 2.3636997866560705e-05
) O 0 4.301111857785145e-07
. O 0 1.7413318573744618e-06

His O 0 2.7680283892550506e-05
brain O 0 6.17796104052104e-05
magnetic O 0 9.987960766011383e-06
resonance O 0 3.90618379242369e-06
image O 0 2.216284201495e-06
( O 0 1.2998775389405637e-07
MRI O 0 1.376333057123702e-05
) O 0 2.9313916627415892e-08
showed O 0 1.8577104299311031e-07
abnormalities B-Disease 0 2.9892707971157506e-06
in I-Disease 0 2.7388066925482235e-08
the I-Disease 0 2.3583710628827248e-07
bilateral I-Disease 0 0.0005911801126785576
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.6905320286750793
and O 0 5.49346111711202e-07
brain O 0 0.004708544351160526
stem O 0 2.0406453131727176e-06
, O 0 5.716375373054916e-09
but O 0 1.0096008473681195e-09
not O 0 1.5605955416830852e-09
in O 0 3.8829797155415235e-09
the O 0 3.677861926121295e-08
cerebral O 0 1.9274071746622212e-05
white O 0 9.433345837805973e-08
matter O 0 7.570875482088013e-08
, O 0 8.409895002614576e-09
where O 0 8.09234634857603e-09
marked O 0 2.1554125595457663e-08
reductions O 0 1.1263329469102246e-07
of O 0 4.6854943036578334e-08
the O 0 9.547110835228523e-08
cerebral O 0 8.222753422160167e-06
blood O 0 5.119537149766984e-07
flow O 0 1.372454789816402e-07
and O 0 1.749325839739413e-08
oxygen O 0 4.928493524403166e-08
metabolism O 0 9.168224579525486e-08
were O 0 3.715733143394573e-08
clearly O 0 5.78510750415262e-08
demonstrated O 0 4.418530252792152e-08
by O 0 3.058146447187937e-08
positron O 0 2.813481614794e-06
emission O 0 1.1430421409386327e-06
tomography O 0 2.969659362861421e-06
( O 0 8.028637239476666e-07
PET O 0 1.5436649846378714e-05
) O 0 4.7398307856383326e-07
. O 0 1.3649092807099805e-06

In O 0 1.2107070688216481e-06
patients O 0 4.608521635418583e-07
2 O 0 8.260900017376116e-07
and O 0 5.5415604549580166e-08
3 O 0 2.69375533434868e-07
, O 0 8.19526668749404e-09
the O 0 4.842447776098879e-09
autopsy O 0 1.4490510125142464e-07
findings O 0 8.625507774695507e-08
showed O 0 7.709795113441942e-08
massive O 0 5.810375114378985e-07
demyelination B-Disease 1 1.0
of I-Disease 0 3.394164423298207e-06
the I-Disease 0 1.1648198778857477e-06
cerebral I-Disease 0 0.4732987880706787
white I-Disease 0 6.967849941474924e-08
matter I-Disease 0 2.031584855899382e-08
with O 0 4.107483242421495e-09
sparing O 0 1.203321176035388e-07
of O 0 1.03614326008028e-07
the O 0 4.4911521968060697e-07
U O 1 0.8443383574485779
- O 0 2.6882993552135304e-05
fibers O 0 1.7371357898809947e-05
, O 0 1.6432487370821036e-08
compatible O 0 1.1044234327073355e-07
with O 0 3.3345612937552005e-09
the O 0 1.7828215348458798e-08
findings O 0 1.2607402766207088e-07
of O 0 8.34984803077532e-07
childhood O 0 0.0020021970849484205
ALD B-Disease 1 1.0
. O 0 0.00016257369134109467

Oleic O 0 0.0004599543462973088
and O 0 1.0801364624057896e-05
erucic O 0 0.0001843470527091995
acids O 0 7.978665962582454e-06
( O 0 4.792630079464288e-07
Lorenzos O 0 4.304983121983241e-06
Oil O 0 9.183895031128486e-07
) O 0 5.911527711788267e-09
were O 0 5.258363078297634e-09
administered O 0 2.662217779558773e-09
to O 0 3.299738038364808e-09
patients O 0 7.704410442954668e-09
1 O 0 4.6604043291154085e-08
and O 0 7.660261758246634e-09
4 O 0 3.0565193043230465e-08
, O 0 2.0909420861414674e-09
but O 0 1.2471709220918115e-09
sufficient O 0 5.731116559104521e-08
effectiveness O 0 1.423693305468987e-07
was O 0 1.2444502317521255e-07
not O 0 5.1202107442804845e-08
obtained O 0 1.87651664873556e-06
. O 0 3.6144087971479166e-06

The O 0 1.958364009624347e-06
findings O 0 8.348048936568375e-07
in O 0 2.2404282873367265e-08
this O 0 8.285909736116537e-09
family O 0 2.5832068928366425e-08
suggest O 0 2.090747841521079e-08
that O 0 4.3384416059666364e-09
delGAG291 O 0 2.3429343798397895e-07
is O 0 2.63607469186411e-09
part O 0 2.2174742042579965e-09
of O 0 5.839859262835034e-09
the O 0 1.2972739327210547e-08
cause O 0 4.240717430548102e-07
of O 0 5.082531515654409e-07
Japanese O 1 0.8654889464378357
ALD B-Disease 1 1.0
with O 0 2.2119969855793897e-07
phenotypic O 0 5.535657237487612e-06
variations O 0 1.5374767826870084e-05
. O 0 8.831907507556025e-06

Moreover O 0 5.384668384067481e-06
, O 0 7.748138131091764e-08
although O 0 2.168533974611364e-08
the O 0 7.707570581771961e-09
scale O 0 3.297575190686075e-08
of O 0 6.9694419124743945e-09
the O 0 4.807587217214859e-09
study O 0 3.80296238944311e-09
is O 0 5.840903871678904e-10
limited O 0 1.8096113496568478e-09
, O 0 1.6340901964895238e-09
there O 0 3.531388736988106e-09
is O 0 1.9141142004741596e-09
a O 0 7.010385605354941e-09
possibility O 0 1.0321313226313578e-07
that O 0 1.2388098546978199e-08
PET O 0 1.0048505600934732e-06
can O 0 1.60559636697144e-08
detect O 0 4.6933476482990955e-07
an O 0 1.1358847729070476e-07
insidious B-Disease 0 1.2535732821561396e-05
lesion I-Disease 0 1.4123425899015274e-05
which O 0 1.7319887746225504e-08
is O 0 1.4534571768365367e-08
undetectable O 0 2.435820363189123e-07
by O 0 2.04101517908839e-08
computed O 0 4.701868761003425e-07
tomogram O 0 1.6499516277690418e-05
( O 0 2.2363728646723757e-07
CT O 0 1.3124254110152833e-05
) O 0 1.1540019606570695e-08
or O 0 6.8588650314893584e-09
MRI O 0 1.2783610259248235e-07
analysis O 0 9.797493483176822e-09
, O 0 1.8577974714162337e-09
and O 0 1.0808341999180016e-09
that O 0 9.349097052080424e-10
the O 0 5.195158525594934e-09
higher O 0 3.428072758993039e-08
level O 0 3.7944364095210403e-08
of O 0 1.7307140609545968e-08
tau O 0 1.1598954330338529e-07
reflects O 0 3.477331489420976e-08
the O 0 1.215778588914418e-08
process O 0 1.9716013710535663e-08
of O 0 1.9034412446217175e-07
neuronal B-Disease 1 0.8937748670578003
degeneration I-Disease 1 1.0
in O 0 1.0781379387481138e-05
ALD B-Disease 1 1.0
. O 0 6.749711610609666e-05

Lorenzos O 0 0.0003336471854709089
Oil O 0 5.513134965440258e-06
should O 0 2.5190438179834018e-08
be O 0 9.13801834201422e-09
given O 0 1.4099566847391998e-08
in O 0 6.1349521018883024e-09
the O 0 2.9663761225151575e-08
early O 0 3.8327152651618235e-07
stage O 0 3.214694004327612e-07
. O 0 2.956390687813837e-07
. O 0 2.3562854494230123e-06

Nonsense O 0 5.966623211861588e-05
mutation O 0 3.4956065064761788e-06
in O 0 3.4086892242157774e-07
exon O 0 5.201112799113616e-06
4 O 0 1.0630940323608229e-06
of O 0 1.3502918250196672e-07
human O 0 1.625034542485082e-07
complement O 0 1.6398411162299453e-06
C9 O 1 0.9999997615814209
gene O 0 7.520115730130783e-08
is O 0 9.86153736448614e-09
the O 0 1.1575357561355304e-08
major O 0 1.5074847681262327e-07
cause O 0 2.978390511998441e-07
of O 0 1.3370318185934593e-07
Japanese O 0 2.9932083634776063e-05
complement B-Disease 0 0.0005219645681791008
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999948740005493
. O 0 4.2081388528458774e-05

Deficiency B-Disease 1 0.9993963241577148
of I-Disease 0 1.1213711331947707e-05
the I-Disease 0 1.3673873127117986e-06
ninth I-Disease 0 6.53274983051233e-05
component I-Disease 0 4.135686594963772e-06
of I-Disease 0 1.7632905269238108e-07
human I-Disease 0 1.6949526582266117e-07
complement I-Disease 0 7.365357532762573e-07
( O 0 4.035895813103707e-07
C9 O 1 1.0
) O 0 1.3819000166392925e-08
is O 0 1.393306248154147e-09
the O 0 1.952507044933327e-09
most O 0 5.251968193675793e-09
common O 0 9.725517458036848e-08
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 6.632960491970152e-08
Japan O 0 2.3873133159213467e-07
but O 0 5.47050316157538e-09
is O 0 2.7857156581490017e-09
rare O 0 1.3322697611783951e-08
in O 0 1.0613113055057966e-08
other O 0 5.6086374655706095e-08
countries O 0 1.6744949959957012e-07
. O 0 3.59753062184609e-06

We O 0 1.0048352123703808e-06
studied O 0 8.6916304553597e-07
the O 0 3.56882878804754e-08
molecular O 0 3.265227519477776e-07
basis O 0 1.9801625228410558e-07
of O 0 3.603446430133772e-07
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999984502792358
in O 0 1.2608605004515994e-07
four O 0 1.7197965007653693e-07
Japanese O 0 2.0447307178983465e-05
C9 B-Disease 1 1.0
- I-Disease 1 0.7921603918075562
deficient I-Disease 0 0.0013771881349384785
patients O 0 6.390851581272727e-07
who O 0 9.701359005021004e-08
had O 0 4.189448929992068e-07
suffered O 0 0.009595667012035847
from O 0 1.8452126369083999e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.851940032793209e-05

Direct O 0 6.173288966238033e-06
sequencing O 0 4.236148015479557e-06
of O 0 2.243237076982041e-06
amplified O 0 1.32378127091215e-05
C9 O 0 0.0010202291887253523
cDNA O 0 5.211813004279975e-06
and O 0 1.5662958219309076e-07
DNA O 0 5.078882736597734e-07
revealed O 0 1.5132216901747597e-07
a O 0 5.867619279342762e-08
nonsense O 0 5.596336905000499e-07
substitution O 0 8.632927688267955e-07
( O 0 3.1208378459268715e-07
CGA O 0 5.190915089769987e-06
- O 0 2.312576043550507e-06
- O 0 1.456289737689076e-06
> O 0 9.371400437885313e-07
TGA O 0 3.930397724616341e-06
) O 0 2.696839196403289e-08
at O 0 4.388520835618692e-08
codon O 0 7.162658732795535e-08
95 O 0 6.778584804578713e-08
in O 0 1.260232540545303e-08
exon O 0 2.239367233869416e-07
4 O 0 1.358888965796723e-07
in O 0 1.3705968804345048e-08
the O 0 9.543160217617697e-08
four O 0 1.061147258951678e-06
C9 B-Disease 1 1.0
- I-Disease 0 0.0013462321367114782
deficient I-Disease 0 5.258353121462278e-05
individuals O 0 9.472395277043688e-07
. O 0 4.694704784924397e-06

An O 0 1.4845425084786257e-06
allele O 0 1.7965921870199963e-06
- O 0 9.671647376308101e-07
specific O 0 5.594074892201206e-08
polymerase O 0 4.901261263512424e-07
chain O 0 1.0302116493221547e-07
reaction O 0 2.3888478750677677e-08
system O 0 1.2355581446854558e-08
designed O 0 6.8577010736703414e-09
to O 0 1.3344002569581903e-09
detect O 0 1.3648107533015263e-08
exclusively O 0 6.0914366883935145e-09
only O 0 8.068653523096714e-10
one O 0 7.836518656212377e-10
of O 0 2.570122781264672e-09
the O 0 6.104859284761233e-09
normal O 0 1.5902264394185295e-08
and O 0 7.220581910161172e-09
mutant O 0 5.828101024007992e-08
alleles O 0 1.6524861479183528e-08
indicated O 0 8.210771618166746e-09
that O 0 7.976308502577467e-10
all O 0 1.7917486383467462e-09
the O 0 1.0216931300988108e-08
four O 0 1.1952300482676037e-08
patients O 0 2.8109774508067176e-09
were O 0 1.7495027648806172e-08
homozygous O 0 2.671242427254583e-08
for O 0 8.436885856610843e-09
the O 0 1.4595772590553224e-08
mutation O 0 9.043192861213356e-09
in O 0 4.548477594568112e-09
exon O 0 7.848372263197234e-08
4 O 0 5.237885147835186e-08
and O 0 2.098093254687683e-09
that O 0 7.148553415881054e-10
the O 0 1.3472646998025084e-08
parents O 0 1.29061783482598e-08
of O 0 4.1410114448581226e-08
patient O 0 2.49907174065811e-07
2 O 0 1.1535506700965925e-06
were O 0 7.483963599952403e-07
heterozygous O 0 2.4116479835356586e-06
. O 0 5.5156901908048894e-06

The O 0 2.4998582830448868e-06
common O 0 5.014238695366657e-07
mutation O 0 2.388999007507664e-07
at O 0 7.828548120869527e-08
codon O 0 3.9625817294108856e-07
95 O 0 2.395695162249467e-07
in O 0 3.685797622665632e-08
exon O 0 5.178699211683124e-07
4 O 0 1.2555258877000597e-07
might O 0 8.883177748941762e-09
be O 0 7.639921584257081e-09
responsible O 0 1.564267826381638e-08
for O 0 1.8310831961798613e-08
most O 0 2.924919613178645e-07
Japanese O 0 0.0002504141884855926
C9 B-Disease 1 1.0
deficiency I-Disease 0 0.2892073690891266
. O 0 1.8634696061781142e-06
. O 0 7.966333214426413e-06

BRCA1 O 0 2.3865719413151965e-05
required O 0 7.418354925903259e-07
for O 0 4.672643285630329e-07
transcription O 0 0.0002575753314886242
- O 0 0.00020323620992712677
coupled O 0 2.1978356016916223e-05
repair O 0 7.022042609605705e-06
of O 0 4.789303602592554e-07
oxidative O 0 1.708649142528884e-05
DNA O 0 5.958856490906328e-05
damage O 0 0.026089759543538094
. O 0 1.1219177395105362e-05

The O 0 1.621044793864712e-05
breast B-Disease 1 0.9999984502792358
and I-Disease 1 0.9642528295516968
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.006755059584975243
gene O 0 5.480957042891532e-06
BRCA1 O 0 3.488087259029271e-06
encodes O 0 5.557060944738623e-07
a O 0 1.4694705896545202e-07
zinc O 0 2.6633574634615798e-06
finger O 0 8.72588145739428e-07
protein O 0 3.096630791787902e-07
of O 0 1.6031962957185897e-07
unknown O 0 1.6646819176457939e-06
function O 0 7.717061407674919e-07
. O 0 2.3337076981988503e-06

Association O 0 2.0886487618554384e-05
of O 0 3.0288949801615672e-06
the O 0 1.4001315093992162e-06
BRCA1 O 0 1.0906236411756254e-06
protein O 0 1.3066711801457132e-07
with O 0 6.0907048293756816e-09
the O 0 3.145548532756948e-08
DNA O 0 3.349763915139192e-07
repair O 0 4.0158579395210836e-07
protein O 0 2.908192300310475e-07
Rad51 O 0 5.465936965265428e-07
and O 0 3.1427760394109328e-09
changes O 0 2.52201348693859e-09
in O 0 2.849575020391626e-09
the O 0 5.30419619337863e-09
phosphorylation O 0 4.2529240573685456e-08
and O 0 9.941195422413784e-09
cellular O 0 9.2134165186053e-08
localization O 0 4.3833509266733017e-07
of O 0 4.388520835618692e-08
the O 0 2.7860677320745708e-08
protein O 0 9.423293789723175e-08
after O 0 3.036733176031703e-08
exposure O 0 8.745862345449495e-08
to O 0 1.8395686751659923e-08
DNA O 0 6.034601369719894e-07
- O 0 8.193870257855451e-07
damaging O 0 1.1005599844793323e-06
agents O 0 5.268424985160891e-08
are O 0 8.908511262006868e-09
consistent O 0 6.427181631352141e-08
with O 0 6.6618408567364895e-09
a O 0 2.7869182517292757e-08
role O 0 1.0466088440352905e-07
for O 0 1.4440088591527456e-07
BRCA1 O 0 2.1194371129240608e-06
in O 0 1.733382646307291e-07
DNA O 0 8.011711543076672e-06
repair O 0 6.048108116374351e-05
. O 0 1.4550677406077739e-05

Here O 0 3.014664571310277e-06
, O 0 9.428380565168482e-08
it O 0 9.053271021741693e-09
is O 0 3.812425486415805e-09
shown O 0 4.912498852149838e-09
that O 0 6.382772532731451e-09
mouse O 0 1.7776761751520098e-07
embryonic O 0 2.647181418069522e-06
stem O 0 1.7953882434085244e-06
cells O 0 5.407117100730829e-07
deficient B-Disease 0 4.731574847482989e-07
in I-Disease 0 1.7996098833350516e-08
BRCA1 I-Disease 0 9.543651202648107e-08
are O 0 4.447394008622041e-09
defective O 0 3.171888920405763e-07
in O 0 1.3498599571448722e-08
the O 0 1.874062860451886e-08
ability O 0 8.742305546149964e-09
to O 0 1.708561647717488e-08
carry O 0 8.469330481375437e-08
out O 0 9.432913827822631e-08
transcription O 0 7.27334872863139e-06
- O 0 7.50334766053129e-06
coupled O 0 3.215050810467801e-06
repair O 0 1.5641149957446032e-06
of O 0 1.5998057278920896e-07
oxidative O 0 8.619732057013607e-07
DNA O 0 2.861277835108922e-06
damage O 0 6.910047522978857e-05
, O 0 6.309448252750371e-08
and O 0 3.071972543011725e-08
are O 0 4.2785941900547186e-08
hypersensitive O 0 7.456510047632037e-06
to O 0 3.1426401392309344e-07
ionizing O 0 0.0008019224042072892
radiation O 0 0.00018305737467017025
and O 0 7.670790864722221e-07
hydrogen O 0 3.883385033986997e-06
peroxide O 0 3.1040050089359283e-05
. O 0 8.310766133945435e-06

These O 0 1.1120378076157067e-06
results O 0 7.487811330975092e-07
suggest O 0 4.009165195384412e-07
that O 0 4.8357684079292085e-08
BRCA1 O 0 1.6004755707399454e-06
participates O 0 2.2973551949689863e-07
, O 0 1.299621832373532e-08
directly O 0 2.794881837075991e-08
or O 0 1.9769107240108497e-08
indirectly O 0 8.032468912233526e-08
, O 0 5.3696589397134176e-09
in O 0 5.465059071951828e-09
transcription O 0 3.832345555565553e-06
- O 0 4.719317530543776e-06
coupled O 0 3.440119598963065e-06
repair O 0 1.505575255578151e-06
of O 0 1.5005181808191992e-07
oxidative O 0 3.233296865801094e-06
DNA O 0 9.736143510963302e-06
damage O 0 5.4964330047369e-05
. O 0 8.094307872852369e-07
. O 0 2.900137360484223e-06

Truncation O 0 6.750284228473902e-05
mutations O 0 5.738456820836291e-06
in O 0 2.3371188717646874e-07
the O 0 4.430598892213311e-07
transactivation O 0 7.611459295731038e-05
region O 0 5.549780780711444e-06
of O 0 1.5122407148737693e-06
PAX6 O 1 0.9893440008163452
result O 0 8.380065992241725e-07
in O 0 3.5604330150817987e-07
dominant O 0 0.0014261947944760323
- O 0 2.3338441678788513e-05
negative O 0 2.1447478957270505e-06
mutants O 0 7.623775672982447e-06
. O 0 5.876842806173954e-06

PAX6 O 0 0.004333149641752243
is O 0 9.628954558138503e-07
a O 0 2.1495957014394662e-07
transcription O 0 2.188254939028411e-06
factor O 0 2.4227816197708307e-07
with O 0 2.0282396206994235e-08
two O 0 3.8807971947107944e-08
DNA O 0 4.33684306244686e-07
- O 0 5.409690970736847e-07
binding O 0 2.8897213155687496e-07
domains O 0 1.2100572348572314e-06
( O 0 1.422893944891257e-07
paired O 0 4.471245915738109e-07
box O 0 6.074720317883475e-07
and O 0 9.385033195030701e-08
homeobox O 0 5.0200078476336785e-06
) O 0 4.918811313814331e-08
and O 0 4.417982424342881e-08
a O 0 1.3160759237962338e-07
proline O 0 1.1795286809501704e-06
- O 0 1.614202233213291e-06
serine O 0 1.440384949091822e-06
- O 0 3.638541556938435e-06
threonine O 0 3.4079585020663217e-06
( O 0 3.3010084621309943e-07
PST O 0 7.407984230667353e-05
) O 0 2.1632715174746409e-07
- O 0 9.151380027105915e-07
rich O 0 5.32514661699679e-07
transactivation O 0 8.875881576386746e-06
domain O 0 7.803942025930155e-06
. O 0 4.070264367328491e-06

PAX6 O 1 0.999996542930603
regulates O 0 0.0008347234688699245
eye O 0 0.11553139984607697
development O 0 1.1711734941854957e-06
in O 0 4.454875934811753e-08
animals O 0 4.4470485960346195e-08
ranging O 0 1.8457600958754483e-07
from O 0 3.6920102530757504e-08
jellyfish O 0 6.1889231517398e-08
to O 0 2.254045661231885e-08
Drosophila O 0 3.360072753366694e-07
to O 0 7.198939755426181e-08
humans O 0 1.2970718898941413e-06
. O 0 3.8092623526608804e-06

Heterozygous O 0 5.352285825210856e-06
mutations O 0 1.4889747035340406e-06
in O 0 6.653601758443983e-08
the O 0 1.9256854955074232e-07
human O 0 7.920395432847727e-07
PAX6 O 1 0.8354613184928894
gene O 0 8.210368918071254e-08
result O 0 3.155343009098033e-08
in O 0 7.237044297170314e-09
various O 0 2.3246123248554795e-08
phenotypes O 0 2.482406102899404e-07
, O 0 2.6332164893005938e-08
including O 0 9.851652293946245e-08
aniridia B-Disease 1 1.0
, O 0 5.28866166860098e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.515976120776031e-07
autosomal B-Disease 0 6.131921691121534e-05
dominant I-Disease 1 0.9336475133895874
keratitis I-Disease 1 0.9999996423721313
, O 0 5.939706966273661e-07
and O 0 1.5817525991224102e-06
familial B-Disease 1 0.9999971389770508
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9978430271148682

It O 0 2.4111849938890373e-07
is O 0 3.729223152504346e-08
believed O 0 7.572652549470149e-08
that O 0 3.8761056586622544e-09
the O 0 1.1868361404765437e-08
mutated O 0 3.579003191589436e-07
allele O 0 3.371557681930426e-07
of O 0 3.2443904274259694e-07
PAX6 O 0 0.0044967313297092915
produces O 0 9.858363370085499e-08
an O 0 1.1228683760577951e-08
inactive O 0 2.4272031851069187e-07
protein O 0 1.690131341547385e-07
and O 0 5.2734115740804555e-08
aniridia B-Disease 1 1.0
is O 0 3.964887085317059e-08
caused O 0 2.1567210239936685e-07
due O 0 1.1602705285440607e-07
to O 0 1.143849672757824e-07
genetic O 0 2.7099962608190253e-05
haploinsufficiency O 0 0.005903423763811588
. O 0 1.0236309208266903e-05

However O 0 2.99899943456694e-06
, O 0 1.3926725728197198e-07
several O 0 9.286439706102101e-08
truncation O 0 1.1321585589030292e-06
mutations O 0 2.0981049431156862e-07
have O 0 1.2860055242924773e-08
been O 0 6.625637372081883e-09
found O 0 3.893295463797131e-09
to O 0 2.2109492014976695e-09
occur O 0 6.985199085818294e-09
in O 0 6.848786426871811e-09
the O 0 6.631113791399912e-08
C O 0 5.18382694281172e-06
- O 0 5.794769890599127e-07
terminal O 0 6.181031722007901e-07
half O 0 3.030882922416822e-08
of O 0 5.1279023693950876e-08
PAX6 O 0 8.122283907141536e-05
in O 0 1.3807223808726121e-08
patients O 0 1.816882111427276e-08
with O 0 2.129870679823398e-08
Aniridia B-Disease 1 1.0
resulting O 0 5.751703611167613e-07
in O 0 1.3300303081109632e-08
mutant O 0 3.689412864105179e-08
proteins O 0 7.276963920332946e-09
that O 0 1.3876360061004789e-09
retain O 0 2.387490560806782e-08
the O 0 2.0756411700517674e-08
DNA O 0 1.2502779611622827e-07
- O 0 9.387271404648345e-08
binding O 0 1.784216152600493e-08
domains O 0 7.274441315985314e-08
but O 0 9.618004170874883e-09
have O 0 1.3718260305495278e-08
lost O 0 1.413386172544051e-07
most O 0 1.6817519821188398e-08
of O 0 5.191328256159977e-08
the O 0 1.620225020815269e-07
transactivation O 0 1.7667307474766858e-05
domain O 0 5.994615548843285e-06
. O 0 7.834963071218226e-06

It O 0 2.4081424498945125e-07
is O 0 3.7418342202499844e-08
not O 0 1.0251794968496597e-08
clear O 0 1.0821099749591667e-07
whether O 0 3.1361008012709135e-08
such O 0 5.30820649657926e-08
mutants O 0 1.4543758197760326e-06
really O 0 2.3528291137608903e-07
behave O 0 1.3650469554704614e-07
as O 0 1.737704167226184e-07
loss O 0 8.639509019303659e-07
- O 0 1.317928877142549e-06
of O 0 7.464525424438762e-07
- O 0 1.2823285260310513e-06
function O 0 5.033028216416824e-08
mutants O 0 2.2480783457012876e-07
as O 0 6.812440034309475e-08
predicted O 0 2.863527868157689e-07
by O 0 3.6311544704403786e-07
haploinsufficiency O 0 0.00017101703269872814
. O 0 1.0616447980282828e-05

Contrary O 0 6.068587026675232e-06
to O 0 4.162487243775104e-08
this O 0 8.355581115893074e-09
theory O 0 2.84584046994496e-07
, O 0 9.388342547822504e-09
our O 0 1.423008644252377e-08
data O 0 7.256731038296493e-08
showed O 0 4.820462962129568e-08
that O 0 3.035532936124241e-09
these O 0 1.3711407120808872e-08
mutants O 0 1.5167933042903314e-07
are O 0 4.166093248159086e-08
dominant O 0 3.681818043332896e-06
- O 0 1.618481292098295e-06
negative O 0 2.1052160548151733e-07
in O 0 2.5780975576594756e-08
transient O 0 4.252016196915065e-07
transfection O 0 5.249993364486727e-07
assays O 0 1.1155381685057364e-07
when O 0 2.4287448496806974e-08
they O 0 1.8638816712268635e-08
are O 0 1.864280108065941e-08
coexpressed O 0 3.742541593965143e-06
with O 0 7.327790285671654e-08
wild O 0 4.2484671212150715e-06
- O 0 2.7072836019215174e-05
type O 0 6.869039498269558e-05
PAX6 O 0 0.4308599531650543
. O 0 2.849918200809043e-05

We O 0 6.826513185842487e-07
found O 0 1.3497343331891898e-07
that O 0 9.118604538116415e-09
the O 0 1.0246794346358001e-07
dominant O 0 2.3027976567391306e-05
- O 0 2.057248366327258e-06
negative O 0 8.790816963255565e-08
effects O 0 8.032606757524263e-08
result O 0 2.008912325379697e-08
from O 0 1.957859474543966e-08
the O 0 1.805688754075163e-08
enhanced O 0 7.633268950257843e-08
DNA O 0 1.222322083549443e-07
binding O 0 9.054051020029874e-08
ability O 0 4.190512115087586e-08
of O 0 1.302304610817373e-07
these O 0 1.952080452838345e-07
mutants O 0 6.809803380747326e-06
. O 0 5.015107944927877e-06

Kinetic O 0 2.3175318347057328e-05
studies O 0 1.360233909508679e-06
of O 0 1.1203444216789649e-07
binding O 0 1.1492776508248426e-07
and O 0 4.8518714379497396e-08
dissociation O 0 3.173907145992416e-07
revealed O 0 7.448668526421898e-08
that O 0 4.0886614094404194e-09
various O 0 4.5144954441411755e-08
truncation O 0 3.8000970903340203e-07
mutants O 0 2.897597255469009e-07
have O 0 3.3229184737137984e-08
3 O 0 2.2982054304065969e-07
- O 0 3.10985086571236e-07
5 O 0 1.6036794647789065e-07
- O 0 1.5580037882045872e-07
fold O 0 1.0026739971635834e-07
higher O 0 3.0421304586525366e-08
affinity O 0 1.1636320351726681e-08
to O 0 4.802445996432425e-09
various O 0 2.2387965259440534e-08
DNA O 0 6.608462399526616e-08
- O 0 4.880923754058131e-08
binding O 0 1.1488957341043715e-08
sites O 0 3.10042764795071e-08
when O 0 3.30103477885757e-09
compared O 0 6.15080431032311e-09
with O 0 3.686013716475145e-09
the O 0 3.185833463703602e-08
wild O 0 1.2219542213642853e-06
- O 0 4.741969405586133e-06
type O 0 1.5013346455816645e-05
PAX6 O 0 0.0047708237543702126
. O 0 1.4056628970138263e-05

These O 0 7.786744617988006e-07
results O 0 2.863476140646526e-07
provide O 0 6.910092764655928e-08
a O 0 2.7165603100343105e-08
new O 0 2.5000266745678346e-08
insight O 0 1.572526571180788e-07
into O 0 1.5940436526307167e-08
the O 0 1.2107085112234017e-08
role O 0 3.476097631960329e-08
of O 0 1.2444158414837148e-07
mutant O 0 8.429067747783847e-06
PAX6 O 1 0.9968699812889099
in O 0 4.040312830966286e-07
causing O 0 3.417701009311713e-05
aniridia B-Disease 1 1.0
. O 0 1.3840440260537434e-06
. O 0 5.676926321029896e-06

Reversal O 0 5.794166645500809e-05
of O 0 1.668424556555692e-05
severe O 1 0.9999998807907104
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.267803817987442
excellent O 0 6.91324457875453e-05
neuropsychologic O 0 0.07909614592790604
outcome O 0 1.65459971412929e-06
in O 0 8.769598736080297e-08
very B-Disease 0 2.1532559912884608e-07
- I-Disease 0 3.927550551452441e-06
long I-Disease 0 5.056120357949112e-07
- I-Disease 0 1.4619728290199419e-06
chain I-Disease 0 6.680554065496835e-07
acyl I-Disease 0 5.738971140090143e-06
- I-Disease 0 2.61648574451101e-06
coenzyme I-Disease 0 1.7106393670474063e-06
A I-Disease 0 8.389059075852856e-06
dehydrogenase I-Disease 0 0.0004020745400339365
deficiency I-Disease 0 0.18128380179405212
. O 0 1.3927448890171945e-05

Very B-Disease 0 1.9158254872309044e-05
- I-Disease 0 4.1899631469277665e-05
long I-Disease 0 2.700339564398746e-06
- I-Disease 0 2.5663530323072337e-06
chain I-Disease 0 5.754588983108988e-07
acyl I-Disease 0 1.835265265981434e-06
- I-Disease 0 4.0575267234999046e-07
coenzyme I-Disease 0 1.8743492091743974e-07
A I-Disease 0 2.1129136484887567e-07
dehydrogenase I-Disease 0 1.5401035398099339e-06
( I-Disease 0 1.3359496620068967e-07
VLCAD I-Disease 1 0.9708830118179321
) I-Disease 0 3.9120557460137206e-08
deficiency I-Disease 0 1.2896244925286737e-06
is O 0 9.162416603203383e-09
a O 0 1.5732084079900233e-08
disorder O 0 0.010077938437461853
of O 0 5.025512450629321e-07
fatty O 0 1.403132330324297e-07
acid O 0 5.7209676995739756e-09
beta O 0 3.7244447526063595e-09
oxidation O 0 2.327810166846689e-09
that O 0 1.0655560878092274e-09
reportedly O 0 1.7184447642648593e-08
has O 0 1.5105342532351074e-09
high O 0 1.3398278930765173e-08
rates O 0 7.561204107275898e-09
of O 0 1.8563177661690133e-08
morbidity O 0 1.0002802810049616e-05
and O 0 4.378742630706256e-07
mortality O 0 2.5820652808761224e-05
. O 0 4.59053308077273e-06

We O 0 5.570192911363847e-07
describe O 0 6.063017394808412e-07
the O 0 1.1428836899085582e-07
outcome O 0 4.0245495824819955e-07
of O 0 1.2196881016279804e-07
a O 0 3.877024212783908e-08
5 O 0 1.4480799848115566e-07
- O 0 1.0137368633422739e-07
year O 0 2.3766226320276473e-08
- O 0 3.400010939458298e-07
old O 0 1.1179562307006563e-06
girl O 0 5.321445541994763e-07
with O 0 3.213103241250792e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.642086312538595e-06
was O 0 1.6959035065156058e-07
first O 0 2.0126554645116812e-08
seen O 0 5.611077114053842e-08
at O 0 2.0064193861912827e-08
5 O 0 1.9156674468945312e-08
months O 0 3.17511306135998e-09
of O 0 6.67084298910936e-09
age O 0 8.270139773003393e-08
with O 0 5.197857433358877e-08
severe O 1 0.9999973773956299
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999879598617554
hepatomegaly B-Disease 1 1.0
, O 1 0.9683836698532104
encephalopathy B-Disease 1 0.9999998807907104
, O 0 6.000844223308377e-06
and O 0 1.479549700889038e-05
hypotonia B-Disease 1 0.9999752044677734
. O 0 0.0008098531397990882

Biochemical O 0 0.0003636183391790837
studies O 0 1.7144369849120267e-05
indicated O 0 0.013406421057879925
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.00014531602209899575
by O 0 6.506032690367647e-08
a O 0 1.1248387465911946e-07
stable O 0 9.93391836345836e-07
yet O 0 2.4535717102480703e-07
inactive O 0 2.492208068360924e-06
enzyme O 0 3.367593535585911e-06
. O 0 4.132587491767481e-06

Molecular O 0 1.6647736629238352e-05
genetic O 0 1.943409188243095e-06
analysis O 0 7.615220170009707e-07
of O 0 6.125203526607947e-07
her O 0 3.370011256720318e-07
VLCAD O 1 0.9999946355819702
gene O 0 2.1785140233987477e-06
revealed O 0 1.1138525906062569e-06
a O 0 2.87840890678126e-07
T1372C O 0 2.1895739337196574e-05
( O 0 3.574940592443454e-07
F458L O 0 4.993783932150109e-06
) O 0 3.396500503072275e-08
missense O 0 5.942358143329329e-07
mutation O 0 7.890880482364082e-08
and O 0 1.1190181936626686e-07
a O 0 6.76597721849248e-07
1668 O 0 0.034999314695596695
ACAG O 1 0.999996542930603
1669 O 0 0.00031861948082223535
splice O 0 8.68734423420392e-05
site O 0 8.710593647265341e-06
mutation O 0 4.035786787426332e-06
. O 0 8.46742568683112e-06

After O 0 1.5464070202142466e-06
initial O 0 5.863741989742266e-07
treatment O 0 2.1649391612754698e-07
with O 0 1.7418079423237032e-08
intravenous O 0 7.489053928111389e-07
glucose O 0 1.0338666243114858e-06
and O 0 2.153526423853691e-08
carnitine O 0 6.973659310460789e-06
, O 0 8.114541039105916e-09
the O 0 9.271445833292091e-09
patient O 0 2.707187896078267e-08
has O 0 8.704784448809733e-09
thrived O 0 1.7054107104286231e-07
on O 0 7.279299296669706e-08
a O 0 6.861223766918556e-08
low O 0 6.172548978611303e-07
- O 0 1.0400810879218625e-06
fat O 0 5.956895279268792e-07
diet O 0 9.393826871928468e-08
supplemented O 0 9.505264841891403e-08
with O 0 1.1068101102296168e-08
medium O 0 4.1918792703654617e-07
- O 0 5.620565843855729e-07
chain O 0 2.457421715007513e-07
triglyceride O 0 1.4597549125028308e-06
oil O 0 1.0311449614164303e-06
and O 0 6.848083700106145e-08
carnitine O 0 4.610935775417602e-06
and O 0 7.735394547125907e-08
avoidance O 0 9.683931239123922e-07
of O 0 9.213625276061066e-07
fasting O 0 4.125334271520842e-06
. O 0 7.712566912232433e-06

Her O 0 1.798382800188847e-05
ventricular O 0 0.29078730940818787
hypertrophy O 0 0.023574190214276314
resolved O 0 4.613575129042147e-06
significantly O 0 5.109976655148785e-07
over O 0 2.1535345950951523e-08
1 O 0 5.5480118277273505e-08
year O 0 4.322269209211527e-09
, O 0 4.217958426977475e-09
and O 0 7.817949843058614e-09
cognitively O 0 5.555190796258103e-07
, O 0 1.5119415053277407e-08
she O 0 6.084481363188843e-09
is O 0 1.6351158205196725e-09
in O 0 2.385058817111485e-09
the O 0 1.1669927246771294e-08
superior O 0 4.046922583711421e-07
range O 0 1.2641837088267494e-07
for O 0 4.110628282205653e-08
age O 0 1.4154096561469487e-06
. O 0 2.8797262530133594e-06

Clinical O 0 1.3143543583282735e-05
recognition O 0 1.172424617834622e-05
of O 1 0.9990799427032471
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.6575405936691823e-07
important O 0 6.547936237666363e-08
because O 0 2.1588306697850612e-09
it O 0 5.158937166349631e-10
is O 0 5.489669829827903e-10
one O 0 1.4030908657147734e-09
of O 0 6.010624886698679e-09
the O 0 2.5108937151685495e-08
few O 0 6.931279017408087e-08
directly O 0 4.871419037044689e-07
treatable O 1 0.9873602986335754
causes O 0 1.884547486952215e-06
of O 0 7.145757763282745e-07
cardiomyopathy B-Disease 1 1.0
in O 0 1.8338605514145456e-06
children O 0 2.5517031190247508e-06
. O 0 1.2260385346962721e-06
. O 0 6.509398190246429e-06

Cloning O 0 9.761784895090386e-06
of O 0 1.0416891882414347e-06
a O 0 1.4992423302828684e-07
novel O 0 2.6916546858046786e-07
member O 0 1.330200802840409e-07
of O 0 1.5539956166321645e-07
the O 0 4.271899456398387e-07
low O 0 6.207571004779311e-06
- O 0 3.089812480538967e-06
density O 0 9.39024062063254e-07
lipoprotein O 0 9.688045793154743e-06
receptor O 0 2.6667414203984663e-05
family O 0 1.7662877098700847e-06
. O 0 2.6343452645960497e-06

A O 0 7.876175004639663e-06
gene O 0 1.124784489547892e-06
encoding O 0 9.867256949291914e-07
a O 0 3.421452845486783e-07
novel O 0 5.487110001922701e-07
transmembrane O 0 1.0726711252573295e-06
protein O 0 3.0370523518286063e-07
was O 0 1.2958251716099767e-07
identified O 0 1.8179253657990557e-08
by O 0 3.3332261395457863e-09
DNA O 0 1.8090672071480185e-08
sequence O 0 3.4182510155744694e-09
analysis O 0 4.0668060030668585e-09
within O 0 5.209019882101984e-09
the O 0 2.304965107668977e-08
insulin B-Disease 0 1.942543804034358e-06
- I-Disease 0 6.959156507946318e-06
dependent I-Disease 0 0.00026429377612657845
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 4.6003983698028605e-06
IDDM B-Disease 1 0.9995790123939514
) O 0 2.8908624472023803e-07
locus O 0 9.071637236957031e-07
IDDM4 O 0 5.67362476431299e-05
on O 0 1.289164515583252e-06
chromosome O 0 1.2471412446757313e-05
11q13 O 0 0.00011452464968897402
. O 0 1.3933003174315672e-05

Based O 0 1.9427106963121332e-06
on O 0 2.7210984399062e-07
its O 0 4.791706587070621e-08
chromosomal O 0 1.377579565087217e-06
position O 0 7.458655204573006e-07
, O 0 1.4787469027055522e-08
this O 0 3.67154529001823e-09
gene O 0 1.0642120074066952e-08
is O 0 4.538096121109447e-09
a O 0 1.0261890004414909e-08
candidate O 0 7.652408839931013e-08
for O 0 2.9620451869050157e-08
conferring O 0 1.4523952813760843e-06
susceptibility O 0 1.5246089787979145e-05
to O 0 2.2159883883432485e-06
diabetes B-Disease 1 0.9999997615814209
. O 0 3.561591074685566e-05

The O 0 5.8095160966331605e-06
gene O 0 2.9337186333577847e-06
, O 0 9.369970257466775e-07
termed O 0 4.90125148644438e-06
low O 0 5.294765287544578e-06
- O 0 2.588847792139859e-06
density O 0 4.2181900994364696e-07
lipoprotein O 0 1.685509687376907e-06
receptor O 0 1.3138641179466504e-06
related O 0 2.838492036971729e-07
protein O 0 2.733135033849976e-07
5 O 0 1.3135468179825693e-07
( O 0 4.157742239385698e-08
LRP5 O 0 8.312700629176106e-06
) O 0 8.5926297188621e-09
, O 0 3.1004021572300644e-09
encodes O 0 7.4300063879206846e-09
a O 0 4.339070436287784e-09
protein O 0 5.329429697553678e-08
of O 0 6.708908273367342e-08
1615 O 0 1.1946964377784752e-06
amino O 0 6.039805811042243e-08
acids O 0 4.304936140897553e-08
that O 0 4.2151433454762355e-09
contains O 0 1.6482427867003935e-08
conserved O 0 4.799316499770612e-08
modules O 0 2.6560314836387988e-08
which O 0 2.3689186168240894e-09
are O 0 2.7500490773491038e-09
characteristic O 0 7.028877746506623e-08
of O 0 6.26309457629759e-08
the O 0 2.112595183234589e-07
low O 0 1.7393334701409913e-06
- O 0 1.5423170225403737e-06
density O 0 1.4080964092499926e-06
lipoprotein O 0 3.708517397171818e-05
( O 0 3.829503384622512e-06
LDL O 0 0.0003218824276700616
) O 0 3.2516322789888363e-07
receptor O 0 4.9652908273856156e-06
family O 0 2.0237321223248728e-06
. O 0 2.2376154902303824e-06

These O 0 8.85925487636996e-07
modules O 0 1.8404973616270581e-06
include O 0 2.2775843433464615e-07
a O 0 9.762763397702656e-08
putative O 0 9.919604053720832e-07
signal O 0 2.6325517410441535e-07
peptide O 0 1.368506303833783e-07
for O 0 1.188873000046442e-08
protein O 0 4.252786567349176e-08
export O 0 9.692629276969456e-08
, O 0 1.1350127948617228e-08
four O 0 4.117164209560542e-08
epidermal O 0 1.8594770381241688e-06
growth O 0 1.655666892474983e-07
factor O 0 7.010694957898522e-07
( O 0 3.862708979340823e-07
EGF O 0 6.327069422695786e-05
) O 0 3.369663659213984e-08
repeats O 0 9.681765078539684e-08
with O 0 1.0703923969401785e-08
associated O 0 1.4877211640396126e-07
spacer O 0 1.1762654139602091e-06
domains O 0 6.938897172403813e-07
, O 0 1.1938612942685722e-07
three O 0 2.0208494788676035e-07
LDL O 0 2.1127629224793054e-05
- O 0 1.3549847608373966e-05
receptor O 0 2.0695193597930484e-05
( O 0 5.874102271263837e-07
LDLR O 0 0.023642392829060555
) O 0 4.0316518123972855e-08
repeats O 0 6.781818484569158e-08
, O 0 7.990672123980858e-09
a O 0 2.2803547494731902e-08
single O 0 6.83627305875234e-08
transmembrane O 0 7.544373943346727e-07
spanning O 0 3.2084764711726166e-07
domain O 0 1.9859456301674072e-07
, O 0 5.424332272241372e-08
and O 0 4.1230659775237655e-08
a O 0 1.2125923376515857e-07
cytoplasmic O 0 4.417217496666126e-06
domain O 0 3.126663614239078e-06
. O 0 3.738614168469212e-06

The O 0 3.652218310890021e-06
encoded O 0 2.1911180283495924e-06
protein O 0 1.091702756639279e-06
has O 0 3.049281716016594e-08
a O 0 1.1269319699636071e-08
unique O 0 3.553593330707372e-08
organization O 0 1.2037872920700465e-07
of O 0 5.271319878374925e-07
EGF O 1 0.9999682903289795
and O 0 1.214274334415677e-06
LDLR O 1 0.9902475476264954
repeats O 0 7.475795769096294e-07
; O 0 1.8330926110365908e-08
therefore O 0 3.48465434285572e-08
, O 0 2.680510924335522e-08
LRP5 O 0 0.01307894941419363
likely O 0 8.97078393791162e-08
represents O 0 2.1815106165945508e-08
a O 0 6.902423077548292e-09
new O 0 1.8887901021003017e-08
category O 0 1.6430269056399993e-07
of O 0 1.2047772202095075e-07
the O 0 1.1643711559372605e-06
LDLR O 1 0.9985935091972351
family O 0 6.896668310218956e-06
. O 0 1.3241120541351847e-05

Both O 0 7.102301424311008e-06
human O 0 3.990853656432591e-06
and O 0 7.707632221354288e-07
mouse O 0 5.612415861833142e-06
LRP5 O 1 0.9875513911247253
cDNAs O 0 1.2168758075858932e-05
have O 0 3.585319419130428e-08
been O 0 2.5178861662311647e-08
isolated O 0 4.858548408037677e-08
and O 0 8.468163059660583e-09
the O 0 2.2019357004410267e-08
encoded O 0 5.2122228311191066e-08
mature O 0 2.3241911506488577e-08
proteins O 0 4.535431141761137e-09
are O 0 9.397026490276517e-10
95 O 0 7.179931316159127e-09
% O 0 7.029850590534181e-10
identical O 0 1.8817412072991146e-09
, O 0 1.1840002311913622e-09
indicating O 0 6.053043399845137e-09
a O 0 3.778502399853778e-09
high O 0 2.7773824129440072e-08
degree O 0 5.926048629589786e-08
of O 0 3.536715809104862e-08
evolutionary O 0 1.3890330592403188e-06
conservation O 0 1.7259561673199642e-06
. O 0 4.295176267987699e-07
. O 0 2.4598746222181944e-06

The O 0 1.1747804819606245e-05
APC B-Disease 0 1.8770497263176367e-05
variants O 0 5.979683919576928e-06
I1307K O 0 1.8764305423246697e-05
and O 0 1.872864459073753e-07
E1317Q O 0 3.2349223602068378e-06
are O 0 1.3976828583395218e-08
associated O 0 3.4896535794359806e-07
with O 0 0.00045417583896778524
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 6.467850255376106e-08
but O 0 4.520240182159796e-09
not O 0 4.668631703452775e-09
always O 0 1.7580761735302985e-08
with O 0 4.237302952958544e-09
a O 0 8.068522561188729e-08
family O 0 3.461906032953266e-07
history O 0 3.613791932366439e-06
. O 0 6.468420451710699e-06

Classical O 1 0.9980085492134094
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.040365174412727356
FAP B-Disease 1 0.9998757839202881
) O 0 5.7284168519800005e-08
is O 0 6.7111969315192255e-09
a O 0 2.6832783106556235e-08
high O 0 5.850667366757989e-05
- O 0 0.18085217475891113
penetrance O 1 0.9999996423721313
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999920129776001
that O 0 1.0782260417840916e-08
predisposes O 0 4.0917765886661073e-07
to O 0 5.414303227979644e-09
hundreds O 0 4.329755398657653e-08
or O 0 1.1102522456951647e-08
thousands O 0 7.23450810369286e-08
of O 0 7.237460977194132e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.15300023555755615
carcinoma I-Disease 1 1.0
and O 0 1.2399776316840416e-08
that O 0 1.999869825297651e-09
results O 0 2.480874172761105e-08
from O 0 2.862994641361638e-08
truncating O 0 1.9453547395187343e-07
mutations O 0 8.702863141252237e-08
in O 0 5.942233727296298e-08
the O 0 4.3306803831910656e-07
APC B-Disease 0 1.3373229194257874e-05
gene O 0 2.2249671474128263e-06
. O 0 7.186974471551366e-06

A O 0 6.299651431618258e-06
variant O 0 1.5021510080259759e-05
of O 0 2.7071728254668415e-06
FAP B-Disease 0 0.0014086804585531354
is O 0 5.005404659641499e-07
attenuated B-Disease 1 0.8075680732727051
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999988079071045
coli I-Disease 1 0.9999878406524658
, O 0 7.000166135640029e-08
which O 0 4.011078580390404e-09
results O 0 1.1837479441112464e-08
from O 0 3.590718833379469e-08
germ O 0 0.07258592545986176
- O 0 5.2672521633212455e-06
line O 0 6.827131642239692e-07
mutations O 0 3.623204491987053e-08
in O 0 1.017880801867932e-08
the O 0 2.5546020410160963e-08
5 O 0 4.174644274712591e-08
and O 0 4.5916426216763284e-09
3 O 0 3.807536685940249e-08
regions O 0 1.571621943696755e-08
of O 0 5.3824276591285525e-08
the O 0 3.0907241921340756e-07
APC B-Disease 0 4.387011813378194e-06
gene O 0 2.39209089158976e-06
. O 0 6.462088549596956e-06

Attenuated B-Disease 1 0.9999642372131348
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999992847442627
patients O 0 2.9884413379477337e-06
have O 0 1.9337843326638904e-08
" O 0 6.321711509826855e-08
multiple O 0 7.477349868167948e-07
" O 0 0.04188886284828186
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 8.11979319337297e-08
typically O 0 5.1786863686231754e-09
fewer O 0 8.185800481896877e-09
than O 0 1.6769433619501228e-09
100 O 0 1.2759198142475725e-08
) O 0 6.627340343179355e-10
without O 0 2.881795913012297e-09
the O 0 2.253693232034948e-08
florid O 0 1.1010954494850012e-06
phenotype O 0 3.995778854459786e-07
of O 0 2.465538955220836e-07
classical O 0 2.12954000744503e-05
FAP B-Disease 0 0.00024523265892639756
. O 0 8.53386791277444e-06

Another O 0 1.4853227412459091e-06
group O 0 2.31987797860711e-07
of O 0 7.401691703989854e-08
patients O 0 1.8590460726386482e-08
with O 0 8.179400268204517e-09
multiple O 0 6.937243597349152e-05
adenomas B-Disease 1 0.9999982118606567
has O 0 8.565336884203134e-09
no O 0 7.390275946761449e-09
mutations O 0 1.1839556890436143e-08
in O 0 2.8560829257173737e-09
the O 0 1.0929269045334422e-08
APC B-Disease 0 1.0221867086102066e-07
gene O 0 1.2114545810959498e-08
, O 0 4.2556078660993535e-09
and O 0 4.268338127388915e-09
their O 0 9.184515370463942e-09
phenotype O 0 4.670896203151642e-08
probably O 0 1.4122525371362826e-08
results O 0 1.5328861735497412e-08
from O 0 1.841169350313976e-08
variation O 0 1.1679774303274826e-07
at O 0 5.165361827152992e-08
a O 0 2.7595715934580767e-08
locus O 0 8.289391217886077e-08
, O 0 1.3151719713277998e-08
or O 0 1.8321136607823973e-08
loci O 0 2.1702642527543503e-07
, O 0 4.873044900932655e-08
elsewhere O 0 1.2276444749659277e-07
in O 0 3.210918464446877e-08
the O 0 3.44938939633721e-07
genome O 0 2.0445061181817437e-06
. O 0 4.0445524973620195e-06

Recently O 0 7.734759492450394e-06
, O 0 2.3189200248907582e-07
however O 0 1.0963911023509354e-07
, O 0 1.864425769326772e-08
a O 0 1.7974588928382218e-08
missense O 0 7.420003385050222e-07
variant O 0 1.6609411659374018e-06
of O 0 7.011738034634618e-07
APC B-Disease 0 1.2829650586354546e-05
( O 0 3.300926891824929e-07
I1307K O 0 6.351480260491371e-05
) O 0 1.4254561975235447e-08
was O 0 1.641265789942281e-08
described O 0 6.701948329634888e-09
that O 0 7.022867842820801e-10
confers O 0 2.3692090067584104e-08
an O 0 1.8406136614856905e-09
increased O 0 1.4961235805799333e-08
risk O 0 1.1779936670563984e-07
of O 0 0.0007093208259902894
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.3644638841014967e-07
including O 0 4.701133349271913e-08
multiple O 0 1.2324369436100824e-06
adenomas B-Disease 0 0.0916176438331604
, O 0 3.873259117881389e-07
in O 0 1.0832783345904318e-06
Ashkenazim O 0 0.05410833656787872
. O 0 1.4441756320593413e-05

We O 0 1.3825954283674946e-06
have O 0 1.7897042425829568e-07
studied O 0 3.3579743785594474e-07
a O 0 2.978707591694274e-08
set O 0 3.688765559672902e-08
of O 0 2.7410276715045256e-08
164 O 0 1.6239408751062e-07
patients O 0 2.3984398467291612e-08
with O 0 3.8943149149872625e-08
multiple O 1 0.9999454021453857
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.23080240190029144
/ I-Disease 1 0.9999926090240479
or I-Disease 0 0.00026247798814438283
carcinoma I-Disease 1 1.0
and O 0 2.7705604566108377e-07
analyzed O 0 9.228381259163143e-07
codons O 0 4.1322286961076315e-06
1263 O 0 3.239837315049954e-05
- O 0 3.0887933917256305e-06
1377 O 0 1.3678653886017855e-05
( O 0 1.9597283085204253e-07
exon O 0 1.724675939840381e-06
15G O 0 6.508852038678015e-06
) O 0 7.323833095540522e-09
of O 0 1.2272693972192883e-08
the O 0 3.8787771217130285e-08
APC B-Disease 0 3.1398272426486074e-07
gene O 0 8.410893315158319e-08
for O 0 1.0287017460086645e-07
germ O 0 0.06543278694152832
- O 0 2.121221950801555e-05
line O 0 7.459981134161353e-06
variants O 0 6.1722935242869426e-06
. O 0 4.85036298414343e-06

Three O 0 2.952478780571255e-06
patients O 0 3.4778460644702136e-07
with O 0 2.5335426201422706e-08
the O 0 8.011827645759695e-08
I1307K O 0 2.9430329959723167e-06
allele O 0 1.0303924824484056e-07
were O 0 2.613253080596678e-08
detected O 0 2.142150279382804e-08
, O 0 1.697762819219406e-09
each O 0 1.9154327013382044e-09
of O 0 5.0525244432719774e-08
Ashkenazi O 0 5.3327312343753874e-06
descent O 0 4.591838205669774e-06
. O 0 6.1063101384206675e-06

Four O 0 6.620045041927369e-06
patients O 0 7.423521424243518e-07
had O 0 2.2446762670824683e-07
a O 0 1.3839368762091908e-07
germ O 0 0.0016080085188150406
- O 0 1.852111381595023e-05
line O 0 3.093701934631099e-06
E1317Q O 0 2.211548689956544e-06
missense O 0 6.463145609814092e-07
variant O 0 3.760598588087305e-07
of O 0 6.271893226994507e-08
APC O 0 2.9049155614302435e-07
that O 0 2.4742288218249087e-09
was O 0 1.1811768452218985e-08
not O 0 7.27952809143062e-10
present O 0 3.109356550012876e-09
in O 0 1.761509049735821e-09
controls O 0 9.521411215018816e-09
; O 0 2.8741329316517295e-09
one O 0 1.7115615591478672e-09
of O 0 3.5652281127340757e-09
these O 0 4.049993229671145e-09
individuals O 0 7.82326026183e-09
had O 0 2.8564603127279042e-08
an O 0 5.763232113764616e-09
unusually O 0 2.427901968360402e-08
large O 0 1.2798245130341002e-08
number O 0 2.2962328927178532e-08
of O 0 1.1569544966505418e-07
metaplastic B-Disease 0 0.0004519768990576267
polyps I-Disease 0 2.1681905764125986e-06
of I-Disease 0 3.2964373986033024e-07
the I-Disease 0 1.7619420304981759e-06
colorectum I-Disease 0 0.0005075155640952289
. O 0 1.5226954019453842e-05

There O 0 8.299791147692304e-07
is O 0 6.091845961009312e-08
increasing O 0 4.119395313750829e-08
evidence O 0 6.64084751633709e-08
that O 0 3.987508101488402e-09
there O 0 1.4095372868894174e-08
exist O 0 1.3023182532378996e-07
germ O 0 5.773307566414587e-05
- O 0 7.351687258960737e-07
line O 0 1.9580619436965208e-07
variants O 0 1.4908515311162773e-07
of O 0 3.4975325746700037e-08
the O 0 8.284270336389454e-08
APC B-Disease 0 4.862349101131258e-07
gene O 0 1.7767415982916646e-08
that O 0 4.363062355849934e-09
predispose O 0 5.018409865442663e-07
to O 0 1.25940600170793e-08
the O 0 3.5733172865093366e-08
development O 0 9.12549822373876e-08
of O 0 7.648250033298609e-08
multiple O 1 0.9152722358703613
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.19288460910320282
carcinoma I-Disease 1 1.0
, O 0 2.089918638148447e-08
but O 0 4.70146277464778e-09
without O 0 1.59153437095938e-08
the O 0 4.900793726392294e-08
florid O 0 1.5185852362264995e-06
phenotype O 0 2.92777201593708e-07
of O 0 8.035150500518284e-08
classical O 0 2.008117235163809e-06
FAP B-Disease 0 2.1929721697233617e-05
, O 0 1.548818140406638e-08
and O 0 5.685819370881973e-09
possibly O 0 2.0032150160886886e-08
with O 0 5.002867897729857e-09
importance O 0 8.801031299299211e-07
for O 0 2.971969843201805e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 4.4671753585134866e-07
in O 0 3.991754038423778e-09
the O 0 9.447999715916922e-09
general O 0 8.114219696153668e-08
population O 0 1.866663978944416e-08
. O 0 6.307667632654557e-08
. O 0 1.1794342071880237e-06

Genomic O 0 1.1966067177127115e-05
structure O 0 1.6401368156948593e-06
of O 0 3.893598545801069e-07
the O 0 1.1461421536296257e-06
human O 1 0.9999728202819824
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999974966049194
CLD B-Disease 1 1.0
) O 0 5.554046538236435e-07
gene O 0 1.0481264780537458e-06
. O 0 1.695794821898744e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999997615814209
CLD B-Disease 1 1.0
) O 0 1.53225826693415e-07
is O 0 5.320610618753108e-09
caused O 0 9.228291908414121e-09
by O 0 1.8284647129718223e-09
mutations O 0 1.749769751313579e-08
in O 0 3.068217457879996e-09
a O 0 4.746314452575007e-09
gene O 0 1.2732359166989227e-08
which O 0 5.5739635129725684e-09
encodes O 0 7.406140412058448e-08
an O 0 9.58182653221229e-08
intestinal O 0 5.1843899200321175e-06
anion O 0 4.6355151425814256e-05
transporter O 0 0.00023998481628950685
. O 0 9.199645319313277e-06

We O 0 1.622771719667071e-06
report O 0 6.574705366801936e-07
here O 0 1.256132975413493e-07
the O 0 2.5499723221855675e-08
complete O 0 4.2746460593434676e-08
genomic O 0 7.419699272759317e-07
organization O 0 2.0058766381225723e-07
of O 0 8.51924681910532e-08
the O 0 2.662887652604695e-07
human O 0 5.852898084413027e-06
CLD B-Disease 1 0.9999983310699463
gene O 0 3.423966177251714e-07
which O 0 1.0843062625554012e-07
spans O 0 5.573211296905356e-07
approximately O 0 5.90585074178307e-08
39kb O 0 2.196949481003685e-06
, O 0 6.989786527356046e-08
and O 0 1.8996836104179238e-07
comprises O 0 1.3751945289186551e-06
21 O 0 5.031031378166517e-06
exons O 0 3.888721403200179e-05
. O 0 1.6875550500117242e-05

All O 0 1.4561297575710341e-05
exon O 0 9.819523256737739e-05
/ O 0 4.2747629777295515e-05
intron O 0 2.424182093818672e-05
boundaries O 0 3.900883314145176e-07
conform O 0 4.6494793082274555e-07
to O 0 8.07514197731507e-08
the O 0 3.8127441825963615e-07
GT O 0 1.8927676137536764e-05
/ O 0 4.6131790440995246e-05
AG O 0 0.0013918443582952023
rule O 0 6.588453743461287e-06
. O 0 6.339645551634021e-06

An O 0 2.032794839124108e-07
analysis O 0 1.958739801466436e-07
of O 0 1.8381714994575304e-07
the O 0 1.7787107253752765e-07
putative O 0 1.8370063116890378e-05
promoter O 0 2.383365062996745e-05
region O 0 6.418839006983035e-07
sequence O 0 1.2351273426247644e-07
shows O 0 1.270911980100209e-07
a O 0 1.0338946765386936e-07
putative O 0 1.8327033103560098e-05
TATA O 0 8.315237937495112e-05
box O 0 5.920082458032994e-06
and O 0 2.968284320559178e-07
predicts O 0 1.3276372783366241e-06
multiple O 0 4.727069153886987e-07
transcription O 0 1.1663255463645328e-05
factor O 0 2.2839601570012746e-06
binding O 0 1.4109205039858352e-06
sites O 0 8.79509298101766e-06
. O 0 9.250547918782104e-06

The O 0 1.7767775943866582e-06
genomic O 0 3.648903884823085e-06
structure O 0 4.757093279295077e-07
was O 0 1.4319751073799125e-07
determined O 0 1.4629357281137345e-08
using O 0 2.8253508421727247e-09
DNA O 0 2.5336586162438834e-08
from O 0 1.1710642233708768e-08
several O 0 7.907918764260558e-09
sources O 0 3.925120140024774e-08
including O 0 7.938006696406319e-09
multiple O 0 1.0323262245037768e-07
large O 0 3.6903000477650494e-07
- O 0 1.0445153293403564e-06
insert O 0 9.685677468951326e-07
libaries O 0 4.6236173147917725e-06
and O 0 2.0470112715997857e-08
genomic O 0 1.0097596714331303e-07
DNA O 0 2.2074196692756232e-07
from O 0 1.4791565661198547e-07
Finnish O 0 0.02679062820971012
CLD B-Disease 1 0.9999995231628418
patients O 0 4.7242522782653396e-07
and O 0 2.784570369840367e-07
controls O 0 4.128309683437692e-06
. O 0 5.115069598105038e-06

Exon O 0 2.9101112886564806e-05
- O 0 4.094121322850697e-06
specific O 0 3.724972259533388e-07
primers O 0 1.9259955479355995e-06
developed O 0 1.2318301401137433e-07
in O 0 5.163852012657344e-09
this O 0 1.6685938186711269e-09
study O 0 5.7393401142746825e-09
will O 0 1.548834949183231e-09
facilitate O 0 3.260736747279225e-08
mutation O 0 9.83535208831654e-09
screening O 0 1.593666709709396e-08
studies O 0 1.298256702142453e-08
of O 0 4.464179248486744e-09
patients O 0 8.181054944600419e-09
with O 0 8.763808345690904e-09
the O 0 1.597063260305731e-06
disease O 0 0.07647443562746048
. O 0 4.09651875088457e-06

Genomic O 0 1.610750587133225e-05
sequencing O 0 9.326018698629923e-06
of O 0 2.2683334464090876e-06
a O 0 2.235806505268556e-06
BAC O 0 0.00024237790785264224
clone O 0 2.7069687348557636e-05
H O 1 1.0
_ O 0 8.925546239879623e-07
RG364P16 O 0 1.3384814337769058e-05
revealed O 0 1.2458870912723796e-07
the O 0 1.5912245743265885e-08
presence O 0 5.284910642444629e-08
of O 0 3.7472982938879795e-08
another O 0 6.154268561431309e-08
, O 0 2.470250315411704e-08
highly O 0 7.037557736566669e-08
homologous O 0 5.2917595638746207e-08
gene O 0 8.636833825903523e-08
3 O 0 1.6716182926757028e-07
of O 0 5.395512303607575e-08
the O 0 2.062401875946307e-07
CLD B-Disease 1 0.9619178175926208
gene O 0 9.313827575851974e-08
, O 0 1.2582917818804162e-08
with O 0 1.4261054559483455e-09
a O 0 3.894773392687512e-09
similar O 0 3.537847570456165e-09
genomic O 0 1.613634594832547e-07
structure O 0 1.0836198072183834e-07
, O 0 1.2402117555154746e-08
recently O 0 2.096322226918801e-08
identified O 0 3.9808984553246773e-08
as O 0 2.3486474987066686e-08
the O 0 3.5648702123580733e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.6834947018651292e-05
( O 0 4.460974196263123e-06
PDS B-Disease 1 0.9999674558639526
) O 0 1.1399021815350352e-07
. O 0 1.285787618598988e-07
. O 0 1.014842951008177e-06

The O 0 8.370661817025393e-06
APCI1307K O 0 0.019189119338989258
allele O 0 7.807901965861674e-06
and O 0 8.102881565719144e-07
cancer B-Disease 0 0.0006273025646805763
risk O 0 1.1179258763149846e-07
in O 0 6.218573656013859e-09
a O 0 7.738372609367161e-09
community O 0 2.1473617550782365e-08
- O 0 6.402625274404272e-08
based O 0 2.4226007866445798e-08
study O 0 1.7844545396883404e-08
of O 0 7.467716045539419e-08
Ashkenazi O 0 6.562479484273354e-06
Jews O 0 1.8202996216132306e-05
. O 0 7.3567262006690726e-06

Mutations O 0 1.0575431588222273e-05
in O 0 5.407596290751826e-07
APC O 0 6.4299556470359676e-06
are O 0 1.0591237042945068e-07
classically O 0 1.4422364529309561e-06
associated O 0 5.754062613050337e-07
with O 0 1.2811550504920888e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999938011169434
FAP B-Disease 1 0.9999997615814209
) O 0 6.444035705044371e-08
, O 0 7.456895545487896e-09
a O 0 1.2952069639027286e-08
highly O 0 6.0547199609573e-07
penetrant O 1 0.9999998807907104
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 6.145073143670743e-07
by O 0 2.9438865567499306e-08
multiple O 0 1.231743681273656e-06
intestinal O 1 0.8278407454490662
polyps B-Disease 0 7.526724061790446e-07
and O 0 9.465026096222573e-09
, O 0 5.60073409872075e-09
without O 0 7.541313351566714e-09
surgical O 0 6.29765395387949e-07
intervention O 0 1.3847871116468013e-07
, O 0 5.13380049582679e-09
the O 0 1.2694602702367774e-08
development O 0 3.9244471849997353e-07
of O 0 0.00056744139874354
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.3544531359220855e-05
CRC B-Disease 1 0.9910640716552734
) O 0 1.4550404330293532e-06
. O 0 2.476818508512224e-06

APC B-Disease 0 0.00021379068493843079
is O 0 1.4472902876150329e-06
a O 0 1.6187499340958311e-06
tumour O 1 0.9999998807907104
- O 0 1.6863003111211583e-05
suppressor O 0 2.112579568347428e-05
gene O 0 2.6793208007802605e-07
, O 0 4.0045218696604934e-08
and O 0 3.2267092109350415e-08
somatic O 1 0.9689651131629944
loss O 0 2.3406135369441472e-05
occurs O 0 5.890909733352601e-07
in O 0 1.0521777085159556e-06
tumours B-Disease 1 1.0
. O 0 1.9179258742951788e-05

The O 0 3.0383545890799724e-05
germline O 0 0.00040667172288522124
T O 0 6.634695455431938e-05
- O 0 2.236719183201785e-06
to O 0 1.3721826519486058e-07
- O 0 5.32543651843298e-07
A O 0 2.3595320897129568e-07
transversion O 0 1.0678352282411652e-06
responsible O 0 3.79330025168656e-08
for O 0 1.2679914895841193e-08
the O 0 7.033236215647776e-08
APC O 0 1.2725993201456731e-06
I1307K O 0 1.6226015304710018e-06
allele O 0 8.544470375682067e-08
converts O 0 1.1645972364249246e-07
the O 0 1.691131679137925e-08
wild O 0 6.113554462672255e-08
- O 0 6.20898816805493e-08
type O 0 1.4428258587884102e-08
sequence O 0 7.368867738222207e-09
to O 0 8.920481242569167e-09
a O 0 5.552606552328143e-08
homopolymer O 0 0.0006140320328995585
tract O 0 2.342967491131276e-05
( O 0 5.45166699339461e-07
A8 O 0 0.012488671578466892
) O 0 5.182016149518631e-09
that O 0 1.3501296747264746e-09
is O 0 4.06733358104816e-09
genetically O 0 4.3257108472971595e-07
unstable O 0 1.922395085784956e-06
and O 0 8.951300145554342e-08
prone O 0 6.667169145657681e-07
to O 0 2.394932323568355e-07
somatic O 0 0.0004401306505315006
mutation O 0 5.571846486418508e-06
. O 0 7.462101166311186e-06

The O 0 1.1385594916646369e-05
I1307K O 0 5.314942973200232e-05
allele O 0 3.46436081599677e-06
was O 0 7.155121011237497e-07
found O 0 1.2389202197482518e-07
in O 0 1.7008078145863692e-07
6 O 0 6.178124294820009e-06
. O 0 3.905602625309257e-06

1 O 0 1.0302415830665268e-05
% O 0 1.610209494629089e-07
of O 0 1.378913481175914e-07
unselected O 0 5.3674360970035195e-05
Ashkenazi O 0 4.510864073381526e-06
Jews O 0 7.536930297646904e-07
and O 0 2.1407041472798483e-08
higher O 0 7.704620230697401e-08
proportions O 0 9.164744341205733e-08
of O 0 7.60720837433837e-08
Ashkenazim O 0 1.1497316336317454e-05
with O 0 2.3223876155498147e-08
family O 0 5.8430604354953175e-08
or O 0 5.2151467144767594e-08
personal O 0 3.531728225425468e-07
histories O 0 3.2670795917510986e-06
of O 0 9.005221727420576e-06
CRC B-Disease 1 0.9999710321426392
( O 0 1.6809973431008984e-06
ref O 0 3.992265556007624e-05
. O 0 4.675116827002057e-07
2 O 0 2.6427119337313343e-06
) O 0 2.908863621087221e-07
. O 0 2.1055645902379183e-06

To O 0 6.139168817753671e-07
evaluate O 0 1.3648832464241423e-06
the O 0 2.774616802980745e-07
role O 0 2.5170177764266555e-07
of O 0 2.2700314161738788e-07
I1307K O 0 0.00025141198420897126
in O 0 1.9399894313210098e-07
cancer B-Disease 0 9.770297765498981e-06
, O 0 3.63955798832194e-08
we O 0 5.222064203280752e-08
genotyped O 0 1.9021297703147866e-05
5 O 0 7.981952876434661e-07
, O 0 9.036608616952435e-08
081 O 0 1.3709802260564175e-05
Ashkenazi O 0 2.3766419872117694e-06
volunteers O 0 1.866418841700579e-07
in O 0 2.093389461776951e-08
a O 0 8.320168376485526e-08
community O 0 3.4869688647631847e-07
survey O 0 1.0944016821667901e-06
. O 0 3.5017160371353384e-06

Risk O 0 2.213208244938869e-05
of O 0 2.5486169761279598e-06
developing O 0 0.009644887410104275
colorectal B-Disease 1 1.0
, I-Disease 0 2.5273488972743507e-06
breast I-Disease 0 2.4003837097552605e-05
and I-Disease 0 1.2066994514725593e-08
other I-Disease 0 4.8418872466982066e-08
cancers I-Disease 0 0.0005548626650124788
were O 0 3.9484426395119954e-08
compared O 0 1.8932480472244606e-08
between O 0 2.824156197789307e-08
genotyped O 0 6.63917489873711e-07
I1307K O 0 3.758590878533141e-07
carriers O 0 2.4316094027199142e-08
and O 0 7.601620666264353e-09
non O 0 5.5634195916809404e-08
- O 0 4.30226023695468e-08
carriers O 0 1.1743746419767831e-08
and O 0 6.601279078921607e-09
their O 0 6.7604282172339936e-09
first O 0 1.1997758520010393e-07
- O 0 1.0212118013441795e-06
degree O 0 1.2604436960828025e-06
relatives O 0 8.938467544794548e-06
. O 0 7.418336736009223e-06

Sperm O 0 1.0637690138537437e-05
DNA O 0 2.446564849378774e-06
analysis O 0 4.2695535285020014e-07
in O 0 6.247393713465499e-08
a O 0 4.058660749706178e-07
Friedreich B-Disease 1 0.9998823404312134
ataxia I-Disease 1 1.0
premutation O 1 0.9999918937683105
carrier O 0 1.1533745691849617e-06
suggests O 0 2.1691903384635225e-07
both O 0 4.0265721423793366e-08
meiotic O 0 2.5072672542592045e-06
and O 0 1.5154456889376888e-07
mitotic O 0 4.358953447081149e-06
expansion O 0 3.0660539778182283e-06
in O 0 1.5808416264917469e-07
the O 0 1.085967824110412e-06
FRDA B-Disease 0 0.0019093252485617995
gene O 0 4.860151875618612e-06
. O 0 7.469307092833333e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 3.0878832149028312e-06
usually O 0 1.663736099999369e-07
caused O 0 4.941473719100031e-08
by O 0 6.228426219223593e-09
an O 0 3.903347867151297e-09
expansion O 0 7.21810664572331e-08
of O 0 4.825679056352783e-08
a O 0 2.312661280257089e-07
GAA O 1 0.9960370659828186
trinucleotide O 1 0.9720746874809265
repeat O 0 1.4927336451364681e-06
in O 0 1.3178215851894493e-07
intron O 0 6.631817541347118e-06
1 O 0 7.602993150612747e-07
of O 0 1.3868408643702423e-07
the O 0 4.264629751560278e-07
FRDA B-Disease 0 0.009675081819295883
gene O 0 4.872087629337329e-06
. O 0 1.2444753338058945e-05

Occasionally O 0 6.275079613260459e-06
, O 0 2.2547600053712813e-07
a O 0 7.56035660742782e-08
fully O 0 1.983085979873067e-07
expanded O 0 8.380867200230568e-08
allele O 0 7.082547170966791e-08
has O 0 3.504101231399659e-09
been O 0 3.297900619259053e-09
found O 0 2.043023750175621e-09
to O 0 2.070894788985811e-09
arise O 0 7.603929930155573e-08
from O 0 2.6739696679101144e-08
a O 0 2.5599868891390543e-08
premutation O 0 3.2812520203151507e-06
of O 0 6.773105809543267e-08
100 O 0 1.2324811393682467e-07
or O 0 6.989306200466672e-08
less O 0 3.18193855264326e-07
triplet O 0 3.079380257986486e-05
repeats O 0 1.3699856026505586e-05
. O 0 9.665546713222284e-06

We O 0 1.5567619584544445e-06
have O 0 1.4861187480619265e-07
examined O 0 1.3226707551439176e-06
the O 0 1.0367461555915725e-07
sperm O 0 3.158266679292865e-07
DNA O 0 2.9253439493004407e-07
of O 0 1.4390144542630878e-07
a O 0 1.750283047385892e-07
premutation O 0 5.894483911106363e-05
carrier O 0 5.082660663902061e-06
. O 0 5.660475835611578e-06

This O 0 1.5256966889864998e-06
mans O 0 5.091444472782314e-05
leucocyte O 0 1.5462519513675943e-05
DNA O 0 1.356746338387893e-06
showed O 0 1.8164703874390398e-07
one O 0 9.314428339735059e-09
normal O 0 1.4046232621467425e-08
allele O 0 1.5777278150608254e-08
and O 0 1.9391648287125918e-09
one O 0 3.913009027911585e-09
allele O 0 2.4895486561149482e-08
of O 0 2.938310750266737e-08
approximately O 0 4.980239509677631e-08
100 O 0 1.8084224961967266e-07
repeats O 0 1.6491035239596386e-06
. O 0 2.1621588075504405e-06

His O 0 4.784172688232502e-06
sperm O 0 3.5376951927901246e-06
showed O 0 3.4899963452517113e-07
an O 0 1.5358244453977932e-08
expanded O 0 3.2380533809828194e-08
allele O 0 3.0078243895559353e-08
in O 0 9.240761933426711e-09
a O 0 2.652396702274018e-08
tight O 0 2.426756680051767e-07
range O 0 2.926381625911745e-07
centering O 0 6.598914978894754e-07
on O 0 5.387008528145998e-08
a O 0 2.2451679626556142e-08
size O 0 1.1530145371807521e-07
of O 0 2.4037095158746524e-07
approximately O 0 4.631560557299963e-07
320 O 0 3.312324452053872e-06
trinucleotide O 0 0.0002733432629611343
repeats O 0 2.9638491469086148e-05
. O 0 1.012160828395281e-05

His O 0 1.5197997527138796e-05
affected O 0 2.932725146820303e-05
son O 0 8.761355275055394e-05
has O 0 1.9910602588879556e-07
repeat O 0 8.609955557403737e-07
sizes O 0 1.8842671352103935e-06
of O 0 6.785246000617917e-07
1040 O 0 4.47352022092673e-06
and O 0 7.615510639880085e-07
540 O 0 1.5781508409418166e-05
. O 0 7.190237738541327e-06

These O 0 5.992792466713581e-07
data O 0 2.320107910236402e-07
suggest O 0 6.827764309491613e-08
that O 0 4.62516691612791e-09
expansion O 0 6.123006812686071e-08
occurs O 0 4.579153056738505e-09
in O 0 1.947311645267291e-09
two O 0 2.648007813021991e-09
stages O 0 1.7452933320782904e-08
, O 0 3.4325853270900097e-09
the O 0 7.056344397682324e-09
first O 0 1.941471339250711e-08
during O 0 3.206842436043189e-08
meiosis O 0 1.7354651049572567e-07
followed O 0 5.523294532849832e-08
by O 0 1.1338702421426206e-08
a O 0 6.413723951936845e-08
second O 0 3.616749495449767e-07
mitotic O 0 8.181787961802911e-06
expansion O 0 2.2110862119006924e-05
. O 0 1.6400070308009163e-05

We O 0 1.3004780612391187e-06
also O 0 2.3756263090035645e-07
show O 0 3.9195466428054715e-08
that O 0 4.670252629068727e-09
in O 0 8.278122187732606e-09
all O 0 9.00115182389527e-09
informative O 0 7.482615416165572e-08
carrier O 0 3.116655378221367e-08
father O 0 2.3355184453066613e-08
to O 0 5.817657910967e-09
affected O 0 6.383955764022176e-08
child O 0 6.465766233532122e-08
transmissions O 0 2.0052588922681025e-07
, O 0 5.545967241005201e-09
with O 0 1.4892557187451416e-09
the O 0 1.1831520652094696e-08
notable O 0 8.313394772585525e-08
exception O 0 3.9013254848896395e-08
of O 0 4.7460275709454436e-08
the O 0 7.004800295362656e-08
premutation O 0 5.451757715491112e-06
carrier O 0 2.0890364282877272e-07
, O 0 1.9193175049281308e-08
the O 0 3.282514526858904e-08
expansion O 0 2.6784979922922503e-07
size O 0 1.8411593316614017e-07
decreases O 0 2.768516367268603e-07
. O 0 1.7044222033746337e-07
. O 0 2.1302196273609297e-06

The O 0 8.324601367348805e-06
R496H O 0 0.00011108111357316375
mutation O 0 2.0252766717021586e-06
of O 0 1.0648433317328454e-06
arylsulfatase O 0 0.0048255338333547115
A O 0 1.4765478226763662e-06
does O 0 1.0329919319929104e-07
not O 0 1.7197768897858623e-07
cause O 0 0.12112142145633698
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 4.022908615297638e-05

Deficiency B-Disease 1 0.9998776912689209
of I-Disease 0 0.0003895007830578834
arylsulfatase I-Disease 1 0.9999876022338867
A I-Disease 0 0.044312965124845505
( O 0 1.2458063793019392e-05
ARSA O 1 0.67036372423172
) O 0 1.112919889578734e-07
enzyme O 0 6.38247058759589e-07
activity O 0 5.744752229475125e-07
causes O 0 9.068445251614321e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.5395897207781672e-05
MLD B-Disease 1 1.0
) O 0 1.060814383890829e-06
. O 0 2.076660621241899e-06

A O 0 6.010948254697723e-06
number O 0 2.0732038592541358e-06
of O 0 2.081589855151833e-06
ARSA O 0 0.001230419846251607
gene O 0 1.5586575727866148e-06
mutations O 0 1.1264484101047856e-06
responsible O 0 8.583212434132292e-07
for O 0 5.705854846382863e-07
MLD B-Disease 1 1.0
have O 0 2.2569028601537866e-07
been O 0 1.811567500453748e-07
identified O 0 1.336789978267916e-06
. O 0 2.192700321757002e-06

Recently O 0 5.233389401837485e-06
, O 0 3.458210073858936e-07
the O 0 1.9302619591599068e-07
R496H O 0 8.745160812395625e-06
mutation O 0 5.605951969300804e-07
of O 0 5.618465479528822e-07
ARSA O 0 0.11180960386991501
was O 0 3.959000878239749e-07
proposed O 0 3.983366880788708e-08
to O 0 6.27366159022813e-09
be O 0 8.397985418184817e-09
a O 0 2.995486525492197e-08
cause O 0 6.938552701285516e-07
of O 0 2.405494342383463e-06
MLD B-Disease 1 1.0
( O 0 2.637598299770616e-06
Draghia O 0 0.00010096786718349904
et O 0 5.34329501533648e-06
al O 0 6.883302830829052e-06
. O 0 6.976519983936669e-08
, O 0 6.540921049236204e-08
1997 O 0 2.507324268208322e-07
) O 0 4.542905003290798e-07
. O 0 1.271297833227436e-06

We O 0 1.2574589618452592e-06
have O 0 1.9131631745494815e-07
investigated O 0 1.0162220860365778e-06
the O 0 2.0449768101116206e-07
R496H O 0 2.4566700176364975e-06
mutation O 0 2.0139765410931432e-08
and O 0 5.643961298318345e-09
found O 0 2.268718102271805e-09
this O 0 1.4488672483992104e-09
mutation O 0 8.521078953549477e-09
at O 0 1.2981923092070247e-08
a O 0 4.106511575230343e-09
relatively O 0 7.296894199981807e-09
high O 0 9.147190560554463e-09
frequency O 0 5.4878301902760995e-09
in O 0 1.873497135207458e-09
an O 0 4.659326702238786e-09
African O 0 1.675055116834301e-08
American O 0 2.608706317630549e-08
population O 0 1.0289721075196212e-08
( O 0 1.7178845013177124e-08
f O 0 2.530940150791139e-07
= O 0 4.624560574484349e-07
0 O 0 2.58096434890831e-07
. O 0 4.6675122433725846e-08
09 O 0 5.512191023626656e-07
, O 0 5.6078885535271183e-08
n O 0 3.1383990517497296e-07
= O 0 1.730181338643888e-06
61 O 0 1.1337964451740845e-06
subjects O 0 1.939299181685783e-06
) O 0 3.768424789996061e-07
. O 0 1.7886666228150716e-06

The O 0 4.957908095093444e-05
ARSA O 0 0.0007091308361850679
enzyme O 0 2.129112772308872e-06
activity O 0 3.8382930256375403e-07
in O 0 1.2978431662702405e-08
subjects O 0 6.211369196762462e-08
with O 0 2.9267197554361246e-09
and O 0 5.206953535008552e-09
without O 0 1.167580521155287e-08
the O 0 5.221317422865468e-08
R496H O 0 6.096955189605069e-07
mutation O 0 1.2216549549748379e-08
was O 0 1.7235327831599534e-08
determined O 0 8.74057093369629e-09
and O 0 6.3803748950874706e-09
found O 0 4.9149915248847265e-09
to O 0 9.043588988788542e-09
be O 0 9.75742011632974e-08
normal O 0 1.1139397884107893e-06
. O 0 3.4711038097157143e-06

It O 0 3.359197933150426e-07
is O 0 8.434412990254714e-08
therefore O 0 1.0910527237228962e-07
concluded O 0 1.0072128731053454e-07
that O 0 6.3461365051864504e-09
the O 0 3.602964682158927e-08
R496H O 0 1.773232952473336e-06
mutation O 0 1.0476113487811745e-07
of O 0 2.2478467087694298e-07
ARSA O 0 0.0001530020235804841
does O 0 1.5963744104396937e-08
not O 0 7.675179602983917e-09
negatively O 0 3.8124493784152946e-08
influence O 0 2.472513038753732e-08
the O 0 8.174472654332021e-09
activity O 0 2.774285157158829e-08
of O 0 4.7251262458303245e-08
ARSA O 0 0.03999947011470795
and O 0 3.776141355160689e-08
is O 0 8.900205905604253e-09
not O 0 1.638650992674684e-08
a O 0 1.4571550366326846e-07
cause O 0 1.1549636838026345e-05
of O 0 9.371059422846884e-05
MLD B-Disease 1 1.0

Down O 0 0.00012496518320403993
- O 0 1.5778845408931375e-05
regulation O 0 4.8182155296672136e-06
of O 0 1.2982686712348368e-06
transmembrane O 0 1.754058939695824e-05
carbonic O 0 0.0039202626794576645
anhydrases O 0 0.18249863386154175
in O 0 1.20721711027727e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 0 0.24872741103172302
lines O 0 1.828753966037766e-07
by O 0 1.3733393089410129e-08
wild O 0 2.723697321016516e-07
- O 0 7.467630211976939e-07
type O 0 1.8192907873526565e-06
von B-Disease 1 0.5724747180938721
Hippel I-Disease 1 0.6633637547492981
- I-Disease 1 0.880412220954895
Lindau I-Disease 1 0.9847500324249268
transgenes O 0 0.001449571456760168
. O 0 4.00082535634283e-05

To O 0 1.6669266642566072e-06
discover O 0 2.1113896764290985e-06
genes O 0 1.5242001154547324e-06
involved O 0 9.587408840161515e-07
in O 0 5.491654064826434e-07
von B-Disease 1 0.9995013475418091
Hippel I-Disease 1 0.9999985694885254
- I-Disease 1 0.999998927116394
Lindau I-Disease 1 0.9999998807907104
( O 0 3.577170355129056e-05
VHL B-Disease 1 0.9999998807907104
) O 0 1.5022851584944874e-06
- O 0 7.592692327307304e-06
mediated O 0 3.743798879440874e-05
carcinogenesis O 0 0.09975632280111313
, O 0 1.3308175539350486e-07
we O 0 3.8998152263047814e-08
used O 0 4.974434659743565e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9998440742492676
lines O 0 7.117890618246747e-06
stably O 0 3.747953087440692e-06
transfected O 0 1.801504367904272e-06
with O 0 4.6883375404149774e-08
wild O 0 7.617188657604856e-07
- O 0 2.9972122774779564e-06
type O 0 7.591208031954011e-06
VHL O 1 0.9996734857559204
- O 0 8.642765897093341e-05
expressing O 0 1.2372048331599217e-05
transgenes O 0 0.00017989827028941363
. O 0 1.2375623555271886e-05

Large O 0 1.5358882592408918e-05
- O 0 5.271176632959396e-06
scale O 0 1.1251921705479617e-06
RNA O 0 1.6993678855214966e-06
differential O 0 6.916941970303014e-07
display O 0 2.2728606552391284e-07
technology O 0 2.565261638665106e-07
applied O 0 3.500161938063684e-08
to O 0 3.800496806150022e-09
these O 0 1.0405692307813297e-08
cell O 0 1.8535091328431008e-07
lines O 0 8.493352510186014e-08
identified O 0 4.066994563345361e-08
several O 0 1.828347251375817e-08
differentially O 0 6.66482947053737e-07
expressed O 0 2.6983931533663963e-08
genes O 0 1.639160451816224e-08
, O 0 7.1877139795617495e-09
including O 0 7.544708857665228e-09
an O 0 2.8564603127279042e-08
alpha O 0 5.115613248563022e-07
carbonic O 0 5.831775524711702e-06
anhydrase O 0 7.287992502824636e-06
gene O 0 4.6764324679315905e-07
, O 0 4.3090068402307224e-07
termed O 0 1.2406952009769157e-05
CA12 O 1 0.8680582642555237
. O 0 1.4582797120965552e-05

The O 0 4.84694101032801e-06
deduced O 0 6.67637186779757e-06
protein O 0 4.776003379447502e-07
sequence O 0 8.704340359599883e-08
was O 0 1.0820192386518102e-07
classified O 0 7.722555039890722e-08
as O 0 1.8523035549833367e-08
a O 0 1.9383300298159156e-08
one O 0 3.656054659018082e-08
- O 0 4.671760791552515e-07
pass O 0 5.582179483099026e-07
transmembrane O 0 1.140277527156286e-05
CA O 0 8.633935976831708e-06
possessing O 0 1.436356228623481e-06
an O 0 2.643702430304984e-07
apparently O 0 7.770128149786615e-07
intact O 0 4.3155253592885856e-07
catalytic O 0 2.0815947721075645e-07
domain O 0 3.3122569220722653e-07
in O 0 4.503212380768673e-08
the O 0 3.95522704366158e-07
extracellular O 0 2.869200579880271e-05
CA O 0 0.00011524064757395536
module O 0 3.7100064218975604e-05
. O 0 1.1025772437278647e-05

Reintroduced O 0 0.0001349891535937786
wild O 0 3.81753416149877e-05
- O 0 1.8325390556128696e-05
type O 0 1.4191688023856841e-05
VHL B-Disease 1 0.9982233643531799
strongly O 0 3.351284760810813e-07
inhibited O 0 1.7396574492067884e-07
the O 0 1.531708448965219e-08
overexpression O 0 2.5098339051510266e-07
of O 0 3.324414876715309e-08
the O 0 3.954630400926362e-08
CA12 O 0 0.046309586614370346
gene O 0 4.7960771354382814e-08
in O 0 1.2215827460693163e-08
the O 0 9.556237756669361e-08
parental O 0 4.544534385786392e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999856948852539
lines O 0 4.414000432007015e-05
. O 0 2.4243679490609793e-06

Similar O 0 9.624877748137806e-07
results O 0 6.80200059832714e-07
were O 0 2.0304834436046804e-07
obtained O 0 3.3908310115293716e-07
with O 0 1.3160708078885364e-07
CA9 O 0 0.016028709709644318
, O 0 8.33452631354703e-08
encoding O 0 3.3704355928421137e-07
another O 0 4.6014378085601493e-07
transmembrane O 0 9.089025297726039e-06
CA O 0 3.6956782878405647e-06
with O 0 7.927388168127436e-08
an O 0 1.61470126158747e-07
intact O 0 2.1563723748840857e-06
catalytic O 0 2.747786084000836e-06
domain O 0 7.487899893021677e-06
. O 0 1.0079091225634329e-05

Although O 0 1.645170186748146e-06
both O 0 2.7829031523651793e-07
domains O 0 1.2335034398347489e-06
of O 0 6.115689075159025e-07
the O 0 9.811473091758671e-07
VHL B-Disease 1 0.999491810798645
protein O 0 4.3783290948340436e-07
contribute O 0 3.482521648834336e-08
to O 0 6.17112227985217e-09
regulation O 0 3.409732869386062e-07
of O 0 3.0014891194696247e-07
CA12 O 1 0.9999805688858032
expression O 0 3.049878216643265e-07
, O 0 6.520630080331102e-08
the O 0 1.3512952534711076e-07
elongin O 0 3.776721541726147e-06
binding O 0 4.3148131112502597e-07
domain O 0 5.647856937684992e-07
alone O 0 3.148276732645172e-07
could O 0 3.6985869655836723e-07
effectively O 0 3.1287693218473578e-06
regulate O 0 1.7278091036132537e-05
CA9 O 1 0.5070530772209167
expression O 0 2.2386302589438856e-05
. O 0 1.2530545973277185e-05

We O 0 1.5967914805514738e-05
mapped O 0 8.39477579575032e-05
CA12 O 1 0.9936937689781189
and O 0 1.3223328096501064e-05
CA9 O 1 0.9565949440002441
loci O 0 9.531509931548499e-06
to O 0 5.337502102520375e-07
chromosome O 0 8.38567575556226e-06
bands O 0 9.43941358855227e-06
15q22 O 0 4.794189953827299e-05
and O 0 2.0455202047742205e-06
17q21 O 0 0.0002892507764045149
. O 0 1.846078703238163e-05

2 O 0 3.870138607453555e-05
respectively O 0 3.723346026163199e-06
, O 0 1.9599711720275081e-07
regions O 0 2.6179557721661695e-07
prone O 0 4.6868845515746216e-07
to O 0 2.059464776493769e-08
amplification O 0 1.361082581752271e-06
in O 0 3.8005641300742354e-08
some O 0 8.581071142543806e-08
human O 0 6.537624813063303e-06
cancers B-Disease 0 0.21046465635299683
. O 0 2.871655169656151e-06

Additional O 0 1.7666700387053424e-06
experiments O 0 9.91398565020063e-07
are O 0 2.2970871427219208e-08
needed O 0 6.18753048797771e-08
to O 0 1.746665390101043e-08
define O 0 1.2473314825456328e-07
the O 0 1.1527198751082324e-07
role O 0 1.768346038488744e-07
of O 0 4.966717028764833e-07
CA O 0 3.974972787545994e-05
IX O 1 1.0
and O 0 3.263372855144553e-05
CA O 0 0.00011494937643874437
XII O 1 0.9936269521713257
enzymes O 0 8.512375870850519e-08
in O 0 9.178578785906666e-09
the O 0 1.1373445296669615e-08
regulation O 0 6.016936282549068e-08
of O 0 2.3043453367677103e-08
pH O 0 1.5840198841488018e-07
in O 0 1.0821529450311118e-08
the O 0 4.8241695083106606e-08
extracellular O 0 7.840477564968751e-07
microenvironment O 0 4.3867148633580655e-06
and O 0 2.6318959456261837e-08
its O 0 9.430751291006345e-09
potential O 0 2.1954151918635034e-07
impact O 0 1.478400690757553e-06
on O 0 1.5312343748519197e-06
cancer B-Disease 0 9.101992873183917e-06
cell O 0 1.62968754011672e-05
growth O 0 3.542742661011289e-06
. O 0 3.057201183764846e-06

A O 0 4.104105300939409e-06
gene O 0 5.575614068220602e-07
encoding O 0 9.639566087571438e-07
a O 0 3.667684040919994e-07
transmembrane O 0 2.1407588519650744e-06
protein O 0 1.95386107293416e-07
is O 0 3.698415129704813e-09
mutated O 0 3.24574536136879e-08
in O 0 5.033966576917237e-09
patients O 0 2.346945926490207e-08
with O 0 1.8667070378342032e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999856948852539
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9833184480667114
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.4698099448651192e-06
. O 0 1.305845671595307e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.998789370059967
WFS B-Disease 1 1.0
; O 0 1.4397229278984014e-05
OMIM O 1 0.9999988079071045
222300 O 0 0.00041228567715734243
) O 0 3.972820294961821e-08
is O 0 7.526699263848968e-09
an O 0 2.0244096177179927e-08
autosomal B-Disease 1 0.9997852444648743
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999992847442627
defined O 0 1.1644806363619864e-07
by O 0 4.7292378013708e-08
young O 0 4.000345143140294e-06
- O 0 3.3246549719478935e-05
onset O 1 0.9999887943267822
non O 1 0.9999345541000366
- O 0 5.61356391699519e-05
immune O 0 1.1260939572821371e-05
insulin B-Disease 0 0.00017703845514915884
- I-Disease 0 0.0010770930675789714
dependent I-Disease 0 0.003953571897000074
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 4.904525849269703e-05
progressive O 1 0.9999978542327881
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9998288154602051
. O 0 6.82706740917638e-05

Linkage O 0 9.489561489317566e-05
to O 0 1.2321125950620626e-06
markers O 0 3.458583159954287e-05
on O 0 2.637130364746554e-06
chromosome O 0 9.762707122717984e-06
4p O 0 0.00036651105619966984
was O 0 9.074171885004034e-07
confirmed O 0 2.526606408537191e-07
in O 0 5.40306110963229e-08
five O 0 1.6720838402761729e-07
families O 0 4.957985879627813e-07
. O 0 4.658698799175909e-06

On O 0 1.6457413494208595e-06
the O 0 1.2364603207970504e-07
basis O 0 2.6357020033174194e-07
of O 0 1.4163384776111343e-07
meiotic O 0 0.007308071944862604
recombinants O 1 0.9999972581863403
and O 0 2.928245748989866e-06
disease O 0 0.0963815376162529
- O 0 1.565499928801728e-06
associated O 0 7.517713243032631e-07
haplotypes O 0 1.1020672900485806e-05
, O 0 3.605700626962971e-08
the O 0 2.1718108200730057e-07
WFS B-Disease 0 0.00017774802108760923
gene O 0 1.2679508643032023e-07
was O 0 8.221714153933135e-08
localized O 0 1.1436294045097384e-07
to O 0 2.2521332354585866e-08
a O 0 1.51163092709794e-07
BAC O 0 2.535812382120639e-05
/ O 0 1.4346121588459937e-06
P1 O 0 3.40265842169174e-06
contig O 0 3.985955117968842e-06
of O 0 5.932947289011281e-08
less O 0 3.240598545062312e-08
than O 0 2.244046370947217e-08
250 O 0 4.814476710635063e-07
kb O 0 2.014350138779264e-05
. O 0 5.478459115693113e-06

Mutations O 0 1.0584209121589083e-05
in O 0 3.6682016002487217e-07
a O 0 3.123994076759118e-07
novel O 0 1.049779143613705e-06
gene O 0 8.871014642863884e-07
( O 0 6.049248781891947e-07
WFS1 O 0 0.001006543985567987
) O 0 3.150339722424178e-08
encoding O 0 1.1509513342389255e-07
a O 0 6.649085548815492e-08
putative O 0 7.745048833385226e-07
transmembrane O 0 3.1698112934464007e-07
protein O 0 3.2278109074468375e-08
were O 0 1.57741197881478e-08
found O 0 3.935598513749028e-09
in O 0 9.638677633816428e-10
all O 0 2.4937865106267054e-09
affected O 0 7.271330648705998e-09
individuals O 0 1.706268126788757e-09
in O 0 9.778954535022422e-09
six O 0 2.1677695372090966e-07
WFS B-Disease 0 0.19005806744098663
families O 0 2.7481839026677335e-08
, O 0 5.169577210750731e-09
and O 0 2.5493438471357877e-09
these O 0 1.811489958036816e-09
mutations O 0 1.0476749245924566e-08
were O 0 1.5003701392402036e-08
associated O 0 2.8232459925447984e-08
with O 0 7.938929513784387e-09
the O 0 9.740273299030378e-07
disease O 0 0.06305836141109467
phenotype O 0 3.425436716497643e-06
. O 0 2.0739789761137217e-06

WFS1 O 1 0.9792453050613403
appears O 0 2.5217295842594467e-06
to O 0 4.960057253811101e-08
function O 0 5.585865281432234e-08
in O 0 3.349236266103617e-08
survival O 0 1.1435938631620957e-06
of O 0 2.8540213747874077e-07
islet O 0 3.2134357752511278e-06
beta O 0 2.1769856175524183e-06
- O 0 1.4377993693415192e-06
cells O 0 4.538583482371905e-07
and O 0 7.620409547826057e-08
neurons O 0 1.0727284234235412e-06
. O 0 2.201207820462514e-07
. O 0 1.2563479003802058e-06

Stable O 0 1.5269779396476224e-05
interaction O 0 9.115753982769093e-07
between O 0 1.1065551319688893e-07
the O 0 1.3022644296256658e-08
products O 0 6.854121181731898e-08
of O 0 1.8760870190703827e-08
the O 0 6.656470930010983e-08
BRCA1 O 0 5.058723672846099e-06
and O 0 9.597773669156595e-07
BRCA2 O 0 3.703318361658603e-05
tumor B-Disease 0 6.0646989368251525e-06
suppressor O 0 1.3041808415437117e-05
genes O 0 1.749126568029169e-07
in O 0 8.571452525529821e-08
mitotic O 0 1.0413075870019384e-05
and O 0 1.3894026551497518e-06
meiotic O 0 0.0003080354072153568
cells O 0 5.529374539037235e-05
. O 0 1.4051629477762617e-05

BRCA1 O 0 0.0002916672092396766
and O 0 3.968139935750514e-06
BRCA2 O 0 1.3581543498730753e-05
account O 0 9.147333912551403e-08
for O 0 6.942482144722817e-09
most O 0 1.1486635642654619e-08
cases O 0 9.67985869237964e-09
of O 0 2.4220694783139152e-08
familial O 0 3.032190249996347e-07
, O 0 2.0460353411522192e-08
early O 0 2.2541451016877545e-07
onset O 0 0.29153287410736084
breast B-Disease 0 0.06168422847986221
and I-Disease 0 5.579754088103073e-06
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.058078685251985e-08
encode O 0 5.194250007889423e-08
products O 0 5.094551625006716e-08
that O 0 6.8761947247253374e-09
each O 0 8.199707579592541e-09
interact O 0 9.134902256846544e-08
with O 0 1.5990826796041802e-07
hRAD51 O 0 2.1587678929790854e-05
. O 0 8.449468623439316e-06

Results O 0 2.8752531306963647e-06
presented O 0 3.062284349653055e-06
here O 0 3.186645471942029e-07
show O 0 9.212063645236412e-08
that O 0 5.869499730692951e-08
BRCA1 O 0 1.577642706251936e-06
and O 0 2.1989060883242928e-07
BRCA2 O 0 7.778241524647456e-06
coexist O 0 5.916900249758328e-07
in O 0 2.8182371991647415e-08
a O 0 2.6068013525559763e-08
biochemical O 0 8.485691296300502e-07
complex O 0 3.297745649888384e-07
and O 0 1.397219620002943e-07
colocalize O 0 3.2452739105792716e-05
in O 0 1.1138627797890877e-07
subnuclear O 0 6.972041592234746e-05
foci O 0 5.4414113037637435e-06
in O 0 4.006622944530136e-08
somatic O 0 6.632924396399176e-06
cells O 0 2.2749249239950586e-07
and O 0 1.0152863438861459e-08
on O 0 1.7187824497000292e-08
the O 0 7.127549661589683e-09
axial O 0 6.888971171292724e-08
elements O 0 4.0465437223247136e-08
of O 0 7.840353077881446e-08
developing O 0 9.088896035791549e-07
synaptonemal O 0 3.557209129212424e-05
complexes O 0 1.0967861271637958e-05
. O 0 7.333694611588726e-06

Like O 0 4.675569653045386e-05
BRCA1 O 0 0.00015754078049212694
and O 0 1.5476063708774745e-05
RAD51 O 1 0.9976308345794678
, O 0 6.310149728960823e-06
BRCA2 O 0 4.6518696763087064e-05
relocates O 0 1.4964331057853997e-05
to O 0 9.623436199035496e-07
PCNA O 0 6.1027993069728836e-05
+ O 0 5.112072472002183e-07
replication O 0 1.1875363270519301e-07
sites O 0 5.513443213089886e-08
following O 0 3.108415214114757e-08
exposure O 0 3.3437794400015264e-07
of O 0 1.4926128244496795e-07
S O 0 3.3022756724676583e-06
phase O 0 5.781808454230486e-07
cells O 0 6.719127441101591e-07
to O 0 2.2103310470811266e-07
hydroxyurea O 0 3.837748590740375e-05
or O 0 2.8554989057738567e-06
UV O 0 0.00163932831492275
irradiation O 0 4.4887561671203e-05
. O 0 1.0335025763197336e-05

Thus O 0 6.876682618894847e-06
, O 0 9.023206644087622e-07
BRCA1 O 0 4.251401605870342e-06
and O 0 5.732023282689624e-07
BRCA2 O 0 1.4479943502010428e-06
participate O 0 1.3448376989799726e-07
, O 0 3.538753645671022e-08
together O 0 1.2117018499679943e-08
, O 0 1.003980631963941e-08
in O 0 7.071070839970162e-09
a O 0 2.8992189982091077e-08
pathway O 0 3.4220175848531653e-07
( O 0 4.765366412584626e-08
s O 0 5.036485006826297e-08
) O 0 3.2734845945014968e-09
associated O 0 8.42688230306976e-09
with O 0 1.3763490347429297e-09
the O 0 1.2535368298927096e-08
activation O 0 1.0396551175517743e-07
of O 0 1.1023735879689411e-07
double O 0 2.274256871714897e-07
- O 0 2.7782491542893695e-06
strand O 0 1.0248793387290789e-06
break O 0 3.1537129530079255e-07
repair O 0 1.5996301954146475e-06
and O 0 4.2402240296723903e-07
/ O 0 5.847229658684228e-06
or O 0 3.931392313916149e-07
homologous O 0 1.8602308955451008e-06
recombination O 0 3.287391109552118e-06
. O 0 3.384874162293272e-06

Dysfunction O 1 0.9958913326263428
of O 0 1.1154695584991714e-06
this O 0 2.572924806543142e-08
pathway O 0 7.186002335402009e-07
may O 0 9.941063083829249e-09
be O 0 2.1968795671512e-09
a O 0 3.679873961104363e-09
general O 0 6.157790721772471e-08
phenomenon O 0 9.070384976439527e-08
in O 0 2.3220674272295128e-09
the O 0 4.7032115979561695e-09
majority O 0 7.436779525527015e-10
of O 0 3.708721774131618e-09
cases O 0 1.0030293928764422e-08
of O 0 1.1230766006065096e-07
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9794406890869141
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.4417169558764726e-07
. O 0 1.4044993577044806e-06

A O 0 3.879187715938315e-05
novel O 0 1.1127188372483943e-05
Arg362Ser O 0 3.299038144177757e-05
mutation O 0 6.942186701053288e-07
in O 0 8.9465544306222e-08
the O 0 3.074874825870211e-07
sterol O 0 5.865655566594796e-06
27 O 0 5.064415290689794e-06
- O 0 2.0569700609485153e-06
hydroxylase O 0 5.5109794629970565e-06
gene O 0 8.366331485376577e-07
( O 0 5.053377662989078e-07
CYP27 O 1 0.6621682643890381
) O 0 3.1766838048952195e-08
: O 0 9.249685462009438e-09
its O 0 6.796136986508827e-09
effects O 0 9.348693907895722e-08
on O 0 2.4790040242805844e-07
pre O 0 5.599315500148805e-07
- O 0 7.643451453986927e-07
mRNA O 0 1.18075320187927e-06
splicing O 0 1.956900405275519e-06
and O 0 1.5454000390491274e-07
enzyme O 0 1.5251890772560728e-06
activity O 0 2.6682691895985045e-06
. O 0 4.297587565815775e-06

A O 0 9.629508895159233e-06
novel O 0 1.4256935401135706e-06
C O 0 1.6800020148366457e-06
to O 0 1.8248561772793437e-08
A O 0 1.1841164848647168e-07
mutation O 0 2.9930536271649544e-08
in O 0 2.507773189108775e-08
the O 0 7.622967501674793e-08
sterol O 0 2.4671508072060533e-06
27 O 0 1.9476433408271987e-06
- O 0 1.3805953358314582e-06
hydroxylase O 0 7.168533102230867e-06
gene O 0 8.295739917230094e-07
( O 0 4.478509083583049e-07
CYP27 O 0 0.25466275215148926
) O 0 1.1460789650641345e-08
was O 0 1.3621840544431052e-08
identified O 0 1.4452798957620416e-08
by O 0 3.6374463441291027e-09
sequencing O 0 1.4340687926051032e-07
amplified O 0 7.526300009885745e-07
CYP27 O 0 9.98274208541261e-06
gene O 0 2.8878941904508793e-08
products O 0 7.139974655956394e-08
from O 0 2.1686373585794172e-08
a O 0 1.7381044159492376e-08
patient O 0 5.902731103901715e-08
with O 0 1.9960224051374098e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 1.6692187273292802e-05
CTX B-Disease 1 0.9940292835235596
) O 0 3.1073477657628246e-06
. O 0 4.524146788753569e-06

The O 0 2.937867748187273e-06
mutation O 0 1.6674132439220557e-06
changed O 0 1.3860160379408626e-06
the O 0 5.946893111286045e-07
adrenodoxin O 0 9.033280548464973e-06
cofactor O 0 1.8549765172792831e-06
binding O 0 5.767220159214048e-07
residue O 0 3.284717877249932e-06
362Arg O 0 3.106367103100638e-06
to O 0 3.0829261277176556e-07
362Ser O 0 1.869076004368253e-05
( O 0 1.965241608559154e-06
CGT O 0 0.00245305011048913
362Arg O 0 1.5253085621225182e-05
to O 0 7.303580673578836e-07
AGT O 0 0.004520178772509098
362Ser O 0 2.4742264486121712e-06
) O 0 2.1330254895701728e-08
, O 0 6.579156330843716e-09
and O 0 5.234956468314067e-09
was O 0 2.7714820660662554e-08
responsible O 0 3.959793204444395e-08
for O 0 5.3989815285149234e-08
deficiency O 1 0.9628651142120361
in O 0 1.4314767327050504e-07
the O 0 4.3442815922389855e-07
sterol O 0 2.9783836907881778e-06
27 O 0 1.176251998913358e-06
- O 0 4.719317132639844e-07
hydroxylase O 0 1.2843761396652553e-06
activity O 0 4.1142836693097706e-08
, O 0 5.655383716884899e-09
as O 0 3.6357259425301436e-09
confirmed O 0 7.806015389633103e-09
by O 0 2.7033888461147626e-09
expression O 0 1.724703402317118e-08
of O 0 3.3396737819657574e-08
mutant O 0 4.701120133177028e-07
cDNA O 0 2.2090803213359322e-06
into O 0 1.919066789923818e-06
COS O 0 0.010051391087472439
- O 0 2.4402255803579465e-05
1 O 0 9.67266532825306e-06
cells O 0 3.819134235527599e-06
. O 0 4.717760475614341e-06

Quantitative O 0 9.613028851163108e-06
analysis O 0 7.719902441749582e-07
showed O 0 2.1284519391429058e-07
that O 0 1.1795873611220031e-08
the O 0 7.437112969910231e-08
expression O 0 2.7892187404177093e-07
of O 0 5.288864031172125e-07
CYP27 O 0 0.00022058341710362583
gene O 0 1.1281390044359796e-07
mRNA O 0 4.569536713461275e-07
in O 0 1.5591059110420247e-08
the O 0 2.6012434872768608e-08
patient O 0 8.953399799338513e-08
represented O 0 7.39541178518266e-07
52 O 0 5.616372618533205e-06
. O 0 4.113442628295161e-06

5 O 0 9.782241249922663e-06
% O 0 1.1059073301566968e-07
of O 0 8.565830000861752e-08
the O 0 1.305209025304066e-07
normal O 0 4.6754780669289175e-07
level O 0 2.2462747892859625e-06
. O 0 2.64327650256746e-06

As O 0 9.817041473070276e-07
the O 0 9.193317396238854e-08
mutation O 0 9.957937407989448e-08
occurred O 0 3.61243365887276e-07
at O 0 6.485948489398652e-08
the O 0 5.3143558886858955e-08
penultimate O 0 1.0900611187025788e-06
nucleotide O 0 6.048147156434425e-07
of O 0 2.926817330717313e-07
exon O 0 1.6633124459985993e-06
6 O 0 1.191217506857356e-06
( O 0 7.313241923156966e-08
- O 0 2.753208150352293e-07
2 O 0 2.0260229405266728e-07
position O 0 1.4623169874994346e-07
of O 0 1.9290364150492678e-07
exon O 0 1.4683107565360842e-06
6 O 0 3.287331537649152e-06
- O 0 2.2242711565922946e-06
intron O 0 8.582749615015928e-06
6 O 0 1.2558172102217213e-06
splice O 0 2.0738602870551404e-06
site O 0 1.926210728697697e-07
) O 0 8.334587242586622e-09
of O 0 6.108376471303245e-09
the O 0 1.1685161283025991e-08
gene O 0 2.3480875910308896e-08
, O 0 1.556933604263122e-08
we O 0 9.640741538419206e-09
hypothesized O 0 4.189377023067209e-08
that O 0 2.8151625475203446e-09
the O 0 1.200510180154879e-08
mutation O 0 3.1127168398370486e-08
may O 0 3.9168487120377904e-08
partially O 0 1.5516054929776146e-07
affect O 0 1.4322531605159838e-08
the O 0 1.7055661771792074e-08
normal O 0 1.1603275673621738e-08
splicing O 0 1.0110315429301409e-07
efficiency O 0 5.267942881914678e-08
in O 0 1.5625980509526016e-08
exon O 0 2.3450333230812248e-07
6 O 0 1.966708111922344e-07
and O 0 6.933060792135848e-09
cause O 0 3.007961879575305e-08
alternative O 0 3.798527714593547e-08
splicing O 0 2.3403661941756582e-07
elsewhere O 0 1.1298207880372502e-07
, O 0 6.46141140592249e-09
which O 0 2.3321831132960824e-09
resulted O 0 2.4577444079909583e-08
in O 0 4.551081289605463e-09
decreased O 0 8.377831051120666e-08
transcript O 0 1.8418283787013934e-07
in O 0 3.0010795626367326e-08
the O 0 1.691661566383118e-07
patient O 0 8.321968607560848e-07
. O 0 3.8496978049806785e-06

Transfection O 0 0.00019199064990971237
of O 0 6.845146344858222e-06
constructed O 0 7.324546004383592e-06
minigenes O 0 2.4609760657767765e-05
, O 0 3.790406921666545e-08
with O 0 4.757598759397297e-09
or O 0 8.161510578474918e-09
without O 0 9.840192660703906e-09
the O 0 9.366325492976557e-09
mutation O 0 8.278705720954349e-09
, O 0 5.512304390720146e-09
into O 0 4.718633306310949e-08
COS O 1 0.9874587059020996
- O 0 2.1849664335604757e-06
1 O 0 2.2707524749421282e-07
cells O 0 3.774456303062834e-08
confirmed O 0 1.2123837933586401e-08
that O 0 1.3250389674368535e-09
the O 0 1.548841765952602e-08
mutant O 0 2.7943707436861587e-07
minigene O 0 2.297425908182049e-06
was O 0 6.082755277247998e-08
responsible O 0 1.4694516714541805e-08
for O 0 7.58059748307005e-09
a O 0 1.0701453945216599e-08
mRNA O 0 2.122275901683679e-07
species O 0 8.396143336142359e-09
alternatively O 0 8.59396109831323e-08
spliced O 0 1.4936238130758284e-06
at O 0 1.1516321052340572e-07
an O 0 4.6537071085595016e-08
activated O 0 1.2393389852149994e-06
cryptic O 0 3.427001956879394e-06
5 O 0 5.152108428774227e-07
splice O 0 4.032754986837972e-06
site O 0 8.321952691403567e-07
88 O 0 7.360371796494292e-07
bp O 0 4.846488650400715e-07
upstream O 0 3.558406547199411e-07
from O 0 6.261709017962858e-08
the O 0 9.347053975261588e-08
3 O 0 3.663363372652384e-07
end O 0 2.0707049941393052e-07
of O 0 4.454901727513061e-07
exon O 0 5.308618256094633e-06
6 O 0 1.2025130672554951e-05
. O 0 4.6934783313190565e-06

Our O 0 2.795097998387064e-06
data O 0 6.534431236104865e-07
suggest O 0 1.3812115184919094e-07
that O 0 1.0722232879345484e-08
the O 0 3.5224033467784466e-08
C O 0 2.1310111719685665e-07
to O 0 8.997890432738131e-09
A O 0 6.264122021093499e-08
mutation O 0 2.802691589920414e-08
at O 0 2.251755404358846e-08
the O 0 2.0545606105315528e-08
penultimate O 0 2.711942954647384e-07
nucleotide O 0 2.8198186896588595e-07
of O 0 8.657185901483899e-08
exon O 0 5.723703679905157e-07
6 O 0 2.239809333559606e-07
of O 0 2.8279940167408313e-08
the O 0 9.603141393199621e-08
CYP27 O 0 0.000758300710003823
gene O 0 2.0270485734386057e-08
not O 0 8.247893923396532e-09
only O 0 1.723841869250009e-08
causes O 0 4.080717417309643e-07
the O 0 1.6443546257960406e-07
deficiency B-Disease 0 2.9453714887495153e-05
in I-Disease 0 4.361733729751904e-08
the I-Disease 0 1.0441443976105802e-07
sterol I-Disease 0 1.5736037539682002e-06
27 I-Disease 0 9.724105893837987e-07
- I-Disease 0 3.530741423674044e-07
hydroxylase I-Disease 0 1.227175516760326e-06
activity I-Disease 0 4.2412750644871267e-08
, O 0 7.236009125222154e-09
but O 0 1.116020786895433e-08
also O 0 1.8407549262633438e-08
partially O 0 1.1872668181922563e-07
leads O 0 4.02489064299516e-08
to O 0 8.949179175488098e-09
alternative O 0 1.4867099196180789e-07
pre O 0 4.933177137900202e-07
- O 0 3.7317209944376373e-07
mRNA O 0 6.702090900034818e-07
splicing O 0 6.219868851076171e-07
of O 0 1.974221106593177e-07
the O 0 2.868234503239364e-07
gene O 0 2.2385718239092967e-06
. O 0 7.227863989101024e-06

To O 0 3.359262166213739e-07
our O 0 1.4741699772002903e-07
knowledge O 0 3.6925391100339766e-07
, O 0 9.10680331145386e-09
this O 0 1.6575614214531242e-09
is O 0 1.8603043550058374e-09
the O 0 5.697511795688115e-09
first O 0 1.3866366721515533e-08
report O 0 2.2314212699825475e-08
regarding O 0 1.2077865108039987e-07
effects O 0 3.985738885603496e-07
on O 0 4.075342303622165e-07
pre O 0 6.873902407278365e-07
- O 0 5.116003194416407e-07
mRNA O 0 7.237191539388732e-07
splicing O 0 2.6017679033429886e-07
of O 0 6.56290382039515e-08
a O 0 1.1805282085219915e-08
mutation O 0 3.044022633957866e-08
at O 0 8.423094755016791e-08
the O 0 7.749822827918251e-08
- O 0 6.193015451572137e-07
2 O 0 4.666907216233085e-07
position O 0 1.585355846600578e-07
of O 0 1.318243931791585e-07
a O 0 3.0704296705152956e-07
5 O 0 1.400778046445339e-06
splice O 0 3.0225752198020928e-05
site O 0 1.0416164514026605e-05
. O 0 4.81127790408209e-06

ATM O 0 0.0028980192728340626
germline O 0 0.0006317547522485256
mutations O 0 8.797197551757563e-06
in O 0 4.434102720551891e-07
classical O 1 0.9999282360076904
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 8.926382724894211e-05
in O 0 2.4015482935624277e-08
the O 0 3.073068555181635e-08
Dutch O 0 1.5368052572739543e-06
population O 0 5.4990231035390025e-08
. O 0 3.6177911511003913e-07

Germline O 0 0.00048658152809366584
mutations O 0 6.171646418806631e-06
in O 0 1.7902196702834772e-07
the O 0 8.957704977774483e-08
ATM O 0 4.798438567377161e-06
gene O 0 5.152196180802093e-08
are O 0 4.959326282971688e-09
responsible O 0 7.027816106841556e-09
for O 0 8.256928474281722e-09
the O 0 1.1636973340500845e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9996815919876099
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.076141284618643e-07
. O 0 2.2348515358316945e-06

In O 0 1.022328547151119e-06
our O 0 3.318836832022498e-07
study O 0 9.452924842889843e-08
, O 0 1.0359748614519049e-08
we O 0 5.909182920760259e-09
have O 0 2.42230369096319e-09
determined O 0 1.4981054619056522e-08
the O 0 1.4126565694994042e-08
ATM O 0 7.462646181011223e-07
mutation O 0 3.1714527892745537e-08
spectrum O 0 1.7814880948208156e-07
in O 0 1.623726397781411e-08
19 O 0 1.3480362781592703e-07
classical O 0 3.4387321647955105e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999963045120239
T I-Disease 1 1.0
patients O 0 7.73023245415061e-08
, O 0 4.0442191817646744e-09
including O 0 1.6431758176338462e-09
some O 0 2.5181441376531666e-09
immigrant O 0 4.324489566442935e-08
populations O 0 2.0628693420121635e-08
, O 0 4.511514717364662e-09
as O 0 4.2527434906958206e-09
well O 0 5.798017621572171e-09
as O 0 1.1149803746945963e-08
12 O 0 2.4895392414236994e-08
of O 0 1.5779326290044082e-08
Dutch O 0 6.70846077355236e-07
ethnic O 0 1.527713351379134e-07
origin O 0 9.330423154096934e-07
. O 0 2.176433554268442e-06

Both O 0 2.94938286060642e-06
the O 0 8.600156888860511e-07
protein O 0 8.209051429730607e-07
truncation O 0 9.425968983123312e-07
test O 0 2.2311239433747687e-07
( O 0 2.802024141601578e-07
PTT O 0 2.9388932034635218e-06
) O 0 1.5679152198799784e-08
and O 0 7.833622639452642e-09
the O 0 1.719674358469092e-08
restriction O 0 1.0071283185197899e-07
endonuclease O 0 9.613218026061077e-07
fingerprinting O 0 6.055505537005956e-07
( O 0 1.8924038158729672e-07
REF O 0 4.948197329213144e-06
) O 0 2.7438038507909823e-09
method O 0 2.953040700859333e-09
were O 0 1.8488752751011361e-09
used O 0 2.8354840697630834e-09
and O 0 2.843786983675045e-09
compared O 0 4.079383941757442e-09
for O 0 1.9147787799767002e-09
their O 0 2.239974206119655e-09
detection O 0 5.196826435849289e-08
efficiency O 0 5.837123495666674e-08
, O 0 1.5024635757754368e-08
identifying O 0 1.202912756070873e-07
76 O 0 1.1156339496665169e-07
% O 0 3.6661917945934874e-09
and O 0 3.855408436947982e-09
60 O 0 1.5815663445550854e-08
% O 0 2.9323912187351198e-09
of O 0 4.636879324948495e-09
the O 0 2.1040975184405397e-08
mutations O 0 1.105017588542978e-07
, O 0 2.0968265346255066e-07
respectively O 0 1.9932310806325404e-06
. O 0 4.427778549143113e-06

Most O 0 2.758422397164395e-06
patients O 0 5.832248461956624e-07
were O 0 1.3556038425122097e-07
found O 0 3.246228175157739e-08
to O 0 2.1489842794153446e-08
be O 0 1.56546988705486e-07
compound O 0 1.298943880101433e-05
heterozygote O 0 0.0004929908900521696
. O 0 1.536720446893014e-05

Seventeen O 0 1.1371933396731038e-05
mutations O 0 1.0104076864081435e-06
were O 0 1.512516263346697e-07
distinct O 0 1.302972947314629e-07
, O 0 1.771148561147129e-08
of O 0 1.7493558601699988e-08
which O 0 4.536019559964188e-09
10 O 0 2.4584991820120194e-08
were O 0 1.776894187344169e-08
not O 0 3.103782475477601e-08
reported O 0 5.352861194296565e-07
previously O 0 1.0655828646122245e-06
. O 0 2.436654995108256e-06

Mutations O 0 1.3810081327392254e-05
are O 0 5.862170837644953e-07
small O 0 4.432191929026885e-07
deletions O 0 3.06543415717897e-06
or O 0 4.629767715869093e-07
point O 0 1.7846930404630257e-06
mutations O 0 8.914835802897869e-07
frequently O 0 5.574507895289571e-07
affecting O 0 1.3002262448935653e-06
splice O 0 2.1622377971652895e-05
sites O 0 6.3464931372436695e-06
. O 0 6.5426456785644405e-06

Moreover O 0 4.506616460275836e-05
, O 0 2.02853743758169e-06
a O 0 2.2139795419207076e-06
16 O 0 1.920521208376158e-05
. O 0 5.836783657287015e-06

7 O 0 8.197214629035443e-05
- O 0 1.5768209777888842e-05
kb O 0 1.012702523439657e-05
genomic O 0 7.136924864425964e-07
deletion O 0 1.6705728000943054e-07
of O 0 9.704208991934138e-08
the O 0 5.2857473065159866e-08
3 O 0 6.729246848635739e-08
end O 0 1.5708936373926008e-08
of O 0 1.0132782612970459e-08
the O 0 6.732017165944626e-09
gene O 0 5.600061303567827e-09
, O 0 4.026547539837111e-09
most O 0 4.373018835934772e-09
likely O 0 1.5730885039033637e-08
a O 0 7.751194353033952e-09
result O 0 1.924911963158138e-08
of O 0 3.4406628657279725e-08
recombination O 0 1.831324070167284e-08
between O 0 4.2463017990712615e-08
two O 0 4.379573681490001e-08
LINE O 0 3.234651103412034e-06
elements O 0 1.410141408086929e-07
, O 0 9.532844558179931e-08
was O 0 2.4053034053395095e-07
identified O 0 1.1400059065636015e-06
. O 0 2.7826640689454507e-06

The O 0 2.584880803624401e-06
most O 0 3.0662070571452205e-07
frequently O 0 9.36979489551959e-08
found O 0 9.385513699555759e-09
mutation O 0 1.1735417082547883e-08
, O 0 7.368263332807601e-09
identified O 0 2.1732875055135992e-08
in O 0 4.294158362228018e-09
three O 0 5.6522999614117e-09
unrelated O 0 9.731473937790724e-08
Turkish O 0 1.3322057839104673e-06
A B-Disease 1 0.9998806715011597
- I-Disease 0 0.03663155809044838
T I-Disease 1 0.9999998807907104
individuals O 0 2.7843359617918395e-08
, O 0 3.595289754798614e-08
was O 0 8.802041406852368e-08
previously O 0 2.1455276666415557e-08
described O 0 5.585042206490698e-09
to O 0 3.475605581115815e-09
be O 0 1.0451282506096504e-08
a O 0 5.8650346801414344e-08
Turkish O 0 5.9408785091363825e-06
A B-Disease 1 0.9999613761901855
- I-Disease 1 0.9997671246528625
T I-Disease 1 1.0
founder O 0 0.00020516841323114932
mutation O 0 8.65530273586046e-06
. O 0 1.3139833754394203e-05

The O 0 2.8333663522062125e-06
presence O 0 1.1398699371056864e-06
of O 0 4.206455912481033e-07
a O 0 1.6064822716543858e-07
founder O 0 1.6316170103891636e-06
mutation O 0 5.455189011627226e-08
among O 0 2.7966361670905826e-08
relatively O 0 1.0823903551226977e-08
small O 0 2.9023878855838348e-09
ethnic O 0 3.191050090833869e-09
population O 0 7.606461016607113e-10
groups O 0 7.023577830445049e-10
in O 0 1.0532724692424722e-09
Western O 0 2.222285111486144e-08
Europe O 0 1.1534518229439072e-08
could O 0 3.548552562904206e-09
indicate O 0 3.539442161581974e-08
a O 0 9.428863911864482e-09
high O 0 4.5428961925608746e-08
carrier O 0 1.2819548089737509e-08
frequency O 0 1.705741858870624e-08
in O 0 7.72356756328918e-09
such O 0 5.7439311973439544e-08
communities O 0 1.607548938409309e-06
. O 0 1.1533258657436818e-05

In O 0 5.35475010110531e-07
patients O 0 1.6354418619357602e-07
of O 0 6.713504063782239e-08
Dutch O 0 3.2470509268023307e-06
ethnic O 0 4.8029153987272366e-08
origin O 0 5.180319462283478e-08
, O 0 6.159950327599972e-09
however O 0 1.025054352510324e-08
, O 0 6.742181923868884e-09
no O 0 2.3284773220666466e-08
significant O 0 2.528790332689823e-07
founder O 0 1.3164931260689627e-06
effect O 0 8.413188368194824e-08
could O 0 8.138383833511398e-08
be O 0 2.1147238271623792e-07
identified O 0 3.962758910347475e-06
. O 0 6.738475349266082e-06

The O 0 1.2764135135512333e-06
observed O 0 4.561625246424228e-07
genetic O 0 2.7534366608961136e-07
heterogeneity O 0 1.0217759154329542e-06
including O 0 4.079611670704253e-08
the O 0 1.9769560211102544e-08
relative O 0 7.687803531553072e-07
high O 0 1.203607439492771e-06
percentage O 0 4.0522058952774387e-07
of O 0 6.93909640858692e-08
splice O 0 9.158441571344156e-06
- O 0 1.4637613503509783e-06
site O 0 3.17177381248257e-07
mutations O 0 1.5111652373889228e-07
had O 0 5.743383724166051e-08
no O 0 4.045146795306209e-08
reflection O 0 1.5648937790047057e-07
on O 0 2.3357684142411017e-07
the O 0 4.070467696237756e-07
phenotype O 0 6.1221589930937625e-06
. O 0 5.235855496721342e-06

All O 0 3.353952706675045e-06
patients O 0 1.4082226016398636e-06
manifested O 0 2.558264895924367e-06
classical O 0 1.127735959016718e-05
A B-Disease 1 0.9999920129776001
- I-Disease 1 0.9968575239181519
T I-Disease 1 1.0
and O 0 1.9963346176155028e-07
increased O 0 3.9246268102033355e-07
cellular O 0 1.6756131344664027e-06
radioresistant O 0 7.254402135004057e-06
DNA O 0 1.7569116153026698e-06
synthesis O 0 5.201445219427114e-06
. O 0 2.3359430088021327e-06

Determination O 0 5.328262886905577e-06
of O 0 9.996593917094287e-07
the O 0 2.1631375091146765e-07
genomic O 0 1.269744416276808e-06
structure O 0 3.254197906699119e-07
of O 0 1.2598965781762672e-07
the O 0 1.6698784577329207e-07
COL4A4 O 1 0.9999830722808838
gene O 0 1.156768121290952e-07
and O 0 2.1568355990098098e-08
of O 0 7.909566335229101e-08
novel O 0 3.579648364393506e-07
mutations O 0 3.073472271353239e-06
causing O 0 6.591082637896761e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.021082043647766113

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.4588001679148874e-07
a O 0 1.199963577391827e-07
progressive O 0 0.15197235345840454
hematuric B-Disease 1 0.9999967813491821
glomerulonephritis I-Disease 1 1.0
characterized O 0 1.5587511370540597e-06
by O 0 1.4549154059295688e-07
glomerular B-Disease 1 0.9999936819076538
basement I-Disease 1 0.9932964444160461
membrane I-Disease 0 8.581726433476433e-06
abnormalities I-Disease 0 0.02207363396883011
and O 0 1.2663503135001974e-08
associated O 0 6.241283756480698e-08
with O 0 4.958881749672628e-09
mutations O 0 4.6638188422321036e-08
in O 0 6.6671543841323455e-09
either O 0 3.350526966983125e-08
the O 0 2.3996966547201737e-07
COL4A3 O 1 0.9999023675918579
or O 0 7.646018929108322e-08
the O 0 1.544147920640171e-07
COL4A4 O 0 7.217171514639631e-05
gene O 0 4.874774006680127e-08
, O 0 2.6299289856979158e-08
which O 0 7.099667076460037e-09
encode O 0 1.3023492329011788e-07
the O 0 1.9782373783527873e-07
alpha3 O 0 2.216596476500854e-05
and O 0 2.5392930069756403e-07
alpha4 O 0 2.0259572920622304e-05
type O 0 5.899888492422178e-06
IV O 1 0.9999997615814209
collagen O 0 0.0007069440325722098
chains O 0 6.908478098921478e-06
, O 0 1.2627224350580946e-06
respectively O 0 3.927040779672097e-06
. O 0 5.946933015366085e-06

To O 0 4.429778925896244e-07
date O 0 1.4982647371653002e-06
, O 0 4.85959539275882e-08
mutation O 0 1.622837686454659e-08
screening O 0 1.7354279790993132e-08
in O 0 6.338854330323329e-09
the O 0 1.4926463620668073e-08
two O 0 1.2622099809789233e-08
genes O 0 3.27292433155435e-08
has O 0 7.617993347253105e-09
been O 0 6.470019187077014e-09
hampered O 0 8.787062455439809e-08
by O 0 7.119220768458945e-09
the O 0 6.616471637244103e-08
lack O 0 2.6582924306239875e-07
of O 0 1.456513274433746e-07
genomic O 0 1.2896391581307398e-06
structure O 0 2.586799382697791e-06
information O 0 5.883016001462238e-06
. O 0 7.158368134696502e-06

We O 0 1.719237161523779e-06
report O 0 6.866276294203999e-07
here O 0 1.3129056242178194e-07
the O 0 4.735231229346937e-08
complete O 0 8.819518626523859e-08
characterization O 0 4.2950532019858656e-07
of O 0 9.957139468497189e-08
the O 0 5.6883610710656285e-08
48 O 0 1.695010922730944e-07
exons O 0 2.622961403631052e-07
of O 0 7.820668201929948e-08
the O 0 1.582375688258253e-07
COL4A4 O 1 0.5186567306518555
gene O 0 6.893926496331915e-08
, O 0 9.419533597565533e-09
a O 0 5.2348663182044675e-09
comprehensive O 0 3.486655586470988e-08
gene O 0 1.4896030187117049e-08
screen O 0 5.187319374044819e-08
, O 0 5.2601185629441716e-09
and O 0 3.5095792938477643e-09
the O 0 4.575154921582225e-09
subsequent O 0 8.895487901838806e-09
detection O 0 6.54394156640592e-08
of O 0 2.771371043763793e-08
10 O 0 4.1935660277658826e-08
novel O 0 2.0398788436182258e-08
mutations O 0 2.3712027896749532e-08
in O 0 8.92065088464733e-09
eight O 0 2.428912182494969e-07
patients O 0 9.995507070925669e-07
diagnosed O 0 0.00047340960009023547
with O 0 9.390616924065398e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00028486509108915925

Furthermore O 0 1.2870693353761453e-05
, O 0 3.231716902973858e-07
we O 0 7.612869268314171e-08
identified O 0 1.6845200434545404e-07
a O 0 3.5520482555284616e-08
glycine O 0 1.2214702849178138e-07
to O 0 1.2511553570959677e-08
alanine O 0 2.902166045259946e-07
substitution O 0 3.3361348528160306e-07
in O 0 3.6485239718331286e-08
the O 0 4.2956841639352206e-08
collagenous O 0 2.556728531999397e-06
domain O 0 3.4993874464817054e-08
that O 0 3.2134042093900916e-09
is O 0 3.2843292530060353e-09
apparently O 0 2.167814550091407e-08
silent O 0 2.3833729656530522e-08
in O 0 2.5192585795252853e-09
the O 0 1.2121942560838761e-08
heterozygous O 0 2.6396632435421452e-08
carriers O 0 5.4286793726987526e-08
, O 0 3.5570653977856637e-08
in O 0 8.752386548849245e-08
11 O 0 2.8702913823508425e-06
. O 0 3.7666643493139418e-06

5 O 0 2.6654411158233415e-06
% O 0 3.809592286074803e-08
of O 0 1.1037911917810561e-08
all O 0 2.3809225702109416e-09
control O 0 5.641152878155253e-09
individuals O 0 2.086444572668711e-09
, O 0 2.9374798149461867e-09
and O 0 2.191535397599864e-09
in O 0 2.211400396134877e-09
one O 0 3.527787173496222e-09
control O 0 1.223464529687135e-08
individual O 0 8.519844385546094e-09
homozygous O 0 4.6089390082215687e-08
for O 0 1.494782964073238e-08
this O 0 2.9115767574694473e-08
glycine O 0 9.973330179491313e-07
substitution O 0 4.355109922471456e-06
. O 0 8.291774065583013e-06

There O 0 1.5695271713411785e-06
has O 0 9.368758213668116e-08
been O 0 2.3647396929504794e-08
no O 0 2.5115834745292887e-08
previous O 0 3.829108408126558e-08
finding O 0 5.957713611337567e-08
of O 0 2.4355175654022787e-08
a O 0 8.584373212272567e-09
glycine O 0 4.305592682385395e-08
substitution O 0 9.365381004045048e-08
that O 0 3.5229930084312855e-09
is O 0 1.5717829260353255e-09
not O 0 9.938271317011527e-10
associated O 0 1.130596327669764e-08
with O 0 2.0623489582760612e-09
any O 0 1.9640534532072706e-08
obvious O 0 9.462932553105929e-07
phenotype O 0 1.7713691136123089e-07
in O 0 5.603515518259883e-08
homozygous O 0 8.255324246420059e-07
individuals O 0 3.8034505678297137e-07
. O 0 8.11060453997925e-06

Founder O 0 0.0014116039965301752
BRCA1 O 0 0.00017048756126314402
and O 0 1.9022196511286893e-06
BRCA2 O 0 4.362771505839191e-06
mutations O 0 1.1115070464029486e-07
in O 0 2.2711091673954797e-08
French O 0 1.585523705216474e-06
Canadian O 0 0.0002928360481746495
breast B-Disease 1 0.9999994039535522
and I-Disease 1 0.9999822378158569
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.7578165625309339e-06
. O 0 3.3767619243008085e-06

We O 0 5.882090476916346e-07
have O 0 5.892067633794795e-08
identified O 0 2.5479408805040293e-07
four O 0 2.8184468092717907e-08
mutations O 0 2.5275479487163466e-08
in O 0 4.506440554052915e-09
each O 0 3.3555072054269885e-09
of O 0 9.123775157604541e-08
the O 0 0.0018184893997386098
breast B-Disease 1 0.9999991655349731
cancer I-Disease 1 0.7451708316802979
- O 0 6.321690761978971e-06
susceptibility O 0 1.2364631629679934e-06
genes O 0 1.775678697413241e-07
, O 0 3.850875884836569e-08
BRCA1 O 0 3.142643265618972e-07
and O 0 6.033392452309272e-08
BRCA2 O 0 3.998458737441979e-07
, O 0 5.47050316157538e-09
in O 0 5.582070805587591e-09
French O 0 1.0972222526106634e-06
Canadian O 0 9.013522685563657e-06
breast B-Disease 0 0.3296867311000824
cancer I-Disease 0 0.031349193304777145
and O 0 0.016630856320261955
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 9.701747671897465e-08
from O 0 4.1089040792030573e-07
Quebec O 0 1.0984274013026152e-05
. O 0 3.324343879285152e-06

To O 0 1.2414316188369412e-06
identify O 0 7.399641162919579e-06
founder O 0 3.7452453398145735e-05
effects O 0 4.194313078187406e-06
, O 0 4.7793751178915045e-08
we O 0 1.2550248840170752e-08
examined O 0 3.283166094547596e-08
independently O 0 6.581139189165697e-09
ascertained O 0 1.0217949153457084e-07
French O 0 1.9094046876944049e-07
Canadian O 0 2.5793477220759087e-07
cancer B-Disease 0 1.155934370444811e-07
families O 0 2.9971136683570876e-09
for O 0 2.2311987812884126e-09
the O 0 4.28810986718986e-09
distribution O 0 2.2228149987313373e-08
of O 0 1.599208587776957e-08
these O 0 3.949278593040617e-08
eight O 0 4.891837761533679e-07
mutations O 0 2.8960193958482705e-06
. O 0 4.704793809651164e-06

Mutations O 0 9.05047454580199e-06
were O 0 5.877570856682723e-07
found O 0 5.412302783724954e-08
in O 0 2.4903181738977764e-08
41 O 0 2.443022992792976e-07
of O 0 5.54144428122072e-08
97 O 0 9.363378126181487e-07
families O 0 6.585850655937975e-07
. O 0 5.377627985581057e-06

Six O 0 2.5772894787223777e-06
of O 0 5.191783429836505e-07
eight O 0 1.634138442341282e-07
mutations O 0 1.317601743267005e-07
were O 0 1.1426983803630719e-07
observed O 0 1.4043264684460155e-07
at O 0 1.0219624613228007e-07
least O 0 1.1623814089034568e-07
twice O 0 1.3885550060876994e-06
. O 0 2.6361724394519115e-06

The O 0 2.010776188399177e-05
BRCA1 O 0 4.9383259465685114e-05
C4446T O 0 3.170135823893361e-05
mutation O 0 3.948375706386287e-07
was O 0 6.227442383988091e-08
the O 0 1.150614981071385e-08
most O 0 6.6018333022555e-09
common O 0 1.0049481247165204e-08
mutation O 0 7.997884132748823e-09
found O 0 7.517101607845689e-09
, O 0 3.76383590960927e-09
followed O 0 1.3369229279192041e-08
by O 0 1.5586568480330243e-08
the O 0 8.013712999854761e-07
BRCA2 O 0 3.239525176468305e-05
8765delAG O 0 1.424000583938323e-05
mutation O 0 2.974421022372553e-06
. O 0 8.776500180829316e-06

Together O 0 9.752599225976155e-07
, O 0 1.140257666065736e-07
these O 0 1.4997693753571184e-08
mutations O 0 3.0572774534221026e-08
were O 0 1.79655756937791e-08
found O 0 7.940277768625492e-09
in O 0 7.202260565719598e-09
28 O 0 1.2937582027916505e-07
of O 0 2.6230356553469392e-08
41 O 0 1.1439435354532179e-07
families O 0 8.671394269299526e-09
identified O 0 4.894861405091433e-08
to O 0 1.38719737918791e-08
have O 0 3.705668660813899e-08
a O 0 1.9638854098502634e-07
mutation O 0 1.3251883501652628e-06
. O 0 4.409826487972168e-06

The O 0 1.6892576013560756e-06
odds O 0 4.091611572221154e-06
of O 0 5.6600484299451637e-08
detection O 0 2.926940112502052e-07
of O 0 2.9952122559961936e-08
any O 0 2.1443167241841365e-08
of O 0 1.0433559793909808e-07
the O 0 1.6359597054815822e-07
four O 0 2.967788930163806e-07
BRCA1 O 0 2.184714276154409e-06
mutations O 0 5.399099336500512e-07
was O 0 1.8783750874717953e-06
18 O 0 2.7760218017647276e-06
. O 0 3.6927858673152514e-06

7x O 0 0.00511053716763854
greater O 0 2.193055934185395e-06
if O 0 8.755592517672994e-08
one O 0 3.2475782063556835e-08
or O 0 4.471422343499398e-09
more O 0 9.831577774122024e-10
cases O 0 9.715705573398736e-09
of O 0 1.165230969490949e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 8.275094387499848e-08
also O 0 3.4119065350779465e-09
present O 0 4.144771192926555e-09
in O 0 1.0705904607277716e-08
the O 0 1.6368272781619453e-07
family O 0 8.004127494132263e-07
. O 0 2.211192168033449e-06

The O 0 1.7079448753065662e-06
odds O 0 2.5771396394702606e-06
of O 0 5.287340343329561e-08
detection O 0 1.7749725600424426e-07
of O 0 1.7382502548457524e-08
any O 0 1.342129873904696e-08
of O 0 7.627825482359185e-08
the O 0 3.056863988604164e-07
four O 0 8.322896860590845e-07
BRCA2 O 0 3.419842187213362e-06
mutations O 0 6.085047061787918e-07
was O 0 1.8769962935039075e-06
5 O 0 2.848744998118491e-06
. O 0 2.8366998776618857e-06

3x O 0 8.921618427848443e-05
greater O 0 1.5179668935161317e-06
if O 0 7.155216508181184e-08
there O 0 7.619856745577636e-08
were O 0 8.758332370462085e-08
at O 0 2.2683645184429224e-08
least O 0 6.579909506143622e-09
five O 0 1.0015821949593828e-08
cases O 0 1.9418676444615812e-08
of O 0 4.602438821166288e-07
breast B-Disease 1 0.9999979734420776
cancer I-Disease 0 0.03173091262578964
in O 0 2.0677422440940063e-08
the O 0 3.0831907338324527e-07
family O 0 1.5101595636224374e-06
. O 0 2.494436103006592e-06

Interestingly O 0 1.1857287972816266e-05
, O 0 2.8134957119618775e-07
the O 0 6.213252845554962e-08
presence O 0 8.35816749145124e-08
of O 0 1.4743554288543237e-07
a O 0 2.8062174806109397e-07
breast B-Disease 0 0.0016073656734079123
cancer I-Disease 0 4.760034073569841e-07
case O 0 3.0476069667884076e-08
< O 0 7.553149572459006e-08
36 O 0 3.102409351640745e-08
years O 0 1.4369260226132496e-09
of O 0 2.8332838297728813e-09
age O 0 8.373562287999903e-09
was O 0 6.859728785002517e-09
strongly O 0 1.827488604888572e-09
predictive O 0 1.4521132740696885e-08
of O 0 4.416674581619873e-09
the O 0 2.9079900709660933e-09
presence O 0 1.3640898188782558e-08
of O 0 5.295431648733029e-09
any O 0 1.1831069457457488e-08
of O 0 9.152010704838176e-08
the O 0 1.3055228009761777e-07
eight O 0 5.102691602587583e-07
mutations O 0 1.6917887251111097e-06
screened O 0 7.768700015731156e-06
. O 0 4.6679401748406235e-06

Carriers O 0 3.306646704004379e-06
of O 0 2.3838667573272687e-07
the O 0 5.395265390006898e-08
same O 0 9.59488044571799e-09
mutation O 0 7.784530353660557e-09
, O 0 2.0666806044289388e-09
from O 0 2.504038976169909e-09
different O 0 2.8310203070702755e-09
families O 0 1.2946438587846387e-08
, O 0 8.302441401042415e-09
shared O 0 1.4478458432165553e-08
similar O 0 6.947569186621649e-09
haplotypes O 0 4.3280795125610894e-07
, O 0 6.962745491279065e-09
indicating O 0 1.6111489031800375e-08
that O 0 1.2269879556825458e-09
the O 0 5.1803361600377684e-09
mutant O 0 2.7397366153536495e-08
alleles O 0 1.4670712644715422e-08
were O 0 1.368126056888741e-08
likely O 0 9.907274112208597e-09
to O 0 3.042401663932992e-09
be O 0 4.22137924616095e-09
identical O 0 1.3699748002693468e-08
by O 0 4.928293773076575e-09
descent O 0 3.9303568399873257e-08
for O 0 9.449982130149692e-09
a O 0 1.607643262957481e-08
mutation O 0 2.0069744977035953e-08
in O 0 1.5320793522732856e-08
the O 0 1.5331646352478856e-07
founder O 0 7.147862561396323e-06
population O 0 3.215061781247641e-07
. O 0 2.687455889827106e-06

The O 0 4.2741527295220294e-07
identification O 0 9.457736496187863e-07
of O 0 7.984031640262401e-07
common O 0 4.449443167686695e-06
BRCA1 O 0 0.00030456241802312434
and O 0 1.8385570683676633e-06
BRCA2 O 0 4.363383141026134e-06
mutations O 0 9.42350908417211e-08
will O 0 9.171998271995108e-09
facilitate O 0 5.216181264700026e-08
carrier O 0 1.9115029559202412e-08
detection O 0 4.073165982276805e-08
in O 0 1.5590613244853557e-08
French O 0 1.6719640143492143e-06
Canadian O 0 1.4538389223162085e-05
breast B-Disease 0 0.44981157779693604
cancer I-Disease 0 0.16881313920021057
and O 0 0.031273189932107925
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.0413322090462316e-06
. O 0 4.565687049762346e-06

Are O 0 7.485486548830522e-06
Dp71 O 0 0.0008224360644817352
and O 0 2.656992364791222e-06
Dp140 O 0 0.0010514139430597425
brain O 0 3.236554766772315e-05
dystrophin O 0 1.125389553635614e-05
isoforms O 0 1.3158967249182751e-06
related O 0 2.649328223469638e-07
to O 0 2.6247771955922872e-08
cognitive B-Disease 0 1.9284072550362907e-05
impairment I-Disease 0 0.35276564955711365
in O 0 7.677958819840569e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999821186065674

Molecular O 0 1.9631621398730204e-05
study O 0 3.44723531497948e-07
and O 0 4.9004011515307866e-08
neuropsychological O 0 2.427897811685398e-07
analysis O 0 4.978900491892091e-08
were O 0 4.0099180864672235e-08
performed O 0 2.874869231561661e-08
concurrently O 0 1.5407279363444104e-07
on O 0 7.200423368658448e-08
49 O 0 2.097404632195321e-07
patients O 0 2.67794550978806e-08
with O 0 2.5716374807416287e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999980926513672
DMD B-Disease 1 1.0
) O 0 4.2499806340856594e-08
in O 0 4.335306336145095e-09
order O 0 3.1459486127261016e-09
to O 0 1.1721854598079062e-09
find O 0 7.067726848219991e-09
a O 0 2.4406503484897257e-09
molecular O 0 2.744569371770922e-08
explanation O 0 2.0719348015063588e-08
for O 0 5.167142713702333e-09
the O 0 2.285414346658854e-08
cognitive B-Disease 0 5.827683708048426e-06
impairment I-Disease 0 1.1996574357908685e-05
observed O 0 1.9142289886531216e-07
in O 0 5.649952683484116e-08
most O 0 6.544640314132266e-07
DMD B-Disease 1 1.0
patients O 0 6.37747280052281e-06
. O 0 9.284088264394086e-06

Complete O 0 1.3622252481582109e-06
analysis O 0 3.905514347479766e-07
of O 0 2.495946773706237e-07
the O 0 1.5357518634573353e-07
dystrophin O 0 4.071479906997411e-06
gene O 0 4.125662940168695e-07
was O 0 3.6872921782560297e-07
performed O 0 1.2024741202765199e-08
to O 0 3.5008480558929023e-09
define O 0 2.4000096132681392e-08
the O 0 2.7994914830742346e-08
localization O 0 6.986826974753058e-07
of O 0 5.3730115467942596e-08
deletions O 0 3.989206902588194e-07
and O 0 8.72936283258241e-08
duplications O 0 2.995300746988505e-06
in O 0 2.3049782527095886e-08
relation O 0 7.463600582013896e-08
to O 0 2.186375880341984e-08
the O 0 8.935265327636444e-08
different O 0 9.577612445355044e-07
DMD B-Disease 1 1.0
promoters O 0 0.00037819668068550527
. O 0 2.1407757230917923e-05

Qualitative O 0 1.0000217116612475e-05
analysis O 0 9.230264481630002e-07
of O 0 5.084407916911005e-07
the O 0 2.8085040071346157e-07
Dp71 O 0 7.173553058237303e-06
transcript O 0 6.512123036372941e-07
and O 0 1.1840640468108177e-08
testing O 0 6.502035798661154e-09
for O 0 4.521697682946524e-09
the O 0 6.837169941320553e-09
specific O 0 1.5413268883435194e-08
first O 0 5.3089863172317564e-08
exon O 0 3.7357304449869844e-07
of O 0 1.4109795642980316e-07
Dp140 O 0 7.131554866646184e-06
were O 0 1.941053540122084e-07
also O 0 1.2304153074182977e-07
carried O 0 6.014710152157932e-07
out O 0 8.058907496888423e-07
. O 0 4.604080913850339e-06

Neuropsychological O 0 4.921316940453835e-05
analysis O 0 1.687381768533669e-06
assessed O 0 2.2817027911514742e-06
verbal O 0 1.9997389699710766e-06
and O 0 3.525529734815791e-07
visuospatial O 0 2.5960869606933556e-05
intelligence O 0 2.6235268251184607e-06
, O 0 9.512411480727678e-08
verbal O 0 6.052872549844324e-07
memory O 0 0.10392620414495468
, O 0 5.028758778280462e-07
and O 0 4.3080083855784324e-07
reading O 0 1.1430919585109223e-05
skills O 0 2.495561602700036e-05
. O 0 2.1245175958028995e-05

Comparison O 0 1.022509877657285e-05
of O 0 1.1048000487789977e-06
molecular O 0 2.1671423837688053e-06
and O 0 1.2834966867103503e-07
psychometric O 0 2.3363440959656145e-06
findings O 0 6.818484621362586e-07
demonstrated O 0 8.216055391585542e-08
that O 0 6.4359508833433665e-09
deletions O 0 3.866929318974144e-07
and O 0 2.924461384168353e-08
duplications O 0 5.608262085843307e-07
that O 0 8.919767147119728e-09
were O 0 2.220721562196104e-08
localized O 0 3.230283880384377e-07
in O 0 6.93261092976627e-09
the O 0 2.6949983578106185e-08
distal O 0 8.545478067389922e-07
part O 0 1.300871765863576e-08
of O 0 6.747007574858799e-08
the O 0 1.2112262481878133e-07
gene O 0 8.77803287835377e-08
seemed O 0 1.2013948946787423e-07
to O 0 6.505409988477595e-09
be O 0 1.0342651179939821e-08
preferentially O 0 7.786627520545153e-08
associated O 0 9.102308951014493e-08
with O 0 3.426124806082953e-08
cognitive B-Disease 0 0.0004260930872987956
impairment I-Disease 1 0.8203128576278687
. O 0 2.133333146048244e-05

Two O 0 1.426912331226049e-05
altered O 0 2.1791043764096685e-05
Dp71 O 0 4.0185484976973385e-05
transcripts O 0 3.456611693763989e-06
and O 0 1.4956535210330912e-07
two O 0 1.396978461798426e-07
deleted O 0 8.34236629998486e-07
Dp140 O 0 7.496700504816545e-07
DNA O 0 5.500701760752236e-08
sequences O 0 1.608262856223064e-08
were O 0 9.711722981364801e-09
found O 0 4.472104908614938e-09
in O 0 2.087702455355611e-09
four O 0 9.320755722797003e-09
patients O 0 1.8203369478442255e-08
with O 0 6.344372138755716e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.00018749432638287544

These O 0 7.322103670048818e-07
findings O 0 5.005337584407243e-07
suggest O 0 7.562462656096614e-08
that O 0 3.931472036811101e-09
some O 0 5.047513074174503e-09
sequences O 0 7.08615166544746e-09
located O 0 2.3474560961744828e-08
in O 0 2.0987378501757803e-09
the O 0 1.0443171660767803e-08
distal O 0 4.921063236906775e-07
part O 0 1.4877461040896378e-08
of O 0 1.6533878266500324e-08
the O 0 1.7050718170708024e-08
gene O 0 1.803843652226078e-08
and O 0 2.3382954239536957e-08
, O 0 5.931835023176291e-09
in O 0 2.87820323130461e-09
particular O 0 2.0727886962390585e-08
, O 0 1.0744854783695246e-08
some O 0 1.7323257495149846e-08
DMD B-Disease 1 0.9999920129776001
isoforms O 0 3.8889265852048993e-07
expressed O 0 4.359305094681076e-08
in O 0 1.1887119732989504e-08
the O 0 4.247760188036409e-08
brain O 0 1.527370955045626e-06
may O 0 8.043672394819623e-09
be O 0 2.6833077981791575e-09
related O 0 1.764024837314082e-08
to O 0 6.5099405865964854e-09
the O 0 6.739907831843084e-08
cognitive B-Disease 0 3.5683053283719346e-05
impairment I-Disease 0 1.225738105858909e-05
associated O 0 9.719581157696666e-07
with O 0 5.726826657337369e-07
DMD B-Disease 1 1.0
. O 0 2.19096546061337e-06
. O 0 7.963210919115227e-06

I1307K O 0 0.0009336317307315767
APC O 0 8.553462248528376e-05
and O 0 1.0296336085957591e-06
hMLH1 O 0 4.809525762539124e-06
mutations O 0 2.895613988584955e-07
in O 0 2.6659540353080047e-08
a O 0 4.135841180641364e-08
non O 0 1.6470036143800826e-06
- O 0 8.036765279939573e-07
Jewish O 0 2.0621062049031025e-06
family O 0 7.271265189956466e-08
with O 0 2.8620720016192536e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6083087504957803e-05

We O 0 7.923017051325587e-07
describe O 0 3.9269104945560684e-07
a O 0 1.413705774666596e-07
French O 0 2.282401283082436e-06
Canadian O 0 4.332488060754258e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.444010853767395
HNPCC B-Disease 1 1.0
) O 0 1.2538338012291206e-07
kindred O 0 2.313242248419556e-06
which O 0 9.794821842490364e-09
carries O 0 5.419947157747629e-08
a O 0 4.0956567914918196e-08
novel O 0 3.679357121200155e-07
truncating O 0 2.13753764910507e-06
mutation O 0 4.724576854187035e-07
in O 0 4.334573020514654e-07
hMLH1 O 0 2.679129465832375e-05
. O 0 6.588133146578912e-06

Interestingly O 0 2.4761671738815494e-05
, O 0 6.527860136884556e-07
the O 0 3.96379903122579e-07
I1307K O 0 8.130213245749474e-06
APC O 0 1.185537371384271e-06
polymorphism O 0 1.6554648141209327e-07
, O 0 7.786669087295195e-09
associated O 0 6.829884213743753e-09
with O 0 9.888542207292517e-10
an O 0 1.8785748512328837e-09
increased O 0 1.3834190681905056e-08
risk O 0 8.773413640028593e-08
of O 0 0.0011550224153324962
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.502009787188399e-08
is O 0 1.92932181342087e-09
also O 0 1.6855631335133126e-09
present O 0 2.6032522804086966e-09
in O 0 6.724484080677939e-09
this O 0 3.221272848463741e-08
family O 0 1.0959839755741996e-06
. O 0 2.8488591397035634e-06

The O 0 4.4891066863783635e-06
I1307K O 0 1.3915076124249026e-05
polymorphism O 0 1.8792728724292829e-06
has O 0 3.639821599676907e-08
previously O 0 2.4712022650419385e-08
only O 0 3.686688732074117e-09
been O 0 5.75862779683689e-09
identified O 0 2.2976305302790934e-08
in O 0 4.856044455436859e-09
individuals O 0 5.858278750991985e-09
of O 0 9.395457567507037e-08
self O 0 3.57494428726568e-07
- O 0 2.6949319362756796e-06
reported O 0 3.862116102482105e-07
Ashkenazi O 0 2.8089455099689076e-06
Jewish O 0 1.8962731473948224e-06
origins O 0 7.774096047796775e-06
. O 0 6.1023288253636565e-06

In O 0 4.730225953153422e-07
addition O 0 1.7734684831793857e-07
, O 0 1.8641662435925355e-08
in O 0 5.03149966135652e-09
this O 0 2.386305597568139e-09
family O 0 2.062444615091863e-08
, O 0 7.0303372012858745e-09
there O 0 6.927006968027172e-09
appears O 0 8.872832246709095e-09
to O 0 1.3661852760193938e-09
be O 0 3.949450100293461e-09
no O 0 1.3108694574270885e-08
relationship O 0 1.0317411813787203e-08
between O 0 2.844770463639179e-08
the O 0 3.190418595977462e-08
I1307K O 0 5.798650590804755e-07
polymorphism O 0 6.070932556667685e-08
and O 0 7.527001244511666e-09
the O 0 1.636708013563748e-08
presence O 0 4.698569711081291e-08
or O 0 4.497375272194404e-08
absence O 0 1.8739771121545346e-06
of O 0 1.3051758287474513e-06
cancer B-Disease 0 9.387623322254512e-06
. O 0 4.024722102258238e-07
. O 0 3.920428753190208e-06

Identification O 0 3.277327778050676e-06
of O 0 5.457217753246368e-07
a O 0 9.591627048166629e-08
novel O 0 6.253950601831093e-08
mutation O 0 3.7395441410126296e-08
of O 0 6.088303194928812e-08
the O 0 1.746229685295475e-07
CPO O 0 2.130913344444707e-05
gene O 0 8.333318390896238e-08
in O 0 3.7907540217929636e-08
a O 0 1.4480052357157547e-07
Japanese O 0 3.796962118940428e-05
hereditary B-Disease 1 0.9999986886978149
coproporphyria I-Disease 1 0.9999324083328247
family O 0 2.433293775538914e-05
. O 0 1.6062651411630213e-05

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.3655892014503479
HCP B-Disease 1 1.0
) O 0 4.103390551790653e-07
is O 0 7.276381275289623e-09
an O 0 5.221673315958242e-09
autosomal B-Disease 1 0.6719745993614197
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9378827214241028
characterized O 0 9.50410150579728e-09
by O 0 2.0737012107474584e-09
a O 0 1.3659383846231776e-08
deficiency B-Disease 0 0.08082330226898193
of I-Disease 0 0.004827829077839851
coproporphyrinogen I-Disease 1 0.9857514500617981
oxidase I-Disease 0 8.77592265169369e-06
( O 0 4.421017365530133e-07
CPO O 0 6.34827347312239e-06
) O 0 2.609501059680497e-09
caused O 0 9.661745181688275e-09
by O 0 1.6408926439837046e-09
a O 0 2.655655251260214e-09
mutation O 0 1.3823560074399666e-08
in O 0 1.574138863702501e-08
the O 0 2.2425581391871674e-07
CPO O 0 5.601564043899998e-05
gene O 0 2.6175089260505047e-06
. O 0 5.975551175652072e-06

Only O 0 1.3513587191482657e-06
11 O 0 5.111638756716275e-07
mutations O 0 1.3869914994302235e-07
of O 0 4.4931827147820513e-08
the O 0 1.424610918121516e-08
gene O 0 2.5975694484259293e-08
have O 0 2.244431662745683e-08
been O 0 5.294152316537293e-08
reported O 0 2.475420330938505e-07
in O 0 2.628435140650254e-07
HCP B-Disease 1 1.0
patients O 0 1.0154074516321998e-05
. O 0 1.1210171578568406e-05

We O 0 8.760476362112968e-07
report O 0 2.3434775187070045e-07
another O 0 6.015238085410601e-08
mutation O 0 7.3391348109908e-08
in O 0 2.5219232924200696e-08
a O 0 1.0497615932081317e-07
Japanese O 0 6.813402251282241e-06
family O 0 5.793808668386191e-06
. O 0 4.790034836332779e-06

Polymerase O 0 4.164798519923352e-05
chain O 0 7.26241160009522e-06
reaction O 0 1.9100616555078886e-06
- O 0 2.217561359429965e-06
single O 0 2.284347146996879e-07
strand O 0 1.8889184616455168e-07
conformational O 0 4.0199346074132336e-08
polymorphism O 0 7.968697701699057e-08
and O 0 1.217063871905566e-08
direct O 0 1.0386042248455851e-08
sequence O 0 8.26682455823402e-09
analyses O 0 4.6363687999928516e-08
demonstrated O 0 1.6150071502352148e-08
a O 0 1.0793782756479686e-08
C O 0 1.4858268571060762e-07
to O 0 8.767219839000973e-09
T O 0 2.044779847665268e-07
substitution O 0 4.78027750716592e-08
in O 0 9.753136964718578e-09
exon O 0 1.4870842335312773e-07
1 O 0 6.832975429915678e-08
of O 0 1.828877316256694e-08
the O 0 5.368043787257193e-08
CPO O 0 1.9948131466662744e-06
gene O 0 2.3452274788837713e-08
at O 0 3.738053777624373e-08
nucleotide O 0 8.161669740047728e-08
position O 0 7.565765969275162e-08
85 O 0 8.119312866483597e-08
, O 0 8.223874914392582e-09
which O 0 8.04611222093854e-09
lies O 0 7.81237901037457e-08
in O 0 1.023345053141611e-08
the O 0 7.464740292562055e-08
putative O 0 3.774571723624831e-06
presequence O 0 7.802706932125147e-06
for O 0 7.184207362342931e-08
targeting O 0 5.788330099676386e-07
to O 0 3.8472643382192473e-07
mitochondria O 0 3.042733260372188e-05
. O 0 1.2652136319957208e-05

This O 0 2.8627277970372234e-07
mutation O 0 1.8820568925548287e-07
changes O 0 5.980825079632268e-08
the O 0 8.111263838372906e-08
codon O 0 2.784684625112277e-07
for O 0 2.7240215416668434e-08
glutamine O 0 1.558917830379869e-07
to O 0 2.2422922185683092e-08
a O 0 5.087666821168568e-08
termination O 0 5.65093273507955e-07
codon O 0 1.4519562228088034e-06
at O 0 4.6896028038645454e-07
amino O 0 2.5221285682164307e-07
acid O 0 4.847759669246443e-07
position O 0 1.8425379266773234e-06
29 O 0 7.952805390232243e-06
. O 0 3.3738554066076176e-06

MaeI O 0 0.0001435121230315417
restriction O 0 1.601167127773806e-06
analysis O 0 3.273477489074139e-07
showed O 0 5.8626412169360265e-08
two O 0 9.158013902776929e-09
other O 0 1.4826867733575e-08
carriers O 0 7.213674280137639e-08
in O 0 2.0721284244018534e-08
the O 0 1.5041601386656112e-07
family O 0 1.5273855069608544e-06
. O 0 4.915809768135659e-06

The O 0 1.5861112842685543e-05
C O 0 0.21213839948177338
- O 0 0.00018162802734877914
T O 0 1.0537569323787466e-05
mutation O 0 6.403199392934766e-08
is O 0 1.2738674115553295e-08
located O 0 3.445601137741505e-08
within O 0 8.012802865664526e-09
a O 0 1.075728128796527e-08
recently O 0 2.7440407279755163e-08
proposed O 0 3.365982692571379e-08
putative O 0 2.9910424359513854e-07
alternative O 0 2.483251364537864e-07
translation O 0 4.4998895987191645e-07
initiation O 0 1.988684346088121e-07
codon O 0 1.262710384253296e-06
( O 0 3.9182768318823946e-07
TIC O 0 2.950741873064544e-06
- O 0 1.0812368600454647e-06
1 O 0 2.868409296752361e-07
) O 0 9.070157069857032e-09
, O 0 5.29788701797429e-09
supporting O 0 1.5341058201556734e-08
that O 0 1.198039800698325e-08
TIC O 0 7.600339699820324e-07
- O 0 5.435309731183224e-07
1 O 0 1.7054790646398033e-07
is O 0 7.686679737162194e-09
the O 0 3.469295606350897e-08
real O 0 1.0523231139814015e-06
TIC O 0 2.0989164113416336e-06
rather O 0 1.4903994838277868e-07
than O 0 1.4871551456963061e-07
TIC O 0 6.357033726089867e-06
- O 0 5.4622028073936235e-06
2 O 0 3.4341865102760494e-06
. O 0 6.369980383169604e-07
. O 0 3.2313148494722554e-06

Human B-Disease 0 1.0614584425638895e-05
complement I-Disease 0 2.0260249584680423e-05
factor I-Disease 0 0.00011168683704454452
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999979734420776
associated O 1 0.9153971672058105
with O 1 0.9973836541175842
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 1.0

This O 0 2.2556763212833175e-07
study O 0 1.247445737817543e-07
reports O 0 1.2952619954376132e-07
on O 0 3.040547014165895e-08
six O 0 1.5744872072787075e-08
cases O 0 1.0304058051247011e-08
of O 0 9.079230522957005e-08
deficiency B-Disease 1 0.9995952248573303
in I-Disease 0 7.286314485099865e-08
the I-Disease 0 6.045372202834187e-08
human I-Disease 0 3.4830531348006843e-08
complement I-Disease 0 4.782101825639984e-08
regulatory I-Disease 0 7.279881941713029e-08
protein I-Disease 0 3.3859578252304345e-07
Factor I-Disease 0 2.9374598398135277e-07
H I-Disease 1 0.9999345541000366
( O 0 1.890185359343377e-07
FH O 0 1.833827445807401e-05
) O 0 6.523601214780683e-09
in O 0 1.814830841162518e-09
the O 0 2.627200235139071e-09
context O 0 4.511327489353789e-08
of O 0 1.692144913079119e-08
an O 0 1.0306224140776976e-07
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 8.812584565021098e-05

Five O 0 1.3528288036468439e-06
of O 0 1.1512740627495077e-07
the O 0 2.0468393202577317e-08
cases O 0 2.2521549070120273e-08
were O 0 3.037897755575614e-08
observed O 0 1.9739456291745228e-08
in O 0 7.876352015045995e-09
children O 0 3.462486475314108e-08
presenting O 0 5.439043206934002e-07
with O 0 1.4657030078524258e-06
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.001087329350411892
. O 0 2.2996879124548286e-05

Two O 0 1.0544328006290016e-06
of O 0 3.6822217452936457e-07
the O 0 2.692412124360999e-07
children O 0 4.6963921818132803e-07
exhibited O 0 6.716180678267847e-07
a O 0 1.1165599289597594e-07
homozygous O 0 2.257166443087044e-06
deficiency O 0 0.0030128618236631155
characterized O 0 7.170491045371818e-08
by O 0 9.874468354098553e-09
the O 0 3.0915284554566824e-08
absence O 0 2.328591222067189e-07
of O 0 1.08438690915591e-07
the O 0 8.383409522139118e-08
150 O 0 1.2175159724847617e-07
- O 0 2.171311876963955e-07
kD O 0 6.802649181736342e-07
form O 0 7.683499170241248e-09
of O 0 2.080111727309486e-08
Factor O 0 9.287379043598776e-08
H O 1 0.9991710186004639
and O 0 1.1576482883413064e-08
the O 0 1.5848941714580178e-08
presence O 0 4.5098307310809105e-08
, O 0 1.373978530949671e-08
upon O 0 7.360302589631829e-08
immunoblotting O 0 2.5741871922946302e-06
, O 0 2.6287253263035382e-08
of O 0 5.906334621386122e-08
the O 0 2.8633232318497903e-07
42 O 0 2.0307093109295238e-06
- O 0 2.9957836886751465e-06
kD O 0 2.0893978216918185e-05
Factor O 0 1.6948700931607164e-06
H O 0 0.00125307054258883
- O 0 2.8907434170832857e-06
like O 0 3.0102640380391676e-07
protein O 0 8.248996437032474e-07
1 O 0 9.140320003098168e-07
( O 0 8.934635076229824e-08
FHL O 0 1.3277791367727332e-05
- O 0 6.598593813578191e-07
1 O 0 2.2451195036410354e-07
) O 0 5.846970463352363e-09
and O 0 1.3468356208079513e-08
other O 0 8.979549193099956e-08
FH O 0 2.09872978302883e-05
- O 0 1.6808402278911672e-06
related O 0 7.38165738312091e-07
protein O 0 1.365147568321845e-06
( O 0 3.641433181655884e-07
FHR O 0 0.00015203461225610226
) O 0 3.630098603935039e-07
bands O 0 3.3199175959452987e-06
. O 0 2.6644904664863134e-06

Southern O 0 2.8832417228841223e-05
blot O 0 1.2743051229335833e-05
and O 0 1.0547651640990807e-07
PCR O 0 3.4905357892967004e-07
analysis O 0 3.9290455333684804e-08
of O 0 1.2302670882036182e-08
DNA O 0 5.12779472217062e-08
of O 0 1.631341106644868e-08
one O 0 1.077905231738896e-08
patient O 0 6.319782386299266e-08
with O 0 4.4908009755317835e-08
homozygous O 0 8.796418114798144e-06
deficiency O 1 0.9046719670295715
ruled O 0 5.274206387184677e-07
out O 0 1.2799709736555087e-08
the O 0 8.451961797106833e-09
presence O 0 7.92236676261382e-09
of O 0 6.17375883749105e-09
a O 0 4.0339265261479795e-09
large O 0 1.3125307063432956e-08
deletion O 0 2.0364732122857276e-08
of O 0 3.753507371584419e-08
the O 0 1.1758499596226102e-07
FH O 0 5.181600135983899e-05
gene O 0 3.8956446957172375e-08
as O 0 3.90685066520291e-08
the O 0 4.279451104594045e-08
underlying O 0 1.6026826870074729e-06
defect O 0 6.090393753765966e-07
for O 0 2.0096140929126705e-07
the O 0 1.3718879017687868e-05
deficiency O 1 0.9999958276748657
. O 0 8.583440649090335e-05

The O 0 8.813579484012735e-07
other O 0 1.541251037906477e-07
four O 0 6.095507387726684e-08
children O 0 1.9154628105866323e-08
presented O 0 6.535060492751654e-08
with O 0 1.807235783246597e-08
heterozygous O 0 6.075218834666885e-07
deficiency O 1 0.970607340335846
and O 0 1.5460398117284058e-07
exhibited O 0 4.862998821408837e-07
a O 0 2.4776113605184946e-08
normal O 0 1.7203771562890324e-07
immunoblotting O 0 2.831575329764746e-06
pattern O 0 1.7893322024065128e-07
of O 0 2.609402827147278e-08
proteins O 0 2.335892546057039e-08
of O 0 1.432042040505621e-07
the O 0 1.0961982752633048e-06
FH O 1 0.787873387336731
family O 0 5.0318471949140076e-06
. O 0 5.290879016683903e-06

Factor B-Disease 1 0.9187937378883362
H I-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
is O 0 9.045869830970332e-08
the O 0 5.655365242773769e-08
only O 0 1.528508875026091e-07
complement B-Disease 1 0.9999992847442627
deficiency I-Disease 1 1.0
associated O 0 0.0012000431306660175
with O 0 9.879057870421093e-06
HUS B-Disease 1 1.0
. O 0 0.00013321940787136555

These O 0 1.842225287873589e-06
observations O 0 1.6098761079774704e-06
suggest O 0 2.795314344439248e-07
a O 0 6.469627322758242e-08
role O 0 1.2419403105923266e-07
for O 0 5.9021342480036765e-08
FH O 0 0.001167142647318542
and O 0 3.4502710377637413e-07
/ O 0 8.581710062571801e-06
or O 0 2.30784706900522e-07
FH O 0 6.611491699004546e-05
receptors O 0 3.186596870818903e-07
in O 0 1.1664229582208918e-08
the O 0 4.7489066901107435e-08
pathogenesis O 0 0.33977940678596497
of O 0 1.88154137958918e-06
idiopathic O 1 0.9999998807907104
HUS B-Disease 1 1.0
. O 0 1.0372389624535572e-05
. O 0 1.705948125163559e-05

Further O 0 2.8033093713020207e-06
evidence O 0 9.061217838279845e-07
for O 0 4.577356804702504e-08
a O 0 6.775947980486308e-08
major O 0 3.268050079441309e-07
ancient O 0 7.887463198130718e-07
mutation O 0 1.1458514563855715e-06
underlying O 0 2.946200402220711e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.8124226244253805e-06
linkage O 0 0.00010485506936674938
disequilibrium O 0 7.326992636080831e-05
studies O 0 7.088493703122367e-08
in O 0 5.3737672089937405e-09
the O 0 2.237225515955288e-08
Japanese O 0 8.186098625628802e-07
population O 0 1.0589520371695471e-07
. O 0 1.350052571069682e-06

The O 0 0.00011186792107764632
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.2328578382730484
DM B-Disease 1 1.0
) O 0 8.792711980731838e-08
mutation O 0 1.2826739670401821e-08
is O 0 3.5510034912533683e-09
an O 0 1.175192565483485e-08
unstable O 0 7.616353627781791e-07
( O 0 2.8220031822456804e-07
CTG O 0 2.3434766262653284e-05
) O 0 2.0460314331671725e-08
n O 0 3.280649352177534e-08
repeat O 0 3.462981723600933e-08
, O 0 1.1482626405268093e-08
present O 0 8.020218267290602e-09
at O 0 7.63014984528354e-09
a O 0 1.5330666736090848e-09
copy O 0 1.8817349456412558e-08
number O 0 9.592062255592282e-09
of O 0 3.142771731745597e-08
5 O 0 9.410953794031229e-08
- O 0 2.1373062963903067e-07
37 O 0 2.437628268125991e-07
repeats O 0 1.6559197035803663e-07
on O 0 9.398074496402842e-08
normal O 0 3.74117803403351e-08
chromosomes O 0 6.071071112501158e-08
but O 0 1.1380779874059499e-08
amplified O 0 2.0082941887267225e-07
to O 0 3.367106771179351e-08
50 O 0 1.8236353582778975e-07
- O 0 3.602037565997307e-07
3000 O 0 5.543526526707865e-07
copies O 0 5.735381023441732e-07
on O 0 3.5609018596005626e-06
DM B-Disease 1 0.9992485642433167
chromosomes O 0 3.2959880627458915e-05
. O 0 1.463375701860059e-05

Previous O 0 4.449685093277367e-06
findings O 0 1.799159008442075e-06
in O 0 1.2914283331610932e-07
Caucasian O 0 9.660640216679894e-07
populations O 0 1.621743166424494e-07
of O 0 9.798805677974087e-08
a O 0 4.6357760652426805e-07
DM B-Disease 1 1.0
founder O 0 0.054740726947784424
chromosome O 0 1.4296882682174328e-06
raise O 0 6.937204233281591e-08
a O 0 1.5480029702530373e-08
question O 0 3.4367797496770436e-08
about O 0 2.1766299873604567e-09
the O 0 5.584690487836497e-09
molecular O 0 5.636734812242139e-08
events O 0 1.4991030639066594e-08
involved O 0 1.4534987435865787e-08
in O 0 8.755037583796366e-09
the O 0 5.056419638549414e-08
expansion O 0 7.612548529323249e-07
mutation O 0 7.73004728671367e-07
. O 0 3.797879344347166e-06

To O 0 6.230852704902645e-07
investigate O 0 6.783984076719207e-07
whether O 0 1.301052066082775e-07
a O 0 9.773290088332942e-08
founder O 0 1.050966261573194e-06
chromosome O 0 3.0165347197907977e-07
for O 0 2.5574783180104532e-08
the O 0 1.2627835133116605e-07
DM B-Disease 1 1.0
mutation O 0 4.030636802099252e-08
exists O 0 1.8507424925928717e-08
in O 0 2.5573063666683993e-09
the O 0 3.561435590881956e-09
Japanese O 0 5.7738635206305844e-08
population O 0 6.256859474973453e-09
, O 0 5.154454196798497e-09
we O 0 1.7181235989482957e-08
genotyped O 0 6.285611675593827e-07
families O 0 1.607385691215768e-08
using O 0 1.644242608733748e-08
polymorphic O 0 3.185737114108633e-07
markers O 0 1.818565692701668e-06
near O 0 1.0364975651100394e-06
the O 0 3.5560859146244184e-07
( O 0 5.855443987456965e-07
CTG O 0 6.359408143907785e-05
) O 0 1.197404060349072e-07
n O 0 1.6305486383316747e-07
repeat O 0 5.139760332895094e-07
region O 0 1.3132139429217204e-06
and O 0 3.8399187474169594e-07
constructed O 0 1.1720657312253024e-05
haplotypes O 0 8.454167254967615e-05
. O 0 1.2499096555984579e-05

Six O 0 2.0915590539516415e-06
different O 0 3.193551663116523e-07
haplotypes O 0 8.607504241808783e-06
were O 0 1.9441361587269057e-07
found O 0 8.448258626003735e-08
and O 0 8.398566109235617e-08
DM B-Disease 1 1.0
alleles O 0 8.087440619419795e-07
were O 0 3.2120522064360557e-07
always O 0 4.075342303622165e-07
haplotype O 0 5.122768470755545e-06
A O 0 8.755851013120264e-06
. O 0 8.206427992263343e-06

To O 0 3.72465279951939e-07
find O 0 1.2068862531577906e-07
an O 0 1.8655498479347443e-08
origin O 0 4.884313398179074e-08
of O 0 1.0536933814364602e-07
the O 0 4.1422291019443946e-07
( O 0 4.368769168650033e-07
CTG O 0 5.068017708254047e-05
) O 0 2.5626933464195645e-08
n O 0 2.8974003640769297e-08
repeat O 0 1.8674510826599544e-08
mutation O 0 5.516332279853486e-09
and O 0 2.146942845726585e-09
to O 0 1.603899679736287e-09
investigate O 0 8.343398860688467e-09
the O 0 6.82474032842606e-09
mechanism O 0 2.610727101171051e-08
of O 0 6.866404778094193e-09
the O 0 8.217587499359524e-09
expansion O 0 2.4455536262735222e-08
mutation O 0 4.517852758567642e-09
in O 0 1.964532092557647e-09
the O 0 4.474758341643792e-09
Japanese O 0 6.642962802061447e-08
population O 0 3.3952876066223325e-09
we O 0 2.5812549875325885e-09
have O 0 4.285951149540779e-09
studied O 0 7.628581499830034e-08
90 O 0 3.9016157415971975e-08
Japanese O 0 5.334626393960207e-07
DM B-Disease 1 0.9989388585090637
families O 0 7.486027442382692e-08
comprising O 0 9.330701544740805e-08
190 O 0 9.47630169889635e-08
affected O 0 6.594410706384224e-08
and O 0 3.905360657086021e-08
130 O 0 2.4023299260989006e-07
unaffected O 0 1.6739870716264704e-06
members O 0 4.070005843459512e-07
. O 0 4.404744686326012e-06

The O 0 1.7784693682187935e-06
results O 0 3.328761692955595e-07
suggest O 0 1.2707666030564724e-07
that O 0 7.657179779130274e-09
a O 0 2.13132160808982e-08
few O 0 5.4283688655232254e-08
common O 0 5.31690069749402e-08
ancestral O 0 3.327669730879279e-07
mutations O 0 3.435351203506798e-08
in O 0 7.21952186921726e-09
both O 0 2.1418886220203603e-08
Caucasian O 0 1.6937100610903144e-07
and O 0 1.245129954696722e-08
Japanese O 0 1.7649007588715904e-07
populations O 0 1.2771006474565638e-08
have O 0 1.5791751240001872e-09
originated O 0 1.834194129912703e-08
by O 0 3.579059049130251e-09
expansion O 0 1.9278171237147035e-07
of O 0 6.340210489952369e-08
an O 0 5.11402262759475e-08
ancestral O 0 1.573555664435844e-06
n O 0 7.715369179095433e-07
= O 0 1.38732798404817e-06
5 O 0 2.705686483750469e-07
repeat O 0 9.626780439475624e-08
to O 0 7.019941250518968e-08
n O 0 1.284383642996545e-06
= O 0 2.9150719456083607e-06
19 O 0 2.375173608015757e-06
- O 0 1.2846321624238044e-06
37 O 0 1.2445409538486274e-06
copies O 0 1.998444304263103e-06
. O 0 4.230484137224266e-06

These O 0 5.106834350954159e-07
data O 0 5.235582989371323e-07
support O 0 6.983696465567846e-08
multistep O 0 6.609407705582271e-07
models O 0 3.1591582683176966e-07
of O 0 1.200580470595014e-07
triplet O 0 3.554147042450495e-06
repeat O 0 5.084131657895341e-07
expansion O 0 7.519692530877364e-07
that O 0 1.0396804306367358e-08
have O 0 4.417676890966504e-09
been O 0 7.640140076148327e-09
proposed O 0 2.602881110647104e-08
for O 0 4.2453542903331254e-08
both O 0 5.217017360337195e-07
DM B-Disease 1 1.0
and O 0 4.057781097799307e-06
Friedreichs B-Disease 1 0.5103866457939148
ataxia I-Disease 1 0.9999966621398926
. O 0 6.7538458097260445e-06
. O 0 1.3167229553801008e-05

The O 0 1.1520531870701234e-06
molecular O 0 4.929461738356622e-06
basis O 0 3.4561107895569876e-06
of O 0 1.6398164007114246e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.709420574679825e-08
the O 0 4.3735713717296676e-08
western O 0 1.857880391753497e-07
Cape O 0 2.3207232402455702e-07
, O 0 3.846237106586159e-08
South O 0 6.098287030908978e-07
Africa O 0 1.6812073226901703e-06
. O 0 2.6154204988415586e-06

Deficiency B-Disease 1 0.9994169473648071
of I-Disease 0 1.737327875162009e-05
the I-Disease 0 8.191095730580855e-07
sixth I-Disease 0 5.563744252867764e-06
component I-Disease 0 8.265982387456461e-07
of I-Disease 0 3.91944965372204e-08
human I-Disease 0 4.3812779182417216e-08
complement I-Disease 0 3.2310049391526263e-07
( O 0 1.6602807306753675e-07
C6 O 1 0.9999927282333374
) O 0 3.5398455278112806e-09
has O 0 6.741959213130144e-10
been O 0 9.089999863931553e-10
reported O 0 1.5549325160790772e-09
in O 0 2.6540891706616776e-10
a O 0 8.440616539040491e-10
number O 0 2.3072292965053975e-09
of O 0 6.10919226318174e-09
families O 0 5.6696514150189614e-09
from O 0 7.895213371966747e-09
the O 0 2.378590657770019e-08
western O 0 3.4352274269622285e-07
Cape O 0 2.2784249154028657e-07
, O 0 7.194190487780361e-08
South O 0 3.766797362914076e-07
Africa O 0 1.4157012628857046e-06
. O 0 3.49199831362057e-06

Meningococcal B-Disease 1 0.9957596659660339
disease I-Disease 1 0.7079547047615051
is O 0 4.203849002237803e-08
endemic O 0 1.840312613410333e-08
in O 0 2.4158302025512057e-09
the O 0 8.25204793386547e-09
Cape O 0 3.9733127010777025e-08
and O 0 2.622428940668442e-09
almost O 0 5.487955867522487e-09
all O 0 5.34459454470948e-09
pedigrees O 0 4.639221344859834e-07
of O 0 1.3165831092010194e-07
total O 0 3.65161258741864e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.583306013548281e-06
C6Q0 O 1 0.999998927116394
) O 0 5.726262131133808e-09
have O 0 1.505747526664436e-09
been O 0 2.7410631542323927e-09
ascertained O 0 1.1418224943327004e-07
because O 0 1.949252315114336e-08
of O 0 2.2202011962235702e-07
recurrent O 0 0.12542195618152618
disease O 1 0.7682049870491028
. O 0 7.00914324625046e-06

We O 0 8.095744306046981e-07
have O 0 1.130376858782256e-07
sequenced O 0 3.997299700131407e-07
the O 0 5.723862983586514e-08
expressed O 0 5.909704015039097e-08
exons O 0 7.900442255959206e-07
of O 0 1.5931188102058513e-07
the O 0 1.7608842028948857e-07
C6 O 0 0.11650014668703079
gene O 0 2.24111644797631e-08
from O 0 1.0312552589653023e-08
selected O 0 1.032826002500542e-08
cases O 0 4.140930709439772e-09
and O 0 1.3193168779679354e-09
have O 0 7.667303458802621e-10
found O 0 2.812693855602788e-09
three O 0 6.128040297426196e-09
molecular O 0 5.321290245774435e-06
defects O 1 0.9997490048408508
leading O 0 2.052531999652274e-05
to O 0 3.4932856607383656e-08
total O 0 3.5895689620701887e-07
deficiency O 1 0.9700685739517212
879delG O 0 7.690642814850435e-05
, O 0 1.1246022779687337e-08
which O 0 1.2978721430911833e-09
is O 0 5.781990441988683e-10
the O 0 2.5874016262861232e-09
common O 0 2.93971211817734e-08
defect O 0 1.0233122793579241e-07
in O 0 1.4196659847698356e-08
the O 0 8.85255104776661e-08
Cape O 0 2.05653520879423e-07
and O 0 3.585018504281834e-08
hitherto O 0 1.631545387681399e-06
unreported O 0 1.2061285588060855e-06
, O 0 3.240190693531986e-08
and O 0 4.57303706014045e-08
1195delC O 0 1.0236788057227386e-06
and O 0 5.911710942996251e-08
1936delG O 0 1.2284414196983562e-06
, O 0 1.938995630723639e-08
which O 0 5.111864709306246e-09
have O 0 3.6295455529966603e-09
been O 0 1.602921884114039e-08
previously O 0 3.9512148219955634e-08
reported O 0 2.7973884542120686e-08
in O 0 2.5014387006194738e-08
African O 0 6.43524174392951e-07
- O 0 3.6516296404442983e-06
Americans O 0 2.300464757354348e-06
. O 0 5.164798494661227e-06

We O 0 2.218068857473554e-06
also O 0 4.774773856297543e-07
show O 0 9.60962722729164e-08
that O 0 7.380965172387732e-09
the O 0 1.0091011404256278e-07
879delG O 0 3.864079644699814e-06
and O 0 1.9775637838392868e-07
1195delC O 0 1.409939068253152e-05
defects O 0 0.0005215256824158132
are O 0 4.876187631452922e-08
associated O 0 2.5201737230418075e-07
with O 0 1.4150208471619408e-07
characteristic O 1 0.9998113512992859
C6 O 1 1.0
/ O 1 0.9999899864196777
C7 O 1 0.9999864101409912
region O 0 3.6308290418674005e-07
DNA O 0 5.342517965800653e-07
marker O 0 1.1348176940373378e-06
haplotypes O 0 1.1675859923343523e-06
, O 0 2.2138069155630546e-08
although O 0 1.7965096077432463e-08
small O 0 2.2381859920983516e-08
variations O 0 2.033527835010318e-07
were O 0 1.8831305226285622e-07
observed O 0 1.5393809462693753e-06
. O 0 3.2106299840961583e-06

The O 0 8.510308362019714e-06
1936delG O 0 5.4150692449184135e-05
defect O 0 9.938145012711175e-06
was O 0 4.5387520231088274e-07
observed O 0 4.320326141282749e-08
only O 0 6.743583469415171e-09
once O 0 1.3496359585474238e-08
in O 0 3.1022537871905342e-09
the O 0 1.896276557999954e-08
Cape O 0 1.094500134968257e-07
, O 0 3.7135776675967236e-09
but O 0 1.8032648707588805e-09
its O 0 4.547974441493352e-09
associated O 0 7.334852369922373e-08
haplotype O 0 9.267097311749239e-07
could O 0 1.4382516155819758e-07
be O 0 2.9993660177751735e-07
deduced O 0 1.5059132238093298e-05
. O 0 8.372274351131637e-06

The O 0 7.958579431033286e-07
data O 0 3.8109448041723226e-07
from O 0 7.014052982867724e-08
the O 0 8.387152661271102e-08
haplotypes O 0 2.257222377011203e-06
indicate O 0 7.260828738253622e-08
that O 0 3.4867337905808427e-09
these O 0 4.747202186905497e-09
three O 0 7.775315502556168e-09
molecular O 0 1.2182412092442974e-06
defects O 0 1.2129572496633045e-05
account O 0 2.2561490453654187e-08
for O 0 9.051043470265085e-09
the O 0 1.5885507309576496e-07
defects O 1 0.9484379887580872
in O 0 1.8539505930448286e-08
all O 0 1.2014723438369401e-08
the O 0 1.0257784310852003e-07
38 O 0 4.646904301353061e-07
unrelated O 0 4.134698485813715e-07
C6Q0 O 0 3.0414537832257338e-05
individuals O 0 1.143266903369522e-08
we O 0 3.022154970722113e-08
have O 0 1.5763442107186165e-08
studied O 0 1.9396640027480316e-07
from O 0 7.301353122102228e-08
the O 0 2.594626664631505e-07
Cape O 0 3.2336486128770048e-06
. O 0 3.3325079584756168e-06

We O 0 5.592207230620261e-07
have O 0 1.0840932418432203e-07
also O 0 7.95501549077926e-08
observed O 0 1.2407221561261395e-07
the O 0 1.1158126511645605e-07
879delG O 0 2.3757945655233925e-06
defect O 0 6.730369932483882e-07
in O 0 7.533827073302746e-08
two O 0 2.7986538952973206e-07
Dutch O 1 0.9999722242355347
C6 B-Disease 1 1.0
- I-Disease 1 0.9999856948852539
deficient I-Disease 1 0.9999996423721313
kindreds O 0 1.1171515325258952e-05
, O 0 1.4020189453844978e-08
but O 0 5.9385145689816454e-09
the O 0 1.6455853568686507e-08
879delG O 0 6.12953954259865e-07
defect O 0 2.881242835428566e-07
in O 0 2.728566173004765e-08
the O 0 1.3870590009901207e-07
Cape O 0 3.8435933902292163e-07
probably O 0 5.802766622764466e-08
did O 0 2.1178029996349323e-08
not O 0 9.604237405369531e-09
come O 0 2.146436450800593e-08
from O 0 4.1838191577880934e-08
The O 0 6.390084195118106e-08
Netherlands O 0 1.6477798681080458e-06
. O 0 4.3017595885430637e-07
. O 0 2.2198846636456437e-06

Complement B-Disease 1 0.9999877214431763
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.3726893257626216e-06
seven O 0 1.5379826834305277e-07
further O 0 1.222670675815607e-07
molecular O 0 7.236043529701419e-06
defects O 0 0.38303378224372864
and O 0 7.257546741357146e-08
their O 0 6.023734044902085e-08
associated O 0 1.1832888048957102e-05
marker O 0 0.018446899950504303
haplotypes O 0 0.000447932630777359
. O 0 1.8746955902315676e-05

Seven O 0 6.5624358285276685e-06
further O 0 7.394339718302945e-07
molecular O 0 2.04357820621226e-06
bases O 0 3.316117499707616e-06
of O 0 7.937422196846455e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.9215392512705876e-06
described O 0 5.579892331297742e-06
. O 0 4.746670128952246e-06

All O 0 4.773344244313193e-07
these O 0 1.0778337156125417e-07
new O 0 1.2652233749577135e-07
molecular O 0 5.725812115997542e-06
defects O 0 6.1068230934324674e-06
involve O 0 2.2521511766626645e-07
single O 0 1.662188253703789e-07
- O 0 4.5686041971748637e-07
nucleotide O 0 4.108116797851835e-07
events O 0 1.0277152995286087e-07
, O 0 1.9998898537210152e-08
deletions O 0 9.190213745569054e-08
and O 0 9.122223865176693e-09
substitutions O 0 1.2256289494416706e-07
, O 0 1.1783123810005236e-08
some O 0 8.868247469706603e-09
of O 0 3.486443134192996e-08
which O 0 1.342035194085156e-08
alter O 0 2.672690584404336e-07
splice O 0 3.5385287446842995e-06
sites O 0 6.591706664949015e-07
, O 0 9.79469447770498e-08
and O 0 7.673265400853779e-08
others O 0 6.678986892438843e-07
codons O 0 2.1684902094420977e-05
. O 0 1.1453497791080736e-05

They O 0 9.600684052202269e-07
are O 0 9.062742378773692e-08
distributed O 0 3.4029628181997396e-07
along O 0 4.185459374639322e-07
the O 0 4.2456460391804285e-07
C7 O 0 0.0005582290468737483
gene O 0 1.717195630135393e-07
, O 0 2.107748819923927e-08
but O 0 1.0689847229627958e-08
predominantly O 0 2.7124441359660523e-08
towards O 0 8.057388356519368e-08
the O 0 7.736708340644327e-08
3 O 0 5.994370440021157e-07
end O 0 7.980993359524291e-07
. O 0 2.673970357136568e-06

All O 0 4.892738161288435e-07
were O 0 2.013950108903373e-07
found O 0 4.181601553909786e-08
in O 0 2.1058720989231006e-08
compound O 0 3.6593723962141667e-07
heterozygous O 0 3.783917463806574e-07
individuals O 0 2.5540302317494934e-07
. O 0 3.2693485536583466e-06

The O 0 0.00030229362891986966
C6 O 1 1.0
/ O 1 0.999771773815155
C7 O 1 0.9999521970748901
marker O 0 2.0313356799306348e-05
haplotypes O 0 1.045624230755493e-05
associated O 0 9.599366421753075e-07
with O 0 1.9624044966803922e-07
most O 0 1.2972046533832327e-05
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999990463256836
are O 0 4.1362170577485813e-07
tabulated O 0 5.083116320747649e-06
. O 0 6.913704169164703e-07
. O 0 3.078964255109895e-06

A O 0 1.0144008228962775e-05
genome O 0 4.7389266910613514e-06
- O 0 2.7302482976665488e-06
wide O 0 3.2539870176151453e-07
search O 0 7.635496501734451e-08
for O 0 2.5623611676905966e-08
chromosomal O 0 3.873218247463228e-06
loci O 0 4.610184078046586e-06
linked O 0 8.358647392014973e-06
to O 0 6.645903027902023e-08
mental O 1 0.9999936819076538
health O 0 0.05373024195432663
wellness O 0 3.5830373690259876e-06
in O 0 1.7273569241638143e-08
relatives O 0 2.8626325843106315e-07
at O 0 1.1391382770398195e-07
high O 0 3.0452918053924805e-07
risk O 0 1.5594009994401858e-07
for O 0 3.982866303431365e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.00018927907512988895
the O 0 3.4459830544619763e-07
Old O 0 1.5633931980119087e-06
Order O 0 6.867953175060393e-07
Amish O 0 3.557690797606483e-05
. O 0 1.4425266272155568e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999531507492065
BPAD B-Disease 1 1.0
; O 0 0.09080679714679718
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 8.857567479481077e-08
is O 0 2.859505965346898e-09
characterized O 0 4.5835832906959695e-09
by O 0 2.7197939456158338e-09
episodes O 0 2.4687242472509752e-08
of O 0 5.4219736256300166e-08
mania B-Disease 0 1.3308927918842528e-05
and O 0 1.0855691243705223e-06
/ O 0 0.024274256080389023
or O 0 1.4606057447963394e-06
hypomania B-Disease 0 0.00907792616635561
interspersed O 0 7.445684673257347e-07
with O 0 2.6537930963854706e-08
periods O 0 1.0937296792690177e-06
of O 0 1.7566402448210283e-06
depression B-Disease 0 6.895908154547215e-05
. O 0 9.529574526823126e-06

Compelling O 0 1.382598748023156e-05
evidence O 0 1.52687277932273e-06
supports O 0 2.491953523531265e-07
a O 0 1.413427419549862e-08
significant O 0 5.689283355536645e-08
genetic O 0 1.735607355612956e-07
component O 0 3.650341398042656e-07
in O 0 1.132633808964556e-08
the O 0 4.216625271169505e-08
susceptibility O 0 3.9678494090367167e-07
to O 0 3.349300925492571e-07
develop O 0 4.684513623942621e-05
BPAD B-Disease 1 1.0
. O 0 3.3800148230511695e-05

To O 0 5.269857297207636e-07
date O 0 1.3757442047790391e-06
, O 0 1.2068264254594396e-07
however O 0 1.2660018455790123e-07
, O 0 4.375966256020547e-08
linkage O 0 1.9276731109130196e-06
studies O 0 6.043470079930557e-08
have O 0 4.665356101440921e-09
attempted O 0 4.482123472371313e-08
only O 0 6.119770468160368e-09
to O 0 6.267633523293625e-09
identify O 0 1.4216799115729373e-07
chromosomal O 0 3.369787691553938e-06
loci O 0 3.228574882996327e-07
that O 0 4.181551549464757e-09
cause O 0 9.741669515506146e-08
or O 0 6.741358582473822e-09
increase O 0 5.452710283293527e-09
the O 0 3.265529002760559e-08
risk O 0 2.0551040336158621e-07
of O 0 2.405119801096589e-07
developing O 0 6.958458106964827e-05
BPAD B-Disease 1 1.0
. O 0 2.4018745534704067e-05

To O 0 1.8272285728926363e-07
determine O 0 2.0924059640492487e-07
whether O 0 5.6506213041984665e-08
there O 0 2.5996811814366083e-08
could O 0 2.1780099501711447e-08
be O 0 3.652827018640892e-08
protective O 0 3.744883656509046e-07
alleles O 0 6.147722331206751e-08
that O 0 1.983470498956308e-09
prevent O 0 1.5011259790753684e-08
or O 0 9.421294855371798e-09
reduce O 0 8.854168065397516e-09
the O 0 7.678473856742585e-09
risk O 0 2.755311534485827e-08
of O 0 5.2702038288998665e-08
developing O 0 3.078403551626252e-06
BPAD B-Disease 1 1.0
, O 0 9.211199802905412e-09
similar O 0 2.507877239210643e-09
to O 0 2.3443182950444452e-09
what O 0 2.8266067264581807e-09
is O 0 1.2626282241967601e-09
observed O 0 3.5546694476806806e-09
in O 0 1.792586079574221e-09
other O 0 7.945370583684053e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 4.7867466435036476e-08
we O 0 9.284877755533216e-09
used O 0 1.077568541063556e-07
mental O 1 0.5973383188247681
health O 0 0.0007286945474334061
wellness O 0 1.2623115253518336e-05
( O 0 4.087820926201857e-08
absence O 0 2.7327831730872276e-07
of O 0 5.4389190040637914e-08
any O 0 2.8114382644162106e-07
psychiatric B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9996222257614136
) O 0 1.2060643150846317e-08
as O 0 1.0140768225141983e-08
the O 0 4.928801367043434e-09
phenotype O 0 6.330905932827591e-08
in O 0 1.2686978578813068e-08
our O 0 1.2148170469572506e-07
genome O 0 3.970642978856631e-07
- O 0 1.9157973838446196e-06
wide O 0 1.361778458885965e-06
linkage O 0 3.6168778478895547e-06
scan O 0 4.475469381759467e-07
of O 0 6.44174988906343e-08
several O 0 7.911256005854739e-08
large O 0 2.3189710418591858e-07
multigeneration O 0 1.1073929272242822e-05
Old O 0 6.343918244056113e-07
Order O 0 1.954093988842942e-07
Amish O 0 3.306072585473885e-06
pedigrees O 0 2.4662685973453335e-06
exhibiting O 0 1.1021849104508874e-06
an O 0 4.240814277522986e-08
extremely O 0 2.9250006150505214e-07
high O 0 1.611853235772287e-06
incidence O 0 8.995284588309005e-06
of O 0 4.711043402494397e-06
BPAD B-Disease 1 1.0
. O 0 4.069787610205822e-05

We O 0 1.422782816007384e-06
have O 0 1.1821306600268144e-07
found O 0 7.154861947356039e-08
strong O 0 5.192912411189354e-08
evidence O 0 1.0161934227426173e-07
for O 0 2.656223863084506e-08
a O 0 6.810270747337199e-08
locus O 0 3.8773612232034793e-07
on O 0 2.9348919383664906e-07
chromosome O 0 1.7347250604871078e-06
4p O 0 6.85227059875615e-05
at O 0 1.5470930065930588e-06
D4S2949 O 0 7.017731149971951e-06
( O 0 1.6432400684607273e-07
maximum O 0 1.220785975419858e-06
GENEHUNTER O 0 0.00016359738947357982
- O 0 8.084401997621171e-06
PLUS O 0 6.4866312641242985e-06
nonparametric O 0 8.11074369266862e-06
linkage O 0 5.155664894118672e-06
score O 0 1.3703586319024907e-06
= O 0 1.5523885394941317e-06
4 O 0 6.159336294331297e-07
. O 0 5.234909039586455e-08
05 O 0 2.4875657800293993e-06
, O 0 2.176197995140683e-07
P O 0 4.444328624231275e-06
= O 0 9.780391110325581e-07
5 O 0 2.6146747700295236e-07
. O 0 1.7243086958274034e-08
22 O 0 8.254034611354655e-08
x O 0 1.1818668355090267e-07
10 O 0 1.306902959186118e-07
( O 0 4.032236589068816e-08
- O 0 1.9052245647799282e-07
4 O 0 1.4058835517971602e-07
) O 0 8.475822710352077e-09
; O 0 2.0660865018840013e-08
SIBPAL O 0 5.7067154557444155e-06
Pempirical O 0 1.3443200259644073e-06
value O 0 7.229294141097853e-08
< O 0 9.541376044808203e-08
3 O 0 7.289858672265837e-08
x O 0 4.6099852823999754e-08
10 O 0 3.119623315228637e-08
( O 0 1.2130315418801274e-08
- O 0 5.683567394498823e-08
5 O 0 2.3793848669129147e-08
) O 0 1.7255449291653235e-09
) O 0 8.265653717032251e-10
and O 0 1.2374701263695442e-09
suggestive O 0 1.1694950785567926e-08
evidence O 0 2.404710919279296e-08
for O 0 9.075071361053233e-09
a O 0 3.1055943594537894e-08
locus O 0 1.4132554326806712e-07
on O 0 3.2514836334485153e-07
chromosome O 0 2.2132639969640877e-06
4q O 0 2.8022832339047454e-05
at O 0 4.0609256757306866e-07
D4S397 O 0 5.591073659161339e-06
( O 0 1.1023020363154501e-07
maximum O 0 4.448380650501349e-07
GENEHUNTER O 0 9.604286606190726e-05
- O 0 6.575328370672651e-06
PLUS O 0 5.637919002765557e-06
nonparametric O 0 4.3296668081893586e-06
linkage O 0 3.890146217599977e-06
score O 0 1.0746812222350854e-06
= O 0 1.0901308087341022e-06
3 O 0 2.5533338998684485e-07
. O 0 3.508724333300961e-08
29 O 0 3.593463588913437e-07
, O 0 1.0213759082944307e-07
P O 0 1.4447323337662965e-06
= O 0 4.134966786750738e-07
2 O 0 1.0545820572360753e-07
. O 0 8.286162866966151e-09
57 O 0 4.395339203711046e-08
x O 0 7.094336496038522e-08
10 O 0 9.49870440081213e-08
( O 0 3.568645112750346e-08
- O 0 1.934574385131782e-07
3 O 0 1.1145556300107273e-07
) O 0 9.642985077107369e-09
; O 0 2.8033440457875258e-08
SIBPAL O 0 6.37868879493908e-06
Pempirical O 0 1.0831998906724039e-06
value O 0 3.775759793711586e-08
< O 0 7.772516852355693e-08
1 O 0 3.3417705935789854e-08
x O 0 4.683904109015202e-08
10 O 0 3.8888739339881795e-08
( O 0 1.4936915704311104e-08
- O 0 5.4922729475492815e-08
3 O 0 4.9793278833476506e-08
) O 0 1.21103349570717e-09
) O 0 3.186875763283581e-10
that O 0 2.407195553999486e-10
are O 0 1.7762223913919684e-09
linked O 0 2.0951375745426049e-07
to O 0 6.685812792284196e-08
mental O 1 0.9999910593032837
health O 1 0.9285855889320374
wellness O 0 0.00014837483467999846
. O 0 1.710931974230334e-05

These O 0 3.4794285852512985e-07
findings O 0 1.886373155457477e-07
are O 0 1.0145855711130025e-08
consistent O 0 4.492180138981894e-08
with O 0 2.605994309234916e-09
the O 0 3.809045967528846e-09
hypothesis O 0 3.9300196874592075e-08
that O 0 8.460409595123508e-10
certain O 0 1.256888637612974e-08
alleles O 0 4.7702499728075054e-08
could O 0 1.6727879526001743e-08
prevent O 0 5.768821509377631e-08
or O 0 9.771944142755729e-09
modify O 0 4.0815884005951375e-08
the O 0 4.561598743180184e-08
clinical O 0 3.181016268172243e-07
manifestations O 0 1.360710939479759e-05
of O 0 1.7671789009909844e-06
BPAD B-Disease 1 1.0
and O 0 1.365175705814181e-07
perhaps O 0 9.13368296551198e-08
other O 0 1.685667569972793e-07
related O 0 0.0009786898735910654
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.00011296992306597531

Segregation O 0 0.00045678220340050757
distortion O 0 0.017619453370571136
in O 0 2.5217865186277777e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0011656986316666007

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997562766075134
DM B-Disease 1 1.0
) O 0 5.237980644778872e-07
is O 0 9.958768920625971e-09
an O 0 8.394542838630059e-09
autosomal B-Disease 0 0.016155239194631577
dominant I-Disease 1 0.9999994039535522
disease I-Disease 1 0.9070387482643127
which O 0 4.052504554152847e-09
, O 0 1.7085771686353723e-09
in O 0 1.3376977303636295e-09
the O 0 6.4657261766853935e-09
typical O 0 4.744035919657108e-08
pedigree O 0 1.8788449551720987e-07
, O 0 1.5822180898794613e-08
shows O 0 1.993712217540633e-08
a O 0 2.5410631820932394e-08
three O 0 4.9575884730757025e-08
generation O 0 2.0497207060543587e-06
anticipation O 0 7.168895535869524e-06
cascade O 0 2.952396243927069e-05
. O 0 1.1890011592186056e-05

This O 0 1.3611081328690489e-07
results O 0 3.7513464690164255e-07
in O 0 2.0480057116856187e-07
infertility B-Disease 1 0.9999992847442627
and O 1 0.9993674159049988
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999935507774353
CDM B-Disease 1 0.8508285284042358
) O 0 7.319783446035899e-09
with O 0 1.2083984923805247e-09
the O 0 1.2317274311612891e-08
disappearance O 0 1.4827918448645505e-07
of O 0 5.751313665314228e-07
DM B-Disease 1 1.0
in O 0 2.1590999210729933e-07
that O 0 1.2379540237361653e-07
pedigree O 0 1.6996797057799995e-05
. O 0 8.83702978171641e-06

The O 0 1.6309792272295454e-06
concept O 0 8.683701366862806e-07
of O 0 4.1507152559461247e-07
segregation O 0 3.2846114663698245e-06
distortion O 0 1.1506705050123855e-05
, O 0 2.9606782803170972e-08
where O 0 1.1332907945416082e-08
there O 0 3.47471718065151e-09
is O 0 3.0132145667494115e-09
preferential O 0 3.2648188152961666e-08
transmission O 0 7.717901695514229e-08
of O 0 1.424214257639278e-08
the O 0 1.1865781246456208e-08
larger O 0 2.9325661898838007e-08
allele O 0 5.4414304173633354e-08
at O 0 3.0637046677384205e-08
the O 0 1.230572621579995e-07
DM B-Disease 1 1.0
locus O 0 2.3596535925207718e-07
, O 0 1.825622142348493e-08
has O 0 7.092060272384515e-09
been O 0 1.813129379968359e-08
put O 0 7.583507510844356e-08
forward O 0 2.6011872478193254e-07
to O 0 3.337216014642763e-08
explain O 0 5.234439868218033e-07
partially O 0 8.916417186810577e-07
the O 0 3.714209384497735e-08
maintenance O 0 3.080748172124004e-07
of O 0 4.458365481241344e-07
DM B-Disease 1 1.0
in O 0 6.325824131181434e-08
the O 0 1.8311257576897333e-07
population O 0 3.2352630796594894e-07
. O 0 1.8381134623268736e-06

In O 0 1.0783925290525076e-06
a O 0 2.3736447474220768e-07
survey O 0 4.6536982267753046e-07
of O 0 5.477938884723699e-07
DM B-Disease 1 1.0
in O 0 2.1010902173657087e-07
Northern O 0 4.994632831767376e-07
Ireland O 0 2.0907502573663805e-07
, O 0 2.830442156209756e-07
59 O 0 1.3376559309108416e-06
pedigrees O 0 7.74397085478995e-06
were O 0 2.4390938051510602e-06
ascertained O 0 5.798539859824814e-05
. O 0 2.0375615349621512e-05

Sibships O 0 8.643038017908111e-05
where O 0 3.066651572680712e-07
the O 0 5.138927505754509e-08
status O 0 4.0936729561735774e-08
of O 0 2.390333797563926e-08
all O 0 5.621014320666973e-09
the O 0 1.0948547846112433e-08
members O 0 4.441112810837922e-09
had O 0 5.250515577870374e-09
been O 0 2.93314639243647e-09
identified O 0 1.3522178043956501e-08
were O 0 9.482699070417766e-09
examined O 0 2.147644373451385e-08
to O 0 1.343953059951275e-09
determine O 0 1.2775465130232533e-08
the O 0 1.7604284252570324e-08
transmission O 0 1.8712843541379698e-07
of O 0 3.104729628944369e-08
the O 0 1.217924818774918e-07
DM B-Disease 1 1.0
expansion O 0 9.642461691328208e-07
from O 0 7.331831142209921e-08
affected O 0 5.936750824275805e-08
parents O 0 3.5349760452163537e-08
to O 0 4.098282246900453e-08
their O 0 3.698946784425061e-07
offspring O 0 1.820084435166791e-05
. O 0 1.4643501344835386e-05

Where O 0 3.753225200853194e-06
the O 0 1.2639162605410093e-06
transmitting O 0 4.453112342162058e-05
parent O 0 2.329795961486525e-06
was O 0 1.3368129430091358e-06
male O 0 9.832971272771829e-07
, O 0 6.093624165259826e-07
58 O 0 4.7209064177877735e-06
. O 0 2.940087597380625e-06

3 O 0 3.6822250422119396e-06
% O 0 5.9145531139392915e-08
of O 0 1.7928742934714137e-08
the O 0 1.264156690439222e-08
offspring O 0 5.454752027844734e-08
were O 0 3.639210532924153e-08
affected O 0 2.1966588548139043e-08
, O 0 5.28224708418179e-09
and O 0 2.709459323568808e-09
in O 0 2.3883637290111892e-09
the O 0 5.06236119690584e-09
case O 0 2.3100838575373928e-08
of O 0 2.2909178554186838e-08
a O 0 6.779503536336051e-08
female O 0 9.224597761203768e-07
transmitting O 0 8.549523954570759e-06
parent O 0 1.3446829143504146e-06
, O 0 1.0325186394766206e-06
68 O 0 7.80636037234217e-06
. O 0 6.337820195767563e-06

7 O 0 4.380265818326734e-05
% O 0 8.517197329638293e-07
were O 0 5.132085902914696e-07
affected O 0 1.6770087540862733e-06
. O 0 5.366116511140717e-06

Studies O 0 1.1377401278878096e-05
on O 0 1.8503421870263992e-06
meiotic O 0 1.2285009688639548e-05
drive O 0 1.5998102753655985e-06
in O 0 2.7080275799562514e-07
DM B-Disease 1 1.0
have O 0 2.1128444771534305e-08
shown O 0 1.4607859810666923e-08
increased O 0 3.6009981663198687e-09
transmission O 0 1.123703885497207e-08
of O 0 3.362560896391642e-09
the O 0 2.4628534767145993e-09
larger O 0 1.0298085051374528e-08
allele O 0 3.354389122023349e-08
at O 0 4.667316488848883e-08
the O 0 9.295601444136992e-08
DM B-Disease 1 0.9999979734420776
locus O 0 3.7655328810615174e-07
in O 0 9.223368380162356e-08
non O 0 1.916532710311003e-05
- O 0 0.0003930564853362739
DM O 1 1.0
heterozygotes O 0 4.5911783672636375e-05
for O 0 1.6359672372345813e-06
CTGn O 0 0.0004162376862950623
. O 0 1.8818927856045775e-05

This O 0 5.996233767291415e-07
study O 0 2.0758476182436425e-07
provides O 0 1.13727331552127e-07
further O 0 4.988025281704722e-08
evidence O 0 8.242660243240607e-08
that O 0 1.4291204664118595e-08
the O 0 4.752962183829368e-07
DM B-Disease 1 1.0
expansion O 0 5.266227162792347e-06
tends O 0 3.3069605365199095e-07
to O 0 2.652189223795176e-08
be O 0 1.0273134876115364e-07
transmitted O 0 1.8363560911893728e-06
preferentially O 0 3.3103824534919113e-06
. O 0 3.168761168126366e-06

Diagnosis O 0 0.017974505200982094
of O 0 0.013609987683594227
hemochromatosis B-Disease 1 1.0
. O 1 0.980473518371582

If O 0 2.2695066945743747e-05
untreated O 1 1.0
, O 0 6.470308107964229e-06
hemochromatosis B-Disease 1 1.0
can O 0 1.8533726233727066e-06
cause O 1 1.0
serious O 1 0.9999996423721313
illness O 1 0.9999947547912598
and O 0 2.749636252019627e-08
early B-Disease 0 2.967472028103657e-07
death I-Disease 0 3.202472385055444e-07
, O 0 7.228863729835666e-09
but O 0 4.487296756394699e-09
the O 0 5.149868087528375e-08
disease O 0 3.4574952678667614e-06
is O 0 9.629530950405751e-09
still O 0 2.4182057245525357e-08
substantially O 0 1.6758401955030422e-07
under O 0 6.777912062716496e-07
- O 0 0.0005366992554627359
diagnosed O 0 4.102465391042642e-05
. O 0 3.3798387448769063e-06

The O 0 8.979111044027377e-06
cornerstone O 0 7.135495252441615e-05
of O 0 4.766166341596545e-07
screening O 0 1.9256064831552067e-07
and O 0 2.9207097185235398e-08
case O 0 3.9013254848896395e-08
detection O 0 1.6659589618939208e-07
is O 0 5.1644724052835045e-09
the O 0 8.931036354908883e-09
measurement O 0 1.6022380577851436e-07
of O 0 2.2659759224552545e-07
serum O 0 9.349101333100407e-07
transferrin O 0 6.390183898474788e-06
saturation O 0 1.5810753666301025e-06
and O 0 1.5951849263728946e-07
the O 0 3.3982635727625166e-07
serum O 0 4.93400057166582e-06
ferritin O 0 4.3137071770615876e-05
level O 0 1.5568477465421893e-05
. O 0 6.479274361481657e-06

Once O 0 6.186095561133698e-06
the O 0 5.750321179220919e-07
diagnosis O 0 2.2866452127345838e-06
is O 0 6.448953371318566e-08
suspected O 0 2.0574800601025345e-06
, O 0 6.655442064129602e-08
physicians O 0 8.83052706512899e-08
must O 0 3.202117682121752e-08
use O 0 1.3166533108233125e-07
serum O 0 3.553821670720936e-06
ferritin O 0 3.8514019252033904e-05
levels O 0 8.098214721030672e-07
and O 0 3.1669620170760027e-07
hepatic O 1 0.9999924898147583
iron O 0 0.1638951599597931
stores O 0 1.151886294792348e-06
on O 0 1.6460569440823747e-07
liver O 0 1.1931069821002893e-06
biopsy O 0 5.8012837200749345e-08
specimens O 0 3.3161061452346985e-08
to O 0 2.9482796204405304e-09
assess O 0 6.201720736953575e-08
patients O 0 6.4289817913731895e-09
for O 0 6.357355086805683e-09
the O 0 4.311567636250402e-08
presence O 0 5.856242069057771e-07
of O 0 3.3290837109234417e-06
iron B-Disease 1 0.8717086911201477
overload I-Disease 1 0.9802556037902832
. O 0 5.428269287222065e-05

Liver O 0 0.027142804116010666
biopsy O 0 9.771593795449007e-06
is O 0 5.9404658969697266e-08
also O 0 8.850740584875894e-09
used O 0 3.920030966497734e-09
to O 0 3.2160287766203055e-09
establish O 0 3.808502668789515e-08
the O 0 3.594097108816641e-08
presence O 0 9.839352799190237e-08
or O 0 6.811218611346703e-08
absence O 0 2.4320372631336795e-06
of O 0 9.042157671501627e-07
cirrhosis B-Disease 1 0.9999998807907104
, O 0 2.2834667490201355e-08
which O 0 3.90905530167629e-09
can O 0 8.984136989909075e-09
affect O 0 6.314896268122538e-07
prognosis O 0 0.0014069390017539263
and O 0 1.2659056665142998e-06
management O 0 6.561822374351323e-06
. O 0 1.0638705134624615e-05

A O 0 4.280135271983454e-06
DNA O 0 1.66706024629093e-06
- O 0 5.047082822784432e-07
based O 0 4.210942705640264e-08
test O 0 4.125274344346508e-09
for O 0 9.490877417306365e-09
the O 0 9.252971011619593e-08
HFE O 0 5.5503740441054106e-05
gene O 0 5.756390564215508e-08
is O 0 4.207600934336142e-09
commercially O 0 1.4051028784933806e-08
available O 0 1.0191123500646881e-08
, O 0 2.341578930753485e-09
but O 0 1.9614767587938786e-09
its O 0 2.600517801099045e-09
place O 0 2.729747805574334e-08
in O 0 4.108886120235411e-09
the O 0 1.6037049022088468e-08
diagnosis O 0 1.715774487820454e-06
of O 0 2.7702142233465565e-06
hemochromatosis B-Disease 1 1.0
is O 0 7.62039292112604e-07
still O 0 5.860885039510322e-07
being O 0 3.8095927834547183e-07
evaluated O 0 1.455522010473942e-06
. O 0 2.7375485842640046e-06

Currently O 0 8.899596650735475e-07
, O 0 6.118068540672539e-08
the O 0 1.2052777442761453e-08
most O 0 6.241566818943056e-09
useful O 0 2.27072369796133e-08
role O 0 1.230433710475154e-08
for O 0 1.9243602267238202e-09
this O 0 6.570098909364219e-10
test O 0 2.2580981529074506e-09
is O 0 1.0333063293899158e-09
in O 0 8.265937934126555e-10
the O 0 3.181836349952505e-09
detection O 0 7.106579147375669e-08
of O 0 2.3838850893298513e-07
hemochromatosis B-Disease 1 1.0
in O 0 1.4587804741950094e-07
the O 0 8.068337820077431e-08
family O 0 2.2082867090489344e-08
members O 0 5.05892483460002e-09
of O 0 1.8667849488451793e-08
patients O 0 9.81153736034912e-09
with O 0 3.820468830184609e-09
a O 0 2.3188333031498587e-08
proven O 0 3.109773842879804e-07
case O 0 4.3301188412669944e-08
of O 0 7.297120419025305e-08
the O 0 9.59521116783435e-07
disease O 0 9.842134750215337e-05
. O 0 5.7977604228653945e-06

It O 0 4.907425932287879e-07
is O 0 1.1994349335964216e-07
crucial O 0 7.667251225029759e-07
to O 0 1.5911828654679994e-07
diagnose O 1 0.9999706745147705
hemochromatosis B-Disease 1 1.0
before O 1 0.9999990463256836
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 6.561884674738394e-06
because O 0 4.457765712118089e-08
phlebotomy O 0 1.4467162145592738e-05
therapy O 0 6.93331472234604e-08
can O 0 9.755313890025263e-09
avert O 0 0.0004766469937749207
serious O 1 0.9999995231628418
chronic O 1 1.0
disease O 1 1.0
and O 0 6.636755145450479e-09
can O 0 1.0740218714389016e-09
even O 0 8.310744092909772e-09
lead O 0 3.322259445326381e-08
to O 0 1.3878033833236714e-08
normal O 0 2.00552847218205e-07
life O 0 1.05952771889406e-07
expectancy O 0 6.330180895020021e-07
. O 0 1.9409462481689843e-07
. O 0 1.3538767689169617e-06

Prevalence O 0 4.564461050904356e-05
of O 0 1.1176055068062851e-06
the O 0 7.254488423313887e-07
I1307K O 0 2.0948664314346388e-05
APC B-Disease 0 1.6465859289382934e-06
gene O 0 4.313747226092346e-08
variant O 0 7.832356629933201e-08
in O 0 4.622370930462694e-09
Israeli O 0 1.2696546036750078e-07
Jews O 0 1.0086585433555229e-07
of O 0 1.010668704282125e-08
differing O 0 3.724077046740604e-08
ethnic O 0 1.61673909815363e-08
origin O 0 2.8435009014060597e-08
and O 0 1.608342614645153e-08
risk O 0 2.874790254736581e-07
for O 0 5.366146979213227e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.5712337699369527e-05

BACKGROUND O 0 0.0006309962482191622
& O 0 3.324236604385078e-05
AIMS O 0 1.0638837011356372e-05
Israeli O 0 2.3197992504719878e-06
Jews O 0 7.214761126306257e-07
of O 0 1.1642363517694321e-07
European O 0 3.562671224699443e-07
birth O 0 8.972767204795673e-07
, O 0 4.626616245673176e-08
i O 0 5.124929813860035e-08
. O 0 1.2664831849917846e-08
e O 0 2.195753978639914e-08
. O 0 7.81020048634673e-09
, O 0 1.7797363582872094e-08
Ashkenazim O 0 3.589768539313809e-06
, O 0 8.80185258012034e-09
have O 0 5.256468149639204e-09
the O 0 6.422671816608272e-08
highest O 1 0.8417487740516663
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 1.94273479792173e-06
of O 0 1.1210237182979199e-08
any O 0 1.558865037054602e-08
Israeli O 0 1.0336931381971226e-06
ethnic O 0 4.045348305226071e-07
group O 0 7.08678953742492e-07
. O 0 1.3518279047275428e-06

The O 0 4.1386749217053875e-05
I1307K O 0 0.0004263342416379601
APC B-Disease 0 2.0358871552161872e-05
gene O 0 7.162917654568446e-07
variant O 0 3.1274896628019633e-06
was O 0 2.998422417022084e-07
found O 0 9.368115172492253e-08
in O 0 1.8409784274808771e-07
6 O 0 6.281522018980468e-06
. O 0 3.3784790502977557e-06

1 O 0 9.402218893228564e-06
% O 0 9.200982731272234e-08
of O 0 3.9659081352283465e-08
American O 0 6.68169448658773e-08
Jews O 0 2.742707181369042e-07
, O 0 1.3272452470403096e-08
28 O 0 6.540035712987446e-08
% O 0 2.692633449541404e-09
of O 0 5.328420371597531e-09
their O 0 9.234475584207757e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.661123434359979e-07
, O 0 4.296665245817621e-09
but O 0 1.7489780734791793e-09
not O 0 3.765832090607546e-09
in O 0 3.408714377428623e-08
non O 0 1.160677129519172e-06
- O 0 3.133442760372418e-06
Jews O 0 1.3538739040086512e-05
. O 0 3.0802946184849134e-06

We O 0 1.164939817499544e-06
assessed O 0 2.0414997834450332e-06
the O 0 3.089336360062589e-07
I1307K O 0 9.573051102051977e-06
prevalence O 0 3.135805286547111e-07
in O 0 6.275480579631676e-09
Israeli O 0 1.1604420535604731e-07
Jews O 0 1.3592595848876954e-07
of O 0 6.21774365328065e-09
differing O 0 3.8709430327799055e-08
ethnic O 0 2.40260202843956e-08
origin O 0 3.835811668295719e-08
and O 0 1.9635590930988656e-08
risk O 0 3.697923887102661e-07
for O 0 2.6919653919321718e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.255990906036459e-06

METHODS O 0 3.830515197478235e-06
DNA O 0 6.429389145523601e-07
samples O 0 8.80214159337811e-08
from O 0 3.295846084938603e-08
500 O 0 5.5882630078940565e-08
unrelated O 0 6.516327744066075e-08
Jews O 0 8.282263053160932e-08
of O 0 1.933669935283433e-08
European O 0 7.203445306913636e-08
or O 0 1.7906801375033865e-08
non O 0 1.0554352769531761e-07
- O 0 4.0638614251520266e-08
European O 0 2.2341637873068976e-08
origin O 0 2.334240178925029e-08
, O 0 1.5042033174594849e-09
with O 0 1.3716946467567936e-09
or O 0 6.530908702728766e-09
without O 0 1.3716377367245514e-08
a O 0 2.0662557886907962e-08
personal O 0 1.825981286174283e-07
and O 0 1.1400228316915673e-07
/ O 0 2.8615806968446122e-06
or O 0 3.7121061779998854e-08
family O 0 2.2372297792117024e-08
history O 0 4.523769803199684e-08
of O 0 2.551505140502286e-08
neoplasia B-Disease 0 8.298522516270168e-06
, O 0 2.556152089994157e-08
were O 0 3.392246838984647e-08
examined O 0 8.354293612455876e-08
for O 0 1.846159314311535e-08
the O 0 4.060963476604229e-08
I1307K O 0 5.280739401314349e-07
variant O 0 5.7270515441132375e-08
by O 0 8.463867828822913e-09
the O 0 3.499634360082382e-08
allele O 0 1.3258744502309128e-07
- O 0 2.888123447064572e-07
specific O 0 1.2876148502982687e-07
oligonucleotide O 0 6.949095222807955e-06
( O 0 8.448160428997653e-07
ASO O 0 2.315521487616934e-05
) O 0 2.0171371772903512e-07
method O 0 9.93495973489189e-07
. O 0 2.8095107609260594e-06

RESULTS O 0 1.8890581486630253e-05
In O 0 3.2580359743406007e-07
persons O 0 4.6851727120156283e-07
at O 0 6.636377491986423e-08
average O 0 8.069876855643088e-08
risk O 0 1.2424496276253194e-07
for O 0 8.191697702386591e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.0747195489102523e-07
I1307K O 0 1.281355480386992e-06
was O 0 6.462055068823247e-08
found O 0 1.6905060462590882e-08
in O 0 4.8936012575495624e-08
5 O 0 1.1993301995971706e-06
. O 0 2.105213070535683e-06

0 O 0 1.2694486940745264e-05
% O 0 2.678866053429374e-07
of O 0 1.0075317646851545e-07
120 O 0 1.8023104075837182e-07
European O 0 3.3381493835804577e-07
and O 0 2.6742915792965505e-07
1 O 0 3.665575604827609e-06
. O 0 2.6895711471297545e-06

6 O 0 3.5313387343194336e-05
% O 0 3.0666163297610183e-07
of O 0 3.648587210136611e-07
188 O 0 7.04761760061956e-07
non O 0 7.924286364868749e-07
- O 0 8.869839120961842e-07
European O 0 1.0276020248056739e-06
Jews O 0 3.1652787129132776e-06
( O 0 3.69154946611161e-07
P O 0 3.08821608996368e-06
= O 0 1.2427666433723061e-06
0 O 0 6.312831146715325e-07
. O 0 8.087889824537342e-08
08 O 0 1.6985237607514136e-06
) O 0 4.057944806845626e-07
. O 0 1.4173954241414322e-06

It O 0 2.7806586331280414e-06
occurred O 0 7.823732630640734e-06
in O 0 1.302035457229067e-06
15 O 0 9.076440619537607e-06
. O 0 6.581369689229177e-06

4 O 0 1.6377221982111223e-05
% O 0 1.5110875040136307e-07
of O 0 1.16123459292794e-07
52 O 0 5.691496767212811e-07
Ashkenazi O 0 2.114962853738689e-06
Israelis O 0 6.022218030921067e-07
with O 0 8.533785944564443e-08
familial O 0 7.614690548507497e-05
cancer B-Disease 0 0.1213582307100296
( O 0 4.518570051459392e-07
P O 0 5.753114692197414e-06
= O 0 4.782024234373239e-07
0 O 0 1.757272514169017e-07
. O 0 8.182912125676012e-09
02 O 0 7.610140073666116e-08
) O 0 9.792779920303474e-10
and O 0 1.2304048890854347e-09
was O 0 5.035340144843303e-09
not O 0 1.0831683328049735e-09
detected O 0 2.577743529741383e-08
in O 0 8.22313772630423e-09
51 O 0 1.033457053267739e-07
non O 0 1.9022905917154276e-07
- O 0 1.218809018155298e-07
European O 0 2.241730499008554e-07
Jews O 0 9.920624961523572e-07
at O 0 1.3017532296544232e-07
increased O 0 4.2279120293642336e-07
cancer B-Disease 0 4.328382601670455e-06
risk O 0 1.1779009128076723e-06
. O 0 3.0542666991095757e-06

Colorectal B-Disease 1 0.9972646236419678
neoplasia I-Disease 1 0.9924350380897522
occurred O 0 1.162449007097166e-05
personally O 0 2.86486908862571e-07
or O 0 1.4753379851129012e-08
in O 0 2.833267398472117e-09
the O 0 4.402468611885979e-09
families O 0 6.284835762926377e-09
of O 0 1.9697408148999784e-08
13 O 0 7.225034437396971e-08
of O 0 3.723267383293205e-08
20 O 0 9.906919729019137e-08
Ashkenazi O 0 5.850743605151365e-07
I1307K O 0 1.0292615115758963e-06
carriers O 0 8.373229576363883e-08
, O 0 1.2577687336090548e-08
8 O 0 6.816339492843326e-08
of O 0 2.5485769938882186e-08
whom O 0 1.7764290305422037e-07
also O 0 8.582642152532571e-08
had O 0 2.8732792145547137e-08
a O 0 2.9511108223800875e-08
personal O 0 7.466034617209516e-07
or O 0 2.675681969321886e-07
family O 0 2.4879639681785193e-07
history O 0 9.741406756802462e-07
of O 0 1.5719508610345656e-06
noncolonic O 0 0.0015053070383146405
neoplasia B-Disease 1 0.9943211078643799
. O 0 4.102414459339343e-05

CONCLUSIONS O 0 9.181694622384384e-05
The O 0 3.330773097331985e-06
I1307K O 0 4.666918539442122e-05
APC O 0 3.971316345996456e-06
variant O 0 7.974146569722507e-07
may O 0 2.1009254780324227e-08
represent O 0 1.8755430986061583e-08
a O 0 1.015600226139668e-08
susceptibility O 0 8.223486958058857e-08
gene O 0 4.093688588113764e-08
for O 0 8.484641256245595e-08
colorectal B-Disease 1 1.0
, I-Disease 0 2.4163337997151757e-08
or I-Disease 0 9.814045576206354e-09
other I-Disease 0 2.5300126438310144e-08
, I-Disease 0 1.448859698882643e-08
cancers I-Disease 0 2.975080235501082e-07
in O 0 5.694925864219158e-09
Ashkenazi O 0 2.3727423013042426e-06
Jews O 0 4.347487447375897e-06
, O 0 2.6134673092315097e-08
and O 0 3.7579702905077284e-08
partially O 0 3.389987170976383e-07
explains O 0 3.526060154968036e-08
the O 0 5.959563065260909e-09
higher O 0 5.922421308923731e-08
incidence O 0 9.691775630926713e-07
of O 0 1.7799609395297011e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 4.7133351444017535e-08
European O 0 4.6638547246402595e-07
Israelis O 0 1.416976488144428e-06
. O 0 3.345388222442125e-06

Systematic O 0 3.98614884034032e-06
analysis O 0 1.3242218983577914e-06
of O 0 1.0309699973731767e-06
coproporphyrinogen O 0 6.910364027135074e-05
oxidase O 0 4.438189716893248e-05
gene O 0 7.95450177974999e-05
defects O 1 0.9999996423721313
in O 0 7.570586149086012e-07
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999994039535522
and O 0 6.361087230288831e-07
mutation O 0 7.034798841232259e-07
update O 0 9.296553798776586e-06
. O 0 4.957965757057536e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999998807907104
( O 0 3.8711095839971676e-05
HC B-Disease 1 1.0
) O 0 1.2541639193841547e-07
is O 0 1.0673161021657052e-08
an O 0 1.933356408301279e-08
acute O 1 0.9999955892562866
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 6.735199713148177e-05
autosomal O 1 0.9999998807907104
dominant O 1 0.9999994039535522
inheritance O 0 6.278419277805369e-06
caused O 0 3.558538708148262e-07
by O 0 3.224912248356304e-08
deficient B-Disease 0 8.881053759068891e-07
activity I-Disease 0 8.527879913344805e-08
of I-Disease 0 1.798918844997388e-07
coproporphyrinogen I-Disease 0 2.4042828954407014e-05
III I-Disease 1 0.9998685121536255
oxidase I-Disease 0 2.039754508587066e-05
( O 0 2.7976395813311683e-06
CPO O 0 8.539159898646176e-05
) O 0 9.863570085144602e-07
. O 0 1.7331540220766328e-06

Clinical O 0 3.690070298034698e-05
manifestations O 0 0.00809822604060173
of O 0 7.562922519355197e-07
the O 0 3.973995887918136e-07
disease O 0 0.0842319056391716
are O 0 1.3798607811921215e-09
characterized O 0 3.9934677786845896e-09
by O 0 2.517500652388094e-09
acute O 0 0.019423462450504303
attacks O 0 2.0237887099483487e-07
of O 0 0.00014139800623524934
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 3.223898374926648e-07
precipitated O 0 2.0907584996621154e-07
by O 0 7.83072451326916e-09
drugs O 0 1.4430368366902258e-07
, O 0 4.177631041102359e-08
fasting O 0 3.3894306739057356e-07
, O 0 9.28369487951386e-08
cyclical O 0 0.0011380676878616214
hormonal O 0 5.3980415941623505e-06
changes O 0 1.966164120403846e-07
, O 0 2.3588120257045375e-07
or O 0 2.130583425241639e-06
infectious B-Disease 1 0.9999198913574219
diseases I-Disease 1 0.9999030828475952
. O 0 1.2679181054409128e-05

Skin O 1 0.9999998807907104
photosensitivity O 1 0.9999997615814209
may O 0 2.7084845442004735e-06
also O 0 1.5943787445849011e-07
be O 0 6.413833375518152e-08
present O 0 5.517608201444091e-07
. O 0 2.504241820133757e-06

The O 0 5.129015789862024e-06
seven O 0 1.6456235698569799e-06
exons O 0 4.7210996854119e-06
, O 0 1.806626244160725e-07
the O 0 2.686231255211169e-07
exon O 0 4.4962444007978775e-06
/ O 0 3.7302588680176996e-06
intron O 0 5.1636466196214315e-06
boundaries O 0 1.2376081315323972e-07
and O 0 4.192702363070566e-08
part O 0 4.4986709468730623e-08
of O 0 8.573578469395216e-08
3 O 0 2.864912858058233e-07
noncoding O 0 2.122656468372952e-07
sequence O 0 2.5458852803694754e-08
of O 0 6.871097468774678e-08
the O 0 1.826428928097812e-07
CPO O 0 5.835503088746918e-06
gene O 0 1.0817819173780663e-07
were O 0 1.1685745704426154e-07
systematically O 0 1.1109686681720632e-07
analyzed O 0 4.277696419308086e-08
by O 0 6.804360186407621e-09
an O 0 1.5028934541305716e-08
exon O 0 2.7402549562793865e-07
- O 0 3.479063366285118e-07
by O 0 1.9996214462025819e-07
- O 0 4.415911917021731e-06
exon O 0 5.678350589732872e-06
denaturing O 0 2.6219704523100518e-05
gradient O 0 7.272079528775066e-06
gel O 0 7.3239311859651934e-06
electrophoresis O 0 4.891179287369596e-06
( O 0 7.52247558466479e-07
DGGE O 0 7.51576226321049e-05
) O 0 1.4851491592082766e-08
strategy O 0 1.1340865135878175e-08
followed O 0 7.84799514264023e-09
by O 0 1.6159306115426375e-09
direct O 0 9.968612602051508e-09
sequencing O 0 1.4364005096467736e-08
in O 0 4.497733296915385e-09
seven O 0 1.9143159946111155e-08
unrelated O 0 2.2357183127041935e-07
heterozygous O 0 1.94803746467187e-07
HC B-Disease 0 0.1724250614643097
patients O 0 7.14700547632674e-08
from O 0 5.563122229546025e-08
France O 0 2.2160381263347517e-07
, O 0 4.593992386503487e-08
Holland O 0 2.5997485408879584e-07
, O 0 3.3107152574984866e-08
and O 0 6.137388197657856e-08
Czech O 0 2.629764367156895e-06
Republic O 0 8.300485205836594e-06
. O 0 1.1993828593404032e-05

Seven O 0 7.083734544721665e-06
novel O 0 1.740923380566528e-06
mutations O 0 7.694573582739395e-07
and O 0 8.788084215893832e-08
two O 0 8.137079987591278e-08
new O 0 1.1648461395452614e-07
polymorphisms O 0 4.138842996326275e-06
were O 0 1.1145783673782717e-06
detected O 0 6.086548637540545e-06
. O 0 3.640790964709595e-06

Among O 0 1.76298419773957e-06
these O 0 1.5927041374652617e-07
mutations O 0 1.8848318461550662e-07
two O 0 6.835947630179362e-08
are O 0 2.8362103776657932e-08
missense O 0 1.9475430690363282e-06
( O 0 2.8155702125332027e-07
G197W O 0 9.572101589583326e-06
, O 0 1.2002210780792666e-07
W427R O 0 1.6793741224319092e-06
) O 0 1.6637004662811705e-08
, O 0 6.935467755653235e-09
two O 0 9.908616149800764e-09
are O 0 1.2111381231250107e-08
nonsense O 0 1.154606138698e-06
( O 0 2.5134676207017037e-07
Q306X O 0 1.0399866368970834e-05
, O 0 1.209907907195884e-07
Q385X O 0 2.2826100121164927e-06
) O 0 8.885923996615475e-09
, O 0 6.013594955334156e-09
two O 0 6.77942324500691e-09
are O 0 8.664119199863762e-09
small O 0 7.426552173228629e-08
deletions O 0 6.802857228649373e-07
( O 0 2.309450195525642e-07
662de14bp O 0 3.979756002081558e-06
; O 0 8.772542514634551e-08
1168del3bp O 0 2.191985231547733e-06
removing O 0 2.481218075445213e-07
a O 0 6.136873764717166e-08
glycine O 0 2.1627495527809515e-07
at O 0 1.0098174385575476e-07
position O 0 1.0365602776118976e-07
390 O 0 1.7896478254897374e-07
) O 0 3.300644424442112e-09
, O 0 3.4067173526608485e-09
and O 0 4.148448251584114e-09
one O 0 9.229101927132888e-09
is O 0 3.2398306260006393e-09
a O 0 1.6597546448338107e-08
splicing O 0 5.265039817459183e-07
mutation O 0 2.3000009718998626e-07
( O 0 3.3241616392842843e-07
IVS1 O 0 5.6568231229903176e-05
- O 0 4.921973868476925e-06
15c O 0 1.141153188655153e-05
- O 0 1.7268270084969117e-06
- O 0 1.0049300271930406e-06
> O 0 3.1332734806710505e-07
g O 0 1.6697063642823196e-07
) O 0 1.5010714449203988e-08
which O 0 4.234749884091116e-09
creates O 0 3.351511068672153e-08
a O 0 2.25972343059766e-08
new O 0 9.09767408074913e-08
acceptor O 0 3.405885763640981e-06
splice O 0 9.323923586634919e-05
site O 0 2.01953953364864e-05
. O 0 1.2257918569957837e-05

The O 0 2.7562896320887376e-06
pathological O 0 1.8591243133414537e-05
significance O 0 5.800398412247887e-06
of O 0 4.621897744527814e-07
the O 0 3.688948879698728e-07
point O 0 9.84824851002486e-07
mutations O 0 3.9024385500852077e-07
G197W O 0 5.810768470837502e-06
, O 0 8.183758382074302e-08
W427R O 0 1.4862621355860028e-06
, O 0 1.8995489625694972e-08
and O 0 9.870531947342442e-09
the O 0 5.65951943087839e-08
in O 0 7.531254908599294e-08
- O 0 6.268347192417423e-07
frame O 0 7.124133389879717e-07
deletion O 0 1.0234040814793843e-07
390delGly O 0 5.104706701786199e-07
were O 0 3.578487195454727e-08
assessed O 0 7.860867157205575e-08
by O 0 6.011106723491366e-09
their O 0 1.3311825419748402e-08
respective O 0 4.4707127244691947e-07
expression O 0 1.2477788402520673e-07
in O 0 1.4856703423049566e-08
a O 0 2.280124178355436e-08
prokaryotic O 0 1.7540676822136447e-07
system O 0 5.839305927679561e-08
using O 0 7.586994144048731e-08
site O 0 9.913239864545176e-07
- O 0 2.3945126486069057e-06
directed O 0 1.3669337022292893e-06
mutagenesis O 0 4.2014988139271736e-05
. O 0 1.0701029168558307e-05

These O 0 4.5896268829892506e-07
mutations O 0 4.968858888787508e-07
resulted O 0 2.910675505063409e-07
in O 0 1.6292329263478678e-08
the O 0 2.172802737732127e-08
absence O 0 1.0385710424998251e-07
or O 0 1.8830778714118424e-08
a O 0 1.4875758402865813e-08
dramatic O 0 1.8179312633037625e-07
decrease O 0 2.957112599233369e-07
of O 0 6.267988510444411e-07
CPO O 0 0.0002556122781243175
activity O 0 5.64140918868361e-06
. O 0 8.446488209301606e-06

The O 0 1.4320027048597694e-06
two O 0 3.633531093782949e-07
polymorphisms O 0 2.604476094347774e-06
were O 0 2.2710101177381148e-07
localized O 0 8.095682346720423e-07
in O 0 2.5691880622957797e-08
noncoding O 0 4.108363498289691e-07
part O 0 2.995897929736202e-08
of O 0 4.886866733500028e-08
the O 0 6.361287319123221e-08
gene O 0 5.97990137407578e-08
1 O 0 1.9542299867225665e-07
) O 0 8.691827702023147e-09
a O 0 3.261918735120162e-08
C O 0 1.4659644875791855e-06
/ O 0 3.7925991591691854e-07
G O 0 7.525711680500535e-07
polymorphism O 0 1.3527420605896623e-07
in O 0 2.8778536886875372e-08
the O 0 1.0577588938076588e-07
promotor O 0 1.5797211744938977e-05
region O 0 9.609404969523894e-07
, O 0 1.8327294526443438e-07
142 O 0 5.747519367105269e-07
bp O 0 7.337671377172228e-07
upstream O 0 1.183203835353197e-06
from O 0 8.854458855012126e-08
the O 0 1.83475449944126e-07
transcriptional O 0 1.215066617987759e-06
initiation O 0 5.595408083536313e-07
site O 0 6.474608085227374e-07
( O 0 1.3486985039889987e-07
- O 0 1.2025576552332495e-06
142C O 0 8.318528671225067e-06
/ O 0 8.873138312992523e-07
G O 0 1.1464438784969389e-06
) O 0 1.7519637296459223e-08
, O 0 5.590637730534809e-09
and O 0 9.879498108489315e-09
2 O 0 5.528385216280185e-08
) O 0 2.794549924800549e-09
a O 0 1.4015803628808499e-08
6 O 0 8.807482743122819e-08
bp O 0 3.34655432254749e-08
deletion O 0 1.2964997075926021e-08
polymorphism O 0 7.683868830099527e-08
in O 0 1.049957454313244e-08
the O 0 3.215833999092865e-08
3 O 0 8.671414519767495e-08
noncoding O 0 1.9336448531248607e-07
part O 0 1.570021801455823e-08
of O 0 3.7946605857541726e-08
the O 0 1.0038469611117762e-07
CPO O 0 1.0690410817915108e-05
gene O 0 1.9629004555099527e-07
, O 0 9.342686979607606e-08
574 O 0 1.4098525298322784e-06
bp O 0 2.955463287435123e-07
downstream O 0 6.770288791813073e-07
of O 0 6.566546773001392e-08
the O 0 4.261458030896392e-08
last O 0 2.8266136098409333e-08
base O 0 1.3163821677153464e-07
of O 0 2.61920618527256e-08
the O 0 5.5026955436687786e-08
normal O 0 1.763568207024946e-07
termination O 0 8.922354481910588e-07
codon O 0 7.523905424022814e-06
( O 0 2.625524075483554e-06
+ O 0 9.377476999361534e-06
574 O 0 1.9990366126876324e-05
delATTCTT O 0 4.201834963168949e-05
) O 0 1.9387350675970083e-06
. O 0 4.911601536150556e-06

Five O 0 1.5388322935905308e-05
intragenic O 0 0.00010886452946579084
dimorphisms O 0 4.1470309952273965e-05
are O 0 8.47726511210567e-08
now O 0 2.6648914186466754e-08
well O 0 1.2209934396878452e-08
characterized O 0 1.868266785720607e-08
and O 0 6.8835044331194695e-09
the O 0 1.797215531951224e-08
high O 0 6.336825464359208e-08
degree O 0 4.792648056195503e-08
of O 0 3.692968064683555e-08
allelic O 0 1.5492870488742483e-06
heterogeneity O 0 2.691477675398346e-06
in O 0 1.377148493020286e-07
HC B-Disease 1 0.9999986886978149
is O 0 1.9062454725826683e-08
demonstrated O 0 1.667232929492002e-08
with O 0 2.266603127409894e-09
seven O 0 5.646803913350595e-09
new O 0 2.5148130244900813e-09
different O 0 1.973489149875718e-09
mutations O 0 9.02351615650332e-09
making O 0 6.335965085924045e-09
a O 0 3.783889646058469e-09
total O 0 7.958548486897143e-09
of O 0 3.743247845022779e-08
nineteen O 0 6.742538062098902e-06
CPO O 0 0.0010438626632094383
gene B-Disease 0 3.180101884936448e-06
defects I-Disease 0 0.06595849245786667
reported O 0 3.385405875633296e-07
so O 0 2.6051958812445264e-08
far O 0 1.471783264150872e-07
. O 0 1.9552759056296054e-07
. O 0 1.644349822527147e-06

Coincidence O 0 3.868227213388309e-05
of O 0 1.4127610938885482e-06
two O 0 3.1821812740417954e-07
novel O 0 4.883661972598929e-07
arylsulfatase O 0 6.642894277320011e-06
A O 0 3.4088941447407706e-07
alleles O 0 1.6448628059606563e-07
and O 0 1.3205580273734085e-07
mutation O 0 3.618384596393298e-07
459 O 0 1.2922602081744117e-06
+ O 0 1.2840675935876789e-06
1G O 0 1.7017460777424276e-05
> O 0 4.314776163028e-07
A O 0 1.2049002862113412e-07
within O 0 1.6332061036905543e-08
a O 0 1.1000165223151726e-08
family O 0 4.325520919223891e-08
with O 0 5.119868973224584e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 3.9503255777617596e-08
molecular O 0 1.4092259448261757e-07
basis O 0 1.0750024159733584e-07
of O 0 7.137523994060757e-08
phenotypic O 0 2.2661474758933764e-06
heterogeneity O 0 7.291654037544504e-05
. O 0 1.4749751244380604e-05

In O 0 6.799588163630688e-07
a O 0 2.225747266493272e-07
family O 0 1.4213082977221347e-07
with O 0 1.959600481882262e-08
three O 0 8.508934712381233e-08
siblings O 0 1.239190055457584e-06
, O 0 3.2239285019386443e-08
one O 0 1.7270242125277946e-08
developed O 0 4.676923026636359e-08
classical O 0 1.209126253343129e-06
late O 0 1.3819857485941611e-05
infantile O 1 0.9999942779541016
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.862055680452613e-06
MLD B-Disease 1 1.0
) O 0 3.63906522693469e-08
, O 0 1.7546724961903237e-08
fatal O 0 2.2255264298109978e-07
at O 0 5.124421775803967e-08
age O 0 8.216102287406102e-08
5 O 0 7.021856163191842e-08
years O 0 9.446035953430965e-09
, O 0 9.550912949407575e-09
with O 0 1.2311802244369119e-08
deficient O 0 2.510303374947398e-06
arylsulfatase O 0 1.3401098840404302e-05
A O 0 3.305744940007571e-06
( O 0 6.060537316443515e-07
ARSA O 0 5.656925350194797e-05
) O 0 3.9214537395082516e-08
activity O 0 4.6056964464469274e-08
and O 0 4.058648173099755e-08
increased O 0 3.0456638455689244e-07
galactosylsulfatide O 0 4.325150803197175e-05
( O 0 2.7580697405937826e-06
GS O 1 1.0
) O 0 1.0819619546964532e-06
excretion O 0 6.521054729091702e-06
. O 0 2.7617468276730506e-06

The O 0 2.0777897589141503e-06
two O 0 2.483938317254797e-07
other O 0 2.456011429785576e-07
siblings O 0 2.5348754206788726e-06
, O 0 1.8094644360644452e-07
apparently O 0 7.987122785380052e-07
healthy O 0 2.6836835331778275e-07
at O 0 1.2751587519232999e-07
12 O 0 8.839019471906795e-08
( O 0 1.7546792463463134e-08
1 O 0 1.0453199905668953e-07
/ O 0 7.133373003398447e-08
2 O 0 4.219706539743129e-08
) O 0 1.5084093973882773e-09
and O 0 1.3602413639901556e-09
15 O 0 7.906244547939423e-09
years O 0 3.882409504996076e-09
, O 0 3.1235747322000407e-09
respectively O 0 8.716032340316815e-09
, O 0 2.2845154656891964e-09
and O 0 4.390753982619344e-09
their O 0 9.559406599635167e-09
father O 0 6.64092283386708e-07
, O 0 7.956958114618828e-08
apparently O 0 4.642948283617443e-07
healthy O 0 7.44780166428427e-08
as O 0 2.6303300870722524e-08
well O 0 4.252307661545274e-08
, O 0 6.771606564370813e-08
presented O 0 2.0744796529470477e-06
ARSA O 0 0.024829046800732613
and O 0 8.786455509834923e-07
GS O 1 1.0
values O 0 1.9975401244209934e-07
within O 0 4.5028084372233934e-08
the O 0 5.2403134276346464e-08
range O 0 5.233301862972439e-07
of O 0 9.425725693290588e-07
MLD B-Disease 1 1.0
patients O 0 1.5449430065928027e-05
. O 0 1.098114353226265e-05

Mutation O 0 1.8874451370720635e-06
screening O 0 2.0545219570067275e-07
and O 0 1.1933326327095983e-08
sequence O 0 1.2663238457832904e-08
analysis O 0 2.138104804316754e-08
disclosed O 0 8.802813766806139e-08
the O 0 1.9368110670825445e-08
involvement O 0 7.194890372375085e-08
of O 0 4.052398239196009e-08
three O 0 2.237020702011705e-08
different O 0 9.200351058780143e-08
ARSA O 0 0.0003193466109223664
mutations O 0 1.6312236539306468e-07
being O 0 3.667991421707484e-08
the O 0 1.0600124333848271e-08
molecular O 0 1.5126100549878174e-07
basis O 0 9.741707174271141e-08
of O 0 1.4967250194786175e-07
intrafamilial O 0 5.5864937166916206e-05
phenotypic O 0 2.3224743927130476e-05
heterogeneity O 0 0.00022318003175314516
. O 0 3.52403185388539e-05

The O 0 4.935045126330806e-06
late O 0 7.184128480730578e-05
infantile O 1 0.9983385801315308
patient O 0 7.26541793483193e-06
inherited O 0 0.0036304749082773924
from O 0 8.308296628456446e-07
his O 0 3.4004162330347754e-07
mother O 0 3.060028745949239e-07
the O 0 1.7228597926077782e-07
frequent O 0 2.5635691258685256e-07
0 O 0 6.683403057650139e-07
- O 0 4.4737367943525896e-07
type O 0 5.571415044869354e-07
mutation O 0 2.5476541054558766e-07
459 O 0 1.07756909528689e-06
+ O 0 4.3135995042575814e-07
1G O 0 4.032139258924872e-06
> O 0 1.1482478612379055e-07
A O 0 6.1565692988097e-08
, O 0 4.898922156826302e-09
and O 0 3.0266644746035354e-09
from O 0 6.219522674655309e-09
his O 0 2.1289366713972413e-08
father O 0 9.758518615399225e-08
a O 0 2.453365155474785e-08
novel O 0 6.284286513391635e-08
, O 0 2.5149198279450502e-08
single O 0 1.3236559937013226e-07
basepair O 0 7.431536232616054e-06
microdeletion O 0 1.0448597095091827e-05
of O 0 3.921951758911746e-07
guanine O 0 2.495449734851718e-06
at O 0 4.0342641227653075e-07
nucleotide O 0 1.2552185353342793e-06
7 O 0 7.052451564959483e-07
in O 0 8.162355413787736e-08
exon O 0 2.193532964156475e-06
1 O 0 2.9469424589478876e-06
( O 0 4.5096416556589247e-07
7delG O 0 6.605421731364913e-06
) O 0 5.567797529693053e-07
. O 0 2.4894952730392106e-06

The O 0 3.1440870316146174e-06
two O 0 1.0676366173356655e-06
clinically O 0 0.005027302540838718
unaffected O 0 6.75668024996412e-06
siblings O 0 1.0311626965631149e-06
carried O 0 2.5997709940384084e-07
the O 0 1.3709556867524952e-07
maternal O 0 2.2196793452167185e-06
mutation O 0 3.1412500334226934e-07
459 O 0 1.2286757282709004e-06
+ O 0 4.226388625738764e-07
1G O 0 2.692584075703053e-06
> O 0 9.865887307114463e-08
A O 0 7.18755259754289e-08
and O 0 9.720247717837083e-09
, O 0 4.5205763576916524e-09
on O 0 1.0434610508980313e-08
their O 0 6.633705140757229e-09
paternal O 0 4.993308948542108e-07
allele O 0 1.1541411737425733e-07
, O 0 2.9686061608913406e-08
a O 0 1.9511380955350432e-08
novel O 0 6.53700524821943e-08
cytosine O 0 1.0169205921783941e-07
to O 0 2.3056598408288664e-08
thymidine O 0 1.854426500358386e-06
transition O 0 4.6837789113851613e-07
at O 0 2.919543931056978e-07
nucleotide O 0 2.662166480149608e-06
2435 O 0 1.716642509563826e-05
in O 0 5.371034106360639e-08
exon O 0 1.0640778782544658e-06
8 O 0 1.9801700545940548e-07
, O 0 1.384253067726604e-08
resulting O 0 1.3209012550419175e-08
in O 0 5.90420334845021e-09
substitution O 0 1.5049623414142843e-07
of O 0 2.2175561298354296e-07
alanine O 0 2.2250796973821707e-06
464 O 0 1.9537171738193138e-06
by O 0 2.8578668320733414e-07
valine O 0 7.667986210435629e-05
( O 0 3.4839549698517658e-06
A464V O 0 7.541536615462974e-05
) O 0 2.0881768705294235e-06
. O 0 3.3873704978759633e-06

The O 0 1.1147994882776402e-05
fathers O 0 1.3608069821202662e-05
genotype O 0 6.755081813025754e-06
thus O 0 2.3112377220968483e-06
was O 0 2.765035787888337e-06
7delG O 0 6.276871135924011e-05
/ O 0 7.388998346868902e-05
A464V O 0 0.0002451298350933939
. O 0 1.9076869648415595e-05

Mutation O 0 6.462630608439213e-06
A464V O 0 4.247059769113548e-05
was O 0 2.139969836889577e-07
not O 0 7.503750509840756e-09
found O 0 1.7945712471600928e-08
in O 0 1.2052663755923732e-08
18 O 0 2.1212743206433515e-07
unrelated O 0 7.42598876968259e-06
MLD B-Disease 1 1.0
patients O 0 2.6451220946910325e-07
and O 0 9.074313567225545e-08
50 O 0 2.60092406279e-07
controls O 0 9.82127517090703e-07
. O 0 1.8620910395839019e-06

A464V O 0 0.0005086992750875652
, O 0 1.222582454829535e-06
although O 0 5.000719056624803e-07
clearly O 0 8.514996352460003e-07
modifying O 0 6.3861816670396365e-06
ARSA O 1 0.9996169805526733
and O 0 1.5264303101503174e-06
GS O 1 1.0
levels O 0 2.0426798528205836e-06
, O 0 5.509458844699111e-08
apparently O 0 1.931490345441489e-07
bears O 0 1.7909435428009601e-06
little O 0 4.3422765827472176e-08
significance O 0 4.081246629539237e-07
for O 0 3.505981638340927e-08
clinical O 0 7.769772309984546e-07
manifestation O 0 0.000514976039994508
of O 0 2.221855720563326e-05
MLD B-Disease 1 1.0
, O 0 1.0818887403729605e-06
mimicking O 0 5.692159447789891e-06
the O 0 2.0575919279508526e-06
frequent O 0 1.978721411433071e-05
ARSA O 1 0.982879102230072
pseudodeficiency O 0 0.0007579525117762387
allele O 0 9.417318506166339e-05
. O 0 4.206164521747269e-05

Our O 0 4.282098871044582e-06
results O 0 6.7714250917561e-07
demonstrate O 0 1.6081040143944847e-07
that O 0 6.959040899090496e-09
in O 0 6.548271702655484e-09
certain O 0 3.04927567640334e-08
genetic O 0 9.573667512086104e-07
conditions O 0 5.064526249043411e-06
MLD B-Disease 1 1.0
- O 0 0.00314163975417614
like O 0 1.33348703457159e-06
ARSA O 1 0.9938380122184753
and O 0 4.906756316813699e-07
GS O 1 1.0
values O 0 6.055677914673652e-08
need O 0 1.0791024074308098e-08
not O 0 2.824644962373668e-09
be O 0 4.431855327169387e-09
paralleled O 0 1.2706841800991242e-07
by O 0 9.26964194292168e-09
clinical O 0 1.102871578950726e-06
disease O 0 2.1134601411176845e-05
, O 0 5.5359272721489106e-09
a O 0 5.092916754989574e-09
finding O 0 2.5527803870772914e-08
with O 0 8.599975842571439e-09
serious O 0 4.0517923594052263e-07
diagnostic O 0 5.0652120080485474e-06
and O 0 1.1045472092519049e-06
prognostic O 1 0.9999982118606567
implications O 0 0.00019405840430408716
. O 0 2.8019012461300008e-05

Moreover O 0 1.1057222764065955e-05
, O 0 7.516767368542787e-07
further O 0 3.340934426887543e-06
ARSA O 0 0.0003874185204040259
alleles O 0 1.114263795898296e-06
functionally O 0 5.595034622274397e-07
similar O 0 1.572836438867853e-08
to O 0 2.8412891595053225e-08
A464V O 0 1.736168201205146e-06
might O 0 7.877407171008599e-08
exist O 0 6.99194586673002e-08
which O 0 1.3166126855423954e-08
, O 0 7.838107052293708e-09
together O 0 8.227546643979622e-09
with O 0 1.1036143554576938e-08
0 O 0 4.2507144826231524e-07
- O 0 1.784337655408308e-07
type O 0 1.0170156627964388e-07
mutations O 0 1.0021214080779828e-07
, O 0 1.1994252702152153e-08
may O 0 3.165457940212946e-08
cause O 0 3.011627541127382e-06
pathological O 1 0.9976956248283386
ARSA O 1 1.0
and O 0 6.4611213019816205e-06
GS O 1 1.0
levels O 0 8.517814649167121e-07
, O 0 5.7578040113526185e-09
but O 0 7.518904387993075e-10
not O 0 1.150346817802017e-09
clinical O 0 2.7145610204115656e-08
outbreak O 0 8.552476060685876e-08
of O 0 4.5674060089595514e-08
the O 0 4.3854166165147035e-07
disease O 0 1.0160032616113313e-05
. O 0 1.9805969486696995e-07
. O 0 1.633666101952258e-06

Human O 1 0.9996071457862854
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 1 0.8784151077270508
to O 0 1.5718084114269004e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 0.9999618530273438
and O 0 1.055235543390154e-06
neurofibromatosis B-Disease 1 0.999998927116394
type I-Disease 0 0.00017934318748302758
1 I-Disease 0 5.390585647546686e-05
. O 0 3.2976556667563273e-06

Heterozygous O 0 2.8453041522880085e-05
germ O 1 0.5326305627822876
- O 0 4.584038470056839e-05
line O 0 1.5824842876099865e-06
mutations O 0 6.766235571831203e-08
in O 0 9.417952639978466e-09
the O 0 1.062556975739426e-08
DNA O 0 3.4613580623954476e-07
mismatch O 0 2.8934660804225132e-05
repair O 0 2.270560571560054e-06
genes O 0 4.7146386350505054e-07
lead O 0 4.728800604425487e-07
to O 0 3.1431227398570627e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.8502046663779765e-05

The O 0 4.002459263574565e-06
disease O 0 0.0001064127282006666
susceptibility O 0 3.7339250411605462e-06
of O 0 4.487367277761223e-07
individuals O 0 8.182166055803464e-08
who O 0 7.534824248978111e-07
constitutionally O 0 3.213333172880084e-07
lack O 0 1.8140502788810409e-07
both O 0 6.50454410333623e-08
wild O 0 4.5415407612381387e-07
- O 0 5.131092279953009e-07
type O 0 2.721057228427526e-07
alleles O 0 1.5388526719561924e-07
is O 0 8.625080027968579e-08
unknown O 0 2.860762378986692e-06
. O 0 3.1572990337735973e-06

We O 0 7.909111445769668e-07
have O 0 1.0477472756065254e-07
identified O 0 3.870674163408694e-07
three O 0 7.98111017275005e-08
offspring O 0 1.870891850330736e-07
in O 0 1.6945898906328694e-08
a O 0 1.0571981334805969e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.6229150168765045e-07
who O 0 4.2728281357540254e-08
developed O 0 2.767272917481023e-07
hematological B-Disease 1 0.9995470643043518
malignancy I-Disease 0 0.0072259060107171535
at O 0 4.9755019659869504e-08
a O 0 3.4565854623025416e-09
very O 0 2.4141215693163076e-09
early O 0 1.708727914717656e-08
age O 0 1.5158194699438354e-08
, O 0 4.483660553944446e-09
and O 0 5.590381935149935e-09
at O 0 1.0784111381667572e-08
least O 0 9.040329373988243e-09
two O 0 6.048461287377904e-09
of O 0 9.711018655877979e-09
them O 0 2.521048081405297e-08
displayed O 0 2.4104660951707046e-06
signs O 0 6.275941359490389e-06
of O 0 1.01303498922789e-06
neurofibromatosis B-Disease 1 0.9998694658279419
type I-Disease 0 4.533807441475801e-05
1 I-Disease 0 4.791941319126636e-05
( O 0 2.4215764824475627e-06
NF1 B-Disease 0 0.002338436432182789
) O 0 2.3289894670597278e-06
. O 0 6.098651283537038e-06

DNA O 0 3.76355478692858e-06
sequence O 0 1.7060777679489547e-07
analysis O 0 9.954063528994084e-08
and O 0 2.4851225077782146e-08
allele O 0 5.801040003916569e-08
- O 0 6.546612496549642e-08
specific O 0 1.2849168840034508e-08
amplification O 0 1.7150402698007383e-07
in O 0 1.4718921192979906e-08
two O 0 6.228167137578566e-08
siblings O 0 5.656562507283525e-07
revealed O 0 3.6893075616717397e-07
a O 0 5.285671704768902e-07
homozygous O 0 5.471295480674598e-06
MLH1 O 0 0.0002022881235461682
mutation O 0 9.67923142525251e-07
( O 0 5.621359946417215e-07
C676T O 0 7.151258159865392e-06
- O 0 3.501438868624973e-06
- O 0 3.463756002020091e-06
> O 0 3.1564650271320716e-06
Arg226Stop O 0 1.671943027758971e-05
) O 0 5.432148668660375e-07
. O 0 1.2115375511712045e-06

Thus O 0 3.056058631045744e-06
, O 0 3.1691251933807507e-07
a O 0 3.3959244660763943e-07
homozygous O 0 5.33894990439876e-06
germ O 1 0.9942090511322021
- O 0 0.003159499727189541
line O 0 7.295681280083954e-05
MLH1 O 0 0.001363395364023745
mutation O 0 2.4952706212388875e-07
and O 0 8.439256049541655e-08
consequent O 0 0.04082599654793739
mismatch O 1 1.0
repair O 1 0.9999997615814209
deficiency O 1 1.0
results O 0 8.228574188251514e-06
in O 0 3.1366692354595216e-08
a O 0 3.800585801627676e-08
mutator O 0 1.0294519597664475e-05
phenotype O 0 3.646468655915669e-07
characterized O 0 4.4845013036365344e-08
by O 0 3.166931605846912e-08
leukemia B-Disease 1 1.0
and O 0 0.2876828908920288
/ O 1 1.0
or O 1 0.8880592584609985
lymphoma B-Disease 1 1.0
associated O 0 7.846017979318276e-05
with O 0 2.300363064478006e-07
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.0006634026067331433
1 I-Disease 0 6.485543053713627e-06
. O 0 1.9340411938628677e-07
. O 0 1.5936658428472583e-06

Missense O 0 7.351039675995708e-05
mutations O 0 3.678466100609512e-06
in O 0 1.193954517475504e-07
the O 0 7.654087852415614e-08
most O 0 1.3396107334529006e-08
ancient O 0 8.722788891191158e-08
residues O 0 1.2760298773173417e-07
of O 0 4.224305172328968e-08
the O 0 4.7411009518327774e-07
PAX6 O 1 0.9998186230659485
paired O 0 1.1798391597039881e-06
domain O 0 2.739256785844191e-07
underlie O 0 1.1056686162191909e-06
a O 0 5.721854634543888e-08
spectrum O 0 4.615383659256622e-06
of O 0 2.050502644124208e-06
human O 1 1.0
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9821383953094482

Mutations O 0 5.462452918436611e-06
of O 0 7.24491883374867e-07
the O 0 3.3408562671866093e-07
human O 0 1.5285717154256417e-06
PAX6 O 1 0.9999253749847412
gene O 0 3.485508932499215e-05
underlie O 1 0.9999996423721313
aniridia B-Disease 1 1.0
( O 1 0.9999998807907104
congenital B-Disease 1 1.0
absence I-Disease 1 0.9999997615814209
of I-Disease 0 0.4567972719669342
the I-Disease 0 9.047316780197434e-06
iris I-Disease 1 0.5818568468093872
) O 0 2.16840980726829e-08
, O 0 4.9411976732471885e-09
a O 0 8.179260824192625e-09
rare O 0 1.07080791167391e-06
dominant O 1 0.9999997615814209
malformation B-Disease 1 1.0
of I-Disease 1 0.9652179479598999
the I-Disease 1 0.5216646194458008
eye I-Disease 1 0.9999815225601196
. O 0 1.6710024283383973e-05

The O 0 1.5296026276701014e-06
spectrum O 0 1.1661487405945081e-05
of O 0 1.8135810933017638e-06
PAX6 O 1 0.9944493770599365
mutations O 0 5.405624960985733e-06
in O 0 2.4999249603752105e-07
aniridia B-Disease 1 1.0
patients O 0 1.0662584060128211e-07
is O 0 3.4626761458156352e-09
highly O 0 1.3086861372357816e-08
biased O 0 5.054857155073478e-08
, O 0 1.5525409846617322e-09
with O 0 3.0853872234892776e-10
92 O 0 2.290686218486826e-08
% O 0 7.040961147453118e-10
of O 0 1.2000426208302883e-09
all O 0 1.6592884843902311e-09
reported O 0 1.647083180955633e-08
mutations O 0 2.1522328808032398e-08
leading O 0 6.013952713601611e-08
to O 0 8.313501886902941e-09
premature O 0 2.3079991251506726e-07
truncation O 0 6.591750434381538e-07
of O 0 1.532004034743295e-07
the O 0 1.7240957106423593e-07
protein O 0 6.630171469623747e-07
( O 0 6.247286421512399e-08
nonsense O 0 3.063503299927106e-07
, O 0 2.233098861381677e-08
splicing O 0 1.431748302138658e-07
, O 0 1.87043820432109e-08
insertions O 0 2.71385772521171e-07
and O 0 3.232185008528177e-08
deletions O 0 1.7069176294626232e-07
) O 0 9.238119602628103e-09
and O 0 1.0932104110850105e-08
just O 0 2.400430787474761e-08
2 O 0 5.7117354401725606e-08
% O 0 2.1663582039366247e-09
leading O 0 6.2406031453576816e-09
to O 0 6.559005560902165e-10
substitution O 0 2.6352815041263966e-08
of O 0 1.731110366165467e-08
one O 0 8.874135204450795e-09
amino O 0 6.007094821569581e-09
acid O 0 5.574495531845969e-09
by O 0 6.0881610863816604e-09
another O 0 9.773644649158086e-08
( O 0 2.0079284013263532e-07
missense O 0 3.0966327813075623e-06
) O 0 7.875947858337895e-07
. O 0 2.660681730048964e-06

The O 0 1.5926813148325891e-06
extraordinary O 0 6.546944177898695e-07
conservation O 0 1.167918981082039e-06
of O 0 2.2088370599249174e-07
the O 0 2.992720169459062e-07
PAX6 O 0 0.00010648825991665944
protein O 0 4.795034556082101e-07
at O 0 9.481870222316502e-08
the O 0 1.2141796013054318e-08
amino O 0 8.112920113489963e-08
acid O 0 4.7839808559047015e-08
level O 0 8.759702296856631e-08
amongst O 0 2.3644538771350199e-07
vertebrates O 0 4.750986306589766e-07
predicts O 0 9.152708457804692e-08
that O 0 4.030673572685828e-09
pathological O 0 4.4789445041715226e-07
missense O 0 8.462811820209026e-07
mutations O 0 8.120706951331158e-08
should O 0 1.0120884574860156e-08
in O 0 3.856004404667601e-09
fact O 0 6.919915751524286e-09
be O 0 1.5336837355661714e-09
common O 0 4.450915636056152e-09
even O 0 2.4053106173482774e-09
though O 0 3.7751810566533095e-09
they O 0 3.699226480691209e-09
are O 0 1.1432646829234727e-08
hardly O 0 4.963436026628187e-07
ever O 0 2.4134257614605303e-07
seen O 0 8.043596722018265e-07
in O 0 6.869806838949444e-07
aniridia B-Disease 1 1.0
patients O 0 6.556117568834452e-06
. O 0 1.268189043912571e-05

This O 0 9.993460992063774e-08
indicates O 0 2.575675068783312e-07
that O 0 5.944668313162538e-09
there O 0 8.884110336282447e-09
is O 0 5.553832505000855e-09
a O 0 1.0702944308604856e-08
heavy O 0 2.5483789158897707e-06
ascertainment O 0 0.0034326594322919846
bias O 0 2.518168003007304e-06
in O 0 1.622636602860439e-08
the O 0 1.5910121220485962e-08
selection O 0 3.89239147580156e-08
of O 0 3.580283092219361e-08
patients O 0 1.889002732013978e-08
for O 0 5.4549602168663114e-08
PAX6 O 0 4.0101225749822333e-05
mutation O 0 3.6772096478898675e-08
analysis O 0 3.3277515854024386e-08
and O 0 8.314041011203699e-09
that O 0 4.3993630960414976e-09
the O 0 7.950282565616362e-08
missing O 0 4.451947006600676e-06
PAX6 O 0 0.13721925020217896
missense O 0 1.6310994396917522e-05
mutations O 0 2.3074740056472365e-06
frequently O 0 3.421351664201211e-07
may O 0 1.5694477895067394e-07
underlie O 0 1.2223340490891133e-05
phenotypes O 0 1.0862310773518402e-05
distinct O 0 9.669746532381396e-07
from O 0 6.876374527564622e-07
textbook O 0 8.27002149890177e-05
aniridia B-Disease 1 0.9999980926513672
. O 0 2.5547989935148507e-05

Here O 0 4.408093900565291e-06
we O 0 3.0214206958589784e-07
present O 0 2.2376273989266338e-07
four O 0 2.7375776312510425e-07
novel O 0 9.622949619370047e-07
PAX6 O 0 0.00013197628140915185
missense O 0 7.107560122676659e-06
mutations O 0 8.170873684321123e-07
, O 0 3.7080869930150584e-08
two O 0 1.596465537545555e-08
in O 0 1.4611314824719557e-08
association O 0 1.1267691490957077e-07
with O 0 3.460149500256193e-08
atypical O 0 2.7241434509051032e-05
phenotypes O 0 0.00010290714271832258
ectopia B-Disease 0 0.25283727049827576
pupillae I-Disease 0 0.0007243234431371093
( O 0 1.683588664036506e-07
displaced B-Disease 0 9.081236385100055e-07
pupils I-Disease 0 2.3330525777964795e-07
) O 0 4.9125482348699734e-08
and O 0 2.951262558781309e-06
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999966621398926
( O 0 3.878134009482892e-07
searching B-Disease 0 7.845467280276353e-07
gaze I-Disease 0 2.087764642055845e-06
) O 0 5.351581844337261e-09
, O 0 4.784316054440296e-09
and O 0 7.437492843820337e-09
two O 0 1.0735821120988476e-08
in O 0 2.069229587675636e-08
association O 0 1.3973500756492285e-07
with O 0 2.0746554696415842e-08
more O 0 1.326323371131366e-07
recognizable O 1 0.9525988101959229
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 6.327847222564742e-05
. O 0 1.0441844096931163e-05

Strikingly O 0 2.3993057766347192e-05
, O 0 3.3102864449574554e-07
all O 0 5.1777117704432385e-08
four O 0 9.700138292600968e-08
mutations O 0 9.18858376053322e-08
are O 0 2.4015069044480697e-08
located O 0 9.748193718905895e-08
within O 0 2.688878097956149e-08
the O 0 3.064657505547075e-07
PAX6 O 0 0.10623446851968765
paired O 0 7.002396387179033e-07
domain O 0 2.218364159034536e-07
and O 0 2.925951037013874e-08
affect O 0 2.920955033403061e-08
amino O 0 3.925225300349666e-08
acids O 0 1.323834641908661e-08
which O 0 1.3742400550853517e-09
are O 0 1.223643519843165e-09
highly O 0 9.219161434259604e-09
conserved O 0 4.8537412311588923e-08
in O 0 4.1441543530140734e-09
all O 0 1.492247747592046e-08
known O 0 1.3361815831558488e-07
paired O 0 5.178956143936375e-07
domain O 0 5.615830218630435e-07
proteins O 0 5.3088194817974e-07
. O 0 2.148506382582127e-06

Our O 0 2.152066372218542e-06
results O 0 5.809245067212032e-07
support O 0 1.1397749943853341e-07
the O 0 2.8743647462192712e-08
hypothesis O 0 8.282847829832463e-08
that O 0 2.1475858869024478e-09
the O 0 1.4876155418619419e-08
under O 0 4.966939570749673e-08
- O 0 1.7781188432763884e-07
representation O 0 2.2317941272831376e-07
of O 0 1.3240332918940112e-07
missense O 0 2.4303797090396984e-06
mutations O 0 4.391275467696687e-07
is O 0 1.4638959378032723e-08
caused O 0 9.0773944805278e-08
by O 0 4.198800596100227e-08
ascertainment O 1 0.9999574422836304
bias O 0 5.191981836105697e-05
and O 0 2.5036056783278582e-08
suggest O 0 1.2753359257544616e-08
that O 0 1.5290222421526778e-09
a O 0 6.75202604938363e-09
substantial O 0 1.7239838712157507e-07
burden O 0 2.012711092902464e-06
of O 0 2.897856575145852e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9999966621398926
related I-Disease 1 0.9999762773513794
disease I-Disease 1 0.9999986886978149
remains O 0 5.614625138150586e-07
to O 0 1.0732627231391234e-08
be O 0 3.385589053550575e-08
uncovered O 0 1.2821586778954952e-06
. O 0 3.7305397881937097e-07
. O 0 2.890327095883549e-06

The O 0 2.967202135550906e-06
chromosomal O 0 6.140401637821924e-06
order O 0 5.684715915776906e-07
of O 0 4.220351002004463e-07
genes O 0 6.493598334600392e-07
controlling O 0 8.437403380412434e-07
the O 0 4.859090836362157e-07
major O 0 2.116267387464177e-05
histocompatibility O 1 0.9980533123016357
complex O 0 1.8944330122394604e-06
, O 0 5.982719386565805e-08
properdin O 0 3.366232022017357e-06
factor O 0 3.007325517501158e-07
B O 0 7.4548888733261265e-06
, O 0 3.369400047859017e-08
and O 0 4.233395145547547e-08
deficiency B-Disease 0 0.1584482043981552
of I-Disease 0 1.5669080312363803e-05
the I-Disease 0 5.206966875448416e-07
second I-Disease 0 8.011328986867738e-07
component I-Disease 0 1.054281938195345e-06
of I-Disease 0 4.107020004084916e-07
complement I-Disease 0 4.200368948659161e-06
. O 0 7.04369313098141e-06

The O 0 1.8948577462651883e-06
relationship O 0 2.499116931176104e-07
of O 0 1.831499503168743e-07
the O 0 6.132473373554603e-08
genes O 0 4.965481181784526e-08
coding O 0 2.864314581074723e-07
for O 0 7.427742332311027e-08
HLA O 0 5.710955520044081e-05
to O 0 3.8081758191310655e-08
those O 0 1.4422811389636081e-08
coding O 0 1.1263930588256699e-07
for O 0 3.38303252078731e-08
properdin O 0 2.4465437036269577e-06
Factor O 0 2.347250784850985e-07
B O 0 9.247603429685114e-07
allotypes O 0 8.374010462830483e-07
and O 0 1.1681417610986955e-08
for O 0 1.8802495560521493e-08
deficiency B-Disease 0 9.123788913711905e-06
of I-Disease 0 3.424191845624591e-07
the I-Disease 0 8.691748831779478e-08
second I-Disease 0 8.39212859204963e-08
component I-Disease 0 2.1787376169868367e-07
of I-Disease 0 6.999538726404353e-08
complement I-Disease 0 1.4497932454560214e-07
( O 0 1.1705443370146895e-07
C2 O 0 2.187220161431469e-06
) O 0 6.848472899889657e-09
was O 0 1.8690295533474455e-08
studied O 0 2.1152315454742165e-08
in O 0 1.0308573994421977e-09
families O 0 4.068443359983576e-09
of O 0 1.184258380249048e-08
patients O 0 9.638612397111501e-08
with O 0 1.0694412821976584e-06
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.00025807778001762927

Patients O 0 1.1681138403218938e-06
were O 0 1.7374772198763822e-07
selected O 0 9.165531622556955e-08
because O 0 1.050285902692849e-08
they O 0 7.442856553296906e-09
were O 0 2.9476511897996716e-08
heterozygous O 0 9.11250523927265e-08
or O 0 9.456729088697102e-08
homozygous O 0 1.6024656588342623e-06
for O 0 1.4312599887489341e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.344008630141616e-05

12 O 0 1.865859485405963e-05
families O 0 6.913967922628217e-07
with O 0 1.4975461226640618e-07
15 O 0 7.788245284245932e-07
matings O 0 3.5353441489860415e-06
informative O 0 2.7105027129437076e-06
for O 0 2.1887183265789645e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.7619546472124057e-06
found O 0 1.313336611019622e-06
. O 0 2.1124571958353044e-06

Of O 0 2.633924850670155e-05
57 O 0 1.584859455761034e-05
informative O 0 4.636891844711499e-06
meioses O 0 1.0022941751230974e-05
, O 0 4.9420769698826916e-08
two O 0 2.0692809243882948e-08
crossovers O 0 5.534726028599835e-07
were O 0 7.208255681234732e-08
noted O 0 8.117965677456596e-08
between O 0 1.2655648617965198e-07
the O 0 2.892331849579932e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
gene O 0 1.7415847253232641e-07
and O 0 4.6358028527038186e-08
the O 0 2.1153914531168994e-07
HLA O 1 0.9998493194580078
- O 0 0.015665780752897263
B O 0 3.455049591138959e-05
gene O 0 2.120984632369982e-08
, O 0 6.7068843812023715e-09
with O 0 1.4832742811776711e-09
a O 0 6.281611675262866e-09
recombinant O 0 7.98982284777594e-08
fraction O 0 1.0567728025989709e-07
of O 0 3.5510532825355767e-07
0 O 0 4.0104832805809565e-06
. O 0 2.4667108391440706e-06

035 O 0 0.04531107097864151
. O 0 0.0006633305456489325

A O 0 2.3957938537932932e-05
lod O 0 8.975633681984618e-05
score O 0 1.3826231679558987e-06
of O 0 3.8584897765758797e-07
13 O 0 2.926940112502052e-07
was O 0 4.2286256274337575e-08
calculated O 0 2.797233733531357e-08
for O 0 9.805121159445207e-09
linkage O 0 1.7244426999241114e-05
between O 0 0.0003616921021603048
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.2148326504757279e-06
HLA O 1 0.9999991655349731
- O 0 0.29587939381599426
B O 0 0.008758212439715862
at O 0 1.2946908434230409e-08
a O 0 6.681740161162963e-10
maximum O 0 2.236499208052578e-09
likelihood O 0 1.5547731990750435e-08
value O 0 4.9383337419328655e-09
of O 0 7.645154731505954e-09
the O 0 1.1530448595920006e-08
recombinant O 0 6.26051530616678e-08
fraction O 0 3.72885722299543e-07
of O 0 4.801455020242429e-07
0 O 0 1.1033912414859515e-05
. O 0 4.0627724047226366e-06

04 O 0 0.019158504903316498
. O 0 0.0004378044977784157

18 O 0 1.3409088751359377e-05
families O 0 6.145600650597771e-07
with O 0 1.2591841880293941e-07
21 O 0 1.4930255929357372e-06
informative O 0 6.623604917876946e-07
matings O 0 1.008691015158547e-06
for O 0 9.434209147229922e-08
both O 0 1.8830496628652327e-07
properdin O 0 1.3542316082748584e-05
Factor O 0 1.3227059980636113e-06
B O 0 6.181943717820104e-06
allotype O 0 5.6267413128807675e-06
and O 0 2.94526927291372e-07
HLA O 0 0.2020750343799591
- O 0 0.0007141733658500016
B O 0 0.00037477558362297714
were O 0 1.973970711333095e-07
found O 0 2.8281729669288325e-07
. O 0 1.1886936590599362e-06

Of O 0 3.6781180824618787e-05
72 O 0 1.5244533642544411e-05
informative O 0 5.537732249649707e-06
meioses O 0 3.592287976061925e-05
, O 0 1.6728796481402242e-07
three O 0 1.0537235084484564e-07
recombinants O 0 6.2754024838795885e-06
were O 0 1.2621767098153214e-07
found O 0 4.8936012575495624e-08
, O 0 2.2317362180501732e-08
giving O 0 3.877164900245589e-08
a O 0 5.5855352343314735e-08
recombinant O 0 5.630287205349305e-07
fraction O 0 8.450980999441526e-07
of O 0 7.639166028639011e-07
0 O 0 1.310121933784103e-05
. O 0 5.819286798214307e-06

042 O 0 0.02103179693222046
. O 0 0.00047235842794179916

A O 0 2.1366395230870694e-05
lod O 0 0.00012189053813926876
score O 0 2.782958745228825e-06
of O 0 1.0842736628546845e-06
16 O 0 1.4250382491809432e-06
between O 0 3.5220011795900064e-07
HLA O 0 0.1622660756111145
- O 0 3.706519419210963e-05
B O 0 1.1287591405562125e-05
and O 0 1.7936608642799e-08
Factor O 0 5.260191215938903e-08
B O 0 7.544992399743933e-07
allotypes O 0 2.6720405799096625e-07
was O 0 1.6524010604257455e-08
calculated O 0 3.0141114049087037e-09
at O 0 2.5279660587074204e-09
a O 0 7.652649625100594e-10
maximum O 0 7.432727766598646e-09
likelihood O 0 2.490650707898112e-08
value O 0 1.990634501680688e-08
of O 0 1.406647420765239e-08
the O 0 1.6922255596796276e-08
recombinant O 0 8.272601093040066e-08
fraction O 0 2.0597288141743775e-07
of O 0 3.5605143011707696e-07
0 O 0 9.423107258044183e-06
. O 0 4.208601239952259e-06

04 O 0 0.00700433598831296
. O 0 0.00038554411730729043

A O 0 3.263255393903819e-06
crossover O 0 1.7907044593812316e-06
was O 0 2.1852653731002647e-07
shown O 0 1.7835901644502883e-08
to O 0 5.10042141854683e-09
have O 0 6.5648912972449125e-09
occurred O 0 1.1487034612400748e-07
between O 0 1.297382734577468e-08
genes O 0 1.3334060966485595e-08
for O 0 1.0335649669457325e-08
Factor O 0 1.740000925565255e-07
B O 0 1.2517255072452826e-06
and O 0 1.301509939821699e-07
HLA O 0 0.00033578166039660573
- O 0 5.7165776524925604e-05
D O 0 8.004013579920866e-06
, O 0 5.928852075953728e-08
in O 0 2.8783038175106412e-08
which O 0 5.22667811253541e-08
HLA O 0 0.00036875010118819773
- O 0 0.0006698016659356654
D O 0 2.1617715901811607e-05
segregared O 0 1.010393043543445e-05
with O 0 1.2130932702802966e-07
HLA O 1 0.984093427658081
- O 0 0.00023479171795770526
A O 0 7.063295015541371e-06
and O 0 7.574586788905435e-07
B O 0 0.00013125012628734112
. O 0 1.7834254322224297e-06

These O 0 8.733724143894506e-07
studies O 0 2.2985648229223443e-07
suggest O 0 4.389617558331338e-08
that O 0 3.904807588384074e-09
the O 0 8.183552502316616e-09
genes O 0 1.2601220511498923e-08
for O 0 1.629525137047949e-08
Factor O 0 3.8743857544432103e-07
B O 0 0.0027013570070266724
and O 0 1.8351569224250852e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 3.037231266489471e-08
located O 0 2.7408969316411458e-08
outside O 0 2.083760897164666e-08
those O 0 5.549321446807198e-09
for O 0 2.4510079299489007e-08
HLA O 1 0.9998960494995117
, O 0 2.321213976586023e-08
that O 0 4.3092880375183995e-09
the O 0 1.2834618701162981e-08
order O 0 3.6692927807280284e-08
of O 0 1.1897842711050544e-07
genese O 0 4.0694576455280185e-06
is O 0 9.528427113991711e-08
HLA O 0 3.475942139630206e-05
- O 0 4.31833041147911e-06
A O 0 1.2427583442331525e-06
, O 0 1.1092514995425518e-07
- O 0 7.725161026428395e-07
B O 0 3.994142844021553e-06
, O 0 6.794972762236284e-08
- O 0 3.298446813460032e-07
D O 0 5.204404942560359e-07
, O 0 2.56403307474784e-08
Factor O 0 1.5870621439262322e-07
B O 0 1.9359327779966407e-05
allotype O 0 0.0048476518131792545
, O 0 7.365058991126716e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 2.8127274731559737e-08
that O 0 2.929473108537195e-09
the O 0 7.565517101681962e-09
genes O 0 2.817672850596864e-08
coding O 0 6.252185471566918e-07
for O 0 1.4700482324769837e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 3.293684756044968e-07
Factor O 0 3.515651769703254e-07
B O 0 1.45376020554977e-06
allotypes O 0 7.473165055671416e-07
are O 0 9.77069447571921e-09
approximately O 0 1.2616948374954973e-08
3 O 0 3.970252393514784e-08
- O 0 4.2420516876973124e-08
- O 0 1.1706961089430479e-07
5 O 0 4.349288929006434e-08
centimorgans O 0 2.2417667366880778e-07
from O 0 1.3184219049833246e-08
the O 0 3.216024069274681e-08
HLA O 0 4.248726327205077e-06
- O 0 5.678170396095084e-07
A O 0 3.267573163157067e-07
and O 0 9.624779551131724e-08
HLA O 0 0.0017408726271241903
- O 0 9.586782653059345e-06
B O 0 8.65420497575542e-06
loci O 0 1.0285722140679354e-07
, O 0 4.175183754284717e-09
and O 0 1.3129006770640217e-09
that O 0 3.787064828397746e-10
the O 0 5.606431319193916e-09
apparent O 0 1.276828385243789e-07
lack O 0 1.3802173270960338e-07
of O 0 1.1692245038830151e-07
recombinants O 0 1.2719387996185105e-05
between O 0 6.651102069099579e-08
the O 0 5.732985997042306e-08
Factor O 0 2.1338439637474949e-07
B O 0 1.0700274287955835e-05
gene O 0 1.0292762908648e-06
and O 0 0.029176587238907814
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 1.8418688796373317e-07
suggests O 0 5.458082341647241e-08
that O 0 9.213724783130317e-10
these O 0 2.2206019245629705e-09
two O 0 7.447088723466777e-09
genes O 0 3.827260997013582e-08
lie O 0 2.5306940187874716e-07
in O 0 2.69220361559519e-08
close O 0 1.5510357798120822e-07
proximity O 0 2.7739312713492836e-07
to O 0 4.1431288622106877e-08
one O 0 1.7605736957193585e-07
another O 0 1.0489225132914726e-06
. O 0 4.194449047645321e-06

Distribution O 0 6.318634405033663e-06
of O 0 2.19096546061337e-06
emerin O 0 0.00013493614096660167
and O 0 3.702249955495063e-07
lamins O 0 0.005080403294414282
in O 0 7.937040891192737e-08
the O 0 2.1306757957972877e-07
heart O 0 7.118374583114928e-07
and O 0 5.492681154350976e-08
implications O 0 3.7257188978401246e-06
for O 0 5.844007660016359e-07
Emery B-Disease 0 0.34313297271728516
- I-Disease 1 0.9999972581863403
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.15606890618801117

Emerin O 0 0.0008737330208532512
is O 0 1.0149591389563284e-06
a O 0 7.556326409030589e-07
nuclear O 0 4.243219336785842e-06
membrane O 0 1.2169082310720114e-06
protein O 0 3.029958577371872e-07
which O 0 1.2630672507896179e-08
is O 0 7.56981854976857e-09
missing O 0 1.5956230470237642e-07
or O 0 4.4773898366656795e-08
defective O 0 7.373379503405886e-06
in O 0 1.605431663165291e-07
Emery B-Disease 0 0.2325344979763031
- I-Disease 1 0.9999964237213135
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999969005584717
EDMD B-Disease 1 1.0
) O 0 9.800402949622367e-06
. O 0 6.024600224918686e-06

It O 0 9.301436421083054e-08
is O 0 1.993925202725677e-08
one O 0 1.874355959330387e-08
member O 0 2.5308958484515642e-08
of O 0 3.163442130471594e-08
a O 0 2.858972969477236e-08
family O 0 6.790308759718755e-08
of O 0 3.366779992575175e-07
lamina O 1 1.0
- O 1 0.956612229347229
associated O 0 1.186193230751087e-06
proteins O 0 7.392578282860995e-08
which O 0 1.6667717872564936e-08
includes O 0 3.9820378106014687e-08
LAP1 O 0 0.0007512604934163392
, O 0 3.5929528507949726e-07
LAP2 O 0 0.013422198593616486
and O 0 1.7749382550391601e-06
lamin O 0 0.00047293645911850035
B O 0 0.00531217735260725
receptor O 0 0.0002946639433503151
( O 0 3.0324697945616208e-05
LBR O 1 0.9999955892562866
) O 0 4.325960162532283e-06
. O 0 8.186393642972689e-06

A O 0 2.375310032221023e-05
panel O 0 9.098990631173365e-06
of O 0 1.5988371160347015e-06
16 O 0 1.6124050716825877e-06
monoclonal O 0 1.6183562365768012e-06
antibodies O 0 5.229165935816127e-07
( O 0 1.8406115032121306e-07
mAbs O 0 3.3153773983940482e-06
) O 0 2.2680053390899957e-08
has O 0 3.771741141633811e-09
been O 0 3.733954478946089e-09
mapped O 0 1.0378457204751612e-08
to O 0 4.024412358916152e-09
six O 0 2.238036600488158e-08
specific O 0 1.8324353590060127e-08
sites O 0 1.8908019683294697e-07
throughout O 0 7.876746366264342e-08
the O 0 1.2908768098895962e-07
emerin O 0 1.962052465387387e-06
molecule O 0 7.245168376357469e-08
using O 0 3.648301216685468e-08
phage O 0 2.607393696507643e-07
- O 0 2.0427137314982247e-07
displayed O 0 1.9951087892877695e-07
peptide O 0 1.4488064437045978e-07
libraries O 0 1.5428628330482752e-07
and O 0 1.3859226655199564e-08
has O 0 5.116225221257764e-09
been O 0 3.5723959346256606e-09
used O 0 6.09787642602555e-09
to O 0 2.2228320517569955e-08
localize O 0 2.0553035938064568e-05
emerin O 0 0.00010376511636422947
in O 0 9.068136819223582e-08
human O 0 5.773708267042821e-07
and O 0 9.085654255613917e-07
rabbit O 0 2.5538221962051466e-05
heart O 0 1.0020781701314263e-05
. O 0 8.605870789324399e-06

Several O 0 7.156743322411785e-06
mAbs O 0 4.755440750159323e-05
against O 0 1.036312710311904e-06
different O 0 3.6897017707815394e-07
emerin O 0 2.1193554857745767e-05
epitopes O 0 3.4249271720909746e-06
did O 0 7.730586304433018e-08
not O 0 2.596658177367317e-08
recognize O 0 9.073015405647311e-08
intercalated O 0 1.380577032250585e-06
discs O 0 7.535952590842498e-07
in O 0 1.958845707861201e-08
the O 0 6.485292658453545e-08
heart O 0 2.064924871092444e-07
, O 0 1.4017755844975e-08
though O 0 6.934423257831668e-09
they O 0 9.761232711014145e-09
recognized O 0 1.7317815093065292e-07
cardiomyocyte O 0 2.5594094950065482e-06
nuclei O 0 2.7420167043601396e-06
strongly O 0 9.664974953693672e-08
, O 0 1.558089124387152e-08
both O 0 2.6251727902604216e-08
at O 0 9.174731729899577e-08
the O 0 1.0207858736066555e-07
rim O 0 1.7109640566559392e-06
and O 0 6.160798449172944e-08
in O 0 2.1561862695307354e-07
intranuclear O 0 0.008014840073883533
spots O 0 9.789006981009152e-06
or O 0 1.1730312508007046e-06
channels O 0 6.596947969228495e-06
. O 0 6.746603048668476e-06

A O 0 6.780542025808245e-05
polyclonal O 0 0.000159707575221546
rabbit O 0 1.9156372218276374e-05
antiserum O 0 3.423487942200154e-05
against O 0 1.5149486216614605e-06
emerin O 0 2.3427082851412706e-05
did O 0 1.1844981884223671e-07
recognize O 0 1.7180572342567757e-07
both O 0 1.6867288366029243e-07
nuclear O 0 2.1763669337815372e-06
membrane O 0 8.938016549109307e-07
and O 0 6.590249057580877e-08
intercalated O 0 6.702807127112465e-07
discs O 0 5.138109031577187e-07
but O 0 4.2095777530448686e-08
, O 0 2.769833251647924e-08
after O 0 3.6124813362903296e-08
affinity O 0 7.237930788051017e-08
purification O 0 1.8285848568666552e-07
against O 0 8.929967520998616e-08
a O 0 7.099047394376612e-08
pure O 0 4.946207354805665e-07
- O 0 6.62668242057407e-07
emerin O 0 2.6534648895903956e-06
band O 0 2.1653313808656094e-07
on O 0 4.819286303359149e-08
a O 0 1.5229108640824052e-08
western O 0 1.9452879485015728e-07
blot O 0 1.8866658137994818e-06
, O 0 4.1385796123449836e-08
it O 0 1.8103373022881897e-08
stained O 0 2.753967009994085e-06
only O 0 8.774668458499946e-08
the O 0 3.98921457644974e-07
nuclear O 0 1.4024746633367613e-05
membrane O 0 1.861201599240303e-05
. O 0 5.838910510647111e-06

These O 0 3.436282440816285e-07
results O 0 9.147716895085978e-08
would O 0 1.5921049367761952e-08
not O 0 8.097086556801969e-09
be O 0 6.851517131423179e-09
expected O 0 2.525952780274565e-08
if O 0 2.769320950335441e-08
immunostaining O 0 2.4469288746331586e-06
at O 0 7.123298217948104e-08
intercalated O 0 2.770100877569348e-07
discs O 0 1.4315790508589998e-07
were O 0 1.622280620949823e-08
due O 0 1.0651684867468703e-08
to O 0 2.856535008533001e-09
a O 0 5.664322344500761e-09
product O 0 1.973885233041983e-08
of O 0 2.6193911040195417e-08
the O 0 6.091823223641768e-08
emerin O 0 2.71697535936255e-06
gene O 0 6.328467350158462e-08
and O 0 2.7135774516295896e-08
, O 0 9.136135403764456e-09
therefore O 0 2.4926370301159295e-08
, O 0 9.734793415816512e-09
cast O 0 8.989228028610796e-09
some O 0 3.88678111917784e-09
doubt O 0 4.795098362819772e-08
upon O 0 2.4510407925504296e-08
the O 0 8.797236716873158e-09
hypothesis O 0 7.392789314053516e-08
that O 0 8.165465636977842e-09
cardiac B-Disease 0 0.22400620579719543
defects I-Disease 1 0.9999809265136719
in O 0 1.1479471595521318e-06
EDMD B-Disease 1 1.0
are O 0 6.811426089825545e-08
caused O 0 2.4360153361158154e-07
by O 0 2.6595090574232927e-08
absence O 0 1.174801764136646e-05
of O 0 5.898515610169852e-06
emerin O 1 0.998681366443634
from O 0 9.636444701754954e-06
intercalated O 0 0.00018215268210042268
discs O 0 0.00011720554903149605
. O 0 2.1376954464358278e-05

Although O 0 5.853015409229556e-06
emerin O 0 5.8202724176226184e-05
was O 0 5.205675961406087e-07
abundant O 0 3.252109763707267e-07
in O 0 1.543265248926673e-08
the O 0 4.6135475884057087e-08
membranes O 0 6.89161197442445e-07
of O 0 2.131939993432752e-07
cardiomyocyte O 0 8.277987944893539e-06
nuclei O 0 0.00011302952043479308
, O 0 1.7247758776761657e-08
it O 0 2.1512920334032515e-09
was O 0 1.858854581371361e-08
absent O 0 3.801984860274388e-08
from O 0 1.6570753658129433e-08
many O 0 2.5910527057249055e-08
non O 0 3.86003512176103e-06
- O 0 3.2803727663122118e-06
myocyte O 0 4.1531617171131074e-05
cells O 0 2.1710218334192177e-07
in O 0 4.542125253692575e-08
the O 0 2.4770616846581106e-07
heart O 0 3.586931597965304e-06
. O 0 3.4165627766924445e-06

This O 0 1.7031385368682095e-07
distribution O 0 8.089677407951967e-07
of O 0 3.8120205658742634e-07
emerin O 0 2.1850330085726455e-05
was O 0 5.8518153878139856e-08
similar O 0 2.5600002118153498e-09
to O 0 1.858477816085724e-09
that O 0 2.7071656027999325e-09
of O 0 6.184958323274259e-08
lamin O 0 1.1768077456508763e-05
A O 0 4.695380368957558e-07
, O 0 1.4769569567363305e-08
a O 0 1.824330730926249e-08
candidate O 0 8.380899174653678e-08
gene O 0 4.3712944375329243e-08
for O 0 3.1451463655685075e-08
an O 0 4.736495640145222e-08
autosomal O 0 3.8908112287572294e-07
form O 0 5.500401698554924e-07
of O 0 0.00010320598812540993
EDMD B-Disease 1 1.0
. O 0 0.00012706410780083388

In O 0 2.134989017577027e-06
contrast O 0 2.5622694010962732e-06
, O 0 1.5381895082100527e-06
lamin O 0 0.042486321181058884
B1 O 1 0.99993896484375
was O 0 3.765654810194974e-06
absent O 0 4.448793788469629e-06
from O 0 4.3204954636166804e-07
cardiomyocyte O 0 2.6568819521344267e-05
nuclei O 0 5.0910170102724805e-05
, O 0 8.887300850801694e-08
showing O 0 1.338816986162783e-07
that O 0 5.9063012258775416e-08
lamin O 0 0.00019423906633164734
B1 O 0 0.010805065743625164
is O 0 1.061736476515307e-08
not O 0 2.5162525396638102e-09
essential O 0 3.4992538644473825e-08
for O 0 1.9402609297003437e-08
localization O 0 1.300202711718157e-06
of O 0 3.9394240047840867e-07
emerin O 0 8.176788469427265e-06
to O 0 1.3560305944793072e-07
the O 0 1.2719514188574976e-06
nuclear O 0 9.265638800570741e-05
lamina O 1 0.9947543144226074
. O 0 3.8802452763775364e-05

Lamin O 1 0.9999431371688843
B1 O 1 0.9999992847442627
is O 0 1.4492750324279768e-06
also O 0 4.3350439682399156e-07
almost O 0 1.1337105831898953e-07
completely O 0 7.486483468710503e-07
absent O 0 2.417070618321304e-06
from O 0 4.84699739899952e-07
skeletal O 0 8.756042370805517e-05
muscle O 0 1.9146693375660107e-05
nuclei O 1 0.7676817774772644
. O 0 9.156721716863103e-06

In O 0 1.0396613106422592e-05
EDMD B-Disease 1 1.0
, O 0 3.006124131843535e-07
the O 0 4.7502659583642526e-08
additional O 0 1.3521925268378254e-07
absence O 0 1.1673587323457468e-06
of O 0 1.7691957054921659e-06
lamin O 1 0.9999961853027344
B1 O 1 1.0
from O 0 0.0013310707872733474
heart O 1 0.9944517016410828
and O 0 3.5487141758494545e-06
skeletal O 1 0.9999939203262329
muscle O 0 0.0020059559028595686
nuclei O 1 0.9999977350234985
which O 0 7.058299900108977e-08
already O 0 1.2040439756333399e-08
lack O 0 1.4061771480555763e-07
emerin O 0 4.459838237380609e-06
may O 0 5.815217196669664e-09
offer O 0 3.891350353057987e-09
an O 0 8.555893771244882e-10
alternative O 0 1.524747617054345e-08
explanation O 0 4.95879888262607e-08
of O 0 1.9771031034565567e-08
why O 0 6.84263952166475e-08
these O 0 4.1261106531464975e-08
tissues O 0 3.3192515047630877e-07
are O 0 3.4221276479229346e-08
particularly O 0 1.8516647060096147e-07
affected O 0 1.7869450630314532e-07
. O 0 2.1126314209141128e-07
. O 0 2.2770766463509062e-06

Genetic O 0 9.835166565608233e-06
mapping O 0 2.6545278615230927e-06
of O 0 1.4843102462691604e-06
the O 0 1.4968621826483286e-06
copper B-Disease 0 0.00026688366779126227
toxicosis I-Disease 1 0.9935124516487122
locus O 0 3.1773158752912423e-06
in O 0 2.178899762839137e-07
Bedlington O 0 0.0007579539087601006
terriers O 0 6.446925544878468e-05
to O 0 5.888843190859916e-08
dog O 0 5.126416340317519e-07
chromosome O 0 1.810434611115852e-07
10 O 0 7.172105398467465e-08
, O 0 5.651857648558689e-09
in O 0 3.0980378262768227e-09
a O 0 2.0494137942250745e-08
region O 0 2.404938470590423e-07
syntenic O 0 6.183853656693827e-06
to O 0 1.3600039494576777e-07
human O 0 1.0620848343023681e-06
chromosome O 0 7.641222509846557e-06
region O 0 9.962122931028716e-06
2p13 O 0 0.0001678512489888817
- O 0 0.00010955391189781949
p16 O 0 9.849157504504547e-05
. O 0 9.174797014566138e-06

Abnormal O 1 0.9999872446060181
hepatic B-Disease 1 1.0
copper I-Disease 0 0.011482845060527325
accumulation I-Disease 0 0.0001481418585171923
is O 0 1.8439598292729897e-08
recognized O 0 1.0660262006467747e-08
as O 0 7.015962921741448e-09
an O 0 3.1139339995434057e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 7.12782366463216e-07
man O 0 6.187735380080994e-06
, O 0 6.303337585222835e-08
mouse O 0 1.9152297170421662e-07
, O 0 1.0983606557601888e-07
rat O 0 2.239274181192741e-06
and O 0 5.346309990272857e-07
dog O 0 1.2765310202667024e-05
. O 0 9.136745575233363e-06

The O 0 4.250294750818284e-06
major O 0 1.822081503632944e-05
cause O 0 0.00047319757868535817
of O 0 0.0005137159605510533
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999899864196777
accumulation I-Disease 1 0.9999872446060181
in O 0 5.549885031541635e-07
man O 0 2.2669883037451655e-06
is O 0 1.6618674436585934e-08
a O 0 3.856271035829195e-08
dysfunctional O 0 1.4041887652638252e-06
ATP7B O 1 0.9986704587936401
gene O 0 6.99929785241693e-07
, O 0 1.963638140978219e-07
causing O 0 1.0296080290572718e-05
Wilson B-Disease 0 2.0023433535243385e-05
disease I-Disease 1 0.9981144666671753
( O 0 2.8643848963838536e-06
WD B-Disease 1 0.9176275730133057
) O 0 1.733972339934553e-06
. O 0 2.7612727535597514e-06

Mutations O 0 7.656424713786691e-06
in O 0 5.210811764300161e-07
the O 0 6.599726702916087e-07
ATP7B O 1 0.9984889030456543
genes O 0 2.9201535767242603e-07
have O 0 2.0878308859550998e-08
also O 0 2.457055536808639e-08
been O 0 1.710570352031482e-08
demonstrated O 0 7.207348318161166e-08
in O 0 4.008258613907856e-08
mouse O 0 1.0965914043481462e-06
and O 0 8.384719194509671e-07
rat O 0 3.971532350988127e-05
. O 0 6.091455816203961e-06

The O 0 1.0562188435869757e-05
ATP7B O 1 0.9356250166893005
gene O 0 8.122370331875572e-07
has O 0 4.2815166523269e-08
been O 0 2.515423602744704e-08
excluded O 0 1.4044040597127605e-07
in O 0 5.62756907740436e-09
the O 0 9.313008142441959e-09
much O 0 2.5525368485546096e-08
rarer O 0 7.061663927743211e-05
human O 0 2.5103704501816537e-06
copper B-Disease 0 0.004994899034500122
overload I-Disease 1 0.9999850988388062
disease O 1 0.9999967813491821
non B-Disease 0 0.2625424563884735
- I-Disease 0 4.304002231947379e-06
Indian I-Disease 0 1.725008615949264e-07
childhood I-Disease 0 4.243502644385444e-06
cirrhosis I-Disease 1 0.9999768733978271
, O 0 9.003868939316817e-08
indicating O 0 6.118418696132721e-07
genetic O 0 2.7734445211535785e-06
heterogeneity O 0 4.717630145023577e-05
. O 0 1.2980757674085908e-05

By O 0 9.817565569392173e-07
investigating O 0 2.2034666926629143e-06
the O 0 3.3123833986792306e-07
common O 0 1.5023124433355406e-06
autosomal O 0 0.08393785357475281
recessive O 1 0.9999192953109741
copper B-Disease 1 0.9944738745689392
toxicosis I-Disease 1 0.9998955726623535
( O 0 1.2064241445841617e-06
CT B-Disease 0 0.0015048382338136435
) O 0 3.013428795384243e-08
in O 0 4.771842299078344e-08
Bedlington O 0 0.0030717814806848764
terriers O 0 0.03618530184030533
, O 0 4.022856714414047e-08
we O 0 8.73443894988668e-09
have O 0 4.211358373140683e-09
identified O 0 2.1348773415752476e-08
a O 0 6.142656161500781e-09
new O 0 1.0262222183143876e-08
locus O 0 8.447002386446911e-08
involved O 0 2.5031186012824946e-08
in O 0 6.029722499079071e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.4023405532934703e-06

We O 0 1.6397503941334435e-06
examined O 0 2.918735845014453e-06
whether O 0 2.5221910959771776e-07
the O 0 6.170412802930514e-07
WD B-Disease 0 0.00038600031984969974
gene O 0 4.104089839529479e-06
ATP7B O 1 0.9999927282333374
was O 0 9.554657935950672e-07
also O 0 4.338940229331456e-08
causative O 0 5.191976697460632e-07
for O 0 5.950672132826185e-08
CT B-Disease 0 3.376465656401706e-06
by O 0 1.2723036846296054e-08
investigating O 0 1.7096137128191913e-07
the O 0 1.4652206914433918e-07
chromosomal O 0 5.157538907951675e-06
co O 0 2.649130919962772e-06
- O 0 4.0684521991352085e-06
localization O 0 1.7403326637577266e-05
of O 0 2.4326682250830345e-06
ATP7B O 1 0.9998472929000854
and O 0 1.8740240648185136e-07
C04107 O 0 4.054338205605745e-06
, O 0 2.3063725151928338e-08
using O 0 1.3316752145442479e-08
fluorescence O 0 1.747539215557481e-07
in O 0 6.630127558082677e-08
situ O 0 1.6280575891869375e-06
hybridization O 0 4.479568644910614e-07
( O 0 2.141070183370175e-07
FISH O 0 5.006955234421184e-06
) O 0 3.0512018156514387e-07
. O 0 1.4200228406480164e-06

C04107 O 0 0.0010564916301518679
is O 0 1.779920125954959e-06
an O 0 3.515581568080961e-07
anonymous O 0 3.276652705608285e-06
microsatellite O 0 2.579313877504319e-05
marker O 0 1.4561297575710341e-05
closely O 0 2.6596314910420915e-06
linked O 0 6.462143574026413e-06
to O 0 2.5338504201499745e-06
CT B-Disease 1 0.9226088523864746
. O 0 1.6136702470248565e-05

However O 0 8.84665860212408e-06
, O 0 3.5109919735987205e-06
BAC O 0 0.00015653259470127523
clones O 0 7.5662806011678185e-06
containing O 0 1.7120200936915353e-06
ATP7B O 0 0.34140267968177795
and O 0 1.9138073525937216e-07
C04107 O 0 3.898770046362188e-06
mapped O 0 1.2327549825386086e-07
to O 0 1.719618580864335e-08
the O 0 1.3783547103685123e-07
canine O 0 2.1059822756797075e-06
chromosome O 0 2.1244518393359613e-06
regions O 0 4.6496569439113955e-07
CFA22q11 O 0 1.5791745681781322e-05
and O 0 1.2188799303203268e-07
CFA10q26 O 0 2.422056240902748e-05
, O 0 8.380851568290382e-08
respectively O 0 1.878776885178013e-07
, O 0 5.413644643681437e-08
demonstrating O 0 2.1818814843754808e-07
that O 0 7.598130480346299e-08
WD B-Disease 0 4.940964208799414e-05
cannot O 0 4.3504383029357996e-07
be O 0 2.504229428268445e-07
homologous O 0 2.9905882001912687e-06
to O 0 2.107069121848326e-06
CT B-Disease 0 0.001243822742253542
. O 0 1.5102350516826846e-05

The O 0 1.5698364222771488e-05
copper O 0 2.446692087687552e-05
transport O 0 6.999310699029593e-06
genes O 0 2.439838453938137e-06
CTR1 O 0 0.4050881564617157
and O 0 2.557203515607398e-07
CTR2 O 1 0.9990633130073547
were O 0 1.6711385342205176e-07
also O 0 4.645610474085515e-08
excluded O 0 1.296910738801671e-07
as O 0 1.3635514051202335e-08
candidate O 0 3.16755368601207e-08
genes O 0 1.5672751985107425e-08
for O 0 1.6071648900606306e-08
CT B-Disease 0 0.00010364961053710431
since O 0 1.6607328845452685e-08
they O 0 5.476161302198079e-09
both O 0 1.8771071808032502e-08
mapped O 0 8.948432395072814e-08
to O 0 8.585065103261513e-08
canine O 0 1.4543228644470219e-05
chromosome O 0 2.1002035282435827e-05
region O 0 1.840411641751416e-05
CFA11q22 O 0 0.00059180345851928
. O 0 2.2025291400495917e-05

2 O 0 0.0007340923766605556
- O 0 0.00021272337471600622
22 O 0 0.00011374431051081046
. O 0 1.4856704183330294e-05

5 O 0 0.0008851345628499985
. O 0 0.00011275307042524219

A O 0 1.3501322428055573e-05
transcribed O 0 6.42741770207067e-06
sequence O 0 3.594231259285152e-07
identified O 0 4.0119383015735366e-07
from O 0 5.062373631403716e-08
the O 0 1.3509718144177896e-07
C04107 O 0 6.367943115037633e-06
- O 0 4.924397103422962e-07
containing O 0 1.7174365041228157e-07
BAC O 0 1.7876382116810419e-06
was O 0 1.3208332205749684e-08
found O 0 9.356535546345413e-10
to O 0 1.2598786458539735e-09
be O 0 3.5762202088562844e-09
homologous O 0 1.5546131493238136e-08
to O 0 4.381425888766444e-09
a O 0 6.735896285192666e-09
gene O 0 2.465928972128495e-08
expressed O 0 2.8020663123129452e-08
from O 0 3.883981491981103e-08
human O 0 1.131412190602532e-07
chromosome O 0 8.308542760460114e-07
2p13 O 0 5.997371772537008e-06
- O 0 8.481889040012902e-07
p16 O 0 7.304283826670144e-07
, O 0 1.137908700599155e-08
a O 0 2.0479484774682533e-08
region O 0 1.554741260179071e-07
devoid O 0 9.729346857056953e-07
of O 0 4.6250811180925666e-08
any O 0 6.500241056528466e-08
positional O 0 1.541480560263153e-05
candidate O 0 7.427242053381633e-06
genes O 0 9.03796808415791e-06
. O 0 9.07543653738685e-06

Molecular O 0 8.403664651268627e-06
analysis O 0 1.0796005653901375e-06
of O 0 6.26343535259366e-07
the O 0 6.248221779969754e-07
APC B-Disease 0 2.646131406436325e-06
gene O 0 2.407984140972985e-07
in O 0 4.2641495667794516e-08
205 O 0 1.503206590314221e-07
families O 0 3.857352126601654e-08
: O 0 3.151962246761286e-08
extended O 0 2.0270510958653176e-07
genotype O 0 4.970437430529273e-07
- O 0 1.9482024526951136e-06
phenotype O 0 7.830442996237252e-07
correlations O 0 1.8971810504808673e-06
in O 0 5.0812658969334734e-08
FAP B-Disease 0 3.2590630780759966e-06
and O 0 8.561759301528582e-09
evidence O 0 6.340537339610819e-08
for O 0 1.0456665755498307e-08
the O 0 3.091139433308854e-08
role O 0 9.508746501296628e-08
of O 0 1.4939072912056872e-07
APC B-Disease 0 1.0531905445532175e-06
amino O 0 7.329720119741978e-08
acid O 0 2.5873980291635235e-08
changes O 0 4.2287467749702046e-08
in O 0 8.853326107782777e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9998887777328491
. O 0 1.720120053505525e-05

BACKGROUND O 0 0.3656609356403351
/ O 0 0.0001393013371853158
AIMS O 0 4.8463170969625935e-06
The O 0 9.991421734412143e-08
development O 0 2.4735888359828095e-07
of O 0 2.9596562853839714e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.882060420489779e-09
a O 0 3.0575850740177657e-09
variable O 0 1.811615391034138e-08
range O 0 2.6827306598420364e-08
of O 0 3.71988129188594e-08
extracolonic O 0 3.890605512424372e-05
manifestations O 0 0.001690822304226458
in O 0 1.821644900701358e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.5277019143104553
FAP B-Disease 1 0.9999831914901733
) O 0 2.007617716515142e-08
is O 0 1.277229100260513e-09
the O 0 1.550413242235038e-09
result O 0 4.455094515520841e-09
of O 0 1.6139539482651344e-08
the O 0 4.702577172110978e-08
dominant O 0 3.056145942537114e-06
inheritance O 0 4.978197011951124e-06
of O 0 1.4492609807348344e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
( O 0 1.140095992013812e-05
APC B-Disease 0 1.4679042578791268e-05
) O 0 2.0606324824257172e-07
gene O 0 7.012486662461015e-07
mutations O 0 3.3983974390139338e-06
. O 0 5.500971383298747e-06

In O 0 3.092991676112433e-07
this O 0 2.2404282873367265e-08
study O 0 2.4382785568377585e-08
, O 0 3.1652509502322346e-09
direct O 0 4.8580917066942675e-09
mutation O 0 2.5478077425589163e-09
analysis O 0 8.745741020277364e-09
of O 0 1.3419712452389376e-08
the O 0 3.9990187161720314e-08
APC B-Disease 0 2.593654357951891e-07
gene O 0 2.6430033273072695e-08
was O 0 5.1097522657528316e-08
performed O 0 3.2798970206471267e-09
to O 0 3.0028415309857337e-09
determine O 0 4.673293574342097e-08
genotype O 0 5.489674776981701e-07
- O 0 6.507472676275938e-07
phenotype O 0 1.8160268666633783e-07
correlations O 0 1.2940382987380872e-07
for O 0 1.5362170202593006e-08
nine O 0 1.5985474988156056e-07
extracolonic O 0 1.5298641301342286e-05
manifestations O 0 1.3907283573644236e-06
and O 0 9.170249448686718e-09
to O 0 8.351454638955147e-09
investigate O 0 1.0218981572052144e-07
the O 0 8.722904709657087e-08
incidence O 0 1.307005504713743e-06
of O 0 9.135546719107879e-08
APC B-Disease 0 1.5682314824516652e-06
mutations O 0 3.051830503864039e-07
in O 0 1.4443517670770234e-07
non O 1 0.9999744892120361
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0328800019342452e-05

METHODS O 0 2.0400249923113734e-05
The O 0 2.2720334982295753e-06
APC B-Disease 0 5.227982001088094e-06
gene O 0 4.1858908161884756e-07
was O 0 2.387670861025981e-07
analysed O 0 2.3402368753977498e-07
in O 0 2.4105981211164362e-08
190 O 0 1.8365402354447724e-07
unrelated O 0 2.9802316703353426e-07
FAP B-Disease 0 7.366828867816366e-06
and O 0 8.761941217017011e-08
15 O 0 6.508838055196975e-07
non O 0 0.008788477629423141
- O 1 0.9965204000473022
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.963916376889756e-08
using O 0 3.0119235105985354e-08
denaturing O 0 2.7668295388139086e-06
gradient O 0 9.299979524257651e-07
gel O 0 6.501957727778063e-07
electrophoresis O 0 2.2818650791123218e-07
, O 0 2.4609013493659404e-08
the O 0 1.9145350194094135e-08
protein O 0 4.8927802254183916e-08
truncation O 0 8.243871008062342e-08
test O 0 9.212429041838277e-09
, O 0 1.9697557362974294e-08
and O 0 5.8095441346495136e-08
direct O 0 3.928259104668541e-07
sequencing O 0 4.969539986632299e-06
. O 0 5.394470008468488e-06

RESULTS O 0 4.539968722383492e-05
Chain O 0 5.047514605394099e-06
terminating O 0 1.072205805030535e-06
signals O 0 4.674314766361931e-07
were O 0 3.771045342659818e-08
only O 0 1.4417446791981092e-08
identified O 0 4.273113418662433e-08
in O 0 7.407931157388248e-09
patients O 0 1.2339449462217544e-08
belonging O 0 8.973728427008609e-08
to O 0 1.800547089203519e-08
the O 0 4.0909654330789635e-07
FAP B-Disease 0 0.0001738667779136449
group O 0 2.7207715902477503e-07
( O 0 1.1456597803771729e-07
105 O 0 8.543775038560852e-07
patients O 0 1.7339927183002146e-07
) O 0 2.5268425929425575e-07
. O 0 2.5361059670103714e-06

Amino O 0 3.2216100862569874e-06
acid O 0 1.8376789512331015e-07
changes O 0 3.609554255490366e-08
were O 0 2.860009296057342e-08
identified O 0 3.2068179223188054e-08
in O 0 3.736334353021675e-09
four O 0 9.036657644401203e-09
patients O 0 4.402368247724553e-09
, O 0 2.8188915646154555e-09
three O 0 4.571299339062307e-09
of O 0 5.011455783687779e-08
whom O 0 5.263353273221583e-07
belonged O 0 1.1937710041820537e-05
to O 0 2.8175977107025574e-08
the O 0 4.470009287160792e-07
non O 0 0.007778687868267298
- O 0 1.9922939827665687e-05
FAP O 0 0.29339903593063354
group O 0 6.323689376586117e-07
of O 0 0.0005967074539512396
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.313570414320566e-05
. O 0 3.447624067121069e-06

Genotype O 0 6.220103387022391e-05
- O 0 2.1536148778977804e-05
phenotype O 0 2.001532493522973e-06
correlations O 0 1.7299437331530498e-06
identified O 0 8.996160971719291e-08
significant O 0 8.760788006156872e-08
differences O 0 1.4617550903039955e-07
in O 0 6.0270877177970306e-09
the O 0 7.904857213247851e-09
nature O 0 1.428828877436672e-08
of O 0 1.0144927564681439e-08
certain O 0 7.360400644529363e-08
extracolonic O 0 0.012899362482130527
manifestations O 0 1.4499230928777251e-05
in O 0 8.586866329096665e-08
FAP B-Disease 0 4.3282041588099673e-05
patients O 0 2.908574003868125e-08
belonging O 0 5.515252254895131e-08
to O 0 2.3967983153738714e-08
three O 0 1.413693553331541e-07
mutation O 0 2.432461769785732e-06
subgroups O 0 4.2028124880744144e-05
. O 0 6.0827305787825026e-06

CONCLUSIONS O 0 6.657207268290222e-05
Extended O 0 7.066468242555857e-06
genotype O 0 1.1098203685833141e-05
- O 0 3.7610357139783446e-06
phenotype O 0 6.64936408156791e-07
correlations O 0 7.63281605031807e-07
made O 0 2.809060184461032e-08
in O 0 2.7319080331267287e-09
this O 0 5.044671902432185e-10
study O 0 2.0056876159912918e-09
may O 0 1.324455323192808e-09
have O 0 1.0161363972471804e-09
the O 0 3.506983148326981e-09
potential O 0 1.0563834251797743e-08
to O 0 1.7628770665467641e-09
determine O 0 7.84917819629527e-09
the O 0 8.621851677048653e-09
most O 0 5.1427977432183525e-09
appropriate O 0 2.0437809666873363e-08
surveillance O 0 7.617619246502727e-08
and O 0 2.8701409249265453e-08
prophylactic O 0 1.7054024965545977e-06
treatment O 0 7.40944656740794e-08
regimens O 0 4.4659188347395684e-08
for O 0 7.606407059768117e-09
those O 0 1.526749926483717e-08
patients O 0 7.786282729682625e-09
with O 0 3.009119620145384e-09
mutations O 0 4.895636607216147e-08
associated O 0 1.29756145383908e-07
with O 0 1.57231738739938e-08
life O 0 2.1133125471806125e-07
threatening O 0 1.8105085928254994e-06
conditions O 0 6.251367267395835e-06
. O 0 8.27048370410921e-06

This O 0 3.743326999483543e-07
study O 0 1.563284257599662e-07
also O 0 1.1061368709874841e-08
provided O 0 1.3245671226513878e-08
evidence O 0 2.5514125923109532e-08
for O 0 4.875747805499486e-09
the O 0 4.680590848238353e-08
pathological O 0 9.978553862310946e-06
nature O 0 1.1706638503028444e-07
of O 0 5.591791918391209e-08
amino O 0 5.1816240187463336e-08
acid O 0 1.6445749650984e-08
changes O 0 1.8326868911344718e-08
in O 0 2.076658667249376e-08
APC O 0 4.1828181451819546e-07
associated O 0 9.139677104030852e-08
with O 0 2.2910095154315968e-08
both O 0 1.231783102184636e-07
FAP B-Disease 0 0.07204535603523254
and O 0 1.1380917612768826e-06
non O 1 0.9999995231628418
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.3929981150795356e-06
. O 0 2.0773111941707612e-07
. O 0 1.3047141464994638e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.5598893165588379
cancer B-Disease 1 0.9999997615814209
risk O 0 6.830493475717958e-06
of O 0 7.153230967560376e-07
the O 0 1.2315475714785862e-06
APC O 0 2.1355212084017694e-05
I1307K O 0 2.554048660385888e-05
polymorphism O 0 5.256167696643388e-06
. O 0 5.426450115919579e-06

Germ O 0 0.28663915395736694
- O 0 0.0001572220353409648
line O 0 1.1861189705086872e-05
and O 0 1.8666733581085282e-07
somatic O 0 1.530491681478452e-05
truncating O 0 2.3901070562715176e-06
mutations O 0 3.2803308158690925e-07
of O 0 1.2209181932121282e-07
the O 0 7.904800014557622e-08
APC B-Disease 0 4.911939299745427e-07
gene O 0 3.28175104868933e-08
are O 0 9.222098640293552e-09
thought O 0 2.3272209048741388e-08
to O 0 1.234340363254205e-08
initiate O 0 8.974221827884321e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00024034637317527086
formation O 0 2.3107309061742853e-06
in O 0 5.054452572039736e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9744110107421875
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 2.8160236524854554e-06
respectively O 0 3.226535682188114e-06
. O 0 3.408007387406542e-06

Recently O 0 1.4056548934604507e-05
, O 0 6.932586984476075e-07
an O 0 6.103756504671765e-07
isoleucine O 0 1.7469374142820016e-05
- O 0 7.83153336669784e-06
- O 0 7.292567261174554e-06
> O 0 1.9745043573493604e-06
lysine O 0 1.7801221474655904e-06
polymorphism O 0 5.162052616469737e-07
at O 0 2.869889783596591e-07
codon O 0 9.958570217349916e-07
1307 O 0 6.815013421146432e-06
( O 0 6.267205776566698e-08
I1307K O 0 8.680174232722493e-07
) O 0 8.01246624604346e-09
of O 0 1.9618294544443415e-08
the O 0 6.673187158412475e-08
APC B-Disease 0 3.5403104448050726e-07
gene O 0 1.486883771661951e-08
has O 0 4.546638621150123e-09
been O 0 4.457602287288864e-09
identified O 0 1.513176250966808e-08
in O 0 5.804491109984156e-09
6 O 0 4.2429988411640807e-08
% O 0 4.91874319052954e-09
- O 0 1.7108966687828797e-08
7 O 0 2.7149649639568452e-08
% O 0 1.756674139485881e-09
of O 0 2.2246802178216285e-09
the O 0 1.030352692055203e-08
Ashkenazi O 0 3.438210001149855e-07
Jewish O 0 3.7650843864867056e-07
population O 0 1.375452711727121e-07
. O 0 1.0435226158733713e-06

To O 0 3.036956570667826e-07
assess O 0 8.755189355724724e-07
the O 0 1.1609721894956238e-07
risk O 0 1.1434788405040308e-07
of O 0 1.769433310983004e-08
this O 0 3.254527758400627e-09
common O 0 3.422747951731253e-08
APC B-Disease 0 5.457925453811185e-07
allelic O 0 7.143672746678931e-07
variant O 0 1.776282715582056e-06
in O 0 1.533250895136007e-07
colorectal O 1 1.0
carcinogenesis O 1 0.999998927116394
, O 0 5.7457285151940596e-08
we O 0 1.5992176471968378e-08
have O 0 9.711166981674069e-09
analyzed O 0 5.869510744105355e-08
a O 0 1.0915227832697383e-08
large O 0 3.8905060506522204e-08
cohort O 0 3.4996455156033335e-07
of O 0 1.0316845333591118e-07
unselected O 0 0.0001396872103214264
Ashkenazi O 0 1.764171611284837e-05
Jewish O 0 4.230528247717302e-06
subjects O 0 9.598753649697755e-07
with O 0 9.505718168156818e-08
adenomatous B-Disease 0 0.0004463413206394762
polyps I-Disease 0 1.7510620864413795e-06
and O 0 6.643140437745387e-08
. O 0 6.468825120009569e-08
or O 1 0.8060694336891174
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.235398438050652e-08
for O 0 2.6514912931929757e-08
the O 0 1.6486586673636339e-07
APC O 0 3.4015197343251202e-06
I1307K O 0 1.2360243999864906e-05
polymorphism O 0 4.3691834434866905e-06
. O 0 4.59388820672757e-06

The O 0 2.275353472214192e-05
APC O 0 2.4825940272421576e-05
I1307K O 0 1.5824865840841085e-05
allele O 0 7.64866513236484e-07
was O 0 2.1657486115600477e-07
identified O 0 7.154944370313387e-08
in O 0 9.107323784007804e-09
48 O 0 6.528283336137974e-08
( O 0 9.928954547433477e-09
10 O 0 1.011752637225527e-08
. O 0 3.2984290854187748e-09
1 O 0 4.0498637332575527e-08
% O 0 2.7820412640267023e-09
) O 0 1.963756490752644e-09
of O 0 1.6273135727828958e-08
476 O 0 1.5240490256474004e-06
patients O 0 2.7434555249783443e-07
. O 0 2.2815895590611035e-06

Compared O 0 6.643754772994725e-07
with O 0 1.0826318508350141e-08
the O 0 9.92083304396374e-09
frequency O 0 1.2224614209799256e-08
in O 0 1.944895133831892e-09
two O 0 1.3826084721557663e-09
separate O 0 1.3581596958189834e-09
population O 0 1.011358552460706e-09
control O 0 4.601198089204672e-09
groups O 0 6.0231339915617355e-09
, O 0 7.799437540256804e-09
the O 0 3.423975414307279e-08
APC O 0 1.2021665725114872e-06
I1307K O 0 1.0999933692801278e-06
allele O 0 8.95599612249498e-08
is O 0 4.253562835287994e-09
associated O 0 7.788243827633323e-09
with O 0 1.5746967063634543e-09
an O 0 4.402426867500253e-09
estimated O 0 9.570315206985924e-09
relative O 0 1.322167122452811e-07
risk O 0 9.478542750684937e-08
of O 0 3.4369642776255205e-07
1 O 0 7.957047273521312e-06
. O 0 4.052625627082307e-06

5 O 0 0.0003470895753707737
- O 0 0.00013850888353772461
1 O 0 5.354087988962419e-05
. O 0 1.043256725097308e-05

7 O 0 7.660713890800253e-05
for O 0 7.173990525188856e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999005794525146
( O 0 3.893813300237525e-06
both O 0 9.210357347910758e-07
P O 0 1.732432247081306e-05
= O 0 2.4281371224788018e-06
. O 0 2.0032193503993767e-07
01 O 0 3.0357311970874434e-06
) O 0 1.7050400913376507e-07
. O 0 8.207672976823233e-07

Furthermore O 0 1.8630717022460885e-05
, O 0 2.962588609989325e-07
compared O 0 1.0235406477931974e-07
with O 0 4.501915285004543e-08
noncarriers O 0 1.3045763807895128e-05
, O 0 1.2487848266573565e-07
APC O 0 1.2422997315297835e-06
I1307K O 0 1.785275230758998e-06
carriers O 0 6.300068378095602e-08
had O 0 9.593142280550637e-09
increased O 0 9.015171720250237e-09
numbers O 0 2.723044900676541e-08
of O 0 7.774532662097045e-08
adenomas B-Disease 1 0.9715626835823059
and O 0 2.6197658371529542e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999984860420227
per O 0 1.8693366143907042e-07
patient O 0 1.1651715681182395e-07
( O 0 1.1064052785059175e-07
P O 0 2.0848681288043736e-06
= O 0 1.9522592253906623e-07
. O 0 1.473937327745034e-08
03 O 0 8.859003486350048e-08
) O 0 1.2762549905787068e-09
, O 0 1.1798252375072593e-09
as O 0 2.4993389580174608e-09
well O 0 2.8043851685310983e-09
as O 0 5.232051680792438e-09
a O 0 1.789935666351994e-08
younger O 0 5.508171057044819e-07
age O 0 1.0136106993741123e-06
at O 0 1.1252146805418306e-06
diagnosis O 0 6.579186447197571e-06
. O 0 7.2826360337785445e-06

We O 0 1.6297633465001127e-06
conclude O 0 3.294575435575098e-06
that O 0 9.560211822190468e-08
the O 0 4.1891215118994296e-07
APC O 0 1.1321724741719663e-05
I1307K O 0 1.9937629986088723e-05
variant O 0 3.8659632082271855e-06
leads O 0 3.1745335604682623e-07
to O 0 5.343638775912041e-08
increased O 0 8.560927540202101e-07
adenoma B-Disease 1 1.0
formation O 0 1.7430199932277901e-06
and O 0 7.203362173413552e-08
directly O 0 9.618374718911582e-08
contributes O 0 2.12599076121478e-08
to O 0 6.501254645741028e-09
3 O 0 4.733686864710762e-08
% O 0 8.712508936525865e-09
- O 0 1.970109053672786e-08
4 O 0 1.4205084220009212e-08
% O 0 6.605709312879071e-10
of O 0 7.790468270485462e-10
all O 0 6.897343141076817e-09
Ashkenazi O 0 9.394663720740937e-06
Jewish O 1 0.8940710425376892
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.306116807129001e-06

The O 0 7.20609023119323e-07
estimated O 0 3.208874090887548e-07
relative O 0 5.273225838209328e-07
risk O 0 9.61360555606916e-08
for O 0 1.0864131816390454e-08
carriers O 0 7.71968302615278e-08
may O 0 1.458864762327039e-08
justify O 0 6.043850220294189e-08
specific O 0 2.437376522834711e-08
clinical O 0 3.537201465064754e-08
screening O 0 9.106334353248258e-09
for O 0 4.0449830152056165e-09
the O 0 1.4263592085228538e-08
360 O 0 3.716520069474427e-08
, O 0 7.163830861856013e-09
000 O 0 5.03812849217411e-08
Americans O 0 4.754179272481451e-09
expected O 0 8.994150313412774e-09
to O 0 8.518219019038042e-09
harbor O 0 3.461945539129374e-07
this O 0 2.3540862592597023e-09
allele O 0 2.6822498000456108e-08
, O 0 3.7412473119502465e-09
and O 0 2.1159165530804103e-09
genetic O 0 1.3457031933228336e-08
testing O 0 3.655947988789876e-09
in O 0 3.291088956913768e-09
the O 0 9.595009231588847e-09
setting O 0 5.660221447101321e-08
of O 0 8.368950688009136e-08
long O 0 1.057230463175074e-07
- O 0 8.155271871146397e-07
term O 0 6.293342948993086e-07
- O 0 5.453367748486926e-07
outcome O 0 1.8421164327264705e-07
studies O 0 6.952132025617175e-08
may O 0 8.724381217461996e-09
impact O 0 1.1639033203891813e-07
significantly O 0 6.351479555632977e-07
on O 0 1.1234969861106947e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 3.915953072919365e-07
in O 0 4.776757211999438e-09
this O 0 6.52932730105249e-09
population O 0 1.0404089323401422e-07
. O 0 1.2862872154073557e-06

Localization O 0 4.028866896987893e-05
of O 0 6.048710474715335e-06
human O 0 4.5322522055357695e-06
BRCA1 O 0 4.4738867472915445e-06
and O 0 7.370262267158978e-08
its O 0 3.178877605591879e-08
loss O 0 1.729830501062679e-07
in O 0 4.575305467824364e-08
high O 0 7.557438948424533e-06
- O 0 1.3730554201174527e-05
grade O 0 2.5855664716800675e-05
, O 0 2.3532733450792875e-07
non B-Disease 1 0.9996987581253052
- I-Disease 1 0.999997615814209
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 9.946154023054987e-05

Although O 0 1.9645406155177625e-06
the O 0 3.891916833254072e-07
link O 0 2.3413647340930765e-06
between O 0 6.93002846219315e-07
the O 0 1.6306790939779603e-06
BRCA1 O 0 0.031224621459841728
tumour B-Disease 1 1.0
- O 0 3.101581387454644e-05
suppressor O 0 0.0001719936408335343
gene O 0 7.582783041470975e-07
and O 0 1.1330561164868413e-06
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.0131102179400386e-08
established O 0 1.4949085525017836e-08
, O 0 2.2643777963793355e-09
the O 0 5.352959853155426e-09
role O 0 1.3955331112924796e-08
, O 0 2.130312370951515e-09
if O 0 1.3973275869716417e-09
any O 0 1.370466140571125e-08
, O 0 1.981168651354892e-08
of O 0 5.527436641727945e-08
BRCA1 O 0 1.5405499880216666e-06
in O 0 3.1329537364399584e-07
non B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999990463256836
familial I-Disease 1 0.9999485015869141
cancers I-Disease 1 0.9999852180480957
is O 0 2.5701368144837033e-07
unclear O 0 3.508371264615562e-06
. O 0 3.476606480035116e-06

BRCA1 O 0 6.709410081384704e-05
mutations O 0 3.0964322377258213e-06
are O 0 8.171732446271562e-08
rare O 0 1.5299060862616898e-07
in O 0 1.8942413859690532e-08
sporadic B-Disease 0 1.012948814604897e-05
cancers I-Disease 1 0.9891760945320129
, O 0 1.14478346802116e-08
but O 0 8.204870560746258e-09
loss O 0 3.247845086207235e-07
of O 0 5.968985306026298e-07
BRCA1 O 0 9.200928161590127e-07
resulting O 0 1.8624200492922682e-07
from O 0 8.960438435678952e-08
reduced O 0 1.1486617523814857e-07
expression O 0 3.470003662187082e-08
or O 0 1.9501595005522177e-08
incorrect O 0 1.6198157481994713e-07
subcellular O 0 1.5113238305275445e-06
localization O 0 6.011579216647078e-07
is O 0 8.236637150105253e-09
postulated O 0 8.289659803040195e-08
to O 0 4.556448551795711e-09
be O 0 9.68471525197856e-09
important O 0 8.834873455043635e-08
in O 0 4.3385593784250887e-08
non B-Disease 0 0.0016168832080438733
- I-Disease 0 0.006259818095713854
familial I-Disease 1 0.99998939037323
breast I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 3.799461046583019e-05

Epigenetic O 0 0.00032239468418993056
loss O 0 3.578911127988249e-05
, O 0 1.8634716525411932e-07
however O 0 9.820303148444509e-08
, O 0 6.651454942385726e-09
has O 0 9.289886637731115e-10
not O 0 6.076487091277727e-10
received O 0 1.293419682468766e-08
general O 0 4.995566271759344e-08
acceptance O 0 1.1736877070234186e-07
due O 0 2.5799570479989598e-08
to O 0 1.1449122538920165e-08
controversy O 0 1.6429486038305186e-07
regarding O 0 1.2196380794193828e-07
the O 0 3.335237153123671e-08
subcellular O 0 2.6584370971249882e-06
localization O 0 1.4966523167458945e-06
of O 0 2.3521245395841106e-07
BRCA1 O 0 2.3410650840105518e-07
proteins O 0 2.410276245257137e-08
, O 0 5.580580442199334e-09
reports O 0 4.0298065329125166e-08
of O 0 1.0154316498756089e-08
which O 0 4.552982435512831e-09
have O 0 4.737198189275205e-09
ranged O 0 1.8953569735913334e-07
from O 0 1.250644832140324e-08
exclusively O 0 4.691539956525048e-08
nuclear O 0 1.387642640793274e-07
, O 0 5.6553512983725795e-09
to O 0 4.564120636985081e-09
conditionally O 0 2.2849116021461668e-07
nuclear O 0 2.523266573462024e-07
, O 0 1.3305124113571765e-08
to O 0 2.4790296038190718e-08
the O 0 6.292755188042065e-07
ER O 1 0.5119464993476868
/ O 0 6.780589956179028e-06
golgi O 0 2.277915336890146e-05
, O 0 1.274742942314333e-07
to O 0 5.69869911259957e-08
cytoplasmic O 0 4.141761110076914e-06
invaginations O 0 1.1265149623795878e-05
into O 0 6.906000749040686e-07
the O 0 1.2725485021292116e-06
nucleus O 0 3.9274364098673686e-05
. O 0 9.444177521800157e-06

In O 0 5.688251576430048e-07
an O 0 6.311675093684244e-08
attempt O 0 8.543215557210715e-08
to O 0 2.0166210035199583e-08
resolve O 0 1.3989608760311967e-07
this O 0 1.809408800568235e-08
issue O 0 1.7747711922311282e-07
, O 0 2.98307973878309e-08
we O 0 5.7963728039567286e-08
have O 0 8.582200194950929e-08
comprehensively O 0 2.4442817903036484e-06
characterized O 0 1.0144540283363312e-06
19 O 0 2.230418431281578e-06
anti O 0 6.839390607638052e-06
- O 0 2.462210613884963e-05
BRCA1 O 0 1.1717918823705986e-05
antibodies O 0 4.8865867938729934e-06
. O 0 4.89601870867773e-06

These O 0 1.8707023627939634e-06
reagents O 0 9.936571586877108e-06
detect O 0 2.3822310595278395e-06
a O 0 4.3982495867567195e-07
220 O 0 9.015018349600723e-07
- O 0 1.1673287190205883e-06
kD O 0 3.2991029002005234e-06
protein O 0 1.8575863691694394e-07
localized O 0 2.1658478033259598e-07
in O 0 5.904225552910702e-09
discrete O 0 3.9395658291141444e-08
nuclear O 0 5.856471716469969e-07
foci O 0 1.1625360230027582e-06
in O 0 8.869126766342106e-09
all O 0 1.605434007956319e-08
epithelial O 0 3.1342167403636267e-06
cell O 0 1.1248059763602214e-06
lines O 0 6.894649828836918e-08
, O 0 2.6719697565624756e-09
including O 0 2.581363345299792e-09
those O 0 1.893110912476459e-08
derived O 0 9.035641141963424e-07
from O 0 3.124460818071384e-06
breast B-Disease 0 0.0001686646428424865
malignancies I-Disease 0 0.0009582594502717257
. O 0 9.710310223454144e-06

Immunohistochemical O 0 0.0009470409131608903
staining O 0 0.0001794181007426232
of O 0 9.462172783969436e-06
human O 0 4.5168046199250966e-05
breast O 0 0.0011726637603715062
specimens O 0 1.71512999713741e-06
also O 0 5.6505562895381445e-08
revealed O 0 2.529181131194491e-07
BRCA1 O 0 3.462022277744836e-06
nuclear O 0 6.3323582253360655e-06
foci O 0 0.00023561608395539224
in O 0 4.71236404564479e-07
benign O 1 0.9999984502792358
breast O 1 0.9224945306777954
, O 0 2.0398793765252776e-07
invasive B-Disease 0 3.3901807910297066e-05
lobular I-Disease 1 0.9999996423721313
cancers I-Disease 1 0.9990612864494324
and O 0 7.654597311557154e-07
low B-Disease 1 0.8764021992683411
- I-Disease 1 0.9999339580535889
grade I-Disease 1 0.9999520778656006
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 3.5791021218756214e-05

Conversely O 0 2.121292709489353e-05
, O 0 1.237895503436448e-06
BRCA1 O 0 1.5482412436540471e-06
expression O 0 9.84772654533117e-08
was O 0 5.886159115675582e-08
reduced O 0 2.9183151895040282e-08
or O 0 7.043019945029982e-09
undetectable O 0 4.5156923533795634e-08
in O 0 1.3084008321229135e-09
the O 0 4.5561536765603705e-09
majority O 0 1.9126871197983064e-09
of O 0 2.4318875802009643e-08
high O 0 1.4425610288526514e-06
- O 0 3.5504203879099805e-06
grade O 0 1.2530917047115508e-05
, O 0 3.0464278211184137e-07
ductal B-Disease 1 0.9999864101409912
carcinomas I-Disease 1 1.0
, O 0 1.8155898118266123e-08
suggesting O 0 1.5247826112840812e-08
that O 0 1.6322866391860202e-09
absence O 0 1.520946284472302e-07
of O 0 2.7283743975203834e-07
BRCA1 O 0 7.109778721314797e-07
may O 0 2.648549468631245e-08
contribute O 0 1.8725334172131625e-08
to O 0 3.991830421767872e-09
the O 0 3.0130898664992856e-08
pathogenesis O 0 0.0006990405963733792
of O 0 1.9049007704552423e-08
a O 0 1.1883106942889299e-08
significant O 0 6.380584238740994e-08
percentage O 0 3.8619981523879687e-07
of O 0 2.505584006939898e-07
sporadic B-Disease 1 0.5309476852416992
breast I-Disease 1 0.9999903440475464
cancers I-Disease 1 0.9846686720848083
. O 0 1.8652654034667648e-06
. O 0 7.429360266542062e-06

